{"402c42fa825627b21ae5f86ef5c741df875c935d": [["S1Average time to hospitalization 5 [5] q Effective rate of non-hospitalized quarantine 0.57 Derived from source data [6, 7] .S1n Effective rate of undocumented infections 2.25 Undocumented rate of 0.75 constrained to g and d [8] [9] [10] .S1t Fraction non-immune 0.30 (varied in some simulations) [11, 12] p Average duration of immunity 5 years (varied in some simulations) [11, 12]", [["infections", "DISEASE", 161, 171], ["undocumented infections", "PROBLEM", 148, 171], ["Undocumented rate", "TEST", 177, 194], ["infections", "OBSERVATION", 161, 171]]]], "2db28d2cd54bf5a567c433e55b4b7071707707d1": [["IntroductionObesity is a problem that represents a significant health and economic burden in Europe and throughout the world.", [["IntroductionObesity", "DISEASE", 0, 19], ["IntroductionObesity", "TREATMENT", 0, 19], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["economic", "OBSERVATION_MODIFIER", 74, 82], ["burden", "OBSERVATION", 83, 89]]], ["The prevalence of obesity across European countries has tripled in the last several decades [1] , making it one of the leading public health challenges.IntroductionA critical part of addressing this global epidemic is to improve the evidence base for more effective treatments for obesity; however, a challenge revealed in the randomized, controlled trials (RCTs) of obesity interventions is the remarkable heterogeneity of interindividual and intraindividual responses among adult patients -whether the intervention pertains to lifestyle (dietary, physical activity [PA]), or is a pharmacological or surgical intervention aiming at weight loss.", [["obesity", "DISEASE", 18, 25], ["obesity", "DISEASE", 281, 288], ["obesity", "DISEASE", 367, 374], ["weight loss", "DISEASE", 633, 644], ["patients", "ORGANISM", 482, 490], ["patients", "SPECIES", 482, 490], ["obesity", "PROBLEM", 18, 25], ["obesity", "PROBLEM", 281, 288], ["a challenge", "TEST", 299, 310], ["obesity interventions", "TREATMENT", 367, 388], ["the intervention", "TREATMENT", 500, 516], ["surgical intervention", "TREATMENT", 601, 622], ["weight loss", "PROBLEM", 633, 644], ["obesity", "OBSERVATION", 18, 25], ["obesity", "OBSERVATION", 281, 288]]], ["Most obesity RCTs include a heterogeneous mixture of patients that, despite meeting the inclusion criteria for the study, vary remarkably when it comes to the medical history of their disease, associated complications, and many other factors (including genetics, lifestyle, environmental, and psychosocial factors) that may drive the varying responses to the same intervention.", [["obesity", "DISEASE", 5, 12], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Most obesity RCTs", "PROBLEM", 0, 17], ["the study", "TEST", 111, 120], ["their disease", "PROBLEM", 178, 191], ["associated complications", "PROBLEM", 193, 217], ["the same intervention", "TREATMENT", 355, 376], ["heterogeneous", "OBSERVATION_MODIFIER", 28, 41], ["mixture", "OBSERVATION_MODIFIER", 42, 49], ["complications", "OBSERVATION", 204, 217]]], ["This emphasizes the need to appropriately stratify patients according to precise phenotyping criteria, as measured using standardized methods, that might predict an individual's response to an intervention: enabling a paradigm shift in individually tailored obesity treatment, going from \"one-size-fits-all\" to precision medicine.IntroductionOne important clinically relevant question is whether, among the patients who respond poorly to a given therapy, a better response might be achieved by applying a different therapy or by administering the current therapy differently.", [["obesity", "DISEASE", 258, 265], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 407, 415], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 407, 415], ["an intervention", "TREATMENT", 190, 205], ["tailored obesity treatment", "TREATMENT", 249, 275], ["therapy", "TREATMENT", 446, 453], ["a different therapy", "TREATMENT", 503, 522], ["the current therapy", "TREATMENT", 543, 562], ["obesity", "OBSERVATION", 258, 265]]], ["Specific patient characteristics could theoretically provide justification for choosing an alternative treatment either as a first choice or, dependent on poor response, as a second choice, but an increased burden is thus placed on researchers to provide evidence for the benefit of choosing or switching between alternative therapies.IntroductionEven for the largest and most comprehensive published clinical studies on obesity, stratification leads to subgroup analyses with reduced statistical power.", [["obesity", "DISEASE", 421, 428], ["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["an alternative treatment", "TREATMENT", 88, 112], ["an increased burden", "PROBLEM", 194, 213], ["alternative therapies", "TREATMENT", 313, 334], ["obesity", "PROBLEM", 421, 428], ["subgroup analyses", "TEST", 454, 471], ["increased", "OBSERVATION_MODIFIER", 197, 206], ["burden", "OBSERVATION", 207, 213]]], ["Moreover, some trials do not report methods for measuring relevant obesity phenotypes in sufficient detail.", [["obesity", "DISEASE", 67, 74], ["measuring relevant obesity phenotypes", "PROBLEM", 48, 85]]], ["Thus, it is necessary to harmonize and merge the data from multiple intervention studies -but data pooling is only possible with trials that include a common set of variables measured in the same way, including samples that are collected using consistent methods or procedures, described in enough detail.IntroductionFunded by a European grant, a group of European obesity researchers convened in 2018 to create a plan for helping shape future RCTs in the field of obesity by identifying the minimal set of variables that should be included in trials of different kinds of obesity interventions, whatever the type and the endpoints of the intervention.", [["obesity", "DISEASE", 365, 372], ["obesity", "DISEASE", 465, 472], ["obesity", "DISEASE", 573, 580], ["multiple intervention studies", "TEST", 59, 88], ["data pooling", "TEST", 94, 106], ["procedures", "TREATMENT", 266, 276], ["obesity", "PROBLEM", 465, 472], ["obesity interventions", "TREATMENT", 573, 594], ["the intervention", "TREATMENT", 635, 651], ["obesity", "OBSERVATION", 465, 472], ["obesity", "OBSERVATION", 573, 580]]], ["The experts intend for this minimal core set to be adopted in future studies while acknowledging that in addition, RCTs or other trials will collect data on extra variables, depending on the specific area of focus.", [["future studies", "TEST", 62, 76], ["RCTs", "TREATMENT", 115, 119], ["focus", "OBSERVATION", 208, 213]]], ["As such, the current initiative, called OBEDIS (OBEsity Diverse Interventions Sharing -focusing on dietary and other interventions) and funded by the Joint Programming Initiative -A Healthy Diet for a Healthy Life (JPI HDHL), was created to provide the research community with a blueprint for designing future RCTs in order to allow the sharing and merging of datasets, and to enable meaningful subgroup analyses.", [["dietary and other interventions", "TREATMENT", 99, 130], ["a Healthy Life (JPI HDHL", "TREATMENT", 199, 223], ["designing future RCTs", "TREATMENT", 293, 314], ["Joint", "ANATOMY", 150, 155]]], ["To achieve this, the OBEDIS experts surveyed the scientific literature, especially the published work on stratifying populations of individuals with obesity.", [["obesity", "DISEASE", 149, 156], ["obesity", "PROBLEM", 149, 156], ["obesity", "OBSERVATION", 149, 156]]], ["They shared their expert opinions on a recommended minimal core set of variables to be included in all future trials of adult obesity interventions and sought to reach consensus on both these variables and the related assessment methods.Expert Involvement and Working MethodsThe OBEDIS project coordinators, supported by the European Association for the Study of Obesity (EASO), invited leading experts to contribute to this consensus on a minimal core set of variables for RCTs of obesity interventions.", [["obesity", "DISEASE", 126, 133], ["Obesity", "DISEASE", 363, 370], ["obesity", "DISEASE", 482, 489], ["adult obesity interventions", "TREATMENT", 120, 147], ["the related assessment methods", "TEST", 206, 236], ["Obesity", "PROBLEM", 363, 370], ["RCTs of obesity interventions", "TREATMENT", 474, 503], ["obesity", "OBSERVATION", 126, 133], ["Obesity", "OBSERVATION", 363, 370], ["obesity", "OBSERVATION", 482, 489]]], ["These European researchers represented 13 countries and were chosen for their research record and expertise related to obesity and intervention studies in the field.", [["obesity", "DISEASE", 119, 126], ["obesity", "PROBLEM", 119, 126], ["intervention studies", "TEST", 131, 151], ["obesity", "OBSERVATION", 119, 126]]], ["These multiple perspectives were considered necessary in the discus-sions, in order to serve the field best by choosing a minimal core set of variables that are applicable across different geographies and cultures.Expert Involvement and Working MethodsThe experts were divided into small working groups according to their expertise.", [["cultures", "TEST", 205, 213], ["small", "OBSERVATION_MODIFIER", 282, 287]]], ["After this foundational preparatory group work, these experts and SAB members met for a 2-day workshop in Paris, France, in October 2018, to discuss the recommendations and come to a consensus on a core set of variables to recommend in each domain.Criteria for Minimal Core SetA variable is defined as \"a property with respect to which individuals in a sample differ in some ascertainable way\" [2] .", [["Minimal", "OBSERVATION_MODIFIER", 261, 268], ["Core SetA", "OBSERVATION_MODIFIER", 269, 278]]], ["The minimal core set is a set of variables recommended to be measured in all trials for obesity, regardless of the type of intervention.", [["obesity", "DISEASE", 88, 95], ["obesity", "PROBLEM", 88, 95], ["intervention", "TREATMENT", 123, 135], ["minimal", "OBSERVATION_MODIFIER", 4, 11], ["core", "OBSERVATION_MODIFIER", 12, 16]]], ["It is understood that over time this core set will be updated according to the scientific advances in each of the identified domains.Criteria for Minimal Core SetFor a variable to be included in the minimal core set, it was required to fulfill the following criteria:Criteria for Minimal Core Set\u2022 It provided information that made it likely to impact treatment response, according to the relevant literature (especially studies that aimed to stratify patients) \u2022 It was feasible: Given that each clinical trial has limits on budget and time as well as research team expertise, the OBEDIS group aimed to minimize the burden of including each variable in future trials.", [["patients", "ORGANISM", 452, 460], ["patients", "SPECIES", 452, 460], ["the OBEDIS group", "TREATMENT", 578, 594]]], ["The scientists paid considerable attention to factors that would encourage widespread adoption of these measures by the European obesity research community, especially the overall number of variables that should be systematically collected.", [["obesity", "DISEASE", 129, 136], ["these measures", "TREATMENT", 98, 112]]], ["The group preferred measures that were: \u2212 Low-cost or free to utilize/able to be collected with minimal equipment or human resources \u2212 Less invasive/quick to implement \u2212 For questionnaires: Available and/or validated in multiple languages or across culturesCriteria for Minimal Core SetThe group provided an estimate of the average cost of including these measures in a European trial (Table 1) .", [["human", "ORGANISM", 117, 122], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["across cultures", "TEST", 242, 257], ["these measures", "TREATMENT", 350, 364], ["a European trial", "TREATMENT", 368, 384]]], ["While inclusion of these variables will in some cases introduce additional cost to individual clinical trials, they will also extend the insights made possible by each trial -making the overall research agenda proceed more purposefully and at a lower cost.Criteria for Minimal Core SetWhile the primary purpose of the initiative was to identify a minimal core set, additional relevant variables and/or measures were identified in some cases, and these were included in what was called the \"expanded set.\"Selection of Minimal Core SetEach group presented the variables frequently used in the studies to date, and selected them based on their experience, the scientific literature, and their projections about the future direction of the field in each domain.", [["the studies", "TEST", 587, 598], ["Minimal", "OBSERVATION_MODIFIER", 517, 524], ["Core", "OBSERVATION_MODIFIER", 525, 529]]], ["The approach to this OBEDIS project was pragmatic and guided at every turn by the existing body of evidence on interventions for obesity while taking into account the constraints of the minimal core set.Selection of Minimal Core SetThe experts understand that few trials will restrict themselves to only this core set and will collect additional variables depending on their specific aims and outcomes.", [["obesity", "DISEASE", 129, 136], ["this OBEDIS project", "TREATMENT", 16, 35], ["interventions", "TREATMENT", 111, 124], ["obesity", "PROBLEM", 129, 136], ["obesity", "OBSERVATION", 129, 136], ["minimal", "OBSERVATION_MODIFIER", 186, 193], ["Minimal", "OBSERVATION_MODIFIER", 216, 223], ["Core", "OBSERVATION_MODIFIER", 224, 228]]], ["Trial investigators may opt to carry out more detailed measurements for a certain variable when it corresponds to the main objective of the study -and in this case, regardless, the OBEDIS group recommends collecting the overlapping measures in the minimal core set to facilitate data integration on a larger scale.Parallel EffortsThe OBEDIS work with European experts occurred in parallel with a similar United States initiative funded by the National Institutes of Health: the ADOPT (Accumulating Data to Optimally Predict obesity Treatment) core measures project [3] .", [["obesity", "DISEASE", 524, 531], ["the study", "TEST", 136, 145], ["a larger scale", "TREATMENT", 299, 313], ["Treatment) core measures", "TREATMENT", 532, 556], ["minimal", "OBSERVATION_MODIFIER", 248, 255]]], ["OBEDIS scientists wish to connect ideas across these two projects and build joint efforts in the same direction, for the overall benefit of the field globally.ResultsThe expert guidelines detailed herein represent a practical advancement in the field of research on obesity interventions.", [["obesity", "DISEASE", 266, 273], ["a practical advancement", "TREATMENT", 214, 237], ["obesity interventions", "TREATMENT", 266, 287], ["joint", "ANATOMY", 76, 81]]], ["Below, the results are described in four categories -environment and context, lifestyle, subject characteristics, and complications -with a final section looking ahead to implications for future medical practice.", [["a final section", "TREATMENT", 138, 153], ["future medical practice", "TREATMENT", 188, 211]]], ["Issues pertaining to obesity interventions are covered in a separate paper.ResultsThe OBEDIS experts unanimously agreed that standard operating procedures (SOPs) are of critical importance, because only with consistent harmonized procedures can data be pooled across studies.", [["obesity", "DISEASE", 21, 28], ["obesity interventions", "TREATMENT", 21, 42], ["standard operating procedures", "TREATMENT", 125, 154], ["obesity", "OBSERVATION", 21, 28]]], ["The recommended detailed assessment methods for these measurements are detailed in the supplementary materials (for all online suppl. materials, see www. karger.com/doi/10.1159/000505342).Environment and Context: Medical History of Obesity, Basic Background Information, Quality of Life/HandicapNo living entity exists in isolation: across the biological sciences, researchers consider environmental influences as major drivers of behavioral change.", [["Obesity", "DISEASE", 232, 239], ["detailed assessment methods", "TEST", 16, 43], ["these measurements", "TEST", 48, 66], ["Obesity", "PROBLEM", 232, 239], ["behavioral change", "PROBLEM", 431, 448], ["Obesity", "OBSERVATION", 232, 239]]], ["Various environmental factors are considered relevant in obesity, since they may contribute to the emergence and maintenance of the condition and relevant behaviors.", [["obesity", "DISEASE", 57, 64]]], ["The context where patients live and work may also impact response to interventions, making contextual factors potentially useful for patient stratification at baseline.Environment and Context: Medical History of Obesity, Basic Background Information, Quality of Life/HandicapMedical History of Obesity Minimal core set recommended variables: \u2022 Age at onset of obesity \u2022 Maximal and minimal body weight after 18 years of age \u2022 Variation of body weight during the past 3 months \u2022 Previous attempts to lose weight and weight maintained after weight loss \u2022 Etiology: categories from Hebebrand et al. [4] \u2022 Parental history, including history of bariatric surgery Expanded set recommended variables: \u2022 Body weight self-monitoringEnvironment and Context: Medical History of Obesity, Basic Background Information, Quality of Life/HandicapThe medical history of obesity is a recall of weight-related events and problems experienced by the patient.", [["body", "ANATOMY", 390, 394], ["body", "ANATOMY", 439, 443], ["Body", "ANATOMY", 697, 701], ["Obesity", "DISEASE", 212, 219], ["Obesity", "DISEASE", 294, 301], ["obesity", "DISEASE", 360, 367], ["weight loss", "DISEASE", 539, 550], ["Obesity", "DISEASE", 768, 775], ["obesity", "DISEASE", 854, 861], ["patients", "ORGANISM", 18, 26], ["patient", "ORGANISM", 133, 140], ["body", "ORGANISM_SUBDIVISION", 390, 394], ["body", "ORGANISM_SUBDIVISION", 439, 443], ["Body", "ORGANISM_SUBDIVISION", 697, 701], ["patient", "ORGANISM", 931, 938], ["patients", "SPECIES", 18, 26], ["patient", "SPECIES", 133, 140], ["patient", "SPECIES", 931, 938], ["interventions", "TREATMENT", 69, 82], ["Obesity", "PROBLEM", 212, 219], ["Obesity", "PROBLEM", 294, 301], ["obesity", "PROBLEM", 360, 367], ["Variation of body weight", "PROBLEM", 426, 450], ["weight", "TEST", 515, 521], ["weight loss", "PROBLEM", 539, 550], ["bariatric surgery", "TREATMENT", 641, 658], ["Body weight", "TEST", 697, 708], ["Obesity", "PROBLEM", 768, 775], ["obesity", "PROBLEM", 854, 861], ["weight-related events", "PROBLEM", 877, 898], ["Obesity", "OBSERVATION", 212, 219], ["Obesity", "OBSERVATION", 294, 301], ["obesity", "OBSERVATION", 360, 367], ["minimal", "OBSERVATION_MODIFIER", 382, 389], ["Obesity", "OBSERVATION", 768, 775], ["obesity", "OBSERVATION", 854, 861]]], ["In adult obesity, the medical history of the disease is important because factors in the history of a patient can not only affect the course of weight gain and loss through the lifespan but may modulate the response to a specific type of intervention.", [["obesity", "DISEASE", 9, 16], ["weight gain", "DISEASE", 144, 155], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["adult obesity", "PROBLEM", 3, 16], ["the disease", "PROBLEM", 41, 52], ["weight gain", "PROBLEM", 144, 155], ["loss through the lifespan", "PROBLEM", 160, 185], ["intervention", "TREATMENT", 238, 250], ["adult", "OBSERVATION_MODIFIER", 3, 8], ["obesity", "OBSERVATION", 9, 16], ["disease", "OBSERVATION", 45, 52]]], ["Medical history variables in three main categories are relevant to intervention responses: the development of the current obesity state and previous attempts to treat it; the disease etiology; and variables related to conception and perinatal history.", [["obesity", "DISEASE", 122, 129], ["the current obesity state", "PROBLEM", 110, 135], ["the disease etiology", "PROBLEM", 171, 191], ["obesity", "OBSERVATION", 122, 129], ["disease", "OBSERVATION", 175, 182]]], ["Comorbid medical conditions that may influence intervention outcome, or disorders for which the treatment influences outcome, are discussed elsewhere in this paper.", [["Comorbid medical conditions", "PROBLEM", 0, 27], ["disorders", "PROBLEM", 72, 81]]], ["In considering the development of the patient's current obesity state, the OBEDIS group recommends documenting both the age of the onset of obesity, and the maximal and minimal body weight during adulthood.", [["body", "ANATOMY", 177, 181], ["obesity", "DISEASE", 56, 63], ["obesity", "DISEASE", 140, 147], ["patient", "ORGANISM", 38, 45], ["body", "ORGANISM_SUBDIVISION", 177, 181], ["patient", "SPECIES", 38, 45], ["the patient's current obesity state", "PROBLEM", 34, 69], ["obesity", "PROBLEM", 140, 147], ["obesity", "OBSERVATION", 56, 63], ["obesity", "OBSERVATION", 140, 147]]], ["The age at obesity onset is important because occurrence prior to age 18 can influence the development of complications later on [5] .", [["obesity", "DISEASE", 11, 18], ["complications", "PROBLEM", 106, 119]]], ["Meanwhile, minimal and maximal body weight in adulthood are also relevant; in particular, using maximum body mass index (BMI; rather than using BMI at the time of study) to assess mortality risks leads to stronger associations between excess weight and mortality [6] .", [["body", "ANATOMY", 31, 35], ["body", "ANATOMY", 104, 108], ["body", "ORGANISM_SUBDIVISION", 31, 35], ["body", "ORGANISM_SUBDIVISION", 104, 108], ["maximum body mass index", "TEST", 96, 119], ["BMI", "TEST", 121, 124], ["BMI", "TEST", 144, 147], ["study", "TEST", 163, 168], ["minimal", "OBSERVATION_MODIFIER", 11, 18]]], ["Another potentially important factor is recent body weight fluctuations [7] ; the group recommended assessing weight changes over the past 3 months.", [["body", "ANATOMY", 47, 51], ["body", "ORGANISM_SUBDIVISION", 47, 51], ["recent body weight fluctuations", "PROBLEM", 40, 71], ["weight changes", "PROBLEM", 110, 124]]], ["Assessing body weight self-monitoring behaviors is not recommended for the minimal core set of variables but may be included in the expanded set.Environment and Context: Medical History of Obesity, Basic Background Information, Quality of Life/HandicapPrevious attempts to treat obesity are also relevant: for instance, in some studies a greater number of previous weight loss attempts predicted greater weight loss [8] and some evidence suggests weight cycling may increase the likelihood of future weight gain [9] .", [["body", "ANATOMY", 10, 14], ["Obesity", "DISEASE", 189, 196], ["obesity", "DISEASE", 279, 286], ["weight loss", "DISEASE", 365, 376], ["weight loss", "DISEASE", 404, 415], ["weight gain", "DISEASE", 500, 511], ["body", "ORGANISM_SUBDIVISION", 10, 14], ["Obesity", "PROBLEM", 189, 196], ["obesity", "PROBLEM", 279, 286], ["previous weight loss", "PROBLEM", 356, 376], ["greater weight loss", "PROBLEM", 396, 415], ["weight cycling", "PROBLEM", 447, 461], ["weight gain", "PROBLEM", 500, 511], ["Obesity", "OBSERVATION", 189, 196]]], ["Data for the minimal core set should include: the number of attempts, whether the patient has undertaken individual/group behavioral interventions (pertaining to nutrition/PA/psychology), whether treatment included obesity drugs or bariatric surgery, and the maximal weight loss and weight regain as a result of these attempts.Environment and Context: Medical History of Obesity, Basic Background Information, Quality of Life/HandicapThe etiology of the patient's obesity may affect response to intervention.", [["obesity", "DISEASE", 215, 222], ["weight loss", "DISEASE", 267, 278], ["Obesity", "DISEASE", 371, 378], ["obesity", "DISEASE", 464, 471], ["patient", "ORGANISM", 82, 89], ["patient", "ORGANISM", 454, 461], ["patient", "SPECIES", 82, 89], ["patient", "SPECIES", 454, 461], ["behavioral interventions", "TREATMENT", 122, 146], ["obesity drugs", "TREATMENT", 215, 228], ["bariatric surgery", "TREATMENT", 232, 249], ["the maximal weight loss", "PROBLEM", 255, 278], ["Obesity", "PROBLEM", 371, 378], ["the patient's obesity", "PROBLEM", 450, 471], ["intervention", "TREATMENT", 495, 507], ["Obesity", "OBSERVATION", 371, 378], ["obesity", "OBSERVATION", 464, 471]]], ["In most individuals with obesity, the disease is multifactorial -that is, resulting from the complex interaction of many genetic/epigenetic and environmental factors.", [["obesity", "DISEASE", 25, 32], ["obesity", "PROBLEM", 25, 32], ["the disease", "PROBLEM", 34, 45], ["obesity", "OBSERVATION", 25, 32], ["disease", "OBSERVATION", 38, 45]]], ["However, in cases where a defined etiological factor can be identified (a genetic mutation, for example), the OBEDIS group recommends using the categories outlined in Hebebrand et al. [4] .", [["a genetic mutation", "PROBLEM", 72, 90]]], ["Trained medical staff should be able to identify syndromic obesity to either avoid the inclusion of these patients if the trial is not specific to genetic obesity or include these patients as a separate subgroup.Environment and Context: Medical History of Obesity, Basic Background Information, Quality of Life/HandicapFactors related to periconceptional and perinatal history of the patient may also affect response to obesity interventions [10] : family disease history, maternal obesity before conception, complications and health conditions during pregnancy (including maternal gestational diabetes), magnitude of gestational weight gain, preterm or term birth, and birth weight (macrosomia).", [["obesity", "DISEASE", 59, 66], ["obesity", "DISEASE", 155, 162], ["Obesity", "DISEASE", 256, 263], ["obesity", "DISEASE", 420, 427], ["maternal obesity", "DISEASE", 473, 489], ["gestational diabetes", "DISEASE", 582, 602], ["weight gain", "DISEASE", 630, 641], ["macrosomia", "DISEASE", 684, 694], ["patients", "ORGANISM", 106, 114], ["patients", "ORGANISM", 180, 188], ["patient", "ORGANISM", 384, 391], ["patients", "SPECIES", 106, 114], ["patients", "SPECIES", 180, 188], ["patient", "SPECIES", 384, 391], ["syndromic obesity", "PROBLEM", 49, 66], ["genetic obesity", "PROBLEM", 147, 162], ["Obesity", "PROBLEM", 256, 263], ["HandicapFactors", "PROBLEM", 311, 326], ["obesity interventions", "TREATMENT", 420, 441], ["maternal obesity", "PROBLEM", 473, 489], ["complications and health conditions", "PROBLEM", 509, 544], ["maternal gestational diabetes", "PROBLEM", 573, 602], ["gestational weight gain", "PROBLEM", 618, 641], ["macrosomia", "PROBLEM", 684, 694], ["Obesity", "OBSERVATION", 256, 263], ["obesity", "OBSERVATION", 482, 489]]], ["Typically, not all of this information is known to the patient, but in the minimal core set the OBEDIS group recommends assessing two particularly important factors prior to conception: parental obesity [11] and maternal history of bariatric surgery.Environment and Context: Medical History of Obesity, Basic Background Information, Quality of Life/HandicapNo standardized medical history questionnaire for obesity is in use throughout Europe.", [["obesity", "DISEASE", 195, 202], ["Obesity", "DISEASE", 294, 301], ["obesity", "DISEASE", 407, 414], ["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["parental obesity", "PROBLEM", 186, 202], ["bariatric surgery", "TREATMENT", 232, 249], ["Obesity", "PROBLEM", 294, 301], ["obesity", "PROBLEM", 407, 414], ["bariatric surgery", "OBSERVATION", 232, 249], ["Obesity", "OBSERVATION", 294, 301], ["obesity", "OBSERVATION", 407, 414]]], ["Where available, medical records (registers or electronic medical charts) may be used to corroborate the information.Environment and Context: Medical History of Obesity, Basic Background Information, Quality of Life/HandicapThe group agrees that, in the future, researchers should set about developing a standardized clinical questionnaire related to the medical history of obesity, which would be translated into different languages for use by researchers and healthcare professionals across Europe.", [["Obesity", "DISEASE", 161, 168], ["obesity", "DISEASE", 374, 381], ["Obesity", "PROBLEM", 161, 168], ["obesity", "PROBLEM", 374, 381], ["Obesity", "OBSERVATION", 161, 168], ["obesity", "OBSERVATION", 374, 381]]], ["A further endeavor -which would prove extremely valuable for research purposes -is to develop a European register of health information that included data on medical history, health status, and treatment of individuals over time.Environment and Context: Medical History of Obesity, Basic Background Information, Quality of Life/HandicapBasic Background Information Minimal core set recommended variables: \u2022 Number of years of education and country Both education and other measures of socioeconomic status, such as income, may modify intervention outcomes for certain kinds of obesity interventions.", [["Obesity", "DISEASE", 273, 280], ["obesity", "DISEASE", 577, 584], ["research purposes", "TEST", 61, 78], ["treatment", "TREATMENT", 194, 203], ["Obesity", "PROBLEM", 273, 280], ["intervention outcomes", "TREATMENT", 534, 555], ["obesity interventions", "TREATMENT", 577, 598], ["Obesity", "OBSERVATION", 273, 280], ["obesity", "OBSERVATION", 577, 584]]], ["Variations across education level were observed for the outcome suicide and self-harm when comparing a dietary/lifestyle modification program and bariatric surgery [12] ; a similar pattern was found for the outcome of sleep medication use [13] .", [["a dietary/lifestyle modification program", "TREATMENT", 101, 141], ["bariatric surgery", "TREATMENT", 146, 163], ["sleep medication", "TREATMENT", 218, 234]]], ["In higher-income countries, an inverse association tends to exist between educational attainment and obesity [14] .Environment and Context: Medical History of Obesity, Basic Background Information, Quality of Life/HandicapNumber of years of education is widely used for assessing patient educational attainment [15] and is recommended in this context.", [["obesity", "DISEASE", 101, 108], ["Obesity", "DISEASE", 159, 166], ["patient", "ORGANISM", 280, 287], ["patient", "SPECIES", 280, 287], ["obesity", "PROBLEM", 101, 108], ["Obesity", "PROBLEM", 159, 166], ["Obesity", "OBSERVATION", 159, 166]]], ["While this measure does not allow complete comparability of data between countries, the minimal core dataset would ideally specify the country along with the number of years of education.Quality of Life/HandicapMinimal core set recommended variables: \u2022 Quality of life (QoL): EQ-5D-5L health profile scores, overall self-rated health status, and index value QoL is a subjective factor that is defined by the World Health Organization (WHO) as \"an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns\" [16] .", [["EQ", "TEST", 276, 278], ["the culture", "TEST", 515, 526]]], ["Health-related QoL is a broad-ranging, multidimensional assessment of one's own health; it is an outcome measure that is frequently assessed along with handicap: \"a disadvantage for a given individual that limits or prevents the fulfillment of a role that is normal for that individual\" [17] .", [["multidimensional assessment", "TEST", 39, 66]]], ["Given that health is \"a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity\" [18] , a complete assessment of health status -especially in chronic diseases -should include both objective measures (using a biomedical framework) and subjective measures (using a psychosocial framework; e.g., QoL) [19, 20] .Quality of Life/HandicapIn the field of obesity research, health-related QoL can be an independent outcome variable for assessing the effectiveness of therapeutic strategies for obesity, complementary to the degree of weight loss and to the improvement in complications [21, 22] .", [["chronic diseases", "DISEASE", 195, 211], ["obesity", "DISEASE", 401, 408], ["obesity", "DISEASE", 539, 546], ["weight loss", "DISEASE", 579, 590], ["disease", "PROBLEM", 112, 119], ["chronic diseases", "PROBLEM", 195, 211], ["a biomedical framework)", "TREATMENT", 259, 282], ["therapeutic strategies", "TREATMENT", 512, 534], ["obesity", "PROBLEM", 539, 546], ["weight loss", "PROBLEM", 579, 590], ["complications", "PROBLEM", 617, 630], ["obesity", "OBSERVATION", 401, 408]]], ["In addition to its outcome value, QoL can also have predictive value (i.e., prediction of biopsychosocial outcomes) and discriminative value (e.g., differentiating between patients with or without other medical conditions) [23] .", [["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["predictive value", "TEST", 52, 68], ["discriminative value", "TEST", 120, 140]]], ["QoL is an important variable in economic evaluation of healthcare interventions, as it is used to calculate quality-adjusted life years, the most commonly used effect measure in cost-effectiveness analyses.Quality of Life/HandicapQoL, as a patient-reported outcome, is assessed using self-administered questionnaires.", [["patient", "ORGANISM", 240, 247], ["patient", "SPECIES", 240, 247], ["economic evaluation", "TEST", 32, 51], ["healthcare interventions", "TREATMENT", 55, 79], ["cost-effectiveness analyses", "TEST", 178, 205], ["HandicapQoL", "TREATMENT", 222, 233]]], ["Many questionnaires have been validated in the field of obesity [for reviews see 24, 25] .", [["obesity", "DISEASE", 56, 63], ["obesity", "PROBLEM", 56, 63]]], ["The OBEDIS group used several criteria (consistent with the general criteria above) to choose the most suitable QoL questionnaire: type of concept assessed (i.e., assessment of QoL, but not symptoms/functional status or handicap), brevity, convergent validity, cross-cultural validation (particularly important in this European work), and copyright (including no or limited fees for use).", [["symptoms", "PROBLEM", 190, 198]]], ["The European group agrees that the EQ-5D-5L satisfies the greatest number of criteria for suitability of widespread use -especially cross-cultural validation, minimal number of items, and free copyright.", [["cross-cultural validation", "TEST", 132, 157], ["minimal", "OBSERVATION_MODIFIER", 159, 166]]], ["The questionnaire includes five dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression, and an overall visual analog scale.", [["pain", "DISEASE", 83, 87], ["anxiety", "DISEASE", 100, 107], ["depression", "DISEASE", 108, 118], ["self-care", "TREATMENT", 54, 63], ["pain/discomfort", "PROBLEM", 83, 98], ["anxiety", "PROBLEM", 100, 107], ["depression", "PROBLEM", 108, 118], ["an overall visual analog scale", "TEST", 124, 154]]], ["Importantly, it has been validated in patients with obesity and who have undergone obesity surgery, and is sensitive to change [28, 29] .", [["obesity", "DISEASE", 52, 59], ["obesity", "DISEASE", 83, 90], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["obesity", "PROBLEM", 52, 59], ["obesity surgery", "TREATMENT", 83, 98], ["obesity", "OBSERVATION", 52, 59], ["obesity", "OBSERVATION_MODIFIER", 83, 90], ["surgery", "OBSERVATION", 91, 98]]], ["In cases where the main goal of the study is related to QoL, however, an additional obesity-specific measure may be useful to assess this parameter in more depth.Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesWhile human behaviors vary substantially and occur in a complex interplay with an individual's social and physical environments, characterization of specific behavior patterns is useful for predicting clinical outcomes.", [["obesity", "DISEASE", 84, 91], ["human", "ORGANISM", 282, 287], ["human", "SPECIES", 282, 287], ["human", "SPECIES", 282, 287], ["the study", "TEST", 32, 41], ["an additional obesity", "PROBLEM", 70, 91], ["main", "OBSERVATION_MODIFIER", 19, 23], ["obesity", "OBSERVATION", 84, 91], ["more depth", "OBSERVATION_MODIFIER", 151, 161]]], ["Discussed in this section are behaviors and lifestyle factors that affect energy balance, weight loss, and/or weight maintenance.", [["weight loss", "DISEASE", 90, 101], ["weight loss", "PROBLEM", 90, 101]]], ["Eating behavior, defined as an individual's food and beverage consumption and habitual eating patterns [30] , is a complex and important modifiable behavior that directly affects weight and nutritional status through the lifespan.", [["Eating behavior", "DISEASE", 0, 15], ["beverage", "ORGANISM_SUBDIVISION", 53, 61]]], ["In obesity, assessment of eating behavior is necessary given the dual burden of disease and potential undernutrition.", [["obesity", "DISEASE", 3, 10], ["eating behavior", "DISEASE", 26, 41], ["undernutrition", "DISEASE", 102, 116], ["obesity", "PROBLEM", 3, 10], ["eating behavior", "PROBLEM", 26, 41], ["the dual burden of disease", "PROBLEM", 61, 87], ["potential undernutrition", "PROBLEM", 92, 116], ["obesity", "OBSERVATION", 3, 10], ["disease", "OBSERVATION", 80, 87], ["undernutrition", "OBSERVATION", 102, 116]]], ["Obesity interventions that target eating behavior mostly aim to decrease energy intake to induce negative energy balance -a necessary condition for weight loss.", [["Obesity", "DISEASE", 0, 7], ["eating behavior", "DISEASE", 34, 49], ["weight loss", "DISEASE", 148, 159], ["Obesity interventions", "TREATMENT", 0, 21], ["weight loss", "PROBLEM", 148, 159]]], ["Modification of dietary intake is a well-known requirement for successful treatment of adult obesity [31] .", [["obesity", "DISEASE", 93, 100], ["adult obesity", "PROBLEM", 87, 100], ["obesity", "OBSERVATION", 93, 100]]], ["The benefits of dietary interventions for obesity go beyond weight loss, since a body of evidence shows that changes in dietary quality per se may decrease the risk of various comorbid health conditions and even reduce all-cause mortality [32, 33] .", [["obesity", "DISEASE", 42, 49], ["weight loss", "DISEASE", 60, 71], ["dietary interventions", "TREATMENT", 16, 37], ["obesity", "PROBLEM", 42, 49], ["weight loss", "PROBLEM", 60, 71], ["various comorbid health conditions", "PROBLEM", 168, 202]]], ["Dietary intake constitutes a critical factor that interfaces with genetic heterogeneity and metabolic phenotypes, resulting in different health outcomes; for example, dietary fat intake can interact with genotype and/or phenotype to affect the risk of obesity [34, 35] .", [["fat", "ANATOMY", 175, 178], ["obesity", "DISEASE", 252, 259], ["fat", "TISSUE", 175, 178], ["genetic heterogeneity", "PROBLEM", 66, 87], ["metabolic phenotypes", "PROBLEM", 92, 112], ["obesity", "PROBLEM", 252, 259], ["metabolic phenotypes", "OBSERVATION", 92, 112], ["obesity", "OBSERVATION", 252, 259]]], ["In addition, dietary fatty acid exposure can also interact with sex and genes together to predict the development of the metabolic syndrome [36, 37] .Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesMany dietitians and nutrition scientists recognize the need to move from populationbased nutrition to personalized subgroup-based nutrition [38] .", [["fatty acid", "CHEMICAL", 21, 31], ["metabolic syndrome", "DISEASE", 121, 139], ["fatty acid", "CHEMICAL", 21, 31], ["dietary fatty acid", "SIMPLE_CHEMICAL", 13, 31], ["dietary fatty acid exposure", "TREATMENT", 13, 40], ["the metabolic syndrome", "PROBLEM", 117, 139], ["populationbased nutrition", "TREATMENT", 337, 362], ["metabolic syndrome", "OBSERVATION", 121, 139]]], ["Obesity is highly heterogeneous, so personalized or targeted interventions are warranted [39] but a major challenge is to determine which diet-related variables stratify individuals into groups that will respond to a given intervention.Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesFor all adult trials on obesity interventions, regardless of whether they focus on diet, the OBEDIS group recommends assessing both dietary intake and overall diet quality.", [["Obesity", "DISEASE", 0, 7], ["obesity", "DISEASE", 374, 381], ["Obesity", "PROBLEM", 0, 7], ["targeted interventions", "TREATMENT", 52, 74], ["a given intervention", "TREATMENT", 215, 235], ["obesity interventions", "TREATMENT", 374, 395], ["highly", "OBSERVATION_MODIFIER", 11, 17], ["heterogeneous", "OBSERVATION_MODIFIER", 18, 31]]], ["The OBEDIS group acknowledges, however, the particular difficulty of identifying dietary assessment tools applicable to the broad range of cultural and geographic groups across Europe.", [["dietary assessment tools", "TEST", 81, 105]]], ["While obtaining data on energy, and macronutrient and micronutrient intake is a major objective, the various assessment tools that exist are each appropriate for a specific country or region.Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesDietary intake is a detailed account of which foods and beverages are consumed, and in what quantities, during a set period of time.", [["the various assessment tools", "TEST", 97, 125]]], ["Initiatives exist (beyond the scope of these guidelines) that propose the most appropriate dietary assessment method in order to collect good quality dietary data, depending on the study objectives.", [["these guidelines", "TREATMENT", 39, 55], ["the study objectives", "TEST", 177, 197]]], ["A 3-day weighed food record is appropriate for detailed studies where greater insights and links to biological readouts are required; such an assessment may capture short-term changes as a result of intervention.", [["detailed studies", "TEST", 47, 63], ["biological readouts", "TEST", 100, 119], ["an assessment", "TEST", 139, 152], ["short-term changes", "PROBLEM", 165, 183], ["intervention", "TREATMENT", 199, 211]]], ["In the expanded set of variables (or depending on the study question) the experts recommend the use of a 3-day weighed food record, which is more suitable for detecting the effects of an intervention.", [["the study", "TEST", 50, 59], ["an intervention", "TREATMENT", 184, 199]]], ["Reviews like Dao et al. [41] can help researchers select and implement the most appropriate dietary assessment method(s) to collect highquality dietary data.Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesThe group also recommends in the minimal core set an assessment of dietary quality, while acknowledging that the healthy eating indices applicable in Europe are linked with country-specific dietary guidelines and guidelines for PA.", [["PA", "GENE_OR_GENE_PRODUCT", 499, 501], ["an assessment", "TEST", 321, 334]]], ["The group also notes that in some contexts, it is important to use additional measures for tracking specific components of diet: for example, fiber intake or sugar-sweetened beverage consumption or the consumption of processed food.Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesThe group agrees the nutrition community should invest in the design and validation of assessment tools for dietary intake (included validated smartphone apps) that improve upon the ones currently available.", [["sugar", "CHEMICAL", 158, 163], ["sugar", "SIMPLE_CHEMICAL", 158, 163], ["additional measures", "TREATMENT", 67, 86], ["assessment tools", "TEST", 433, 449]]], ["Dietary intake assessment is highly challenged by the lack of accurate biomarkers, particularly in relation to energy intake and macronutrient intake, whilst micronutrient status may be more feasible.Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesBiomarkers of dietary compliance were discussed by the OBEDIS experts.", [["Dietary intake assessment", "TEST", 0, 25]]], ["Such biomarkers are required to provide subjective insight in relation to habitual diet, as well as compliance to dietary interventions.", [["dietary interventions", "TREATMENT", 114, 135]]], ["However, those currently available have inherent limitations; for example, serum fatty acids only provide a short-term and limited assessment/reflection of dietary fatty acid intake.", [["serum", "ANATOMY", 75, 80], ["fatty acids", "CHEMICAL", 81, 92], ["fatty acid", "CHEMICAL", 164, 174], ["fatty acids", "CHEMICAL", 81, 92], ["fatty acid", "CHEMICAL", 164, 174], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["fatty acids", "SIMPLE_CHEMICAL", 81, 92], ["dietary fatty acid", "SIMPLE_CHEMICAL", 156, 174], ["serum fatty acids", "TEST", 75, 92], ["limited assessment", "TEST", 123, 141], ["dietary fatty acid intake", "PROBLEM", 156, 181]]], ["These biomarkers are not recommended for the minimal core set, but the experts note the critical importance for trials with free-living interventions of having an objective measure of compliance to identify nonresponse due to either noncompliance or lack of biological response.Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesWhen faced with stress, individuals exhibit differences in eating patterns: approximately 40% increase and 40% decrease their energy intake, while around 20% do not change [44] .", [["These biomarkers", "TEST", 0, 16], ["free-living interventions", "TREATMENT", 124, 149]]], ["Regardless of whether overall energy intake is increased, however, stress begets a shift toward choosing foods higher in sugar and fat.", [["fat", "ANATOMY", 131, 134], ["sugar", "CHEMICAL", 121, 126], ["sugar", "SIMPLE_CHEMICAL", 121, 126], ["fat", "TISSUE", 131, 134], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["fat", "ANATOMY", 131, 134]]], ["Hyper-palatable foods may act as a distress coping mechanism, particularly in those who have previously associated intake with relief [45] .", [["a distress coping mechanism", "PROBLEM", 33, 60]]], ["Dieting constitutes a risk factor for emotional eating, since stress and negative affect can be consequences of energy restriction, and paradoxically, may lead to food-related coping strategies [46] .", [["emotional eating", "PROBLEM", 38, 54], ["stress and negative affect", "PROBLEM", 62, 88]]], ["There may also be a biological basis for emotional eating, as individuals who exhibit this pattern demonstrate a blunted hypothalamic-pituitary-adrenal axis response to cortisol that leads to increased food intake [47] .Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesEmotional eating is associated with current and prospective weight, and interacts with perceived stress, negative life events, and short sleep duration [47] .", [["cortisol", "CHEMICAL", 169, 177], ["Emotional eating", "DISEASE", 334, 350], ["cortisol", "CHEMICAL", 169, 177], ["pituitary", "ORGAN", 134, 143], ["adrenal", "ORGAN", 144, 151], ["cortisol", "SIMPLE_CHEMICAL", 169, 177], ["a blunted hypothalamic-pituitary-adrenal axis response", "PROBLEM", 111, 165], ["cortisol", "TREATMENT", 169, 177], ["increased food intake", "PROBLEM", 192, 213], ["pituitary", "ANATOMY", 134, 143], ["adrenal axis", "ANATOMY", 144, 156]]], ["Greater weight loss success has been associated with decreased emotional eating score during a behavioral weight loss program [48] .", [["weight loss", "DISEASE", 8, 19], ["decreased emotional eating", "DISEASE", 53, 79], ["weight loss", "DISEASE", 106, 117], ["Greater weight loss success", "PROBLEM", 0, 27], ["decreased emotional eating score", "PROBLEM", 53, 85], ["a behavioral weight loss program", "PROBLEM", 93, 125]]], ["Eating in response to distress may also influence the timing of meal consumption -and because recent studies have indicated that meal timing in relation to sleep phase is an important factor for weight regulation, clinical trials should capture individuals' tendency toward emotional eating.", [["meal", "ORGANISM_SUBDIVISION", 64, 68], ["distress", "PROBLEM", 22, 30], ["recent studies", "TEST", 94, 108], ["sleep phase", "PROBLEM", 156, 167], ["weight regulation", "TREATMENT", 195, 212], ["clinical trials", "TREATMENT", 214, 229]]], ["The recommended tool for assessing these behaviors in the OBEDIS minimal core set is the Emotional PA is any bodily movement produced by the contraction of skeletal muscles that results in energy expenditure (EE) above resting levels [50] , while exercise is a subtype of PA: one that is planned, structured, repetitive, and designed to improve or maintain physical fitness, physical performance, or health [50] .Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesPA helps adjust energy balance in those with obesity.", [["skeletal muscles", "ANATOMY", 156, 172], ["EE", "CHEMICAL", 209, 211], ["obesity", "DISEASE", 572, 579], ["skeletal muscles", "TISSUE", 156, 172], ["PA", "GENE_OR_GENE_PRODUCT", 272, 274], ["resting levels", "TEST", 219, 233], ["obesity", "PROBLEM", 572, 579], ["skeletal muscles", "ANATOMY", 156, 172], ["obesity", "OBSERVATION", 572, 579]]], ["Yet when diet is held constant, individuals in different BMI categories may experience different effects of PA on weight [51] .", [["PA", "GENE_OR_GENE_PRODUCT", 108, 110], ["PA on weight", "TEST", 108, 120]]], ["Overall, studies report inconsistent results on how increased PA (including exercise training) affects weight loss; however, an inverse association has been shown between PA and longterm weight gain [52] , although it is recognized that relatively high levels of PA might be required.", [["weight loss", "DISEASE", 103, 114], ["weight gain", "DISEASE", 187, 198], ["PA", "GENE_OR_GENE_PRODUCT", 62, 64], ["PA", "GENE_OR_GENE_PRODUCT", 171, 173], ["PA", "GENE_OR_GENE_PRODUCT", 263, 265], ["exercise training", "TREATMENT", 76, 93], ["weight loss", "PROBLEM", 103, 114]]], ["There is general agreement that a major benefit of PA in subjects with obesity is prevention of weight regain after weight loss [53] .Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesStudies show PA attenuates many health risks that are associated with overweight or obesity, and importantly, numerous health benefits result from increased PA even with no weight loss or only modest weight loss [54] .", [["obesity", "DISEASE", 71, 78], ["weight regain", "DISEASE", 96, 109], ["weight loss", "DISEASE", 116, 127], ["overweight", "DISEASE", 318, 328], ["obesity", "DISEASE", 332, 339], ["weight loss", "DISEASE", 421, 432], ["weight loss", "DISEASE", 448, 459], ["PA", "GENE_OR_GENE_PRODUCT", 51, 53], ["PA", "GENE_OR_GENE_PRODUCT", 261, 263], ["PA", "GENE_OR_GENE_PRODUCT", 405, 407], ["obesity", "PROBLEM", 71, 78], ["weight loss", "PROBLEM", 116, 127], ["obesity", "PROBLEM", 332, 339], ["increased PA", "PROBLEM", 395, 407], ["weight loss", "PROBLEM", 421, 432], ["modest weight loss", "PROBLEM", 441, 459], ["obesity", "OBSERVATION", 332, 339]]], ["Current evidence indicates that PA, at levels that are feasible to perform in subjects with overweight or obesity, only results in modest weight loss [52] .Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesSB is defined as any waking behavior characterized by an EE equal to or lower than 1.5 metabolic equivalent tasks (or MET, with 1 MET representing EE by a subject at rest, sitting); this includes behaviors carried out while sitting, reclining, or lying [55] .", [["overweight", "DISEASE", 92, 102], ["obesity", "DISEASE", 106, 113], ["weight loss", "DISEASE", 138, 149], ["EE", "CHEMICAL", 327, 329], ["EE", "CHEMICAL", 417, 419], ["PA", "GENE_OR_GENE_PRODUCT", 32, 34], ["obesity", "PROBLEM", 106, 113], ["modest weight loss", "PROBLEM", 131, 149]]], ["Independent of PA levels, SB is associated with a higher risk of cardiometabolic disease and other complications.", [["SB", "CHEMICAL", 26, 28], ["cardiometabolic disease", "DISEASE", 65, 88], ["PA", "GENE_OR_GENE_PRODUCT", 15, 17], ["cardiometabolic disease", "PROBLEM", 65, 88], ["other complications", "PROBLEM", 93, 112], ["cardiometabolic disease", "OBSERVATION", 65, 88]]], ["Decreasing SB is promoted in parallel with interventions that aim to increase habitual PA [55] .Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesThe OBEDIS group agrees on the importance of including both objective and subjective measures of PA and SB in each clinical trial.", [["SB", "CHEMICAL", 11, 13], ["PA", "GENE_OR_GENE_PRODUCT", 87, 89], ["PA", "GENE_OR_GENE_PRODUCT", 307, 309], ["interventions", "TREATMENT", 43, 56], ["PA and SB", "TREATMENT", 307, 316]]], ["Objective data on both of these can be gathered most commonly using an accelerometer -a type of movement sensor that is feasibly used in large-scale studies to quantify PA intensity and duration as well as SB duration, including breaks in sedentary time, with minimal inconvenience to the participant.", [["PA", "GENE_OR_GENE_PRODUCT", 169, 171], ["participant", "SPECIES", 289, 300], ["Objective data", "TEST", 0, 14], ["movement sensor", "PROBLEM", 96, 111], ["large-scale studies", "TEST", 137, 156]]], ["The group recommends this method while noting several limitations: when worn on the hip, accelerometers typically miss upper body movement; neither do they provide data on body posture nor data in cycling or aquatic activities [56] .", [["hip", "ANATOMY", 84, 87], ["body", "ANATOMY", 125, 129], ["body", "ANATOMY", 172, 176], ["hip", "ORGANISM_SUBDIVISION", 84, 87], ["upper body", "ORGANISM_SUBDIVISION", 119, 129], ["body", "ORGANISM_SUBDIVISION", 172, 176], ["this method", "TREATMENT", 21, 32], ["body posture", "TEST", 172, 184], ["hip", "ANATOMY", 84, 87]]], ["The required accelerometer data comprises PA level as well as week day time in SB and weekend day time in SB.", [["PA", "GENE_OR_GENE_PRODUCT", 42, 44], ["accelerometer data", "TEST", 13, 31], ["PA level", "TEST", 42, 50], ["SB", "ANATOMY", 106, 108]]], ["A subjective measure of PA and SB is also needed to add important information, such as the specific types of activities performed, the perceived level of exertion during exercise, and additional information about the context (place, time) of the PA.", [["PA", "GENE_OR_GENE_PRODUCT", 24, 26], ["PA", "GENE_OR_GENE_PRODUCT", 246, 248]]], ["This widely used instrument is available in multiple languages and has ten questions that focus on moderate-to-vigorous PA, ranging from common activities such as stair climbing and walking to specific leisure activities [57] .Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesIn addition to PA and SB, physical fitness is an important patient characteristic that may also relate to outcomes of the intervention(s).", [["PA", "GENE_OR_GENE_PRODUCT", 120, 122], ["patient", "ORGANISM", 400, 407], ["patient", "SPECIES", 400, 407], ["the intervention", "TREATMENT", 459, 475]]], ["Physical fitness is a physiological attribute determining a person's ability to perform muscle-powered work, and it has been defined as \"the ability to carry out daily tasks with vigor and alertness, without undue fatigue, and with ample energy to enjoy leisure-time pursuits and respond to emergencies\" [52] .", [["muscle", "ANATOMY", 88, 94], ["fatigue", "DISEASE", 214, 221], ["muscle", "ORGAN", 88, 94], ["person", "SPECIES", 60, 66], ["vigor and alertness", "PROBLEM", 179, 198], ["undue fatigue", "PROBLEM", 208, 221]]], ["One major component of physical fitness is CRF.", [["CRF", "DISEASE", 43, 46], ["CRF", "GENE_OR_GENE_PRODUCT", 43, 46], ["CRF", "PROBLEM", 43, 46], ["major", "OBSERVATION_MODIFIER", 4, 9], ["component", "OBSERVATION_MODIFIER", 10, 19], ["physical fitness", "OBSERVATION", 23, 39], ["CRF", "OBSERVATION", 43, 46]]], ["High CRF is associated with greater longevity and reduced cardiovascular risk in all BMI categories [58, 59] .Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesWhile the usual measure of CRF is maximal oxygen uptake (VO 2 max, or maximal aerobic power) during an exercise test [60] , requirements for specialized equipment and expertise render it impractical for the minimal core set.", [["cardiovascular", "ANATOMY", 58, 72], ["CRF", "DISEASE", 5, 8], ["CRF", "DISEASE", 251, 254], ["oxygen", "CHEMICAL", 266, 272], ["oxygen", "CHEMICAL", 266, 272], ["CRF", "GENE_OR_GENE_PRODUCT", 5, 8], ["oxygen", "SIMPLE_CHEMICAL", 266, 272], ["High CRF", "PROBLEM", 0, 8], ["greater longevity", "PROBLEM", 28, 45], ["reduced cardiovascular risk", "PROBLEM", 50, 77], ["CRF", "PROBLEM", 251, 254], ["maximal oxygen uptake", "PROBLEM", 258, 279], ["an exercise test", "TEST", 324, 340], ["specialized equipment", "TREATMENT", 365, 386], ["CRF", "OBSERVATION", 5, 8], ["greater", "OBSERVATION_MODIFIER", 28, 35], ["longevity", "OBSERVATION_MODIFIER", 36, 45], ["reduced", "OBSERVATION_MODIFIER", 50, 57], ["cardiovascular risk", "OBSERVATION", 58, 77]]], ["The OBEDIS experts instead recommend the use of the 6-min walk test [61] , a field submaximal exercise test for assessment of physical function that requires a 30-m hallway and no specialized training or equipment.", [["a field submaximal exercise test", "TEST", 75, 107]]], ["The test measures the distance an individual can quickly walk on a flat, hard surface over a period of 6 min, and it can be used to predict VO 2 max [62, 63] .", [["surface", "ANATOMY", 78, 85], ["The test", "TEST", 0, 8]]], ["The expanded set, however, may include the Chester step test as a measure of CRF: in this validated assessment of aerobic capacity, the participant is asked to step on and off an elevated platform in time with an audible metronome beat [64] .Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesAnother important component of physical fitness is muscular fitness.", [["muscular", "ANATOMY", 407, 415], ["CRF", "DISEASE", 77, 80], ["CRF", "GENE_OR_GENE_PRODUCT", 77, 80], ["muscular", "ORGAN", 407, 415], ["participant", "SPECIES", 136, 147], ["the Chester step test", "TEST", 39, 60], ["CRF", "PROBLEM", 77, 80], ["this validated assessment", "TEST", 85, 110], ["aerobic capacity", "PROBLEM", 114, 130], ["an elevated platform", "PROBLEM", 176, 196], ["an audible metronome beat", "PROBLEM", 210, 235], ["Stress and Other Psychological Variables", "PROBLEM", 316, 356], ["muscular fitness", "PROBLEM", 407, 423], ["muscular fitness", "OBSERVATION", 407, 423]]], ["A measure of muscle strength, as an important component of muscular fitness, is therefore also recommended for the minimal core set, since the evidence in aggregate shows that muscle strength is associated with reduced mortality in all BMI categories and that resistance training (designed to increase muscle strength), even without weight loss, improves health risk [53] .", [["muscle", "ANATOMY", 13, 19], ["muscular", "ANATOMY", 59, 67], ["muscle", "ANATOMY", 176, 182], ["muscle", "ANATOMY", 302, 308], ["weight loss", "DISEASE", 333, 344], ["muscle", "ORGAN", 13, 19], ["muscle", "ORGAN", 176, 182], ["muscle", "ORGAN", 302, 308], ["muscular fitness", "PROBLEM", 59, 75], ["muscle strength", "PROBLEM", 176, 191], ["reduced mortality in all BMI categories", "PROBLEM", 211, 250], ["resistance training", "TREATMENT", 260, 279], ["weight loss", "PROBLEM", 333, 344], ["muscle", "ANATOMY", 13, 19], ["strength", "OBSERVATION", 20, 28], ["muscle", "ANATOMY", 176, 182]]], ["More importantly, weight loss treatments may be associated with decreases in muscle strength, especially if the treatment does not include exercise.", [["muscle", "ANATOMY", 77, 83], ["weight loss", "DISEASE", 18, 29], ["muscle", "ORGAN", 77, 83], ["weight loss treatments", "TREATMENT", 18, 40], ["decreases in muscle strength", "PROBLEM", 64, 92], ["muscle", "ANATOMY", 77, 83]]], ["The Southampton grip-strength measurement is chosen for this purpose [65] .Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesGiven these recommendations, the group notes an added value of the assessment methods in the minimal core set: some of the chosen methods are useful for assessing several variables.", [["The Southampton grip-strength measurement", "TEST", 0, 41], ["the assessment methods", "TEST", 252, 274]]], ["This is the case for the use of accelerometers to assess both PA and sleep behaviors; grip strength to measure both muscular fitness and (in the expanded set) sarcopenia; and the 6-min walk test to predict CRF.Lifestyle and Behavior: Dietary Intake, PA and Sedentary Behavior, Sleep, Stress and Other Psychological VariablesHabitual PA, SB, and physical fitness all must be measured at baseline (before any exercise training or intervention occurs) and at the end of an intervention; in trials longer than 6 months, these variables should be measured every 6 months.SleepMinimal core set recommended variables: \u2022 Sleep duration and timing \u2022 Presence of sleep apnea: STOP-BANG Expanded set recommended variables: \u2022 Sleep duration and timing: accelerometry Sleep is influenced by the circadian clock -a self-sustained molecular oscillator, which aligns endogenous rhythms with daily exogenous signals to coordinate metabolism and behavior [66] .", [["muscular", "ANATOMY", 116, 124], ["sarcopenia", "DISEASE", 159, 169], ["CRF", "DISEASE", 206, 209], ["sleep apnea", "DISEASE", 653, 664], ["CRF", "GENE_OR_GENE_PRODUCT", 206, 209], ["both PA and sleep behaviors", "PROBLEM", 57, 84], ["grip strength", "TEST", 86, 99], ["both muscular fitness", "PROBLEM", 111, 132], ["sarcopenia", "PROBLEM", 159, 169], ["walk test", "TEST", 185, 194], ["CRF", "PROBLEM", 206, 209], ["any exercise training", "TREATMENT", 403, 424], ["intervention", "TREATMENT", 428, 440], ["an intervention", "TREATMENT", 467, 482], ["sleep apnea", "PROBLEM", 653, 664], ["a self-sustained molecular oscillator", "TREATMENT", 799, 836], ["muscular", "ANATOMY", 116, 124], ["sarcopenia", "OBSERVATION", 159, 169]]], ["Ample data show mistimed sleep contributes to \"chronodisruption\" [67] or \"circadian-phase misalignment\" [68] and promotes weight-related pathologies [69, 70] .SleepCommonly, sleep disruption occurs because of atypical work schedules: night shift work patterns are associated with the risk of overweight/obesity -especially abdominal obesity -and permanent night shifts appear to confer a higher risk than rotating night shifts [71] .", [["abdominal", "ANATOMY", 323, 332], ["chronodisruption", "DISEASE", 47, 63], ["sleep disruption", "DISEASE", 174, 190], ["overweight", "DISEASE", 292, 302], ["obesity", "DISEASE", 303, 310], ["abdominal obesity", "DISEASE", 323, 340], ["abdominal", "ORGANISM_SUBDIVISION", 323, 332], ["Ample data", "TEST", 0, 10], ["mistimed sleep", "PROBLEM", 16, 30], ["\"chronodisruption\"", "PROBLEM", 46, 64], ["sleep disruption", "PROBLEM", 174, 190], ["overweight/obesity", "PROBLEM", 292, 310], ["abdominal obesity", "PROBLEM", 323, 340], ["obesity", "OBSERVATION", 303, 310], ["abdominal", "ANATOMY", 323, 332], ["obesity", "OBSERVATION", 333, 340]]], ["A lesser degree of chronodisruption called \"social jetlag,\" however, can result from social activities and has been associated with an increased BMI [72] .", [["chronodisruption", "DISEASE", 19, 35], ["an increased BMI", "PROBLEM", 132, 148], ["lesser", "OBSERVATION_MODIFIER", 2, 8], ["degree", "OBSERVATION_MODIFIER", 9, 15], ["chronodisruption", "OBSERVATION", 19, 35]]], ["Although the Munich Chronotype Questionnaire (MCTQ) is sometimes used for these purposes, the OBEDIS group recommends a shorter custom assessment (see supplementary material) for patients to self-administer.", [["patients", "ORGANISM", 179, 187], ["patients", "SPECIES", 179, 187], ["a shorter custom assessment", "TEST", 118, 145]]], ["Quantitative sleep data acquired from an accelerometer may be used (as part of the expanded set) in trials where resources allow.SleepProlonged wakefulness and sleep deprivation are hallmarks of modern lifestyles.", [["Quantitative sleep data", "PROBLEM", 0, 23], ["SleepProlonged wakefulness", "PROBLEM", 129, 155], ["sleep deprivation", "PROBLEM", 160, 177]]], ["Across cross-sectional and longitudinal studies, individuals' sleep duration shows a somewhat in consistent pattern of association with obesity [73] .", [["obesity", "DISEASE", 136, 143], ["longitudinal studies", "TEST", 27, 47], ["obesity", "PROBLEM", 136, 143], ["obesity", "OBSERVATION", 136, 143]]], ["Experimental data suggest that sleep restriction increases food intake and alters EE [74] .", [["EE", "CHEMICAL", 82, 84], ["Experimental data", "TEST", 0, 17], ["sleep restriction", "PROBLEM", 31, 48]]], ["The OBEDIS group advocates for a basic assessment of sleep duration in the minimal core set.", [["a basic assessment", "TEST", 31, 49], ["sleep duration", "PROBLEM", 53, 67]]], ["Specific questionnaires exist that capture various dimensions of sleep, including sleep duration, but many are subject to copyright restrictions and/or lack validated translations into different languages.", [["Specific questionnaires", "TEST", 0, 23]]], ["For assessing sleep duration, the OBEDIS group recommends a custom, self-administered questionnaire (shown below).SleepIn individuals with obesity, disordered breathing during sleep is prevalent.", [["obesity", "DISEASE", 139, 146], ["obesity", "PROBLEM", 139, 146], ["disordered breathing", "PROBLEM", 148, 168], ["obesity", "OBSERVATION", 139, 146]]], ["Well-documented is the idea that obstructive sleep apnea (OSA) overlaps with obesity-related risks [75] and impacts metabolic risk [76] .", [["obstructive sleep apnea", "DISEASE", 33, 56], ["OSA", "DISEASE", 58, 61], ["obesity", "DISEASE", 77, 84], ["obstructive sleep apnea (OSA)", "PROBLEM", 33, 62], ["obesity", "PROBLEM", 77, 84], ["obstructive", "OBSERVATION_MODIFIER", 33, 44], ["sleep apnea", "OBSERVATION", 45, 56], ["obesity", "OBSERVATION", 77, 84]]], ["Use of the OSA therapy continuous positive airway pressure (CPAP) may also change energy balance or metabolism [77] , with potentially positive effects on glycemic control [78] .", [["airway", "ANATOMY", 43, 49], ["OSA", "DISEASE", 11, 14], ["airway", "MULTI-TISSUE_STRUCTURE", 43, 49], ["the OSA therapy", "TREATMENT", 7, 22], ["continuous positive airway pressure (CPAP", "TREATMENT", 23, 64], ["glycemic control", "TREATMENT", 155, 171], ["airway pressure", "OBSERVATION", 43, 58]]], ["The presence of OSA and the use of CPAP should therefore be assessed.", [["OSA", "DISEASE", 16, 19], ["CPAP", "CHEMICAL", 35, 39], ["OSA", "PROBLEM", 16, 19], ["CPAP", "TREATMENT", 35, 39], ["OSA", "OBSERVATION", 16, 19]]], ["While the gold-standard objective measure of OSA is the apnea-hypopnea index with nocturnal polysomnography, the OBEDIS group recommends subjective assessment using a brief questionnaire called the STOP-BANG [79] .", [["OSA", "DISEASE", 45, 48], ["apnea-hypopnea", "DISEASE", 56, 70], ["OSA", "PROBLEM", 45, 48], ["the apnea-hypopnea index", "PROBLEM", 52, 76], ["nocturnal polysomnography", "TEST", 82, 107], ["subjective assessment", "TEST", 137, 158], ["OSA", "OBSERVATION", 45, 48]]], ["This questionnaire, which is freely available, was created to screen for symptoms of OSA in surgical patients and in all individuals.", [["OSA", "DISEASE", 85, 88], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["symptoms", "PROBLEM", 73, 81], ["OSA", "PROBLEM", 85, 88], ["OSA", "OBSERVATION", 85, 88]]], ["It can be completed in approximatively 1 min and has good predictive ability for mild, moderate, and severe OSA [80] .", [["OSA", "DISEASE", 108, 111], ["mild, moderate, and severe OSA", "PROBLEM", 81, 111], ["mild", "OBSERVATION_MODIFIER", 81, 85], ["moderate", "OBSERVATION_MODIFIER", 87, 95], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["OSA", "OBSERVATION", 108, 111]]], ["CPAP use may be assessed using a custom questionnaire item.Stress and Other Psychological VariablesMinimal core set recommended variables: \u2022 Perceived stress: Perceived Stress Scale (PSS) Previous research has indicated the necessity for simultaneous assessment of sleep and stress in trials on obesity [81] .", [["obesity", "DISEASE", 295, 302], ["CPAP", "CHEMICAL", 0, 4], ["CPAP", "TREATMENT", 0, 4], ["simultaneous assessment", "TEST", 238, 261], ["sleep", "PROBLEM", 265, 270], ["obesity", "PROBLEM", 295, 302]]], ["Poor sleep and emotional stress are predictors of incident obesity and may have an additive role [82] .", [["obesity", "DISEASE", 59, 66], ["Poor sleep", "PROBLEM", 0, 10], ["emotional stress", "PROBLEM", 15, 31], ["incident obesity", "PROBLEM", 50, 66]]], ["Not only does perceived stress associate with BMI, waist circumference, and serum triglyceride level [83] , but also, those with poor sleep and incident obesity appear to have the greatest emotional stress and the shortest subjective sleep duration [84] .Stress and Other Psychological VariablesPerceived stress is the degree to which situations in life are appraised as stressful by the individual.", [["serum", "ANATOMY", 76, 81], ["triglyceride", "CHEMICAL", 82, 94], ["obesity", "DISEASE", 153, 160], ["triglyceride", "CHEMICAL", 82, 94], ["waist", "ORGANISM_SUBDIVISION", 51, 56], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["triglyceride", "SIMPLE_CHEMICAL", 82, 94], ["BMI", "TEST", 46, 49], ["waist circumference", "TEST", 51, 70], ["serum triglyceride level", "TEST", 76, 100], ["poor sleep and incident obesity", "PROBLEM", 129, 160]]], ["The expert group recommends subjective assessment of individuals' stress levels via the PSS [85] .", [["subjective assessment", "TEST", 28, 49], ["stress levels", "TEST", 66, 79], ["the PSS", "TEST", 84, 91]]], ["As the most widely used psychological instrument for measuring the perception of stress, the scale includes direct queries about a patient's current levels of experienced stress.", [["patient", "ORGANISM", 131, 138], ["patient", "SPECIES", 131, 138], ["psychological instrument", "TREATMENT", 24, 48], ["stress", "PROBLEM", 81, 87], ["stress", "PROBLEM", 171, 177]]], ["An additional advantage of the tool is the availability of validated versions in many languages.Subject Characteristics: Anthropometry, Body Composition, EE, and Hormonal StatusAll trials involving individuals with obesity include measures of participants' characteristics, including anthropometric measures, body composition, and/or EE.", [["body", "ANATOMY", 309, 313], ["obesity", "DISEASE", 215, 222], ["EE", "CHEMICAL", 334, 336], ["body", "ORGANISM_SUBDIVISION", 309, 313], ["participants", "SPECIES", 243, 255], ["obesity", "PROBLEM", 215, 222], ["anthropometric measures", "TEST", 284, 307], ["body composition", "TEST", 309, 325]]], ["Aspects of hormonal status are also important characteristics to consider in trials, as detailed below.Subject Characteristics: Anthropometry, Body Composition, EE, and Hormonal StatusAnthropometry, Body Composition, and EE Minimal core set recommended variables: \u2022 Weight and BMI \u2022 Anthropometry (waist, hip, neck circumference) \u2022 Fat mass and fat-free mass: dual energy X-ray absorptiometry (DXA) Expanded set recommended variables:Subject Characteristics: Anthropometry, Body Composition, EE, and Hormonal StatusThe WHO defines obesity as \"a condition of abnormal or excessive fat accumulation in adipose tissue, to the extent that health may be impaired\" [86] .", [["hip", "ANATOMY", 305, 308], ["neck", "ANATOMY", 310, 314], ["Fat mass", "ANATOMY", 332, 340], ["fat", "ANATOMY", 345, 348], ["fat", "ANATOMY", 580, 583], ["adipose tissue", "ANATOMY", 600, 614], ["EE", "CHEMICAL", 492, 494], ["obesity", "DISEASE", 531, 538], ["waist", "ORGANISM_SUBDIVISION", 298, 303], ["hip", "ORGANISM_SUBDIVISION", 305, 308], ["neck", "ORGANISM_SUBDIVISION", 310, 314], ["Fat", "TISSUE", 332, 335], ["fat", "TISSUE", 345, 348], ["fat", "TISSUE", 580, 583], ["adipose tissue", "TISSUE", 600, 614], ["Hormonal StatusAnthropometry", "TREATMENT", 169, 197], ["Weight", "TEST", 266, 272], ["BMI", "TEST", 277, 280], ["Anthropometry", "TEST", 283, 296], ["(waist, hip, neck circumference)", "TREATMENT", 297, 329], ["Fat mass", "PROBLEM", 332, 340], ["fat-free mass", "PROBLEM", 345, 358], ["dual energy X-ray absorptiometry", "TREATMENT", 360, 392], ["obesity", "PROBLEM", 531, 538], ["a condition", "PROBLEM", 543, 554], ["abnormal or excessive fat accumulation in adipose tissue", "PROBLEM", 558, 614], ["hip", "ANATOMY", 305, 308], ["neck", "ANATOMY", 310, 314], ["mass", "OBSERVATION", 336, 340], ["fat", "ANATOMY", 345, 348], ["free", "OBSERVATION_MODIFIER", 349, 353], ["mass", "OBSERVATION", 354, 358], ["obesity", "OBSERVATION", 531, 538]]], ["In clinical trials on obesity, researchers must quantify this increased adiposity in a way that allows comparisons between Alligier et al.: OBEDIS Core Variables Project www.karger.com/ofa subjects, and over time in the same subject.", [["obesity", "DISEASE", 22, 29], ["obesity", "PROBLEM", 22, 29], ["this increased adiposity", "PROBLEM", 57, 81], ["obesity", "OBSERVATION", 22, 29]]], ["Patient-reported data are not adequate for these purposes.", [["Patient", "SPECIES", 0, 7], ["these purposes", "TEST", 43, 57]]], ["The OBEDIS experts acknowledge that the study of body composition assessment methods is rapidly moving forward, far beyond basic calculations of BMI, and this may present an important opportunity for identifying precise body composition subgroups that may respond predictably to an intervention.Subject Characteristics: Anthropometry, Body Composition, EE, and Hormonal StatusBMI -calculated from measures of a subject's height and weight -is the simplest and most frequent way of classifying an individual as underweight, normal weight, overweight, or obese, and is therefore recommended for inclusion in the minimal core set.", [["body", "ANATOMY", 49, 53], ["body", "ANATOMY", 220, 224], ["EE", "CHEMICAL", 353, 355], ["underweight", "DISEASE", 510, 521], ["overweight", "DISEASE", 538, 548], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["body", "ORGANISM_SUBDIVISION", 220, 224], ["the study of body composition assessment", "TEST", 36, 76], ["an intervention", "TREATMENT", 279, 294], ["Hormonal StatusBMI", "TEST", 361, 379], ["weight", "TEST", 432, 438], ["obese", "PROBLEM", 553, 558]]], ["Although the relationship between BMI and all-cause mortality has been confirmed [87] , BMI as a \"surrogate measure\" of obesity does not directly capture large interindividual variation in excess adipose tissue.", [["adipose tissue", "ANATOMY", 196, 210], ["obesity", "DISEASE", 120, 127], ["adipose tissue", "TISSUE", 196, 210], ["BMI", "TEST", 34, 37], ["BMI", "PROBLEM", 88, 91], ["obesity", "PROBLEM", 120, 127], ["large interindividual variation in excess adipose tissue", "PROBLEM", 154, 210], ["obesity", "OBSERVATION", 120, 127], ["interindividual variation", "OBSERVATION", 160, 185], ["excess adipose tissue", "OBSERVATION", 189, 210]]], ["This makes BMI misleading for individuals who exhibit differences in proportions of lean body mass and fat mass (for instance, elite athletes and those with sarcopenia) [88] .", [["lean body mass", "ANATOMY", 84, 98], ["fat mass", "ANATOMY", 103, 111], ["sarcopenia", "DISEASE", 157, 167], ["lean body", "TISSUE", 84, 93], ["fat", "TISSUE", 103, 106], ["lean body mass", "PROBLEM", 84, 98], ["fat mass", "PROBLEM", 103, 111], ["sarcopenia", "PROBLEM", 157, 167], ["lean", "OBSERVATION_MODIFIER", 84, 88], ["body", "ANATOMY", 89, 93], ["mass", "OBSERVATION", 94, 98], ["fat", "ANATOMY", 103, 106], ["mass", "OBSERVATION", 107, 111]]], ["Indeed, going beyond a patient's BMI adds valuable additional information about health [89] [90] [91] .", [["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30]]], ["Recent work shows it is the excess fat that constitutes a risk factor for a range of comorbid diseases: type 2 diabetes (T2D), ischemic heart disease, hyperlipidemia, sleep apnea, certain forms of cancer, and others [92] .Subject Characteristics: Anthropometry, Body Composition, EE, and Hormonal StatusFurther anthropometric measures -waist, hip, and neck circumferences -are recommended in all clinical trials focusing on obesity, as ways to assess subjects' fat distribution.", [["fat", "ANATOMY", 35, 38], ["heart", "ANATOMY", 136, 141], ["cancer", "ANATOMY", 197, 203], ["hip", "ANATOMY", 343, 346], ["neck", "ANATOMY", 352, 356], ["fat", "ANATOMY", 461, 464], ["type 2 diabetes", "DISEASE", 104, 119], ["T2D", "DISEASE", 121, 124], ["ischemic heart disease", "DISEASE", 127, 149], ["hyperlipidemia", "DISEASE", 151, 165], ["sleep apnea", "DISEASE", 167, 178], ["cancer", "DISEASE", 197, 203], ["EE", "CHEMICAL", 280, 282], ["obesity", "DISEASE", 424, 431], ["fat", "TISSUE", 35, 38], ["heart", "ORGAN", 136, 141], ["cancer", "CANCER", 197, 203], ["waist", "ORGANISM_SUBDIVISION", 336, 341], ["hip", "ORGANISM_SUBDIVISION", 343, 346], ["neck", "ORGANISM_SUBDIVISION", 352, 356], ["circumferences", "ORGANISM_SUBDIVISION", 357, 371], ["fat", "TISSUE", 461, 464], ["the excess fat", "PROBLEM", 24, 38], ["comorbid diseases", "PROBLEM", 85, 102], ["type 2 diabetes (T2D)", "PROBLEM", 104, 125], ["ischemic heart disease", "PROBLEM", 127, 149], ["hyperlipidemia", "PROBLEM", 151, 165], ["sleep apnea", "PROBLEM", 167, 178], ["cancer", "PROBLEM", 197, 203], ["Hormonal StatusFurther anthropometric measures", "TREATMENT", 288, 334], ["waist, hip, and neck circumferences", "TEST", 336, 371], ["obesity", "PROBLEM", 424, 431], ["ischemic", "OBSERVATION_MODIFIER", 127, 135], ["heart", "ANATOMY", 136, 141], ["disease", "OBSERVATION", 142, 149], ["hyperlipidemia", "OBSERVATION", 151, 165], ["sleep apnea", "OBSERVATION", 167, 178], ["cancer", "OBSERVATION", 197, 203], ["hip", "ANATOMY", 343, 346], ["neck", "ANATOMY", 352, 356]]], ["Ample evidence shows increased central or android fat distribution (assessed via waist-toheight ratio) is associated with greater risk to health [93, 94] compared to more peripheral or gynoid fat distribution.", [["fat", "ANATOMY", 50, 53], ["gynoid fat", "ANATOMY", 185, 195], ["fat", "TISSUE", 50, 53], ["waist", "ORGANISM_SUBDIVISION", 81, 86], ["peripheral", "TISSUE", 171, 181], ["fat", "TISSUE", 192, 195], ["increased central or android fat distribution", "PROBLEM", 21, 66], ["waist", "TEST", 81, 86], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["central", "OBSERVATION_MODIFIER", 31, 38], ["android fat distribution", "OBSERVATION", 42, 66], ["peripheral", "ANATOMY_MODIFIER", 171, 181], ["gynoid fat", "ANATOMY", 185, 195]]], ["Adding waist circumference to other anthropometric measures is valuable for predicting metabolic phenotypes [95] and a rationale even exists for how variables that include waist circumference directly affect intervention response [96] .", [["waist", "ORGANISM_SUBDIVISION", 7, 12], ["waist", "ORGANISM_SUBDIVISION", 172, 177], ["waist circumference", "TREATMENT", 7, 26], ["anthropometric measures", "TEST", 36, 59], ["predicting metabolic phenotypes", "PROBLEM", 76, 107], ["waist circumference", "TEST", 172, 191]]], ["Waist-tohip ratio predicts cardiovascular morbidity and mortality in those with obesity and T2D [97] [98] [99] .", [["cardiovascular", "ANATOMY", 27, 41], ["obesity", "DISEASE", 80, 87], ["T2D", "DISEASE", 92, 95], ["cardiovascular", "ANATOMICAL_SYSTEM", 27, 41], ["Waist", "TEST", 0, 5], ["cardiovascular morbidity", "PROBLEM", 27, 51], ["obesity", "PROBLEM", 80, 87], ["T2D", "TEST", 92, 95]]], ["In addition, neck circumference has been shown valuable for identifying excess body weight [100, 101] and associates with the presence or severity of different comorbidities [102] [103] [104] .Subject Characteristics: Anthropometry, Body Composition, EE, and Hormonal StatusMany options exist for more precise measurements of body composition.", [["neck", "ANATOMY", 13, 17], ["body", "ANATOMY", 79, 83], ["body", "ANATOMY", 326, 330], ["neck", "ORGANISM_SUBDIVISION", 13, 17], ["body", "ORGANISM_SUBDIVISION", 79, 83], ["body", "ORGANISM_SUBDIVISION", 326, 330], ["neck circumference", "TEST", 13, 31], ["excess body weight", "TEST", 72, 90], ["different comorbidities", "PROBLEM", 150, 173], ["neck", "ANATOMY", 13, 17]]], ["Available methods, each with their pros and cons, include bioelectrical impedance analysis (BIA), magnetic resonance imaging, computerized tomography scan, air displacement plethysmography (BOD POD), underwater weighing, and DXA.", [["bioelectrical impedance analysis", "TEST", 58, 90], ["magnetic resonance imaging", "TEST", 98, 124], ["computerized tomography scan", "TEST", 126, 154], ["air displacement plethysmography", "TEST", 156, 188], ["underwater weighing", "TREATMENT", 200, 219], ["DXA", "TEST", 225, 228]]], ["Body weight, BMI, or variables derived from weight alone are unable to distinguish between fat-free mass and fat mass, yet these components have specific medical relevance: increased fat-free mass may be found in athletes, who are not obese despite a high body weight/BMI; decreased fat-free mass is characteristic of a pathological condition called sarcopenia (or sarcopenic obesity), which needs to be detected; and fat-free mass is a determinant of EE (see below).", [["Body", "ANATOMY", 0, 4], ["fat", "ANATOMY", 91, 94], ["fat mass", "ANATOMY", 109, 117], ["fat", "ANATOMY", 183, 186], ["body", "ANATOMY", 256, 260], ["fat", "ANATOMY", 283, 286], ["fat", "ANATOMY", 418, 421], ["sarcopenia", "DISEASE", 350, 360], ["obesity", "DISEASE", 376, 383], ["EE", "CHEMICAL", 452, 454], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["fat", "TISSUE", 91, 94], ["fat", "TISSUE", 109, 112], ["fat", "TISSUE", 183, 186], ["body", "ORGANISM_SUBDIVISION", 256, 260], ["fat", "TISSUE", 283, 286], ["fat", "TISSUE", 418, 421], ["Body weight", "TEST", 0, 11], ["BMI", "TEST", 13, 16], ["weight", "TEST", 44, 50], ["fat-free mass", "PROBLEM", 91, 104], ["fat mass", "PROBLEM", 109, 117], ["increased fat-free mass", "PROBLEM", 173, 196], ["obese", "PROBLEM", 235, 240], ["a high body weight/BMI", "PROBLEM", 249, 271], ["decreased fat-free mass", "PROBLEM", 273, 296], ["a pathological condition", "PROBLEM", 318, 342], ["sarcopenia", "PROBLEM", 350, 360], ["sarcopenic obesity", "PROBLEM", 365, 383], ["fat-free mass", "PROBLEM", 418, 431], ["free", "OBSERVATION_MODIFIER", 95, 99], ["mass", "OBSERVATION", 100, 104], ["fat", "ANATOMY", 109, 112], ["mass", "OBSERVATION", 113, 117], ["increased", "OBSERVATION_MODIFIER", 173, 182], ["free", "OBSERVATION_MODIFIER", 187, 191], ["mass", "OBSERVATION", 192, 196], ["decreased", "OBSERVATION_MODIFIER", 273, 282], ["fat", "ANATOMY", 283, 286], ["free", "OBSERVATION_MODIFIER", 287, 291], ["mass", "OBSERVATION", 292, 296], ["pathological", "OBSERVATION_MODIFIER", 320, 332], ["condition", "OBSERVATION", 333, 342], ["sarcopenia", "OBSERVATION", 350, 360], ["sarcopenic", "OBSERVATION_MODIFIER", 365, 375], ["obesity", "OBSERVATION", 376, 383], ["free", "OBSERVATION_MODIFIER", 422, 426], ["mass", "OBSERVATION", 427, 431]]], ["Meanwhile, the visceral component of total body fat has unique physiological characteristics, which influence diseaserelated processes in the body [105] .", [["visceral", "ANATOMY", 15, 23], ["body fat", "ANATOMY", 43, 51], ["body", "ANATOMY", 142, 146], ["visceral", "ORGANISM_SUBDIVISION", 15, 23], ["body fat", "TISSUE", 43, 51], ["visceral", "ANATOMY", 15, 23], ["total", "OBSERVATION_MODIFIER", 37, 42], ["body fat", "OBSERVATION", 43, 51], ["physiological characteristics", "OBSERVATION_MODIFIER", 63, 92], ["body", "ANATOMY", 142, 146]]], ["Increased visceral adipose tissue in those with obesity is associated with an increased risk of metabolic (glucose intolerance, T2D) and cardiovascular disease (CVD).Subject Characteristics: Anthropometry, Body Composition, EE, and Hormonal StatusThe OBEDIS group agrees that precisely capturing the amount and distribution of body fat is required for the minimal core set of variables.", [["visceral adipose tissue", "ANATOMY", 10, 33], ["cardiovascular", "ANATOMY", 137, 151], ["body fat", "ANATOMY", 327, 335], ["obesity", "DISEASE", 48, 55], ["metabolic (glucose intolerance", "DISEASE", 96, 126], ["T2D", "DISEASE", 128, 131], ["cardiovascular disease", "DISEASE", 137, 159], ["CVD", "DISEASE", 161, 164], ["glucose", "CHEMICAL", 107, 114], ["visceral adipose tissue", "TISSUE", 10, 33], ["glucose", "SIMPLE_CHEMICAL", 107, 114], ["body fat", "TISSUE", 327, 335], ["Increased visceral adipose tissue", "PROBLEM", 0, 33], ["obesity", "PROBLEM", 48, 55], ["metabolic (glucose intolerance", "PROBLEM", 96, 126], ["cardiovascular disease (CVD)", "PROBLEM", 137, 165], ["visceral", "ANATOMY_MODIFIER", 10, 18], ["adipose tissue", "OBSERVATION", 19, 33], ["obesity", "OBSERVATION", 48, 55], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["metabolic", "OBSERVATION_MODIFIER", 96, 105], ["glucose intolerance", "OBSERVATION", 107, 126], ["cardiovascular", "ANATOMY", 137, 151], ["disease", "OBSERVATION", 152, 159], ["amount", "OBSERVATION_MODIFIER", 300, 306], ["body fat", "OBSERVATION", 327, 335]]], ["At present, however, no easy methods exist for assessment.", [["assessment", "TEST", 47, 57]]], ["BOD POD and BIA are two-compartment models (capturing fat mass and fat-free mass), while DXA is a three-compartment method (dividing the body into fat mass, lean body mass, and bone mineral content).", [["fat mass", "ANATOMY", 54, 62], ["fat", "ANATOMY", 67, 70], ["body", "ANATOMY", 137, 141], ["fat mass", "ANATOMY", 147, 155], ["lean body", "ANATOMY", 157, 166], ["bone", "ANATOMY", 177, 181], ["BIA", "SIMPLE_CHEMICAL", 12, 15], ["fat", "TISSUE", 54, 57], ["fat", "TISSUE", 67, 70], ["body", "ORGANISM_SUBDIVISION", 137, 141], ["fat", "TISSUE", 147, 150], ["lean body", "TISSUE", 157, 166], ["bone", "TISSUE", 177, 181], ["mineral", "MULTI-TISSUE_STRUCTURE", 182, 189], ["BIA", "TEST", 12, 15], ["fat mass", "PROBLEM", 54, 62], ["fat-free mass", "PROBLEM", 67, 80], ["DXA", "TEST", 89, 92], ["fat mass", "PROBLEM", 147, 155], ["lean body mass", "PROBLEM", 157, 171], ["fat", "ANATOMY", 67, 70], ["free", "OBSERVATION_MODIFIER", 71, 75], ["mass", "OBSERVATION", 76, 80], ["fat", "ANATOMY", 147, 150], ["mass", "OBSERVATION", 151, 155], ["mass", "OBSERVATION", 167, 171], ["bone", "ANATOMY", 177, 181], ["mineral content", "OBSERVATION", 182, 197]]], ["This relatively accurate, noninvasive method enables rapid measurement of percent body fat, although it remains dependent on several assumptions (namely, the constancy of fat-free mass composition) and exposes participants to a small dose of ionizing radiation.", [["body fat", "ANATOMY", 82, 90], ["fat", "ANATOMY", 171, 174], ["body fat", "TISSUE", 82, 90], ["fat", "TISSUE", 171, 174], ["participants", "SPECIES", 210, 222], ["percent body fat", "PROBLEM", 74, 90], ["fat-free mass composition", "PROBLEM", 171, 196], ["ionizing radiation", "TREATMENT", 242, 260], ["percent", "OBSERVATION_MODIFIER", 74, 81], ["body fat", "OBSERVATION", 82, 90], ["dependent", "OBSERVATION_MODIFIER", 112, 121], ["free", "OBSERVATION_MODIFIER", 175, 179], ["mass", "OBSERVATION", 180, 184], ["small", "OBSERVATION_MODIFIER", 228, 233]]], ["But because DXA is validated for those with obesity, it is the OBEDIS group's recommendation.", [["obesity", "DISEASE", 44, 51], ["DXA", "TEST", 12, 15], ["obesity", "PROBLEM", 44, 51]]], ["The use of DXA, a method that requires specialized equipment, is an exception to the general principle of simplicity in the OBEDIS minimal core set, but the group agrees that the potential predictive value of DXA-generated data is sufficiently great to enable rapid progress in the field.", [["DXA", "TEST", 11, 14], ["a method", "TREATMENT", 16, 24], ["specialized equipment", "TREATMENT", 39, 60], ["DXA", "TEST", 209, 212]]], ["In cases where trial limitations in budget, equipment, or expertise render it impossible to incorporate DXA, the group recommends BIA or plethysmography as an alternative to measuring fat mass and fat-free mass.", [["fat mass", "ANATOMY", 184, 192], ["fat", "ANATOMY", 197, 200], ["fat", "TISSUE", 184, 187], ["fat", "TISSUE", 197, 200], ["DXA", "TEST", 104, 107], ["plethysmography", "TEST", 137, 152], ["fat mass", "PROBLEM", 184, 192], ["fat-free mass", "PROBLEM", 197, 210], ["mass", "OBSERVATION", 188, 192], ["fat", "ANATOMY", 197, 200], ["free", "OBSERVATION_MODIFIER", 201, 205], ["mass", "OBSERVATION", 206, 210]]], ["Overall, the expert group concurs that the field needs more research and development on easy and inexpensive tools for precise measurements of body composition.Subject Characteristics: Anthropometry, Body Composition, EE, and Hormonal StatusEnergy balance in obesity may be important for prediction of intervention outcomes [106] .", [["body", "ANATOMY", 143, 147], ["EE", "CHEMICAL", 218, 220], ["obesity", "DISEASE", 259, 266], ["body", "ORGANISM_SUBDIVISION", 143, 147], ["obesity", "PROBLEM", 259, 266]]], ["EE is one component of energy balance, and hence, highly relevant for evaluating body weight changes.", [["body", "ANATOMY", 81, 85], ["EE", "CHEMICAL", 0, 2], ["body", "ORGANISM_SUBDIVISION", 81, 85], ["body weight changes", "PROBLEM", 81, 100], ["energy balance", "OBSERVATION", 23, 37]]], ["A subject's EE is likely to change in the course of an intervention, as it can vary with changes in body weight [107] or fat-free mass; changes in the composition of body weight gained or lost; adaptive thermogenesis (thyroid hormones, sympathetic nervous system, brown adipose tissue); and pharmacologic agents [108] .Subject Characteristics: Anthropometry, Body Composition, EE, and Hormonal StatusTwenty-four-hour EE is the sum of basal metabolic rate (BMR), adaptive thermogenesis (food, thermoregulation, etc.), and PA/exercise thermogenesis; it can be measured in freeliving individuals with doubly labelled water, but this method is expensive and restricted to a few specialized centers.", [["body", "ANATOMY", 100, 104], ["fat", "ANATOMY", 121, 124], ["body", "ANATOMY", 166, 170], ["thyroid", "ANATOMY", 218, 225], ["sympathetic nervous system", "ANATOMY", 236, 262], ["brown adipose tissue", "ANATOMY", 264, 284], ["EE", "CHEMICAL", 12, 14], ["EE", "CHEMICAL", 377, 379], ["EE", "CHEMICAL", 417, 419], ["body", "ORGANISM_SUBDIVISION", 100, 104], ["fat", "TISSUE", 121, 124], ["body", "ORGANISM_SUBDIVISION", 166, 170], ["thyroid", "ORGAN", 218, 225], ["sympathetic nervous system", "ANATOMICAL_SYSTEM", 236, 262], ["brown adipose tissue", "TISSUE", 264, 284], ["PA", "GENE_OR_GENE_PRODUCT", 521, 523], ["an intervention", "TREATMENT", 52, 67], ["body weight", "TEST", 100, 111], ["fat-free mass", "PROBLEM", 121, 134], ["adaptive thermogenesis (thyroid hormones", "PROBLEM", 194, 234], ["sympathetic nervous system", "PROBLEM", 236, 262], ["brown adipose tissue", "PROBLEM", 264, 284], ["pharmacologic agents", "TREATMENT", 291, 311], ["Hormonal StatusTwenty", "TEST", 385, 406], ["adaptive thermogenesis", "TREATMENT", 462, 484], ["PA/exercise thermogenesis", "TREATMENT", 521, 546], ["free", "OBSERVATION_MODIFIER", 125, 129], ["mass", "OBSERVATION", 130, 134], ["thyroid", "ANATOMY", 218, 225], ["sympathetic nervous", "ANATOMY", 236, 255], ["brown adipose", "ANATOMY", 264, 277]]], ["Resting EE can be measured by indirect calorimetry -but again, this method is not feasible in all centers, and accurate measurements require very strict conditions (overnight fast; no PA prior to measurement, requiring that measurement is done on inpatients; thermoneutrality, etc.).", [["EE", "CHEMICAL", 8, 10], ["indirect calorimetry", "TEST", 30, 50]]], ["BMR varies according to body composition (mainly fat-free mass), and hormonal status (thyroid hormones, sympathetic nervous system/catecholamines, brown adipose tissue).", [["body", "ANATOMY", 24, 28], ["fat", "ANATOMY", 49, 52], ["thyroid", "ANATOMY", 86, 93], ["sympathetic nervous system", "ANATOMY", 104, 130], ["brown adipose tissue", "ANATOMY", 147, 167], ["catecholamines", "CHEMICAL", 131, 145], ["catecholamines", "CHEMICAL", 131, 145], ["body", "ORGANISM_SUBDIVISION", 24, 28], ["fat", "TISSUE", 49, 52], ["thyroid", "ORGAN", 86, 93], ["sympathetic nervous system", "ANATOMICAL_SYSTEM", 104, 130], ["catecholamines", "GENE_OR_GENE_PRODUCT", 131, 145], ["brown adipose tissue", "TISSUE", 147, 167], ["BMR varies", "PROBLEM", 0, 10], ["body composition", "TEST", 24, 40], ["mainly fat-free mass", "PROBLEM", 42, 62], ["hormonal status (thyroid hormones", "PROBLEM", 69, 102], ["sympathetic nervous system/catecholamines", "PROBLEM", 104, 145], ["brown adipose tissue", "PROBLEM", 147, 167], ["free", "OBSERVATION_MODIFIER", 53, 57], ["mass", "OBSERVATION", 58, 62], ["thyroid", "ANATOMY", 86, 93], ["sympathetic nervous", "ANATOMY", 104, 123], ["brown adipose tissue", "OBSERVATION", 147, 167]]], ["BMR can be predicted with equations based on body weight or body composition: BMR = a \u2022 body weight + b (where a and b are different for males and females); or BMR = a \u2022 fat-free mass + b (where a and b are identical for both males and females).Subject Characteristics: Anthropometry, Body Composition, EE, and Hormonal StatusExpressing results as kcal expended per kg body weight or per kg fat-free mass invariably underestimates values in overweight/obese individuals and should not be used.", [["body", "ANATOMY", 45, 49], ["body", "ANATOMY", 60, 64], ["body", "ANATOMY", 88, 92], ["body", "ANATOMY", 369, 373], ["fat", "ANATOMY", 391, 394], ["EE", "CHEMICAL", 303, 305], ["body", "ORGANISM_SUBDIVISION", 45, 49], ["body", "ORGANISM_SUBDIVISION", 60, 64], ["body", "ORGANISM_SUBDIVISION", 88, 92], ["body", "ORGANISM_SUBDIVISION", 369, 373], ["fat", "ORGANISM_SUBDIVISION", 391, 394], ["body weight", "TEST", 45, 56], ["BMR", "TEST", 78, 81], ["body weight", "TEST", 88, 99], ["weight", "TEST", 374, 380], ["free mass", "PROBLEM", 395, 404], ["obese individuals", "PROBLEM", 452, 469], ["mass", "OBSERVATION", 179, 183], ["free", "OBSERVATION_MODIFIER", 395, 399], ["mass", "OBSERVATION", 400, 404], ["obese", "OBSERVATION", 452, 457]]], ["Results should instead be expressed as percentages of predicted value based on validated equations (Mifflin Jeor or others; see supplementary materials).Subject Characteristics: Anthropometry, Body Composition, EE, and Hormonal StatusEE is an essential feature for metabolic phenotyping, but direct measurement of EE should be included in the OBEDIS expanded set rather than in the minimal core set.", [["EE", "CHEMICAL", 211, 213], ["EE", "CHEMICAL", 314, 316], ["metabolic phenotyping", "TEST", 265, 286], ["direct measurement of EE", "TEST", 292, 316]]], ["The energy requirements of individuals included in a study can instead be predicted based on the BMR prediction equations above, multiplied by a PA level of 1.1-1.9 for PA level [109] .", [["PA", "GENE_OR_GENE_PRODUCT", 169, 171], ["a study", "TEST", 51, 58], ["the BMR prediction equations", "TEST", 93, 121], ["a PA level", "TEST", 143, 153], ["PA level", "TEST", 169, 177]]], ["Measurement of EE may nonetheless be highly relevant in some mechanistic studies, since variations in BMR may occur during interventions due to changes in body weight/fat-free mass (body composition-dependent changes) and changes in tissue (fat-free mass) metabolic activity.", [["body", "ANATOMY", 155, 159], ["fat", "ANATOMY", 167, 170], ["body", "ANATOMY", 182, 186], ["tissue", "ANATOMY", 233, 239], ["fat", "ANATOMY", 241, 244], ["EE", "CHEMICAL", 15, 17], ["body", "ORGANISM_SUBDIVISION", 155, 159], ["fat", "TISSUE", 167, 170], ["body", "ORGANISM_SUBDIVISION", 182, 186], ["tissue", "TISSUE", 233, 239], ["fat", "TISSUE", 241, 244], ["Measurement of EE", "TEST", 0, 17], ["some mechanistic studies", "TEST", 56, 80], ["variations in BMR", "PROBLEM", 88, 105], ["changes in body weight", "PROBLEM", 144, 166], ["fat-free mass", "PROBLEM", 167, 180], ["dependent changes)", "PROBLEM", 199, 217], ["changes in tissue (fat-free mass", "PROBLEM", 222, 254], ["fat", "ANATOMY", 167, 170], ["free", "OBSERVATION_MODIFIER", 171, 175], ["mass", "OBSERVATION", 176, 180], ["tissue", "ANATOMY", 233, 239], ["free", "OBSERVATION_MODIFIER", 245, 249], ["mass", "OBSERVATION", 250, 254], ["metabolic activity", "OBSERVATION", 256, 274]]], ["Such measurements are best done by open-circuit indirect calorimetry using standardized procedures.", [["Such measurements", "TEST", 0, 17], ["standardized procedures", "TREATMENT", 75, 98]]], ["Simultaneous measurement of body composition is strongly recommended for data interpretation.", [["body", "ANATOMY", 28, 32], ["body", "ORGANISM_SUBDIVISION", 28, 32], ["Simultaneous measurement of body composition", "TEST", 0, 44], ["data interpretation", "TEST", 73, 92]]], ["Endocrine and gynecological system alterations can occur in obese individuals, and many different measurements give insights into these complications; these include markers of thyroid status, that can be related to regulation of energy balance, and markers of gonadal axis in both sexes [110, 111] .", [["Endocrine", "ANATOMY", 0, 9], ["gynecological system", "ANATOMY", 14, 34], ["thyroid", "ANATOMY", 176, 183], ["gonadal axis", "ANATOMY", 260, 272], ["Endocrine and gynecological system alterations", "DISEASE", 0, 46], ["thyroid", "ORGAN", 176, 183], ["gonadal axis", "MULTI-TISSUE_STRUCTURE", 260, 272], ["these complications", "PROBLEM", 130, 149], ["gynecological system", "ANATOMY", 14, 34], ["thyroid", "ANATOMY", 176, 183], ["energy balance", "OBSERVATION", 229, 243]]], ["Among these hormones, the group recommends the measurement of TSH to assess thyroid function; FSH and LH may be used in the expanded set to confirm, when necessary, menopausal status in women.", [["thyroid", "ANATOMY", 76, 83], ["TSH", "GENE_OR_GENE_PRODUCT", 62, 65], ["thyroid", "ORGAN", 76, 83], ["FSH", "GENE_OR_GENE_PRODUCT", 94, 97], ["LH", "GENE_OR_GENE_PRODUCT", 102, 104], ["women", "ORGANISM", 186, 191], ["women", "SPECIES", 186, 191], ["the measurement of TSH", "TEST", 43, 65], ["FSH", "TEST", 94, 97], ["LH", "TEST", 102, 104], ["thyroid", "ANATOMY", 76, 83]]], ["In both males and females, androgens might provide valuable additional information; however, should their measurement be included, it should be mandatorily accomplished by mass spectrometry-based assays [112] .Subject Characteristics: Anthropometry, Body Composition, EE, and Hormonal StatusA panel of peptides and cytokines is usually characterized in studies focusing on obesity, including leptin, as a marker of body fat; adiponectin, as a predictor of metabolic dysregulation; tumor necrosis factor alpha and interleukin-6, as markers of inflammation; ghrelin, as a hunger signal; glucagon-like peptide-1 and peptide YY as a measure of satiation signal function.", [["body fat", "ANATOMY", 415, 423], ["EE", "CHEMICAL", 268, 270], ["obesity", "DISEASE", 373, 380], ["tumor", "DISEASE", 481, 486], ["inflammation", "DISEASE", 542, 554], ["androgens", "CHEMICAL", 27, 36], ["androgens", "SIMPLE_CHEMICAL", 27, 36], ["leptin", "GENE_OR_GENE_PRODUCT", 392, 398], ["body fat", "TISSUE", 415, 423], ["adiponectin", "GENE_OR_GENE_PRODUCT", 425, 436], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 481, 508], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 513, 526], ["ghrelin", "GENE_OR_GENE_PRODUCT", 556, 563], ["glucagon-like peptide-1", "GENE_OR_GENE_PRODUCT", 585, 608], ["peptide YY", "GENE_OR_GENE_PRODUCT", 613, 623], ["cytokines", "PROTEIN", 315, 324], ["adiponectin", "PROTEIN", 425, 436], ["tumor necrosis factor alpha", "PROTEIN", 481, 508], ["interleukin-6", "PROTEIN", 513, 526], ["mass spectrometry", "TEST", 172, 189], ["Body Composition", "TEST", 250, 266], ["Hormonal StatusA panel", "TEST", 276, 298], ["cytokines", "PROBLEM", 315, 324], ["obesity", "PROBLEM", 373, 380], ["leptin", "TREATMENT", 392, 398], ["adiponectin", "TREATMENT", 425, 436], ["metabolic dysregulation", "PROBLEM", 456, 479], ["tumor necrosis factor alpha", "PROBLEM", 481, 508], ["interleukin", "TEST", 513, 524], ["inflammation", "PROBLEM", 542, 554], ["ghrelin", "PROBLEM", 556, 563], ["a hunger signal", "PROBLEM", 568, 583], ["glucagon", "TEST", 585, 593], ["obesity", "OBSERVATION", 373, 380], ["metabolic dysregulation", "OBSERVATION", 456, 479], ["tumor", "OBSERVATION_MODIFIER", 481, 486], ["necrosis", "OBSERVATION", 487, 495], ["inflammation", "OBSERVATION", 542, 554]]], ["Consequently, measurement of each of these hormones may be included in clinical trials for obesity, according to the specific research question.", [["obesity", "DISEASE", 91, 98], ["obesity", "PROBLEM", 91, 98]]], ["However, preanalytical and analytical issues related to the measurement of most of these substances dramatically affect the consistency of the results.", [["preanalytical and analytical issues", "PROBLEM", 9, 44]]], ["Assay standardization and harmonization among labs are urgently needed to generate normative values.", [["Assay standardization", "TEST", 0, 21], ["harmonization among labs", "TEST", 26, 50]]], ["In addition, mass spectrometry-based assays for the quantitative and qualitative (isoforms, posttranslational modifications, etc.) assessment of peptide hormones are regarded as promising for their thorough characterization; however, the introduction of such techniques into routine clinical labs does not appear feasible in the near future.Complications: T2D, Cardiovascular Risk, Liver Disease, and Other Long-Term Obesity ComplicationsThe many complications of obesity are of interest because of their associations with poorer overall health and with more complex clinical management.", [["Cardiovascular", "ANATOMY", 361, 375], ["Liver", "ANATOMY", 382, 387], ["T2D", "DISEASE", 356, 359], ["Cardiovascular Risk, Liver Disease", "DISEASE", 361, 395], ["Obesity", "DISEASE", 417, 424], ["obesity", "DISEASE", 464, 471], ["Liver", "ORGAN", 382, 387], ["mass spectrometry", "TEST", 13, 30], ["based assays", "TEST", 31, 43], ["the quantitative and qualitative (isoforms, posttranslational modifications", "PROBLEM", 48, 123], ["assessment of peptide hormones", "TEST", 131, 161], ["their thorough characterization", "TEST", 192, 223], ["routine clinical labs", "TEST", 275, 296], ["T2D", "PROBLEM", 356, 359], ["Liver Disease", "PROBLEM", 382, 395], ["Other Long-Term Obesity", "PROBLEM", 401, 424], ["Complications", "PROBLEM", 425, 438], ["obesity", "PROBLEM", 464, 471], ["mass", "OBSERVATION", 13, 17], ["Cardiovascular", "ANATOMY", 361, 375], ["Liver", "ANATOMY", 382, 387], ["Disease", "OBSERVATION", 388, 395], ["Long-Term", "OBSERVATION_MODIFIER", 407, 416], ["Obesity", "OBSERVATION", 417, 424], ["many", "OBSERVATION_MODIFIER", 442, 446], ["complications", "OBSERVATION", 447, 460], ["obesity", "OBSERVATION", 464, 471]]], ["These comorbid conditions, and the medications taken to ameliorate them, may affect response to intervention.", [["These comorbid conditions", "PROBLEM", 0, 25], ["the medications", "TREATMENT", 31, 46], ["intervention", "TREATMENT", 96, 108]]], ["The major comorbid conditions in obesity are addressed in this section.Complications: T2D, Cardiovascular Risk, Liver Disease, and Other Long-Term Obesity ComplicationsType 2 Diabetes Minimal core set recommended variables: \u2022 Fasting glycemia (two measurements) \u2022 Hemoglobin A1c: HPLC-CE or HPLC-MS \u2022 Fasting insulin and insulin-derived insulin sensitivity indices \u2022 Family history of diabetes Expanded set recommended variables: \u2022 Hyperinsulinemic-euglycemic clamp Obesity is associated with alterations in normal endocrine and metabolic functions, leading to a number of pathological conditions: among these, T2D -affecting around 30-40% of obese individuals [113] .", [["Cardiovascular", "ANATOMY", 91, 105], ["Liver", "ANATOMY", 112, 117], ["endocrine", "ANATOMY", 515, 524], ["obesity", "DISEASE", 33, 40], ["T2D", "DISEASE", 86, 89], ["Cardiovascular Risk, Liver Disease", "DISEASE", 91, 125], ["Obesity", "DISEASE", 147, 154], ["Diabetes", "DISEASE", 175, 183], ["diabetes", "DISEASE", 385, 393], ["Obesity", "DISEASE", 466, 473], ["T2D", "DISEASE", 611, 614], ["Liver", "ORGAN", 112, 117], ["Fasting", "ORGANISM_SUBSTANCE", 226, 233], ["Hemoglobin A1c", "SIMPLE_CHEMICAL", 264, 278], ["insulin", "GENE_OR_GENE_PRODUCT", 309, 316], ["insulin", "GENE_OR_GENE_PRODUCT", 321, 328], ["insulin", "GENE_OR_GENE_PRODUCT", 337, 344], ["insulin", "PROTEIN", 321, 328], ["The major comorbid conditions", "PROBLEM", 0, 29], ["obesity", "PROBLEM", 33, 40], ["T2D", "PROBLEM", 86, 89], ["Liver Disease", "PROBLEM", 112, 125], ["Other Long-Term Obesity", "PROBLEM", 131, 154], ["Complications", "PROBLEM", 155, 168], ["Type 2 Diabetes", "PROBLEM", 168, 183], ["Fasting glycemia", "TEST", 226, 242], ["Hemoglobin", "TEST", 264, 274], ["A1c", "TEST", 275, 278], ["HPLC", "TEST", 280, 284], ["CE", "TEST", 285, 287], ["HPLC", "TEST", 291, 295], ["MS", "TEST", 296, 298], ["Fasting insulin", "TREATMENT", 301, 316], ["insulin", "TREATMENT", 321, 328], ["insulin sensitivity indices", "TEST", 337, 364], ["diabetes", "PROBLEM", 385, 393], ["Hyperinsulinemic", "PROBLEM", 432, 448], ["euglycemic clamp Obesity", "PROBLEM", 449, 473], ["T2D", "TEST", 611, 614], ["obese individuals", "PROBLEM", 643, 660], ["major", "OBSERVATION_MODIFIER", 4, 9], ["comorbid", "OBSERVATION_MODIFIER", 10, 18], ["conditions", "OBSERVATION", 19, 29], ["obesity", "OBSERVATION", 33, 40], ["Cardiovascular", "ANATOMY", 91, 105], ["Liver", "ANATOMY", 112, 117], ["Disease", "OBSERVATION", 118, 125], ["Long-Term", "OBSERVATION_MODIFIER", 137, 146], ["Obesity", "OBSERVATION", 147, 154], ["Diabetes", "OBSERVATION", 175, 183], ["normal", "OBSERVATION", 508, 514]]], ["Although metabolically healthy obese individuals exist, epidemiological evidence shows a high incidence of metabolic syndrome in those with obesity [114] .", [["metabolic syndrome", "DISEASE", 107, 125], ["obesity", "DISEASE", 140, 147], ["metabolic syndrome", "PROBLEM", 107, 125], ["obesity", "PROBLEM", 140, 147], ["high", "OBSERVATION_MODIFIER", 89, 93], ["metabolic syndrome", "OBSERVATION", 107, 125], ["obesity", "OBSERVATION", 140, 147]]], ["In patients with both obesity and T2D, interventions that lead to successful weight management substantially improve outcomes related to metabolic control [115] .", [["obesity", "DISEASE", 22, 29], ["T2D", "DISEASE", 34, 37], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["both obesity", "PROBLEM", 17, 29], ["T2D", "PROBLEM", 34, 37], ["interventions", "TREATMENT", 39, 52], ["successful weight management", "TREATMENT", 66, 94], ["metabolic control", "TREATMENT", 137, 154], ["obesity", "OBSERVATION", 22, 29]]], ["Response to interventions may also be modified by the use of various antidiabetic medications, which might affect weight either positively or negatively [113] .Complications: T2D, Cardiovascular Risk, Liver Disease, and Other Long-Term Obesity ComplicationsThe OBEDIS group recommends including several T2D-related variables in all clinical trials on obesity interventions: two measurements of fasting plasma glucose for assessing T2D, hemoglobin A1c (HbA1c) for screening and monitoring of glycemic control, and fasting insulin as a surrogate marker for insulin resistance as well as indicating the secretory capacity of the beta cells.", [["Cardiovascular", "ANATOMY", 180, 194], ["Liver", "ANATOMY", 201, 206], ["plasma", "ANATOMY", 402, 408], ["beta cells", "ANATOMY", 626, 636], ["T2D", "DISEASE", 175, 178], ["Cardiovascular Risk, Liver Disease", "DISEASE", 180, 214], ["Obesity", "DISEASE", 236, 243], ["T2D", "DISEASE", 303, 306], ["obesity", "DISEASE", 351, 358], ["glucose", "CHEMICAL", 409, 416], ["T2D", "DISEASE", 431, 434], ["glucose", "CHEMICAL", 409, 416], ["Liver", "ORGAN", 201, 206], ["plasma", "ORGANISM_SUBSTANCE", 402, 408], ["glucose", "SIMPLE_CHEMICAL", 409, 416], ["hemoglobin A1c", "GENE_OR_GENE_PRODUCT", 436, 450], ["HbA1c", "SIMPLE_CHEMICAL", 452, 457], ["insulin", "GENE_OR_GENE_PRODUCT", 521, 528], ["insulin", "GENE_OR_GENE_PRODUCT", 555, 562], ["beta cells", "CELL", 626, 636], ["hemoglobin", "PROTEIN", 436, 446], ["HbA1c", "PROTEIN", 452, 457], ["fasting insulin", "PROTEIN", 513, 528], ["beta cells", "CELL_TYPE", 626, 636], ["interventions", "TREATMENT", 12, 25], ["various antidiabetic medications", "TREATMENT", 61, 93], ["T2D", "PROBLEM", 175, 178], ["Liver Disease", "PROBLEM", 201, 214], ["Other Long-Term Obesity", "PROBLEM", 220, 243], ["obesity interventions", "TREATMENT", 351, 372], ["fasting plasma glucose", "TEST", 394, 416], ["T2D", "TEST", 431, 434], ["hemoglobin A1c", "TEST", 436, 450], ["HbA1c", "TEST", 452, 457], ["screening", "TEST", 463, 472], ["glycemic control", "TREATMENT", 491, 507], ["fasting insulin", "TREATMENT", 513, 528], ["insulin resistance", "TREATMENT", 555, 573], ["Liver", "ANATOMY", 201, 206], ["Disease", "OBSERVATION", 207, 214], ["beta cells", "OBSERVATION", 626, 636]]], ["HbA1c measurement is recommended both for assessing blood glucose control in people with diagnosed T2D, and for diagnosing the disease or its early stages (\"prediabetes\").", [["blood", "ANATOMY", 52, 57], ["T2D", "DISEASE", 99, 102], ["prediabetes", "DISEASE", 157, 168], ["glucose", "CHEMICAL", 58, 65], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["glucose", "SIMPLE_CHEMICAL", 58, 65], ["people", "ORGANISM", 77, 83], ["people", "SPECIES", 77, 83], ["HbA1c measurement", "TEST", 0, 17], ["blood glucose control", "TREATMENT", 52, 73], ["the disease", "PROBLEM", 123, 134], ["disease", "OBSERVATION", 127, 134]]], ["The group agrees that C-peptide could take the place of fasting insulin as a marker of remaining insulin secretion.", [["C-peptide", "SIMPLE_CHEMICAL", 22, 31], ["insulin", "GENE_OR_GENE_PRODUCT", 64, 71], ["insulin", "GENE_OR_GENE_PRODUCT", 97, 104], ["fasting insulin", "PROTEIN", 56, 71], ["C-peptide", "TREATMENT", 22, 31], ["fasting insulin", "TREATMENT", 56, 71], ["remaining insulin secretion", "TREATMENT", 87, 114]]], ["Further, insulin-derived insulin sensitivity indices should be calculated [116] : Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) represents the presence and extent of insulin resistance; whereas HOMA-beta reflects beta cell function.", [["beta cell", "ANATOMY", 228, 237], ["insulin", "GENE_OR_GENE_PRODUCT", 9, 16], ["insulin", "GENE_OR_GENE_PRODUCT", 25, 32], ["Insulin", "GENE_OR_GENE_PRODUCT", 114, 121], ["insulin", "GENE_OR_GENE_PRODUCT", 181, 188], ["HOMA-beta", "GENE_OR_GENE_PRODUCT", 209, 218], ["beta cell", "CELL", 228, 237], ["insulin", "PROTEIN", 9, 16], ["insulin", "TREATMENT", 9, 16], ["insulin sensitivity indices", "TEST", 25, 52], ["Insulin Resistance (HOMA-IR", "TREATMENT", 114, 141], ["insulin resistance", "PROBLEM", 181, 199], ["HOMA", "TEST", 209, 213], ["beta cell function", "TEST", 228, 246], ["Insulin Resistance", "OBSERVATION", 114, 132], ["insulin resistance", "OBSERVATION", 181, 199], ["beta cell", "OBSERVATION", 228, 237]]], ["Both calculations are mainly used in clinical studies.", [["clinical studies", "TEST", 37, 53]]], ["Several additional factors related to T2D are important to know -the individual's family history of T2D (to indicate possible genetic risk), as well as current medication and dosages.", [["T2D", "DISEASE", 38, 41], ["T2D", "DISEASE", 100, 103], ["T2D", "PROBLEM", 100, 103], ["current medication", "TREATMENT", 152, 170]]], ["There are more invasive measures of insulin secretion and sensitivity (hyperinsulinemic-euglycemic clamp, intravenous glucose tolerance test, etc.) and more comprehensive measures of key aspects of metabolic flexibility, but these tests are not feasible for all large-scale clinical interventions.Cardiovascular RiskMinimal core set recommended variables: \u2022 Smoking habits \u2022 Blood pressure and heart rate: automatic blood pressure device \u2022 Total cholesterol, high-density lipoprotein cholesterol, triglyceride \u2022 Inflammation: C-reactive protein (CRP) \u2022 Heart electrical activity: 1-to 5-min electrocardiography (ECG) \u2022 CRF: 6-min walk test Individuals with obesity often exhibit disordered vascular and heart function, and an elevated risk of CVD.", [["intravenous", "ANATOMY", 106, 117], ["Cardiovascular", "ANATOMY", 297, 311], ["Blood", "ANATOMY", 375, 380], ["heart", "ANATOMY", 394, 399], ["blood", "ANATOMY", 416, 421], ["Heart", "ANATOMY", 553, 558], ["vascular", "ANATOMY", 690, 698], ["heart", "ANATOMY", 703, 708], ["cholesterol", "CHEMICAL", 446, 457], ["cholesterol", "CHEMICAL", 484, 495], ["triglyceride", "CHEMICAL", 497, 509], ["CRF", "DISEASE", 619, 622], ["obesity", "DISEASE", 657, 664], ["CVD", "DISEASE", 743, 746], ["glucose", "CHEMICAL", 118, 125], ["cholesterol", "CHEMICAL", 446, 457], ["cholesterol", "CHEMICAL", 484, 495], ["triglyceride", "CHEMICAL", 497, 509], ["insulin", "GENE_OR_GENE_PRODUCT", 36, 43], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 106, 117], ["glucose", "SIMPLE_CHEMICAL", 118, 125], ["Blood", "ORGANISM_SUBSTANCE", 375, 380], ["heart", "ORGAN", 394, 399], ["blood", "ORGANISM_SUBSTANCE", 416, 421], ["cholesterol", "SIMPLE_CHEMICAL", 446, 457], ["high-density lipoprotein cholesterol", "SIMPLE_CHEMICAL", 459, 495], ["triglyceride", "SIMPLE_CHEMICAL", 497, 509], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 526, 544], ["CRP", "GENE_OR_GENE_PRODUCT", 546, 549], ["Heart", "ORGAN", 553, 558], ["vascular", "MULTI-TISSUE_STRUCTURE", 690, 698], ["heart", "ORGAN", 703, 708], ["high-density lipoprotein cholesterol", "PROTEIN", 459, 495], ["C-reactive protein", "PROTEIN", 526, 544], ["CRP", "PROTEIN", 546, 549], ["insulin secretion", "TREATMENT", 36, 53], ["sensitivity", "TEST", 58, 69], ["hyperinsulinemic", "TEST", 71, 87], ["euglycemic clamp", "TREATMENT", 88, 104], ["intravenous glucose tolerance test", "TEST", 106, 140], ["metabolic flexibility", "PROBLEM", 198, 219], ["these tests", "TEST", 225, 236], ["all large-scale clinical interventions", "TREATMENT", 258, 296], ["Blood pressure", "TEST", 375, 389], ["heart rate", "TEST", 394, 404], ["automatic blood pressure device", "TREATMENT", 406, 437], ["Total cholesterol", "TEST", 440, 457], ["high-density lipoprotein cholesterol", "TEST", 459, 495], ["triglyceride", "TEST", 497, 509], ["C-reactive protein", "TEST", 526, 544], ["CRP", "TEST", 546, 549], ["Heart electrical activity", "TEST", 553, 578], ["electrocardiography", "TEST", 591, 610], ["ECG", "TEST", 612, 615], ["CRF", "PROBLEM", 619, 622], ["walk test", "TEST", 630, 639], ["obesity", "PROBLEM", 657, 664], ["disordered vascular and heart function", "PROBLEM", 679, 717], ["an elevated risk of CVD", "PROBLEM", 723, 746], ["more", "OBSERVATION_MODIFIER", 10, 14], ["invasive", "OBSERVATION_MODIFIER", 15, 23], ["metabolic flexibility", "OBSERVATION", 198, 219], ["heart", "ANATOMY", 394, 399], ["high-density", "OBSERVATION_MODIFIER", 459, 471], ["lipoprotein cholesterol", "OBSERVATION", 472, 495], ["obesity", "OBSERVATION", 657, 664], ["vascular", "ANATOMY", 690, 698], ["heart", "ANATOMY", 703, 708], ["elevated", "OBSERVATION", 726, 734], ["CVD", "OBSERVATION", 743, 746]]], ["Intervention strategies may be modified by the presence of CVD or its various risk factors [117] .Cardiovascular RiskMost CVD risk is driven by age plus three other major CVD risk factors in addition to diabetes; namely, high cholesterol, high blood pressure, and smoking, together accounting for about 80% of population-attributable risk [118] .", [["Cardiovascular", "ANATOMY", 98, 112], ["blood", "ANATOMY", 244, 249], ["CVD", "DISEASE", 59, 62], ["Cardiovascular RiskMost CVD", "DISEASE", 98, 125], ["CVD", "DISEASE", 171, 174], ["diabetes", "DISEASE", 203, 211], ["cholesterol", "CHEMICAL", 226, 237], ["smoking", "CHEMICAL", 264, 271], ["cholesterol", "CHEMICAL", 226, 237], ["cholesterol", "SIMPLE_CHEMICAL", 226, 237], ["blood", "ORGANISM_SUBSTANCE", 244, 249], ["Intervention strategies", "TREATMENT", 0, 23], ["CVD", "PROBLEM", 59, 62], ["Cardiovascular RiskMost CVD risk", "PROBLEM", 98, 130], ["three other major CVD risk factors", "PROBLEM", 153, 187], ["diabetes", "PROBLEM", 203, 211], ["high cholesterol", "PROBLEM", 221, 237], ["high blood pressure", "PROBLEM", 239, 258], ["diabetes", "OBSERVATION", 203, 211]]], ["Cardiovascular risk algorithms exist [119] [120] [121] [122] , but due to the imprecise estimates they provide and the factors that are included in these algorithms, they may not prove useful in the context of short-term interventions for obesity.", [["Cardiovascular", "ANATOMY", 0, 14], ["obesity", "DISEASE", 239, 246], ["[119] [120] [121]", "CHEMICAL", 37, 54], ["Cardiovascular risk algorithms exist", "TEST", 0, 36], ["short-term interventions", "TREATMENT", 210, 234], ["obesity", "PROBLEM", 239, 246], ["obesity", "OBSERVATION", 239, 246]]], ["While risk scores were not included in the minimal core set, the OBEDIS group proposes measuring smoking status as well as several parameters related to vascular and cardiac function, which may help, now and in the future, to stratify individuals in order to optimize intervention outcomes.Cardiovascular RiskAssessment of current smoking habits in the minimal core set is achieved using two custom questions: number of cigarettes per day and duration of smoking.Cardiovascular RiskRelated to vasculature (atherosclerosis), the group recommended obtaining data on selected serum biomarkers: total cholesterol, high-density lipoprotein cholesterol, triglycerides, and high-sensitivity CRP (hsCRP).", [["vascular", "ANATOMY", 153, 161], ["cardiac", "ANATOMY", 166, 173], ["Cardiovascular", "ANATOMY", 290, 304], ["Cardiovascular", "ANATOMY", 463, 477], ["vasculature", "ANATOMY", 493, 504], ["serum", "ANATOMY", 573, 578], ["smoking", "CHEMICAL", 455, 462], ["atherosclerosis", "DISEASE", 506, 521], ["cholesterol", "CHEMICAL", 597, 608], ["cholesterol", "CHEMICAL", 635, 646], ["cholesterol", "CHEMICAL", 597, 608], ["cholesterol", "CHEMICAL", 635, 646], ["triglycerides", "CHEMICAL", 648, 661], ["vascular", "MULTI-TISSUE_STRUCTURE", 153, 161], ["cardiac", "ORGAN", 166, 173], ["vasculature", "MULTI-TISSUE_STRUCTURE", 493, 504], ["serum", "ORGANISM_SUBSTANCE", 573, 578], ["cholesterol", "SIMPLE_CHEMICAL", 597, 608], ["high-density lipoprotein cholesterol", "SIMPLE_CHEMICAL", 610, 646], ["triglycerides", "SIMPLE_CHEMICAL", 648, 661], ["high-sensitivity CRP", "GENE_OR_GENE_PRODUCT", 667, 687], ["hsCRP", "GENE_OR_GENE_PRODUCT", 689, 694], ["high-sensitivity CRP", "PROTEIN", 667, 687], ["hsCRP", "PROTEIN", 689, 694], ["intervention outcomes", "TREATMENT", 268, 289], ["atherosclerosis", "PROBLEM", 506, 521], ["selected serum biomarkers", "TEST", 564, 589], ["total cholesterol", "TEST", 591, 608], ["lipoprotein cholesterol", "TEST", 623, 646], ["triglycerides", "TEST", 648, 661], ["hsCRP", "TEST", 689, 694], ["vascular", "ANATOMY", 153, 161], ["cardiac", "ANATOMY", 166, 173], ["function", "OBSERVATION", 174, 182], ["vasculature", "ANATOMY", 493, 504], ["atherosclerosis", "OBSERVATION", 506, 521]]], ["Fasting hsCRP is included as a surrogate marker of inflammation, and CRP appears to be one of the best-established CVD risk markers [123] [124] [125] [126] [127] while having the advantage of being analyzed in a standardized and relatively inexpensive way.", [["inflammation", "DISEASE", 51, 63], ["CVD", "DISEASE", 115, 118], ["Fasting", "ORGANISM_SUBSTANCE", 0, 7], ["hsCRP", "GENE_OR_GENE_PRODUCT", 8, 13], ["CRP", "GENE_OR_GENE_PRODUCT", 69, 72], ["hsCRP", "PROTEIN", 8, 13], ["CRP", "PROTEIN", 69, 72], ["Fasting hsCRP", "TEST", 0, 13], ["inflammation", "PROBLEM", 51, 63], ["CRP", "TEST", 69, 72], ["inflammation", "OBSERVATION", 51, 63]]], ["Additional measures relevant to CVD, including blood glucose and insulin concentrations, which capture insulin resistance and beta-cell function [128] , are covered in the T2D section.", [["blood", "ANATOMY", 47, 52], ["beta-cell", "ANATOMY", 126, 135], ["CVD", "DISEASE", 32, 35], ["glucose", "CHEMICAL", 53, 60], ["T2D", "DISEASE", 172, 175], ["glucose", "CHEMICAL", 53, 60], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["glucose", "SIMPLE_CHEMICAL", 53, 60], ["insulin", "GENE_OR_GENE_PRODUCT", 65, 72], ["insulin", "GENE_OR_GENE_PRODUCT", 103, 110], ["beta-cell", "CELL", 126, 135], ["CVD", "PROBLEM", 32, 35], ["blood glucose", "TEST", 47, 60], ["insulin concentrations", "TREATMENT", 65, 87], ["insulin resistance", "TEST", 103, 121], ["beta-cell function", "TEST", 126, 144]]], ["The adipokine interleukin-6 also seems promising [129] , and is recommended for the expanded set, with the recommendations about its measurement proposed in the supplementary materials.Cardiovascular RiskAmong the variables related to cardiac function that could potentially modulate response to interventions for obesity, the following are recommended by the OBEDIS group for assessment: blood pressure, cardiopulmonary function, and electrical activity of the heart as measured by ECG.", [["Cardiovascular", "ANATOMY", 185, 199], ["cardiac", "ANATOMY", 235, 242], ["blood", "ANATOMY", 389, 394], ["heart", "ANATOMY", 462, 467], ["obesity", "DISEASE", 314, 321], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 14, 27], ["cardiac", "ORGAN", 235, 242], ["blood", "ORGANISM_SUBSTANCE", 389, 394], ["heart", "ORGAN", 462, 467], ["adipokine interleukin-6", "PROTEIN", 4, 27], ["The adipokine interleukin", "TEST", 0, 25], ["Cardiovascular RiskAmong", "TEST", 185, 209], ["interventions", "TREATMENT", 296, 309], ["obesity", "PROBLEM", 314, 321], ["blood pressure", "TEST", 389, 403], ["cardiopulmonary function", "TEST", 405, 429], ["ECG", "TEST", 483, 486], ["cardiopulmonary", "ANATOMY", 405, 420], ["heart", "ANATOMY", 462, 467]]], ["It is well-established that blood pressure may be modified by certain interventions, with weight loss causing important decreases in blood pressure [130] .", [["blood", "ANATOMY", 28, 33], ["blood", "ANATOMY", 133, 138], ["weight loss", "DISEASE", 90, 101], ["decreases in blood pressure", "DISEASE", 120, 147], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["blood pressure", "TEST", 28, 42], ["weight loss", "PROBLEM", 90, 101], ["blood pressure", "TEST", 133, 147], ["decreases", "OBSERVATION_MODIFIER", 120, 129]]], ["Despite somewhat limited reproducibility for automatic blood pressure devices, the group recommends using these in order to reduce human error.", [["blood", "ANATOMY", 55, 60], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["human", "ORGANISM", 131, 136], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["automatic blood pressure devices", "TREATMENT", 45, 77]]], ["As an indirect but validated way to assess CRF, the group identifies the 6-min walk test [131] [132] [133] [134] rather than the determination of maximal aerobic capacity (VO 2 max), which is expensive and has a poor association with fat mass and the loss thereof [135] [136] [137] .", [["fat mass", "ANATOMY", 234, 242], ["CRF", "DISEASE", 43, 46], ["fat", "TISSUE", 234, 237], ["CRF", "PROBLEM", 43, 46], ["walk test", "TEST", 79, 88], ["maximal aerobic capacity", "PROBLEM", 146, 170], ["fat mass", "PROBLEM", 234, 242], ["the loss thereof", "PROBLEM", 247, 263]]], ["Although not fully validated for hard endpoints, 1-to 5-min ECG is often used in small intervention clinical trials [138] and predicts cardiovascular death; thus, it may be used as a noninvasive means of risk stratification [139] .Cardiovascular RiskAssessing the presence of OSA is also essential, since OSA is associated with hypertension and an increased risk for CVD and T2D [140] .", [["cardiovascular", "ANATOMY", 135, 149], ["Cardiovascular", "ANATOMY", 231, 245], ["cardiovascular death", "DISEASE", 135, 155], ["OSA", "DISEASE", 276, 279], ["OSA", "DISEASE", 305, 308], ["hypertension", "DISEASE", 328, 340], ["CVD", "DISEASE", 367, 370], ["T2D", "DISEASE", 375, 378], ["cardiovascular", "ANATOMICAL_SYSTEM", 135, 149], ["ECG", "TEST", 60, 63], ["predicts cardiovascular death", "PROBLEM", 126, 155], ["OSA", "PROBLEM", 276, 279], ["OSA", "PROBLEM", 305, 308], ["hypertension", "PROBLEM", 328, 340], ["an increased risk", "PROBLEM", 345, 362], ["CVD", "PROBLEM", 367, 370], ["T2D", "PROBLEM", 375, 378], ["OSA", "OBSERVATION", 276, 279], ["hypertension", "OBSERVATION", 328, 340], ["increased", "OBSERVATION_MODIFIER", 348, 357]]], ["These measures are detailed in the section on sleep behaviors.Liver DiseaseMinimal core set recommended variables: \u2022 Nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) and fibrosis-4 index (FIB-4):Liver DiseaseALT, AST, GGT, platelet count, and albumin from blood \u2022 Alcohol intake: WHO AUDIT questionnaire Obesity comes with an increased risk of different forms of NAFLD: steatohepatitis (increased liver triglycerides), possibly progressing to fibrosis (irreversible scarring of the liver) [141] .", [["Liver", "ANATOMY", 62, 67], ["Nonalcoholic fatty liver", "ANATOMY", 117, 141], ["Liver", "ANATOMY", 208, 213], ["platelet", "ANATOMY", 236, 244], ["blood", "ANATOMY", 269, 274], ["liver", "ANATOMY", 410, 415], ["liver", "ANATOMY", 495, 500], ["sleep behaviors", "DISEASE", 46, 61], ["Nonalcoholic fatty liver disease", "DISEASE", 117, 149], ["NAFLD", "DISEASE", 151, 156], ["fibrosis", "DISEASE", 158, 166], ["fibrosis", "DISEASE", 183, 191], ["Alcohol", "CHEMICAL", 277, 284], ["Obesity", "DISEASE", 317, 324], ["NAFLD", "DISEASE", 376, 381], ["steatohepatitis", "DISEASE", 383, 398], ["increased liver triglycerides", "DISEASE", 400, 429], ["fibrosis", "DISEASE", 456, 464], ["scarring of the liver", "DISEASE", 479, 500], ["triglycerides", "CHEMICAL", 416, 429], ["Liver", "ORGAN", 62, 67], ["liver", "ORGAN", 136, 141], ["Liver", "ORGAN", 208, 213], ["AST", "SIMPLE_CHEMICAL", 226, 229], ["GGT", "SIMPLE_CHEMICAL", 231, 234], ["platelet", "CELL", 236, 244], ["albumin", "GENE_OR_GENE_PRODUCT", 256, 263], ["blood", "ORGANISM_SUBSTANCE", 269, 274], ["liver", "ORGAN", 410, 415], ["triglycerides", "SIMPLE_CHEMICAL", 416, 429], ["liver", "ORGAN", 495, 500], ["AST", "PROTEIN", 226, 229], ["GGT", "PROTEIN", 231, 234], ["Nonalcoholic fatty liver disease", "PROBLEM", 117, 149], ["NAFLD) fibrosis score", "PROBLEM", 151, 172], ["NFS", "TEST", 174, 177], ["fibrosis", "PROBLEM", 183, 191], ["FIB", "TEST", 201, 204], ["Liver DiseaseALT", "TEST", 208, 224], ["AST", "TEST", 226, 229], ["GGT", "TEST", 231, 234], ["platelet count", "TEST", 236, 250], ["albumin", "TEST", 256, 263], ["Obesity", "PROBLEM", 317, 324], ["NAFLD", "PROBLEM", 376, 381], ["steatohepatitis", "PROBLEM", 383, 398], ["increased liver triglycerides", "PROBLEM", 400, 429], ["fibrosis (irreversible scarring of the liver", "PROBLEM", 456, 500], ["Nonalcoholic", "OBSERVATION_MODIFIER", 117, 129], ["fatty", "OBSERVATION", 130, 135], ["liver", "ANATOMY", 136, 141], ["fibrosis", "OBSERVATION", 158, 166], ["fibrosis", "OBSERVATION", 183, 191], ["Liver", "ANATOMY", 208, 213], ["platelet count", "OBSERVATION", 236, 250], ["NAFLD", "OBSERVATION", 376, 381], ["steatohepatitis", "OBSERVATION", 383, 398], ["increased", "OBSERVATION_MODIFIER", 400, 409], ["liver", "ANATOMY", 410, 415], ["fibrosis", "OBSERVATION", 456, 464], ["irreversible", "OBSERVATION_MODIFIER", 466, 478], ["scarring", "OBSERVATION", 479, 487], ["liver", "ANATOMY", 495, 500]]], ["Tracking the occurrence of these liver conditions is deemed important for the minimal core set, as these conditions may affect a subject's response to intervention.", [["liver", "ANATOMY", 33, 38], ["liver", "ORGAN", 33, 38], ["intervention", "TREATMENT", 151, 163], ["liver", "ANATOMY", 33, 38]]], ["To detect fibrosis noninvasively, most guidelines [142, 143] recommend using the FIB-4 or the NFS, both of which are low cost and straightforward.Liver DiseaseGiven the relationship of alcohol intake to liver disease, the OBEDIS group also recommends a brief assessment of alcohol intake using the WHO's AUDIT questionnaire [144] .Liver DiseaseOther Long-Term Obesity Complications: Osteoarthritis and Cancer Minimal core set recommended variables: \u2022 QoL: EQ-5D-5LLiver DiseaseExpanded set recommended variables: \u2022 Pain-related physical functioning: WOMAC VA 3.0Liver DiseaseOver the long term, besides the significantly increased risk of CVD and T2D, obesity confers an increased risk for several other conditions: major medical complications (cancer), and functional complications (arthrosis).", [["Liver", "ANATOMY", 146, 151], ["liver", "ANATOMY", 203, 208], ["Liver", "ANATOMY", 331, 336], ["Liver", "ANATOMY", 562, 567], ["cancer", "ANATOMY", 745, 751], ["fibrosis", "DISEASE", 10, 18], ["alcohol", "CHEMICAL", 185, 192], ["liver disease", "DISEASE", 203, 216], ["alcohol", "CHEMICAL", 273, 280], ["Obesity", "DISEASE", 360, 367], ["Osteoarthritis", "DISEASE", 383, 397], ["Cancer", "DISEASE", 402, 408], ["Pain", "DISEASE", 515, 519], ["CVD", "DISEASE", 639, 642], ["T2D", "DISEASE", 647, 650], ["obesity", "DISEASE", 652, 659], ["cancer", "DISEASE", 745, 751], ["arthrosis", "DISEASE", 784, 793], ["alcohol", "CHEMICAL", 185, 192], ["alcohol", "CHEMICAL", 273, 280], ["Liver", "ORGAN", 146, 151], ["alcohol", "SIMPLE_CHEMICAL", 185, 192], ["liver", "ORGAN", 203, 208], ["alcohol", "SIMPLE_CHEMICAL", 273, 280], ["Liver", "ORGAN", 331, 336], ["cancer", "CANCER", 745, 751], ["fibrosis noninvasively", "PROBLEM", 10, 32], ["the FIB", "TREATMENT", 77, 84], ["Liver DiseaseGiven", "PROBLEM", 146, 164], ["liver disease", "PROBLEM", 203, 216], ["Liver DiseaseOther Long-Term Obesity", "PROBLEM", 331, 367], ["Osteoarthritis", "PROBLEM", 383, 397], ["Cancer", "PROBLEM", 402, 408], ["Pain", "PROBLEM", 515, 519], ["CVD", "PROBLEM", 639, 642], ["T2D", "PROBLEM", 647, 650], ["obesity", "PROBLEM", 652, 659], ["major medical complications (cancer)", "PROBLEM", 716, 752], ["functional complications (arthrosis)", "PROBLEM", 758, 794], ["fibrosis", "OBSERVATION", 10, 18], ["DiseaseGiven", "OBSERVATION", 152, 164], ["alcohol intake", "OBSERVATION", 185, 199], ["liver", "ANATOMY", 203, 208], ["disease", "OBSERVATION", 209, 216], ["Long-Term", "OBSERVATION_MODIFIER", 350, 359], ["Obesity", "OBSERVATION", 360, 367], ["Osteoarthritis", "OBSERVATION", 383, 397], ["Cancer", "OBSERVATION", 402, 408], ["Liver", "ANATOMY", 562, 567], ["long term", "OBSERVATION_MODIFIER", 584, 593], ["increased", "OBSERVATION_MODIFIER", 671, 680], ["cancer", "OBSERVATION", 745, 751], ["arthrosis", "OBSERVATION", 784, 793]]], ["Data on these conditions are part of a comprehensive assessment of the obesity phenotype.Liver DiseaseObesity increases the risk for osteoarthritis, a degenerative condition of joint pain and dysfunction [145] .", [["Liver", "ANATOMY", 89, 94], ["joint", "ANATOMY", 177, 182], ["obesity", "DISEASE", 71, 78], ["Liver DiseaseObesity", "DISEASE", 89, 109], ["osteoarthritis", "DISEASE", 133, 147], ["pain", "DISEASE", 183, 187], ["Liver", "ORGAN", 89, 94], ["joint", "MULTI-TISSUE_STRUCTURE", 177, 182], ["a comprehensive assessment", "TEST", 37, 63], ["the obesity phenotype", "PROBLEM", 67, 88], ["Liver DiseaseObesity", "PROBLEM", 89, 109], ["osteoarthritis", "PROBLEM", 133, 147], ["a degenerative condition", "PROBLEM", 149, 173], ["joint pain", "PROBLEM", 177, 187], ["dysfunction", "PROBLEM", 192, 203], ["obesity", "OBSERVATION", 71, 78], ["DiseaseObesity", "OBSERVATION", 95, 109], ["risk for", "UNCERTAINTY", 124, 132], ["osteoarthritis", "OBSERVATION", 133, 147], ["degenerative", "OBSERVATION_MODIFIER", 151, 163], ["joint", "ANATOMY", 177, 182]]], ["The presence of this condition is normally assessed through specific selfadministered validated osteoarthritis questionnaires.", [["osteoarthritis", "DISEASE", 96, 110], ["this condition", "PROBLEM", 16, 30], ["specific selfadministered validated osteoarthritis questionnaires", "PROBLEM", 60, 125], ["osteoarthritis", "OBSERVATION", 96, 110]]], ["But (pain-related) physical functioning is the most important factor related to osteoarthritis that may change with an intervention [146] , and the OBEDIS group decided this factor is adequately assessed by an overall QoL questionnaire.", [["pain", "DISEASE", 5, 9], ["osteoarthritis", "DISEASE", 80, 94], ["pain", "PROBLEM", 5, 9], ["osteoarthritis", "PROBLEM", 80, 94], ["an intervention", "TREATMENT", 116, 131], ["osteoarthritis", "OBSERVATION", 80, 94]]], ["The addition of a specific osteoarthritis questionnaire to the QoL questionnaire recommended above would provide marginal improvement in predictive ability.", [["osteoarthritis", "DISEASE", 27, 41], ["a specific osteoarthritis", "PROBLEM", 16, 41], ["osteoarthritis", "OBSERVATION", 27, 41]]], ["In the expanded set of variables, however, investigators may want to include the Western Ontario and McMaster Universities (WOMAC VA 3.0) osteoarthritis index, a self-report questionnaire covering hip and knee osteoarthritis [147] .Liver DiseaseThose with obesity experience cancer at a higher rate than the general population [148] and a patient's history of cancer may be relevant to the exclusion criteria in a clinical trial.", [["hip", "ANATOMY", 197, 200], ["knee", "ANATOMY", 205, 209], ["Liver", "ANATOMY", 232, 237], ["cancer", "ANATOMY", 275, 281], ["cancer", "ANATOMY", 360, 366], ["osteoarthritis", "DISEASE", 138, 152], ["osteoarthritis", "DISEASE", 210, 224], ["Liver DiseaseThose", "DISEASE", 232, 250], ["obesity", "DISEASE", 256, 263], ["cancer", "DISEASE", 275, 281], ["cancer", "DISEASE", 360, 366], ["hip", "ORGANISM_SUBDIVISION", 197, 200], ["Liver", "ORGAN", 232, 237], ["cancer", "CANCER", 275, 281], ["patient", "ORGANISM", 339, 346], ["cancer", "CANCER", 360, 366], ["patient", "SPECIES", 339, 346], ["WOMAC VA", "TEST", 124, 132], ["osteoarthritis index", "PROBLEM", 138, 158], ["hip and knee osteoarthritis", "PROBLEM", 197, 224], ["Liver DiseaseThose", "PROBLEM", 232, 250], ["obesity experience cancer", "PROBLEM", 256, 281], ["cancer", "PROBLEM", 360, 366], ["osteoarthritis", "OBSERVATION", 138, 152], ["hip", "ANATOMY", 197, 200], ["knee", "ANATOMY", 205, 209], ["osteoarthritis", "OBSERVATION", 210, 224], ["obesity", "OBSERVATION", 256, 263], ["cancer", "OBSERVATION", 275, 281], ["cancer", "OBSERVATION", 360, 366]]], ["Once a patient is enrolled in a trial, however, investigators may want to track cancer occurrence.", [["cancer", "ANATOMY", 80, 86], ["cancer", "DISEASE", 80, 86], ["patient", "ORGANISM", 7, 14], ["cancer", "CANCER", 80, 86], ["patient", "SPECIES", 7, 14]]], ["The OBEDIS group decided that including cancer data in the minimal core set was not necessary; because of the long delay before cancer occurrence, the following data need only be collected in cohorts with more than 5 or 10 years of follow-up: date of diagnosis and cancer type (according to the International Classification of Diseases).", [["cancer", "ANATOMY", 40, 46], ["cancer", "ANATOMY", 128, 134], ["cancer", "ANATOMY", 265, 271], ["cancer", "DISEASE", 40, 46], ["cancer", "DISEASE", 128, 134], ["cancer", "DISEASE", 265, 271], ["cancer", "CANCER", 40, 46], ["cancer", "CANCER", 128, 134], ["cancer", "CANCER", 265, 271], ["cancer data", "TEST", 40, 51], ["the long delay before cancer occurrence", "PROBLEM", 106, 145], ["cancer type", "PROBLEM", 265, 276], ["cancer", "OBSERVATION", 265, 271], ["Diseases", "OBSERVATION", 327, 335]]], ["The data should be obtained from medical records where possible and validated by independent medical experts.Future Medical PracticeSeveral areas of analysis have the potential to advance precision medicine within the field of obesity: tissue phenotyping, as well as genetics, and omics.Future Medical PracticeIt is already known that researchers may gain insights into the molecular underpinnings of variability in weight loss by precisely analyzing different body tissues in individuals with obesity [149] : apart from components of blood, urine, and stool, this may include biopsies and/or assessments of white adipose tissue, skeletal muscle, and the liver.", [["tissue", "ANATOMY", 236, 242], ["body tissues", "ANATOMY", 461, 473], ["blood", "ANATOMY", 535, 540], ["urine", "ANATOMY", 542, 547], ["stool", "ANATOMY", 553, 558], ["white adipose tissue", "ANATOMY", 608, 628], ["skeletal muscle", "ANATOMY", 630, 645], ["liver", "ANATOMY", 655, 660], ["obesity", "DISEASE", 227, 234], ["weight loss", "DISEASE", 416, 427], ["obesity", "DISEASE", 494, 501], ["tissue", "TISSUE", 236, 242], ["body tissues", "TISSUE", 461, 473], ["blood", "ORGANISM_SUBSTANCE", 535, 540], ["urine", "ORGANISM_SUBSTANCE", 542, 547], ["stool", "ORGANISM_SUBSTANCE", 553, 558], ["biopsies", "TISSUE", 577, 585], ["white adipose tissue", "TISSUE", 608, 628], ["skeletal muscle", "TISSUE", 630, 645], ["liver", "ORGAN", 655, 660], ["precision medicine", "TREATMENT", 188, 206], ["obesity", "PROBLEM", 227, 234], ["tissue phenotyping", "TEST", 236, 254], ["Future Medical PracticeIt", "TREATMENT", 287, 312], ["weight loss", "PROBLEM", 416, 427], ["obesity", "PROBLEM", 494, 501], ["blood, urine", "TEST", 535, 547], ["biopsies", "TEST", 577, 585], ["white adipose tissue, skeletal muscle, and the liver", "PROBLEM", 608, 660], ["obesity", "OBSERVATION", 227, 234], ["stool", "OBSERVATION", 553, 558], ["white adipose tissue", "OBSERVATION", 608, 628], ["skeletal muscle", "ANATOMY", 630, 645], ["liver", "ANATOMY", 655, 660]]], ["Precise phenotyping of patients by tissue analysis is a promising area within the field of obesity; some studies have successfully used this approach to identify subgroups of participants that have increased susceptibility to obesity or that will predictably respond to a treatment [150, 151] .", [["tissue", "ANATOMY", 35, 41], ["obesity", "DISEASE", 91, 98], ["obesity", "DISEASE", 226, 233], ["patients", "ORGANISM", 23, 31], ["tissue", "TISSUE", 35, 41], ["participants", "ORGANISM", 175, 187], ["patients", "SPECIES", 23, 31], ["participants", "SPECIES", 175, 187], ["tissue analysis", "TEST", 35, 50], ["obesity", "PROBLEM", 91, 98], ["some studies", "TEST", 100, 112], ["this approach", "TREATMENT", 136, 149], ["increased susceptibility to obesity", "PROBLEM", 198, 233], ["obesity", "OBSERVATION", 91, 98], ["increased", "OBSERVATION_MODIFIER", 198, 207], ["obesity", "OBSERVATION", 226, 233]]], ["However, the complexity of these methods rules them out for the minimal core set at present.Future Medical PracticeIn the future, patients may be stratified based on the presence of specific genetic markers.", [["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["these methods", "TREATMENT", 27, 40], ["minimal", "OBSERVATION_MODIFIER", 64, 71]]], ["Data from family, twin, and adoption studies show that both body weight (40-70%) and body fat distribution are highly heritable [152] .", [["body", "ANATOMY", 60, 64], ["body fat", "ANATOMY", 85, 93], ["body", "ORGANISM_SUBDIVISION", 60, 64], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["fat", "TISSUE", 90, 93], ["adoption studies", "TEST", 28, 44], ["both body weight", "TEST", 55, 71], ["body fat distribution", "TEST", 85, 106]]], ["Heritability also seems to play a role in the nature, magnitude, and/or timing of response to obesity interventions [153] : studies have shown genetic influences on dietary interventions [154, 155] and heritability of response to bariatric surgery (Roux-en-Y) [156] .", [["obesity", "DISEASE", 94, 101], ["obesity interventions", "TREATMENT", 94, 115], ["dietary interventions", "TREATMENT", 165, 186], ["bariatric surgery", "TREATMENT", 230, 247]]], ["Obesity-related gene expression may be attenuated by PA.", [["Obesity", "DISEASE", 0, 7], ["PA", "GENE_OR_GENE_PRODUCT", 53, 55], ["Obesity", "PROBLEM", 0, 7], ["gene expression", "PROBLEM", 16, 31]]], ["This field is expected to advance rapidly over the next few years and zero in on very specific genetic markers for patient stratification.Future Medical PracticeBeyond human genes, advances in high-throughput technologies for analysis of biologic molecules have created the potential for defining the biological characteristics of those with obesity with great precision.", [["obesity", "DISEASE", 342, 349], ["patient", "ORGANISM", 115, 122], ["human", "ORGANISM", 168, 173], ["Medical PracticeBeyond human genes", "DNA", 145, 179], ["patient", "SPECIES", 115, 122], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["Future Medical PracticeBeyond human genes", "TREATMENT", 138, 179], ["biologic molecules", "PROBLEM", 238, 256], ["obesity", "PROBLEM", 342, 349]]], ["New omics technologies enable examination, not only of a patient's genome, but also of complete sets of transcripts, proteins, and metabolites.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["New omics technologies", "TEST", 0, 22], ["enable examination", "TEST", 23, 41], ["a patient's genome", "PROBLEM", 55, 73]]], ["Analyses that fall under the category of omics are those that provide \"a comprehensive, or global, assessment of a set of molecules\" [157] : genomics, epigenomics (reversible modifications of DNA or DNA-associated proteins across the genome), proteomics, metabolomics (small molecule types), microbiomics, lipidomics, transcriptomics, and others.", [["DNA", "CELLULAR_COMPONENT", 192, 195], ["DNA", "CELLULAR_COMPONENT", 199, 202], ["DNA or DNA-associated proteins", "PROTEIN", 192, 222], ["epigenomics (reversible modifications of DNA", "PROBLEM", 151, 195], ["DNA", "PROBLEM", 199, 202], ["associated proteins", "PROBLEM", 203, 222], ["proteomics", "TEST", 243, 253], ["metabolomics", "TEST", 255, 267], ["small molecule types)", "PROBLEM", 269, 290], ["microbiomics", "PROBLEM", 292, 304]]], ["Already, findings from omics studies have identified important avenues of research in obesity: for instance, epigenomic studies have mechanistically linked aspects of the environment before conception with the probability of becoming obese later in life [158, 159] , while weight loss induced by gastric bypass surgery affects a patient's DNA methylation and gene expression profile [160] .Future Medical PracticeThe analyses mentioned above are key components of certain obesity intervention studies, depending on their aims.", [["gastric", "ANATOMY", 296, 303], ["obesity", "DISEASE", 86, 93], ["weight loss", "DISEASE", 273, 284], ["obesity", "DISEASE", 472, 479], ["gastric", "ORGAN", 296, 303], ["patient", "ORGANISM", 329, 336], ["DNA", "CELLULAR_COMPONENT", 339, 342], ["patient", "SPECIES", 329, 336], ["omics studies", "TEST", 23, 36], ["epigenomic studies", "TEST", 109, 127], ["obese", "PROBLEM", 234, 239], ["weight loss", "PROBLEM", 273, 284], ["gastric bypass surgery", "TREATMENT", 296, 318], ["a patient's DNA methylation", "TREATMENT", 327, 354], ["gene expression profile", "TEST", 359, 382], ["The analyses", "TEST", 413, 425], ["certain obesity intervention studies", "PROBLEM", 464, 500], ["obese", "OBSERVATION", 234, 239], ["gastric", "ANATOMY", 296, 303], ["bypass", "OBSERVATION", 304, 310]]], ["The OBEDIS group considered the pros and cons of including genetic and omics data, as well as tissue analyses, in the minimal core set for all obesityfocused clinical trials; the group concludes that at present, the ability of these tests to explain variability in weight loss is not great enough to justify the added costs.", [["tissue", "ANATOMY", 94, 100], ["weight loss", "DISEASE", 265, 276], ["tissue", "TISSUE", 94, 100], ["omics data", "TEST", 71, 81], ["tissue analyses", "TEST", 94, 109], ["these tests", "TEST", 227, 238], ["weight loss", "PROBLEM", 265, 276]]], ["The group strongly suspects, however, that as costs fall and evidence increases, researchers will soon have adequate justification for including such analyses in all trials.Future Medical PracticeIn anticipation of the probability that certain blood measurements may yield new insights in the near-term future, biobanking is highly recommended by the group -whole blood where possible, but at a minimum, samples of whole blood dried on paper.", [["blood", "ANATOMY", 244, 249], ["blood", "ANATOMY", 364, 369], ["samples", "ANATOMY", 404, 411], ["blood", "ANATOMY", 421, 426], ["blood", "ORGANISM_SUBSTANCE", 244, 249], ["blood", "ORGANISM_SUBSTANCE", 364, 369], ["blood", "ORGANISM_SUBSTANCE", 421, 426], ["such analyses", "TEST", 145, 158], ["Future Medical PracticeIn anticipation", "TREATMENT", 173, 211], ["blood measurements", "TEST", 244, 262], ["whole blood", "TEST", 415, 426], ["increases", "OBSERVATION_MODIFIER", 70, 79]]], ["Dried blood spots are suitable for many potential future measurements, and also have the advantages of easy and low-cost collection and storage.Future Medical PracticeThe OBEDIS group agrees that consent is another important issue to address for this field: a challenge is to develop SOPs around consent, which will allow sharing and reuse of omics and other data over the long term and as new discoveries are made.", [["blood spots", "ANATOMY", 6, 17], ["blood", "ORGANISM_SUBSTANCE", 6, 11], ["Dried blood spots", "PROBLEM", 0, 17], ["easy and low-cost collection", "TREATMENT", 103, 131]]], ["The group envisions a set of consent-related SOPs implemented across Europe, adapted to local circumstances.ConclusionThe expert consensus detailed herein represents a practical advancement in the field of obesity research -with the group members supporting the adoption of these variables in future clinical trials, collected systematically either before or both before and after intervention.", [["obesity", "DISEASE", 206, 213], ["a practical advancement", "TREATMENT", 166, 189], ["intervention", "TREATMENT", 381, 393]]], ["Basic and preclinical research should, of course, continue in tandem, building a larger context for informing better intervention strategies and identifying the appropriate adult patient groups for each specific intervention.ConclusionThe translational potential of the work begun here is therefore of high value: over time, this project should enable more efficient convergence of evidence to support better care for those with obesity.", [["obesity", "DISEASE", 429, 436], ["patient", "ORGANISM", 179, 186], ["patient", "SPECIES", 179, 186], ["better intervention strategies", "TREATMENT", 110, 140], ["each specific intervention", "TREATMENT", 198, 224], ["obesity", "PROBLEM", 429, 436]]], ["The OBEDIS group sees the ability to pool datasets and compare very large numbers of trial participants as key to the advancement of \"precision\" or \"personalized\" medicine.", [["participants", "SPECIES", 91, 103]]], ["In the future, when a clinician encounters a newly referred adult patient with obesity, he or she will be able to group the patient according to baseline characteristics and suggest a tailored intervention plan, backed by robust data.ConclusionThe OBEDIS workshop and the resulting guidelines, achieved only through the support of EASO, represent an historic collaboration in the field of obesity in Europe.", [["obesity", "DISEASE", 79, 86], ["obesity", "DISEASE", 389, 396], ["patient", "ORGANISM", 66, 73], ["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 66, 73], ["patient", "SPECIES", 124, 131], ["obesity", "PROBLEM", 79, 86], ["a tailored intervention plan", "TREATMENT", 182, 210], ["obesity", "PROBLEM", 389, 396], ["obesity", "OBSERVATION", 389, 396]]], ["Cl\u00e9ment is a consultant for Danone Research and LNC therapeutics for work unassociated with the present study.", [["LNC therapeutics", "TREATMENT", 48, 64], ["the present study", "TEST", 92, 109]]], ["No other authors have conflicts of interest to declare.Funding SourcesThis initiative was funded by the Joint Programming Initiative Heathy Diet for Healthy Life.Author ContributionsAll authors contributed to the guidelines described in this paper.", [["Joint", "ANATOMY", 104, 109]]], ["K. Campbell prepared the manuscript.", [["K", "CHEMICAL", 0, 1], ["K", "GENE_OR_GENE_PRODUCT", 0, 1], ["K", "TEST", 0, 1]]]], "9a6e973e76eafd025e3d73c2acf1c6b09e116c39": [["I. Information of the metal halide lamp applied for thedimerization of methyl-linderoneThe metal halide lamp (400W) was purchased from Xian Bilon Biological Technology Co., LTD in China.", [["methyl-linderone", "CHEMICAL", 71, 87], ["metal halide", "CHEMICAL", 91, 103], ["metal halide", "CHEMICAL", 22, 34], ["methyl-linderone", "CHEMICAL", 71, 87], ["metal halide", "CHEMICAL", 91, 103], ["methyl-linderone", "SIMPLE_CHEMICAL", 71, 87], ["metal halide", "SIMPLE_CHEMICAL", 91, 103], ["the metal halide lamp", "TREATMENT", 18, 39], ["methyl-linderone", "TREATMENT", 71, 87], ["The metal halide lamp", "TREATMENT", 87, 108]]], ["And the relative spectral energy distribution curve obtained from the manufacturer is shown as below: To 0 -2 \u2103 pre-cooled solution of chloroform (6.45 mL, 0.08 mol) in 25 mL anhydrous DMF was added powdered potassium hydroxide (4.5 g, 0.08 mol).", [["chloroform", "CHEMICAL", 135, 145], ["anhydrous DMF", "CHEMICAL", 175, 188], ["potassium hydroxide", "CHEMICAL", 208, 227], ["chloroform", "CHEMICAL", 135, 145], ["DMF", "CHEMICAL", 185, 188], ["potassium hydroxide", "CHEMICAL", 208, 227], ["chloroform", "SIMPLE_CHEMICAL", 135, 145], ["anhydrous DMF", "SIMPLE_CHEMICAL", 175, 188], ["potassium hydroxide", "SIMPLE_CHEMICAL", 208, 227], ["the relative spectral energy distribution curve", "TEST", 4, 51], ["chloroform", "TREATMENT", 135, 145], ["potassium hydroxide", "TREATMENT", 208, 227]]], ["After 30min, cinnamaldehyde (2.52 mL, 0.02 mol) was slowly added to the mixture by syringe.", [["cinnamaldehyde", "CHEMICAL", 13, 27], ["cinnamaldehyde", "CHEMICAL", 13, 27], ["cinnamaldehyde", "SIMPLE_CHEMICAL", 13, 27], ["cinnamaldehyde", "TREATMENT", 13, 27]]], ["The reaction was monitored by thin layer chromatography (TLC).", [["The reaction", "PROBLEM", 0, 12], ["thin layer chromatography", "TEST", 30, 55]]], ["After the reaction finished, the mixture was poured into 10 mL distilled water and extracted with ethyl acetate.", [["ethyl acetate", "CHEMICAL", 98, 111], ["ethyl acetate", "CHEMICAL", 98, 111], ["ethyl acetate", "SIMPLE_CHEMICAL", 98, 111], ["the reaction", "PROBLEM", 6, 18], ["ethyl acetate", "TREATMENT", 98, 111]]], ["The combined organic extract was washed with water, dried (Na 2 SO 4 ) and evaporated.", [["organic extract", "CHEMICAL", 13, 28], ["Na 2 SO 4", "CHEMICAL", 59, 68], ["Na 2 SO 4", "CHEMICAL", 59, 68], ["The combined organic extract", "TREATMENT", 0, 28], ["organic extract", "OBSERVATION", 13, 28]]], ["The crude product was purified by column chromatography using ethyl acetate and petroleum ether (1/30 = v/v) as an eluent to afford A (4.91 g, 97.6%b ATo a flame dried reaction tube was added A (0.005 mol), CuCl (1.00 g, 0.01 mol) and dry 1,2-dichloroethane (DCE) (10 mL).", [["ethyl acetate", "CHEMICAL", 62, 75], ["petroleum ether", "CHEMICAL", 80, 95], ["CuCl", "CHEMICAL", 207, 211], ["dry 1,2-dichloroethane", "CHEMICAL", 235, 257], ["DCE", "CHEMICAL", 259, 262], ["ethyl acetate", "CHEMICAL", 62, 75], ["petroleum ether", "CHEMICAL", 80, 95], ["CuCl", "CHEMICAL", 207, 211], ["1,2-dichloroethane", "CHEMICAL", 239, 257], ["DCE", "CHEMICAL", 259, 262], ["ethyl acetate", "SIMPLE_CHEMICAL", 62, 75], ["petroleum ether", "SIMPLE_CHEMICAL", 80, 95], ["CuCl", "SIMPLE_CHEMICAL", 207, 211], ["dry 1,2-dichloroethane", "SIMPLE_CHEMICAL", 235, 257], ["ethyl acetate and petroleum ether", "TREATMENT", 62, 95], ["a flame dried reaction tube", "TREATMENT", 154, 181]]], ["The solution of 2,2-bi-pyridine (bpy) (1.562 g, 0.01 mol) in DCE (10 mL) was injected into the tube through the rubber septum.", [["tube", "ANATOMY", 95, 99], ["rubber septum", "ANATOMY", 112, 125], ["2,2-bi-pyridine", "CHEMICAL", 16, 31], ["bpy", "CHEMICAL", 33, 36], ["DCE", "CHEMICAL", 61, 64], ["2,2-bi-pyridine", "CHEMICAL", 16, 31], ["bpy", "CHEMICAL", 33, 36], ["DCE", "CHEMICAL", 61, 64], ["2,2-bi-pyridine", "SIMPLE_CHEMICAL", 16, 31], ["bpy)", "SIMPLE_CHEMICAL", 33, 37], ["DCE", "SIMPLE_CHEMICAL", 61, 64], ["tube", "TISSUE", 95, 99], ["rubber septum", "MULTI-TISSUE_STRUCTURE", 112, 125], ["The solution of 2,2-bi-pyridine (bpy)", "TREATMENT", 0, 37], ["tube", "OBSERVATION", 95, 99], ["rubber septum", "ANATOMY", 112, 125]]], ["After the completion of the reaction, the reaction mixture was cooled and filtered and the filtrate was evaporated under reduced pressure.", [["the reaction", "PROBLEM", 24, 36], ["the reaction mixture", "TREATMENT", 38, 58], ["the filtrate", "TREATMENT", 87, 99], ["reduced", "OBSERVATION_MODIFIER", 121, 128], ["pressure", "OBSERVATION_MODIFIER", 129, 137]]], ["The crude product was purified by flash column chromatography (ether : petroleum ether = 1 : 10) to give pure chloromethyl ketone 6b (560 mg, 62%).", [["ether : petroleum ether", "CHEMICAL", 63, 86], ["chloromethyl ketone 6b", "CHEMICAL", 110, 132], ["ether", "CHEMICAL", 63, 68], ["petroleum ether", "CHEMICAL", 71, 86], ["chloromethyl ketone", "CHEMICAL", 110, 129], ["ether", "SIMPLE_CHEMICAL", 63, 68], ["chloromethyl ketone 6b", "SIMPLE_CHEMICAL", 110, 132], ["flash column chromatography", "TEST", 34, 61], ["pure chloromethyl ketone 6b", "TREATMENT", 105, 132]]], ["1 To the 75 mL acetone charged with 6b (654 mg, 3.62 mmol) was added NaI (1 eq), the reaction mixture under an argon atmosphere was stirred at room temperature about 1 h.", [["acetone charged", "CHEMICAL", 15, 30], ["NaI", "CHEMICAL", 69, 72], ["acetone", "CHEMICAL", 15, 22], ["NaI", "CHEMICAL", 69, 72], ["6b", "TREATMENT", 36, 38], ["the reaction mixture", "PROBLEM", 81, 101], ["an argon atmosphere", "TREATMENT", 108, 127]]], ["TLC showed the presence of a single compound having the same Rf value as the starting material.", [["TLC", "TEST", 0, 3], ["a single compound", "PROBLEM", 27, 44], ["Rf value", "TEST", 61, 69]]], ["After the completion of the reaction, the reaction mixture was filtered and concentrated.", [["the reaction", "PROBLEM", 24, 36], ["the reaction mixture", "TREATMENT", 38, 58]]], ["The crude product was quickly purified by flash column chromatography (ether : petroleum ether = 1 : 5) to give pure 886.6 mg 6c in 90% yield Table 1 .", [["ether : petroleum ether", "CHEMICAL", 71, 94], ["ether", "CHEMICAL", 71, 76], ["petroleum ether", "CHEMICAL", 79, 94], ["ether", "SIMPLE_CHEMICAL", 71, 76], ["flash column chromatography", "TEST", 42, 69]]], ["Crystal data and structure refinement for bi-linderone.", [["bi-linderone", "CHEMICAL", 42, 54], ["bi-linderone", "CHEMICAL", 42, 54], ["bi-linderone", "SIMPLE_CHEMICAL", 42, 54], ["Crystal data", "TEST", 0, 12], ["bi-linderone", "TREATMENT", 42, 54]]], ["(7) 1.342(7) C(3)-C (7) 1.458(7) C(4)-C (5) 1.471(8) C(5)-C (6) 1.465(6) C(6)- C(8) 1.352(6) C(6)-C (7) 1.484(7) C(8)- C(10) 1.496(6) C(9)-H(9A) 0.9600 C(9)-H(9B) 0.9600 C(9)-H(9C) 0.9600 C(10)- C(11) 1.521(6) C(10)- C(15) 1.531(7) C(10)-H(10) 0.9800 C(11)- C(12) 1.313(6) C(12)- C(13) 1.501(6) C(12)-H(12) 0.9300 C(13)- C(29) 1.505(6) C(13)- C(14) 1.559 (6)", [["H", "CHEMICAL", 175, 176], ["H", "CHEMICAL", 238, 239], ["H", "CHEMICAL", 301, 302], ["3)-C (7) 1.458(7) C(4)-C (5) 1.471(8) C(5)-C (6) 1.465(6) C(6)- C(8) 1.352(6) C(6)-C (7) 1.484(7) C(8)- C(10) 1.496(6) C(9", "SIMPLE_CHEMICAL", 15, 137], ["C", "TEST", 33, 34], ["C", "TEST", 53, 54], ["C", "TEST", 58, 59], ["C", "TEST", 73, 74], ["C", "TEST", 79, 80], ["C", "TEST", 93, 94], ["C", "TEST", 98, 99], ["C", "TEST", 113, 114], ["C", "TEST", 134, 135], ["C", "TEST", 152, 153], ["C", "TEST", 170, 171], ["C", "TEST", 210, 211], ["C", "TEST", 217, 218], ["C", "TEST", 232, 233], ["C", "TEST", 280, 281], ["C", "TEST", 321, 322], ["C", "TEST", 336, 337]]]], "e394bb1508e17cd28216b998cf2822f611ac4b45": [["INTRODUCTIONIn December 2019, a new type of coronavirus was discovered in Wuhan province, China, causing a condition of severe respiratory failure called COVID-19.", [["respiratory", "ANATOMY", 127, 138], ["coronavirus", "DISEASE", 44, 55], ["respiratory failure", "DISEASE", 127, 146], ["coronavirus", "ORGANISM", 44, 55], ["coronavirus", "PROBLEM", 44, 55], ["severe respiratory failure", "PROBLEM", 120, 146], ["COVID", "TEST", 154, 159], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["respiratory failure", "OBSERVATION", 127, 146]]], ["SARS-CoV-2, the technical name of this new infectious agent, is genetically linked to SARS-CoV-1 and MERS-CoV, two other human coronaviruses that have caused severe lower respiratory tract infections in China in 2002-2003 and in the Middle East since 2012, respectively [1] .", [["lower respiratory tract", "ANATOMY", 165, 188], ["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 86, 90], ["human coronaviruses", "DISEASE", 121, 140], ["lower respiratory tract infections", "DISEASE", 165, 199], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV-1", "ORGANISM", 86, 96], ["MERS-CoV", "ORGANISM", 101, 109], ["human", "ORGANISM", 121, 126], ["tract", "ORGANISM_SUBDIVISION", 183, 188], ["CoV-1", "SPECIES", 91, 96], ["human", "SPECIES", 121, 126], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV-1", "SPECIES", 86, 96], ["MERS-CoV", "SPECIES", 101, 109], ["human coronaviruses", "SPECIES", 121, 140], ["SARS", "TEST", 86, 90], ["CoV", "TEST", 91, 94], ["MERS", "PROBLEM", 101, 105], ["CoV", "PROBLEM", 106, 109], ["two other human coronaviruses", "PROBLEM", 111, 140], ["severe lower respiratory tract infections", "PROBLEM", 158, 199], ["severe", "OBSERVATION_MODIFIER", 158, 164], ["lower", "ANATOMY_MODIFIER", 165, 170], ["respiratory tract", "ANATOMY", 171, 188], ["infections", "OBSERVATION", 189, 199], ["Middle", "ANATOMY_MODIFIER", 233, 239]]], ["From China, SARS-Cov-2 quickly spread across the world, making the World Health Organization (WHO) decree this pathology a pandemic in mid-March 2020 (https://www.who.int/dg/speeches).", [["SARS", "DISEASE", 12, 16]]], ["As of the 13 th July 2020, more than 13 The rapid transmissibility of SARS-CoV-2 has led several countries to adopt strategies to mitigate contagion spread, which includes social isolation/distancing, lockdown and temporary closure of educational institutions [2] , [3] .", [["SARS", "DISEASE", 70, 74], ["contagion", "DISEASE", 139, 148], ["SARS-CoV", "SPECIES", 70, 78], ["SARS", "PROBLEM", 70, 74], ["contagion spread", "PROBLEM", 139, 155], ["temporary closure of educational institutions", "TREATMENT", 214, 259]]], ["Such measures aim to prevent an accumulation of a large number of people with the severe form of the disease in need of hospital care simultaneously, which could lead to a collapse in health systems worldwide [4] .", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72], ["the disease", "PROBLEM", 97, 108], ["hospital care", "TREATMENT", 120, 133], ["a collapse in health systems", "PROBLEM", 170, 198], ["accumulation", "OBSERVATION_MODIFIER", 32, 44], ["large", "OBSERVATION_MODIFIER", 50, 55], ["number", "OBSERVATION_MODIFIER", 56, 62], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["disease", "OBSERVATION", 101, 108], ["collapse", "OBSERVATION", 172, 180]]], ["However, the great concern and need for such governmental policies has led part of the affected nations to an unprecedented economic and social crisis, since unemployment rates, the number of companies' bankruptcies and reports of depressive conditions and other mental disorders have greatly increased in this period [5] - [8] .INTRODUCTIONIn this context, the global scientific community has engaged in a worldwide effort to understand the pathophysiology of COVID-19, in order to develop an effective treatment as quickly as possible.INTRODUCTIONResults obtained so far have proved this journey very fruitful.", [["bankruptcies", "DISEASE", 203, 215], ["depressive", "DISEASE", 231, 241], ["COVID-19", "CHEMICAL", 461, 469], ["such governmental policies", "TREATMENT", 40, 66], ["depressive conditions", "PROBLEM", 231, 252], ["other mental disorders", "PROBLEM", 257, 279], ["COVID", "TEST", 461, 466], ["an effective treatment", "TREATMENT", 491, 513], ["great", "OBSERVATION_MODIFIER", 13, 18], ["social crisis", "OBSERVATION", 137, 150]]], ["For instance, it has been demonstrated that although SARS-CoV-2 is directly related to respiratory tract dysfunction due to an intense inflammatory process called \"cytokine storm\", which promotes the accumulation of fluid in alveoli [9] , the infection can also be systemic, with evidence of the presence of viral genetic material in the gastrointestinal tract and the central nervous system [10] , [11] .", [["respiratory tract", "ANATOMY", 87, 104], ["fluid", "ANATOMY", 216, 221], ["alveoli", "ANATOMY", 225, 232], ["gastrointestinal tract", "ANATOMY", 338, 360], ["central nervous system", "ANATOMY", 369, 391], ["respiratory tract dysfunction", "DISEASE", 87, 116], ["infection", "DISEASE", 243, 252], ["SARS-CoV-2", "ORGANISM", 53, 63], ["respiratory tract", "ORGANISM_SUBDIVISION", 87, 104], ["fluid", "ORGANISM_SUBSTANCE", 216, 221], ["gastrointestinal tract", "ORGAN", 338, 360], ["central nervous system", "ANATOMICAL_SYSTEM", 369, 391], ["cytokine", "PROTEIN", 164, 172], ["SARS-CoV", "SPECIES", 53, 61], ["SARS", "PROBLEM", 53, 57], ["respiratory tract dysfunction", "PROBLEM", 87, 116], ["an intense inflammatory process", "PROBLEM", 124, 155], ["fluid in alveoli", "PROBLEM", 216, 232], ["the infection", "PROBLEM", 239, 252], ["viral genetic material in the gastrointestinal tract", "PROBLEM", 308, 360], ["respiratory tract", "ANATOMY", 87, 104], ["intense", "OBSERVATION_MODIFIER", 127, 134], ["inflammatory", "OBSERVATION", 135, 147], ["cytokine storm", "OBSERVATION", 164, 178], ["accumulation", "OBSERVATION_MODIFIER", 200, 212], ["fluid", "OBSERVATION", 216, 221], ["alveoli", "ANATOMY", 225, 232], ["infection", "OBSERVATION", 243, 252], ["viral genetic material", "OBSERVATION", 308, 330], ["gastrointestinal tract", "ANATOMY", 338, 360], ["central", "ANATOMY_MODIFIER", 369, 376], ["nervous", "ANATOMY", 377, 384]]], ["These findings can potentially explain why symptoms unrelated to the respiratory tract, like vomiting and diarrhea [12] , as well as neurological disorders [13] , are found in COVID-19 patients.INTRODUCTIONStudies developed so far have also started to shed a light on the molecular mechanisms mediating the process of viral infection in human cells.", [["respiratory tract", "ANATOMY", 69, 86], ["neurological", "ANATOMY", 133, 145], ["cells", "ANATOMY", 343, 348], ["respiratory tract", "DISEASE", 69, 86], ["vomiting", "DISEASE", 93, 101], ["diarrhea", "DISEASE", 106, 114], ["neurological disorders", "DISEASE", 133, 155], ["viral infection", "DISEASE", 318, 333], ["respiratory tract", "ORGANISM_SUBDIVISION", 69, 86], ["patients", "ORGANISM", 185, 193], ["human", "ORGANISM", 337, 342], ["cells", "CELL", 343, 348], ["human cells", "CELL_TYPE", 337, 348], ["patients", "SPECIES", 185, 193], ["human", "SPECIES", 337, 342], ["human", "SPECIES", 337, 342], ["why symptoms", "PROBLEM", 39, 51], ["the respiratory tract", "PROBLEM", 65, 86], ["vomiting", "PROBLEM", 93, 101], ["diarrhea", "PROBLEM", 106, 114], ["neurological disorders", "PROBLEM", 133, 155], ["viral infection in human cells", "PROBLEM", 318, 348], ["respiratory tract", "ANATOMY", 69, 86], ["viral", "OBSERVATION_MODIFIER", 318, 323], ["infection", "OBSERVATION", 324, 333], ["human cells", "OBSERVATION", 337, 348]]], ["The entry of viral particles in host cells depends on the specific binding of virus Spike protein to the human membrane receptor ACE2 -from Angiotensin-Convertor Enzyme 2 [14] , [15] .", [["cells", "ANATOMY", 37, 42], ["membrane", "ANATOMY", 111, 119], ["Angiotensin", "CHEMICAL", 140, 151], ["host cells", "CELL", 32, 42], ["human", "ORGANISM", 105, 110], ["ACE2", "GENE_OR_GENE_PRODUCT", 129, 133], ["Angiotensin-Convertor Enzyme 2", "GENE_OR_GENE_PRODUCT", 140, 170], ["[15]", "SIMPLE_CHEMICAL", 178, 182], ["host cells", "CELL_TYPE", 32, 42], ["virus Spike protein", "PROTEIN", 78, 97], ["human membrane receptor", "PROTEIN", 105, 128], ["ACE2", "PROTEIN", 129, 133], ["Angiotensin", "PROTEIN", 140, 151], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["viral particles in host cells", "PROBLEM", 13, 42], ["virus Spike protein", "PROBLEM", 78, 97], ["ACE2", "TEST", 129, 133], ["Angiotensin", "TEST", 140, 151], ["Enzyme", "TEST", 162, 168], ["viral particles", "OBSERVATION", 13, 28], ["host cells", "OBSERVATION", 32, 42]]], ["This receptor is distributed all over the surface of a large diversity of cell types, such as those from the central nervous system, upper airways and lungs, liver, kidneys, pancreas, heart and endothelial cells [16] .", [["surface", "ANATOMY", 42, 49], ["cell", "ANATOMY", 74, 78], ["central nervous system", "ANATOMY", 109, 131], ["upper airways", "ANATOMY", 133, 146], ["lungs", "ANATOMY", 151, 156], ["liver", "ANATOMY", 158, 163], ["kidneys", "ANATOMY", 165, 172], ["pancreas", "ANATOMY", 174, 182], ["heart", "ANATOMY", 184, 189], ["endothelial cells", "ANATOMY", 194, 211], ["surface", "CELLULAR_COMPONENT", 42, 49], ["cell", "CELL", 74, 78], ["central nervous system", "ANATOMICAL_SYSTEM", 109, 131], ["upper airways", "MULTI-TISSUE_STRUCTURE", 133, 146], ["lungs", "ORGAN", 151, 156], ["liver", "ORGAN", 158, 163], ["kidneys", "ORGAN", 165, 172], ["pancreas", "ORGAN", 174, 182], ["heart", "ORGAN", 184, 189], ["endothelial cells", "CELL", 194, 211], ["endothelial cells", "CELL_TYPE", 194, 211], ["a large diversity of cell types", "PROBLEM", 53, 84], ["upper airways and lungs, liver, kidneys, pancreas, heart and endothelial cells", "PROBLEM", 133, 211], ["distributed", "OBSERVATION_MODIFIER", 17, 28], ["all", "OBSERVATION_MODIFIER", 29, 32], ["surface", "OBSERVATION_MODIFIER", 42, 49], ["large", "OBSERVATION_MODIFIER", 55, 60], ["diversity", "OBSERVATION", 61, 70], ["cell types", "OBSERVATION", 74, 84], ["central", "ANATOMY_MODIFIER", 109, 116], ["nervous system", "ANATOMY", 117, 131], ["upper", "ANATOMY_MODIFIER", 133, 138], ["airways", "ANATOMY", 139, 146], ["lungs", "ANATOMY", 151, 156], ["liver", "ANATOMY", 158, 163], ["kidneys", "ANATOMY", 165, 172], ["pancreas", "ANATOMY", 174, 182], ["heart", "ANATOMY", 184, 189], ["endothelial cells", "OBSERVATION", 194, 211]]], ["Its function is equally diverse depending on the cell type where it lies, ranging from blood pressure regulation, through the renin-angiotensin-aldosterone system, to controlling blood glucose and renal activity [17] , [18] .", [["cell", "ANATOMY", 49, 53], ["blood", "ANATOMY", 87, 92], ["blood", "ANATOMY", 179, 184], ["renal", "ANATOMY", 197, 202], ["angiotensin", "CHEMICAL", 132, 143], ["aldosterone", "CHEMICAL", 144, 155], ["glucose", "CHEMICAL", 185, 192], ["aldosterone", "CHEMICAL", 144, 155], ["glucose", "CHEMICAL", 185, 192], ["cell type", "CELL", 49, 58], ["blood", "ORGANISM_SUBSTANCE", 87, 92], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 126, 155], ["blood", "ORGANISM_SUBSTANCE", 179, 184], ["glucose", "SIMPLE_CHEMICAL", 185, 192], ["renal", "ORGAN", 197, 202], ["renin", "PROTEIN", 126, 131], ["blood pressure regulation", "TEST", 87, 112], ["the renin-angiotensin-aldosterone system", "TREATMENT", 122, 162], ["blood glucose", "TEST", 179, 192], ["equally", "OBSERVATION_MODIFIER", 16, 23], ["diverse", "OBSERVATION_MODIFIER", 24, 31], ["renal", "ANATOMY", 197, 202]]], ["Despite the central role of ACE2 in the virus-human cell interaction, other host molecules have also been recognized as important players in the infectious process, such as the transmembrane proteins CD147 [19] , [20] and TMPRSS2 [21] .INTRODUCTIONCD147 (also known as EMMPRIN, from Extracellular Matrix Metalloproteinase Inducer, basigin, M6, neurothelin and HAb18G) is believed to function as a coreceptor for the novel coronavirus attachment to host cells [20] .", [["cell", "ANATOMY", 52, 56], ["transmembrane", "ANATOMY", 177, 190], ["cells", "ANATOMY", 453, 458], ["ACE2", "GENE_OR_GENE_PRODUCT", 28, 32], ["human", "ORGANISM", 46, 51], ["cell", "CELL", 52, 56], ["transmembrane", "CELLULAR_COMPONENT", 177, 190], ["CD147", "GENE_OR_GENE_PRODUCT", 200, 205], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 269, 276], ["Extracellular Matrix Metalloproteinase Inducer", "GENE_OR_GENE_PRODUCT", 283, 329], ["basigin", "GENE_OR_GENE_PRODUCT", 331, 338], ["M6", "GENE_OR_GENE_PRODUCT", 340, 342], ["neurothelin", "GENE_OR_GENE_PRODUCT", 344, 355], ["HAb18G", "GENE_OR_GENE_PRODUCT", 360, 366], ["coronavirus", "ORGANISM", 422, 433], ["host cells", "CELL", 448, 458], ["ACE2", "PROTEIN", 28, 32], ["transmembrane proteins", "PROTEIN", 177, 199], ["CD147", "PROTEIN", 200, 205], ["INTRODUCTIONCD147", "PROTEIN", 236, 253], ["EMMPRIN", "PROTEIN", 269, 276], ["Extracellular Matrix Metalloproteinase Inducer", "PROTEIN", 283, 329], ["basigin", "PROTEIN", 331, 338], ["M6", "PROTEIN", 340, 342], ["neurothelin", "PROTEIN", 344, 355], ["HAb18G", "PROTEIN", 360, 366], ["host cells", "CELL_TYPE", 448, 458], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["the transmembrane proteins CD147", "TEST", 173, 205], ["TMPRSS2", "TEST", 222, 229], ["Extracellular Matrix Metalloproteinase Inducer", "TREATMENT", 283, 329], ["neurothelin and HAb18G", "TREATMENT", 344, 366], ["a coreceptor", "TREATMENT", 395, 407], ["the novel coronavirus attachment", "PROBLEM", 412, 444]]], ["It is a type I transmembrane protein heavily glycosylated that plays roles in spermatogenesis and fertilization, neural network formation and development, tumor metastasis and angiogenesis, and cardiovascular disease [22] , [23] .", [["neural network", "ANATOMY", 113, 127], ["tumor", "ANATOMY", 155, 160], ["cardiovascular", "ANATOMY", 194, 208], ["tumor", "DISEASE", 155, 160], ["cardiovascular disease", "DISEASE", 194, 216], ["neural network", "MULTI-TISSUE_STRUCTURE", 113, 127], ["tumor", "CANCER", 155, 160], ["type I transmembrane protein", "PROTEIN", 8, 36], ["a type I transmembrane protein heavily glycosylated", "PROBLEM", 6, 57], ["fertilization", "TREATMENT", 98, 111], ["neural network formation", "TREATMENT", 113, 137], ["tumor metastasis", "PROBLEM", 155, 171], ["angiogenesis", "PROBLEM", 176, 188], ["cardiovascular disease", "PROBLEM", 194, 216], ["tumor", "OBSERVATION_MODIFIER", 155, 160], ["metastasis", "OBSERVATION", 161, 171]]], ["In turn, TMPRSS2 (from Transmembrane Protease Serine type 2) has been reported to promote cleavage of Spike protein in two different sites to induce SARS-CoV-1 and SARS-CoV-2 invasion [24] - [26] , since application of a clinically available inhibitor of its protease activity blocks SARS-CoV-2 entry in cell culture [21] .INTRODUCTIONTMPRSS2 is lightly glycosylated, playing important roles in human and mammal development and homeostasis, as well as in several diseases, such as cancer [27] and infecton by influenza [28] .INTRODUCTIONA couple of preprint reports and a study using large-scale genetic data from infected and non-infected patients have identified a significant association between type A blood individuals (from the ABO blood system) and higher susceptibility to both infection with SARS-CoV-2 and development of more severe forms of COVID-19 [29] - [31] .", [["sites", "ANATOMY", 133, 138], ["cell culture", "ANATOMY", 304, 316], ["cancer", "ANATOMY", 481, 487], ["blood", "ANATOMY", 706, 711], ["blood system", "ANATOMY", 738, 750], ["cancer", "DISEASE", 481, 487], ["influenza", "DISEASE", 509, 518], ["infection", "DISEASE", 786, 795], ["SARS", "DISEASE", 801, 805], ["COVID-19 [29] -", "CHEMICAL", 852, 867], ["COVID-19", "CHEMICAL", 852, 860], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 9, 16], ["Transmembrane Protease Serine type 2", "GENE_OR_GENE_PRODUCT", 23, 59], ["Spike", "GENE_OR_GENE_PRODUCT", 102, 107], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 149, 159], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 284, 294], ["cell", "CELL", 304, 308], ["human", "ORGANISM", 395, 400], ["mammal", "ORGANISM_SUBDIVISION", 405, 411], ["cancer", "CANCER", 481, 487], ["patients", "ORGANISM", 640, 648], ["blood", "ORGANISM_SUBSTANCE", 706, 711], ["blood", "ORGANISM_SUBSTANCE", 738, 743], ["CoV-2", "ORGANISM", 806, 811], ["COVID-19", "SIMPLE_CHEMICAL", 852, 860], ["TMPRSS2", "PROTEIN", 9, 16], ["Spike protein", "PROTEIN", 102, 115], ["protease", "PROTEIN", 259, 267], ["INTRODUCTIONTMPRSS2", "PROTEIN", 323, 342], ["human", "SPECIES", 395, 400], ["patients", "SPECIES", 640, 648], ["human", "SPECIES", 395, 400], ["SARS-CoV", "SPECIES", 801, 809], ["TMPRSS2", "TEST", 9, 16], ["Transmembrane Protease Serine type", "TREATMENT", 23, 57], ["Spike protein", "PROBLEM", 102, 115], ["SARS", "TEST", 149, 153], ["CoV", "TEST", 154, 157], ["SARS", "TEST", 164, 168], ["CoV", "TEST", 169, 172], ["its protease activity blocks", "TREATMENT", 255, 283], ["SARS", "TEST", 284, 288], ["CoV", "TEST", 289, 292], ["cell culture", "TEST", 304, 316], ["influenza", "PROBLEM", 509, 518], ["a study", "TEST", 570, 577], ["type A blood individuals", "PROBLEM", 699, 723], ["the ABO blood system", "TEST", 730, 750], ["higher susceptibility to both infection", "PROBLEM", 756, 795], ["SARS", "TEST", 801, 805], ["CoV", "TEST", 806, 809], ["COVID", "TEST", 852, 857], ["lightly glycosylated", "OBSERVATION_MODIFIER", 346, 366], ["infection", "OBSERVATION", 786, 795], ["more severe", "OBSERVATION_MODIFIER", 831, 842]]], ["Although a correlation between ABO blood type and infection susceptibility is not unique of the new coronavirus, since it was previously reported also for the infection by the protozoan that causes malaria [32] - [34] , the molecular mechanism underlying this relationship is still poorly understood.HYPOTHESISSupported by an extensive bibliographic review highlighting (i) the mode of binding of SARS-CoV-2HYPOTHESISto cell receptors, as well as (ii) the biochemical aspects of ABO blood group system and its association to infection and some circulatory conditions, we hypothesize that the influence of blood type on COVID-19 severity relies on the differential clustering of glycoproteins receptors to SARS-CoV-2 on host cell surface, induced by ABH antigens through carbohydrate-carbohydrate interactions with the glycan portions of these receptors, which could modulate virus binding to the target cell.SARS-CoV-2 binding to host cellsAlthough SARS-CoV-2 is a new virus, much has been studied about its biochemical characteristics, especially regarding its Spike protein, within less than a year since its discovery [35] - [38] .", [["blood", "ANATOMY", 35, 40], ["cell", "ANATOMY", 420, 424], ["blood", "ANATOMY", 483, 488], ["blood", "ANATOMY", 605, 610], ["cell surface", "ANATOMY", 724, 736], ["cell", "ANATOMY", 903, 907], ["cells", "ANATOMY", 935, 940], ["ABO blood type", "DISEASE", 31, 45], ["infection", "DISEASE", 50, 59], ["coronavirus", "DISEASE", 100, 111], ["infection", "DISEASE", 159, 168], ["malaria", "DISEASE", 198, 205], ["infection", "DISEASE", 525, 534], ["SARS", "DISEASE", 908, 912], ["SARS", "DISEASE", 949, 953], ["carbohydrate", "CHEMICAL", 770, 782], ["carbohydrate", "CHEMICAL", 783, 795], ["ABO", "GENE_OR_GENE_PRODUCT", 31, 34], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["coronavirus", "ORGANISM", 100, 111], ["SARS-CoV-2HYPOTHESISto cell receptors", "GENE_OR_GENE_PRODUCT", 397, 434], ["ABO", "GENE_OR_GENE_PRODUCT", 479, 482], ["blood", "ORGANISM_SUBSTANCE", 483, 488], ["blood", "ORGANISM_SUBSTANCE", 605, 610], ["COVID-19", "ORGANISM", 619, 627], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 705, 715], ["host cell", "CELL", 719, 728], ["surface", "CELLULAR_COMPONENT", 729, 736], ["ABH antigens", "GENE_OR_GENE_PRODUCT", 749, 761], ["cell", "CELL", 903, 907], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 908, 918], ["host cells", "CELL", 930, 940], ["SARS-CoV-2", "ORGANISM", 949, 959], ["Spike", "GENE_OR_GENE_PRODUCT", 1062, 1067], ["SARS-CoV-2HYPOTHESISto cell receptors", "PROTEIN", 397, 434], ["glycoproteins receptors", "PROTEIN", 678, 701], ["ABH antigens", "PROTEIN", 749, 761], ["target cell", "CELL_TYPE", 896, 907], ["host cells", "CELL_TYPE", 930, 940], ["Spike protein", "PROTEIN", 1062, 1075], ["SARS-CoV", "SPECIES", 949, 957], ["ABO blood type", "TEST", 31, 45], ["infection susceptibility", "PROBLEM", 50, 74], ["the new coronavirus", "PROBLEM", 92, 111], ["the infection", "PROBLEM", 155, 168], ["the protozoan", "PROBLEM", 172, 185], ["malaria", "PROBLEM", 198, 205], ["SARS-CoV-2HYPOTHESISto cell receptors", "TREATMENT", 397, 434], ["ABO blood group system", "PROBLEM", 479, 501], ["infection", "PROBLEM", 525, 534], ["some circulatory conditions", "PROBLEM", 539, 566], ["blood type", "TEST", 605, 615], ["COVID", "TEST", 619, 624], ["glycoproteins receptors", "PROBLEM", 678, 701], ["SARS", "TEST", 705, 709], ["CoV", "TEST", 710, 713], ["host cell surface", "TREATMENT", 719, 736], ["carbohydrate-carbohydrate interactions", "TREATMENT", 770, 808], ["these receptors", "TREATMENT", 837, 852], ["modulate virus binding", "PROBLEM", 866, 888], ["SARS", "PROBLEM", 908, 912], ["SARS", "PROBLEM", 949, 953], ["a new virus", "PROBLEM", 963, 974], ["Spike protein", "PROBLEM", 1062, 1075], ["infection", "OBSERVATION", 50, 59], ["new", "OBSERVATION_MODIFIER", 96, 99], ["coronavirus", "OBSERVATION", 100, 111], ["infection", "OBSERVATION", 159, 168], ["infection", "OBSERVATION", 525, 534], ["circulatory conditions", "OBSERVATION", 544, 566], ["host cell", "OBSERVATION_MODIFIER", 719, 728], ["target cell", "OBSERVATION", 896, 907], ["host cells", "OBSERVATION", 930, 940]]], ["In this way, because our focus is on trying to understand how an individual's blood type turns him more or less susceptible to being infected, it is important to address the main known aspects of the virus-host cell interaction.SARS-CoV-2 binding to host cellsFrom the pathogen perspective, the interaction is mediated by Spike (S) -a structural glycoprotein that emerges from the viral envelope in a homotrimeric arrangement, i.e., through the non-covalent association of three equal monomers or polypeptide chains.", [["blood", "ANATOMY", 78, 83], ["cell", "ANATOMY", 211, 215], ["cells", "ANATOMY", 255, 260], ["SARS", "DISEASE", 228, 232], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["host cell", "CELL", 206, 215], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 228, 238], ["host cells", "CELL", 250, 260], ["host cells", "CELL_TYPE", 250, 260], ["Spike (S) -a structural glycoprotein", "PROTEIN", 322, 358], ["polypeptide chains", "PROTEIN", 497, 515], ["the virus", "PROBLEM", 196, 205], ["SARS", "PROBLEM", 228, 232], ["Spike (S) -a structural glycoprotein", "PROBLEM", 322, 358], ["polypeptide chains", "TREATMENT", 497, 515], ["host cell interaction", "OBSERVATION", 206, 227], ["host cells", "OBSERVATION", 250, 260], ["viral envelope", "OBSERVATION", 381, 395], ["polypeptide chains", "OBSERVATION", 497, 515]]], ["Each monomer is composed of two subunits called S1 and S2, which are essential for the binding of the virus to receptors present on host cells surface and for the fusion of the viral coat with the plasma membrane, respectively.", [["cells surface", "ANATOMY", 137, 150], ["plasma membrane", "ANATOMY", 197, 212], ["S1", "GENE_OR_GENE_PRODUCT", 48, 50], ["S2", "GENE_OR_GENE_PRODUCT", 55, 57], ["host cells", "CELL", 132, 142], ["surface", "CELLULAR_COMPONENT", 143, 150], ["plasma membrane", "CELLULAR_COMPONENT", 197, 212], ["S1", "PROTEIN", 48, 50], ["S2", "PROTEIN", 55, 57], ["the virus", "PROBLEM", 98, 107], ["host cells surface", "TREATMENT", 132, 150], ["the fusion", "TREATMENT", 159, 169], ["S2", "ANATOMY", 55, 57], ["viral coat", "OBSERVATION", 177, 187]]], ["The two subunits are connected by an amino acid segment that in some coronaviruses species, including SARS-CoV-2, is cleaved by TMPRSS2 at a stage prior to the membrane fusion [39] .", [["membrane", "ANATOMY", 160, 168], ["amino acid", "CHEMICAL", 37, 47], ["amino acid", "CHEMICAL", 37, 47], ["amino acid", "AMINO_ACID", 37, 47], ["coronaviruses", "ORGANISM", 69, 82], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 102, 112], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 128, 135], ["membrane", "CELLULAR_COMPONENT", 160, 168], ["amino acid segment", "PROTEIN", 37, 55], ["TMPRSS2", "PROTEIN", 128, 135], ["SARS-CoV", "SPECIES", 102, 110], ["The two subunits", "TREATMENT", 0, 16], ["an amino acid segment", "TREATMENT", 34, 55], ["some coronaviruses species", "PROBLEM", 64, 90], ["SARS", "PROBLEM", 102, 106], ["TMPRSS2", "PROBLEM", 128, 135], ["the membrane fusion", "TREATMENT", 156, 175], ["amino acid segment", "OBSERVATION", 37, 55], ["some", "OBSERVATION_MODIFIER", 64, 68], ["coronaviruses species", "OBSERVATION", 69, 90]]], ["However, it is suggested that the high pathogenicity of the novel coronavirus is attributed to the additional Spike protein priming by furin, a specialized serine endoprotease that cleaves multibasic motifs, a peculiar characteristic not seen in any coronavirus species up to date [40] , [41] .", [["coronavirus", "DISEASE", 66, 77], ["serine", "CHEMICAL", 156, 162], ["coronavirus", "ORGANISM", 66, 77], ["Spike", "GENE_OR_GENE_PRODUCT", 110, 115], ["furin", "GENE_OR_GENE_PRODUCT", 135, 140], ["Spike protein", "PROTEIN", 110, 123], ["furin", "PROTEIN", 135, 140], ["serine endoprotease", "PROTEIN", 156, 175], ["multibasic motifs", "PROTEIN", 189, 206], ["the high pathogenicity", "PROBLEM", 30, 52], ["the novel coronavirus", "PROBLEM", 56, 77], ["the additional Spike protein priming", "PROBLEM", 95, 131], ["a specialized serine endoprotease", "TREATMENT", 142, 175], ["multibasic motifs", "PROBLEM", 189, 206], ["any coronavirus species", "PROBLEM", 246, 269]]], ["S1 is subdivided into two domains named S1A (or S A ) and S1B (or S B ), arranged in a \"V\"SARS-CoV-2 binding to host cellsconformation.", [["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["S1A", "GENE_OR_GENE_PRODUCT", 40, 43], ["S A )", "GENE_OR_GENE_PRODUCT", 48, 53], ["S1B", "GENE_OR_GENE_PRODUCT", 58, 61], ["S B", "GENE_OR_GENE_PRODUCT", 66, 69], ["CoV-2", "GENE_OR_GENE_PRODUCT", 95, 100], ["S1", "PROTEIN", 0, 2], ["S1A", "PROTEIN", 40, 43], ["S A", "PROTEIN", 48, 51], ["S1B", "PROTEIN", 58, 61], ["S B", "PROTEIN", 66, 69]]], ["The former corresponds to the N-terminal region of the polypeptide chain (hereafter called NTD, from N-Terminal Domain) and, in most coronaviruses, interacts with glycoproteins and glycolipids that have sialic acid molecules at the distal end of the glycan portion, especially if the monosaccharide is in the modified form of 5-N-acetyl-9-O-acetyl-sialoside [42] .", [["sialic acid", "CHEMICAL", 203, 214], ["5-N-acetyl-9-O-acetyl-sialoside", "CHEMICAL", 326, 357], ["N", "CHEMICAL", 30, 31], ["N", "CHEMICAL", 101, 102], ["sialic acid", "CHEMICAL", 203, 214], ["monosaccharide", "CHEMICAL", 284, 298], ["5-N-acetyl-9-O-acetyl-sialoside", "CHEMICAL", 326, 357], ["sialic acid", "SIMPLE_CHEMICAL", 203, 214], ["5-N-acetyl-9-O-acetyl-sialoside [42]", "SIMPLE_CHEMICAL", 326, 362], ["N-terminal region", "PROTEIN", 30, 47], ["polypeptide chain", "PROTEIN", 55, 72], ["NTD", "PROTEIN", 91, 94], ["N", "PROTEIN", 101, 102], ["Terminal Domain", "PROTEIN", 103, 118], ["glycoproteins", "PROTEIN", 163, 176], ["sialic acid molecules", "PROTEIN", 203, 224], ["the polypeptide chain", "PROBLEM", 51, 72], ["NTD", "PROBLEM", 91, 94], ["glycoproteins", "TREATMENT", 163, 176], ["glycolipids", "TREATMENT", 181, 192], ["sialic acid molecules", "PROBLEM", 203, 224], ["the monosaccharide", "TEST", 280, 298], ["N-acetyl", "TREATMENT", 328, 336], ["acetyl", "TREATMENT", 341, 347], ["distal", "ANATOMY_MODIFIER", 232, 238]]], ["S1B (hereafter named RBD -from Receptor-Binding Domain), on the other hand, binds to the ACE2 receptor, which is largely recognized as the main entry route for some coronaviruses into host cells [37] .", [["cells", "ANATOMY", 189, 194], ["S1B", "GENE_OR_GENE_PRODUCT", 0, 3], ["Receptor-Binding Domain", "GENE_OR_GENE_PRODUCT", 31, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["host cells", "CELL", 184, 194], ["S1B", "PROTEIN", 0, 3], ["RBD", "PROTEIN", 21, 24], ["Receptor-Binding Domain", "PROTEIN", 31, 54], ["ACE2 receptor", "PROTEIN", 89, 102], ["host cells", "CELL_TYPE", 184, 194], ["RBD", "PROBLEM", 21, 24], ["some coronaviruses into host cells", "PROBLEM", 160, 194]]], ["For other coronaviruses, instead, this function is played by diptidyl-peptidase 4 -DPP4 [43] , [44] or aminopeptidase N -APN [45] , [46] receptors.SARS-CoV-2 binding to host cellsIn some coronaviruses species, like MERS-CoV, the likelihood interaction of its RBD domain to DPP4 receptor seems to be increased by prior binding of NTD domain to sialosides [47] , [48] .", [["cells", "ANATOMY", 174, 179], ["SARS", "DISEASE", 147, 151], ["diptidyl", "CHEMICAL", 61, 69], ["sialosides", "CHEMICAL", 343, 353], ["diptidyl-peptidase 4", "GENE_OR_GENE_PRODUCT", 61, 81], ["DPP4", "GENE_OR_GENE_PRODUCT", 83, 87], ["[44]", "SIMPLE_CHEMICAL", 95, 99], ["aminopeptidase N -APN [45]", "SIMPLE_CHEMICAL", 103, 129], ["[46] receptors", "SIMPLE_CHEMICAL", 132, 146], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 147, 157], ["host cells", "CELL", 169, 179], ["coronaviruses", "ORGANISM", 187, 200], ["MERS-CoV", "ORGANISM", 215, 223], ["DPP4 receptor", "GENE_OR_GENE_PRODUCT", 273, 286], ["diptidyl-peptidase 4", "PROTEIN", 61, 81], ["DPP4", "PROTEIN", 83, 87], ["aminopeptidase N -APN [45] , [46] receptors", "PROTEIN", 103, 146], ["host cells", "CELL_TYPE", 169, 179], ["RBD domain", "PROTEIN", 259, 269], ["DPP4 receptor", "PROTEIN", 273, 286], ["NTD domain", "PROTEIN", 329, 339], ["MERS-CoV", "SPECIES", 215, 223], ["other coronaviruses", "PROBLEM", 4, 23], ["peptidase", "TEST", 70, 79], ["DPP4", "TEST", 83, 87], ["aminopeptidase N", "TEST", 103, 119], ["APN", "TEST", 121, 124], ["SARS", "PROBLEM", 147, 151], ["some coronaviruses species", "PROBLEM", 182, 208], ["DPP4 receptor", "TEST", 273, 286], ["host cells", "OBSERVATION", 169, 179], ["coronaviruses species", "OBSERVATION", 187, 208]]], ["For most coronaviruses, however, it is not known if both domains are used for viral entry [49] , [50] , altought studies from others mammalian coronaviruses indicate that sialosides may facilitate the interaction between Spike protein and transmembrane receptors, and can be even essential in more advanced stages of infection [51] , [52] , suggesting that both domains are equally necessary for virus attachment, entry and spread.SARS-CoV-2 binding to host cellsInterestingly, it is reported that SARS-CoV-1 does not bind sialic acid, a feature that could be extended to the novel coronavirus [53] .", [["transmembrane", "ANATOMY", 239, 252], ["cells", "ANATOMY", 458, 463], ["sialosides", "CHEMICAL", 171, 181], ["infection", "DISEASE", 317, 326], ["SARS", "DISEASE", 431, 435], ["SARS", "DISEASE", 498, 502], ["sialic acid", "CHEMICAL", 523, 534], ["sialic acid", "CHEMICAL", 523, 534], ["mammalian coronaviruses", "ORGANISM", 133, 156], ["sialosides", "GENE_OR_GENE_PRODUCT", 171, 181], ["Spike", "GENE_OR_GENE_PRODUCT", 221, 226], ["transmembrane", "CELLULAR_COMPONENT", 239, 252], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 431, 441], ["host cells", "CELL", 453, 463], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 498, 508], ["sialic acid", "SIMPLE_CHEMICAL", 523, 534], ["Spike protein", "PROTEIN", 221, 234], ["transmembrane receptors", "PROTEIN", 239, 262], ["host cells", "CELL_TYPE", 453, 463], ["most coronaviruses", "PROBLEM", 4, 22], ["viral entry", "TEST", 78, 89], ["altought studies", "TEST", 104, 120], ["mammalian coronaviruses", "PROBLEM", 133, 156], ["sialosides", "TREATMENT", 171, 181], ["Spike protein and transmembrane receptors", "PROBLEM", 221, 262], ["infection", "PROBLEM", 317, 326], ["virus attachment", "PROBLEM", 396, 412], ["SARS", "PROBLEM", 431, 435], ["SARS-CoV", "TEST", 498, 506], ["sialic acid", "TEST", 523, 534], ["the novel coronavirus", "PROBLEM", 572, 593], ["most coronaviruses", "OBSERVATION_MODIFIER", 4, 22], ["infection", "OBSERVATION", 317, 326], ["spread", "OBSERVATION_MODIFIER", 424, 430], ["host cells", "OBSERVATION", 453, 463]]], ["In fact, a recent preprint study using glycan microarray did not detect significant fluorescent signals when SARS-CoV-2 Spike protein was incubated with sialic acid-containing oligosaccharides [54] .", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 109, 119], ["Spike", "GENE_OR_GENE_PRODUCT", 120, 125], ["sialic acid-containing oligosaccharides", "SIMPLE_CHEMICAL", 153, 192], ["SARS-CoV-2 Spike protein", "PROTEIN", 109, 133], ["a recent preprint study", "TEST", 9, 32], ["glycan microarray", "TEST", 39, 56], ["significant fluorescent signals", "PROBLEM", 72, 103], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117], ["Spike protein", "TEST", 120, 133], ["sialic acid-containing oligosaccharides", "TEST", 153, 192]]], ["However, in silico preprint analyses through molecular docking simulations and electronic density mapping surface predict the existence of a sialic acidbinding site in SARS-CoV-2 NTD domain similar to that one in MERS-CoV [55] , [56] .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 213, 221], ["sialic acidbinding site", "PROTEIN", 141, 164], ["SARS-CoV-2 NTD domain", "PROTEIN", 168, 189], ["MERS-CoV", "SPECIES", 213, 221], ["molecular docking simulations", "TREATMENT", 45, 74], ["electronic density mapping surface", "TREATMENT", 79, 113], ["a sialic acidbinding site", "TREATMENT", 139, 164], ["SARS", "PROBLEM", 168, 172], ["CoV", "TEST", 173, 176], ["NTD domain", "PROBLEM", 179, 189]]], ["Surprisingly, sialoside moieties are present in glycans attached to both ACE2 [57] and CD147 [58] receptors, which are potentially necessary for the virus anchoring to host cells [59] .SARS-CoV-2 binding to host cellsTaken together, these conflictant reports urge more deeply studies to clarify the sialoside participation in SARS-CoV-2 infectivity and pathogenicity.", [["cells", "ANATOMY", 173, 178], ["cells", "ANATOMY", 212, 217], ["sialoside", "CHEMICAL", 14, 23], ["SARS", "DISEASE", 185, 189], ["sialoside", "CHEMICAL", 299, 308], ["SARS", "DISEASE", 326, 330], ["sialoside", "CHEMICAL", 14, 23], ["sialoside", "CHEMICAL", 299, 308], ["sialoside moieties", "SIMPLE_CHEMICAL", 14, 32], ["ACE2 [57]", "GENE_OR_GENE_PRODUCT", 73, 82], ["CD147 [58] receptors", "GENE_OR_GENE_PRODUCT", 87, 107], ["host cells", "CELL", 168, 178], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 185, 195], ["host cells", "CELL", 207, 217], ["sialoside", "SIMPLE_CHEMICAL", 299, 308], ["SARS-CoV-2", "ORGANISM", 326, 336], ["ACE2 [57] and CD147 [58] receptors", "PROTEIN", 73, 107], ["host cells", "CELL_TYPE", 168, 178], ["host cells", "CELL_TYPE", 207, 217], ["sialoside moieties", "TREATMENT", 14, 32], ["CD147", "TEST", 87, 92], ["the virus", "PROBLEM", 145, 154], ["SARS", "PROBLEM", 185, 189], ["deeply studies", "TEST", 269, 283], ["SARS", "PROBLEM", 326, 330], ["pathogenicity", "PROBLEM", 353, 366], ["host cells", "OBSERVATION", 207, 217]]], ["The translated product of FUT1 recognizes and adds an L-fucose residue to the terminal disaccharide of a glycan precursor anchored to lipids or proteins on cell surface [62] .", [["cell surface", "ANATOMY", 156, 168], ["L-fucose", "CHEMICAL", 54, 62], ["disaccharide", "CHEMICAL", 87, 99], ["FUT1", "GENE_OR_GENE_PRODUCT", 26, 30], ["lipids", "SIMPLE_CHEMICAL", 134, 140], ["cell surface", "CELLULAR_COMPONENT", 156, 168], ["FUT1", "PROTEIN", 26, 30], ["an L-fucose residue", "TREATMENT", 51, 70], ["a glycan precursor", "TREATMENT", 103, 121]]], ["The disaccharide is formed by a terminal galactose residue connected to an N-acetylglucosamine molecule, either through a \u03b23 or \u03b24 glycosidic bond.", [["galactose", "CHEMICAL", 41, 50], ["N-acetylglucosamine", "CHEMICAL", 75, 94], ["disaccharide", "CHEMICAL", 4, 16], ["galactose", "CHEMICAL", 41, 50], ["N-acetylglucosamine", "CHEMICAL", 75, 94], ["galactose", "SIMPLE_CHEMICAL", 41, 50], ["\u03b23", "GENE_OR_GENE_PRODUCT", 122, 124], ["\u03b24 glycosidic bond", "SIMPLE_CHEMICAL", 128, 146], ["N-acetylglucosamine molecule", "PROTEIN", 75, 103], ["\u03b23", "PROTEIN", 122, 124], ["a terminal galactose residue", "PROBLEM", 30, 58], ["an N-acetylglucosamine molecule", "TREATMENT", 72, 103], ["terminal", "OBSERVATION_MODIFIER", 32, 40], ["galactose residue", "OBSERVATION", 41, 58], ["glycosidic bond", "OBSERVATION", 131, 146]]], ["Addition of L-fucose to galactose creates the antigen H, the chemical determinant of the O phenotype [62] .", [["L-fucose", "CHEMICAL", 12, 20], ["galactose", "CHEMICAL", 24, 33], ["L-fucose", "CHEMICAL", 12, 20], ["galactose", "CHEMICAL", 24, 33], ["L-fucose", "SIMPLE_CHEMICAL", 12, 20], ["galactose", "SIMPLE_CHEMICAL", 24, 33], ["antigen H", "GENE_OR_GENE_PRODUCT", 46, 55], ["antigen H", "PROTEIN", 46, 55], ["L-fucose to galactose", "TREATMENT", 12, 33]]], ["Antigens A and B, on the other hand, arise from enzymatic modification of the H epitope through the attachment of the D isomer of N-acetylgalactosamine or galactose to the terminal galactosil residue, which is mediated by enzymes A and B, respectively.Biochemistry of ABO blood systemThe AB phenotype arises from the simultaneous expression of the two transferases, promoting the formation of their respective antigens in the same cell [62] .Biochemistry of ABO blood systemABH antigens are not restricted to the erythrocyte membrane, being found in a wide variety of other cells such as lymphocytes, platelets, venular and arterial capillary endothelium, spleen sinusoid cells, bone marrow, gastric mucosa, in addition to secretions and other fluids such as saliva, urine and milk [63] , a feature involved with numerous physiological and pathological processes, as discussed below.ABO blood system relationship to infections and other pathological conditionsIndividuals with certain types of ABO blood groups are more susceptible to diverse kinds of infections [64] .", [["blood system", "ANATOMY", 272, 284], ["cell", "ANATOMY", 431, 435], ["blood", "ANATOMY", 462, 467], ["erythrocyte membrane", "ANATOMY", 513, 533], ["cells", "ANATOMY", 574, 579], ["lymphocytes", "ANATOMY", 588, 599], ["platelets", "ANATOMY", 601, 610], ["venular", "ANATOMY", 612, 619], ["arterial capillary endothelium", "ANATOMY", 624, 654], ["spleen sinusoid cells", "ANATOMY", 656, 677], ["bone marrow", "ANATOMY", 679, 690], ["gastric mucosa", "ANATOMY", 692, 706], ["secretions", "ANATOMY", 723, 733], ["fluids", "ANATOMY", 744, 750], ["saliva", "ANATOMY", 759, 765], ["urine", "ANATOMY", 767, 772], ["blood", "ANATOMY", 887, 892], ["blood", "ANATOMY", 998, 1003], ["N-acetylgalactosamine", "CHEMICAL", 130, 151], ["galactose", "CHEMICAL", 155, 164], ["galactosil", "CHEMICAL", 181, 191], ["infections", "DISEASE", 916, 926], ["infections", "DISEASE", 1052, 1062], ["H", "CHEMICAL", 78, 79], ["N-acetylgalactosamine", "CHEMICAL", 130, 151], ["galactose", "CHEMICAL", 155, 164], ["galactosil", "CHEMICAL", 181, 191], ["B", "GENE_OR_GENE_PRODUCT", 15, 16], ["D isomer", "SIMPLE_CHEMICAL", 118, 126], ["N-acetylgalactosamine", "SIMPLE_CHEMICAL", 130, 151], ["galactose", "SIMPLE_CHEMICAL", 155, 164], ["B", "GENE_OR_GENE_PRODUCT", 236, 237], ["ABO", "GENE_OR_GENE_PRODUCT", 268, 271], ["blood", "ORGANISM_SUBSTANCE", 272, 277], ["cell", "CELL", 431, 435], ["ABO blood systemABH antigens", "GENE_OR_GENE_PRODUCT", 458, 486], ["erythrocyte membrane", "CELLULAR_COMPONENT", 513, 533], ["cells", "CELL", 574, 579], ["lymphocytes", "CELL", 588, 599], ["platelets", "CELL", 601, 610], ["venular", "CELL", 612, 619], ["arterial capillary endothelium", "TISSUE", 624, 654], ["spleen sinusoid cells", "CELL", 656, 677], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 679, 690], ["gastric mucosa", "MULTI-TISSUE_STRUCTURE", 692, 706], ["saliva", "ORGANISM_SUBSTANCE", 759, 765], ["urine", "ORGANISM_SUBSTANCE", 767, 772], ["milk", "ORGANISM_SUBSTANCE", 777, 781], ["ABO", "GENE_OR_GENE_PRODUCT", 883, 886], ["blood", "ORGANISM_SUBSTANCE", 887, 892], ["ABO", "ORGANISM", 994, 997], ["blood", "ORGANISM_SUBSTANCE", 998, 1003], ["Antigens A and B", "PROTEIN", 0, 16], ["H epitope", "PROTEIN", 78, 87], ["enzymes A", "PROTEIN", 222, 231], ["B", "PROTEIN", 236, 237], ["transferases", "PROTEIN", 352, 364], ["antigens", "PROTEIN", 410, 418], ["ABO blood systemABH antigens", "PROTEIN", 458, 486], ["lymphocytes", "CELL_TYPE", 588, 599], ["platelets", "CELL_TYPE", 601, 610], ["venular", "CELL_TYPE", 612, 619], ["spleen sinusoid cells", "CELL_TYPE", 656, 677], ["the H epitope", "TREATMENT", 74, 87], ["N-acetylgalactosamine", "TREATMENT", 130, 151], ["galactose", "TREATMENT", 155, 164], ["the terminal galactosil residue", "PROBLEM", 168, 199], ["ABO blood system", "TEST", 268, 284], ["The AB phenotype", "TEST", 284, 300], ["ABO blood systemABH antigens", "TEST", 458, 486], ["the erythrocyte membrane", "TEST", 509, 533], ["lymphocytes", "TEST", 588, 599], ["platelets", "TEST", 601, 610], ["venular", "TEST", 612, 619], ["arterial capillary endothelium", "TEST", 624, 654], ["gastric mucosa", "PROBLEM", 692, 706], ["secretions", "PROBLEM", 723, 733], ["other fluids", "TREATMENT", 738, 750], ["saliva, urine", "TEST", 759, 772], ["numerous physiological and pathological processes", "PROBLEM", 813, 862], ["ABO blood system", "TEST", 883, 899], ["infections", "PROBLEM", 916, 926], ["other pathological conditions", "PROBLEM", 931, 960], ["ABO blood groups", "PROBLEM", 994, 1010], ["infections", "PROBLEM", 1052, 1062], ["terminal", "ANATOMY_MODIFIER", 172, 180], ["galactosil", "ANATOMY", 181, 191], ["erythrocyte membrane", "OBSERVATION", 513, 533], ["lymphocytes", "OBSERVATION", 588, 599], ["venular", "ANATOMY_MODIFIER", 612, 619], ["arterial", "ANATOMY_MODIFIER", 624, 632], ["capillary endothelium", "ANATOMY", 633, 654], ["spleen", "ANATOMY", 656, 662], ["sinusoid cells", "OBSERVATION", 663, 677], ["bone marrow", "ANATOMY", 679, 690], ["gastric mucosa", "ANATOMY", 692, 706], ["secretions", "OBSERVATION", 723, 733], ["infections", "OBSERVATION", 916, 926], ["infections", "OBSERVATION", 1052, 1062]]], ["For instance, blood types A and AB predisposes individuals to severe malaria, while type O confers resistance to the protozoan agent.", [["blood", "ANATOMY", 14, 19], ["malaria", "DISEASE", 69, 76], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["blood types", "TEST", 14, 25], ["severe malaria", "PROBLEM", 62, 76], ["the protozoan agent", "TREATMENT", 113, 132], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["malaria", "OBSERVATION", 69, 76]]], ["Additionally, this blood system is directly or indirectly associated to some cardiovascular conditions.", [["blood system", "ANATOMY", 19, 31], ["cardiovascular", "ANATOMY", 77, 91], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["this blood system", "TEST", 14, 31], ["some cardiovascular conditions", "PROBLEM", 72, 102], ["cardiovascular conditions", "OBSERVATION", 77, 102]]], ["Groot et al [65] observed that type A individuals are more likely to have an unhealthier aging than those bearing the O phenotype.", [["individuals", "ORGANISM", 38, 49]]], ["These authors also reported that people with A, B and AB blood types are more likely to develop thrombosis and myocardial infarction, while those with type O are more likely to develop hypertensive conditions.", [["AB blood", "ANATOMY", 54, 62], ["myocardial", "ANATOMY", 111, 121], ["thrombosis", "DISEASE", 96, 106], ["myocardial infarction", "DISEASE", 111, 132], ["hypertensive", "DISEASE", 185, 197], ["people", "ORGANISM", 33, 39], ["B", "CELL", 48, 49], ["AB", "ORGANISM", 54, 56], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["myocardial", "MULTI-TISSUE_STRUCTURE", 111, 121], ["people", "SPECIES", 33, 39], ["A, B and AB blood types", "PROBLEM", 45, 68], ["thrombosis", "PROBLEM", 96, 106], ["myocardial infarction", "PROBLEM", 111, 132], ["hypertensive conditions", "PROBLEM", 185, 208], ["thrombosis", "OBSERVATION", 96, 106], ["myocardial", "ANATOMY", 111, 121], ["infarction", "OBSERVATION", 122, 132]]], ["The A antigen also seems to predispose individuals to a greater risk of thromboembolism and metabolic disorders, such as hyperlipidemia, hypercholesterolemia and diabetes mellitus [66] .ABO blood system relationship to infections and other pathological conditionsThe mechanisms involved in these relationships are, however, poorly understood, with speculative explanations offered to most cases, whereas solid explanations are rare.", [["blood", "ANATOMY", 190, 195], ["thromboembolism", "DISEASE", 72, 87], ["metabolic disorders", "DISEASE", 92, 111], ["hyperlipidemia", "DISEASE", 121, 135], ["hypercholesterolemia", "DISEASE", 137, 157], ["diabetes mellitus", "DISEASE", 162, 179], ["infections", "DISEASE", 219, 229], ["A antigen", "GENE_OR_GENE_PRODUCT", 4, 13], ["ABO", "GENE_OR_GENE_PRODUCT", 186, 189], ["blood", "ORGANISM_SUBSTANCE", 190, 195], ["A antigen", "PROTEIN", 4, 13], ["thromboembolism", "PROBLEM", 72, 87], ["metabolic disorders", "PROBLEM", 92, 111], ["hyperlipidemia", "PROBLEM", 121, 135], ["hypercholesterolemia", "PROBLEM", 137, 157], ["diabetes mellitus", "PROBLEM", 162, 179], ["ABO blood system", "TEST", 186, 202], ["infections", "PROBLEM", 219, 229], ["other pathological conditions", "PROBLEM", 234, 263], ["thromboembolism", "OBSERVATION", 72, 87], ["metabolic disorders", "OBSERVATION", 92, 111], ["hyperlipidemia", "OBSERVATION", 121, 135], ["hypercholesterolemia", "OBSERVATION", 137, 157], ["infections", "OBSERVATION", 219, 229]]], ["For malaria infection, for example, it has been reported that type A blood induces rosette formation of erythrocytes, a known virulence factor and contributor to microvascular ischemia and thrombosis [65] .", [["blood", "ANATOMY", 69, 74], ["rosette", "ANATOMY", 83, 90], ["erythrocytes", "ANATOMY", 104, 116], ["microvascular", "ANATOMY", 162, 175], ["malaria infection", "DISEASE", 4, 21], ["microvascular ischemia", "DISEASE", 162, 184], ["thrombosis", "DISEASE", 189, 199], ["type A", "GENE_OR_GENE_PRODUCT", 62, 68], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["rosette", "TISSUE", 83, 90], ["erythrocytes", "CELL", 104, 116], ["microvascular", "TISSUE", 162, 175], ["erythrocytes", "CELL_TYPE", 104, 116], ["virulence factor", "PROTEIN", 126, 142], ["malaria infection", "PROBLEM", 4, 21], ["type A blood induces rosette formation of erythrocytes", "PROBLEM", 62, 116], ["a known virulence factor", "PROBLEM", 118, 142], ["microvascular ischemia", "PROBLEM", 162, 184], ["thrombosis", "PROBLEM", 189, 199], ["malaria", "OBSERVATION_MODIFIER", 4, 11], ["infection", "OBSERVATION", 12, 21], ["rosette formation", "OBSERVATION", 83, 100], ["erythrocytes", "ANATOMY", 104, 116], ["microvascular", "ANATOMY", 162, 175], ["ischemia", "OBSERVATION", 176, 184], ["thrombosis", "OBSERVATION", 189, 199]]], ["For cardiovascular effects, it is suggested that individuals carrying the A antigen have a higher prevalence of thromboembolism due its association with high levels of von Willebrand factor [67] , a glycoprotein synthesized and secreted by endothelial cells and megakaryocytes that stimulates coagulation [68] .ABO blood system relationship to infections and other pathological conditionsIn this particular case, it is speculated that antigen A, as well as B, act by increasing the secretion of the factor or by decreasing its clearance, or both [66] .ABO blood system relationship to infections and other pathological conditionsThese explanations, however, do not take into account a molecular perspective for the ABO blood group participation in the pathological conditions discussed.", [["cardiovascular", "ANATOMY", 4, 18], ["endothelial cells", "ANATOMY", 240, 257], ["megakaryocytes", "ANATOMY", 262, 276], ["blood", "ANATOMY", 315, 320], ["blood", "ANATOMY", 556, 561], ["blood", "ANATOMY", 719, 724], ["thromboembolism", "DISEASE", 112, 127], ["infections", "DISEASE", 344, 354], ["infections", "DISEASE", 585, 595], ["cardiovascular", "ANATOMICAL_SYSTEM", 4, 18], ["A antigen", "GENE_OR_GENE_PRODUCT", 74, 83], ["von Willebrand factor [67]", "GENE_OR_GENE_PRODUCT", 168, 194], ["endothelial cells", "CELL", 240, 257], ["megakaryocytes", "CELL", 262, 276], ["ABO", "GENE_OR_GENE_PRODUCT", 311, 314], ["blood", "ORGANISM_SUBSTANCE", 315, 320], ["antigen A", "GENE_OR_GENE_PRODUCT", 435, 444], ["B", "GENE_OR_GENE_PRODUCT", 457, 458], ["ABO", "GENE_OR_GENE_PRODUCT", 552, 555], ["blood", "ORGANISM_SUBSTANCE", 556, 561], ["ABO", "GENE_OR_GENE_PRODUCT", 715, 718], ["blood", "ORGANISM_SUBSTANCE", 719, 724], ["A antigen", "PROTEIN", 74, 83], ["von Willebrand factor", "PROTEIN", 168, 189], ["glycoprotein", "PROTEIN", 199, 211], ["endothelial cells", "CELL_TYPE", 240, 257], ["megakaryocytes", "CELL_TYPE", 262, 276], ["antigen A", "PROTEIN", 435, 444], ["thromboembolism", "PROBLEM", 112, 127], ["von Willebrand factor", "TEST", 168, 189], ["a glycoprotein synthesized", "TREATMENT", 197, 223], ["megakaryocytes", "PROBLEM", 262, 276], ["ABO blood system", "TEST", 311, 327], ["infections", "PROBLEM", 344, 354], ["other pathological conditions", "PROBLEM", 359, 388], ["ABO blood system", "TEST", 552, 568], ["infections", "PROBLEM", 585, 595], ["other pathological conditions", "PROBLEM", 600, 629], ["thromboembolism", "OBSERVATION", 112, 127], ["endothelial", "ANATOMY", 240, 251], ["infections", "OBSERVATION", 344, 354], ["infections", "OBSERVATION", 585, 595]]], ["In other words, they do not respond the question \"how exactly do ABH antigens correlate with infection and cardiovascular pathophysiology?\".ABO blood system relationship to infections and other pathological conditionsA more detailed answer can be found in a work carried out in 2009 by Cohen, Hurtado-Ziola andABO blood system relationship to infections and other pathological conditionsVarki [69] .", [["cardiovascular", "ANATOMY", 107, 121], ["blood", "ANATOMY", 144, 149], ["blood", "ANATOMY", 314, 319], ["infection", "DISEASE", 93, 102], ["cardiovascular pathophysiology", "DISEASE", 107, 137], ["infections", "DISEASE", 173, 183], ["infections", "DISEASE", 343, 353], ["ABH antigens", "GENE_OR_GENE_PRODUCT", 65, 77], ["cardiovascular", "ANATOMICAL_SYSTEM", 107, 121], ["ABO", "GENE_OR_GENE_PRODUCT", 140, 143], ["blood", "ORGANISM_SUBSTANCE", 144, 149], ["blood", "ORGANISM_SUBSTANCE", 314, 319], ["ABH antigens", "PROTEIN", 65, 77], ["infection", "PROBLEM", 93, 102], ["ABO blood system", "TEST", 140, 156], ["infections", "PROBLEM", 173, 183], ["other pathological conditions", "PROBLEM", 188, 217], ["infections", "PROBLEM", 343, 353], ["other pathological conditions", "PROBLEM", 358, 387], ["infections", "OBSERVATION", 173, 183], ["infections", "OBSERVATION", 343, 353]]], ["Using three proteins that specifically bind to sialosides, the group analyzed the pattern of interaction between these molecules and human erythrocytes representing the four ABO blood phenotypes.", [["erythrocytes", "ANATOMY", 139, 151], ["blood", "ANATOMY", 178, 183], ["sialosides", "CHEMICAL", 47, 57], ["sialosides", "GENE_OR_GENE_PRODUCT", 47, 57], ["human", "ORGANISM", 133, 138], ["erythrocytes", "CELL", 139, 151], ["ABO", "GENE_OR_GENE_PRODUCT", 174, 177], ["blood", "ORGANISM_SUBSTANCE", 178, 183], ["human erythrocytes", "CELL_TYPE", 133, 151], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["human erythrocytes", "PROBLEM", 133, 151], ["the four ABO blood phenotypes", "PROBLEM", 165, 194]]], ["They observed that proteins interacted more strongly with A, B and AB cell types, with a certain preference for the first, and less with the O cell type.", [["AB cell", "ANATOMY", 67, 74], ["O cell", "ANATOMY", 141, 147], ["B", "CELL", 61, 62], ["AB cell", "CELL", 67, 74], ["O cell type", "CELL", 141, 152], ["A, B and AB cell types", "CELL_TYPE", 58, 80], ["AB cell types", "OBSERVATION", 67, 80]]], ["When using specific glycosidases that converted determinants A and B to H, they found that interactions between all three proteins included in the study and the antigens decreased to the levels observed for the original type O red blood cells.ABO blood system relationship to infections and other pathological conditionsTo explain these findings, the authors proposed a model where blood antigens modulate the distribution of sialosides in the plasma membrane, with antigens A and B (specially the former) stimulating the formation of carbohydrate clusters, whereas the H antigen would not promote such effect.", [["red blood cells", "ANATOMY", 227, 242], ["blood", "ANATOMY", 247, 252], ["blood", "ANATOMY", 382, 387], ["plasma membrane", "ANATOMY", 444, 459], ["infections", "DISEASE", 276, 286], ["H", "CHEMICAL", 72, 73], ["sialosides", "CHEMICAL", 426, 436], ["carbohydrate", "CHEMICAL", 535, 547], ["B", "GENE_OR_GENE_PRODUCT", 67, 68], ["O red blood cells", "CELL", 225, 242], ["ABO", "GENE_OR_GENE_PRODUCT", 243, 246], ["blood", "ORGANISM_SUBSTANCE", 247, 252], ["blood", "ORGANISM_SUBSTANCE", 382, 387], ["sialosides", "GENE_OR_GENE_PRODUCT", 426, 436], ["plasma membrane", "CELLULAR_COMPONENT", 444, 459], ["antigens A", "GENE_OR_GENE_PRODUCT", 466, 476], ["B", "GENE_OR_GENE_PRODUCT", 481, 482], ["H antigen", "GENE_OR_GENE_PRODUCT", 570, 579], ["B", "PROTEIN", 67, 68], ["antigens", "PROTEIN", 161, 169], ["O red blood cells", "CELL_TYPE", 225, 242], ["blood antigens", "PROTEIN", 382, 396], ["sialosides", "PROTEIN", 426, 436], ["antigens A", "PROTEIN", 466, 476], ["B", "PROTEIN", 481, 482], ["H antigen", "PROTEIN", 570, 579], ["the study", "TEST", 143, 152], ["the antigens", "TEST", 157, 169], ["red blood cells", "TEST", 227, 242], ["ABO blood system", "TEST", 243, 259], ["infections", "PROBLEM", 276, 286], ["other pathological conditions", "PROBLEM", 291, 320], ["blood antigens", "TEST", 382, 396], ["carbohydrate clusters", "PROBLEM", 535, 556], ["the H antigen", "TEST", 566, 579], ["infections", "OBSERVATION", 276, 286], ["plasma membrane", "ANATOMY", 444, 459]]], ["The mechanistic causal explanation to these observations was attributed to the presence of carbohydrate-carbohydrate interactions (CCIs) between ABO blood determinants and sialic acidcontaining glycans, which could influence, even indirectly, cell recognition and communication [70] , [71] .", [["blood", "ANATOMY", 149, 154], ["cell", "ANATOMY", 243, 247], ["carbohydrate", "CHEMICAL", 91, 103], ["carbohydrate", "CHEMICAL", 104, 116], ["ABO", "GENE_OR_GENE_PRODUCT", 145, 148], ["blood", "ORGANISM_SUBSTANCE", 149, 154], ["sialic acidcontaining glycans", "SIMPLE_CHEMICAL", 172, 201], ["cell", "CELL", 243, 247], ["ABO blood determinants", "PROTEIN", 145, 167], ["carbohydrate-carbohydrate interactions", "PROBLEM", 91, 129], ["ABO blood determinants", "TEST", 145, 167], ["sialic acidcontaining glycans", "TREATMENT", 172, 201]]], ["CCIs can occur in cis, when the interacting carbohydrates are anchored on the same cell, or in trans, when they are anchored on different cells [69] .ABO blood system relationship to infections and other pathological conditionsCCIs have been reported since 1963, when Humphreys [72] demonstrated the participation of proteoglycans in cell adhesion of marine sponge.", [["cell", "ANATOMY", 83, 87], ["cells", "ANATOMY", 138, 143], ["blood", "ANATOMY", 154, 159], ["cell", "ANATOMY", 334, 338], ["CCIs", "DISEASE", 0, 4], ["infections", "DISEASE", 183, 193], ["carbohydrates", "CHEMICAL", 44, 57], ["cell", "CELL", 83, 87], ["cells", "CELL", 138, 143], ["ABO", "GENE_OR_GENE_PRODUCT", 150, 153], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["proteoglycans", "GENE_OR_GENE_PRODUCT", 317, 330], ["cell", "CELL", 334, 338], ["ABO blood system", "TEST", 150, 166], ["infections", "PROBLEM", 183, 193], ["other pathological conditionsCCIs", "PROBLEM", 198, 231], ["proteoglycans in cell adhesion of marine sponge", "TREATMENT", 317, 364], ["infections", "OBSERVATION", 183, 193], ["marine sponge", "OBSERVATION", 351, 364]]], ["Since then, other studies have supported these findings, showing that self-association of surface carbohydrates guides cell aggregation in marine sponge and mouse embryo [73] - [75] .", [["surface", "ANATOMY", 90, 97], ["cell", "ANATOMY", 119, 123], ["embryo", "ANATOMY", 163, 169], ["carbohydrates", "CHEMICAL", 98, 111], ["cell", "CELL", 119, 123], ["mouse", "ORGANISM", 157, 162], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 163, 169], ["mouse", "SPECIES", 157, 162], ["mouse", "SPECIES", 157, 162], ["other studies", "TEST", 12, 25], ["surface carbohydrates", "PROBLEM", 90, 111], ["cell aggregation", "PROBLEM", 119, 135], ["marine sponge", "TREATMENT", 139, 152]]], ["The first two decades of the 21st century have been characterized by great advances on this subject, specially concerning methodological developments for studying CCIs [76] - [82] , as well as by showing their participation in antibody-receptor binding [83] , neonatal immunity stimulation [84] , oncogenesis [85] and potential application in drug delivery approaches [86] .ABO blood system relationship to infections and other pathological conditionsInterestingly, divalent ions, mainly Ca 2+ , seem to be very important to promote CCIs.", [["blood", "ANATOMY", 378, 383], ["infections", "DISEASE", 407, 417], ["Ca", "CHEMICAL", 488, 490], ["Ca 2+", "CHEMICAL", 488, 493], ["antibody-receptor", "GENE_OR_GENE_PRODUCT", 227, 244], ["ABO", "GENE_OR_GENE_PRODUCT", 374, 377], ["blood", "ORGANISM_SUBSTANCE", 378, 383], ["divalent ions", "SIMPLE_CHEMICAL", 466, 479], ["Ca 2+", "SIMPLE_CHEMICAL", 488, 493], ["CCIs", "PATHOLOGICAL_FORMATION", 533, 537], ["studying CCIs", "TEST", 154, 167], ["neonatal immunity stimulation", "TREATMENT", 260, 289], ["potential application in drug delivery approaches", "TREATMENT", 318, 367], ["ABO blood system", "TEST", 374, 390], ["infections", "PROBLEM", 407, 417], ["other pathological conditions", "PROBLEM", 422, 451], ["infections", "OBSERVATION", 407, 417], ["divalent ions", "OBSERVATION", 466, 479], ["CCIs", "OBSERVATION", 533, 537]]], ["Several studies have showed that this kind of interaction only occur in the presence of these ions [87] - [90] , possibly because they coordinate forces to mediate interactions, although ionic forces could also be involved [91] .CONSEQUENCES OF THE HYPOTHESIS AND DISCUSSIONIt is in light of this whole picture that we formulate the hypothesis that the ABO blood system correlates to COVID-19 severity due to CCIs.", [["blood", "ANATOMY", 357, 362], ["CCIs", "DISEASE", 409, 413], ["ABO", "ORGANISM", 353, 356], ["blood", "ORGANISM_SUBSTANCE", 357, 362], ["Several studies", "TEST", 0, 15], ["the ABO blood system", "TEST", 349, 369], ["COVID", "TEST", 384, 389], ["CCIs", "TEST", 409, 413]]], ["We speculate that the antigens that determine A, B, AB and O blood cell phenotypes can modulate the distribution of sialic acid-containing receptors in the plasma membrane of host cells.", [["blood cell", "ANATOMY", 61, 71], ["plasma membrane", "ANATOMY", 156, 171], ["cells", "ANATOMY", 180, 185], ["A", "GENE_OR_GENE_PRODUCT", 46, 47], ["B", "GENE_OR_GENE_PRODUCT", 49, 50], ["AB", "CELL", 52, 54], ["O blood cell", "CELL", 59, 71], ["sialic acid-containing receptors", "GENE_OR_GENE_PRODUCT", 116, 148], ["plasma membrane", "CELLULAR_COMPONENT", 156, 171], ["host cells", "CELL", 175, 185], ["antigens", "PROTEIN", 22, 30], ["sialic acid-containing receptors", "PROTEIN", 116, 148], ["host cells", "CELL_TYPE", 175, 185], ["AB and O blood cell phenotypes", "TEST", 52, 82], ["sialic acid-containing receptors", "PROBLEM", 116, 148], ["sialic acid-containing receptors", "OBSERVATION", 116, 148], ["plasma membrane", "ANATOMY", 156, 171], ["host cells", "OBSERVATION", 175, 185]]], ["Specifically, we hypothesize that mostly antigen A, but also antigens B and AB at a lesser extent, can stimulate the formation of sialoside clusters in target cells through cis CCIs.", [["cells", "ANATOMY", 159, 164], ["sialoside", "CHEMICAL", 130, 139], ["antigen A", "GENE_OR_GENE_PRODUCT", 41, 50], ["antigens B", "GENE_OR_GENE_PRODUCT", 61, 71], ["sialoside", "GENE_OR_GENE_PRODUCT", 130, 139], ["cells", "CELL", 159, 164], ["antigen A", "PROTEIN", 41, 50], ["antigens B", "PROTEIN", 61, 71], ["AB", "PROTEIN", 76, 78], ["target cells", "CELL_TYPE", 152, 164], ["antigens B and AB", "PROBLEM", 61, 78], ["lesser extent", "OBSERVATION_MODIFIER", 84, 97], ["target cells", "OBSERVATION", 152, 164]]], ["This would maximize the interaction of the cells with SARS-CoV-2 by increasing the likelihood of binding of the NTD and (possibly) RBD domains to CD147 and ACE2 receptors, respectively, through multivalency and avidity.", [["cells", "ANATOMY", 43, 48], ["cells", "CELL", 43, 48], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 54, 64], ["CD147", "GENE_OR_GENE_PRODUCT", 146, 151], ["ACE2", "GENE_OR_GENE_PRODUCT", 156, 160], ["NTD", "PROTEIN", 112, 115], ["RBD domains", "PROTEIN", 131, 142], ["CD147", "PROTEIN", 146, 151], ["ACE2 receptors", "PROTEIN", 156, 170], ["SARS-CoV", "SPECIES", 54, 62], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62], ["the NTD", "PROBLEM", 108, 115], ["CD147", "TEST", 146, 151], ["ACE2 receptors", "TEST", 156, 170]]], ["The participation of RBD is proposed based on a recent preprint report showing that ACE2 is also decorated with sialoside glycans [57] .", [["RBD", "DISEASE", 21, 24], ["sialoside", "CHEMICAL", 112, 121], ["ACE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["RBD", "PROTEIN", 21, 24], ["ACE2", "PROTEIN", 84, 88], ["RBD", "PROBLEM", 21, 24], ["ACE2", "TEST", 84, 88]]], ["Additionally, trans CCIs cannot be neglected, since Spike can be decorated with glycans from host cells [92] .", [["cells", "ANATOMY", 98, 103], ["trans CCIs", "SIMPLE_CHEMICAL", 14, 24], ["host cells", "CELL", 93, 103], ["Spike", "PROTEIN", 52, 57], ["host cells", "CELL_TYPE", 93, 103], ["Spike", "PROBLEM", 52, 57]]], ["In this case, natural or monoclonal anti-histo-blood group antibodies could bind to Spike glycans, inhibiting its interaction to host cell glycoprotein receptors, as reported previously for SARS-CoV-1 [93] and recently proposed for SARS-CoV-2 [94] .CONSEQUENCES OF THE HYPOTHESIS AND DISCUSSIONIt is important to note that a recent preprint study reporting the inability to detect the interaction between the novel coronavirus Spike protein and sialic acid through glycan microarray [54] does not argues against the proposed model of trans CCI, since it is based on the modulation of the distribution of sialoside-containing receptors in plasma membrane.", [["blood", "ANATOMY", 47, 52], ["cell", "ANATOMY", 134, 138], ["plasma membrane", "ANATOMY", 638, 653], ["sialic acid", "CHEMICAL", 445, 456], ["sialoside", "CHEMICAL", 604, 613], ["sialic acid", "CHEMICAL", 445, 456], ["sialoside", "CHEMICAL", 604, 613], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["Spike glycans", "GENE_OR_GENE_PRODUCT", 84, 97], ["host cell glycoprotein receptors", "GENE_OR_GENE_PRODUCT", 129, 161], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 190, 200], ["coronavirus", "ORGANISM", 415, 426], ["Spike", "GENE_OR_GENE_PRODUCT", 427, 432], ["sialic acid", "SIMPLE_CHEMICAL", 445, 456], ["sialoside-containing receptors", "GENE_OR_GENE_PRODUCT", 604, 634], ["plasma membrane", "CELLULAR_COMPONENT", 638, 653], ["monoclonal anti-histo-blood group antibodies", "PROTEIN", 25, 69], ["Spike glycans", "PROTEIN", 84, 97], ["host cell glycoprotein receptors", "PROTEIN", 129, 161], ["coronavirus Spike protein", "PROTEIN", 415, 440], ["sialoside-containing receptors", "PROTEIN", 604, 634], ["SARS-CoV-1", "SPECIES", 190, 200], ["SARS-CoV", "SPECIES", 232, 240], ["natural or monoclonal anti-histo-blood group antibodies", "TREATMENT", 14, 69], ["Spike glycans", "PROBLEM", 84, 97], ["host cell glycoprotein receptors", "TREATMENT", 129, 161], ["SARS", "TEST", 190, 194], ["CoV", "TEST", 195, 198], ["SARS", "PROBLEM", 232, 236], ["CoV", "TEST", 237, 240], ["a recent preprint study", "TEST", 323, 346], ["the novel coronavirus", "PROBLEM", 405, 426], ["sialic acid", "TEST", 445, 456], ["glycan microarray", "TEST", 465, 482], ["plasma membrane", "OBSERVATION", 638, 653]]], ["In this perspective, even the possibility of occurrance of trans CCIs in the reported assay presumably would not induce detectable fluorescent signals due the immobilization of the tested glycans on the array chip, therefore not allowing the formation of carbohydrate clusters, which would accordingly increase the Spike binding.CONSEQUENCES OF THE HYPOTHESIS AND DISCUSSIONThe present hypothesis becomes more interesting when we take into account that (i) COVID-19CONSEQUENCES OF THE HYPOTHESIS AND DISCUSSIONincreases the risk of coagulopathies and venous thromboembolism in those patients who develop a severe condition [95] and (ii) a recent proposition that these traits can be related to deregulatory balance of von Willebrand factor levels [96] : two features more prevalent in individuals with type A blood, as mentioned early.CONSEQUENCES OF THE HYPOTHESIS AND DISCUSSIONA last point to be addressed is that some reports have proposed the use of zinc as a coadjuvant component in the treatment of COVID-19 [97] , [98] .", [["venous", "ANATOMY", 551, 557], ["blood", "ANATOMY", 809, 814], ["coagulopathies", "DISEASE", 532, 546], ["venous thromboembolism", "DISEASE", 551, 573], ["zinc", "CHEMICAL", 955, 959], ["carbohydrate", "CHEMICAL", 255, 267], ["zinc", "CHEMICAL", 955, 959], ["COVID-19", "CHEMICAL", 1006, 1014], ["Spike", "GENE_OR_GENE_PRODUCT", 315, 320], ["venous thromboembolism", "PATHOLOGICAL_FORMATION", 551, 573], ["patients", "ORGANISM", 583, 591], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 718, 739], ["blood", "ORGANISM_SUBSTANCE", 809, 814], ["zinc", "SIMPLE_CHEMICAL", 955, 959], ["Spike", "PROTEIN", 315, 320], ["von Willebrand factor", "PROTEIN", 718, 739], ["patients", "SPECIES", 583, 591], ["trans CCIs", "PROBLEM", 59, 69], ["detectable fluorescent signals", "PROBLEM", 120, 150], ["the array chip", "TREATMENT", 199, 213], ["carbohydrate clusters", "PROBLEM", 255, 276], ["the Spike binding", "PROBLEM", 311, 328], ["THE HYPOTHESIS", "PROBLEM", 481, 495], ["coagulopathies", "PROBLEM", 532, 546], ["venous thromboembolism", "PROBLEM", 551, 573], ["a severe condition", "PROBLEM", 604, 622], ["von Willebrand factor levels", "TEST", 718, 746], ["type A blood", "PROBLEM", 802, 814], ["zinc", "TREATMENT", 955, 959], ["a coadjuvant component", "TREATMENT", 963, 985], ["COVID", "TEST", 1006, 1011], ["trans CCIs", "OBSERVATION", 59, 69], ["coagulopathies", "OBSERVATION", 532, 546], ["venous", "ANATOMY", 551, 557], ["thromboembolism", "OBSERVATION", 558, 573], ["severe", "OBSERVATION_MODIFIER", 606, 612], ["more prevalent", "OBSERVATION_MODIFIER", 767, 781]]], ["Although a rigid body of evidence for its efficacy is missing, it is suggested that zinc supplementation performs antiviral activity by various mechanisms, such as restoration of depleted immune function, blocking of virus attachment and infection, and inhibition of virus replication [99] .", [["zinc", "CHEMICAL", 84, 88], ["infection", "DISEASE", 238, 247], ["zinc", "CHEMICAL", 84, 88], ["zinc", "SIMPLE_CHEMICAL", 84, 88], ["zinc supplementation", "TREATMENT", 84, 104], ["antiviral activity", "TREATMENT", 114, 132], ["depleted immune function", "TREATMENT", 179, 203], ["virus attachment", "PROBLEM", 217, 233], ["infection", "PROBLEM", 238, 247], ["virus replication", "TREATMENT", 267, 284], ["evidence for", "UNCERTAINTY", 25, 37], ["depleted immune function", "OBSERVATION", 179, 203]]], ["The hypothesis described here can be considered in future (pre)clinical studies to understand the possible role of this micronutrient in this context.", [["clinical studies", "TEST", 63, 79]]], ["AsCONSEQUENCES OF THE HYPOTHESIS AND DISCUSSIONCCIs are commonly mediated by Ca 2+ , zinc ions (Zn 2+ ) could disrupt its proposed coordinated forces and consequently break the interactions between ABH antigens and sialoside moieties, blocking or at least diminishing SARS-CoV-2 anchoring to host cells.", [["cells", "ANATOMY", 297, 302], ["Ca", "CHEMICAL", 77, 79], ["zinc", "CHEMICAL", 85, 89], ["Zn", "CHEMICAL", 96, 98], ["Ca 2+", "CHEMICAL", 77, 82], ["zinc", "CHEMICAL", 85, 89], ["Zn 2+ )", "CHEMICAL", 96, 103], ["sialoside", "CHEMICAL", 215, 224], ["Ca 2+", "SIMPLE_CHEMICAL", 77, 82], ["zinc ions", "SIMPLE_CHEMICAL", 85, 94], ["Zn 2+", "SIMPLE_CHEMICAL", 96, 101], ["ABH antigens", "GENE_OR_GENE_PRODUCT", 198, 210], ["sialoside moieties", "SIMPLE_CHEMICAL", 215, 233], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 268, 278], ["host cells", "CELL", 292, 302], ["ABH antigens", "PROTEIN", 198, 210], ["sialoside moieties", "PROTEIN", 215, 233], ["host cells", "CELL_TYPE", 292, 302], ["Ca", "TEST", 77, 79], ["zinc ions (Zn 2+ )", "TREATMENT", 85, 103], ["sialoside moieties", "TREATMENT", 215, 233], ["blocking", "TREATMENT", 235, 243], ["diminishing SARS", "PROBLEM", 256, 272], ["CoV", "TEST", 273, 276], ["host cells", "OBSERVATION", 292, 302]]], ["This idea arises from studies with hydroxyapatite crystals, where substitution of Zn 2+ for Ca 2+ cause remarkable rearrangement of the unit cells [100] , [101] .", [["cells", "ANATOMY", 141, 146], ["Zn", "CHEMICAL", 82, 84], ["Ca", "CHEMICAL", 92, 94], ["hydroxyapatite", "CHEMICAL", 35, 49], ["Zn 2+", "CHEMICAL", 82, 87], ["Ca 2+", "CHEMICAL", 92, 97], ["hydroxyapatite crystals", "SIMPLE_CHEMICAL", 35, 58], ["Zn 2+", "SIMPLE_CHEMICAL", 82, 87], ["Ca 2+", "SIMPLE_CHEMICAL", 92, 97], ["cells", "CELL", 141, 146], ["hydroxyapatite crystals", "TREATMENT", 35, 58], ["substitution of Zn", "TREATMENT", 66, 84], ["Ca", "TEST", 92, 94]]], ["Extending this observation to our model, it is possible that similar changes also occur in the molecular environment of CCIs.CONSEQUENCES OF THE HYPOTHESIS AND DISCUSSIONIn summary, this work proposes that the molecular mechanism underlying the influence of ABO blood groups on COVID-19 susceptibility and severity relies on carbohydrate-carbohydrate interactions between ABH antigens and sialoside glycans present on host cell receptors.", [["blood", "ANATOMY", 262, 267], ["cell", "ANATOMY", 423, 427], ["CCIs", "DISEASE", 120, 124], ["carbohydrate", "CHEMICAL", 325, 337], ["carbohydrate", "CHEMICAL", 338, 350], ["sialoside", "CHEMICAL", 389, 398], ["CCIs", "PATHOLOGICAL_FORMATION", 120, 124], ["ABO", "GENE_OR_GENE_PRODUCT", 258, 261], ["blood", "ORGANISM_SUBSTANCE", 262, 267], ["COVID-19", "GENE_OR_GENE_PRODUCT", 278, 286], ["ABH antigens", "GENE_OR_GENE_PRODUCT", 372, 384], ["sialoside glycans", "GENE_OR_GENE_PRODUCT", 389, 406], ["host cell", "CELL", 418, 427], ["ABH antigens", "PROTEIN", 372, 384], ["sialoside glycans", "PROTEIN", 389, 406], ["host cell receptors", "PROTEIN", 418, 437], ["ABO blood groups", "PROBLEM", 258, 274], ["COVID", "TEST", 278, 283], ["carbohydrate-carbohydrate interactions", "TREATMENT", 325, 363], ["ABH antigens", "TEST", 372, 384], ["sialoside glycans", "TREATMENT", 389, 406], ["host cell receptors", "TREATMENT", 418, 437], ["host cell", "OBSERVATION_MODIFIER", 418, 427]]], ["It is important to highlight that as a review work, its conclusions should be seen and interpreted carefully as an attempt to contribute to a better understand of the pathophysiology of COVID-19, which may be further supported or not with experimental and clinical studies.Funding and SupportThis work has not receveid funding research.Conflicts of interestThe authors declare no conflict of interest.Conflicts of interestCRediT authorship contribution statement Jos\u00e9 Caetano Silva-Filho: Conceptualization, Writing -original draft, Writing -review and editing.", [["COVID-19", "CHEMICAL", 186, 194], ["COVID", "TEST", 186, 191], ["clinical studies", "TEST", 256, 272]]]], "09bb68388e585bc8a743f915e5e3df696ec80c10": [["IntroductionIn theriogenology practice, emergencies are defined not only in terms of concerns for the welfare of the patient, but also for its future reproductive life.", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124]]], ["The challenge often faced with reproductive emergencies is how to preserve the life of the patient and maximize the chance to maintain reproductive ability.", [["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98]]], ["In camelids, this is even more important, as assisted reproductive technologies have either not yet been perfected (semen preservation, in vitro embryo production, nuclear transfer) or are not allowed (embryo transfer) by some breed registries.", [["semen", "ANATOMY", 116, 121], ["embryo", "ANATOMY", 145, 151], ["nuclear", "ANATOMY", 164, 171], ["embryo", "ANATOMY", 202, 208], ["semen", "ORGANISM_SUBDIVISION", 116, 121], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 145, 151], ["nuclear", "CELLULAR_COMPONENT", 164, 171], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 202, 208], ["semen preservation", "TREATMENT", 116, 134]]], ["In the case of pregnant females, which constitute the majority of reproductive emergencies, the life and welfare of the neonate must also be considered.", [["neonate", "ORGANISM", 120, 127]]], ["This review draws primarily on the clinical experience of the authors, as there are very limited controlled studies regarding clinical reproduction and emergency care in camelids.Reproductive emergencies in the maleAlthough many disease processes that present as emergencies may have some severe repercussions on the reproductive process in the male, our review will be limited to diseases and accidents with sudden onset that are directly linked to the urogenital system.", [["urogenital system", "ANATOMY", 454, 471], ["accidents", "DISEASE", 394, 403], ["urogenital", "ORGAN", 454, 464], ["system", "ANATOMICAL_SYSTEM", 465, 471], ["emergency care", "TREATMENT", 152, 166], ["Reproductive emergencies", "PROBLEM", 179, 203], ["some severe repercussions", "PROBLEM", 284, 309], ["diseases", "PROBLEM", 381, 389], ["disease", "OBSERVATION", 229, 236], ["severe", "OBSERVATION_MODIFIER", 289, 295], ["repercussions", "OBSERVATION", 296, 309], ["urogenital system", "ANATOMY", 454, 471]]], ["Reproductive emergencies in the male camelid are primarily due to sudden onset of visible abnormalities in the external genitalia.", [["genitalia", "ANATOMY", 120, 129], ["genitalia", "ORGAN", 120, 129], ["Reproductive emergencies", "PROBLEM", 0, 24], ["visible abnormalities in the external genitalia", "PROBLEM", 82, 129], ["visible", "OBSERVATION_MODIFIER", 82, 89], ["abnormalities", "OBSERVATION", 90, 103], ["external genitalia", "ANATOMY", 111, 129]]], ["These abnormalities can be summarized as acute scrotal or preputial swelling, preputial prolapse or paraphymosis, and post-surgical emergencies [1] [2] [3] .", [["scrotal", "ANATOMY", 47, 54], ["preputial", "ANATOMY", 58, 67], ["preputial", "ANATOMY", 78, 87], ["swelling", "DISEASE", 68, 76], ["preputial prolapse", "DISEASE", 78, 96], ["paraphymosis", "DISEASE", 100, 112], ["scrotal", "ORGANISM_SUBDIVISION", 47, 54], ["preputial", "ORGAN", 58, 67], ["These abnormalities", "PROBLEM", 0, 19], ["acute scrotal", "PROBLEM", 41, 54], ["preputial swelling", "PROBLEM", 58, 76], ["preputial prolapse", "PROBLEM", 78, 96], ["paraphymosis", "PROBLEM", 100, 112], ["post-surgical emergencies", "PROBLEM", 118, 143], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["scrotal", "ANATOMY", 47, 54], ["preputial", "ANATOMY", 58, 67], ["swelling", "OBSERVATION", 68, 76], ["preputial prolapse", "OBSERVATION", 78, 96]]], ["In camels, preputial swelling is also a primary clinical sign of acute trypanosomiasis, a disease with high morbidity and mortality in many countries where camel breeding is important [3] . www.theriojournal.com 2.1.", [["preputial", "ANATOMY", 11, 20], ["preputial swelling", "DISEASE", 11, 29], ["trypanosomiasis", "DISEASE", 71, 86], ["camels", "ORGANISM", 3, 9], ["preputial", "ORGAN", 11, 20], ["camel", "SPECIES", 156, 161], ["preputial swelling", "PROBLEM", 11, 29], ["acute trypanosomiasis", "PROBLEM", 65, 86], ["a disease", "PROBLEM", 88, 97], ["high morbidity", "PROBLEM", 103, 117], ["preputial", "ANATOMY", 11, 20], ["swelling", "OBSERVATION", 21, 29], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["trypanosomiasis", "OBSERVATION", 71, 86]]], ["General approach to examination of the male for reproductive emergency As with any other emergency, accurate body weight, body condition score, physical examination, degree of dehydration, baseline complete blood count (CBC), blood biochemistry, and urinalysis should be part of the initial evaluation.", [["body", "ANATOMY", 109, 113], ["body", "ANATOMY", 122, 126], ["blood", "ANATOMY", 207, 212], ["blood", "ANATOMY", 226, 231], ["dehydration", "DISEASE", 176, 187], ["body", "ORGANISM_SUBDIVISION", 109, 113], ["body", "ORGANISM_SUBDIVISION", 122, 126], ["blood", "ORGANISM_SUBSTANCE", 207, 212], ["blood", "ORGANISM_SUBSTANCE", 226, 231], ["examination", "TEST", 20, 31], ["body condition score", "TEST", 122, 142], ["physical examination", "TEST", 144, 164], ["dehydration", "PROBLEM", 176, 187], ["baseline complete blood count", "TEST", 189, 218], ["CBC", "TEST", 220, 223], ["blood biochemistry", "TEST", 226, 244], ["urinalysis", "TEST", 250, 260], ["the initial evaluation", "TEST", 279, 301], ["dehydration", "OBSERVATION", 176, 187]]], ["Immediate placement of an intravenous catheter is indicated in severely compromised or recumbent animals.", [["intravenous", "ANATOMY", 26, 37], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 26, 37], ["an intravenous catheter", "TREATMENT", 23, 46], ["severely compromised or recumbent animals", "PROBLEM", 63, 104], ["intravenous catheter", "OBSERVATION", 26, 46], ["severely", "OBSERVATION_MODIFIER", 63, 71], ["compromised", "OBSERVATION", 72, 83]]], ["Ultrasonography of the urogenital organs should also be conducted.Acute scrotal swellingTesticular thermoregulation is very important for normal spermatogenesis in camelids.", [["urogenital organs", "ANATOMY", 23, 40], ["scrotal", "ANATOMY", 72, 79], ["Testicular", "ANATOMY", 88, 98], ["swelling", "DISEASE", 80, 88], ["urogenital organs", "ORGAN", 23, 40], ["Testicular", "ORGAN", 88, 98], ["Ultrasonography", "TEST", 0, 15], ["Acute scrotal swelling", "PROBLEM", 66, 88], ["urogenital organs", "ANATOMY", 23, 40], ["scrotal", "ANATOMY", 72, 79], ["swelling", "OBSERVATION", 80, 88], ["Testicular", "ANATOMY", 88, 98]]], ["Therefore, compromised testicular thermoregulation in these animals should considered serious, as the effect on spermatogenesis can be long lasting or permanent.", [["testicular", "ANATOMY", 23, 33], ["testicular", "ORGAN", 23, 33], ["compromised testicular thermoregulation", "PROBLEM", 11, 50], ["testicular", "ANATOMY", 23, 33]]], ["Acute scrotal swelling is generally due to heat stress, trauma, or a local or systemic infectious process.", [["scrotal", "ANATOMY", 6, 13], ["scrotal swelling", "DISEASE", 6, 22], ["trauma", "DISEASE", 56, 62], ["Acute scrotal swelling", "PROBLEM", 0, 22], ["heat stress", "PROBLEM", 43, 54], ["trauma", "PROBLEM", 56, 62], ["a local or systemic infectious process", "PROBLEM", 67, 105], ["scrotal", "ANATOMY", 6, 13], ["swelling", "OBSERVATION", 14, 22], ["trauma", "OBSERVATION", 56, 62], ["systemic", "OBSERVATION_MODIFIER", 78, 86], ["infectious", "OBSERVATION", 87, 97]]], ["Testicular torsion and scrotal hernia are commonly considered as differential diagnoses in other large animal species, but have never been encountered in camelids in our practice [2] .Heat stressScrotal and preputial edema and development of severe hydrocele are features of heat stress in the male llama and alpaca [2] .", [["Testicular", "ANATOMY", 0, 10], ["scrotal hernia", "ANATOMY", 23, 37], ["preputial edema", "ANATOMY", 207, 222], ["hydrocele", "ANATOMY", 249, 258], ["Testicular torsion", "DISEASE", 0, 18], ["scrotal hernia", "DISEASE", 23, 37], ["edema", "DISEASE", 217, 222], ["hydrocele", "DISEASE", 249, 258], ["Testicular", "ORGAN", 0, 10], ["scrotal hernia", "PATHOLOGICAL_FORMATION", 23, 37], ["preputial edema", "PATHOLOGICAL_FORMATION", 207, 222], ["llama", "ORGANISM", 299, 304], ["llama", "SPECIES", 299, 304], ["Testicular torsion and scrotal hernia", "PROBLEM", 0, 37], ["other large animal species", "PROBLEM", 91, 117], ["Heat stressScrotal", "PROBLEM", 184, 202], ["preputial edema", "PROBLEM", 207, 222], ["severe hydrocele", "PROBLEM", 242, 258], ["heat stress", "PROBLEM", 275, 286], ["torsion", "OBSERVATION", 11, 18], ["scrotal", "ANATOMY", 23, 30], ["hernia", "OBSERVATION", 31, 37], ["large", "OBSERVATION_MODIFIER", 97, 102], ["animal species", "OBSERVATION", 103, 117], ["preputial", "ANATOMY", 207, 216], ["edema", "OBSERVATION", 217, 222], ["severe", "OBSERVATION_MODIFIER", 242, 248], ["hydrocele", "OBSERVATION", 249, 258], ["heat stress", "OBSERVATION", 275, 286]]], ["This syndrome is relatively common in the USA.", [["This syndrome", "PROBLEM", 0, 13], ["syndrome", "OBSERVATION", 5, 13], ["relatively", "OBSERVATION_MODIFIER", 17, 27], ["common", "OBSERVATION_MODIFIER", 28, 34]]], ["Factors predisposing to heat stress include prolonged high ambient temperature and humidity, inadequate shade, long fleece, dark coat color, and obesity.", [["obesity", "DISEASE", 145, 152], ["fleece", "ORGANISM_SUBDIVISION", 116, 122], ["heat stress", "PROBLEM", 24, 35], ["prolonged high ambient temperature", "PROBLEM", 44, 78], ["inadequate shade", "PROBLEM", 93, 109], ["long fleece, dark coat color", "PROBLEM", 111, 139], ["obesity", "PROBLEM", 145, 152], ["dark coat color", "OBSERVATION", 124, 139], ["obesity", "OBSERVATION", 145, 152]]], ["The risk for heat stress is exacerbated by stresses such as transportation, exercise, fighting, and breeding [4, 5] .", [["heat stress", "PROBLEM", 13, 24]]], ["Hyperthermia results from impaired evaporative cooling, particularly under hot and humid conditions [5] .", [["Hyperthermia", "DISEASE", 0, 12], ["Hyperthermia", "PROBLEM", 0, 12], ["impaired evaporative cooling", "TREATMENT", 26, 54], ["impaired", "OBSERVATION_MODIFIER", 26, 34], ["evaporative cooling", "OBSERVATION", 35, 54]]], ["Scrotal edema may be the first clinical sign in the male.", [["Scrotal edema", "ANATOMY", 0, 13], ["Scrotal edema", "DISEASE", 0, 13], ["Scrotal edema", "PATHOLOGICAL_FORMATION", 0, 13], ["Scrotal edema", "PROBLEM", 0, 13], ["edema", "OBSERVATION", 8, 13]]], ["The exact pathophysiology of the scrotal and ventral abdominal edema is not well understood.", [["scrotal", "ANATOMY", 33, 40], ["ventral abdominal edema", "ANATOMY", 45, 68], ["abdominal edema", "DISEASE", 53, 68], ["scrotal", "ORGANISM_SUBDIVISION", 33, 40], ["abdominal", "ORGANISM_SUBDIVISION", 53, 62], ["edema", "PATHOLOGICAL_FORMATION", 63, 68], ["the scrotal and ventral abdominal edema", "PROBLEM", 29, 68], ["scrotal", "ANATOMY", 33, 40], ["ventral", "ANATOMY_MODIFIER", 45, 52], ["abdominal", "ANATOMY", 53, 62], ["edema", "OBSERVATION", 63, 68]]], ["Contributing factors may include inability of the pampiniform plexus and testicular artery to cope with the fluid turnover, or vascular thermal injury resulting in impaired wall permeability and extravasation of intravascular proteins, electrolytes, and fluid into the interstitium.Heat stressMany cases may resolve spontaneously, but leave the male infertile for various intervals, usually lasting from 2 months to years [2] .", [["pampiniform plexus", "ANATOMY", 50, 68], ["testicular artery", "ANATOMY", 73, 90], ["fluid", "ANATOMY", 108, 113], ["vascular", "ANATOMY", 127, 135], ["wall", "ANATOMY", 173, 177], ["intravascular", "ANATOMY", 212, 225], ["fluid", "ANATOMY", 254, 259], ["interstitium", "ANATOMY", 269, 281], ["pampiniform plexus", "MULTI-TISSUE_STRUCTURE", 50, 68], ["testicular artery", "MULTI-TISSUE_STRUCTURE", 73, 90], ["fluid", "ORGANISM_SUBSTANCE", 108, 113], ["vascular", "MULTI-TISSUE_STRUCTURE", 127, 135], ["wall", "TISSUE", 173, 177], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 212, 225], ["interstitium", "TISSUE", 269, 281], ["intravascular proteins", "PROTEIN", 212, 234], ["inability of the pampiniform plexus", "PROBLEM", 33, 68], ["the fluid turnover", "TEST", 104, 122], ["vascular thermal injury", "PROBLEM", 127, 150], ["impaired wall permeability", "PROBLEM", 164, 190], ["extravasation of intravascular proteins", "PROBLEM", 195, 234], ["electrolytes", "TEST", 236, 248], ["Heat stress", "PROBLEM", 282, 293], ["pampiniform plexus", "ANATOMY", 50, 68], ["testicular artery", "ANATOMY", 73, 90], ["fluid turnover", "OBSERVATION", 108, 122], ["vascular", "ANATOMY", 127, 135], ["thermal", "OBSERVATION_MODIFIER", 136, 143], ["injury", "OBSERVATION", 144, 150], ["impaired", "OBSERVATION_MODIFIER", 164, 172], ["wall permeability", "OBSERVATION", 173, 190], ["extravasation", "OBSERVATION", 195, 208], ["intravascular proteins", "OBSERVATION", 212, 234], ["fluid", "OBSERVATION", 254, 259], ["interstitium", "ANATOMY", 269, 281], ["stress", "OBSERVATION", 287, 293]]], ["Spermatogenesis (sperm production and semen quality) was severely impaired in llamas housed at an ambient temperature of 29 8C for 4 weeks [6] .", [["sperm", "ANATOMY", 17, 22], ["semen", "ANATOMY", 38, 43], ["sperm", "ORGANISM_SUBSTANCE", 17, 22], ["semen", "ORGANISM_SUBSTANCE", 38, 43], ["llamas", "ORGANISM", 78, 84], ["sperm", "CELL_TYPE", 17, 22], ["Spermatogenesis (sperm production", "PROBLEM", 0, 33], ["severely impaired in llamas", "PROBLEM", 57, 84], ["an ambient temperature", "TEST", 95, 117], ["severely", "OBSERVATION_MODIFIER", 57, 65], ["impaired", "OBSERVATION", 66, 74]]], ["These temperatures, relatively common in summer months in many countries outside the native range of South American camelids, can result in infertility due to decreased sperm numbers, decreased motility, and increased abnormalities.", [["sperm", "ANATOMY", 169, 174], ["infertility", "DISEASE", 140, 151], ["decreased motility", "DISEASE", 184, 202], ["sperm", "ORGANISM_SUBSTANCE", 169, 174], ["sperm", "CELL_TYPE", 169, 174], ["infertility", "PROBLEM", 140, 151], ["decreased sperm numbers", "PROBLEM", 159, 182], ["decreased motility", "PROBLEM", 184, 202], ["increased abnormalities", "PROBLEM", 208, 231], ["decreased", "OBSERVATION_MODIFIER", 184, 193], ["motility", "OBSERVATION_MODIFIER", 194, 202], ["increased", "OBSERVATION_MODIFIER", 208, 217], ["abnormalities", "OBSERVATION", 218, 231]]], ["The heat index (ambient temperature \u00c2 humidity) would cause even more severe changes in hot and humid summers [6] .Heat stressIn advanced cases, other clinical signs appear and include hyperthermia, increased salivation, anorexia, depression, ataxia, muscular weakness, dehydration, ketosis/hepatic lipidosis, and dyspnea/hyperpnea [4, 5] .", [["muscular", "ANATOMY", 251, 259], ["hepatic", "ANATOMY", 291, 298], ["hyperthermia", "DISEASE", 185, 197], ["anorexia", "DISEASE", 221, 229], ["depression", "DISEASE", 231, 241], ["ataxia", "DISEASE", 243, 249], ["muscular weakness", "DISEASE", 251, 268], ["dehydration", "DISEASE", 270, 281], ["ketosis", "DISEASE", 283, 290], ["hepatic lipidosis", "DISEASE", 291, 308], ["dyspnea", "DISEASE", 314, 321], ["hyperpnea", "DISEASE", 322, 331], ["hepatic", "ORGAN", 291, 298], ["The heat index", "TEST", 0, 14], ["ambient temperature \u00c2 humidity", "TREATMENT", 16, 46], ["more severe changes in hot and humid summers", "PROBLEM", 65, 109], ["Heat stressIn advanced cases", "TREATMENT", 115, 143], ["other clinical signs", "TEST", 145, 165], ["hyperthermia", "PROBLEM", 185, 197], ["increased salivation", "PROBLEM", 199, 219], ["anorexia", "PROBLEM", 221, 229], ["depression", "PROBLEM", 231, 241], ["ataxia", "PROBLEM", 243, 249], ["muscular weakness", "PROBLEM", 251, 268], ["dehydration", "PROBLEM", 270, 281], ["ketosis", "PROBLEM", 283, 290], ["hepatic lipidosis", "PROBLEM", 291, 308], ["dyspnea", "PROBLEM", 314, 321], ["hyperpnea", "PROBLEM", 322, 331], ["muscular", "ANATOMY", 251, 259], ["weakness", "OBSERVATION", 260, 268], ["ketosis", "OBSERVATION", 283, 290], ["hepatic", "ANATOMY", 291, 298], ["lipidosis", "OBSERVATION", 299, 308], ["hyperpnea", "OBSERVATION", 322, 331]]], ["These animals generally display an inflammatory or stress leukogram.", [["an inflammatory or stress leukogram", "PROBLEM", 32, 67], ["inflammatory", "OBSERVATION", 35, 47], ["stress leukogram", "OBSERVATION", 51, 67]]], ["Anemia may be secondary to hemolysis.", [["Anemia", "DISEASE", 0, 6], ["hemolysis", "DISEASE", 27, 36], ["Anemia", "PROBLEM", 0, 6], ["hemolysis", "PROBLEM", 27, 36], ["may be", "UNCERTAINTY", 7, 13], ["hemolysis", "OBSERVATION", 27, 36]]], ["Serum biochemical abnormalities may include hypophosphatemia, hypocalcaemia, hypomagnesaemia, hyponatremia, hypochloridemia, hypo-or hyperkalemia, hyperglycemia, and elevated serum AST and CPK concentrations.", [["Serum", "ANATOMY", 0, 5], ["serum", "ANATOMY", 175, 180], ["hypophosphatemia", "DISEASE", 44, 60], ["hypocalcaemia", "DISEASE", 62, 75], ["hypomagnesaemia", "DISEASE", 77, 92], ["hyponatremia", "DISEASE", 94, 106], ["hypochloridemia", "DISEASE", 108, 123], ["hyperkalemia", "DISEASE", 133, 145], ["hyperglycemia", "DISEASE", 147, 160], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 175, 180], ["AST", "SIMPLE_CHEMICAL", 181, 184], ["CPK", "GENE_OR_GENE_PRODUCT", 189, 192], ["CPK", "PROTEIN", 189, 192], ["Serum biochemical abnormalities", "PROBLEM", 0, 31], ["hypophosphatemia", "PROBLEM", 44, 60], ["hypocalcaemia", "PROBLEM", 62, 75], ["hypomagnesaemia", "PROBLEM", 77, 92], ["hyponatremia", "PROBLEM", 94, 106], ["hypochloridemia", "PROBLEM", 108, 123], ["hypo-or hyperkalemia", "PROBLEM", 125, 145], ["hyperglycemia", "PROBLEM", 147, 160], ["elevated serum AST", "PROBLEM", 166, 184], ["CPK concentrations", "TEST", 189, 207], ["may include", "UNCERTAINTY", 32, 43], ["hypophosphatemia", "OBSERVATION", 44, 60], ["hypocalcaemia", "OBSERVATION", 62, 75], ["hypomagnesaemia", "OBSERVATION", 77, 92], ["hyponatremia", "OBSERVATION", 94, 106], ["hyperkalemia", "OBSERVATION", 133, 145], ["hyperglycemia", "OBSERVATION", 147, 160], ["elevated", "OBSERVATION_MODIFIER", 166, 174], ["serum AST", "OBSERVATION_MODIFIER", 175, 184]]], ["Serum glucose concentration >300 mg/dL has been associated with a poor prognosis.", [["Serum", "ANATOMY", 0, 5], ["glucose", "CHEMICAL", 6, 13], ["glucose", "CHEMICAL", 6, 13], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["glucose", "SIMPLE_CHEMICAL", 6, 13], ["Serum glucose concentration", "TEST", 0, 27]]], ["Severe electrolyte imbalances and damage to the thermoregulatory center in the hypothalamus will be the end point of the disease progress in nontreated animals, leading to multi-organ damage or failure and increased mortality [4, 5] .Heat stressStabilization of the heat-stressed animal should include urgent cooling of the core body temperature to the normal range (shearing, spraying the ventral abdomen with cold water, fan), and fluid therapy to rehydrate the animal and correct metabolic abnormalities.", [["hypothalamus", "ANATOMY", 79, 91], ["multi-organ", "ANATOMY", 172, 183], ["body", "ANATOMY", 329, 333], ["ventral abdomen", "ANATOMY", 390, 405], ["fluid", "ANATOMY", 433, 438], ["multi-organ damage", "DISEASE", 172, 190], ["metabolic abnormalities", "DISEASE", 483, 506], ["hypothalamus", "ORGAN", 79, 91], ["multi-organ", "ORGAN", 172, 183], ["body", "ORGANISM_SUBDIVISION", 329, 333], ["abdomen", "ORGANISM_SUBDIVISION", 398, 405], ["Severe electrolyte imbalances", "PROBLEM", 0, 29], ["damage to the thermoregulatory center", "PROBLEM", 34, 71], ["multi-organ damage", "PROBLEM", 172, 190], ["failure", "PROBLEM", 194, 201], ["increased mortality", "PROBLEM", 206, 225], ["urgent cooling", "TREATMENT", 302, 316], ["cold water, fan)", "TREATMENT", 411, 427], ["fluid therapy", "TREATMENT", 433, 446], ["correct metabolic abnormalities", "PROBLEM", 475, 506], ["electrolyte imbalances", "OBSERVATION", 7, 29], ["hypothalamus", "ANATOMY", 79, 91], ["disease", "OBSERVATION", 121, 128], ["multi-organ", "ANATOMY", 172, 183], ["damage", "OBSERVATION", 184, 190], ["failure", "OBSERVATION", 194, 201], ["increased", "OBSERVATION_MODIFIER", 206, 215], ["normal range", "OBSERVATION_MODIFIER", 353, 365], ["ventral", "ANATOMY_MODIFIER", 390, 397], ["abdomen", "ANATOMY", 398, 405], ["metabolic abnormalities", "OBSERVATION", 483, 506]]], ["Intravenous isotonic sodium bicarbonate solution may be required to treat metabolic acidosis.", [["sodium bicarbonate", "CHEMICAL", 21, 39], ["metabolic acidosis", "DISEASE", 74, 92], ["sodium bicarbonate", "CHEMICAL", 21, 39], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 21, 39], ["Intravenous isotonic sodium bicarbonate solution", "TREATMENT", 0, 48], ["metabolic acidosis", "PROBLEM", 74, 92], ["metabolic acidosis", "OBSERVATION", 74, 92]]], ["Maintenance fluid rates are 30-40 and 80-120 mL/kg/day in adults and crias, respectively.", [["fluid", "ANATOMY", 12, 17], ["Maintenance fluid rates", "TREATMENT", 0, 23], ["fluid", "OBSERVATION", 12, 17]]], ["Pulmonary edema is a serious risk if fluids are administered too fast (>20 mL/ kg/h).", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary edema", "DISEASE", 0, 15], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary edema", "PROBLEM", 0, 15], ["edema", "OBSERVATION", 10, 15]]], ["Palliative therapies against other complications should include nasal oxygen insufflation in hypoxemic patients, nonsteroidal anti-inflammatory drugs (NSAIDs; e.g. flunixin meglumine), antioxidants (vitamin E and selenium), and broad-spectrum antibiotics.", [["nasal", "ANATOMY", 64, 69], ["nonsteroidal", "ANATOMY", 113, 125], ["oxygen", "CHEMICAL", 70, 76], ["hypoxemic", "DISEASE", 93, 102], ["flunixin meglumine", "CHEMICAL", 164, 182], ["vitamin E", "CHEMICAL", 199, 208], ["selenium", "CHEMICAL", 213, 221], ["oxygen", "CHEMICAL", 70, 76], ["flunixin meglumine", "CHEMICAL", 164, 182], ["vitamin E", "CHEMICAL", 199, 208], ["selenium", "CHEMICAL", 213, 221], ["nasal", "ORGANISM_SUBDIVISION", 64, 69], ["oxygen", "SIMPLE_CHEMICAL", 70, 76], ["patients", "ORGANISM", 103, 111], ["nonsteroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 113, 149], ["NSAIDs", "SIMPLE_CHEMICAL", 151, 157], ["flunixin meglumine", "SIMPLE_CHEMICAL", 164, 182], ["vitamin E", "SIMPLE_CHEMICAL", 199, 208], ["selenium", "SIMPLE_CHEMICAL", 213, 221], ["patients", "SPECIES", 103, 111], ["Palliative therapies", "TREATMENT", 0, 20], ["other complications", "PROBLEM", 29, 48], ["nasal oxygen insufflation", "TREATMENT", 64, 89], ["hypoxemic patients", "TREATMENT", 93, 111], ["nonsteroidal anti-inflammatory drugs", "TREATMENT", 113, 149], ["NSAIDs", "TREATMENT", 151, 157], ["flunixin meglumine)", "TREATMENT", 164, 183], ["antioxidants", "TREATMENT", 185, 197], ["vitamin E and selenium)", "TREATMENT", 199, 222], ["broad-spectrum antibiotics", "TREATMENT", 228, 254], ["nasal", "ANATOMY", 64, 69], ["oxygen insufflation", "OBSERVATION", 70, 89]]], ["Steroids such as dexamethasone may be indicated in advanced cases, but should not be used in females in the second half of pregnancy.", [["dexamethasone", "CHEMICAL", 17, 30], ["Steroids", "CHEMICAL", 0, 8], ["dexamethasone", "CHEMICAL", 17, 30], ["dexamethasone", "SIMPLE_CHEMICAL", 17, 30], ["Steroids", "TREATMENT", 0, 8], ["dexamethasone", "TREATMENT", 17, 30]]], ["Therapeutic diuresis with furosemide is indicated in animals with respiratory distress due to pulmonary edema.Heat stressHeat stress is best prevented by timely shearing, adequate hydration (clean, cool water) and providing shade and cooling mechanisms such as sprinklers, a pond, or wading pool.", [["respiratory", "ANATOMY", 66, 77], ["pulmonary", "ANATOMY", 94, 103], ["furosemide", "CHEMICAL", 26, 36], ["respiratory distress", "DISEASE", 66, 86], ["pulmonary edema", "DISEASE", 94, 109], ["furosemide", "CHEMICAL", 26, 36], ["furosemide", "SIMPLE_CHEMICAL", 26, 36], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 94, 109], ["Therapeutic diuresis", "TREATMENT", 0, 20], ["furosemide", "TREATMENT", 26, 36], ["respiratory distress", "PROBLEM", 66, 86], ["pulmonary edema", "PROBLEM", 94, 109], ["Heat stress", "PROBLEM", 110, 121], ["Heat stress", "PROBLEM", 121, 132], ["shade and cooling mechanisms", "TREATMENT", 224, 252], ["diuresis", "OBSERVATION", 12, 20], ["respiratory distress", "OBSERVATION", 66, 86], ["pulmonary", "ANATOMY", 94, 103], ["edema", "OBSERVATION", 104, 109], ["stress", "OBSERVATION", 115, 121], ["stress", "OBSERVATION", 126, 132]]], ["Prevention of obesity and reduction of stresses of long transportation, handling and breeding during the hottest part of the day also reduce the risk for heat stress.", [["obesity", "DISEASE", 14, 21], ["obesity", "PROBLEM", 14, 21], ["heat stress", "PROBLEM", 154, 165], ["obesity", "OBSERVATION", 14, 21], ["reduction", "OBSERVATION_MODIFIER", 26, 35], ["stresses", "OBSERVATION_MODIFIER", 39, 47], ["long", "OBSERVATION_MODIFIER", 51, 55]]], ["The primary indicator of heat stress risk is not only the ambient temperature, but also the humidity.", [["heat stress risk", "PROBLEM", 25, 41], ["stress risk", "OBSERVATION", 30, 41]]], ["The heat stress index (HSI), expressed as the ambient temperature (8F) + humidity (%), is considered too high when it reaches or surpasses 160 (e.g. combination of 100 8F and 60% humidity).TraumaTraumatic injuries to the scrotal area are relatively common in the male camelid and are usually inflicted by other males; they occur when new, mature males are added to a paddock, particularly when competing for breeding.", [["scrotal area", "ANATOMY", 221, 233], ["injuries", "DISEASE", 205, 213], ["scrotal area", "MULTI-TISSUE_STRUCTURE", 221, 233], ["The heat stress index", "TEST", 0, 21], ["TraumaTraumatic injuries to the scrotal area", "PROBLEM", 189, 233], ["a paddock", "TREATMENT", 365, 374], ["stress index", "OBSERVATION", 9, 21], ["injuries", "OBSERVATION", 205, 213], ["scrotal", "ANATOMY", 221, 228], ["area", "ANATOMY_MODIFIER", 229, 233], ["relatively", "OBSERVATION_MODIFIER", 238, 248], ["common", "OBSERVATION", 249, 255]]], ["Severe traumatic fighting injuries are more common in camels during the rutting season [7, 8] .", [["injuries", "DISEASE", 26, 34], ["camels", "ORGANISM_SUBDIVISION", 54, 60], ["Severe traumatic fighting injuries", "PROBLEM", 0, 34], ["traumatic", "OBSERVATION_MODIFIER", 7, 16], ["fighting", "OBSERVATION_MODIFIER", 17, 25], ["injuries", "OBSERVATION", 26, 34]]], ["Scrotal traumatic injuries are relatively rare in wild camelids, probably because of their strict social organization.TraumaTraumatic injuries are often due to bites and can range from a superficial scrotal laceration to severe testicular rupture and hemorrhage.", [["Scrotal", "ANATOMY", 0, 7], ["scrotal", "ANATOMY", 199, 206], ["testicular", "ANATOMY", 228, 238], ["traumatic injuries", "DISEASE", 8, 26], ["TraumaTraumatic injuries", "DISEASE", 118, 142], ["scrotal laceration", "DISEASE", 199, 217], ["testicular rupture", "DISEASE", 228, 246], ["hemorrhage", "DISEASE", 251, 261], ["scrotal", "ORGAN", 199, 206], ["testicular", "ORGAN", 228, 238], ["Scrotal traumatic injuries", "PROBLEM", 0, 26], ["TraumaTraumatic injuries", "PROBLEM", 118, 142], ["bites", "PROBLEM", 160, 165], ["a superficial scrotal laceration", "PROBLEM", 185, 217], ["severe testicular rupture", "PROBLEM", 221, 246], ["hemorrhage", "PROBLEM", 251, 261], ["traumatic", "OBSERVATION_MODIFIER", 8, 17], ["injuries", "OBSERVATION", 18, 26], ["injuries", "OBSERVATION", 134, 142], ["superficial", "ANATOMY_MODIFIER", 187, 198], ["scrotal", "ANATOMY", 199, 206], ["laceration", "OBSERVATION", 207, 217], ["severe", "OBSERVATION_MODIFIER", 221, 227], ["testicular", "ANATOMY", 228, 238], ["rupture", "OBSERVATION", 239, 246], ["hemorrhage", "OBSERVATION", 251, 261]]], ["Testicular hemorrhage may occur without external lacerations, but requires ultrasonographic evaluation of scrotal contents [7] .", [["Testicular", "ANATOMY", 0, 10], ["scrotal", "ANATOMY", 106, 113], ["Testicular hemorrhage", "DISEASE", 0, 21], ["Testicular", "ORGAN", 0, 10], ["scrotal", "ORGANISM_SUBDIVISION", 106, 113], ["Testicular hemorrhage", "PROBLEM", 0, 21], ["external lacerations", "PROBLEM", 40, 60], ["ultrasonographic evaluation", "TEST", 75, 102], ["hemorrhage", "OBSERVATION", 11, 21], ["lacerations", "OBSERVATION", 49, 60], ["scrotal", "ANATOMY", 106, 113], ["contents", "OBSERVATION", 114, 122]]], ["Treatment protocols should focus on reducing local swelling, preventing infectious complications, and providing a tetanus toxoid booster.", [["swelling", "DISEASE", 51, 59], ["tetanus", "DISEASE", 114, 121], ["Treatment protocols", "TREATMENT", 0, 19], ["reducing local swelling", "PROBLEM", 36, 59], ["infectious complications", "PROBLEM", 72, 96], ["a tetanus toxoid booster", "TREATMENT", 112, 136], ["swelling", "OBSERVATION", 51, 59], ["infectious", "OBSERVATION_MODIFIER", 72, 82]]], ["Unilateral castration is the treatment method of choice for severe unilateral testicular trauma involving the tunica vaginalis and testis [8] .OrchitisTesticular and epididymal inflammation may present as an emergency in the male camelid.", [["testicular", "ANATOMY", 78, 88], ["tunica vaginalis", "ANATOMY", 110, 126], ["testis", "ANATOMY", 131, 137], ["epididymal", "ANATOMY", 166, 176], ["testicular trauma", "DISEASE", 78, 95], ["epididymal inflammation", "DISEASE", 166, 189], ["testicular", "ORGAN", 78, 88], ["tunica vaginalis", "ORGANISM_SUBSTANCE", 110, 126], ["testis", "ORGAN", 131, 137], ["epididymal", "TISSUE", 166, 176], ["tunica vaginalis", "SPECIES", 110, 126], ["Unilateral castration", "TREATMENT", 0, 21], ["the treatment method of choice", "TREATMENT", 25, 55], ["severe unilateral testicular trauma", "PROBLEM", 60, 95], ["OrchitisTesticular and epididymal inflammation", "PROBLEM", 143, 189], ["castration", "OBSERVATION", 11, 21], ["unilateral", "ANATOMY_MODIFIER", 67, 77], ["testicular", "ANATOMY", 78, 88], ["trauma", "OBSERVATION", 89, 95], ["tunica vaginalis", "ANATOMY", 110, 126], ["testis", "ANATOMY", 131, 137], ["epididymal", "ANATOMY", 166, 176], ["inflammation", "OBSERVATION", 177, 189]]], ["The most common complaint is a sudden onset of lameness or reluctance to breed and visible swelling of the scrotum.", [["scrotum", "ANATOMY", 107, 114], ["lameness", "DISEASE", 47, 55], ["swelling of the scrotum", "DISEASE", 91, 114], ["scrotum", "ORGAN", 107, 114], ["lameness", "PROBLEM", 47, 55], ["reluctance to breed", "PROBLEM", 59, 78], ["visible swelling of the scrotum", "PROBLEM", 83, 114], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["lameness", "OBSERVATION", 47, 55], ["visible", "OBSERVATION_MODIFIER", 83, 90], ["swelling", "OBSERVATION", 91, 99], ["scrotum", "ANATOMY", 107, 114]]], ["Various infectious agents have been reported in cases of orchitis that are spread by hematogenous routes, such as Brucella abortus, Brucella meletensis and Streptococcus equi zooepidemicus, or the agent may ascend from scrotal wounds [9, 10] .", [["scrotal wounds", "ANATOMY", 219, 233], ["orchitis", "DISEASE", 57, 65], ["Brucella abortus", "DISEASE", 114, 130], ["Brucella meletensis", "DISEASE", 132, 151], ["scrotal wounds", "DISEASE", 219, 233], ["Brucella abortus", "ORGANISM", 114, 130], ["Brucella meletensis", "ORGANISM", 132, 151], ["Streptococcus equi", "ORGANISM", 156, 174], ["zooepidemicus", "ORGANISM", 175, 188], ["scrotal wounds", "PATHOLOGICAL_FORMATION", 219, 233], ["Brucella abortus", "SPECIES", 114, 130], ["Brucella meletensis", "SPECIES", 132, 151], ["Streptococcus equi", "SPECIES", 156, 174], ["zooepidemicus", "SPECIES", 175, 188], ["Brucella abortus", "SPECIES", 114, 130], ["Brucella meletensis", "SPECIES", 132, 151], ["Streptococcus equi zooepidemicus", "SPECIES", 156, 188], ["Various infectious agents", "TREATMENT", 0, 25], ["orchitis", "PROBLEM", 57, 65], ["hematogenous routes", "PROBLEM", 85, 104], ["Brucella abortus", "PROBLEM", 114, 130], ["Brucella meletensis", "PROBLEM", 132, 151], ["Streptococcus equi zooepidemicus", "PROBLEM", 156, 188], ["the agent", "TREATMENT", 193, 202], ["scrotal wounds", "PROBLEM", 219, 233], ["infectious", "OBSERVATION", 8, 18], ["orchitis", "OBSERVATION", 57, 65], ["scrotal", "ANATOMY", 219, 226], ["wounds", "OBSERVATION", 227, 233]]], ["Treatment with systemic antimicrobials is often unrewarding.", [["systemic antimicrobials", "TREATMENT", 15, 38]]], ["Therefore, for unilateral orchitis, unilateral orchidectomy is the best option for the welfare of the male and salvage of reproductive ability [8, 9] .Orchitis2.6.", [["orchitis", "DISEASE", 26, 34], ["unilateral orchitis", "PROBLEM", 15, 34], ["unilateral orchidectomy", "TREATMENT", 36, 59], ["unilateral", "OBSERVATION_MODIFIER", 15, 25], ["orchitis", "OBSERVATION", 26, 34], ["unilateral", "OBSERVATION_MODIFIER", 36, 46], ["orchidectomy", "OBSERVATION", 47, 59]]], ["Acute penile/preputial swelling Acute penile or preputial swelling may be due to complications from urolithiasis or traumatic injuries.", [["penile", "ANATOMY", 6, 12], ["preputial", "ANATOMY", 13, 22], ["penile", "ANATOMY", 38, 44], ["preputial", "ANATOMY", 48, 57], ["swelling", "DISEASE", 23, 31], ["penile or preputial swelling", "DISEASE", 38, 66], ["urolithiasis", "DISEASE", 100, 112], ["traumatic injuries", "DISEASE", 116, 134], ["penile", "ORGANISM_SUBDIVISION", 6, 12], ["preputial", "ORGAN", 13, 22], ["penile", "ORGANISM_SUBDIVISION", 38, 44], ["preputial", "ORGAN", 48, 57], ["Acute penile/preputial swelling", "PROBLEM", 0, 31], ["Acute penile", "PROBLEM", 32, 44], ["preputial swelling", "PROBLEM", 48, 66], ["complications", "PROBLEM", 81, 94], ["urolithiasis", "PROBLEM", 100, 112], ["traumatic injuries", "PROBLEM", 116, 134], ["penile", "ANATOMY", 6, 12], ["preputial", "ANATOMY", 13, 22], ["swelling", "OBSERVATION", 23, 31], ["Acute", "OBSERVATION_MODIFIER", 32, 37], ["penile", "ANATOMY", 38, 44], ["preputial", "ANATOMY", 48, 57], ["swelling", "OBSERVATION", 58, 66], ["may be due to", "UNCERTAINTY", 67, 80], ["complications", "OBSERVATION", 81, 94], ["urolithiasis", "OBSERVATION", 100, 112], ["traumatic", "OBSERVATION_MODIFIER", 116, 125], ["injuries", "OBSERVATION", 126, 134]]], ["The etiology of urinary calculi in the camelid is not well understood, but is suggested to be similar to that in other domestic ruminants [11] [12] [13] [14] [15] [16] [17] .", [["urinary calculi", "ANATOMY", 16, 31], ["urinary calculi", "DISEASE", 16, 31], ["urinary calculi", "PATHOLOGICAL_FORMATION", 16, 31], ["[11] [12] [13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 138, 172], ["urinary calculi", "PROBLEM", 16, 31], ["urinary", "ANATOMY", 16, 23], ["calculi", "OBSERVATION", 24, 31]]], ["Early clinical signs of urethral obstruction often go undetected.", [["urethral", "ANATOMY", 24, 32], ["urethral obstruction", "DISEASE", 24, 44], ["urethral obstruction", "PATHOLOGICAL_FORMATION", 24, 44], ["urethral obstruction", "PROBLEM", 24, 44], ["urethral", "ANATOMY", 24, 32], ["obstruction", "OBSERVATION", 33, 44]]], ["Some males may show increased straining to defecate, odontoprisis, inappetence and ileus, followed by anorexia, frequent unsuccessful attempts at micturition or dribbling blood tinged urine, and signs of abdominal discomfort [13] [14] [15] [16] .OrchitisComplications of urethral obstruction include urethral or urinary bladder rupture.", [["blood", "ANATOMY", 171, 176], ["urine", "ANATOMY", 184, 189], ["abdominal", "ANATOMY", 204, 213], ["urethral", "ANATOMY", 271, 279], ["urethral", "ANATOMY", 300, 308], ["urinary bladder", "ANATOMY", 312, 327], ["odontoprisis", "DISEASE", 53, 65], ["inappetence", "DISEASE", 67, 78], ["ileus", "DISEASE", 83, 88], ["anorexia", "DISEASE", 102, 110], ["urethral obstruction", "DISEASE", 271, 291], ["urinary bladder rupture", "DISEASE", 312, 335], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["urine", "ORGANISM_SUBSTANCE", 184, 189], ["abdominal", "ORGANISM_SUBDIVISION", 204, 213], ["urethral obstruction", "PATHOLOGICAL_FORMATION", 271, 291], ["urethral", "MULTI-TISSUE_STRUCTURE", 300, 308], ["urinary bladder", "ORGANISM_SUBDIVISION", 312, 327], ["Some males", "PROBLEM", 0, 10], ["increased straining to defecate", "PROBLEM", 20, 51], ["odontoprisis", "PROBLEM", 53, 65], ["inappetence", "PROBLEM", 67, 78], ["ileus", "PROBLEM", 83, 88], ["anorexia", "PROBLEM", 102, 110], ["frequent unsuccessful attempts at micturition", "PROBLEM", 112, 157], ["dribbling blood tinged urine", "PROBLEM", 161, 189], ["abdominal discomfort", "PROBLEM", 204, 224], ["urethral obstruction", "PROBLEM", 271, 291], ["urethral or urinary bladder rupture", "PROBLEM", 300, 335], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["straining", "OBSERVATION", 30, 39], ["ileus", "OBSERVATION", 83, 88], ["abdominal", "ANATOMY", 204, 213], ["discomfort", "OBSERVATION", 214, 224], ["urethral", "ANATOMY", 271, 279], ["obstruction", "OBSERVATION", 280, 291], ["urethral", "ANATOMY", 300, 308], ["urinary bladder", "ANATOMY", 312, 327], ["rupture", "OBSERVATION", 328, 335]]], ["In emergency cases, the animal presents with anorexia, inability to pass urine, and signs of depression.", [["urine", "ANATOMY", 73, 78], ["anorexia", "DISEASE", 45, 53], ["inability to pass urine", "DISEASE", 55, 78], ["depression", "DISEASE", 93, 103], ["urine", "ORGANISM_SUBSTANCE", 73, 78], ["anorexia", "PROBLEM", 45, 53], ["inability to pass urine", "PROBLEM", 55, 78], ["depression", "PROBLEM", 93, 103], ["anorexia", "OBSERVATION", 45, 53], ["depression", "OBSERVATION", 93, 103]]], ["Physical examination often reveals tachycardia, tachypnea, and elevated rectal temperature.", [["rectal", "ANATOMY", 72, 78], ["tachycardia", "DISEASE", 35, 46], ["tachypnea", "DISEASE", 48, 57], ["rectal", "ORGAN", 72, 78], ["Physical examination", "TEST", 0, 20], ["tachycardia", "PROBLEM", 35, 46], ["tachypnea", "PROBLEM", 48, 57], ["elevated rectal temperature", "PROBLEM", 63, 90], ["tachycardia", "OBSERVATION", 35, 46], ["tachypnea", "OBSERVATION", 48, 57], ["elevated", "OBSERVATION_MODIFIER", 63, 71], ["rectal", "ANATOMY", 72, 78]]], ["Complete blood count may reveal an elevated white cell count and neutrophilia with a left shift, increases in fibrinogen, increased creatinine kinase and aspartate aminotransferase activity, hyperglycemia, hypercreatininemia and increased urea nitrogen.", [["blood", "ANATOMY", 9, 14], ["white cell", "ANATOMY", 44, 54], ["neutrophilia", "DISEASE", 65, 77], ["creatinine", "CHEMICAL", 132, 142], ["aspartate", "CHEMICAL", 154, 163], ["hyperglycemia", "DISEASE", 191, 204], ["hypercreatininemia", "DISEASE", 206, 224], ["urea nitrogen", "CHEMICAL", 239, 252], ["creatinine", "CHEMICAL", 132, 142], ["aspartate", "CHEMICAL", 154, 163], ["urea", "CHEMICAL", 239, 243], ["nitrogen", "CHEMICAL", 244, 252], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["cell", "CELL", 50, 54], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 110, 120], ["creatinine kinase", "GENE_OR_GENE_PRODUCT", 132, 149], ["aspartate", "SIMPLE_CHEMICAL", 154, 163], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 164, 180], ["urea nitrogen", "SIMPLE_CHEMICAL", 239, 252], ["fibrinogen", "PROTEIN", 110, 120], ["creatinine kinase", "PROTEIN", 132, 149], ["Complete blood count", "TEST", 0, 20], ["an elevated white cell count", "PROBLEM", 32, 60], ["neutrophilia", "PROBLEM", 65, 77], ["a left shift", "PROBLEM", 83, 95], ["increases in fibrinogen", "PROBLEM", 97, 120], ["increased creatinine kinase", "PROBLEM", 122, 149], ["aspartate aminotransferase activity", "PROBLEM", 154, 189], ["hyperglycemia", "PROBLEM", 191, 204], ["hypercreatininemia", "PROBLEM", 206, 224], ["increased urea nitrogen", "PROBLEM", 229, 252], ["blood", "ANATOMY", 9, 14], ["elevated", "OBSERVATION_MODIFIER", 35, 43], ["white cell count", "OBSERVATION", 44, 60], ["neutrophilia", "OBSERVATION", 65, 77], ["left", "ANATOMY_MODIFIER", 85, 89], ["shift", "OBSERVATION", 90, 95], ["increases", "OBSERVATION_MODIFIER", 97, 106], ["fibrinogen", "OBSERVATION_MODIFIER", 110, 120], ["increased", "OBSERVATION_MODIFIER", 122, 131], ["creatinine kinase", "OBSERVATION", 132, 149], ["hyperglycemia", "OBSERVATION", 191, 204], ["increased", "OBSERVATION_MODIFIER", 229, 238], ["urea nitrogen", "OBSERVATION", 239, 252]]], ["Serum electrolyte abnormalities included hyponatraemia, hypochloraemia, and hyperkalaemia.", [["Serum", "ANATOMY", 0, 5], ["electrolyte abnormalities", "DISEASE", 6, 31], ["hyponatraemia", "DISEASE", 41, 54], ["hypochloraemia", "DISEASE", 56, 70], ["hyperkalaemia", "DISEASE", 76, 89], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum electrolyte abnormalities", "PROBLEM", 0, 31], ["hyponatraemia", "PROBLEM", 41, 54], ["hypochloraemia", "PROBLEM", 56, 70], ["hyperkalaemia", "PROBLEM", 76, 89], ["hyponatraemia", "OBSERVATION", 41, 54], ["hyperkalaemia", "OBSERVATION", 76, 89]]], ["Fluid obtained by abdominocentesis or from the preputial swelling has increased creatinine concentration [12] [13] [14] [15] [16] .OrchitisIncreased serum urea nitrogen and creatinine concentrations suggest uroperitoneum [16] .", [["preputial", "ANATOMY", 47, 56], ["serum", "ANATOMY", 149, 154], ["swelling", "DISEASE", 57, 65], ["creatinine", "CHEMICAL", 80, 90], ["Orchitis", "DISEASE", 131, 139], ["urea nitrogen", "CHEMICAL", 155, 168], ["creatinine", "CHEMICAL", 173, 183], ["creatinine", "CHEMICAL", 80, 90], ["urea", "CHEMICAL", 155, 159], ["nitrogen", "CHEMICAL", 160, 168], ["creatinine", "CHEMICAL", 173, 183], ["preputial", "ORGAN", 47, 56], ["creatinine", "SIMPLE_CHEMICAL", 80, 90], ["[12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 105, 129], ["serum", "ORGANISM_SUBSTANCE", 149, 154], ["urea", "SIMPLE_CHEMICAL", 155, 159], ["nitrogen", "SIMPLE_CHEMICAL", 160, 168], ["creatinine", "SIMPLE_CHEMICAL", 173, 183], ["the preputial swelling", "PROBLEM", 43, 65], ["increased creatinine concentration", "PROBLEM", 70, 104], ["Orchitis", "PROBLEM", 131, 139], ["serum urea nitrogen", "TEST", 149, 168], ["creatinine concentrations", "TEST", 173, 198], ["uroperitoneum", "PROBLEM", 207, 220], ["preputial", "ANATOMY", 47, 56], ["swelling", "OBSERVATION", 57, 65]]], ["Transcutaneous ultrasonography of the ventral abdomen may enable visualization of subcutaneous free fluid and tissue edema in the case of urethral rupture and a large volume of free fluid in the abdominal cavity in the case of urinary bladder rupture.", [["ventral abdomen", "ANATOMY", 38, 53], ["subcutaneous free fluid", "ANATOMY", 82, 105], ["tissue edema", "ANATOMY", 110, 122], ["urethral", "ANATOMY", 138, 146], ["fluid", "ANATOMY", 182, 187], ["abdominal cavity", "ANATOMY", 195, 211], ["urinary bladder", "ANATOMY", 227, 242], ["edema", "DISEASE", 117, 122], ["urethral rupture", "DISEASE", 138, 154], ["urinary bladder rupture", "DISEASE", 227, 250], ["ventral abdomen", "ORGANISM_SUBDIVISION", 38, 53], ["subcutaneous free fluid", "ORGANISM_SUBSTANCE", 82, 105], ["tissue", "TISSUE", 110, 116], ["edema", "PATHOLOGICAL_FORMATION", 117, 122], ["urethral", "ORGAN", 138, 146], ["fluid", "ORGANISM_SUBSTANCE", 182, 187], ["abdominal cavity", "ORGANISM_SUBDIVISION", 195, 211], ["urinary bladder", "ORGANISM_SUBDIVISION", 227, 242], ["Transcutaneous ultrasonography of the ventral abdomen", "TEST", 0, 53], ["subcutaneous free fluid", "PROBLEM", 82, 105], ["tissue edema", "PROBLEM", 110, 122], ["urethral rupture", "PROBLEM", 138, 154], ["a large volume of free fluid in the abdominal cavity", "PROBLEM", 159, 211], ["urinary bladder rupture", "PROBLEM", 227, 250], ["ventral", "ANATOMY_MODIFIER", 38, 45], ["abdomen", "ANATOMY", 46, 53], ["subcutaneous", "ANATOMY", 82, 94], ["free fluid", "OBSERVATION", 95, 105], ["tissue", "OBSERVATION_MODIFIER", 110, 116], ["edema", "OBSERVATION", 117, 122], ["urethral", "ANATOMY", 138, 146], ["rupture", "OBSERVATION", 147, 154], ["large", "OBSERVATION_MODIFIER", 161, 166], ["volume", "OBSERVATION_MODIFIER", 167, 173], ["free", "OBSERVATION_MODIFIER", 177, 181], ["fluid", "OBSERVATION", 182, 187], ["abdominal cavity", "ANATOMY", 195, 211], ["urinary bladder", "ANATOMY", 227, 242], ["rupture", "OBSERVATION", 243, 250]]], ["With the latter, it may not be possible to visualize the urinary bladder.", [["urinary bladder", "ANATOMY", 57, 72], ["urinary bladder", "ORGAN", 57, 72], ["may not be possible", "UNCERTAINTY", 20, 39], ["urinary bladder", "ANATOMY", 57, 72]]], ["Transrectal ultrasonography may reveal dilation of the pelvic urethra if the bladder is intact.", [["Transrectal", "ANATOMY", 0, 11], ["pelvic urethra", "ANATOMY", 55, 69], ["bladder", "ANATOMY", 77, 84], ["Transrectal", "MULTI-TISSUE_STRUCTURE", 0, 11], ["pelvic urethra", "ORGAN", 55, 69], ["bladder", "ORGAN", 77, 84], ["Transrectal ultrasonography", "TEST", 0, 27], ["dilation of the pelvic urethra", "PROBLEM", 39, 69], ["dilation", "OBSERVATION", 39, 47], ["pelvic urethra", "ANATOMY", 55, 69], ["bladder", "ANATOMY", 77, 84], ["intact", "OBSERVATION", 88, 94]]], ["The prognosis is grave if there is hydroureter and hydronephrosis [16] .OrchitisUroliths are often located in the distal penile urethra, approximately 7-12 cm from the penile orifice, but are occasionally immediately proximal to the sigmoid flexure.", [["distal penile urethra", "ANATOMY", 114, 135], ["penile orifice", "ANATOMY", 168, 182], ["sigmoid flexure", "ANATOMY", 233, 248], ["hydronephrosis", "DISEASE", 51, 65], ["OrchitisUroliths", "DISEASE", 72, 88], ["hydroureter", "CANCER", 35, 46], ["penile urethra", "ORGAN", 121, 135], ["penile orifice", "MULTI-TISSUE_STRUCTURE", 168, 182], ["sigmoid flexure", "MULTI-TISSUE_STRUCTURE", 233, 248], ["hydroureter", "PROBLEM", 35, 46], ["hydronephrosis", "PROBLEM", 51, 65], ["OrchitisUroliths", "TREATMENT", 72, 88], ["grave", "OBSERVATION", 17, 22], ["hydroureter", "OBSERVATION", 35, 46], ["hydronephrosis", "OBSERVATION", 51, 65], ["distal", "ANATOMY_MODIFIER", 114, 120], ["penile urethra", "ANATOMY", 121, 135], ["approximately", "OBSERVATION_MODIFIER", 137, 150], ["7-12 cm", "OBSERVATION_MODIFIER", 151, 158], ["penile", "ANATOMY", 168, 174], ["orifice", "ANATOMY_MODIFIER", 175, 182], ["sigmoid", "ANATOMY", 233, 240], ["flexure", "ANATOMY_MODIFIER", 241, 248]]], ["Camelids, like domestic ruminants, have a urethral recess at the ischial arch, making catheterization of the urinary bladder exceedingly difficult.", [["urethral", "ANATOMY", 42, 50], ["ischial arch", "ANATOMY", 65, 77], ["urinary bladder", "ANATOMY", 109, 124], ["urethral recess", "MULTI-TISSUE_STRUCTURE", 42, 57], ["ischial arch", "MULTI-TISSUE_STRUCTURE", 65, 77], ["urinary bladder", "ORGAN", 109, 124], ["catheterization", "TEST", 86, 101], ["the urinary bladder", "PROBLEM", 105, 124], ["domestic ruminants", "OBSERVATION", 15, 33], ["urethral", "ANATOMY", 42, 50], ["recess", "ANATOMY_MODIFIER", 51, 57], ["ischial arch", "ANATOMY", 65, 77], ["catheterization", "OBSERVATION", 86, 101], ["urinary bladder", "ANATOMY", 109, 124]]], ["Management techniques for obstructive urolithiais is similar to those reported in ruminants and include repair of the ruptured urinary bladder and relief of the obstruction via retrograde flushing and urethrotomy.", [["urinary bladder", "ANATOMY", 127, 142], ["obstructive urolithiais", "DISEASE", 26, 49], ["ruptured urinary bladder", "DISEASE", 118, 142], ["obstruction", "DISEASE", 161, 172], ["urinary bladder", "ORGAN", 127, 142], ["Management techniques", "TREATMENT", 0, 21], ["obstructive urolithiais", "PROBLEM", 26, 49], ["repair", "TREATMENT", 104, 110], ["the ruptured urinary bladder", "PROBLEM", 114, 142], ["the obstruction", "PROBLEM", 157, 172], ["retrograde flushing", "TREATMENT", 177, 196], ["urethrotomy", "TREATMENT", 201, 212], ["obstructive", "OBSERVATION", 26, 37], ["ruptured", "OBSERVATION", 118, 126], ["urinary bladder", "ANATOMY", 127, 142], ["relief", "OBSERVATION_MODIFIER", 147, 153], ["obstruction", "OBSERVATION", 161, 172], ["retrograde flushing", "OBSERVATION", 177, 196], ["urethrotomy", "OBSERVATION", 201, 212]]], ["Flushing, followed by tube cystotomy, may be the only option to try to salvage the reproductive life of the animal [16] .OrchitisPostsurgical management should include multiple therapies, including antimicrobial (procaine penicillin, 30,000 IU/kg IM, twice daily; and gentamicin sulphate, 6.6 mg/kg IV, once daily), anti-inflammatory (flunixin meglumine, 1 mg/kg IV, twice daily) and intravenous fluids.", [["tube", "ANATOMY", 22, 26], ["intravenous", "ANATOMY", 384, 395], ["procaine", "CHEMICAL", 213, 221], ["penicillin", "CHEMICAL", 222, 232], ["gentamicin sulphate", "CHEMICAL", 268, 287], ["flunixin meglumine", "CHEMICAL", 335, 353], ["procaine penicillin", "CHEMICAL", 213, 232], ["gentamicin sulphate", "CHEMICAL", 268, 287], ["flunixin meglumine", "CHEMICAL", 335, 353], ["tube", "TISSUE", 22, 26], ["procaine", "SIMPLE_CHEMICAL", 213, 221], ["penicillin", "SIMPLE_CHEMICAL", 222, 232], ["gentamicin sulphate", "SIMPLE_CHEMICAL", 268, 287], ["flunixin meglumine", "SIMPLE_CHEMICAL", 335, 353], ["Flushing", "TREATMENT", 0, 8], ["tube cystotomy", "TREATMENT", 22, 36], ["salvage", "TREATMENT", 71, 78], ["OrchitisPostsurgical management", "TREATMENT", 121, 152], ["multiple therapies", "TREATMENT", 168, 186], ["antimicrobial (procaine penicillin", "TREATMENT", 198, 232], ["gentamicin sulphate", "TREATMENT", 268, 287], ["anti-inflammatory (flunixin meglumine", "TREATMENT", 316, 353], ["intravenous fluids", "TREATMENT", 384, 402], ["tube cystotomy", "OBSERVATION", 22, 36]]], ["Prognosis for life is fair, but prognosis for return to breeding is usually guarded [16] .Preputial/penile traumaPreputial lacerations are relatively common in breeding males.", [["penile", "ANATOMY", 100, 106], ["Preputial/penile traumaPreputial lacerations", "PROBLEM", 90, 134], ["penile", "ANATOMY", 100, 106], ["traumaPreputial lacerations", "OBSERVATION", 107, 134], ["relatively", "OBSERVATION_MODIFIER", 139, 149], ["common", "OBSERVATION_MODIFIER", 150, 156], ["breeding males", "OBSERVATION", 160, 174]]], ["They are usually a consequence of masturbation (breeding the ground or objects) or complications from foreign objects within the prepuce.", [["prepuce", "ANATOMY", 129, 136], ["prepuce", "TISSUE", 129, 136], ["masturbation", "PROBLEM", 34, 46], ["complications from foreign objects within the prepuce", "PROBLEM", 83, 136], ["foreign objects", "OBSERVATION", 102, 117], ["prepuce", "ANATOMY", 129, 136]]], ["Hair-ring lacerations of the penis are common in llamas and Suri alpacas.", [["Hair-ring", "ANATOMY", 0, 9], ["penis", "ANATOMY", 29, 34], ["penis", "ORGAN", 29, 34], ["llamas", "ORGANISM", 49, 55], ["Hair-ring lacerations of the penis", "PROBLEM", 0, 34], ["ring", "OBSERVATION_MODIFIER", 5, 9], ["lacerations", "OBSERVATION", 10, 21], ["penis", "ANATOMY", 29, 34], ["common", "OBSERVATION_MODIFIER", 39, 45], ["llamas", "OBSERVATION", 49, 55]]], ["Males may present because the owner has observed an abnormal protrusion of the prepuce, or discomfort during urination or mating.", [["prepuce", "ANATOMY", 79, 86], ["abnormal protrusion of the prepuce", "DISEASE", 52, 86], ["prepuce", "PATHOLOGICAL_FORMATION", 79, 86], ["an abnormal protrusion of the prepuce", "PROBLEM", 49, 86], ["discomfort during urination", "PROBLEM", 91, 118], ["abnormal", "OBSERVATION_MODIFIER", 52, 60], ["protrusion", "OBSERVATION", 61, 71], ["prepuce", "ANATOMY", 79, 86]]], ["However, bloody or purulent discharge may be the only clinical sign.", [["bloody or purulent discharge", "PROBLEM", 9, 37], ["bloody", "OBSERVATION", 9, 15], ["purulent", "OBSERVATION", 19, 27]]], ["Preputial and penile lacerations can quickly become complicated and jeopardize the reproductive life of the male due to development of severe inflammation and adhesions.", [["penile", "ANATOMY", 14, 20], ["adhesions", "ANATOMY", 159, 168], ["penile lacerations", "DISEASE", 14, 32], ["inflammation", "DISEASE", 142, 154], ["adhesions", "DISEASE", 159, 168], ["penile lacerations", "PATHOLOGICAL_FORMATION", 14, 32], ["Preputial and penile lacerations", "PROBLEM", 0, 32], ["severe inflammation", "PROBLEM", 135, 154], ["adhesions", "PROBLEM", 159, 168], ["penile", "ANATOMY", 14, 20], ["lacerations", "OBSERVATION", 21, 32], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["inflammation", "OBSERVATION", 142, 154], ["adhesions", "OBSERVATION", 159, 168]]], ["Injured males may continue to attempt breeding, further exacerbating the lesions [7] .Preputial/penile traumaEvaluation of penile and preputial injuries is best performed under heavy sedation or general anesthesia.", [["lesions", "ANATOMY", 73, 80], ["penile", "ANATOMY", 96, 102], ["penile", "ANATOMY", 123, 129], ["preputial", "ANATOMY", 134, 143], ["preputial injuries", "DISEASE", 134, 152], ["penile", "ORGANISM_SUBDIVISION", 96, 102], ["penile", "ORGANISM_SUBDIVISION", 123, 129], ["preputial", "ORGAN", 134, 143], ["breeding", "TREATMENT", 38, 46], ["further exacerbating the lesions", "PROBLEM", 48, 80], ["Preputial/penile traumaEvaluation", "TREATMENT", 86, 119], ["penile and preputial injuries", "PROBLEM", 123, 152], ["heavy sedation", "TREATMENT", 177, 191], ["general anesthesia", "TREATMENT", 195, 213], ["lesions", "OBSERVATION", 73, 80], ["penile", "ANATOMY", 96, 102], ["traumaEvaluation", "OBSERVATION", 103, 119], ["penile", "ANATOMY", 123, 129], ["preputial", "ANATOMY", 134, 143], ["injuries", "OBSERVATION", 144, 152]]], ["The penis should be completely exteriorized and inspected for lesions.", [["penis", "ANATOMY", 4, 9], ["lesions", "ANATOMY", 62, 69], ["penis", "ORGAN", 4, 9], ["lesions", "PATHOLOGICAL_FORMATION", 62, 69], ["lesions", "PROBLEM", 62, 69], ["penis", "ANATOMY", 4, 9], ["lesions", "OBSERVATION", 62, 69]]], ["Early management of preputial and penile injuries should center on providing adequate protection of the traumatized tissue and prevention of infection and complication with urine scalding.", [["preputial", "ANATOMY", 20, 29], ["penile", "ANATOMY", 34, 40], ["tissue", "ANATOMY", 116, 122], ["urine", "ANATOMY", 173, 178], ["penile injuries", "DISEASE", 34, 49], ["traumatized", "DISEASE", 104, 115], ["infection", "DISEASE", 141, 150], ["preputial", "ORGAN", 20, 29], ["penile", "ORGANISM_SUBDIVISION", 34, 40], ["tissue", "TISSUE", 116, 122], ["urine", "ORGANISM_SUBSTANCE", 173, 178], ["Early management", "TREATMENT", 0, 16], ["preputial and penile injuries", "PROBLEM", 20, 49], ["the traumatized tissue", "PROBLEM", 100, 122], ["infection", "PROBLEM", 141, 150], ["complication", "PROBLEM", 155, 167], ["urine scalding", "PROBLEM", 173, 187], ["preputial", "ANATOMY", 20, 29], ["penile", "ANATOMY", 34, 40], ["injuries", "OBSERVATION", 41, 49], ["traumatized", "OBSERVATION", 104, 115], ["infection", "OBSERVATION", 141, 150]]], ["The initial treatment is to replace viable prolapsed preputial mucosa and maintain it in place with a purse string suture.", [["preputial mucosa", "ANATOMY", 53, 69], ["preputial mucosa", "MULTI-TISSUE_STRUCTURE", 53, 69], ["The initial treatment", "TREATMENT", 0, 21], ["viable prolapsed preputial mucosa", "PROBLEM", 36, 69], ["a purse string suture", "TREATMENT", 100, 121], ["prolapsed", "OBSERVATION", 43, 52], ["preputial mucosa", "ANATOMY", 53, 69]]], ["Daily cleaning of the sheath with saline, and application of local anti-inflammatory and antimicrobial ointment (petercillin) for 3-5 days will reduce the chance of further complications.", [["sheath", "ANATOMY", 22, 28], ["petercillin", "CHEMICAL", 113, 124], ["petercillin", "CHEMICAL", 113, 124], ["saline", "SIMPLE_CHEMICAL", 34, 40], ["petercillin", "SIMPLE_CHEMICAL", 113, 124], ["the sheath", "TREATMENT", 18, 28], ["saline", "TREATMENT", 34, 40], ["local anti-inflammatory and antimicrobial ointment (petercillin)", "TREATMENT", 61, 125], ["further complications", "PROBLEM", 165, 186]]], ["Sutures may be removed after 7-10 days.", [["Sutures", "TREATMENT", 0, 7]]], ["Excessive preputial prolapse with slight necrosis requires circumferential resection and anastomosis of the prepuce.", [["preputial", "ANATOMY", 10, 19], ["prepuce", "ANATOMY", 108, 115], ["preputial prolapse", "DISEASE", 10, 28], ["necrosis", "DISEASE", 41, 49], ["preputial", "ORGAN", 10, 19], ["prepuce", "PATHOLOGICAL_FORMATION", 108, 115], ["Excessive preputial prolapse", "PROBLEM", 0, 28], ["slight necrosis", "PROBLEM", 34, 49], ["circumferential resection", "TREATMENT", 59, 84], ["anastomosis of the prepuce", "TREATMENT", 89, 115], ["preputial", "ANATOMY", 10, 19], ["prolapse", "OBSERVATION", 20, 28], ["slight", "OBSERVATION_MODIFIER", 34, 40], ["necrosis", "OBSERVATION", 41, 49], ["circumferential", "OBSERVATION_MODIFIER", 59, 74], ["resection", "OBSERVATION", 75, 84], ["anastomosis", "OBSERVATION", 89, 100], ["prepuce", "ANATOMY", 108, 115]]], ["Prognosis for return to normal breeding activity is poor if adhesions or abscesses develop at the base of the prepuce [2, 18] .Post-surgical emergenciesThe most common post-surgical complication in the male camelid is post-castration hemorrhage, often secondary to inadequate time to insure hemostasis of the testicular cord.", [["adhesions", "ANATOMY", 60, 69], ["abscesses", "ANATOMY", 73, 82], ["prepuce", "ANATOMY", 110, 117], ["testicular cord", "ANATOMY", 309, 324], ["abscesses", "DISEASE", 73, 82], ["hemorrhage", "DISEASE", 234, 244], ["abscesses", "PATHOLOGICAL_FORMATION", 73, 82], ["prepuce", "TISSUE", 110, 117], ["testicular cord", "ORGAN", 309, 324], ["adhesions", "PROBLEM", 60, 69], ["abscesses", "PROBLEM", 73, 82], ["surgical emergencies", "TREATMENT", 132, 152], ["The most common post-surgical complication", "PROBLEM", 152, 194], ["post-castration hemorrhage", "PROBLEM", 218, 244], ["hemostasis of the testicular cord", "PROBLEM", 291, 324], ["abscesses", "OBSERVATION", 73, 82], ["prepuce", "ANATOMY", 110, 117], ["surgical", "OBSERVATION", 132, 140], ["most", "OBSERVATION_MODIFIER", 156, 160], ["common", "OBSERVATION_MODIFIER", 161, 167], ["surgical", "OBSERVATION_MODIFIER", 173, 181], ["complication", "OBSERVATION", 182, 194], ["hemorrhage", "OBSERVATION", 234, 244], ["hemostasis", "OBSERVATION", 291, 301], ["testicular cord", "ANATOMY", 309, 324]]], ["Management of these conditions is not different from other species and includes placing the male in a calm environment and packing the bursa for 6-24 h.", [["bursa", "ANATOMY", 135, 140], ["bursa", "ORGAN", 135, 140], ["these conditions", "PROBLEM", 14, 30], ["packing the bursa", "TREATMENT", 123, 140], ["bursa", "ANATOMY", 135, 140]]], ["Several commercial hemostatic agents are available and may be helpful [19] .Soft palate prolapseExteriorization of the soft palate (Dulla) is a characteristic rutting behavior in the dromedary camel [7] .", [["Soft palate", "ANATOMY", 76, 87], ["soft palate", "ANATOMY", 119, 130], ["soft palate", "DISEASE", 119, 130], ["palate", "ORGAN", 81, 87], ["palate", "ORGAN", 124, 130], ["Several commercial hemostatic agents", "TREATMENT", 0, 36], ["palate", "ANATOMY", 81, 87], ["prolapseExteriorization", "OBSERVATION", 88, 111], ["soft palate", "ANATOMY", 119, 130]]], ["Furthermore, permanent exteriorization of the soft palate during the rut season is a common in the dromedary.", [["soft palate", "ANATOMY", 46, 57], ["palate", "ORGAN", 51, 57], ["permanent exteriorization of the soft palate", "TREATMENT", 13, 57], ["permanent", "OBSERVATION_MODIFIER", 13, 22], ["exteriorization", "OBSERVATION_MODIFIER", 23, 38], ["soft palate", "ANATOMY", 46, 57]]], ["This usually starts with an impaction of the diverticulum with food or a foreign body [20, 21] .", [["diverticulum", "ANATOMY", 45, 57], ["body", "ANATOMY", 81, 85], ["diverticulum", "PATHOLOGICAL_FORMATION", 45, 57], ["an impaction of the diverticulum", "PROBLEM", 25, 57], ["a foreign body", "PROBLEM", 71, 85], ["impaction", "OBSERVATION", 28, 37], ["diverticulum", "OBSERVATION", 45, 57], ["foreign body", "OBSERVATION", 73, 85]]], ["Part of the impacted soft palate becomes trapped under the molars and is traumatized during mastication.", [["soft palate", "ANATOMY", 21, 32], ["molars", "ANATOMY", 59, 65], ["palate", "ORGAN", 26, 32], ["molars", "ORGAN", 59, 65], ["the impacted soft palate", "PROBLEM", 8, 32], ["traumatized", "PROBLEM", 73, 84], ["impacted", "OBSERVATION_MODIFIER", 12, 20], ["soft palate", "ANATOMY", 21, 32], ["trapped", "OBSERVATION", 41, 48], ["molars", "ANATOMY", 59, 65], ["traumatized", "OBSERVATION", 73, 84]]], ["Traumatic lesions of the soft palate range in severity from superficial cuts and bruises to severe lacerations accompanied by hemorrhage; these lesions are rapidly complicated by infection and development of severe inflammation and edema.", [["lesions", "ANATOMY", 10, 17], ["soft palate", "ANATOMY", 25, 36], ["lesions", "ANATOMY", 144, 151], ["edema", "ANATOMY", 232, 237], ["Traumatic lesions of the soft palate", "DISEASE", 0, 36], ["bruises", "DISEASE", 81, 88], ["lacerations", "DISEASE", 99, 110], ["hemorrhage", "DISEASE", 126, 136], ["infection", "DISEASE", 179, 188], ["inflammation", "DISEASE", 215, 227], ["edema", "DISEASE", 232, 237], ["lesions", "PATHOLOGICAL_FORMATION", 10, 17], ["palate", "ORGAN", 30, 36], ["lacerations", "PATHOLOGICAL_FORMATION", 99, 110], ["lesions", "PATHOLOGICAL_FORMATION", 144, 151], ["edema", "PATHOLOGICAL_FORMATION", 232, 237], ["Traumatic lesions", "PROBLEM", 0, 17], ["the soft palate range in severity", "PROBLEM", 21, 54], ["superficial cuts", "PROBLEM", 60, 76], ["bruises", "PROBLEM", 81, 88], ["severe lacerations", "PROBLEM", 92, 110], ["hemorrhage", "PROBLEM", 126, 136], ["these lesions", "PROBLEM", 138, 151], ["infection", "PROBLEM", 179, 188], ["severe inflammation", "PROBLEM", 208, 227], ["edema", "PROBLEM", 232, 237], ["lesions", "OBSERVATION", 10, 17], ["soft palate", "ANATOMY", 25, 36], ["severity", "OBSERVATION_MODIFIER", 46, 54], ["superficial", "ANATOMY_MODIFIER", 60, 71], ["bruises", "OBSERVATION", 81, 88], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["lacerations", "OBSERVATION", 99, 110], ["hemorrhage", "OBSERVATION", 126, 136], ["lesions", "OBSERVATION", 144, 151], ["infection", "OBSERVATION", 179, 188], ["severe", "OBSERVATION_MODIFIER", 208, 214], ["inflammation", "OBSERVATION", 215, 227], ["edema", "OBSERVATION", 232, 237]]], ["Formation of large abscesses is not uncommon.", [["abscesses", "ANATOMY", 19, 28], ["abscesses", "DISEASE", 19, 28], ["abscesses", "PATHOLOGICAL_FORMATION", 19, 28], ["large abscesses", "PROBLEM", 13, 28], ["large", "OBSERVATION_MODIFIER", 13, 18], ["abscesses", "OBSERVATION", 19, 28], ["not uncommon", "UNCERTAINTY", 32, 44]]], ["In most cases, the inflamed organ is permanently hanging from the side of the mouth and becomes progressively necrotic [22] [23] [24] .", [["organ", "ANATOMY", 28, 33], ["mouth", "ANATOMY", 78, 83], ["necrotic", "DISEASE", 110, 118], ["organ", "ORGAN", 28, 33], ["mouth", "ORGAN", 78, 83], ["progressively necrotic", "PROBLEM", 96, 118], ["inflamed", "OBSERVATION", 19, 27], ["organ", "ANATOMY", 28, 33], ["mouth", "ANATOMY", 78, 83], ["progressively", "OBSERVATION_MODIFIER", 96, 109], ["necrotic", "OBSERVATION", 110, 118]]], ["In a few cases, the soft palate is swollen, but not exteriorized, and blocks air exchange, which may lead to asphyxiation.", [["soft palate", "ANATOMY", 20, 31], ["asphyxiation", "DISEASE", 109, 121], ["palate", "ORGAN", 25, 31], ["swollen", "PROBLEM", 35, 42], ["blocks air exchange", "PROBLEM", 70, 89], ["asphyxiation", "PROBLEM", 109, 121], ["soft palate", "ANATOMY", 20, 31], ["swollen", "OBSERVATION", 35, 42], ["air exchange", "OBSERVATION", 77, 89]]], ["If the condition is not treated, the animals become emaciated due to dysphagia and impairment of mastication and deglutition.", [["dysphagia", "DISEASE", 69, 78], ["impairment of mastication and deglutition", "DISEASE", 83, 124], ["animals", "ORGANISM", 37, 44], ["emaciated", "PROBLEM", 52, 61], ["dysphagia", "PROBLEM", 69, 78], ["impairment of mastication and deglutition", "PROBLEM", 83, 124], ["dysphagia", "OBSERVATION", 69, 78]]], ["Management of these cases requires surgical ablation of the soft palate [20] .", [["soft palate", "ANATOMY", 60, 71], ["palate", "ORGAN", 65, 71], ["surgical ablation of the soft palate", "TREATMENT", 35, 71], ["soft palate", "ANATOMY", 60, 71]]], ["Surgical excision of the soft palate can be performed under heavy sedation and a local block.", [["soft palate", "ANATOMY", 25, 36], ["palate", "ORGAN", 30, 36], ["Surgical excision of the soft palate", "TREATMENT", 0, 36], ["heavy sedation", "TREATMENT", 60, 74], ["a local block", "TREATMENT", 79, 92], ["excision", "OBSERVATION", 9, 17], ["soft palate", "ANATOMY", 25, 36]]], ["Large vessels are ligated with resorbable suture material.", [["vessels", "ANATOMY", 6, 13], ["vessels", "MULTI-TISSUE_STRUCTURE", 6, 13], ["resorbable suture material", "TREATMENT", 31, 57], ["vessels", "ANATOMY", 6, 13], ["ligated", "OBSERVATION", 18, 25], ["resorbable", "OBSERVATION", 31, 41], ["suture material", "OBSERVATION", 42, 57]]], ["Laser ablation is the best approach.", [["Laser ablation", "TREATMENT", 0, 14], ["ablation", "OBSERVATION", 6, 14]]], ["Postsurgical management includes administration of NSAIDs, antimicrobials, and tetanus prophylaxis.", [["NSAIDs", "CHEMICAL", 51, 57], ["tetanus", "DISEASE", 79, 86], ["NSAIDs", "SIMPLE_CHEMICAL", 51, 57], ["Postsurgical management", "TREATMENT", 0, 23], ["NSAIDs", "TREATMENT", 51, 57], ["antimicrobials", "TREATMENT", 59, 73], ["tetanus prophylaxis", "TREATMENT", 79, 98]]], ["Animals should be on soft feed for at least 3-4 days after surgery.Rupture of the urethraUrethral rupture and subcutaneous infiltration of urine is relatively common in draught camels and is due to a tight strap.", [["urethraUrethral", "ANATOMY", 82, 97], ["subcutaneous", "ANATOMY", 110, 122], ["urine", "ANATOMY", 139, 144], ["urethraUrethral rupture", "DISEASE", 82, 105], ["Animals", "ORGANISM", 0, 7], ["urine", "ORGANISM_SUBSTANCE", 139, 144], ["soft feed", "TREATMENT", 21, 30], ["surgery", "TREATMENT", 59, 66], ["Rupture", "PROBLEM", 67, 74], ["the urethraUrethral rupture", "PROBLEM", 78, 105], ["subcutaneous infiltration of urine", "PROBLEM", 110, 144], ["a tight strap", "TREATMENT", 198, 211], ["urethraUrethral", "ANATOMY", 82, 97], ["rupture", "OBSERVATION", 98, 105], ["subcutaneous", "ANATOMY", 110, 122], ["infiltration", "OBSERVATION", 123, 135], ["urine", "OBSERVATION", 139, 144], ["tight", "OBSERVATION_MODIFIER", 200, 205], ["strap", "OBSERVATION", 206, 211]]], ["Advanced stages are managed surgically by complete urethrostomy.", [["Advanced stages", "PROBLEM", 0, 15]]], ["Animals present with varying degrees of ventral swelling and prolapse of mucocutaneous junction of the penis and prepuce.", [["ventral", "ANATOMY", 40, 47], ["mucocutaneous junction", "ANATOMY", 73, 95], ["penis", "ANATOMY", 103, 108], ["prepuce", "ANATOMY", 113, 120], ["ventral swelling", "DISEASE", 40, 56], ["Animals", "ORGANISM", 0, 7], ["mucocutaneous junction", "MULTI-TISSUE_STRUCTURE", 73, 95], ["penis", "ORGANISM_SUBDIVISION", 103, 108], ["prepuce", "TISSUE", 113, 120], ["ventral swelling", "PROBLEM", 40, 56], ["prolapse of mucocutaneous junction of the penis and prepuce", "PROBLEM", 61, 120], ["varying degrees", "OBSERVATION_MODIFIER", 21, 36], ["ventral", "ANATOMY_MODIFIER", 40, 47], ["swelling", "OBSERVATION", 48, 56], ["prolapse", "OBSERVATION", 61, 69], ["mucocutaneous junction", "OBSERVATION", 73, 95], ["penis", "ANATOMY", 103, 108], ["prepuce", "ANATOMY", 113, 120]]], ["Tissue necrosis is common, and may include the penis due to pressure ischemia.", [["Tissue", "ANATOMY", 0, 6], ["penis", "ANATOMY", 47, 52], ["necrosis", "DISEASE", 7, 15], ["pressure ischemia", "DISEASE", 60, 77], ["Tissue", "TISSUE", 0, 6], ["penis", "ORGANISM_SUBDIVISION", 47, 52], ["Tissue necrosis", "PROBLEM", 0, 15], ["the penis", "PROBLEM", 43, 52], ["pressure ischemia", "PROBLEM", 60, 77], ["necrosis", "OBSERVATION", 7, 15], ["penis", "ANATOMY", 47, 52], ["pressure", "OBSERVATION_MODIFIER", 60, 68], ["ischemia", "OBSERVATION", 69, 77]]], ["Surgical debridement [25] , phalectomy, or both, may be required [26] .Reproductive emergencies in the femaleReproductive emergencies in female camelidae can be divided into emergencies occurring in the nonpregnant female, severe pregnancy complications, obstetrical emergencies, and postpartum emergencies.", [["phalectomy", "DISEASE", 28, 38], ["pregnancy complications", "DISEASE", 230, 253], ["female camelidae", "ORGANISM", 137, 153], ["Surgical debridement", "TREATMENT", 0, 20], ["phalectomy", "TREATMENT", 28, 38], ["Reproductive emergencies", "PROBLEM", 71, 95], ["severe pregnancy complications", "PROBLEM", 223, 253], ["obstetrical emergencies", "PROBLEM", 255, 278], ["postpartum emergencies", "PROBLEM", 284, 306], ["debridement", "OBSERVATION", 9, 20], ["severe", "OBSERVATION_MODIFIER", 223, 229]]], ["Emergencies requiring intervention during parturition and the immediate postpartum phase must concurrently take into account emergencies pertaining to the neonate.Emergencies in the nonpregnant femaleThe most common reproductive emergencies in nonpregnant females are traumatic injuries during breeding or iatrogenic injuries during reproductive examinations.", [["traumatic injuries", "DISEASE", 268, 286], ["iatrogenic injuries", "DISEASE", 306, 325], ["neonate", "ORGANISM", 155, 162], ["female", "ORGANISM", 194, 200], ["intervention", "TREATMENT", 22, 34], ["parturition", "TREATMENT", 42, 53], ["traumatic injuries", "PROBLEM", 268, 286], ["iatrogenic injuries", "PROBLEM", 306, 325], ["reproductive examinations", "TEST", 333, 358], ["most", "OBSERVATION_MODIFIER", 204, 208], ["common", "OBSERVATION_MODIFIER", 209, 215], ["reproductive", "OBSERVATION_MODIFIER", 216, 228], ["traumatic", "OBSERVATION_MODIFIER", 268, 277], ["injuries", "OBSERVATION", 278, 286], ["iatrogenic", "OBSERVATION_MODIFIER", 306, 316], ["injuries", "OBSERVATION", 317, 325]]], ["Although rare, breeding trauma may occur during an unsupervised paddock mating.", [["trauma", "DISEASE", 24, 30], ["breeding trauma", "PROBLEM", 15, 30]]], ["In camels, traumatic injuries are not always restricted to the reproductive tract, and include bite wounds and fractures of the pelvis and/or dislocations.", [["reproductive tract", "ANATOMY", 63, 81], ["wounds", "ANATOMY", 100, 106], ["pelvis", "ANATOMY", 128, 134], ["traumatic injuries", "DISEASE", 11, 29], ["bite wounds", "DISEASE", 95, 106], ["fractures", "DISEASE", 111, 120], ["dislocations", "DISEASE", 142, 154], ["reproductive tract", "ORGANISM_SUBDIVISION", 63, 81], ["wounds", "PATHOLOGICAL_FORMATION", 100, 106], ["pelvis", "ORGAN", 128, 134], ["traumatic injuries", "PROBLEM", 11, 29], ["bite wounds", "PROBLEM", 95, 106], ["fractures of the pelvis", "PROBLEM", 111, 134], ["dislocations", "PROBLEM", 142, 154], ["traumatic", "OBSERVATION_MODIFIER", 11, 20], ["injuries", "OBSERVATION", 21, 29], ["fractures", "OBSERVATION", 111, 120], ["pelvis", "ANATOMY", 128, 134], ["dislocations", "OBSERVATION", 142, 154]]], ["These traumatic injuries are seen in multiple-sire breeding systems.", [["traumatic injuries", "DISEASE", 6, 24], ["These traumatic injuries", "PROBLEM", 0, 24], ["traumatic", "OBSERVATION_MODIFIER", 6, 15], ["injuries", "OBSERVATION", 16, 24], ["multiple", "OBSERVATION_MODIFIER", 37, 45], ["breeding systems", "OBSERVATION", 51, 67]]], ["In South American camelids, breeding trauma may occur by heavy llama males trying to breed alpacas.", [["trauma", "DISEASE", 37, 43], ["alpacas", "ORGANISM", 91, 98], ["breeding trauma", "PROBLEM", 28, 43]]], ["Discussion of these types of traumatic injuries are beyond the scope of this paper, but should be considered in downer syndrome in females with a history of recent (<24 h) mating.Emergencies in the nonpregnant femaleIatrogenic traumatic injuries are by far the most common emergency in camelid practice; they include perforation of the rectum, colon, vagina, or uterus.", [["rectum", "ANATOMY", 336, 342], ["colon", "ANATOMY", 344, 349], ["vagina", "ANATOMY", 351, 357], ["uterus", "ANATOMY", 362, 368], ["traumatic injuries", "DISEASE", 29, 47], ["Iatrogenic traumatic injuries", "DISEASE", 216, 245], ["perforation of the rectum, colon, vagina", "DISEASE", 317, 357], ["female", "ORGANISM", 210, 216], ["rectum", "MULTI-TISSUE_STRUCTURE", 336, 342], ["colon", "ORGAN", 344, 349], ["vagina", "ORGAN", 351, 357], ["uterus", "ORGAN", 362, 368], ["traumatic injuries", "PROBLEM", 29, 47], ["Iatrogenic traumatic injuries", "PROBLEM", 216, 245], ["perforation of the rectum, colon, vagina, or uterus", "PROBLEM", 317, 368], ["traumatic", "OBSERVATION_MODIFIER", 29, 38], ["injuries", "OBSERVATION", 39, 47], ["traumatic", "OBSERVATION_MODIFIER", 227, 236], ["injuries", "OBSERVATION", 237, 245], ["perforation", "OBSERVATION", 317, 328], ["rectum", "ANATOMY", 336, 342], ["colon", "ANATOMY", 344, 349], ["vagina", "ANATOMY", 351, 357], ["uterus", "ANATOMY", 362, 368]]], ["Anal sphincter bleeding due to excessive stretching and rectal prolapse can occur secondary to transrectal palpation, particularly when there is already a predisposing factor for excessive straining (e.g. pelvic mass, urinary bladder disease).", [["Anal sphincter", "ANATOMY", 0, 14], ["rectal", "ANATOMY", 56, 62], ["transrectal", "ANATOMY", 95, 106], ["pelvic mass", "ANATOMY", 205, 216], ["urinary bladder", "ANATOMY", 218, 233], ["Anal sphincter bleeding", "DISEASE", 0, 23], ["rectal prolapse", "DISEASE", 56, 71], ["urinary bladder disease", "DISEASE", 218, 241], ["Anal sphincter", "MULTI-TISSUE_STRUCTURE", 0, 14], ["rectal", "ORGAN", 56, 62], ["pelvic", "ORGAN", 205, 211], ["urinary", "ORGANISM_SUBDIVISION", 218, 225], ["bladder", "ORGAN", 226, 233], ["Anal sphincter bleeding", "PROBLEM", 0, 23], ["excessive stretching", "PROBLEM", 31, 51], ["rectal prolapse", "PROBLEM", 56, 71], ["transrectal palpation", "TEST", 95, 116], ["a predisposing factor", "PROBLEM", 153, 174], ["excessive straining (e.g. pelvic mass", "PROBLEM", 179, 216], ["urinary bladder disease", "PROBLEM", 218, 241], ["sphincter", "ANATOMY", 5, 14], ["bleeding", "OBSERVATION", 15, 23], ["excessive", "OBSERVATION_MODIFIER", 31, 40], ["stretching", "OBSERVATION", 41, 51], ["rectal", "ANATOMY", 56, 62], ["prolapse", "OBSERVATION", 63, 71], ["palpation", "OBSERVATION", 107, 116], ["pelvic", "ANATOMY", 205, 211], ["mass", "OBSERVATION", 212, 216], ["urinary bladder", "ANATOMY", 218, 233], ["disease", "OBSERVATION", 234, 241]]], ["However, these are not life threatening and can be managed successfully with sedation, a caudal epidural, and protection of the prolapsed tissue.Rectal/colonic perforationRectal and colonic injuries have been reported in llamas and alpacas, and are a common reason for malpractice suits.", [["caudal epidural", "ANATOMY", 89, 104], ["prolapsed tissue", "ANATOMY", 128, 144], ["Rectal", "ANATOMY", 145, 151], ["colonic", "ANATOMY", 152, 159], ["colonic", "ANATOMY", 182, 189], ["Rectal/colonic perforationRectal and colonic injuries", "DISEASE", 145, 198], ["tissue", "TISSUE", 138, 144], ["Rectal", "MULTI-TISSUE_STRUCTURE", 145, 151], ["colonic perforationRectal", "MULTI-TISSUE_STRUCTURE", 152, 177], ["colonic", "ORGAN", 182, 189], ["llamas", "ORGANISM", 221, 227], ["sedation", "TREATMENT", 77, 85], ["a caudal epidural", "TREATMENT", 87, 104], ["the prolapsed tissue", "PROBLEM", 124, 144], ["Rectal/colonic perforationRectal", "PROBLEM", 145, 177], ["colonic injuries", "PROBLEM", 182, 198], ["caudal", "ANATOMY_MODIFIER", 89, 95], ["epidural", "ANATOMY", 96, 104], ["prolapsed tissue", "OBSERVATION", 128, 144], ["colonic", "ANATOMY", 152, 159], ["perforationRectal", "OBSERVATION", 160, 177], ["colonic", "ANATOMY", 182, 189], ["injuries", "OBSERVATION", 190, 198]]], ["Rectal or colonic injuries may happen during breeding, but they more commonly are due to excessive manipulation during transrectal palpation or ultrasonography [27, 28] .Rectal/colonic perforationThe examiner will usually recognize that an injury has occurred when palpating llamas and camels.", [["Rectal", "ANATOMY", 0, 6], ["colonic", "ANATOMY", 10, 17], ["transrectal", "ANATOMY", 119, 130], ["Rectal", "ANATOMY", 170, 176], ["colonic", "ANATOMY", 177, 184], ["Rectal or colonic injuries", "DISEASE", 0, 26], ["Rectal", "MULTI-TISSUE_STRUCTURE", 0, 6], ["colonic", "ORGAN", 10, 17], ["transrectal", "MULTI-TISSUE_STRUCTURE", 119, 130], ["Rectal", "ORGAN", 170, 176], ["colonic", "ORGAN", 177, 184], ["llamas", "ORGANISM", 275, 281], ["camels", "ORGANISM_SUBDIVISION", 286, 292], ["Rectal or colonic injuries", "PROBLEM", 0, 26], ["excessive manipulation", "PROBLEM", 89, 111], ["transrectal palpation", "TEST", 119, 140], ["ultrasonography", "TEST", 144, 159], ["Rectal/colonic perforation", "PROBLEM", 170, 196], ["an injury", "PROBLEM", 237, 246], ["colonic", "ANATOMY", 10, 17], ["injuries", "OBSERVATION", 18, 26], ["colonic", "ANATOMY", 177, 184], ["perforation", "OBSERVATION", 185, 196], ["injury", "OBSERVATION", 240, 246]]], ["However, in alpacas, when the ultrasound transducer is mounted on an extension for reproductive examination, the practitioner may not detect evidence of perforation until it is too late.", [["perforation", "DISEASE", 153, 164], ["alpacas", "ORGANISM", 12, 19], ["the ultrasound transducer", "TEST", 26, 51], ["reproductive examination", "TEST", 83, 107], ["perforation", "PROBLEM", 153, 164], ["perforation", "OBSERVATION", 153, 164]]], ["The amount of blood retrieved with the palpating hand is variable; it is the sensation of rupture or tear that is most indicative of the seriousness of the injury.", [["blood", "ANATOMY", 14, 19], ["palpating hand", "ANATOMY", 39, 53], ["rupture", "DISEASE", 90, 97], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["hand", "ORGANISM_SUBDIVISION", 49, 53], ["rupture", "PROBLEM", 90, 97], ["tear", "PROBLEM", 101, 105], ["the injury", "PROBLEM", 152, 162], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["blood retrieved", "OBSERVATION", 14, 29], ["variable", "OBSERVATION_MODIFIER", 57, 65], ["rupture", "OBSERVATION", 90, 97], ["tear", "OBSERVATION", 101, 105], ["most indicative of", "UNCERTAINTY", 114, 132], ["injury", "OBSERVATION", 156, 162]]], ["Since the distance between the anus and the peritoneal reflection is very short (2-3 cm in alpacas, 4 cm in llamas, and 6-10 cm in camel), complete rectal tears in camelids are rapidly complicated by peritonitis.", [["anus", "ANATOMY", 31, 35], ["peritoneal", "ANATOMY", 44, 54], ["llamas", "ANATOMY", 108, 114], ["rectal", "ANATOMY", 148, 154], ["camelids", "ANATOMY", 164, 172], ["rectal tears", "DISEASE", 148, 160], ["camelids", "DISEASE", 164, 172], ["peritonitis", "DISEASE", 200, 211], ["anus", "ORGAN", 31, 35], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 44, 54], ["rectal tears", "MULTI-TISSUE_STRUCTURE", 148, 160], ["camelids", "CANCER", 164, 172], ["alpacas", "TEST", 91, 98], ["llamas", "TEST", 108, 114], ["complete rectal tears in camelids", "PROBLEM", 139, 172], ["peritonitis", "PROBLEM", 200, 211], ["distance", "OBSERVATION_MODIFIER", 10, 18], ["anus", "ANATOMY", 31, 35], ["peritoneal", "ANATOMY", 44, 54], ["reflection", "ANATOMY_MODIFIER", 55, 65], ["very", "OBSERVATION_MODIFIER", 69, 73], ["short", "OBSERVATION_MODIFIER", 74, 79], ["2-3 cm", "OBSERVATION_MODIFIER", 81, 87], ["4 cm", "OBSERVATION_MODIFIER", 100, 104], ["llamas", "ANATOMY", 108, 114], ["6-10 cm", "OBSERVATION_MODIFIER", 120, 127], ["rectal", "ANATOMY", 148, 154], ["tears", "OBSERVATION", 155, 160], ["peritonitis", "OBSERVATION", 200, 211]]], ["Often the only clinical sign is reluctance to stand, lethargy and progressive dehydration a few hours after a reproductive examination.Rectal/colonic perforationSevere toxic shock and death follows within 8-24 h if no medical action is taken.Rectal/colonic perforationAll suspected rectal or colonic injuries should be immediately referred to a surgical facility.", [["Rectal", "ANATOMY", 135, 141], ["colonic", "ANATOMY", 142, 149], ["Rectal", "ANATOMY", 242, 248], ["colonic", "ANATOMY", 249, 256], ["rectal", "ANATOMY", 282, 288], ["colonic", "ANATOMY", 292, 299], ["lethargy", "DISEASE", 53, 61], ["dehydration", "DISEASE", 78, 89], ["toxic shock", "DISEASE", 168, 179], ["death", "DISEASE", 184, 189], ["rectal or colonic injuries", "DISEASE", 282, 308], ["Rectal", "ORGAN", 135, 141], ["colonic", "ORGAN", 142, 149], ["Rectal", "ORGAN", 242, 248], ["colonic", "ORGAN", 249, 256], ["rectal", "ORGAN", 282, 288], ["colonic", "ORGAN", 292, 299], ["lethargy", "PROBLEM", 53, 61], ["progressive dehydration", "PROBLEM", 66, 89], ["a reproductive examination", "TEST", 108, 134], ["Rectal/colonic perforation", "PROBLEM", 135, 161], ["Severe toxic shock", "PROBLEM", 161, 179], ["death", "PROBLEM", 184, 189], ["Rectal/colonic perforation", "PROBLEM", 242, 268], ["All suspected rectal or colonic injuries", "PROBLEM", 268, 308], ["progressive", "OBSERVATION_MODIFIER", 66, 77], ["dehydration", "OBSERVATION", 78, 89], ["colonic", "ANATOMY", 142, 149], ["perforation", "OBSERVATION", 150, 161], ["toxic", "OBSERVATION_MODIFIER", 168, 173], ["shock", "OBSERVATION", 174, 179], ["colonic", "ANATOMY", 249, 256], ["perforation", "OBSERVATION", 257, 268], ["rectal", "ANATOMY", 282, 288], ["colonic", "ANATOMY", 292, 299], ["injuries", "OBSERVATION", 300, 308]]], ["The animal should be sedated and started on intravenous antimicrobial and anti-inflammatory therapy for transport.", [["intravenous", "ANATOMY", 44, 55], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 44, 55], ["sedated", "TREATMENT", 21, 28], ["intravenous antimicrobial", "TREATMENT", 44, 69], ["anti-inflammatory therapy", "TREATMENT", 74, 99]]], ["Further evaluation at the referral facility includes CBC, blood chemistry, transabdominal ultrasonography, and abdominocentesis.", [["blood", "ANATOMY", 58, 63], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["Further evaluation", "TEST", 0, 18], ["CBC", "TEST", 53, 56], ["blood chemistry", "TEST", 58, 73], ["transabdominal ultrasonography", "TEST", 75, 105], ["abdominocentesis", "TREATMENT", 111, 127]]], ["Animals with evidence of peritonitis should be immediately prepared for surgical correction by celiotomy or celiotomy and pubic symphysiotomy to allow peritoneal lavage.", [["peritoneal lavage", "ANATOMY", 151, 168], ["peritonitis", "DISEASE", 25, 36], ["Animals", "ORGANISM", 0, 7], ["pubic", "ORGAN", 122, 127], ["peritoneal lavage", "MULTI-TISSUE_STRUCTURE", 151, 168], ["peritonitis", "PROBLEM", 25, 36], ["surgical correction", "TREATMENT", 72, 91], ["celiotomy", "TREATMENT", 95, 104], ["celiotomy", "TREATMENT", 108, 117], ["pubic symphysiotomy", "TREATMENT", 122, 141], ["peritoneal lavage", "TREATMENT", 151, 168], ["peritonitis", "OBSERVATION", 25, 36], ["celiotomy", "OBSERVATION", 95, 104], ["celiotomy", "OBSERVATION", 108, 117], ["pubic", "ANATOMY", 122, 127], ["peritoneal", "ANATOMY", 151, 161], ["lavage", "OBSERVATION", 162, 168]]], ["Stable patients without alarming changes in their blood and peritoneal fluid characteristics may be further evaluated under epidural anesthesia to decide if a transanal repair is possible.", [["blood", "ANATOMY", 50, 55], ["peritoneal fluid", "ANATOMY", 60, 76], ["epidural", "ANATOMY", 124, 132], ["patients", "ORGANISM", 7, 15], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["peritoneal fluid", "MULTI-TISSUE_STRUCTURE", 60, 76], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 124, 132], ["patients", "SPECIES", 7, 15], ["alarming changes in their blood and peritoneal fluid characteristics", "PROBLEM", 24, 92], ["epidural anesthesia", "TREATMENT", 124, 143], ["a transanal repair", "TREATMENT", 157, 175], ["without", "UNCERTAINTY", 16, 23], ["peritoneal", "ANATOMY", 60, 70], ["fluid", "OBSERVATION", 71, 76], ["repair", "OBSERVATION", 169, 175]]], ["Evaluation of the injury can be performed under general anesthesia.", [["Evaluation", "TEST", 0, 10], ["the injury", "PROBLEM", 14, 24], ["general anesthesia", "TREATMENT", 48, 66], ["injury", "OBSERVATION", 18, 24]]], ["The anal sphincter is dilated using stay sutures on the mucocutaneous junction.", [["anal sphincter", "ANATOMY", 4, 18], ["mucocutaneous junction", "ANATOMY", 56, 78], ["anal sphincter", "MULTI-TISSUE_STRUCTURE", 4, 18], ["mucocutaneous junction", "MULTI-TISSUE_STRUCTURE", 56, 78], ["dilated", "PROBLEM", 22, 29], ["stay sutures on the mucocutaneous junction", "TREATMENT", 36, 78], ["anal sphincter", "ANATOMY", 4, 18], ["dilated", "OBSERVATION", 22, 29], ["stay sutures", "OBSERVATION", 36, 48], ["mucocutaneous junction", "ANATOMY", 56, 78]]], ["Gentle evacuation of the rectal cavity may be attempted by low-power vacuum aspiration until the lesions can be visualized.", [["rectal cavity", "ANATOMY", 25, 38], ["lesions", "ANATOMY", 97, 104], ["rectal cavity", "MULTI-TISSUE_STRUCTURE", 25, 38], ["lesions", "PATHOLOGICAL_FORMATION", 97, 104], ["Gentle evacuation of the rectal cavity", "TREATMENT", 0, 38], ["low-power vacuum aspiration", "TREATMENT", 59, 86], ["the lesions", "PROBLEM", 93, 104], ["evacuation", "OBSERVATION", 7, 17], ["rectal cavity", "ANATOMY", 25, 38], ["power vacuum", "OBSERVATION_MODIFIER", 63, 75], ["aspiration", "OBSERVATION", 76, 86], ["lesions", "OBSERVATION", 97, 104]]], ["Use of a flexible videoendoscope can facilitate this evaluation.", [["a flexible videoendoscope", "TREATMENT", 7, 32], ["this evaluation", "TEST", 48, 63]]], ["In llamas and camels, lacerations due to transrectal palpation are usually located in the ventral aspect of the rectum, 5-20 cm anterior to the anus.", [["transrectal", "ANATOMY", 41, 52], ["ventral aspect", "ANATOMY", 90, 104], ["rectum", "ANATOMY", 112, 118], ["anus", "ANATOMY", 144, 148], ["lacerations", "DISEASE", 22, 33], ["llamas", "ORGANISM", 3, 9], ["camels", "ORGANISM_SUBDIVISION", 14, 20], ["ventral aspect", "MULTI-TISSUE_STRUCTURE", 90, 104], ["rectum", "ORGAN", 112, 118], ["anterior", "ORGAN", 128, 136], ["anus", "ORGAN", 144, 148], ["lacerations", "PROBLEM", 22, 33], ["transrectal palpation", "TEST", 41, 62], ["llamas", "ANATOMY", 3, 9], ["lacerations", "OBSERVATION", 22, 33], ["palpation", "OBSERVATION", 53, 62], ["ventral", "ANATOMY_MODIFIER", 90, 97], ["rectum", "ANATOMY", 112, 118], ["5-20 cm", "OBSERVATION_MODIFIER", 120, 127], ["anterior", "ANATOMY_MODIFIER", 128, 136], ["anus", "ANATOMY", 144, 148]]], ["However, in alpacas, particularly when the perforation has occurred with a transducer mounted on an extension, the lesion can be dorsal.", [["lesion", "ANATOMY", 115, 121], ["dorsal", "ANATOMY", 129, 135], ["perforation", "DISEASE", 43, 54], ["alpacas", "ORGANISM", 12, 19], ["lesion", "CANCER", 115, 121], ["the perforation", "PROBLEM", 39, 54], ["the lesion", "PROBLEM", 111, 121], ["alpacas", "OBSERVATION", 12, 19], ["perforation", "OBSERVATION", 43, 54], ["lesion", "OBSERVATION", 115, 121], ["can be", "UNCERTAINTY", 122, 128], ["dorsal", "OBSERVATION_MODIFIER", 129, 135]]], ["Also, in these cases, the presence of more than one perforation is possible, perhaps due to faulty alignment between the extremity of the transducer and the extension rod.", [["extremity", "ANATOMY", 121, 130], ["perforation", "DISEASE", 52, 63], ["extremity", "ORGANISM_SUBDIVISION", 121, 130], ["one perforation", "PROBLEM", 48, 63], ["faulty alignment", "PROBLEM", 92, 108], ["the extension rod", "TREATMENT", 153, 170], ["perforation", "OBSERVATION", 52, 63], ["perhaps due to", "UNCERTAINTY", 77, 91], ["faulty alignment", "OBSERVATION", 92, 108], ["extremity", "ANATOMY", 121, 130], ["extension rod", "OBSERVATION", 157, 170]]], ["Transanal repair is successful if the laceration is not deep [28] .", [["laceration", "DISEASE", 38, 48], ["Transanal repair", "TREATMENT", 0, 16], ["the laceration", "PROBLEM", 34, 48], ["repair", "OBSERVATION", 10, 16], ["laceration", "OBSERVATION", 38, 48]]], ["Celiotomy with pubic symphysiotomy is the only option for caudal injuries and in particular for alpacas.", [["caudal", "ANATOMY", 58, 64], ["Celiotomy", "DISEASE", 0, 9], ["caudal injuries", "DISEASE", 58, 73], ["alpacas", "ORGANISM", 96, 103], ["Celiotomy", "TREATMENT", 0, 9], ["pubic symphysiotomy", "TREATMENT", 15, 34], ["caudal injuries", "PROBLEM", 58, 73], ["alpacas", "PROBLEM", 96, 103], ["pubic", "ANATOMY", 15, 20], ["symphysiotomy", "OBSERVATION", 21, 34], ["injuries", "OBSERVATION", 65, 73]]], ["Successful repair of rectal and colonic injuries by celiotomy or celiotomy/pubic symphysiotomy has been reported in a few llamas [28] .Rectal/colonic perforationPreventive measures for colonic rectal injuries include use of caution when choosing the candidate for transrectal palpation, ample lubrication, and cautious use of an extension rod, particularly in maiden or agitated females.", [["rectal", "ANATOMY", 21, 27], ["colonic", "ANATOMY", 32, 39], ["Rectal", "ANATOMY", 135, 141], ["colonic", "ANATOMY", 142, 149], ["colonic rectal", "ANATOMY", 185, 199], ["transrectal", "ANATOMY", 264, 275], ["rectal and colonic injuries", "DISEASE", 21, 48], ["colonic rectal injuries", "DISEASE", 185, 208], ["rectal", "MULTI-TISSUE_STRUCTURE", 21, 27], ["colonic", "ORGAN", 32, 39], ["Rectal", "ORGAN", 135, 141], ["colonic", "ORGAN", 142, 149], ["colonic rectal", "MULTI-TISSUE_STRUCTURE", 185, 199], ["transrectal", "MULTI-TISSUE_STRUCTURE", 264, 275], ["Successful repair", "TREATMENT", 0, 17], ["rectal and colonic injuries", "PROBLEM", 21, 48], ["celiotomy", "TREATMENT", 52, 61], ["celiotomy/pubic symphysiotomy", "TREATMENT", 65, 94], ["Rectal/colonic perforation", "PROBLEM", 135, 161], ["Preventive measures", "TREATMENT", 161, 180], ["colonic rectal injuries", "PROBLEM", 185, 208], ["caution", "TREATMENT", 224, 231], ["transrectal palpation", "TEST", 264, 285], ["ample lubrication", "TREATMENT", 287, 304], ["an extension rod", "TREATMENT", 326, 342], ["agitated females", "PROBLEM", 370, 386], ["repair", "OBSERVATION", 11, 17], ["rectal", "ANATOMY", 21, 27], ["colonic", "ANATOMY", 32, 39], ["injuries", "OBSERVATION", 40, 48], ["celiotomy", "OBSERVATION", 52, 61], ["celiotomy", "OBSERVATION", 65, 74], ["pubic", "ANATOMY", 75, 80], ["symphysiotomy", "OBSERVATION", 81, 94], ["colonic", "ANATOMY", 142, 149], ["perforation", "OBSERVATION", 150, 161], ["rectal", "ANATOMY", 193, 199], ["injuries", "OBSERVATION", 200, 208]]], ["Sedation of the female or relaxation of the rectum and rectal sphincter may be obtained by epidural anesthesia or instillation of 2% lidocaine into the rectal cavity before examination.Uterine and vaginal perforationMost cases of uterine perforations seen in our practice are iatrogenic, due to aggressive placement of Foley catheters, infusion pipettes, and biopsy forceps.", [["rectum", "ANATOMY", 44, 50], ["rectal sphincter", "ANATOMY", 55, 71], ["epidural", "ANATOMY", 91, 99], ["rectal cavity", "ANATOMY", 152, 165], ["Uterine", "ANATOMY", 185, 192], ["vaginal", "ANATOMY", 197, 204], ["uterine", "ANATOMY", 230, 237], ["lidocaine", "CHEMICAL", 133, 142], ["vaginal perforation", "DISEASE", 197, 216], ["uterine perforations", "DISEASE", 230, 250], ["lidocaine", "CHEMICAL", 133, 142], ["rectum", "ORGAN", 44, 50], ["rectal sphincter", "MULTI-TISSUE_STRUCTURE", 55, 71], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 91, 99], ["lidocaine", "SIMPLE_CHEMICAL", 133, 142], ["rectal cavity", "MULTI-TISSUE_STRUCTURE", 152, 165], ["Uterine", "MULTI-TISSUE_STRUCTURE", 185, 192], ["vaginal", "PATHOLOGICAL_FORMATION", 197, 204], ["uterine perforations", "PATHOLOGICAL_FORMATION", 230, 250], ["Sedation", "TREATMENT", 0, 8], ["rectal sphincter", "TREATMENT", 55, 71], ["epidural anesthesia", "TREATMENT", 91, 110], ["instillation", "TREATMENT", 114, 126], ["2% lidocaine", "TREATMENT", 130, 142], ["examination", "TEST", 173, 184], ["Uterine and vaginal perforation", "PROBLEM", 185, 216], ["uterine perforations", "PROBLEM", 230, 250], ["iatrogenic", "PROBLEM", 276, 286], ["aggressive placement of Foley catheters", "TREATMENT", 295, 334], ["infusion pipettes", "TREATMENT", 336, 353], ["biopsy forceps", "TREATMENT", 359, 373], ["rectum", "ANATOMY", 44, 50], ["rectal sphincter", "ANATOMY", 55, 71], ["rectal cavity", "ANATOMY", 152, 165], ["vaginal", "ANATOMY", 197, 204], ["perforation", "OBSERVATION", 205, 216], ["uterine", "ANATOMY", 230, 237], ["perforations", "OBSERVATION", 238, 250], ["iatrogenic", "OBSERVATION", 276, 286], ["Foley catheters", "OBSERVATION", 319, 334]]], ["These are more common in alpacas than in llamas and camels.", [["alpacas", "ORGANISM", 25, 32], ["llamas", "ORGANISM", 41, 47], ["camels", "ORGANISM_SUBDIVISION", 52, 58], ["llamas", "SPECIES", 41, 47], ["more", "OBSERVATION_MODIFIER", 10, 14], ["common", "OBSERVATION_MODIFIER", 15, 21], ["alpacas", "OBSERVATION", 25, 32]]], ["They become an emergency if a major blood vessel is damaged, or if an irritating substance (e.g. iodine) is infused into the abdominal cavity.", [["blood vessel", "ANATOMY", 36, 48], ["abdominal cavity", "ANATOMY", 125, 141], ["iodine", "CHEMICAL", 97, 103], ["iodine", "CHEMICAL", 97, 103], ["blood vessel", "MULTI-TISSUE_STRUCTURE", 36, 48], ["iodine", "SIMPLE_CHEMICAL", 97, 103], ["abdominal cavity", "MULTI-TISSUE_STRUCTURE", 125, 141], ["an irritating substance", "PROBLEM", 67, 90], ["iodine)", "TREATMENT", 97, 104], ["vessel", "ANATOMY", 42, 48], ["abdominal cavity", "ANATOMY", 125, 141]]], ["Females with these injuries may present with colicky signs consistent with peritonitis or hemoperitoneum.", [["injuries", "DISEASE", 19, 27], ["peritonitis", "DISEASE", 75, 86], ["hemoperitoneum", "DISEASE", 90, 104], ["these injuries", "PROBLEM", 13, 27], ["colicky signs", "PROBLEM", 45, 58], ["peritonitis", "PROBLEM", 75, 86], ["hemoperitoneum", "PROBLEM", 90, 104], ["injuries", "OBSERVATION", 19, 27], ["consistent with", "UNCERTAINTY", 59, 74], ["peritonitis", "OBSERVATION", 75, 86], ["hemoperitoneum", "OBSERVATION", 90, 104]]], ["Anemia is a feature if there is sufficient blood loss; for example, one animal had a PCV of 10% following an endometrial biopsy.", [["blood", "ANATOMY", 43, 48], ["endometrial", "ANATOMY", 109, 120], ["Anemia", "DISEASE", 0, 6], ["blood loss", "DISEASE", 43, 53], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["endometrial biopsy", "MULTI-TISSUE_STRUCTURE", 109, 127], ["Anemia", "PROBLEM", 0, 6], ["sufficient blood loss", "PROBLEM", 32, 53], ["a PCV", "TEST", 83, 88], ["an endometrial biopsy", "TEST", 106, 127], ["blood loss", "OBSERVATION", 43, 53], ["endometrial", "ANATOMY", 109, 120], ["biopsy", "OBSERVATION", 121, 127]]], ["Suspicion is based on a history of recent gynecological examination and the feel of a ''pop'' during manipulation.", [["gynecological", "ANATOMY", 42, 55], ["recent gynecological examination", "TEST", 35, 67]]], ["The patient should be worked up as for any case of colic of abdominal origin [12] .", [["abdominal", "ANATOMY", 60, 69], ["colic", "DISEASE", 51, 56], ["patient", "ORGANISM", 4, 11], ["abdominal", "ORGANISM_SUBDIVISION", 60, 69], ["patient", "SPECIES", 4, 11], ["colic of abdominal origin", "PROBLEM", 51, 76], ["colic", "OBSERVATION", 51, 56], ["abdominal", "ANATOMY", 60, 69]]], ["Supportive therapy includes NSAID's and antimicrobials.", [["NSAID", "SIMPLE_CHEMICAL", 28, 33], ["Supportive therapy", "TREATMENT", 0, 18], ["NSAID's", "TREATMENT", 28, 35], ["antimicrobials", "TREATMENT", 40, 54]]], ["Blood transfusion and surgical intervention may be indicated if the PCV is <8%.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood transfusion", "TREATMENT", 0, 17], ["surgical intervention", "TREATMENT", 22, 43], ["the PCV", "TEST", 64, 71]]], ["Vaginal perforation with severe bleeding may be controlled by vaginal compression packs.Emergencies in the pregnant femaleAny clinical syndrome occurring during pregnancy may have a serious effect on the fetus.", [["Vaginal", "ANATOMY", 0, 7], ["vaginal", "ANATOMY", 62, 69], ["fetus", "ANATOMY", 204, 209], ["Vaginal perforation", "DISEASE", 0, 19], ["bleeding", "DISEASE", 32, 40], ["Vaginal", "PATHOLOGICAL_FORMATION", 0, 7], ["vaginal", "ORGANISM_SUBDIVISION", 62, 69], ["female", "ORGANISM", 116, 122], ["fetus", "ORGAN", 204, 209], ["Vaginal perforation", "PROBLEM", 0, 19], ["severe bleeding", "PROBLEM", 25, 40], ["vaginal compression packs", "TREATMENT", 62, 87], ["Any clinical syndrome", "PROBLEM", 122, 143], ["a serious effect on the fetus", "PROBLEM", 180, 209], ["perforation", "OBSERVATION", 8, 19], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["bleeding", "OBSERVATION", 32, 40], ["vaginal", "ANATOMY", 62, 69], ["compression", "OBSERVATION", 70, 81], ["serious", "OBSERVATION_MODIFIER", 182, 189]]], ["Therefore, monitoring fetal well-being should be part of any protocol for medical management of the pregnant female and particularly in the case of emergencies.", [["fetal", "ANATOMY", 22, 27], ["fetal", "ANATOMICAL_SYSTEM", 22, 27], ["any protocol", "TREATMENT", 57, 69], ["medical management", "TREATMENT", 74, 92]]], ["Camelids rely exclusively on the CL for progesterone secretion and maintenance of pregnancy.", [["CL", "ANATOMY", 33, 35], ["progesterone", "CHEMICAL", 40, 52], ["progesterone", "CHEMICAL", 40, 52], ["CL", "MULTI-TISSUE_STRUCTURE", 33, 35], ["progesterone", "SIMPLE_CHEMICAL", 40, 52], ["progesterone secretion", "TREATMENT", 40, 62], ["pregnancy", "PROBLEM", 82, 91]]], ["Therefore, severe illness associated with an inflammatory or extreme stress response may rapidly lead to luteolysis and abortion (with all its complications).Emergencies in the pregnant femalePregnant females may present with a variety of emergency clinical syndromes, ranging from severe colic, downer (lateral or sternal continuous recumbency), anorexia, diarrhea, depression, neurologic conditions, excessive straining, vaginal discharge, premature lactation, vulvar dilation, or vaginal prolapse.", [["neurologic", "ANATOMY", 379, 389], ["vaginal", "ANATOMY", 423, 430], ["vulvar", "ANATOMY", 463, 469], ["vaginal", "ANATOMY", 483, 490], ["illness", "DISEASE", 18, 25], ["luteolysis", "DISEASE", 105, 115], ["abortion", "DISEASE", 120, 128], ["colic", "DISEASE", 289, 294], ["anorexia", "DISEASE", 347, 355], ["diarrhea", "DISEASE", 357, 365], ["depression", "DISEASE", 367, 377], ["neurologic conditions", "DISEASE", 379, 400], ["premature lactation", "DISEASE", 442, 461], ["vulvar dilation", "DISEASE", 463, 478], ["vaginal prolapse", "DISEASE", 483, 499], ["female", "ORGANISM", 186, 192], ["vaginal", "ORGANISM_SUBDIVISION", 423, 430], ["vulvar", "ORGANISM_SUBDIVISION", 463, 469], ["vaginal", "ORGANISM_SUBDIVISION", 483, 490], ["severe illness", "PROBLEM", 11, 25], ["an inflammatory", "PROBLEM", 42, 57], ["extreme stress response", "PROBLEM", 61, 84], ["luteolysis", "PROBLEM", 105, 115], ["abortion", "PROBLEM", 120, 128], ["all its complications", "PROBLEM", 135, 156], ["emergency clinical syndromes", "PROBLEM", 239, 267], ["severe colic", "PROBLEM", 282, 294], ["downer (lateral or sternal continuous recumbency)", "PROBLEM", 296, 345], ["anorexia", "PROBLEM", 347, 355], ["diarrhea", "PROBLEM", 357, 365], ["depression", "PROBLEM", 367, 377], ["neurologic conditions", "PROBLEM", 379, 400], ["excessive straining", "PROBLEM", 402, 421], ["vaginal discharge", "PROBLEM", 423, 440], ["premature lactation", "PROBLEM", 442, 461], ["vulvar dilation", "PROBLEM", 463, 478], ["vaginal prolapse", "PROBLEM", 483, 499], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["illness", "OBSERVATION", 18, 25], ["inflammatory", "OBSERVATION", 45, 57], ["luteolysis", "OBSERVATION", 105, 115], ["severe", "OBSERVATION_MODIFIER", 282, 288], ["colic", "OBSERVATION", 289, 294], ["sternal", "ANATOMY", 315, 322], ["anorexia", "OBSERVATION", 347, 355], ["diarrhea", "OBSERVATION", 357, 365], ["vaginal", "ANATOMY", 423, 430], ["vulvar", "ANATOMY", 463, 469], ["dilation", "OBSERVATION", 470, 478], ["vaginal", "ANATOMY", 483, 490], ["prolapse", "OBSERVATION", 491, 499]]], ["Some of these presentations may have a genital origin.", [["genital", "ANATOMY", 39, 46], ["genital", "ORGANISM_SUBDIVISION", 39, 46], ["genital", "ANATOMY", 39, 46], ["origin", "ANATOMY_MODIFIER", 47, 53]]], ["The cardinal rules in handling emergencies in the pregnant females are a thorough physical evaluation of the dam, evaluation of the fetus, and ruling in or out the genital origin of the presenting complaint after stabilization of the dam.", [["fetus", "ANATOMY", 132, 137], ["genital", "ANATOMY", 164, 171], ["dam", "ORGANISM_SUBDIVISION", 109, 112], ["fetus", "ORGAN", 132, 137], ["genital", "ORGANISM_SUBDIVISION", 164, 171], ["a thorough physical evaluation", "TEST", 71, 101], ["evaluation", "TEST", 114, 124], ["cardinal rules", "OBSERVATION", 4, 18], ["fetus", "ANATOMY", 132, 137]]], ["The main emergencies of genital origin in the pregnant female are uterine torsion, vaginal prolapse, impending abortion, and uterine rupture.", [["genital", "ANATOMY", 24, 31], ["uterine", "ANATOMY", 66, 73], ["vaginal", "ANATOMY", 83, 90], ["uterine", "ANATOMY", 125, 132], ["uterine torsion", "DISEASE", 66, 81], ["vaginal prolapse", "DISEASE", 83, 99], ["impending abortion", "DISEASE", 101, 119], ["uterine rupture", "DISEASE", 125, 140], ["genital", "ORGANISM_SUBDIVISION", 24, 31], ["female", "ORGANISM", 55, 61], ["uterine", "ORGAN", 66, 73], ["vaginal", "ORGANISM_SUBDIVISION", 83, 90], ["uterine", "ORGAN", 125, 132], ["uterine torsion", "PROBLEM", 66, 81], ["vaginal prolapse", "PROBLEM", 83, 99], ["impending abortion", "PROBLEM", 101, 119], ["uterine rupture", "PROBLEM", 125, 140], ["main", "OBSERVATION_MODIFIER", 4, 8], ["genital origin", "ANATOMY", 24, 38], ["uterine", "ANATOMY", 66, 73], ["torsion", "OBSERVATION", 74, 81], ["vaginal", "ANATOMY", 83, 90], ["prolapse", "OBSERVATION", 91, 99], ["impending abortion", "OBSERVATION", 101, 119], ["uterine", "ANATOMY", 125, 132], ["rupture", "OBSERVATION", 133, 140]]], ["The main complication of any emergency in late pregnant females is hepatic lipidosis.", [["hepatic", "ANATOMY", 67, 74], ["hepatic lipidosis", "DISEASE", 67, 84], ["hepatic", "ORGAN", 67, 74], ["hepatic lipidosis", "PROBLEM", 67, 84], ["main", "OBSERVATION_MODIFIER", 4, 8], ["complication", "OBSERVATION", 9, 21], ["hepatic", "ANATOMY", 67, 74], ["lipidosis", "OBSERVATION", 75, 84]]], ["Pregnancy can also exacerbate clinical diseases.", [["clinical diseases", "PROBLEM", 30, 47]]], ["For example, in a recent outbreak of respiratory diseases in alpacas and llamas in North America, morbidity and mortality was highest in females in their last trimester of pregnancy.Clinical evaluation of the pregnant femaleAn important principle in our practice is that any suspicion by an owner that ''something is wrong'' with a pregnant female is taken seriously.", [["respiratory", "ANATOMY", 37, 48], ["respiratory diseases", "DISEASE", 37, 57], ["alpacas", "ORGANISM", 61, 68], ["respiratory diseases in alpacas", "PROBLEM", 37, 68], ["Clinical evaluation", "TEST", 182, 201], ["respiratory diseases", "OBSERVATION", 37, 57], ["alpacas", "OBSERVATION_MODIFIER", 61, 68], ["llamas", "OBSERVATION_MODIFIER", 73, 79], ["highest", "OBSERVATION_MODIFIER", 126, 133]]], ["Behavioral assessment may be conducted while taking history, unless the female is obviously depressed or painful.", [["depressed", "DISEASE", 92, 101], ["Behavioral assessment", "TEST", 0, 21], ["depressed", "PROBLEM", 92, 101], ["painful", "PROBLEM", 105, 112]]], ["A detailed history should be obtained and include breeding dates, time and methods used for pregnancy diagnosis, history of previous illness of reproductive disorders, onset and duration of the clinical problem, and recent treatments.", [["reproductive disorders", "DISEASE", 144, 166], ["reproductive disorders", "PROBLEM", 144, 166], ["the clinical problem", "PROBLEM", 190, 210], ["recent treatments", "TREATMENT", 216, 233]]], ["If the female is obviously in severe distress, blood samples should be taken immediately and the female stabilized before further examination.", [["blood samples", "ANATOMY", 47, 60], ["blood samples", "ORGANISM_SUBSTANCE", 47, 60], ["severe distress", "PROBLEM", 30, 45], ["blood samples", "TEST", 47, 60], ["further examination", "TEST", 122, 141], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["distress", "OBSERVATION", 37, 45]]], ["Oxygen therapy may be indicated for severely compromised females.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen therapy", "TREATMENT", 0, 14], ["severely compromised females", "PROBLEM", 36, 64]]], ["A jugular catheter should be placed immediately to allow fluid therapy and emergency anesthesia if needed.Clinical evaluation of the pregnant femaleSedation may be needed for some females in order to complete evaluation.", [["jugular catheter", "ANATOMY", 2, 18], ["fluid", "ANATOMY", 57, 62], ["jugular catheter", "MULTI-TISSUE_STRUCTURE", 2, 18], ["A jugular catheter", "TREATMENT", 0, 18], ["fluid therapy", "TREATMENT", 57, 70], ["emergency anesthesia", "TREATMENT", 75, 95], ["Clinical evaluation", "TEST", 106, 125], ["the pregnant femaleSedation", "TREATMENT", 129, 156], ["complete evaluation", "TEST", 200, 219], ["jugular", "ANATOMY", 2, 9], ["catheter", "OBSERVATION", 10, 18]]], ["Choices of drugs and dosage for sedation should take into account their effect on the fetus.", [["fetus", "ANATOMY", 86, 91], ["fetus", "ORGANISM", 86, 91], ["drugs", "TREATMENT", 11, 16], ["dosage", "TREATMENT", 21, 27], ["sedation", "TREATMENT", 32, 40], ["fetus", "ANATOMY", 86, 91]]], ["Butorphanol tartrate (0.05-0.1 mg/kg) provides good sedation and has minimal effect on the cardiovascular system.", [["cardiovascular", "ANATOMY", 91, 105], ["Butorphanol tartrate", "CHEMICAL", 0, 20], ["Butorphanol tartrate", "CHEMICAL", 0, 20], ["Butorphanol tartrate", "SIMPLE_CHEMICAL", 0, 20], ["cardiovascular", "ANATOMICAL_SYSTEM", 91, 105], ["system", "ANATOMICAL_SYSTEM", 106, 112], ["Butorphanol tartrate", "TREATMENT", 0, 20], ["minimal effect on the cardiovascular system", "PROBLEM", 69, 112], ["minimal effect", "OBSERVATION", 69, 83], ["cardiovascular system", "ANATOMY", 91, 112]]], ["However, there is a mild decrease in systemic vascular resistance that can be relevant if uterine blood flow is already compromised [29] .Clinical evaluation of the pregnant femaleTransabdominal ultrasonography should be used to determine fetal well-being, and the integrity of the uterus and placenta.", [["vascular", "ANATOMY", 46, 54], ["uterine", "ANATOMY", 90, 97], ["blood", "ANATOMY", 98, 103], ["fetal", "ANATOMY", 239, 244], ["uterus", "ANATOMY", 282, 288], ["placenta", "ANATOMY", 293, 301], ["vascular", "MULTI-TISSUE_STRUCTURE", 46, 54], ["uterine", "MULTI-TISSUE_STRUCTURE", 90, 97], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["fetal", "ANATOMICAL_SYSTEM", 239, 244], ["uterus", "ORGAN", 282, 288], ["placenta", "ORGAN", 293, 301], ["a mild decrease in systemic vascular resistance", "PROBLEM", 18, 65], ["uterine blood flow", "TEST", 90, 108], ["Clinical evaluation", "TEST", 138, 157], ["Transabdominal ultrasonography", "TEST", 180, 210], ["mild", "OBSERVATION_MODIFIER", 20, 24], ["decrease", "OBSERVATION_MODIFIER", 25, 33], ["systemic vascular resistance", "OBSERVATION", 37, 65], ["uterus", "ANATOMY", 282, 288], ["placenta", "ANATOMY", 293, 301]]], ["In addition to the reproductive organs, abdominal viscera and the peritoneal cavity should be assessed [30] .", [["organs", "ANATOMY", 32, 38], ["abdominal viscera", "ANATOMY", 40, 57], ["peritoneal cavity", "ANATOMY", 66, 83], ["organs", "ORGAN", 32, 38], ["abdominal viscera", "MULTI-TISSUE_STRUCTURE", 40, 57], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 66, 83], ["abdominal viscera and the peritoneal cavity", "PROBLEM", 40, 83], ["abdominal viscera", "ANATOMY", 40, 57], ["peritoneal", "ANATOMY", 66, 76], ["cavity", "OBSERVATION", 77, 83]]], ["In advanced pregnancy, imaging of abdominal viscera becomes very difficult in the absence of severe displacement.", [["abdominal viscera", "ANATOMY", 34, 51], ["abdominal viscera", "ORGAN", 34, 51], ["advanced pregnancy", "PROBLEM", 3, 21], ["imaging of abdominal viscera", "TEST", 23, 51], ["severe displacement", "PROBLEM", 93, 112], ["abdominal viscera", "ANATOMY", 34, 51], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["displacement", "OBSERVATION", 100, 112]]], ["For complete imaging of abdominal contents, the lower abdomen should be clipped and cleaned with alcohol from the xyphoid region to the base of the mammary gland.", [["abdominal", "ANATOMY", 24, 33], ["lower abdomen", "ANATOMY", 48, 61], ["mammary gland", "ANATOMY", 148, 161], ["alcohol", "CHEMICAL", 97, 104], ["alcohol", "CHEMICAL", 97, 104], ["abdominal", "ORGANISM_SUBDIVISION", 24, 33], ["lower abdomen", "ORGANISM_SUBDIVISION", 48, 61], ["alcohol", "SIMPLE_CHEMICAL", 97, 104], ["mammary gland", "ORGAN", 148, 161], ["complete imaging of abdominal contents", "TEST", 4, 42], ["alcohol", "TREATMENT", 97, 104], ["abdominal", "ANATOMY", 24, 33], ["lower", "ANATOMY_MODIFIER", 48, 53], ["abdomen", "ANATOMY", 54, 61], ["clipped", "OBSERVATION", 72, 79], ["base", "ANATOMY_MODIFIER", 136, 140], ["mammary gland", "ANATOMY", 148, 161]]], ["The area to be examined may need to be extended dorsally to the flank in order to visualize the dorsal aspect of the abdomen and the kidneys.", [["flank", "ANATOMY", 64, 69], ["dorsal aspect", "ANATOMY", 96, 109], ["abdomen", "ANATOMY", 117, 124], ["kidneys", "ANATOMY", 133, 140], ["flank", "ORGANISM_SUBDIVISION", 64, 69], ["dorsal aspect", "MULTI-TISSUE_STRUCTURE", 96, 109], ["abdomen", "ORGAN", 117, 124], ["kidneys", "ORGAN", 133, 140], ["flank", "ANATOMY", 64, 69], ["dorsal", "ANATOMY_MODIFIER", 96, 102], ["abdomen", "ANATOMY", 117, 124], ["kidneys", "ANATOMY", 133, 140]]], ["Cranially, the projection area of the liver may also need to be prepared for examination.", [["projection area", "ANATOMY", 15, 30], ["liver", "ANATOMY", 38, 43], ["liver", "ORGAN", 38, 43], ["examination", "TEST", 77, 88], ["liver", "ANATOMY", 38, 43]]], ["For transabdominal ultrasonography, a 5 MHz linear-array transducer may be sufficient for mid-pregnancy and in small patients, whereas in the last trimester, the use of a 2.5-3.5 MHz sector transducer provides better penetration and imaging of the abdomen.", [["abdomen", "ANATOMY", 248, 255], ["patients", "ORGANISM", 117, 125], ["abdomen", "ORGAN", 248, 255], ["patients", "SPECIES", 117, 125], ["transabdominal ultrasonography", "TEST", 4, 34], ["a 5 MHz linear-array transducer", "TREATMENT", 36, 67], ["mid-pregnancy", "PROBLEM", 90, 103], ["a 2.5-3.5 MHz sector transducer", "TREATMENT", 169, 200], ["imaging of the abdomen", "TEST", 233, 255], ["small", "OBSERVATION_MODIFIER", 111, 116], ["abdomen", "ANATOMY", 248, 255]]], ["Transabdomimal ultrasonography may also be used to locate distinct pockets of free peritoneal fluid and to perform abdominocentesis.Clinical evaluation of the pregnant femaleOther imaging techniques such as radiography, MRI or CT scanning may be indicated in the case of downer females, but they are not routine procedures and are only a possibility in referral centers.", [["peritoneal fluid", "ANATOMY", 83, 99], ["peritoneal fluid", "MULTI-TISSUE_STRUCTURE", 83, 99], ["Transabdomimal ultrasonography", "TEST", 0, 30], ["distinct pockets of free peritoneal fluid", "PROBLEM", 58, 99], ["abdominocentesis", "TREATMENT", 115, 131], ["Clinical evaluation", "TEST", 132, 151], ["the pregnant femaleOther imaging techniques", "TEST", 155, 198], ["radiography", "TEST", 207, 218], ["MRI", "TEST", 220, 223], ["CT scanning", "TEST", 227, 238], ["routine procedures", "TEST", 304, 322], ["distinct", "OBSERVATION_MODIFIER", 58, 66], ["pockets", "OBSERVATION", 67, 74], ["free", "OBSERVATION_MODIFIER", 78, 82], ["peritoneal", "ANATOMY", 83, 93], ["fluid", "OBSERVATION", 94, 99]]], ["Following transabdominal ultrasonography, transrectal palpation and ultrasonography should be performed, albeit, cautiously, as this may cause additional stress.", [["transrectal", "ANATOMY", 42, 53], ["transrectal", "MULTI-TISSUE_STRUCTURE", 42, 53], ["transabdominal ultrasonography", "TEST", 10, 40], ["transrectal palpation", "TEST", 42, 63], ["ultrasonography", "TEST", 68, 83], ["additional stress", "PROBLEM", 143, 160]]], ["Administration of an epidural and infusion of a mixture of lidocaine and lubricant in the rectal cavity may reduce straining, provide some relaxation, and facilitate the examination in llamas and alpacas.", [["epidural", "ANATOMY", 21, 29], ["rectal cavity", "ANATOMY", 90, 103], ["lidocaine", "CHEMICAL", 59, 68], ["lubricant", "CHEMICAL", 73, 82], ["lidocaine", "CHEMICAL", 59, 68], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 21, 29], ["lidocaine", "SIMPLE_CHEMICAL", 59, 68], ["rectal cavity", "MULTI-TISSUE_STRUCTURE", 90, 103], ["llamas", "ORGANISM", 185, 191], ["alpacas", "ORGANISM", 196, 203], ["an epidural", "TREATMENT", 18, 29], ["a mixture of lidocaine", "TREATMENT", 46, 68], ["lubricant in the rectal cavity", "TREATMENT", 73, 103], ["straining", "PROBLEM", 115, 124], ["the examination", "TEST", 166, 181], ["epidural", "OBSERVATION", 21, 29], ["rectal cavity", "ANATOMY", 90, 103]]], ["The primary objective of transrectal palpation is to determine the location and direction of the broad ligaments and evaluate the caudal abdomen for any masses or abnormalities of the pelvic area, kidneys, and urinary bladder.", [["transrectal", "ANATOMY", 25, 36], ["ligaments", "ANATOMY", 103, 112], ["caudal abdomen", "ANATOMY", 130, 144], ["masses", "ANATOMY", 153, 159], ["pelvic area", "ANATOMY", 184, 195], ["kidneys", "ANATOMY", 197, 204], ["urinary bladder", "ANATOMY", 210, 225], ["urinary bladder", "DISEASE", 210, 225], ["transrectal", "MULTI-TISSUE_STRUCTURE", 25, 36], ["ligaments", "TISSUE", 103, 112], ["caudal abdomen", "ORGAN", 130, 144], ["masses", "CANCER", 153, 159], ["pelvic area", "MULTI-TISSUE_STRUCTURE", 184, 195], ["kidneys", "ORGAN", 197, 204], ["urinary bladder", "ORGAN", 210, 225], ["transrectal palpation", "TEST", 25, 46], ["any masses", "PROBLEM", 149, 159], ["abnormalities of the pelvic area, kidneys, and urinary bladder", "PROBLEM", 163, 225], ["broad ligaments", "ANATOMY", 97, 112], ["caudal", "ANATOMY_MODIFIER", 130, 136], ["abdomen", "ANATOMY", 137, 144], ["masses", "OBSERVATION", 153, 159], ["abnormalities", "OBSERVATION", 163, 176], ["pelvic", "ANATOMY", 184, 190], ["area", "ANATOMY_MODIFIER", 191, 195], ["kidneys", "ANATOMY", 197, 204], ["urinary bladder", "ANATOMY", 210, 225]]], ["Transrectal palpation in the female sitting in a sternal position may offer some challenges for the inexperienced practitioner.", [["Transrectal", "ANATOMY", 0, 11], ["sternal", "ANATOMY", 49, 56], ["Transrectal", "MULTI-TISSUE_STRUCTURE", 0, 11], ["Transrectal palpation", "TEST", 0, 21], ["palpation", "OBSERVATION", 12, 21], ["sternal", "ANATOMY", 49, 56]]], ["The quantity and quality of fecal material in the rectal cavity should be evaluated.", [["fecal material", "ANATOMY", 28, 42], ["rectal cavity", "ANATOMY", 50, 63], ["fecal material", "MULTI-TISSUE_STRUCTURE", 28, 42], ["rectal cavity", "MULTI-TISSUE_STRUCTURE", 50, 63], ["fecal material in the rectal cavity", "PROBLEM", 28, 63], ["quantity", "OBSERVATION_MODIFIER", 4, 12], ["quality", "OBSERVATION_MODIFIER", 17, 24], ["fecal material", "OBSERVATION", 28, 42], ["rectal cavity", "ANATOMY", 50, 63]]], ["Severely stressed camelids often have profuse diarrhea, whereas an absence of fecal material and/or the presence of scant mucoid feces may be due to intestinal transit disorders or tenesmus.Clinical evaluation of the pregnant femaleVaginal examination should be performed with a speculum after thoroughly cleaning the perineal area.", [["camelids", "ANATOMY", 18, 26], ["fecal material", "ANATOMY", 78, 92], ["mucoid feces", "ANATOMY", 122, 134], ["intestinal", "ANATOMY", 149, 159], ["perineal area", "ANATOMY", 318, 331], ["diarrhea", "DISEASE", 46, 54], ["mucoid feces", "DISEASE", 122, 134], ["intestinal transit disorders", "DISEASE", 149, 177], ["tenesmus", "DISEASE", 181, 189], ["fecal material", "MULTI-TISSUE_STRUCTURE", 78, 92], ["feces", "ORGANISM_SUBSTANCE", 129, 134], ["intestinal", "ORGAN", 149, 159], ["perineal area", "PATHOLOGICAL_FORMATION", 318, 331], ["Severely stressed camelids", "PROBLEM", 0, 26], ["profuse diarrhea", "PROBLEM", 38, 54], ["fecal material", "PROBLEM", 78, 92], ["scant mucoid feces", "PROBLEM", 116, 134], ["intestinal transit disorders", "PROBLEM", 149, 177], ["tenesmus", "PROBLEM", 181, 189], ["Clinical evaluation", "TEST", 190, 209], ["the pregnant femaleVaginal examination", "TEST", 213, 251], ["a speculum", "TREATMENT", 277, 287], ["profuse", "OBSERVATION_MODIFIER", 38, 45], ["diarrhea", "OBSERVATION", 46, 54], ["fecal material", "OBSERVATION", 78, 92], ["scant", "OBSERVATION_MODIFIER", 116, 121], ["mucoid feces", "OBSERVATION", 122, 134], ["may be due to", "UNCERTAINTY", 135, 148], ["intestinal", "ANATOMY", 149, 159], ["transit disorders", "OBSERVATION", 160, 177], ["tenesmus", "OBSERVATION", 181, 189], ["perineal", "ANATOMY", 318, 326]]], ["The speculum should be advanced slowly, while concurrently examining the vagina for any abnormalities.", [["vagina", "ANATOMY", 73, 79], ["vagina", "ORGAN", 73, 79], ["any abnormalities", "PROBLEM", 84, 101], ["speculum", "OBSERVATION", 4, 12], ["vagina", "ANATOMY", 73, 79], ["abnormalities", "OBSERVATION", 88, 101]]], ["The cervix is evaluated for the degree of relaxation and opening.", [["cervix", "ANATOMY", 4, 10], ["cervix", "CANCER", 4, 10], ["cervix", "ANATOMY", 4, 10], ["relaxation", "OBSERVATION", 42, 52]]], ["The cervix of the llama and alpaca is often difficult to visualize during late pregnancy, but it should be obvious if it is patent.", [["cervix", "ANATOMY", 4, 10], ["cervix", "CANCER", 4, 10], ["llama", "ORGANISM", 18, 23], ["alpaca", "ORGANISM", 28, 34], ["llama", "SPECIES", 18, 23], ["cervix", "ANATOMY", 4, 10], ["llama", "ANATOMY_MODIFIER", 18, 23], ["alpaca", "OBSERVATION", 28, 34], ["patent", "OBSERVATION", 124, 130]]], ["Manual examination of the vagina and cervix may be indicated in some cases, but this procedure is often limited by the size of the examiner's hands.Fetal and utero-placental evaluationAssessment of fetal well-being is an important component in the evaluation of medical crises.", [["vagina", "ANATOMY", 26, 32], ["cervix", "ANATOMY", 37, 43], ["Fetal", "ANATOMY", 148, 153], ["fetal", "ANATOMY", 198, 203], ["vagina", "ORGAN", 26, 32], ["cervix", "ORGAN", 37, 43], ["hands", "ORGANISM_SUBDIVISION", 142, 147], ["Fetal", "ORGAN", 148, 153], ["fetal", "ANATOMICAL_SYSTEM", 198, 203], ["Manual examination", "TEST", 0, 18], ["this procedure", "TREATMENT", 80, 94], ["Fetal and utero-placental evaluation", "TEST", 148, 184], ["the evaluation", "TEST", 244, 258], ["medical crises", "PROBLEM", 262, 276], ["vagina", "ANATOMY", 26, 32], ["cervix", "ANATOMY", 37, 43], ["size", "OBSERVATION_MODIFIER", 119, 123], ["hands", "ANATOMY", 142, 147]]], ["Unfortunately, there is a paucity of information regarding fetal biophysical characteristics in camelids.", [["fetal", "ANATOMY", 59, 64], ["fetal", "ANATOMICAL_SYSTEM", 59, 64], ["fetal biophysical characteristics in camelids", "PROBLEM", 59, 104]]], ["However, based on clinical experience in the authors' laboratory, the two main indicators for fetal distress are fetal heart rate and rhythm.", [["fetal", "ANATOMY", 94, 99], ["fetal heart", "ANATOMY", 113, 124], ["fetal distress", "DISEASE", 94, 108], ["fetal", "ORGANISM_SUBDIVISION", 94, 99], ["fetal", "MULTI-TISSUE_STRUCTURE", 113, 118], ["heart", "ORGAN", 119, 124], ["fetal distress", "PROBLEM", 94, 108], ["fetal heart rate", "TEST", 113, 129], ["fetal distress", "OBSERVATION", 94, 108], ["heart", "ANATOMY", 119, 124]]], ["Normal fetal heart rate in mid-to late-pregnancy range from 1.6 to 1.8 times that of the dam.", [["fetal heart", "ANATOMY", 7, 18], ["fetal", "MULTI-TISSUE_STRUCTURE", 7, 12], ["heart", "ORGAN", 13, 18], ["fetal", "ANATOMY_MODIFIER", 7, 12], ["heart", "ANATOMY", 13, 18], ["rate", "OBSERVATION_MODIFIER", 19, 23]]], ["In that regard, fetal heart rate is usually 80-115 bpm in the last trimester of pregnancy, but decreases to 80 bpm a few days before parturition.", [["fetal heart", "ANATOMY", 16, 27], ["fetal", "MULTI-TISSUE_STRUCTURE", 16, 21], ["heart", "ORGAN", 22, 27], ["fetal heart rate", "TEST", 16, 32], ["pregnancy", "PROBLEM", 80, 89], ["fetal", "ANATOMY_MODIFIER", 16, 21], ["heart", "ANATOMY", 22, 27]]], ["Fetal heart rates that are consistently >130 or <50 bpm suggest fetal distress.", [["heart", "ANATOMY", 6, 11], ["fetal", "ANATOMY", 64, 69], ["fetal distress", "DISEASE", 64, 78], ["Fetal", "ORGAN", 0, 5], ["heart", "ORGAN", 6, 11], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 64, 69], ["Fetal heart rates", "TEST", 0, 17], ["fetal distress", "PROBLEM", 64, 78], ["heart", "ANATOMY", 6, 11], ["fetal distress", "OBSERVATION", 64, 78]]], ["The fetal heart rhythm should be regular and respond to phase of activity by a 10-20% increase in rate.", [["fetal heart", "ANATOMY", 4, 15], ["heart", "ORGAN", 10, 15], ["The fetal heart rhythm", "TEST", 0, 22], ["fetal", "ANATOMY_MODIFIER", 4, 9], ["heart", "ANATOMY", 10, 15]]], ["Fetal activity is maximal in the first half of pregnancy, but substantially reduced in the last 2 months.", [["Fetal", "ANATOMY", 0, 5], ["Fetal", "ORGAN", 0, 5], ["Fetal activity", "PROBLEM", 0, 14], ["activity", "OBSERVATION_MODIFIER", 6, 14], ["substantially", "OBSERVATION_MODIFIER", 62, 75], ["reduced", "OBSERVATION_MODIFIER", 76, 83]]], ["The entire fetus should be examined to determine fetal position and number.", [["fetus", "ANATOMY", 11, 16], ["fetal", "ANATOMY", 49, 54], ["fetus", "ORGANISM", 11, 16], ["fetal", "ANATOMICAL_SYSTEM", 49, 54]]], ["Normal fetal positioning for parturition appears to occur a few hours before parturition.", [["fetal", "ANATOMY", 7, 12], ["fetal", "MULTI-TISSUE_STRUCTURE", 7, 12], ["fetal positioning", "OBSERVATION", 7, 24]]], ["It is not uncommon to image the fetus low in the abdomen with the dorsum against the diaphragm and all limbs pointing to the pelvic area.", [["fetus", "ANATOMY", 32, 37], ["abdomen", "ANATOMY", 49, 56], ["dorsum", "ANATOMY", 66, 72], ["diaphragm", "ANATOMY", 85, 94], ["limbs", "ANATOMY", 103, 108], ["pelvic area", "ANATOMY", 125, 136], ["fetus", "ORGAN", 32, 37], ["abdomen", "ORGAN", 49, 56], ["dorsum", "ORGANISM_SUBDIVISION", 66, 72], ["diaphragm", "ORGAN", 85, 94], ["limbs", "ORGANISM_SUBDIVISION", 103, 108], ["pelvic area", "MULTI-TISSUE_STRUCTURE", 125, 136], ["fetus", "ANATOMY", 32, 37], ["low", "OBSERVATION", 38, 41], ["abdomen", "ANATOMY", 49, 56], ["dorsum", "ANATOMY_MODIFIER", 66, 72], ["diaphragm", "ANATOMY", 85, 94], ["all", "ANATOMY_MODIFIER", 99, 102], ["limbs", "ANATOMY", 103, 108], ["pelvic", "ANATOMY", 125, 131], ["area", "ANATOMY_MODIFIER", 132, 136]]], ["Transverse position of the fetus in the abdomen does not mean a transverse position inside the horn, but rather reflects the position of the entire pregnant horn.", [["fetus", "ANATOMY", 27, 32], ["abdomen", "ANATOMY", 40, 47], ["horn", "ANATOMY", 95, 99], ["horn", "ANATOMY", 157, 161], ["fetus", "ORGAN", 27, 32], ["abdomen", "ORGAN", 40, 47], ["horn", "ORGAN", 95, 99], ["horn", "ORGANISM_SUBDIVISION", 157, 161], ["fetus", "OBSERVATION", 27, 32], ["abdomen", "ANATOMY", 40, 47], ["transverse position", "OBSERVATION_MODIFIER", 64, 83], ["horn", "OBSERVATION_MODIFIER", 95, 99], ["position", "OBSERVATION_MODIFIER", 125, 133]]], ["That the fetus is entirely in the left horn and the special arrangement of the pregnant horn vis-\u00e0-vis the abdominal viscera may contribute to signs of discomfort in some females in late pregnancy.", [["fetus", "ANATOMY", 9, 14], ["left horn", "ANATOMY", 34, 43], ["abdominal viscera", "ANATOMY", 107, 124], ["fetus", "ORGANISM", 9, 14], ["left horn", "ORGAN", 34, 43], ["abdominal viscera", "ORGAN", 107, 124], ["discomfort", "PROBLEM", 152, 162], ["left", "ANATOMY_MODIFIER", 34, 38], ["abdominal viscera", "ANATOMY", 107, 124], ["discomfort", "OBSERVATION", 152, 162]]], ["Late in pregnancy, the presence of twins is best confirmed by abdominal radiography [31] .Fetal and utero-placental evaluationFetal biometrics may provide data regarding fetal growth and stage of pregnancy, but in our experience, most measurements are not very accurate and cannot be used for physical bioprofiling [32, 33] .", [["abdominal", "ANATOMY", 62, 71], ["Fetal", "ANATOMY", 90, 95], ["Fetal", "ANATOMY", 126, 131], ["fetal", "ANATOMY", 170, 175], ["abdominal", "ORGANISM_SUBDIVISION", 62, 71], ["Fetal", "ANATOMICAL_SYSTEM", 90, 95], ["fetal", "ANATOMICAL_SYSTEM", 170, 175], ["abdominal radiography", "TEST", 62, 83], ["Fetal and utero-placental evaluation", "TEST", 90, 126], ["Fetal biometrics", "TEST", 126, 142], ["fetal growth", "PROBLEM", 170, 182], ["stage of pregnancy", "PROBLEM", 187, 205], ["physical bioprofiling", "TEST", 293, 314], ["abdominal", "ANATOMY", 62, 71]]], ["Fetal fluids are difficult to assess, due to the low volume of amniotic and allantoic fluid in camelids.Fetal and utero-placental evaluationUteroplacental thickness should be evaluated in the horn containing the fetus (left horn) only, as the placenta may appear thicker in the nonpregnant horn.", [["Fetal fluids", "ANATOMY", 0, 12], ["amniotic", "ANATOMY", 63, 71], ["allantoic fluid", "ANATOMY", 76, 91], ["camelids", "ANATOMY", 95, 103], ["Fetal", "ANATOMY", 104, 109], ["Uteroplacental", "ANATOMY", 140, 154], ["horn", "ANATOMY", 192, 196], ["fetus", "ANATOMY", 212, 217], ["left horn", "ANATOMY", 219, 228], ["placenta", "ANATOMY", 243, 251], ["horn", "ANATOMY", 290, 294], ["amniotic", "ORGANISM_SUBSTANCE", 63, 71], ["allantoic fluid", "ORGANISM_SUBSTANCE", 76, 91], ["Fetal", "MULTI-TISSUE_STRUCTURE", 104, 109], ["Uteroplacental", "TISSUE", 140, 154], ["horn", "ORGANISM_SUBDIVISION", 192, 196], ["fetus", "ORGAN", 212, 217], ["left horn", "ORGAN", 219, 228], ["placenta", "ORGAN", 243, 251], ["horn", "ORGAN", 290, 294], ["Fetal fluids", "TEST", 0, 12], ["amniotic and allantoic fluid in camelids", "TREATMENT", 63, 103], ["Fetal and utero-placental evaluation", "TEST", 104, 140], ["Uteroplacental thickness", "TREATMENT", 140, 164], ["fluids", "OBSERVATION", 6, 12], ["allantoic fluid", "OBSERVATION", 76, 91], ["Uteroplacental thickness", "OBSERVATION", 140, 164], ["fetus", "ANATOMY", 212, 217], ["left", "ANATOMY_MODIFIER", 219, 223], ["placenta", "ANATOMY", 243, 251], ["may appear", "UNCERTAINTY", 252, 262], ["thicker", "OBSERVATION", 263, 270]]], ["The combined uteroplacental thickness should be <8 mm in the last trimester.", [["uteroplacental", "ANATOMY", 13, 27], ["uteroplacental", "MULTI-TISSUE_STRUCTURE", 13, 27], ["The combined uteroplacental thickness", "TREATMENT", 0, 37], ["uteroplacental", "ANATOMY", 13, 27], ["thickness", "OBSERVATION_MODIFIER", 28, 37], ["<8 mm", "OBSERVATION_MODIFIER", 48, 53]]], ["Excessive edema of the uterine horn or premature placental detachment are relatively easy to detect and require immediate intervention if the female is at term.Ancillary laboratory testingA minimum baseline evaluation of a severely depressed or colicky pregnant female should include complete blood count (CBC), blood chemistry, and fibrinogen.", [["uterine horn", "ANATOMY", 23, 35], ["placental", "ANATOMY", 49, 58], ["blood", "ANATOMY", 293, 298], ["blood", "ANATOMY", 312, 317], ["edema", "DISEASE", 10, 15], ["placental detachment", "DISEASE", 49, 69], ["depressed", "DISEASE", 232, 241], ["edema", "PATHOLOGICAL_FORMATION", 10, 15], ["uterine horn", "ORGAN", 23, 35], ["placental", "ORGAN", 49, 58], ["blood", "ORGANISM_SUBSTANCE", 293, 298], ["blood", "ORGANISM_SUBSTANCE", 312, 317], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 333, 343], ["fibrinogen", "PROTEIN", 333, 343], ["Excessive edema of the uterine horn", "PROBLEM", 0, 35], ["premature placental detachment", "PROBLEM", 39, 69], ["immediate intervention", "TREATMENT", 112, 134], ["Ancillary laboratory testing", "TEST", 160, 188], ["A minimum baseline evaluation", "TEST", 188, 217], ["a severely depressed or colicky pregnant female", "PROBLEM", 221, 268], ["complete blood count", "TEST", 284, 304], ["CBC", "TEST", 306, 309], ["blood chemistry", "TEST", 312, 327], ["fibrinogen", "TEST", 333, 343], ["edema", "OBSERVATION", 10, 15], ["uterine horn", "ANATOMY", 23, 35], ["premature", "OBSERVATION_MODIFIER", 39, 48], ["placental detachment", "OBSERVATION", 49, 69]]], ["Evaluation of peritoneal fluid (abdominocentesis), fecal evaluation, and urinalysis should be considered in select cases.", [["peritoneal fluid", "ANATOMY", 14, 30], ["fecal", "ANATOMY", 51, 56], ["peritoneal fluid", "MULTI-TISSUE_STRUCTURE", 14, 30], ["fecal", "ORGANISM_SUBSTANCE", 51, 56], ["Evaluation of peritoneal fluid (abdominocentesis)", "TEST", 0, 49], ["fecal evaluation", "TEST", 51, 67], ["urinalysis", "TEST", 73, 83], ["peritoneal", "ANATOMY", 14, 24], ["fluid", "OBSERVATION", 25, 30]]], ["Although a stress leukogram is often present in many females, neutrophil count, immature neutrophil count, neutrophil morphology, packed cell volume, and fibrinogen concentration are very valuable in evaluating inflammatory and toxic states.", [["neutrophil", "ANATOMY", 62, 72], ["neutrophil", "ANATOMY", 89, 99], ["neutrophil", "ANATOMY", 107, 117], ["cell", "ANATOMY", 137, 141], ["neutrophil", "CELL", 62, 72], ["neutrophil", "CELL", 89, 99], ["neutrophil", "CELL", 107, 117], ["cell", "CELL", 137, 141], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 154, 164], ["fibrinogen", "PROTEIN", 154, 164], ["a stress leukogram", "TEST", 9, 27], ["neutrophil count", "TEST", 62, 78], ["immature neutrophil count", "TEST", 80, 105], ["neutrophil morphology", "TEST", 107, 128], ["packed cell volume", "TEST", 130, 148], ["fibrinogen concentration", "TEST", 154, 178], ["inflammatory and toxic states", "PROBLEM", 211, 240], ["neutrophil count", "OBSERVATION", 62, 78], ["immature neutrophil count", "OBSERVATION", 80, 105], ["packed cell volume", "OBSERVATION", 130, 148], ["inflammatory", "OBSERVATION", 211, 223], ["toxic", "OBSERVATION_MODIFIER", 228, 233]]], ["Anemia may be due to blood loss, or the onset of other problems such as Mycoplasma hemolamae.", [["blood", "ANATOMY", 21, 26], ["Anemia", "DISEASE", 0, 6], ["blood loss", "DISEASE", 21, 31], ["Mycoplasma hemolamae", "DISEASE", 72, 92], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["Mycoplasma hemolamae", "ORGANISM", 72, 92], ["Mycoplasma hemolamae", "SPECIES", 72, 92], ["Mycoplasma hemolamae", "SPECIES", 72, 92], ["Anemia", "PROBLEM", 0, 6], ["blood loss", "PROBLEM", 21, 31], ["other problems", "PROBLEM", 49, 63], ["Mycoplasma hemolamae", "PROBLEM", 72, 92], ["may be due to", "UNCERTAINTY", 7, 20], ["blood loss", "OBSERVATION", 21, 31]]], ["Blood chemistry will determine electrolyte imbalances and risk for hepatic lipidosis, a major concern in anorectic, stressed pregnant females.", [["Blood", "ANATOMY", 0, 5], ["hepatic", "ANATOMY", 67, 74], ["hepatic lipidosis", "DISEASE", 67, 84], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["hepatic", "ORGAN", 67, 74], ["Blood chemistry", "TEST", 0, 15], ["electrolyte imbalances", "PROBLEM", 31, 53], ["hepatic lipidosis", "PROBLEM", 67, 84], ["hepatic", "ANATOMY", 67, 74], ["lipidosis", "OBSERVATION", 75, 84]]], ["Hypoprotenemia is often present in old pregnant females and may predispose to metabolic complications.", [["Hypoprotenemia", "DISEASE", 0, 14], ["metabolic complications", "DISEASE", 78, 101], ["Hypoprotenemia", "PROBLEM", 0, 14], ["metabolic complications", "PROBLEM", 78, 101], ["may predispose to", "UNCERTAINTY", 60, 77], ["metabolic complications", "OBSERVATION", 78, 101]]], ["In some cases, the serum may be grossly hyperlipemic (white).", [["serum", "ANATOMY", 19, 24], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["the serum", "TEST", 15, 24], ["grossly hyperlipemic", "PROBLEM", 32, 52], ["grossly", "OBSERVATION_MODIFIER", 32, 39], ["hyperlipemic", "OBSERVATION", 40, 52]]], ["However, lipemia and ketonemia are not always present in hepatic lipidosis.", [["hepatic", "ANATOMY", 57, 64], ["lipemia", "DISEASE", 9, 16], ["ketonemia", "DISEASE", 21, 30], ["hepatic lipidosis", "DISEASE", 57, 74], ["hepatic lipidosis", "CANCER", 57, 74], ["lipemia", "PROBLEM", 9, 16], ["ketonemia", "PROBLEM", 21, 30], ["hepatic lipidosis", "PROBLEM", 57, 74], ["lipemia", "OBSERVATION", 9, 16], ["ketonemia", "OBSERVATION", 21, 30], ["not always", "UNCERTAINTY", 35, 45], ["hepatic", "ANATOMY", 57, 64], ["lipidosis", "OBSERVATION", 65, 74]]], ["Elevated concentrations of nonesterified fatty acid (NEFA; >400 mmol/L) and b-hydroxybutyrate (BHB) are important indicators of stress and liver compromise.", [["liver", "ANATOMY", 139, 144], ["nonesterified fatty acid", "CHEMICAL", 27, 51], ["NEFA", "CHEMICAL", 53, 57], ["b-hydroxybutyrate", "CHEMICAL", 76, 93], ["BHB", "CHEMICAL", 95, 98], ["liver compromise", "DISEASE", 139, 155], ["nonesterified fatty acid", "CHEMICAL", 27, 51], ["NEFA", "CHEMICAL", 53, 57], ["b-hydroxybutyrate", "CHEMICAL", 76, 93], ["BHB", "CHEMICAL", 95, 98], ["nonesterified fatty acid", "SIMPLE_CHEMICAL", 27, 51], ["NEFA", "SIMPLE_CHEMICAL", 53, 57], ["b-hydroxybutyrate", "SIMPLE_CHEMICAL", 76, 93], ["BHB", "SIMPLE_CHEMICAL", 95, 98], ["liver", "ORGAN", 139, 144], ["Elevated concentrations", "PROBLEM", 0, 23], ["nonesterified fatty acid", "TEST", 27, 51], ["NEFA", "TEST", 53, 57], ["b-hydroxybutyrate (BHB", "PROBLEM", 76, 98], ["stress and liver compromise", "PROBLEM", 128, 155], ["liver", "ANATOMY", 139, 144], ["compromise", "OBSERVATION", 145, 155]]], ["Liver compromise is also indicated by elevated bile acids, gamma-glutamyl transferase, aspartate transaminase, and sorbitol dehydrogenase [17, 34] .", [["Liver", "ANATOMY", 0, 5], ["aspartate", "CHEMICAL", 87, 96], ["sorbitol", "CHEMICAL", 115, 123], ["bile acids", "CHEMICAL", 47, 57], ["gamma-glutamyl", "CHEMICAL", 59, 73], ["aspartate", "CHEMICAL", 87, 96], ["sorbitol", "CHEMICAL", 115, 123], ["Liver", "ORGAN", 0, 5], ["bile acids", "SIMPLE_CHEMICAL", 47, 57], ["gamma-glutamyl transferase", "GENE_OR_GENE_PRODUCT", 59, 85], ["aspartate transaminase", "GENE_OR_GENE_PRODUCT", 87, 109], ["sorbitol dehydrogenase", "GENE_OR_GENE_PRODUCT", 115, 137], ["gamma-glutamyl transferase", "PROTEIN", 59, 85], ["aspartate transaminase", "PROTEIN", 87, 109], ["sorbitol dehydrogenase", "PROTEIN", 115, 137], ["Liver compromise", "PROBLEM", 0, 16], ["elevated bile acids", "PROBLEM", 38, 57], ["gamma-glutamyl transferase", "TEST", 59, 85], ["aspartate transaminase", "TEST", 87, 109], ["sorbitol dehydrogenase", "TEST", 115, 137], ["compromise", "OBSERVATION", 6, 16], ["elevated", "OBSERVATION_MODIFIER", 38, 46], ["bile acids", "OBSERVATION", 47, 57]]], ["Furthermore, arginal calcium and magnesium concentrations or hypocalcemia may be present in late-pregnant females and require correction and monitoring.Endocrine evaluation of the damProgesterone is the major hormone evaluated routinely during pregnancy [35, 36] .", [["calcium", "CHEMICAL", 21, 28], ["magnesium", "CHEMICAL", 33, 42], ["hypocalcemia", "DISEASE", 61, 73], ["damProgesterone", "CHEMICAL", 180, 195], ["calcium", "CHEMICAL", 21, 28], ["magnesium", "CHEMICAL", 33, 42], ["damProgesterone", "CHEMICAL", 180, 195], ["arginal calcium", "SIMPLE_CHEMICAL", 13, 28], ["magnesium", "SIMPLE_CHEMICAL", 33, 42], ["damProgesterone", "GENE_OR_GENE_PRODUCT", 180, 195], ["arginal calcium", "TEST", 13, 28], ["magnesium concentrations", "PROBLEM", 33, 57], ["hypocalcemia", "PROBLEM", 61, 73], ["monitoring", "TEST", 141, 151], ["Endocrine evaluation", "TEST", 152, 172]]], ["Determining baseline progesterone concentration is a good practice if an assay is readily available.", [["progesterone", "CHEMICAL", 21, 33], ["progesterone", "CHEMICAL", 21, 33], ["progesterone", "SIMPLE_CHEMICAL", 21, 33], ["baseline progesterone concentration", "PROBLEM", 12, 47], ["an assay", "TEST", 70, 78]]], ["The CL is the primary source of progesterone throughout pregnancy in camelids; pregnancy cannot be maintained if blood progesterone concentrations are <1 ng/mL [37] .", [["blood", "ANATOMY", 113, 118], ["progesterone", "CHEMICAL", 32, 44], ["progesterone", "CHEMICAL", 119, 131], ["progesterone", "CHEMICAL", 32, 44], ["progesterone", "CHEMICAL", 119, 131], ["CL", "MULTI-TISSUE_STRUCTURE", 4, 6], ["progesterone", "SIMPLE_CHEMICAL", 32, 44], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["progesterone", "SIMPLE_CHEMICAL", 119, 131], ["progesterone throughout pregnancy in camelids", "PROBLEM", 32, 77], ["blood progesterone concentrations", "TEST", 113, 146], ["CL", "OBSERVATION", 4, 6]]], ["Progesterone concentrations may be substantially altered by level of hydration and weight and body condition score of the female.", [["body", "ANATOMY", 94, 98], ["Progesterone", "CHEMICAL", 0, 12], ["Progesterone", "CHEMICAL", 0, 12], ["Progesterone", "SIMPLE_CHEMICAL", 0, 12], ["body", "ORGANISM_SUBDIVISION", 94, 98], ["Progesterone concentrations", "TREATMENT", 0, 27], ["hydration", "TREATMENT", 69, 78], ["weight", "TEST", 83, 89], ["body condition score", "TEST", 94, 114]]], ["Progesterone supplementation is still a subject of debate.", [["Progesterone", "CHEMICAL", 0, 12], ["Progesterone", "CHEMICAL", 0, 12], ["Progesterone", "SIMPLE_CHEMICAL", 0, 12], ["Progesterone supplementation", "TREATMENT", 0, 28]]], ["Estrone sulfate concentrations in plasma increase after 80 days of pregnancy, reaching a peak immediately before parturition.Endocrine evaluation of the damDetermination of relaxin concentration may be helpful in the evaluation of placental function, but this assay is not widely used [35] .", [["plasma", "ANATOMY", 34, 40], ["placental", "ANATOMY", 231, 240], ["Estrone sulfate", "CHEMICAL", 0, 15], ["Estrone sulfate", "CHEMICAL", 0, 15], ["Estrone sulfate", "SIMPLE_CHEMICAL", 0, 15], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["relaxin", "GENE_OR_GENE_PRODUCT", 173, 180], ["placental", "ORGAN", 231, 240], ["Estrone sulfate concentrations", "TREATMENT", 0, 30], ["pregnancy", "PROBLEM", 67, 76], ["Endocrine evaluation", "TEST", 125, 145], ["relaxin concentration", "TREATMENT", 173, 194], ["the evaluation", "TEST", 213, 227], ["placental function", "TEST", 231, 249], ["this assay", "TEST", 255, 265]]], ["There are no studies on the effect of a compromised liver (typically due to hepatic lipidosis) on steroid metabolism and blood steroid concentrations.Supportive therapy of the compromised pregnant femaleSupportive therapy in pregnant females depends on the symptoms and degree of compromise.", [["liver", "ANATOMY", 52, 57], ["hepatic", "ANATOMY", 76, 83], ["blood", "ANATOMY", 121, 126], ["steroid", "CHEMICAL", 98, 105], ["steroid", "CHEMICAL", 127, 134], ["steroid", "CHEMICAL", 98, 105], ["steroid", "CHEMICAL", 127, 134], ["liver", "ORGAN", 52, 57], ["hepatic", "ORGAN", 76, 83], ["steroid", "SIMPLE_CHEMICAL", 98, 105], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["steroid", "SIMPLE_CHEMICAL", 127, 134], ["a compromised liver", "PROBLEM", 38, 57], ["hepatic lipidosis", "PROBLEM", 76, 93], ["steroid metabolism", "TREATMENT", 98, 116], ["blood steroid concentrations", "TREATMENT", 121, 149], ["Supportive therapy", "TREATMENT", 150, 168], ["the compromised pregnant femaleSupportive therapy", "TREATMENT", 172, 221], ["the symptoms", "PROBLEM", 253, 265], ["compromise", "PROBLEM", 280, 290], ["liver", "ANATOMY", 52, 57], ["hepatic", "ANATOMY", 76, 83], ["lipidosis", "OBSERVATION", 84, 93], ["steroid metabolism", "OBSERVATION", 98, 116], ["compromise", "OBSERVATION", 280, 290]]], ["It may include oxygen therapy, fluid therapy, antimicrobials, and NSAID's.", [["fluid", "ANATOMY", 31, 36], ["oxygen", "CHEMICAL", 15, 21], ["oxygen", "CHEMICAL", 15, 21], ["oxygen", "SIMPLE_CHEMICAL", 15, 21], ["NSAID", "SIMPLE_CHEMICAL", 66, 71], ["oxygen therapy", "TREATMENT", 15, 29], ["fluid therapy", "TREATMENT", 31, 44], ["antimicrobials", "TREATMENT", 46, 60], ["NSAID's", "TREATMENT", 66, 73], ["may include", "UNCERTAINTY", 3, 14], ["oxygen therapy", "OBSERVATION", 15, 29], ["fluid therapy", "OBSERVATION", 31, 44]]], ["Compromised pregnant females should be placed immediately on broad spectrum systemic antimicrobials.", [["broad spectrum systemic antimicrobials", "TREATMENT", 61, 99]]], ["Our primary choices of antimicrobials have been ceftiofur in alpacas and llamas and longacting tetracycline in camels.Uterine torsionUterine torsion remains the main genital cause of colic or depression in pregnant New World camelids.", [["Uterine", "ANATOMY", 118, 125], ["genital", "ANATOMY", 166, 173], ["ceftiofur", "CHEMICAL", 48, 57], ["tetracycline", "CHEMICAL", 95, 107], ["torsionUterine torsion", "DISEASE", 126, 148], ["colic", "DISEASE", 183, 188], ["depression", "DISEASE", 192, 202], ["ceftiofur", "CHEMICAL", 48, 57], ["tetracycline", "CHEMICAL", 95, 107], ["ceftiofur", "SIMPLE_CHEMICAL", 48, 57], ["alpacas", "ORGANISM", 61, 68], ["llamas", "ORGANISM", 73, 79], ["tetracycline", "SIMPLE_CHEMICAL", 95, 107], ["camels", "ORGANISM", 111, 117], ["Uterine", "ORGAN", 118, 125], ["genital", "ORGANISM_SUBDIVISION", 166, 173], ["llamas", "SPECIES", 73, 79], ["antimicrobials", "TREATMENT", 23, 37], ["ceftiofur", "TREATMENT", 48, 57], ["longacting tetracycline", "TREATMENT", 84, 107], ["Uterine torsionUterine torsion", "PROBLEM", 118, 148], ["colic", "PROBLEM", 183, 188], ["depression", "PROBLEM", 192, 202], ["ceftiofur", "OBSERVATION_MODIFIER", 48, 57], ["torsionUterine torsion", "OBSERVATION", 126, 148], ["main genital", "ANATOMY", 161, 173], ["colic", "OBSERVATION", 183, 188], ["depression", "OBSERVATION", 192, 202]]], ["There are no detailed studies regarding the epidemiology of this disorder.", [["detailed studies", "TEST", 13, 29], ["this disorder", "PROBLEM", 60, 73]]], ["It is noteworthy that uterine torsion is not common in camels (A. Tibary, unpublished observations), nor is it common in llamas and alpacas in South America (J. Sumar, personal communication).", [["uterine", "ANATOMY", 22, 29], ["uterine torsion", "DISEASE", 22, 37], ["uterine", "ORGAN", 22, 29], ["llamas", "ORGANISM", 121, 127], ["uterine torsion", "PROBLEM", 22, 37], ["uterine", "ANATOMY", 22, 29], ["torsion", "OBSERVATION", 30, 37]]], ["Perhaps this apparent difference is due to nutrition or body size.Uterine torsionIn our experience, there are two common stages of pregnancy at presentation: 8-10 months and at parturition.", [["body", "ANATOMY", 56, 60], ["Uterine", "ANATOMY", 66, 73], ["body", "ORGANISM_SUBDIVISION", 56, 60], ["Uterine", "ORGAN", 66, 73], ["size", "OBSERVATION_MODIFIER", 61, 65]]], ["Clinical signs of uterine torsion are quite variable, ranging from mild discomfort to severe colic, diarrhea, and anorexia.", [["uterine", "ANATOMY", 18, 25], ["uterine torsion", "DISEASE", 18, 33], ["colic", "DISEASE", 93, 98], ["diarrhea", "DISEASE", 100, 108], ["anorexia", "DISEASE", 114, 122], ["uterine", "ORGAN", 18, 25], ["uterine torsion", "PROBLEM", 18, 33], ["mild discomfort to severe colic", "PROBLEM", 67, 98], ["diarrhea", "PROBLEM", 100, 108], ["anorexia", "PROBLEM", 114, 122], ["uterine", "ANATOMY", 18, 25], ["torsion", "OBSERVATION", 26, 33], ["variable", "OBSERVATION_MODIFIER", 44, 52], ["mild", "OBSERVATION_MODIFIER", 67, 71], ["discomfort", "OBSERVATION", 72, 82], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["colic", "OBSERVATION", 93, 98], ["diarrhea", "OBSERVATION", 100, 108], ["anorexia", "OBSERVATION", 114, 122]]], ["We have had cases present simply as ''quieter than usual'' and ''decreased appetite'' or ''just a little off her normal routine'' [31] .Uterine torsionThe female may display signs of pain, circling, kicking at the belly, lateral recumbency, and excessive vocalization.", [["Uterine", "ANATOMY", 136, 143], ["pain", "DISEASE", 183, 187], ["Uterine", "ORGAN", 136, 143], ["belly", "ORGANISM_SUBDIVISION", 214, 219], ["Uterine torsion", "PROBLEM", 136, 151], ["pain", "PROBLEM", 183, 187], ["circling", "PROBLEM", 189, 197], ["kicking at the belly", "PROBLEM", 199, 219], ["lateral recumbency", "PROBLEM", 221, 239], ["excessive vocalization", "PROBLEM", 245, 267], ["torsion", "OBSERVATION", 144, 151], ["pain", "OBSERVATION", 183, 187], ["belly", "ANATOMY", 214, 219], ["lateral", "ANATOMY_MODIFIER", 221, 228], ["excessive vocalization", "OBSERVATION", 245, 267]]], ["Tachypnea and tachycardia are very common.", [["Tachypnea", "DISEASE", 0, 9], ["tachycardia", "DISEASE", 14, 25], ["Tachypnea", "PROBLEM", 0, 9], ["tachycardia", "PROBLEM", 14, 25], ["tachycardia", "OBSERVATION", 14, 25], ["very", "OBSERVATION_MODIFIER", 30, 34], ["common", "OBSERVATION_MODIFIER", 35, 41]]], ["The CBC and blood chemistry are consistent with a stress leukogram, with various metabolic changes (hepatic lipidosis) depending on the duration and severity of the problem [38] .Uterine torsionDiagnosis is based on transrectal palpation of the broad ligaments, as described in other large animal species [31, 38] .", [["CBC", "ANATOMY", 4, 7], ["blood", "ANATOMY", 12, 17], ["hepatic", "ANATOMY", 100, 107], ["Uterine", "ANATOMY", 179, 186], ["transrectal", "ANATOMY", 216, 227], ["ligaments", "ANATOMY", 251, 260], ["hepatic lipidosis", "DISEASE", 100, 117], ["CBC", "CELL", 4, 7], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["hepatic", "ORGAN", 100, 107], ["Uterine", "ORGAN", 179, 186], ["transrectal", "MULTI-TISSUE_STRUCTURE", 216, 227], ["ligaments", "ORGAN", 251, 260], ["The CBC", "TEST", 0, 7], ["blood chemistry", "TEST", 12, 27], ["a stress leukogram", "PROBLEM", 48, 66], ["various metabolic changes", "PROBLEM", 73, 98], ["hepatic lipidosis", "PROBLEM", 100, 117], ["Uterine torsionDiagnosis", "PROBLEM", 179, 203], ["transrectal palpation", "TEST", 216, 237], ["consistent with", "UNCERTAINTY", 32, 47], ["metabolic changes", "OBSERVATION", 81, 98], ["hepatic", "ANATOMY", 100, 107], ["lipidosis", "OBSERVATION", 108, 117], ["torsionDiagnosis", "OBSERVATION", 187, 203], ["broad ligaments", "ANATOMY", 245, 260]]], ["Clockwise torsion is indicated if the left broad ligament is stretched across midline to the right and over the uterus, whereas the right ligament is shorter and pulled ventrally and medially under the uterus.", [["left broad ligament", "ANATOMY", 38, 57], ["midline", "ANATOMY", 78, 85], ["right", "ANATOMY", 93, 98], ["uterus", "ANATOMY", 112, 118], ["right ligament", "ANATOMY", 132, 146], ["ventrally", "ANATOMY", 169, 178], ["uterus", "ANATOMY", 202, 208], ["ligament", "TISSUE", 49, 57], ["midline", "ORGAN", 78, 85], ["uterus", "ORGAN", 112, 118], ["ligament", "ORGAN", 138, 146], ["uterus", "ORGAN", 202, 208], ["Clockwise torsion", "PROBLEM", 0, 17], ["torsion", "OBSERVATION", 10, 17], ["left", "ANATOMY_MODIFIER", 38, 42], ["broad ligament", "ANATOMY", 43, 57], ["stretched", "OBSERVATION", 61, 70], ["midline", "OBSERVATION_MODIFIER", 78, 85], ["right", "ANATOMY_MODIFIER", 93, 98], ["uterus", "ANATOMY", 112, 118], ["right", "ANATOMY_MODIFIER", 132, 137], ["ligament", "ANATOMY", 138, 146], ["shorter", "OBSERVATION_MODIFIER", 150, 157], ["medially", "ANATOMY_MODIFIER", 183, 191], ["uterus", "ANATOMY", 202, 208]]], ["Palpation of the broad ligament may elicit a severe painful reaction.", [["ligament", "ANATOMY", 23, 31], ["ligament", "TISSUE", 23, 31], ["Palpation", "TEST", 0, 9], ["a severe painful reaction", "PROBLEM", 43, 68], ["broad ligament", "ANATOMY", 17, 31], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["painful", "OBSERVATION_MODIFIER", 52, 59], ["reaction", "OBSERVATION", 60, 68]]], ["Difficulties encountered in transrectal evaluation for uterine torsion include physical limitations, particularly in alpacas (tight anal sphincter, narrow pelvis and size of the examiner's hand and arm), as well as a lack of experience palpating late-pregnant camelids in a sternal position.", [["transrectal", "ANATOMY", 28, 39], ["uterine", "ANATOMY", 55, 62], ["anal sphincter", "ANATOMY", 132, 146], ["pelvis", "ANATOMY", 155, 161], ["hand", "ANATOMY", 189, 193], ["camelids", "ANATOMY", 260, 268], ["sternal", "ANATOMY", 274, 281], ["uterine torsion", "DISEASE", 55, 70], ["transrectal", "MULTI-TISSUE_STRUCTURE", 28, 39], ["uterine", "ORGAN", 55, 62], ["alpacas", "ORGANISM_SUBDIVISION", 117, 124], ["anal sphincter", "MULTI-TISSUE_STRUCTURE", 132, 146], ["pelvis", "ORGAN", 155, 161], ["hand", "ORGANISM_SUBDIVISION", 189, 193], ["arm", "ORGANISM_SUBDIVISION", 198, 201], ["transrectal evaluation", "TEST", 28, 50], ["uterine torsion", "PROBLEM", 55, 70], ["physical limitations", "PROBLEM", 79, 99], ["uterine", "ANATOMY", 55, 62], ["torsion", "OBSERVATION", 63, 70], ["anal sphincter", "ANATOMY", 132, 146], ["pelvis", "ANATOMY", 155, 161], ["size", "OBSERVATION_MODIFIER", 166, 170], ["arm", "ANATOMY", 198, 201], ["sternal", "ANATOMY", 274, 281]]], ["Although diagnosis by vaginal palpation has been reported by practitioners, in our experience, it is not reliable unless the torsion includes the cervix.", [["vaginal", "ANATOMY", 22, 29], ["cervix", "ANATOMY", 146, 152], ["torsion", "DISEASE", 125, 132], ["vaginal", "ORGANISM_SUBDIVISION", 22, 29], ["cervix", "CANCER", 146, 152], ["vaginal palpation", "TEST", 22, 39], ["torsion", "OBSERVATION", 125, 132], ["cervix", "ANATOMY", 146, 152]]], ["With a severe colic, a definitive diagnosis may not be possible until exploratory laparotomy.", [["colic", "DISEASE", 14, 19], ["a severe colic", "PROBLEM", 5, 19], ["exploratory laparotomy", "TEST", 70, 92], ["severe", "OBSERVATION_MODIFIER", 7, 13], ["colic", "OBSERVATION", 14, 19], ["may not be possible", "UNCERTAINTY", 44, 63], ["laparotomy", "OBSERVATION", 82, 92]]], ["Alternatively, the female could be palpated under general anesthesia, which provides greater relaxation of the anal sphincter and perineal area [39] .", [["anal sphincter", "ANATOMY", 111, 125], ["perineal area", "ANATOMY", 130, 143], ["female", "ORGANISM", 19, 25], ["anal sphincter", "MULTI-TISSUE_STRUCTURE", 111, 125], ["general anesthesia", "TREATMENT", 50, 68], ["anal sphincter", "ANATOMY", 111, 125], ["perineal", "ANATOMY", 130, 138]]], ["Transrectal ultrasonography may sometimes reveal increased dilation of the blood vessels.", [["Transrectal", "ANATOMY", 0, 11], ["blood vessels", "ANATOMY", 75, 88], ["Transrectal", "MULTI-TISSUE_STRUCTURE", 0, 11], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 75, 88], ["Transrectal ultrasonography", "TEST", 0, 27], ["increased dilation of the blood vessels", "PROBLEM", 49, 88], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["dilation", "OBSERVATION", 59, 67], ["blood vessels", "ANATOMY", 75, 88]]], ["Although it was reported that the majority (>90%) of camelid uterine torsions are clockwise [38] , this has not been our experience; therefore, direction of the torsion needs to be ascertained before attempting nonsurgical correction.Uterine torsionCorrection of uterine torsion can be accomplished nonsurgically by rolling or surgically after coeliotomy.", [["uterine", "ANATOMY", 61, 68], ["Uterine", "ANATOMY", 234, 241], ["uterine", "ANATOMY", 263, 270], ["torsion", "DISEASE", 161, 168], ["uterine torsion", "DISEASE", 263, 278], ["camelid uterine torsions", "CANCER", 53, 77], ["Uterine", "ORGAN", 234, 241], ["uterine", "ORGAN", 263, 270], ["camelid uterine torsions", "PROBLEM", 53, 77], ["nonsurgical correction", "TREATMENT", 211, 233], ["Uterine torsionCorrection of uterine torsion", "PROBLEM", 234, 278], ["coeliotomy", "TREATMENT", 344, 354], ["uterine", "ANATOMY", 61, 68], ["torsions", "OBSERVATION", 69, 77], ["torsion", "OBSERVATION", 161, 168], ["uterine", "ANATOMY", 263, 270], ["torsion", "OBSERVATION", 271, 278]]], ["Rolling should be considered only if the uterus and its vasculature are not compromised.", [["uterus", "ANATOMY", 41, 47], ["vasculature", "ANATOMY", 56, 67], ["uterus", "ORGAN", 41, 47], ["vasculature", "MULTI-TISSUE_STRUCTURE", 56, 67], ["uterus", "ANATOMY", 41, 47], ["vasculature", "ANATOMY", 56, 67], ["not", "UNCERTAINTY", 72, 75], ["compromised", "OBSERVATION", 76, 87]]], ["Rolling may be performed done under general anesthesia, sedation, or without sedation.", [["general anesthesia", "TREATMENT", 36, 54], ["sedation", "TREATMENT", 56, 64], ["sedation", "TREATMENT", 77, 85]]], ["The female is placed on lateral recumbency on the side of the direction of the torsion and rolled while the fetus is maintained in position with a small plank or with the fists [31, 38] .", [["fetus", "ANATOMY", 108, 113], ["torsion", "DISEASE", 79, 86], ["fetus", "ORGANISM", 108, 113], ["female", "OBSERVATION", 4, 10], ["lateral", "OBSERVATION_MODIFIER", 24, 31], ["recumbency", "OBSERVATION", 32, 42], ["torsion", "OBSERVATION", 79, 86], ["fetus", "ANATOMY", 108, 113], ["small", "OBSERVATION_MODIFIER", 147, 152]]], ["The pain usually disappears immediately after correction of the torsion and females may return to normal activity immediately.", [["pain", "DISEASE", 4, 8], ["torsion", "DISEASE", 64, 71], ["The pain", "PROBLEM", 0, 8], ["the torsion", "PROBLEM", 60, 71], ["pain", "OBSERVATION", 4, 8], ["torsion", "OBSERVATION", 64, 71]]], ["However, if they have been anorexic, correction of metabolic disorders should included in post-surgical management.", [["metabolic disorders", "DISEASE", 51, 70], ["anorexic", "PROBLEM", 27, 35], ["metabolic disorders", "PROBLEM", 51, 70], ["post-surgical management", "TREATMENT", 90, 114]]], ["Surgical correction may be performed following flank or midline laparotomy.", [["flank", "ANATOMY", 47, 52], ["flank", "ORGANISM_SUBDIVISION", 47, 52], ["Surgical correction", "TREATMENT", 0, 19], ["flank or midline laparotomy", "TEST", 47, 74], ["flank", "ANATOMY", 47, 52], ["midline", "ANATOMY", 56, 63], ["laparotomy", "OBSERVATION", 64, 74]]], ["Midline laparotomy is the preferred method in late pregnancy [39] [40] [41] [42] .", [["Midline laparotomy", "TREATMENT", 0, 18], ["laparotomy", "OBSERVATION", 8, 18]]], ["The success rate of both rolling and surgical correction is very high, as is survival of the fetus.", [["fetus", "ANATOMY", 93, 98], ["fetus", "ORGAN", 93, 98], ["surgical correction", "TREATMENT", 37, 56], ["both", "OBSERVATION_MODIFIER", 20, 24], ["rolling", "OBSERVATION_MODIFIER", 25, 32], ["high", "OBSERVATION_MODIFIER", 65, 69], ["fetus", "ANATOMY", 93, 98]]], ["No special management is needed if the torsion has been diagnosed and corrected early.", [["torsion", "DISEASE", 39, 46], ["special management", "TREATMENT", 3, 21], ["the torsion", "PROBLEM", 35, 46], ["torsion", "OBSERVATION", 39, 46]]], ["However, anorexia and pain may cause hepatic lipidosis, in which case the patient should be placed on broad spectrum antimicrobial therapy [39] .", [["hepatic", "ANATOMY", 37, 44], ["anorexia", "DISEASE", 9, 17], ["pain", "DISEASE", 22, 26], ["hepatic lipidosis", "DISEASE", 37, 54], ["hepatic", "ORGAN", 37, 44], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["anorexia", "PROBLEM", 9, 17], ["pain", "PROBLEM", 22, 26], ["hepatic lipidosis", "PROBLEM", 37, 54], ["broad spectrum antimicrobial therapy", "TREATMENT", 102, 138], ["anorexia", "OBSERVATION", 9, 17], ["hepatic", "ANATOMY", 37, 44], ["lipidosis", "OBSERVATION", 45, 54]]], ["Monitoring blood progesterone is useful, particularly if an assay is readily available.", [["blood", "ANATOMY", 11, 16], ["progesterone", "CHEMICAL", 17, 29], ["progesterone", "CHEMICAL", 17, 29], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["progesterone", "SIMPLE_CHEMICAL", 17, 29], ["Monitoring blood progesterone", "TEST", 0, 29], ["an assay", "TEST", 57, 65]]], ["The need for progesterone supplementation after correction of a torsion remains controversial.Uterine torsionComplications of uterine torsion include abortion, uterine rupture/hemorrhage, endotoxemia, and death of the dam [38, 40] .", [["Uterine", "ANATOMY", 94, 101], ["uterine", "ANATOMY", 126, 133], ["uterine", "ANATOMY", 160, 167], ["progesterone", "CHEMICAL", 13, 25], ["torsion", "DISEASE", 64, 71], ["uterine torsion", "DISEASE", 126, 141], ["abortion", "DISEASE", 150, 158], ["uterine rupture", "DISEASE", 160, 175], ["hemorrhage", "DISEASE", 176, 186], ["endotoxemia", "DISEASE", 188, 199], ["death", "DISEASE", 205, 210], ["progesterone", "CHEMICAL", 13, 25], ["progesterone", "SIMPLE_CHEMICAL", 13, 25], ["Uterine", "ORGAN", 94, 101], ["uterine", "ORGAN", 126, 133], ["uterine", "ORGANISM_SUBDIVISION", 160, 167], ["progesterone supplementation", "TREATMENT", 13, 41], ["a torsion", "PROBLEM", 62, 71], ["Uterine torsionComplications of uterine torsion", "PROBLEM", 94, 141], ["abortion", "PROBLEM", 150, 158], ["uterine rupture", "PROBLEM", 160, 175], ["hemorrhage", "PROBLEM", 176, 186], ["endotoxemia", "PROBLEM", 188, 199], ["torsion", "OBSERVATION", 64, 71], ["uterine", "ANATOMY", 126, 133], ["torsion", "OBSERVATION", 134, 141], ["uterine", "ANATOMY", 160, 167], ["rupture", "OBSERVATION", 168, 175], ["hemorrhage", "OBSERVATION", 176, 186], ["endotoxemia", "OBSERVATION_MODIFIER", 188, 199]]], ["Splenic torsion concurrent with uterine torsion has been described in one case, with persistent pain following correction of the uterine torsion [39] .Uterine ruptureUterine rupture is often secondary to severe or inadequate clinical management of a uterine torsion.", [["Splenic", "ANATOMY", 0, 7], ["uterine", "ANATOMY", 32, 39], ["uterine", "ANATOMY", 129, 136], ["Uterine", "ANATOMY", 151, 158], ["uterine", "ANATOMY", 250, 257], ["Splenic torsion", "DISEASE", 0, 15], ["uterine torsion", "DISEASE", 32, 47], ["pain", "DISEASE", 96, 100], ["uterine torsion", "DISEASE", 129, 144], ["Uterine ruptureUterine rupture", "DISEASE", 151, 181], ["uterine torsion", "DISEASE", 250, 265], ["Splenic", "ORGAN", 0, 7], ["uterine", "ORGAN", 32, 39], ["uterine", "ORGAN", 129, 136], ["Uterine ruptureUterine", "MULTI-TISSUE_STRUCTURE", 151, 173], ["uterine", "ORGAN", 250, 257], ["Splenic torsion", "PROBLEM", 0, 15], ["uterine torsion", "PROBLEM", 32, 47], ["persistent pain", "PROBLEM", 85, 100], ["the uterine torsion", "PROBLEM", 125, 144], ["Uterine ruptureUterine rupture", "PROBLEM", 151, 181], ["a uterine torsion", "PROBLEM", 248, 265], ["torsion", "OBSERVATION", 8, 15], ["uterine", "ANATOMY", 32, 39], ["torsion", "OBSERVATION", 40, 47], ["persistent", "OBSERVATION_MODIFIER", 85, 95], ["pain", "OBSERVATION", 96, 100], ["uterine", "ANATOMY", 129, 136], ["torsion", "OBSERVATION", 137, 144], ["ruptureUterine", "OBSERVATION_MODIFIER", 159, 173], ["rupture", "OBSERVATION", 174, 181], ["severe", "OBSERVATION_MODIFIER", 204, 210], ["uterine", "ANATOMY", 250, 257], ["torsion", "OBSERVATION", 258, 265]]], ["Females usually present in an advanced stage of shock, in lateral recumbency.", [["shock", "DISEASE", 48, 53], ["shock", "PROBLEM", 48, 53], ["lateral recumbency", "PROBLEM", 58, 76], ["advanced stage", "OBSERVATION_MODIFIER", 30, 44], ["shock", "OBSERVATION", 48, 53], ["lateral", "ANATOMY_MODIFIER", 58, 65], ["recumbency", "OBSERVATION_MODIFIER", 66, 76]]], ["Abdominocentesis may reveal large amount of serosanguinous or bloody fluid.", [["serosanguinous", "ANATOMY", 44, 58], ["bloody fluid", "ANATOMY", 62, 74], ["Abdominocentesis", "DISEASE", 0, 16], ["Abdominocentesis", "TREATMENT", 0, 16], ["serosanguinous or bloody fluid", "PROBLEM", 44, 74], ["large", "OBSERVATION_MODIFIER", 28, 33], ["amount", "OBSERVATION_MODIFIER", 34, 40], ["serosanguinous", "OBSERVATION", 44, 58], ["bloody fluid", "OBSERVATION", 62, 74]]], ["Severe pain with presence of serosanguinous peritoneal fluid may also be due to splenic torsion [39] .", [["peritoneal fluid", "ANATOMY", 44, 60], ["splenic", "ANATOMY", 80, 87], ["pain", "DISEASE", 7, 11], ["splenic torsion", "DISEASE", 80, 95], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 44, 54], ["fluid", "ORGANISM_SUBSTANCE", 55, 60], ["Severe pain", "PROBLEM", 0, 11], ["serosanguinous peritoneal fluid", "PROBLEM", 29, 60], ["splenic torsion", "PROBLEM", 80, 95], ["pain", "OBSERVATION", 7, 11], ["serosanguinous", "OBSERVATION_MODIFIER", 29, 43], ["peritoneal", "ANATOMY", 44, 54], ["fluid", "OBSERVATION", 55, 60], ["may also be due to", "UNCERTAINTY", 61, 79], ["splenic", "ANATOMY", 80, 87], ["torsion", "OBSERVATION", 88, 95]]], ["The only option is surgical intervention to remove the fetus and salvage the uterus.", [["fetus", "ANATOMY", 55, 60], ["uterus", "ANATOMY", 77, 83], ["fetus", "ORGAN", 55, 60], ["uterus", "ORGAN", 77, 83], ["surgical intervention", "TREATMENT", 19, 40], ["the fetus and salvage the uterus", "PROBLEM", 51, 83], ["surgical", "OBSERVATION", 19, 27], ["fetus", "ANATOMY", 55, 60], ["uterus", "ANATOMY", 77, 83]]], ["Complete hysterectomy should be considered if the uterus is severely compromised.Vaginal prolapseVaginal prolapse has been described during the first half of pregnancy, but the condition is more common during the last 2 months of pregnancy [31, [43] [44] [45] .", [["uterus", "ANATOMY", 50, 56], ["Vaginal", "ANATOMY", 81, 88], ["prolapseVaginal prolapse", "DISEASE", 89, 113], ["uterus", "ORGAN", 50, 56], ["Complete hysterectomy", "TREATMENT", 0, 21], ["severely compromised", "PROBLEM", 60, 80], ["Vaginal prolapseVaginal prolapse", "PROBLEM", 81, 113], ["hysterectomy", "OBSERVATION", 9, 21], ["uterus", "ANATOMY", 50, 56], ["severely", "OBSERVATION_MODIFIER", 60, 68], ["compromised", "OBSERVATION", 69, 80], ["prolapseVaginal prolapse", "OBSERVATION", 89, 113]]], ["It is likely due to softening of tissues due to increased estrogen concentration during the last part of pregnancy.", [["tissues", "ANATOMY", 33, 40], ["estrogen", "CHEMICAL", 58, 66], ["estrogen", "CHEMICAL", 58, 66], ["tissues", "TISSUE", 33, 40], ["estrogen", "SIMPLE_CHEMICAL", 58, 66], ["softening of tissues", "PROBLEM", 20, 40], ["increased estrogen concentration", "PROBLEM", 48, 80], ["likely due to", "UNCERTAINTY", 6, 19], ["softening", "OBSERVATION", 20, 29], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["estrogen concentration", "OBSERVATION", 58, 80]]], ["Predisposing factors include age (older females), parity, and body condition (obese and very thin females) [31, 45] .Vaginal prolapseThe prolapse tissue may be limited to 3-5 cm, and visible only in the recumbent female.", [["body", "ANATOMY", 62, 66], ["Vaginal", "ANATOMY", 117, 124], ["prolapse tissue", "ANATOMY", 137, 152], ["Vaginal prolapse", "DISEASE", 117, 133], ["body", "ORGANISM_SUBDIVISION", 62, 66], ["prolapse tissue", "TISSUE", 137, 152], ["body condition", "PROBLEM", 62, 76], ["obese", "PROBLEM", 78, 83], ["Vaginal prolapse", "PROBLEM", 117, 133], ["The prolapse tissue", "PROBLEM", 133, 152], ["body", "ANATOMY", 62, 66], ["obese", "OBSERVATION", 78, 83], ["prolapse", "OBSERVATION", 125, 133], ["prolapse", "OBSERVATION", 137, 145], ["may be", "UNCERTAINTY", 153, 159], ["3-5 cm", "OBSERVATION_MODIFIER", 171, 177], ["recumbent female", "ANATOMY", 203, 219]]], ["However, with increased inflammation and edema of the tissues, the degree of prolapse increases and becomes permanently exteriorized.", [["tissues", "ANATOMY", 54, 61], ["inflammation", "DISEASE", 24, 36], ["edema", "DISEASE", 41, 46], ["prolapse", "DISEASE", 77, 85], ["edema", "PATHOLOGICAL_FORMATION", 41, 46], ["tissues", "TISSUE", 54, 61], ["increased inflammation", "PROBLEM", 14, 36], ["edema of the tissues", "PROBLEM", 41, 61], ["prolapse", "PROBLEM", 77, 85], ["increased", "OBSERVATION_MODIFIER", 14, 23], ["inflammation", "OBSERVATION", 24, 36], ["edema", "OBSERVATION", 41, 46], ["tissues", "ANATOMY", 54, 61], ["degree", "OBSERVATION_MODIFIER", 67, 73], ["prolapse", "OBSERVATION", 77, 85], ["increases", "OBSERVATION_MODIFIER", 86, 95], ["permanently", "OBSERVATION_MODIFIER", 108, 119], ["exteriorized", "OBSERVATION_MODIFIER", 120, 132]]], ["Prolapse of the entire vagina and exteriorisation of the cervix is rare, but possible.", [["vagina", "ANATOMY", 23, 29], ["cervix", "ANATOMY", 57, 63], ["vagina", "ORGAN", 23, 29], ["cervix", "ORGAN", 57, 63], ["Prolapse of the entire vagina", "PROBLEM", 0, 29], ["entire", "ANATOMY_MODIFIER", 16, 22], ["vagina", "ANATOMY", 23, 29], ["cervix", "ANATOMY", 57, 63], ["rare", "OBSERVATION", 67, 71]]], ["Prolonged periods of prolapse increase inflammation and can cause severe necrosis of the vaginal mucosa, potentially resulting in ascending infectious placentitis.", [["vaginal mucosa", "ANATOMY", 89, 103], ["inflammation", "DISEASE", 39, 51], ["necrosis", "DISEASE", 73, 81], ["placentitis", "DISEASE", 151, 162], ["vaginal mucosa", "MULTI-TISSUE_STRUCTURE", 89, 103], ["prolapse increase inflammation", "PROBLEM", 21, 51], ["severe necrosis of the vaginal mucosa", "PROBLEM", 66, 103], ["ascending infectious placentitis", "PROBLEM", 130, 162], ["prolapse", "OBSERVATION", 21, 29], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["inflammation", "OBSERVATION", 39, 51], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["necrosis", "OBSERVATION", 73, 81], ["vaginal mucosa", "ANATOMY", 89, 103], ["ascending", "OBSERVATION_MODIFIER", 130, 139], ["infectious", "OBSERVATION", 140, 150]]], ["Increased tenesmus with risk of abortion and/or rectal prolapse occurs in chronic cases.", [["rectal", "ANATOMY", 48, 54], ["tenesmus", "DISEASE", 10, 18], ["abortion", "DISEASE", 32, 40], ["rectal prolapse", "DISEASE", 48, 63], ["tenesmus", "CANCER", 10, 18], ["rectal", "ORGAN", 48, 54], ["Increased tenesmus", "PROBLEM", 0, 18], ["abortion", "PROBLEM", 32, 40], ["rectal prolapse", "PROBLEM", 48, 63], ["chronic cases", "PROBLEM", 74, 87], ["tenesmus", "OBSERVATION", 10, 18], ["abortion", "OBSERVATION", 32, 40], ["rectal", "ANATOMY", 48, 54], ["prolapse", "OBSERVATION", 55, 63], ["chronic", "OBSERVATION_MODIFIER", 74, 81]]], ["Furthermore, rectal and vaginal prolapse may be the only indications of dystocia or abortion [45] .Vaginal prolapseThe prognosis for the life of the fetus and dam is relatively good if the condition is treated early.", [["rectal", "ANATOMY", 13, 19], ["vaginal", "ANATOMY", 24, 31], ["Vaginal", "ANATOMY", 99, 106], ["fetus", "ANATOMY", 149, 154], ["vaginal prolapse", "DISEASE", 24, 40], ["dystocia", "DISEASE", 72, 80], ["abortion", "DISEASE", 84, 92], ["Vaginal prolapse", "DISEASE", 99, 115], ["rectal", "ORGAN", 13, 19], ["vaginal", "ORGANISM_SUBDIVISION", 24, 31], ["fetus", "ORGAN", 149, 154], ["rectal and vaginal prolapse", "PROBLEM", 13, 40], ["dystocia", "PROBLEM", 72, 80], ["abortion", "PROBLEM", 84, 92], ["Vaginal prolapse", "PROBLEM", 99, 115], ["rectal", "ANATOMY", 13, 19], ["vaginal", "ANATOMY", 24, 31], ["prolapse", "OBSERVATION", 32, 40], ["dystocia", "OBSERVATION", 72, 80], ["prolapse", "OBSERVATION", 107, 115]]], ["In camels, the vaginal tissue is maintained in place with a B\u00fchner suture around the vulva.", [["vaginal tissue", "ANATOMY", 15, 29], ["vulva", "ANATOMY", 85, 90], ["camels", "ORGANISM", 3, 9], ["vaginal tissue", "TISSUE", 15, 29], ["vulva", "ORGAN", 85, 90], ["a B\u00fchner suture", "TREATMENT", 58, 73], ["vaginal tissue", "ANATOMY", 15, 29], ["maintained", "OBSERVATION", 33, 43], ["B\u00fchner suture", "OBSERVATION", 60, 73], ["vulva", "ANATOMY", 85, 90]]], ["In the alpaca and llama, a shoelace suture pattern is sufficient.", [["alpaca", "ORGANISM", 7, 13], ["llama", "ORGANISM", 18, 23], ["a shoelace suture pattern", "TREATMENT", 25, 50], ["alpaca", "ANATOMY_MODIFIER", 7, 13], ["llama", "ANATOMY", 18, 23]]], ["More advanced cases of prolapsed vagina with increased tenesmus may require epidural anesthesia [44] .", [["vagina", "ANATOMY", 33, 39], ["epidural", "ANATOMY", 76, 84], ["tenesmus", "DISEASE", 55, 63], ["vagina", "ORGAN", 33, 39], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 76, 84], ["prolapsed vagina", "PROBLEM", 23, 39], ["increased tenesmus", "PROBLEM", 45, 63], ["epidural anesthesia", "TREATMENT", 76, 95], ["prolapsed", "OBSERVATION", 23, 32], ["vagina", "ANATOMY", 33, 39], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["tenesmus", "OBSERVATION", 55, 63]]], ["The animal should be monitored regularly and the suture removed if signs of impending parturition are observed [41] .Other complications of pregnancyOther complications of pregnancy in camelids include ventral abdomen herniation, prepartum downer syndrome, metabolic diseases, and premature lactation/ placentitis.", [["ventral abdomen", "ANATOMY", 202, 217], ["ventral abdomen herniation", "DISEASE", 202, 228], ["prepartum downer syndrome", "DISEASE", 230, 255], ["metabolic diseases", "DISEASE", 257, 275], ["premature lactation", "DISEASE", 281, 300], ["placentitis", "DISEASE", 302, 313], ["abdomen", "ORGANISM_SUBDIVISION", 210, 217], ["the suture", "TREATMENT", 45, 55], ["impending parturition", "PROBLEM", 76, 97], ["Other complications of pregnancy", "PROBLEM", 117, 149], ["Other complications", "PROBLEM", 149, 168], ["pregnancy in camelids", "PROBLEM", 172, 193], ["ventral abdomen herniation", "PROBLEM", 202, 228], ["prepartum downer syndrome", "PROBLEM", 230, 255], ["metabolic diseases", "PROBLEM", 257, 275], ["premature lactation/ placentitis", "PROBLEM", 281, 313], ["pregnancy", "OBSERVATION", 172, 181], ["ventral", "ANATOMY_MODIFIER", 202, 209], ["abdomen", "ANATOMY", 210, 217], ["herniation", "OBSERVATION", 218, 228], ["downer syndrome", "OBSERVATION", 240, 255], ["metabolic diseases", "OBSERVATION", 257, 275]]], ["Hydrops of fetal fluid is extremely rare in camelids.", [["fetal fluid", "ANATOMY", 11, 22], ["fetal fluid", "MULTI-TISSUE_STRUCTURE", 11, 22], ["Hydrops of fetal fluid", "PROBLEM", 0, 22], ["fetal", "ANATOMY", 11, 16], ["fluid", "OBSERVATION", 17, 22]]], ["Ventral herniation during pregnancy is often a complication of previous abdominal surgeries, including cesarean section.", [["abdominal", "ANATOMY", 72, 81], ["Ventral herniation", "DISEASE", 0, 18], ["abdominal", "ORGANISM_SUBDIVISION", 72, 81], ["Ventral herniation", "PROBLEM", 0, 18], ["previous abdominal surgeries", "TREATMENT", 63, 91], ["cesarean section", "TREATMENT", 103, 119], ["herniation", "OBSERVATION", 8, 18], ["abdominal", "ANATOMY", 72, 81], ["surgeries", "OBSERVATION", 82, 91]]], ["In addition to determining the primary cause of these disorders and assessing the chances for survival of the female, determination of fetal well-being and the possibility of induction of abortion or parturition should be contemplated.", [["fetal", "ANATOMY", 135, 140], ["fetal", "ANATOMICAL_SYSTEM", 135, 140], ["these disorders", "PROBLEM", 48, 63], ["induction of abortion", "TREATMENT", 175, 196]]], ["Abortion can be induced with the prostaglandin F 2a analogue, cloprostenol (250 mg in llamas and alpacas, and 500 mg in camels).", [["prostaglandin F 2a", "CHEMICAL", 33, 51], ["cloprostenol", "CHEMICAL", 62, 74], ["prostaglandin F 2a", "CHEMICAL", 33, 51], ["cloprostenol", "CHEMICAL", 62, 74], ["prostaglandin F 2a", "SIMPLE_CHEMICAL", 33, 51], ["cloprostenol", "SIMPLE_CHEMICAL", 62, 74], ["llamas", "ORGANISM", 86, 92], ["Abortion", "TREATMENT", 0, 8], ["the prostaglandin F 2a analogue", "TREATMENT", 29, 60], ["cloprostenol", "TREATMENT", 62, 74]]], ["The same dose is sufficient for induction of parturition, with good neonatal survival at >330 days of pregnancy and sufficient mammary gland development and colostrum production.", [["mammary gland", "ANATOMY", 127, 140], ["colostrum", "ANATOMY", 157, 166], ["mammary gland", "MULTI-TISSUE_STRUCTURE", 127, 140], ["colostrum", "ORGANISM_SUBSTANCE", 157, 166], ["pregnancy", "PROBLEM", 102, 111], ["mammary gland", "ANATOMY", 127, 140]]], ["Abortion or parturition occurs approximately 18-22 h after prostaglandin treatment.", [["prostaglandin", "CHEMICAL", 59, 72], ["prostaglandin", "CHEMICAL", 59, 72], ["prostaglandin", "SIMPLE_CHEMICAL", 59, 72], ["Abortion", "PROBLEM", 0, 8], ["prostaglandin treatment", "TREATMENT", 59, 82]]], ["In a few situations, a second treatment with a prostaglandin F 2a analogue is necessary [45] [46] [47] .", [["prostaglandin F 2a", "CHEMICAL", 47, 65], ["prostaglandin F 2a", "CHEMICAL", 47, 65], ["prostaglandin F 2a", "SIMPLE_CHEMICAL", 47, 65], ["a second treatment", "TREATMENT", 21, 39], ["a prostaglandin F 2a analogue", "TREATMENT", 45, 74]]], ["Giving llamas or alpacas >5 mg of PGF 2a (dinoprost thrometamine) has been associated with severe respiratory distress.Obstetrical emergenciesMost neonatal deaths occur during birth or shortly thereafter.", [["respiratory", "ANATOMY", 98, 109], ["PGF 2a", "CHEMICAL", 34, 40], ["dinoprost thrometamine", "CHEMICAL", 42, 64], ["respiratory distress", "DISEASE", 98, 118], ["deaths", "DISEASE", 156, 162], ["PGF 2a", "CHEMICAL", 34, 40], ["dinoprost thrometamine", "CHEMICAL", 42, 64], ["llamas", "ORGANISM", 7, 13], ["alpacas", "ORGANISM", 17, 24], ["PGF 2a", "SIMPLE_CHEMICAL", 34, 40], ["dinoprost thrometamine", "SIMPLE_CHEMICAL", 42, 64], ["alpacas", "TREATMENT", 17, 24], ["PGF 2a (dinoprost thrometamine", "TREATMENT", 34, 64], ["severe respiratory distress", "PROBLEM", 91, 118], ["Obstetrical emergencies", "PROBLEM", 119, 142], ["Most neonatal deaths", "PROBLEM", 142, 162], ["associated with", "UNCERTAINTY", 75, 90], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["respiratory distress", "OBSERVATION", 98, 118]]], ["Adequate obstetrical management and monitoring for early signs of distress are closely linked with the chances of survival of the cria and the reproductive future of the dam.", [["dam", "ORGANISM_SUBDIVISION", 170, 173], ["Adequate obstetrical management", "TREATMENT", 0, 31], ["monitoring", "TEST", 36, 46], ["distress", "PROBLEM", 66, 74], ["obstetrical management", "OBSERVATION", 9, 31], ["distress", "OBSERVATION", 66, 74]]], ["Proper procedures, immediate neonatal care, and close of observation of the newborn, are the best means of reducing neonatal losses.Obstetrical emergenciesNormal parturition and proper obstetrical techniques have been reviewed in detail elsewhere and are not very different from the approach used in other large animal species (especially horses) [31] .", [["horses", "ORGANISM_SUBDIVISION", 339, 345], ["Proper procedures", "TREATMENT", 0, 17], ["immediate neonatal care", "TREATMENT", 19, 42], ["reducing neonatal losses", "PROBLEM", 107, 131], ["Obstetrical emergencies", "PROBLEM", 132, 155], ["parturition", "OBSERVATION", 162, 173]]], ["It is estimated that approximately 5% of all camelid births will require some assistance and $2% will require advanced obstetrical expertise.", [["advanced obstetrical expertise", "TREATMENT", 110, 140]]], ["Obstetrical problems are an emergency in camelids, due to the relatively explosive and short duration of stages of parturition (similar to the mare).", [["Obstetrical problems", "PROBLEM", 0, 20], ["parturition", "PROBLEM", 115, 126], ["short duration", "OBSERVATION_MODIFIER", 87, 101]]], ["All normal births are in an anterior longitudinal presentation.Obstetrical emergenciesDystocia of maternal origin include uterine inertia, uterine rupture, and failure of appropriate dilation of the cervix or vestibulum [31, 45, 48] .", [["uterine", "ANATOMY", 122, 129], ["uterine", "ANATOMY", 139, 146], ["cervix", "ANATOMY", 199, 205], ["vestibulum", "ANATOMY", 209, 219], ["uterine inertia", "DISEASE", 122, 137], ["uterine rupture", "DISEASE", 139, 154], ["dilation of the cervix or vestibulum", "DISEASE", 183, 219], ["uterine", "ORGANISM_SUBDIVISION", 122, 129], ["uterine", "ORGAN", 139, 146], ["cervix", "ORGAN", 199, 205], ["uterine inertia", "PROBLEM", 122, 137], ["uterine rupture", "PROBLEM", 139, 154], ["failure of appropriate dilation of the cervix", "PROBLEM", 160, 205], ["normal", "OBSERVATION", 4, 10], ["anterior", "ANATOMY_MODIFIER", 28, 36], ["uterine", "ANATOMY", 122, 129], ["inertia", "OBSERVATION", 130, 137], ["uterine", "ANATOMY", 139, 146], ["rupture", "OBSERVATION", 147, 154], ["failure", "OBSERVATION_MODIFIER", 160, 167], ["dilation", "OBSERVATION", 183, 191], ["cervix", "ANATOMY", 199, 205]]], ["Uterine torsion and failure of cervical dilation require delivery by cesarean section.", [["Uterine", "ANATOMY", 0, 7], ["cervical", "ANATOMY", 31, 39], ["Uterine torsion", "DISEASE", 0, 15], ["Uterine", "ORGAN", 0, 7], ["cervical", "ORGAN", 31, 39], ["Uterine torsion", "PROBLEM", 0, 15], ["failure of cervical dilation", "PROBLEM", 20, 48], ["delivery", "TREATMENT", 57, 65], ["cesarean section", "TREATMENT", 69, 85], ["torsion", "OBSERVATION", 8, 15], ["failure", "OBSERVATION", 20, 27], ["cervical", "ANATOMY", 31, 39], ["dilation", "OBSERVATION", 40, 48]]], ["However, it is important to confirm that the dam is at term and to first rule-out uterine torsion [31, 49] .Obstetrical emergenciesDystocia of fetal origin occur most commonly as a result of malpositioning or malposture, and to a lesser degree, presence of malformations, twins, and large fetuses.", [["uterine", "ANATOMY", 82, 89], ["fetal", "ANATOMY", 143, 148], ["fetuses", "ANATOMY", 289, 296], ["uterine torsion", "DISEASE", 82, 97], ["malpositioning", "DISEASE", 191, 205], ["malposture", "DISEASE", 209, 219], ["malformations", "DISEASE", 257, 270], ["uterine", "ORGAN", 82, 89], ["fetal", "ANATOMICAL_SYSTEM", 143, 148], ["malformations", "PATHOLOGICAL_FORMATION", 257, 270], ["fetuses", "ORGAN", 289, 296], ["uterine torsion", "PROBLEM", 82, 97], ["malpositioning or malposture", "PROBLEM", 191, 219], ["malformations", "PROBLEM", 257, 270], ["large fetuses", "PROBLEM", 283, 296], ["uterine", "ANATOMY", 82, 89], ["torsion", "OBSERVATION", 90, 97], ["fetal origin", "OBSERVATION_MODIFIER", 143, 155], ["malpositioning", "OBSERVATION", 191, 205], ["lesser degree", "OBSERVATION_MODIFIER", 230, 243], ["malformations", "OBSERVATION", 257, 270], ["large", "OBSERVATION_MODIFIER", 283, 288], ["fetuses", "OBSERVATION", 289, 296]]], ["The most common fetal causes of dystocia are carpal or shoulder flexure or head deviations (lateral and ventral).", [["fetal", "ANATOMY", 16, 21], ["carpal", "ANATOMY", 45, 51], ["shoulder flexure", "ANATOMY", 55, 71], ["head", "ANATOMY", 75, 79], ["ventral", "ANATOMY", 104, 111], ["dystocia", "DISEASE", 32, 40], ["fetal", "ANATOMICAL_SYSTEM", 16, 21], ["carpal", "MULTI-TISSUE_STRUCTURE", 45, 51], ["head", "ORGANISM_SUBDIVISION", 75, 79], ["dystocia", "PROBLEM", 32, 40], ["carpal or shoulder flexure", "PROBLEM", 45, 71], ["head deviations (lateral and ventral)", "PROBLEM", 75, 112], ["dystocia", "OBSERVATION", 32, 40], ["carpal", "ANATOMY", 45, 51], ["shoulder", "ANATOMY", 55, 63], ["flexure", "ANATOMY_MODIFIER", 64, 71], ["head", "ANATOMY", 75, 79], ["ventral", "ANATOMY_MODIFIER", 104, 111]]], ["Breech and transverse presentations are possible and are common reasons for cesarean section [31, 50] .Obstetrical emergenciesFetal abnormalities causing dystocia include Schistosoma reflexus, contracted tendons, and ankylosis of the hind limbs or neck [7] .", [["Fetal", "ANATOMY", 126, 131], ["tendons", "ANATOMY", 204, 211], ["hind limbs", "ANATOMY", 234, 244], ["neck", "ANATOMY", 248, 252], ["Fetal abnormalities", "DISEASE", 126, 145], ["dystocia", "DISEASE", 154, 162], ["Schistosoma reflexus", "DISEASE", 171, 191], ["ankylosis", "DISEASE", 217, 226], ["Schistosoma", "ORGANISM", 171, 182], ["tendons", "ORGANISM_SUBDIVISION", 204, 211], ["hind limbs", "ORGANISM_SUBDIVISION", 234, 244], ["neck", "ORGANISM_SUBDIVISION", 248, 252], ["Schistosoma reflexus", "SPECIES", 171, 191], ["Schistosoma reflexus", "SPECIES", 171, 191], ["Breech and transverse presentations", "PROBLEM", 0, 35], ["cesarean section", "TREATMENT", 76, 92], ["Obstetrical emergencies", "PROBLEM", 103, 126], ["Fetal abnormalities", "PROBLEM", 126, 145], ["dystocia", "PROBLEM", 154, 162], ["Schistosoma reflexus", "PROBLEM", 171, 191], ["contracted tendons", "PROBLEM", 193, 211], ["ankylosis of the hind limbs or neck", "PROBLEM", 217, 252], ["transverse", "OBSERVATION_MODIFIER", 11, 21], ["Schistosoma reflexus", "OBSERVATION", 171, 191], ["contracted tendons", "OBSERVATION", 193, 211], ["ankylosis", "OBSERVATION", 217, 226], ["hind limbs", "ANATOMY", 234, 244], ["neck", "ANATOMY", 248, 252]]], ["Other anomalies that may complicate delivery include fetal anasarca and an emphysematous fetus resulting from fetal death and gas production during decomposition [31] .Obstetrical emergenciesAlthough twining is rare in camelids, a few twin births have been reported.", [["fetal anasarca", "ANATOMY", 53, 67], ["emphysematous fetus", "ANATOMY", 75, 94], ["fetal", "ANATOMY", 110, 115], ["fetal death", "DISEASE", 110, 121], ["fetal anasarca", "MULTI-TISSUE_STRUCTURE", 53, 67], ["emphysematous fetus", "ORGAN", 75, 94], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 110, 115], ["camelids", "CANCER", 219, 227], ["Other anomalies", "PROBLEM", 0, 15], ["fetal anasarca", "PROBLEM", 53, 67], ["an emphysematous fetus", "PROBLEM", 72, 94], ["fetal death", "PROBLEM", 110, 121], ["gas production", "PROBLEM", 126, 140], ["Obstetrical emergencies", "PROBLEM", 168, 191], ["a few twin births", "PROBLEM", 229, 246], ["anomalies", "OBSERVATION", 6, 15], ["may complicate", "UNCERTAINTY", 21, 35], ["anasarca", "OBSERVATION", 59, 67], ["emphysematous", "OBSERVATION", 75, 88]]], ["Delivery of twins may be complicated by both fetuses in the birth canal at the same time.", [["fetuses", "ANATOMY", 45, 52], ["canal", "ANATOMY", 66, 71], ["fetuses", "ORGANISM", 45, 52], ["canal", "MULTI-TISSUE_STRUCTURE", 66, 71], ["both fetuses in the birth canal", "PROBLEM", 40, 71], ["both", "OBSERVATION_MODIFIER", 40, 44], ["fetuses", "OBSERVATION", 45, 52], ["birth canal", "ANATOMY", 60, 71]]], ["In our experience, all dystocias due to twins required a cesarean section to preserve the integrity of the female reproductive tract [31] .General considerations for obstetrical manipulationsRegarding obstetrical procedures, there are three major differences between camelids and ruminants: (1) the pelvic inlet is narrower; (2) the cervix and vaginal are more prone to laceration and severe inflammation (often leading to adhesions); (3) risks for neonatal hypoxia and death are increased by the forceful uterine and abdominal contractions and the rapid detachment of the microcotyledonary placenta.", [["pelvic inlet", "ANATOMY", 299, 311], ["cervix", "ANATOMY", 333, 339], ["vaginal", "ANATOMY", 344, 351], ["adhesions", "ANATOMY", 423, 432], ["uterine", "ANATOMY", 506, 513], ["abdominal", "ANATOMY", 518, 527], ["microcotyledonary placenta", "ANATOMY", 573, 599], ["dystocias", "DISEASE", 23, 32], ["laceration", "DISEASE", 370, 380], ["inflammation", "DISEASE", 392, 404], ["adhesions", "DISEASE", 423, 432], ["hypoxia", "DISEASE", 458, 465], ["death", "DISEASE", 470, 475], ["female reproductive", "ORGANISM_SUBDIVISION", 107, 126], ["tract", "ORGANISM_SUBDIVISION", 127, 132], ["pelvic inlet", "MULTI-TISSUE_STRUCTURE", 299, 311], ["cervix", "ORGAN", 333, 339], ["vaginal", "ORGANISM_SUBDIVISION", 344, 351], ["uterine", "MULTI-TISSUE_STRUCTURE", 506, 513], ["abdominal", "ORGANISM_SUBDIVISION", 518, 527], ["placenta", "ORGAN", 591, 599], ["all dystocias", "PROBLEM", 19, 32], ["a cesarean section", "TREATMENT", 55, 73], ["obstetrical manipulations", "TREATMENT", 166, 191], ["obstetrical procedures", "TREATMENT", 201, 223], ["laceration", "PROBLEM", 370, 380], ["severe inflammation", "PROBLEM", 385, 404], ["adhesions", "PROBLEM", 423, 432], ["neonatal hypoxia", "PROBLEM", 449, 465], ["death", "PROBLEM", 470, 475], ["the forceful uterine and abdominal contractions", "PROBLEM", 493, 540], ["the rapid detachment of the microcotyledonary placenta", "PROBLEM", 545, 599], ["pelvic", "ANATOMY", 299, 305], ["inlet", "ANATOMY_MODIFIER", 306, 311], ["narrower", "OBSERVATION", 315, 323], ["cervix", "ANATOMY", 333, 339], ["vaginal", "ANATOMY", 344, 351], ["laceration", "OBSERVATION", 370, 380], ["severe", "OBSERVATION_MODIFIER", 385, 391], ["inflammation", "OBSERVATION", 392, 404], ["adhesions", "OBSERVATION", 423, 432], ["hypoxia", "OBSERVATION", 458, 465], ["increased", "OBSERVATION_MODIFIER", 480, 489], ["uterine", "ANATOMY", 506, 513], ["abdominal contractions", "ANATOMY", 518, 540], ["rapid", "OBSERVATION_MODIFIER", 549, 554], ["detachment", "OBSERVATION", 555, 565], ["microcotyledonary placenta", "ANATOMY", 573, 599]]], ["Consequently, (1) early recognition of dystocia is paramount, (2) obstetrical decisions and manipulations should be rapid, and (3) supportive care should be provided to the dam and fetus (if alive) before and during manipulation.General considerations for obstetrical manipulationsDystocia is recognized by prolongation of the first or second stage of labor.", [["fetus", "ANATOMY", 181, 186], ["dystocia", "DISEASE", 39, 47], ["Dystocia", "DISEASE", 281, 289], ["dam", "ORGANISM_SUBDIVISION", 173, 176], ["fetus", "ORGAN", 181, 186], ["dystocia", "PROBLEM", 39, 47], ["supportive care", "TREATMENT", 131, 146], ["obstetrical manipulations", "TREATMENT", 256, 281], ["Dystocia", "PROBLEM", 281, 289], ["labor", "PROBLEM", 352, 357], ["dystocia", "OBSERVATION", 39, 47], ["prolongation", "OBSERVATION_MODIFIER", 307, 319], ["labor", "OBSERVATION", 352, 357]]], ["Assessment of the health of the female and viability of the fetus is the first step in managing obstetrical cases.", [["fetus", "ANATOMY", 60, 65], ["fetus", "ORGAN", 60, 65]]], ["Providing analgesia (epidural and administration of butorphanol) may facilitate examination of the parturient alpaca.", [["epidural", "ANATOMY", 21, 29], ["butorphanol", "CHEMICAL", 52, 63], ["butorphanol", "CHEMICAL", 52, 63], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 21, 29], ["butorphanol", "SIMPLE_CHEMICAL", 52, 63], ["alpaca", "ORGANISM", 110, 116], ["analgesia (epidural", "TREATMENT", 10, 29], ["butorphanol", "TREATMENT", 52, 63], ["examination", "TEST", 80, 91], ["the parturient alpaca", "PROBLEM", 95, 116]]], ["Prolongation of the first stage of parturition is primarily due to failure of cervical relaxation and uterine torsion [50] .General considerations for obstetrical manipulationsExamination of the parturient female is continued by vaginal palpation to judge cervical dilation, determine the presentation, posture and position of the fetus and its viability, and to formulate a course of action based on the findings.", [["cervical", "ANATOMY", 78, 86], ["uterine", "ANATOMY", 102, 109], ["vaginal", "ANATOMY", 229, 236], ["cervical", "ANATOMY", 256, 264], ["fetus", "ANATOMY", 331, 336], ["cervical", "ORGAN", 78, 86], ["uterine", "ORGAN", 102, 109], ["female", "ORGANISM", 206, 212], ["vaginal", "ORGANISM_SUBDIVISION", 229, 236], ["cervical", "ORGAN", 256, 264], ["fetus", "ORGAN", 331, 336], ["failure of cervical relaxation", "PROBLEM", 67, 97], ["uterine torsion", "PROBLEM", 102, 117], ["obstetrical manipulations", "TREATMENT", 151, 176], ["Examination", "TEST", 176, 187], ["vaginal palpation", "TEST", 229, 246], ["cervical dilation", "PROBLEM", 256, 273], ["first stage", "OBSERVATION_MODIFIER", 20, 31], ["parturition", "OBSERVATION", 35, 46], ["primarily due to", "UNCERTAINTY", 50, 66], ["failure", "OBSERVATION", 67, 74], ["cervical", "ANATOMY", 78, 86], ["relaxation", "OBSERVATION", 87, 97], ["uterine", "ANATOMY", 102, 109], ["torsion", "OBSERVATION", 110, 117], ["cervical", "ANATOMY", 256, 264], ["dilation", "OBSERVATION", 265, 273]]], ["Abdominal radiography may be helpful in determining position, posture and number of fetuses in alpacas [31, 50] .General considerations for obstetrical manipulationsFetal manipulations are similar to other species, but need to be restricted to a maximum of 15-20 min.", [["Abdominal", "ANATOMY", 0, 9], ["fetuses", "ANATOMY", 84, 91], ["Fetal", "ANATOMY", 165, 170], ["fetuses", "DEVELOPING_ANATOMICAL_STRUCTURE", 84, 91], ["Fetal", "ORGAN", 165, 170], ["Abdominal radiography", "TEST", 0, 21], ["obstetrical manipulations", "TREATMENT", 140, 165], ["Fetal manipulations", "PROBLEM", 165, 184]]], ["A different approach should be attempted if fetal position, presentation, and posture suggest that manipulation is not possible, or if manipulations are not fruitful after 15 min.", [["fetal", "ANATOMY", 44, 49], ["fetal", "ANATOMICAL_SYSTEM", 44, 49], ["A different approach", "TREATMENT", 0, 20]]], ["We consider that fetotomy is not an option in alpacas and most llamas and camels.", [["alpacas", "ORGANISM", 46, 53], ["llamas", "ORGANISM", 63, 69], ["camels", "ORGANISM_SUBDIVISION", 74, 80], ["fetotomy", "TREATMENT", 17, 25]]], ["Surgical relief of dystocia (cesarean section) remains the best approach if controlled vaginal delivery cannot be achieved in <20 min.", [["vaginal", "ANATOMY", 87, 94], ["dystocia", "DISEASE", 19, 27], ["vaginal", "ORGANISM_SUBDIVISION", 87, 94], ["Surgical relief", "TREATMENT", 0, 15], ["dystocia", "PROBLEM", 19, 27], ["cesarean section", "TREATMENT", 29, 45], ["vaginal delivery", "TREATMENT", 87, 103], ["relief", "OBSERVATION_MODIFIER", 9, 15], ["dystocia", "OBSERVATION", 19, 27]]], ["Techniques for cesarean delivery in camelids are well described [41, 51] .", [["cesarean delivery", "TREATMENT", 15, 32]]], ["We recommend a flank approach in camels and any severely compromised dam.", [["flank", "ORGANISM_SUBDIVISION", 15, 20], ["dam", "ORGANISM_SUBDIVISION", 69, 72], ["a flank approach", "TREATMENT", 13, 29], ["any severely compromised dam", "PROBLEM", 44, 72], ["flank", "ANATOMY", 15, 20], ["compromised", "OBSERVATION", 57, 68]]], ["This technique does not require deep general anesthesia and can be performed under sedation and a regional block, which is a good choice under field conditions.", [["deep general anesthesia", "TREATMENT", 32, 55], ["sedation", "TREATMENT", 83, 91], ["a regional block", "PROBLEM", 96, 112]]], ["A midline celiotomy approach is ideal if the uterus is compromised or needs to be completely exteriorized [41, 51] .General considerations for obstetrical manipulationsRegardless of the type of obstetrical intervention, adequate oxygen delivery to the uterus is essential for a healthy neonate.", [["uterus", "ANATOMY", 45, 51], ["uterus", "ANATOMY", 252, 258], ["oxygen", "CHEMICAL", 229, 235], ["oxygen", "CHEMICAL", 229, 235], ["uterus", "ORGAN", 45, 51], ["oxygen", "SIMPLE_CHEMICAL", 229, 235], ["uterus", "ORGAN", 252, 258], ["neonate", "ORGANISM", 286, 293], ["A midline celiotomy approach", "TREATMENT", 0, 28], ["obstetrical manipulations", "TREATMENT", 143, 168], ["obstetrical intervention", "TREATMENT", 194, 218], ["adequate oxygen delivery", "TREATMENT", 220, 244], ["midline", "OBSERVATION_MODIFIER", 2, 9], ["celiotomy", "OBSERVATION", 10, 19], ["uterus", "ANATOMY", 45, 51], ["compromised", "OBSERVATION", 55, 66], ["uterus", "ANATOMY", 252, 258]]], ["Reducing uterine blood flow or oxygen-carrying capacity of the blood is liable to harm the fetus and may increase fetal or neonatal mortality.", [["uterine", "ANATOMY", 9, 16], ["blood", "ANATOMY", 17, 22], ["blood", "ANATOMY", 63, 68], ["fetus", "ANATOMY", 91, 96], ["fetal", "ANATOMY", 114, 119], ["oxygen", "CHEMICAL", 31, 37], ["oxygen", "CHEMICAL", 31, 37], ["uterine blood", "MULTI-TISSUE_STRUCTURE", 9, 22], ["oxygen", "SIMPLE_CHEMICAL", 31, 37], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["fetus", "ORGAN", 91, 96], ["fetal", "ANATOMICAL_SYSTEM", 114, 119], ["uterine blood flow", "TEST", 9, 27], ["increase fetal or neonatal mortality", "PROBLEM", 105, 141], ["uterine", "ANATOMY", 9, 16], ["flow", "OBSERVATION_MODIFIER", 23, 27], ["oxygen", "OBSERVATION_MODIFIER", 31, 37], ["capacity", "OBSERVATION_MODIFIER", 47, 55]]], ["In most species, uterine blood flow is reduced when the dam is exposed to pain or stressful conditions.", [["uterine blood", "ANATOMY", 17, 30], ["pain", "DISEASE", 74, 78], ["uterine blood", "MULTI-TISSUE_STRUCTURE", 17, 30], ["uterine blood flow", "TEST", 17, 35], ["pain", "PROBLEM", 74, 78], ["stressful conditions", "PROBLEM", 82, 102], ["most", "OBSERVATION_MODIFIER", 3, 7], ["species", "OBSERVATION", 8, 15], ["uterine", "ANATOMY", 17, 24], ["blood flow", "OBSERVATION", 25, 35], ["reduced", "OBSERVATION_MODIFIER", 39, 46]]], ["Sedatives, analgesics, and anesthetics may all supress cardiac output and therefore decrease blood flow to the fetus.", [["cardiac", "ANATOMY", 55, 62], ["blood", "ANATOMY", 93, 98], ["fetus", "ANATOMY", 111, 116], ["Sedatives", "DISEASE", 0, 9], ["cardiac", "ORGAN", 55, 62], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["fetus", "ORGAN", 111, 116], ["Sedatives", "TREATMENT", 0, 9], ["analgesics", "TREATMENT", 11, 21], ["anesthetics", "TREATMENT", 27, 38], ["cardiac output", "TEST", 55, 69], ["blood flow", "TEST", 93, 103], ["fetus", "ANATOMY", 111, 116]]], ["In addition, certain drugs or drug combinations may further decrease uteroplacental perfusion, due to their tonic effect on the myometrium.", [["uteroplacental", "ANATOMY", 69, 83], ["myometrium", "ANATOMY", 128, 138], ["uteroplacental", "MULTI-TISSUE_STRUCTURE", 69, 83], ["myometrium", "MULTI-TISSUE_STRUCTURE", 128, 138], ["certain drugs", "TREATMENT", 13, 26], ["drug combinations", "TREATMENT", 30, 47], ["uteroplacental perfusion", "TREATMENT", 69, 93], ["their tonic effect on the myometrium", "PROBLEM", 102, 138], ["uteroplacental perfusion", "OBSERVATION", 69, 93], ["tonic effect", "OBSERVATION", 108, 120], ["myometrium", "ANATOMY", 128, 138]]], ["Unfortunately, there are no studies on the effects of anesthetics on the uterus and fetus in camelid.General considerations for obstetrical manipulationsXylazine, a drug of choice for sedation of camelids in the field, markedly reduced blood flow (by as much as 59%) and availability of oxygen to the uterus.", [["uterus", "ANATOMY", 73, 79], ["fetus", "ANATOMY", 84, 89], ["blood", "ANATOMY", 236, 241], ["uterus", "ANATOMY", 301, 307], ["Xylazine", "CHEMICAL", 153, 161], ["oxygen", "CHEMICAL", 287, 293], ["Xylazine", "CHEMICAL", 153, 161], ["oxygen", "CHEMICAL", 287, 293], ["uterus", "ORGAN", 73, 79], ["fetus", "ORGAN", 84, 89], ["Xylazine", "SIMPLE_CHEMICAL", 153, 161], ["blood", "ORGANISM_SUBSTANCE", 236, 241], ["oxygen", "SIMPLE_CHEMICAL", 287, 293], ["uterus", "ORGAN", 301, 307], ["anesthetics", "TREATMENT", 54, 65], ["fetus in camelid", "PROBLEM", 84, 100], ["obstetrical manipulations", "TREATMENT", 128, 153], ["Xylazine", "TREATMENT", 153, 161], ["sedation of camelids", "TREATMENT", 184, 204], ["markedly reduced blood flow", "PROBLEM", 219, 246], ["uterus", "ANATOMY", 73, 79], ["markedly", "OBSERVATION_MODIFIER", 219, 227], ["reduced", "OBSERVATION_MODIFIER", 228, 235], ["blood flow", "OBSERVATION", 236, 246], ["uterus", "ANATOMY", 301, 307]]], ["Furthermore, 5 min after xylazine treatment, uterine artery resistance increased by 165%.", [["uterine artery", "ANATOMY", 45, 59], ["xylazine", "CHEMICAL", 25, 33], ["xylazine", "CHEMICAL", 25, 33], ["xylazine", "SIMPLE_CHEMICAL", 25, 33], ["uterine artery", "MULTI-TISSUE_STRUCTURE", 45, 59], ["xylazine treatment", "TREATMENT", 25, 43], ["uterine artery resistance", "TREATMENT", 45, 70], ["uterine artery", "ANATOMY", 45, 59], ["resistance", "OBSERVATION", 60, 70]]], ["Xylazine has also been associated with increased myometrial contraction in ruminants and could cause increase fetal morbidity and mortality, at least in these species [52, 53] .", [["myometrial", "ANATOMY", 49, 59], ["fetal", "ANATOMY", 110, 115], ["Xylazine", "CHEMICAL", 0, 8], ["Xylazine", "CHEMICAL", 0, 8], ["Xylazine", "SIMPLE_CHEMICAL", 0, 8], ["myometrial", "MULTI-TISSUE_STRUCTURE", 49, 59], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 110, 115], ["Xylazine", "TREATMENT", 0, 8], ["increased myometrial contraction", "PROBLEM", 39, 71], ["increase fetal morbidity", "PROBLEM", 101, 125], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["myometrial contraction", "OBSERVATION", 49, 71], ["increase", "OBSERVATION_MODIFIER", 101, 109], ["fetal morbidity", "OBSERVATION", 110, 125]]], ["This effect was not significant in mares.", [["mares", "ORGANISM_SUBDIVISION", 35, 40], ["not", "UNCERTAINTY", 16, 19], ["significant", "OBSERVATION_MODIFIER", 20, 31]]], ["There are no studies on the effect of xylazine on uterine perfusion in camelids.General considerations for obstetrical manipulationsIn sheep, the fetus responds to hypoxia, hypotension and hypovolumia with increased concentrations of ACTH, vasopressin and cortisol, via activation of the hypothalamic-pituitary axis, mediated by changes in afferent neural activity of arterial baroreceptors and chemoreceptors; it has been suggested that the fetal response is primarily mediated through chemoreceptors [54] .", [["uterine", "ANATOMY", 50, 57], ["fetus", "ANATOMY", 146, 151], ["afferent neural", "ANATOMY", 340, 355], ["arterial baroreceptors", "ANATOMY", 368, 390], ["fetal", "ANATOMY", 442, 447], ["xylazine", "CHEMICAL", 38, 46], ["hypoxia", "DISEASE", 164, 171], ["hypotension", "DISEASE", 173, 184], ["hypovolumia", "DISEASE", 189, 200], ["vasopressin", "CHEMICAL", 240, 251], ["cortisol", "CHEMICAL", 256, 264], ["xylazine", "CHEMICAL", 38, 46], ["vasopressin", "CHEMICAL", 240, 251], ["cortisol", "CHEMICAL", 256, 264], ["xylazine", "SIMPLE_CHEMICAL", 38, 46], ["uterine", "ORGAN", 50, 57], ["sheep", "ORGANISM", 135, 140], ["fetus", "ORGANISM", 146, 151], ["ACTH", "GENE_OR_GENE_PRODUCT", 234, 238], ["vasopressin", "GENE_OR_GENE_PRODUCT", 240, 251], ["cortisol", "GENE_OR_GENE_PRODUCT", 256, 264], ["pituitary", "ORGAN", 301, 310], ["arterial baroreceptors", "MULTI-TISSUE_STRUCTURE", 368, 390], ["fetal", "ANATOMICAL_SYSTEM", 442, 447], ["sheep", "SPECIES", 135, 140], ["sheep", "SPECIES", 135, 140], ["xylazine", "TREATMENT", 38, 46], ["uterine perfusion in camelids", "TREATMENT", 50, 79], ["obstetrical manipulations", "TREATMENT", 107, 132], ["hypoxia", "PROBLEM", 164, 171], ["hypotension", "PROBLEM", 173, 184], ["hypovolumia", "PROBLEM", 189, 200], ["increased concentrations of ACTH", "PROBLEM", 206, 238], ["vasopressin", "TREATMENT", 240, 251], ["cortisol", "TEST", 256, 264], ["the hypothalamic-pituitary axis", "PROBLEM", 284, 315], ["the fetal response", "PROBLEM", 438, 456], ["no", "UNCERTAINTY", 10, 12], ["uterine", "ANATOMY", 50, 57], ["hypoxia", "OBSERVATION", 164, 171], ["hypotension", "OBSERVATION", 173, 184], ["pituitary axis", "ANATOMY", 301, 315], ["afferent neural activity", "OBSERVATION", 340, 364], ["arterial baroreceptors", "ANATOMY", 368, 390]]], ["Ketamine, a dissociative anesthetic and known noncompetitive inhibitor of glutamatergic N-methyl-Daspartate (NMDA) receptors, blocks the fetal reflex bradycardic response to maternal ventilatory hypoxia and may not be a good choice for anesthesia.", [["fetal", "ANATOMY", 137, 142], ["Ketamine", "CHEMICAL", 0, 8], ["N-methyl-Daspartate", "CHEMICAL", 88, 107], ["NMDA", "CHEMICAL", 109, 113], ["hypoxia", "DISEASE", 195, 202], ["Ketamine", "CHEMICAL", 0, 8], ["N-methyl-Daspartate", "CHEMICAL", 88, 107], ["NMDA", "CHEMICAL", 109, 113], ["Ketamine", "SIMPLE_CHEMICAL", 0, 8], ["glutamatergic N-methyl-Daspartate", "SIMPLE_CHEMICAL", 74, 107], ["NMDA", "SIMPLE_CHEMICAL", 109, 113], ["fetal", "ANATOMICAL_SYSTEM", 137, 142], ["glutamatergic N-methyl-Daspartate (NMDA) receptors", "PROTEIN", 74, 124], ["Ketamine", "TREATMENT", 0, 8], ["a dissociative anesthetic", "TREATMENT", 10, 35], ["known noncompetitive inhibitor", "TREATMENT", 40, 70], ["glutamatergic N", "TREATMENT", 74, 89], ["methyl-Daspartate (NMDA) receptors", "TREATMENT", 90, 124], ["the fetal reflex", "TEST", 133, 149], ["maternal ventilatory hypoxia", "PROBLEM", 174, 202], ["anesthesia", "TREATMENT", 236, 246], ["ventilatory hypoxia", "OBSERVATION", 183, 202]]], ["This corroborates our observations in camelids where use of ketamine as a preanesthesic has been associated with severely depressed neonates.General considerations for obstetrical manipulationsPropofol (2,6-di-isopylphenol compound) is a small molecule that is rapidly metabolized; its advantages are rapid onset and offset of action and redistribution from the central nervous system.", [["central nervous system", "ANATOMY", 362, 384], ["ketamine", "CHEMICAL", 60, 68], ["depressed", "DISEASE", 122, 131], ["Propofol", "CHEMICAL", 193, 201], ["2,6-di-isopylphenol", "CHEMICAL", 203, 222], ["ketamine", "CHEMICAL", 60, 68], ["Propofol", "CHEMICAL", 193, 201], ["2,6-di-isopylphenol", "CHEMICAL", 203, 222], ["ketamine", "SIMPLE_CHEMICAL", 60, 68], ["neonates", "ORGANISM", 132, 140], ["Propofol", "SIMPLE_CHEMICAL", 193, 201], ["2,6-di-isopylphenol compound", "SIMPLE_CHEMICAL", 203, 231], ["central nervous system", "ANATOMICAL_SYSTEM", 362, 384], ["ketamine", "TREATMENT", 60, 68], ["severely depressed neonates", "PROBLEM", 113, 140], ["obstetrical manipulations", "TREATMENT", 168, 193], ["Propofol", "TREATMENT", 193, 201], ["di-isopylphenol compound", "TREATMENT", 207, 231], ["a small molecule", "PROBLEM", 236, 252], ["redistribution from the central nervous system", "PROBLEM", 338, 384], ["small molecule", "OBSERVATION", 238, 252], ["redistribution", "OBSERVATION_MODIFIER", 338, 352], ["central", "ANATOMY_MODIFIER", 362, 369], ["nervous system", "ANATOMY", 370, 384]]], ["Even with continuous propofol anesthesia, maternal and fetal heart rate and blood pressure were not affected in pregnant ewes [55] .", [["fetal", "ANATOMY", 55, 60], ["heart", "ANATOMY", 61, 66], ["blood", "ANATOMY", 76, 81], ["propofol", "CHEMICAL", 21, 29], ["propofol", "CHEMICAL", 21, 29], ["propofol", "SIMPLE_CHEMICAL", 21, 29], ["fetal", "MULTI-TISSUE_STRUCTURE", 55, 60], ["heart", "ORGAN", 61, 66], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["continuous propofol anesthesia", "TREATMENT", 10, 40], ["maternal and fetal heart rate", "TEST", 42, 71], ["blood pressure", "TEST", 76, 90], ["heart", "ANATOMY", 61, 66]]], ["This makes the drug ideal for induction of anesthesia for cesarean section or for surgical management of uterine torsion.", [["uterine", "ANATOMY", 105, 112], ["uterine torsion", "DISEASE", 105, 120], ["uterine", "ORGAN", 105, 112], ["induction of anesthesia", "TREATMENT", 30, 53], ["cesarean section", "TREATMENT", 58, 74], ["surgical management", "TREATMENT", 82, 101], ["uterine torsion", "PROBLEM", 105, 120], ["uterine", "ANATOMY", 105, 112], ["torsion", "OBSERVATION", 113, 120]]], ["Propofol decreased myometrial activity in the gravid ovine uterus in vivo [56] and in uterine muscle from gravid humans in vitro [57] .", [["myometrial", "ANATOMY", 19, 29], ["uterus", "ANATOMY", 59, 65], ["uterine muscle", "ANATOMY", 86, 100], ["Propofol", "CHEMICAL", 0, 8], ["Propofol", "CHEMICAL", 0, 8], ["Propofol", "SIMPLE_CHEMICAL", 0, 8], ["myometrial", "MULTI-TISSUE_STRUCTURE", 19, 29], ["ovine uterus", "ORGAN", 53, 65], ["uterine muscle", "TISSUE", 86, 100], ["humans", "ORGANISM", 113, 119], ["humans", "SPECIES", 113, 119], ["humans", "SPECIES", 113, 119], ["Propofol", "TREATMENT", 0, 8], ["myometrial activity", "PROBLEM", 19, 38], ["the gravid ovine uterus", "TREATMENT", 42, 65], ["uterus", "ANATOMY", 59, 65], ["uterine muscle", "ANATOMY", 86, 100]]], ["In vivo, there is no effect on placental perfusion.", [["placental", "ANATOMY", 31, 40], ["placental", "ORGAN", 31, 40], ["effect on placental perfusion", "PROBLEM", 21, 50], ["no", "UNCERTAINTY", 18, 20], ["effect", "OBSERVATION_MODIFIER", 21, 27], ["placental", "ANATOMY", 31, 40], ["perfusion", "OBSERVATION", 41, 50]]], ["It can induce a transient tachycardia and decrease in PO2 and pH in the dam, but these effects have minimal repercussions on fetal heart rate and blood pressure.", [["fetal", "ANATOMY", 125, 130], ["heart", "ANATOMY", 131, 136], ["blood", "ANATOMY", 146, 151], ["tachycardia", "DISEASE", 26, 37], ["PO2", "CHEMICAL", 54, 57], ["PO2", "SIMPLE_CHEMICAL", 54, 57], ["fetal", "MULTI-TISSUE_STRUCTURE", 125, 130], ["heart", "ORGAN", 131, 136], ["blood", "ORGANISM_SUBSTANCE", 146, 151], ["a transient tachycardia", "PROBLEM", 14, 37], ["PO2", "TEST", 54, 57], ["pH", "TEST", 62, 64], ["fetal heart rate", "TEST", 125, 141], ["blood pressure", "TEST", 146, 160], ["transient", "OBSERVATION_MODIFIER", 16, 25], ["tachycardia", "OBSERVATION", 26, 37], ["decrease", "OBSERVATION_MODIFIER", 42, 50], ["minimal", "OBSERVATION_MODIFIER", 100, 107], ["heart", "ANATOMY", 131, 136]]], ["Because propofol is primarily metabolized by the liver, it should be used with caution in females with hepatic lipidosis.", [["liver", "ANATOMY", 49, 54], ["hepatic", "ANATOMY", 103, 110], ["propofol", "CHEMICAL", 8, 16], ["hepatic lipidosis", "DISEASE", 103, 120], ["propofol", "CHEMICAL", 8, 16], ["propofol", "SIMPLE_CHEMICAL", 8, 16], ["liver", "ORGAN", 49, 54], ["hepatic", "ORGAN", 103, 110], ["propofol", "TREATMENT", 8, 16], ["hepatic lipidosis", "PROBLEM", 103, 120], ["liver", "ANATOMY", 49, 54], ["hepatic", "ANATOMY", 103, 110], ["lipidosis", "OBSERVATION", 111, 120]]], ["Maintenance of general anesthesia with isoflurane or sevoflurane are ideal, because these inhalation anesthetics are rapidly eliminated [56] .", [["isoflurane", "CHEMICAL", 39, 49], ["sevoflurane", "CHEMICAL", 53, 64], ["isoflurane", "CHEMICAL", 39, 49], ["sevoflurane", "CHEMICAL", 53, 64], ["isoflurane", "SIMPLE_CHEMICAL", 39, 49], ["sevoflurane", "SIMPLE_CHEMICAL", 53, 64], ["general anesthesia", "TREATMENT", 15, 33], ["isoflurane", "TREATMENT", 39, 49], ["sevoflurane", "TREATMENT", 53, 64], ["these inhalation anesthetics", "TREATMENT", 84, 112]]], ["The combination propofol/isoflurane has been used successfully by our group in emergency cesarean section in camelids; a similar combination was also very good for cesarean section in the bitch [60, 61] .", [["propofol", "CHEMICAL", 16, 24], ["isoflurane", "CHEMICAL", 25, 35], ["propofol", "CHEMICAL", 16, 24], ["isoflurane", "CHEMICAL", 25, 35], ["propofol", "SIMPLE_CHEMICAL", 16, 24], ["isoflurane", "SIMPLE_CHEMICAL", 25, 35], ["The combination propofol", "TREATMENT", 0, 24], ["isoflurane", "TREATMENT", 25, 35], ["emergency cesarean section", "TREATMENT", 79, 105], ["cesarean section", "TREATMENT", 164, 180]]], ["It is noteworthy that the effects of these anesthetics may be exacerbated by pre-existing conditions in the fetus (e.g. hypoxia) [56, 58, 59] .Postpartum emergenciesPostpartum emergencies are often due to complications of obstetrical situations.", [["fetus", "ANATOMY", 108, 113], ["hypoxia", "DISEASE", 120, 127], ["fetus", "ORGAN", 108, 113], ["these anesthetics", "TREATMENT", 37, 54], ["pre-existing conditions in the fetus", "PROBLEM", 77, 113], ["hypoxia", "PROBLEM", 120, 127], ["Postpartum emergencies", "PROBLEM", 143, 165], ["complications of obstetrical situations", "PROBLEM", 205, 244], ["fetus", "ANATOMY", 108, 113]]], ["However, females may present for emergency critical care with a history of what appears to have been an uncomplicated parturition.", [["an uncomplicated parturition", "PROBLEM", 101, 129], ["uncomplicated", "OBSERVATION_MODIFIER", 104, 117], ["parturition", "OBSERVATION", 118, 129]]], ["In addition to the primary genital problems that may alarm the owner (i.e. traumatic injuries, bleeding, uterine prolapse, and retained placenta) some of these cases present with ataxia, prolonged recumbency, and varying degrees of anorexia or depression as primary complaint.", [["genital", "ANATOMY", 27, 34], ["uterine", "ANATOMY", 105, 112], ["placenta", "ANATOMY", 136, 144], ["traumatic injuries", "DISEASE", 75, 93], ["bleeding", "DISEASE", 95, 103], ["uterine prolapse", "DISEASE", 105, 121], ["ataxia", "DISEASE", 179, 185], ["anorexia", "DISEASE", 232, 240], ["depression", "DISEASE", 244, 254], ["genital", "ORGANISM_SUBDIVISION", 27, 34], ["uterine", "ORGANISM_SUBDIVISION", 105, 112], ["placenta", "ORGAN", 136, 144], ["the primary genital problems", "PROBLEM", 15, 43], ["traumatic injuries", "PROBLEM", 75, 93], ["bleeding", "PROBLEM", 95, 103], ["uterine prolapse", "PROBLEM", 105, 121], ["retained placenta", "PROBLEM", 127, 144], ["ataxia", "PROBLEM", 179, 185], ["prolonged recumbency", "PROBLEM", 187, 207], ["anorexia", "PROBLEM", 232, 240], ["depression", "PROBLEM", 244, 254], ["traumatic", "OBSERVATION_MODIFIER", 75, 84], ["injuries", "OBSERVATION", 85, 93], ["uterine", "ANATOMY", 105, 112], ["prolapse", "OBSERVATION", 113, 121], ["placenta", "ANATOMY", 136, 144], ["varying degrees", "OBSERVATION_MODIFIER", 213, 228], ["anorexia", "OBSERVATION", 232, 240]]], ["Evaluation of the postpartum female should include a complete history and a detailed account of the obstetrical situation, including delivery of the placenta.", [["placenta", "ANATOMY", 149, 157], ["placenta", "ORGAN", 149, 157], ["Evaluation", "TEST", 0, 10], ["the obstetrical situation", "PROBLEM", 96, 121], ["delivery", "TREATMENT", 133, 141], ["placenta", "ANATOMY", 149, 157]]], ["The female should be assessed by complete physical examination, CBC, blood chemistry, transabdominal and transrectal ultrasonography, and vaginal examination.", [["blood", "ANATOMY", 69, 74], ["transabdominal", "ANATOMY", 86, 100], ["transrectal", "ANATOMY", 105, 116], ["vaginal", "ANATOMY", 138, 145], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["transabdominal", "MULTI-TISSUE_STRUCTURE", 86, 100], ["transrectal", "MULTI-TISSUE_STRUCTURE", 105, 116], ["vaginal", "ORGANISM_SUBDIVISION", 138, 145], ["complete physical examination", "TEST", 33, 62], ["CBC", "TEST", 64, 67], ["blood chemistry", "TEST", 69, 84], ["transabdominal and transrectal ultrasonography", "TEST", 86, 132], ["vaginal examination", "TEST", 138, 157], ["vaginal", "ANATOMY", 138, 145]]], ["Excessive fluid in the abdomen would warrant abdominocentesis.Rectal-vaginal tearDue to their small perineal body and powerful expulsive efforts, rectal-vaginal tear is common following overt obstetrical manipulations in camelids.", [["fluid", "ANATOMY", 10, 15], ["abdomen", "ANATOMY", 23, 30], ["Rectal", "ANATOMY", 62, 68], ["vaginal", "ANATOMY", 69, 76], ["perineal body", "ANATOMY", 100, 113], ["rectal", "ANATOMY", 146, 152], ["vaginal", "ANATOMY", 153, 160], ["rectal-vaginal tear", "DISEASE", 146, 165], ["fluid", "ORGANISM_SUBSTANCE", 10, 15], ["abdomen", "ORGAN", 23, 30], ["Rectal", "ORGAN", 62, 68], ["perineal body", "ORGANISM_SUBDIVISION", 100, 113], ["rectal", "ORGANISM_SUBDIVISION", 146, 152], ["vaginal", "ORGANISM_SUBDIVISION", 153, 160], ["Excessive fluid in the abdomen", "PROBLEM", 0, 30], ["abdominocentesis", "TREATMENT", 45, 61], ["rectal-vaginal tear", "PROBLEM", 146, 165], ["overt obstetrical manipulations in camelids", "PROBLEM", 186, 229], ["fluid", "OBSERVATION", 10, 15], ["abdomen", "ANATOMY", 23, 30], ["vaginal", "ANATOMY", 69, 76], ["tearDue", "OBSERVATION", 77, 84], ["small", "OBSERVATION_MODIFIER", 94, 99], ["perineal body", "ANATOMY", 100, 113], ["powerful", "OBSERVATION_MODIFIER", 118, 126], ["expulsive", "OBSERVATION", 127, 136], ["rectal", "ANATOMY", 146, 152], ["vaginal", "ANATOMY", 153, 160], ["tear", "OBSERVATION", 161, 165]]], ["A common cause of these tears is rapid vaginal delivery of the fetus without sufficient preparation of the vulva and vestibular area.", [["vaginal", "ANATOMY", 39, 46], ["fetus", "ANATOMY", 63, 68], ["vulva", "ANATOMY", 107, 112], ["vestibular area", "ANATOMY", 117, 132], ["tears", "DISEASE", 24, 29], ["vaginal", "ORGANISM_SUBDIVISION", 39, 46], ["fetus", "ORGAN", 63, 68], ["vulva", "ORGAN", 107, 112], ["vestibular area", "MULTI-TISSUE_STRUCTURE", 117, 132], ["these tears", "PROBLEM", 18, 29], ["rapid vaginal delivery", "TREATMENT", 33, 55], ["tears", "OBSERVATION", 24, 29], ["fetus", "ANATOMY", 63, 68], ["vulva", "ANATOMY", 107, 112], ["vestibular", "ANATOMY", 117, 127], ["area", "ANATOMY_MODIFIER", 128, 132]]], ["Episiotomy should be considered in females with insufficient dilation of the vulva, particularly maidens.", [["vulva", "ANATOMY", 77, 82], ["Episiotomy", "DISEASE", 0, 10], ["dilation of the vulva", "DISEASE", 61, 82], ["vulva", "ORGAN", 77, 82], ["Episiotomy", "TREATMENT", 0, 10], ["insufficient dilation of the vulva", "PROBLEM", 48, 82], ["dilation", "OBSERVATION", 61, 69], ["vulva", "ANATOMY", 77, 82]]], ["Cases seen in our practice are often a complication of fetotomy.", [["a complication of fetotomy", "PROBLEM", 37, 63], ["fetotomy", "OBSERVATION", 55, 63]]], ["Rectal-vaginal tears may be repaired immediately, or a few weeks later, after second-intention healing [41] .Uterine bruising and tearPostpartum uterine tears are not as dramatic as in the mare, unless there is involvement of a large vessel or severe contamination of the uterus and peritonitis.", [["Rectal", "ANATOMY", 0, 6], ["vaginal", "ANATOMY", 7, 14], ["Uterine", "ANATOMY", 109, 116], ["uterine", "ANATOMY", 145, 152], ["vessel", "ANATOMY", 234, 240], ["uterus", "ANATOMY", 272, 278], ["Uterine bruising", "DISEASE", 109, 125], ["uterine tears", "DISEASE", 145, 158], ["contamination of the uterus", "DISEASE", 251, 278], ["peritonitis", "DISEASE", 283, 294], ["Rectal", "ORGAN", 0, 6], ["Uterine", "ORGAN", 109, 116], ["uterine tears", "PATHOLOGICAL_FORMATION", 145, 158], ["vessel", "MULTI-TISSUE_STRUCTURE", 234, 240], ["uterus", "ORGAN", 272, 278], ["vaginal tears", "PROBLEM", 7, 20], ["Uterine bruising", "PROBLEM", 109, 125], ["tearPostpartum uterine tears", "PROBLEM", 130, 158], ["a large vessel", "PROBLEM", 226, 240], ["severe contamination of the uterus", "PROBLEM", 244, 278], ["peritonitis", "PROBLEM", 283, 294], ["vaginal", "ANATOMY", 7, 14], ["tears", "OBSERVATION", 15, 20], ["bruising", "OBSERVATION", 117, 125], ["uterine", "ANATOMY", 145, 152], ["tears", "OBSERVATION", 153, 158], ["dramatic", "OBSERVATION_MODIFIER", 170, 178], ["large", "OBSERVATION_MODIFIER", 228, 233], ["vessel", "ANATOMY", 234, 240], ["severe", "OBSERVATION_MODIFIER", 244, 250], ["contamination", "OBSERVATION", 251, 264], ["uterus", "ANATOMY", 272, 278], ["peritonitis", "OBSERVATION", 283, 294]]], ["Uterine bruising is often seen following excessive obstetrical manipulation (particularly fetotomy).", [["Uterine", "ANATOMY", 0, 7], ["Uterine bruising", "DISEASE", 0, 16], ["Uterine", "ORGAN", 0, 7], ["Uterine bruising", "PROBLEM", 0, 16], ["excessive obstetrical manipulation", "TREATMENT", 41, 75], ["bruising", "OBSERVATION", 8, 16]]], ["Uterine involution is very rapid in the camelid and small, dorsal uterine tears may heal spontaneously; the only sequela may be infertility due to peri-uterine adhesions.", [["Uterine", "ANATOMY", 0, 7], ["camelid", "ANATOMY", 40, 47], ["dorsal uterine tears", "ANATOMY", 59, 79], ["peri-uterine adhesions", "ANATOMY", 147, 169], ["Uterine involution", "DISEASE", 0, 18], ["uterine tears", "DISEASE", 66, 79], ["infertility", "DISEASE", 128, 139], ["Uterine", "ORGAN", 0, 7], ["camelid", "CANCER", 40, 47], ["uterine tears", "TISSUE", 66, 79], ["Uterine involution", "PROBLEM", 0, 18], ["small, dorsal uterine tears", "PROBLEM", 52, 79], ["infertility", "PROBLEM", 128, 139], ["peri-uterine adhesions", "PROBLEM", 147, 169], ["involution", "OBSERVATION", 8, 18], ["very", "OBSERVATION_MODIFIER", 22, 26], ["rapid", "OBSERVATION_MODIFIER", 27, 32], ["small", "OBSERVATION_MODIFIER", 52, 57], ["dorsal", "ANATOMY_MODIFIER", 59, 65], ["uterine", "ANATOMY", 66, 73], ["tears", "OBSERVATION", 74, 79], ["may be", "UNCERTAINTY", 121, 127], ["infertility", "OBSERVATION", 128, 139], ["peri-uterine", "OBSERVATION_MODIFIER", 147, 159], ["adhesions", "OBSERVATION", 160, 169]]], ["Complications from uterine tears are often due to severe contamination, either during obstetrical manipulation or following partial or total retention of the placenta [62] .", [["uterine", "ANATOMY", 19, 26], ["placenta", "ANATOMY", 158, 166], ["uterine tears", "DISEASE", 19, 32], ["uterine tears", "PATHOLOGICAL_FORMATION", 19, 32], ["Complications from uterine tears", "PROBLEM", 0, 32], ["severe contamination", "PROBLEM", 50, 70], ["obstetrical manipulation", "TREATMENT", 86, 110], ["uterine", "ANATOMY", 19, 26], ["tears", "OBSERVATION", 27, 32], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["contamination", "OBSERVATION", 57, 70], ["placenta", "ANATOMY", 158, 166]]], ["These females may initially appear comfortable, then slowly develop a fulminating peritonitis.", [["peritonitis", "DISEASE", 82, 93], ["a fulminating peritonitis", "PROBLEM", 68, 93], ["fulminating", "OBSERVATION_MODIFIER", 70, 81], ["peritonitis", "OBSERVATION", 82, 93]]], ["Clinical signs of toxemia may appear within the first 24 h, but it may take as long as 3-4 days for the clinical picture to become recognizable.", [["toxemia", "DISEASE", 18, 25], ["toxemia", "PROBLEM", 18, 25], ["toxemia", "OBSERVATION", 18, 25]]], ["It is important that these cases be stabilized, with antimicrobial and anti-inflammatory therapy initiated at the first sign of compromise.", [["antimicrobial", "TREATMENT", 53, 66], ["anti-inflammatory therapy", "TREATMENT", 71, 96], ["compromise", "OBSERVATION", 128, 138]]], ["Uterine lavage should be considered only after verification of the integrity of the uterine wall and should be monitored by transabdominal ultrasonography to visualize remnants of the placenta.", [["Uterine lavage", "ANATOMY", 0, 14], ["uterine wall", "ANATOMY", 84, 96], ["placenta", "ANATOMY", 184, 192], ["Uterine lavage", "MULTI-TISSUE_STRUCTURE", 0, 14], ["uterine wall", "MULTI-TISSUE_STRUCTURE", 84, 96], ["placenta", "ORGAN", 184, 192], ["Uterine lavage", "TREATMENT", 0, 14], ["transabdominal ultrasonography", "TEST", 124, 154], ["lavage", "OBSERVATION", 8, 14], ["uterine wall", "ANATOMY", 84, 96], ["placenta", "ANATOMY", 184, 192]]], ["A case of complete passage of the placenta into the abdominal cavity was described in a llama with progressive deterioration of health, which eventually succumbed to peritonitis 11 days after dystocia [62] .Uterine bruising and tearIt is not clear how uterine tears occur in camelids; although most are associated with obstetrical manipulation, we have seen cases following spontaneous and apparently uneventful parturition.", [["placenta", "ANATOMY", 34, 42], ["abdominal cavity", "ANATOMY", 52, 68], ["Uterine", "ANATOMY", 207, 214], ["tear", "ANATOMY", 228, 232], ["uterine tears", "ANATOMY", 252, 265], ["deterioration of health", "DISEASE", 111, 134], ["peritonitis", "DISEASE", 166, 177], ["dystocia", "DISEASE", 192, 200], ["Uterine bruising", "DISEASE", 207, 223], ["uterine tears", "DISEASE", 252, 265], ["placenta", "ORGAN", 34, 42], ["abdominal cavity", "ORGAN", 52, 68], ["Uterine", "ORGAN", 207, 214], ["uterine tears", "MULTI-TISSUE_STRUCTURE", 252, 265], ["complete passage of the placenta into the abdominal cavity", "PROBLEM", 10, 68], ["progressive deterioration of health", "PROBLEM", 99, 134], ["peritonitis", "PROBLEM", 166, 177], ["dystocia", "PROBLEM", 192, 200], ["Uterine bruising", "PROBLEM", 207, 223], ["tear", "PROBLEM", 228, 232], ["uterine tears", "PROBLEM", 252, 265], ["obstetrical manipulation", "TREATMENT", 319, 343], ["passage", "OBSERVATION", 19, 26], ["placenta", "ANATOMY", 34, 42], ["abdominal cavity", "ANATOMY", 52, 68], ["progressive", "OBSERVATION_MODIFIER", 99, 110], ["deterioration", "OBSERVATION", 111, 124], ["peritonitis", "OBSERVATION", 166, 177], ["bruising", "OBSERVATION", 215, 223], ["tear", "OBSERVATION", 228, 232], ["not", "UNCERTAINTY", 238, 241], ["clear", "OBSERVATION", 242, 247], ["uterine", "ANATOMY", 252, 259], ["tears", "OBSERVATION", 260, 265]]], ["Therefore, every female should be monitored to ensure delivery of the placenta, followed by inspection of the placenta to ensure that it is complete.", [["placenta", "ANATOMY", 70, 78], ["placenta", "ANATOMY", 110, 118], ["placenta", "ORGAN", 70, 78], ["placenta", "ORGAN", 110, 118], ["placenta", "ANATOMY", 70, 78]]], ["The camelid placenta is epitheliochorial, mircocotytledonary and is rarely retained more than 36 h, even after dystocia.Uterine bruising and tearIf a uterine tear is detected in the early postpartum period by direct vaginal palpation, an attempt could be made to induce uterine prolapse after treatment with epinephrine and epidural anesthesia.", [["camelid placenta", "ANATOMY", 4, 20], ["Uterine", "ANATOMY", 120, 127], ["tear", "ANATOMY", 141, 145], ["uterine tear", "ANATOMY", 150, 162], ["vaginal", "ANATOMY", 216, 223], ["uterine", "ANATOMY", 270, 277], ["epidural", "ANATOMY", 324, 332], ["dystocia", "DISEASE", 111, 119], ["Uterine bruising", "DISEASE", 120, 136], ["uterine tear", "DISEASE", 150, 162], ["uterine prolapse", "DISEASE", 270, 286], ["epinephrine", "CHEMICAL", 308, 319], ["epinephrine", "CHEMICAL", 308, 319], ["camelid placenta", "TISSUE", 4, 20], ["Uterine", "ORGAN", 120, 127], ["uterine tear", "MULTI-TISSUE_STRUCTURE", 150, 162], ["vaginal", "ORGANISM_SUBDIVISION", 216, 223], ["uterine", "ORGAN", 270, 277], ["epinephrine", "SIMPLE_CHEMICAL", 308, 319], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 324, 332], ["mircocotytledonary", "TREATMENT", 42, 60], ["dystocia", "PROBLEM", 111, 119], ["Uterine bruising", "PROBLEM", 120, 136], ["tear", "PROBLEM", 141, 145], ["a uterine tear", "PROBLEM", 148, 162], ["direct vaginal palpation", "TEST", 209, 233], ["uterine prolapse", "PROBLEM", 270, 286], ["treatment", "TREATMENT", 293, 302], ["epinephrine", "TREATMENT", 308, 319], ["epidural anesthesia", "TREATMENT", 324, 343], ["camelid placenta", "OBSERVATION", 4, 20], ["bruising", "OBSERVATION", 128, 136], ["tear", "OBSERVATION", 141, 145], ["uterine", "ANATOMY", 150, 157], ["tear", "OBSERVATION", 158, 162], ["uterine", "ANATOMY", 270, 277], ["prolapse", "OBSERVATION", 278, 286], ["epidural", "ANATOMY", 324, 332]]], ["Alternately, the uterine tear can be repaired after celiotomy.", [["uterine tear", "ANATOMY", 17, 29], ["uterine tear", "DISEASE", 17, 29], ["uterine tear", "TISSUE", 17, 29], ["the uterine tear", "PROBLEM", 13, 29], ["celiotomy", "TREATMENT", 52, 61], ["uterine", "ANATOMY", 17, 24], ["tear", "OBSERVATION", 25, 29], ["celiotomy", "OBSERVATION", 52, 61]]], ["If the placenta is still present, it should be pealed from the endometrium around the tear before suturing.", [["placenta", "ANATOMY", 7, 15], ["endometrium", "ANATOMY", 63, 74], ["tear", "ANATOMY", 86, 90], ["placenta", "ORGAN", 7, 15], ["endometrium", "MULTI-TISSUE_STRUCTURE", 63, 74], ["tear", "TISSUE", 86, 90], ["suturing", "TREATMENT", 98, 106], ["placenta", "ANATOMY", 7, 15], ["endometrium", "ANATOMY", 63, 74], ["tear", "OBSERVATION", 86, 90]]], ["In cases of unexplained fever, abdominal pain or anorexia in the postpartum female, exploratory celiotomy or laparoscopy should be considered.", [["abdominal", "ANATOMY", 31, 40], ["fever", "DISEASE", 24, 29], ["abdominal pain", "DISEASE", 31, 45], ["anorexia", "DISEASE", 49, 57], ["abdominal", "ORGANISM_SUBDIVISION", 31, 40], ["unexplained fever", "PROBLEM", 12, 29], ["abdominal pain", "PROBLEM", 31, 45], ["anorexia", "PROBLEM", 49, 57], ["exploratory celiotomy", "TEST", 84, 105], ["laparoscopy", "TREATMENT", 109, 120], ["unexplained", "OBSERVATION_MODIFIER", 12, 23], ["fever", "OBSERVATION", 24, 29], ["abdominal", "ANATOMY", 31, 40], ["anorexia", "OBSERVATION", 49, 57], ["celiotomy", "OBSERVATION", 96, 105], ["laparoscopy", "OBSERVATION", 109, 120]]], ["Adjunctive therapy for peritonitis is indicated and should include abdominal lavage and systemic broad-spectrum antimicrobial and anti-inflammatory therapy, along with intravenous fluid therapy for cardiovascular support.Postpartum hemorrhagePostpartum hemorrhage from the uterine arteries is less common in camelids than mares.", [["abdominal lavage", "ANATOMY", 67, 83], ["intravenous", "ANATOMY", 168, 179], ["cardiovascular", "ANATOMY", 198, 212], ["uterine arteries", "ANATOMY", 273, 289], ["peritonitis", "DISEASE", 23, 34], ["hemorrhagePostpartum hemorrhage", "DISEASE", 232, 263], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 168, 179], ["cardiovascular", "ANATOMICAL_SYSTEM", 198, 212], ["uterine arteries", "MULTI-TISSUE_STRUCTURE", 273, 289], ["Adjunctive therapy", "TREATMENT", 0, 18], ["peritonitis", "PROBLEM", 23, 34], ["abdominal lavage", "TREATMENT", 67, 83], ["systemic broad-spectrum antimicrobial", "TREATMENT", 88, 125], ["anti-inflammatory therapy", "TREATMENT", 130, 155], ["intravenous fluid therapy", "TREATMENT", 168, 193], ["cardiovascular support", "TREATMENT", 198, 220], ["Postpartum hemorrhagePostpartum hemorrhage from the uterine arteries", "PROBLEM", 221, 289], ["peritonitis", "OBSERVATION", 23, 34], ["abdominal", "ANATOMY", 67, 76], ["lavage", "OBSERVATION", 77, 83], ["anti-inflammatory therapy", "OBSERVATION", 130, 155], ["hemorrhagePostpartum", "OBSERVATION_MODIFIER", 232, 252], ["hemorrhage", "OBSERVATION", 253, 263], ["uterine arteries", "ANATOMY", 273, 289], ["less", "OBSERVATION_MODIFIER", 293, 297], ["common", "OBSERVATION_MODIFIER", 298, 304]]], ["Most of the postpartum hemorrhage cases diagnosed by our group consist of rupture or laceration of the vaginal uterine artery.", [["vaginal uterine artery", "ANATOMY", 103, 125], ["hemorrhage", "DISEASE", 23, 33], ["rupture", "DISEASE", 74, 81], ["vaginal uterine artery", "MULTI-TISSUE_STRUCTURE", 103, 125], ["the postpartum hemorrhage cases", "PROBLEM", 8, 39], ["rupture", "PROBLEM", 74, 81], ["laceration of the vaginal uterine artery", "PROBLEM", 85, 125], ["hemorrhage", "OBSERVATION", 23, 33], ["rupture", "OBSERVATION", 74, 81], ["laceration", "OBSERVATION", 85, 95], ["vaginal uterine artery", "ANATOMY", 103, 125]]], ["This artery is easily recognized by palpation per vaginum during obstetrical manipulation and is peculiarly large in camelids.", [["artery", "ANATOMY", 5, 11], ["artery", "MULTI-TISSUE_STRUCTURE", 5, 11], ["camelids", "CANCER", 117, 125], ["palpation", "TEST", 36, 45], ["obstetrical manipulation", "TREATMENT", 65, 89], ["peculiarly large in camelids", "PROBLEM", 97, 125], ["artery", "ANATOMY", 5, 11], ["palpation", "OBSERVATION", 36, 45], ["large", "OBSERVATION_MODIFIER", 108, 113]]], ["Excessive manipulation, and in particular fetotomy, may cause erosion of the mucosa and laceration of the artery.", [["mucosa", "ANATOMY", 77, 83], ["artery", "ANATOMY", 106, 112], ["erosion of the mucosa", "DISEASE", 62, 83], ["mucosa", "MULTI-TISSUE_STRUCTURE", 77, 83], ["artery", "MULTI-TISSUE_STRUCTURE", 106, 112], ["Excessive manipulation", "TREATMENT", 0, 22], ["erosion of the mucosa", "PROBLEM", 62, 83], ["laceration of the artery", "PROBLEM", 88, 112], ["manipulation", "OBSERVATION", 10, 22], ["may cause", "UNCERTAINTY", 52, 61], ["erosion", "OBSERVATION", 62, 69], ["mucosa", "ANATOMY", 77, 83], ["laceration", "OBSERVATION", 88, 98], ["artery", "ANATOMY", 106, 112]]], ["Unfortunately, many of these hemorrhages are missed, as no outward signs are apparent until it is too late.", [["hemorrhages", "DISEASE", 29, 40], ["these hemorrhages", "PROBLEM", 23, 40], ["outward signs", "PROBLEM", 59, 72], ["hemorrhages", "OBSERVATION", 29, 40]]], ["Typically, blood accumulates within the uterus for a few hours, followed by cardiovascular collapse.", [["blood", "ANATOMY", 11, 16], ["uterus", "ANATOMY", 40, 46], ["cardiovascular", "ANATOMY", 76, 90], ["cardiovascular collapse", "DISEASE", 76, 99], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["uterus", "ORGAN", 40, 46], ["cardiovascular collapse", "PROBLEM", 76, 99], ["uterus", "ANATOMY", 40, 46], ["cardiovascular", "ANATOMY", 76, 90], ["collapse", "OBSERVATION", 91, 99]]], ["In one case, the female was found dead in her stall 2 h after delivery.", [["female", "ORGANISM", 17, 23], ["dead", "PROBLEM", 34, 38], ["delivery", "TREATMENT", 62, 70], ["dead", "OBSERVATION", 34, 38]]], ["Ruptured vaginal arteries may be sutured and blood transfusion should be considered in females with a PCV <10%.", [["vaginal arteries", "ANATOMY", 9, 25], ["blood", "ANATOMY", 45, 50], ["vaginal arteries", "MULTI-TISSUE_STRUCTURE", 9, 25], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["Ruptured vaginal arteries", "PROBLEM", 0, 25], ["blood transfusion", "TREATMENT", 45, 62], ["a PCV", "TREATMENT", 100, 105], ["vaginal arteries", "ANATOMY", 9, 25], ["may be", "UNCERTAINTY", 26, 32], ["sutured", "OBSERVATION", 33, 40]]], ["Packing of the vaginal with compresses, i.e. a device similar to the ''umbrella pack'' used in humans, may be helpful.Uterine prolapsePartial or total uterine prolapse occur secondary to dystocia, manual removal of a retained placenta, and excessive use of oxytocin (dose and frequency).", [["vaginal", "ANATOMY", 15, 22], ["Uterine prolapsePartial", "ANATOMY", 118, 141], ["uterine", "ANATOMY", 151, 158], ["placenta", "ANATOMY", 226, 234], ["uterine prolapse", "DISEASE", 151, 167], ["dystocia", "DISEASE", 187, 195], ["oxytocin", "CHEMICAL", 257, 265], ["oxytocin", "CHEMICAL", 257, 265], ["vaginal", "ORGANISM_SUBDIVISION", 15, 22], ["humans", "ORGANISM", 95, 101], ["uterine", "ORGAN", 151, 158], ["placenta", "ORGAN", 226, 234], ["oxytocin", "SIMPLE_CHEMICAL", 257, 265], ["humans", "SPECIES", 95, 101], ["humans", "SPECIES", 95, 101], ["Packing of the vaginal with compresses", "TREATMENT", 0, 38], ["a device", "TREATMENT", 45, 53], ["the ''umbrella pack", "TREATMENT", 65, 84], ["Uterine prolapsePartial", "PROBLEM", 118, 141], ["total uterine prolapse", "PROBLEM", 145, 167], ["dystocia", "PROBLEM", 187, 195], ["manual removal", "TREATMENT", 197, 211], ["a retained placenta", "PROBLEM", 215, 234], ["oxytocin", "TREATMENT", 257, 265], ["vaginal", "ANATOMY", 15, 22], ["compresses", "OBSERVATION", 28, 38], ["total uterine prolapse", "OBSERVATION", 145, 167], ["dystocia", "OBSERVATION", 187, 195], ["retained", "OBSERVATION_MODIFIER", 217, 225], ["placenta", "OBSERVATION", 226, 234], ["excessive", "OBSERVATION_MODIFIER", 240, 249]]], ["Uterine prolapse is far more common in camels than in llamas and alpacas, and is often associated with hypocalcemia, selenium deficiencies, and retained placenta [49, 50] .", [["Uterine", "ANATOMY", 0, 7], ["placenta", "ANATOMY", 153, 161], ["Uterine prolapse", "DISEASE", 0, 16], ["hypocalcemia", "DISEASE", 103, 115], ["selenium", "CHEMICAL", 117, 125], ["selenium", "CHEMICAL", 117, 125], ["Uterine", "ORGAN", 0, 7], ["llamas", "ORGANISM", 54, 60], ["alpacas", "ORGANISM", 65, 72], ["selenium", "SIMPLE_CHEMICAL", 117, 125], ["placenta", "ORGAN", 153, 161], ["llamas", "SPECIES", 54, 60], ["Uterine prolapse", "PROBLEM", 0, 16], ["hypocalcemia", "PROBLEM", 103, 115], ["selenium deficiencies", "PROBLEM", 117, 138], ["prolapse", "OBSERVATION", 8, 16], ["more common", "OBSERVATION_MODIFIER", 24, 35], ["llamas", "ANATOMY", 54, 60], ["hypocalcemia", "OBSERVATION", 103, 115], ["selenium deficiencies", "OBSERVATION", 117, 138], ["placenta", "ANATOMY", 153, 161]]], ["Dairy camels seem to be more prone to uterine prolapse [63] [64] [65] [66] [67] [68] [69] .", [["uterine", "ANATOMY", 38, 45], ["uterine prolapse", "DISEASE", 38, 54], ["uterine", "ORGAN", 38, 45]]], ["Uterine prolapse occurs generally immediately (first 30 min) after parturition or abortion [50] .Uterine prolapseTechniques for replacement are similar to those reported in cattle and small ruminants, and are usually done under sedation and epidural analgesia.", [["Uterine", "ANATOMY", 0, 7], ["Uterine", "ANATOMY", 97, 104], ["epidural", "ANATOMY", 241, 249], ["Uterine prolapse", "DISEASE", 0, 16], ["Uterine", "ORGAN", 0, 7], ["Uterine", "ORGAN", 97, 104], ["cattle", "ORGANISM", 173, 179], ["epidural", "IMMATERIAL_ANATOMICAL_ENTITY", 241, 249], ["cattle", "SPECIES", 173, 179], ["cattle", "SPECIES", 173, 179], ["Uterine prolapse", "PROBLEM", 0, 16], ["Uterine prolapseTechniques", "TREATMENT", 97, 123], ["replacement", "TREATMENT", 128, 139], ["sedation", "TREATMENT", 228, 236], ["epidural analgesia", "TREATMENT", 241, 259], ["prolapse", "OBSERVATION", 8, 16], ["replacement", "OBSERVATION", 128, 139], ["small", "OBSERVATION_MODIFIER", 184, 189], ["ruminants", "OBSERVATION", 190, 199]]], ["The placenta is often easily peeled off and should be removed if possible before replacement of the uterus.", [["placenta", "ANATOMY", 4, 12], ["uterus", "ANATOMY", 100, 106], ["placenta", "ORGAN", 4, 12], ["uterus", "ORGAN", 100, 106], ["replacement of the uterus", "TREATMENT", 81, 106], ["placenta", "ANATOMY", 4, 12], ["uterus", "ANATOMY", 100, 106]]], ["The female is positioned in sternal recumbency, with the hind quarters slightly elevated.", [["hind", "ANATOMY", 57, 61], ["sternal recumbency", "ORGANISM_SUBDIVISION", 28, 46], ["hind", "ORGANISM_SUBDIVISION", 57, 61], ["the hind quarters slightly elevated", "PROBLEM", 53, 88], ["female", "OBSERVATION", 4, 10], ["sternal", "ANATOMY", 28, 35], ["recumbency", "OBSERVATION", 36, 46], ["hind", "ANATOMY", 57, 61], ["elevated", "OBSERVATION", 80, 88]]], ["The uterus should be inspected for any lacerations or hemorrhage.", [["uterus", "ANATOMY", 4, 10], ["lacerations", "DISEASE", 39, 50], ["hemorrhage", "DISEASE", 54, 64], ["uterus", "ORGAN", 4, 10], ["any lacerations", "PROBLEM", 35, 50], ["hemorrhage", "PROBLEM", 54, 64], ["uterus", "ANATOMY", 4, 10], ["lacerations", "OBSERVATION", 39, 50], ["hemorrhage", "OBSERVATION", 54, 64]]], ["The area of major risk for hemorrhage is located near the cervix where the uterine artery may be exposed.", [["cervix", "ANATOMY", 58, 64], ["uterine artery", "ANATOMY", 75, 89], ["hemorrhage", "DISEASE", 27, 37], ["cervix", "ORGAN", 58, 64], ["uterine artery", "MULTI-TISSUE_STRUCTURE", 75, 89], ["hemorrhage", "PROBLEM", 27, 37], ["area", "OBSERVATION_MODIFIER", 4, 8], ["major", "OBSERVATION_MODIFIER", 12, 17], ["hemorrhage", "OBSERVATION", 27, 37], ["cervix", "ANATOMY", 58, 64], ["uterine artery", "ANATOMY", 75, 89], ["may be", "UNCERTAINTY", 90, 96], ["exposed", "OBSERVATION", 97, 104]]], ["The uterus is cleaned with warm dilute povidone iodine solution before replacement.", [["uterus", "ANATOMY", 4, 10], ["povidone iodine", "CHEMICAL", 39, 54], ["povidone iodine", "CHEMICAL", 39, 54], ["uterus", "ORGAN", 4, 10], ["povidone iodine", "SIMPLE_CHEMICAL", 39, 54], ["warm dilute povidone iodine solution", "TREATMENT", 27, 63], ["replacement", "TREATMENT", 71, 82], ["uterus", "ANATOMY", 4, 10], ["cleaned", "OBSERVATION", 14, 21]]], ["A B\u00fchner suture is used in camels and a shoelace pattern can be used around the vulvar lips in alpacas and llamas.", [["vulvar lips", "ANATOMY", 80, 91], ["camels", "ORGANISM", 27, 33], ["vulvar lips", "ORGAN", 80, 91], ["alpacas", "ORGANISM", 95, 102], ["llamas", "ORGANISM_SUBDIVISION", 107, 113], ["B\u00fchner suture", "TREATMENT", 2, 15], ["a shoelace pattern", "TREATMENT", 38, 56], ["suture", "OBSERVATION", 9, 15], ["vulvar lips", "ANATOMY", 80, 91], ["alpacas", "OBSERVATION", 95, 102], ["llamas", "ANATOMY", 107, 113]]], ["Uterine prolapse tends to reoccur if the uterine horns are not fully extended.", [["Uterine", "ANATOMY", 0, 7], ["uterine horns", "ANATOMY", 41, 54], ["Uterine prolapse", "DISEASE", 0, 16], ["Uterine", "ORGAN", 0, 7], ["uterine horns", "MULTI-TISSUE_STRUCTURE", 41, 54], ["Uterine prolapse", "PROBLEM", 0, 16], ["prolapse", "OBSERVATION", 8, 16], ["uterine horns", "ANATOMY", 41, 54]]], ["Hysterectomy should be considered if the uterine tissue has sustained severe damage [8, 31, 70] .Rectal prolapseRectal prolapse has been reported in llamas and camels.", [["uterine tissue", "ANATOMY", 41, 55], ["Rectal", "ANATOMY", 97, 103], ["prolapseRectal prolapse", "DISEASE", 104, 127], ["uterine tissue", "TISSUE", 41, 55], ["llamas", "ORGANISM", 149, 155], ["llamas", "SPECIES", 149, 155], ["Hysterectomy", "TREATMENT", 0, 12], ["the uterine tissue", "PROBLEM", 37, 55], ["sustained severe damage", "PROBLEM", 60, 83], ["Rectal prolapseRectal prolapse", "PROBLEM", 97, 127], ["uterine", "ANATOMY", 41, 48], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["prolapseRectal prolapse", "OBSERVATION", 104, 127]]], ["Pregnant females with tenesmus and diarrhea are predisposed.", [["tenesmus", "DISEASE", 22, 30], ["diarrhea", "DISEASE", 35, 43], ["tenesmus", "PROBLEM", 22, 30], ["diarrhea", "PROBLEM", 35, 43], ["tenesmus", "OBSERVATION", 22, 30], ["diarrhea", "OBSERVATION", 35, 43]]], ["Rectal prolapse can be intermittent.", [["Rectal", "ANATOMY", 0, 6], ["Rectal prolapse", "DISEASE", 0, 15], ["Rectal", "ORGAN", 0, 6], ["Rectal prolapse", "PROBLEM", 0, 15], ["prolapse", "OBSERVATION", 7, 15], ["intermittent", "OBSERVATION_MODIFIER", 23, 35]]], ["In a case of a dromedary female near term, rectal prolapse was noticed intermittently, without vaginal prolapse.", [["rectal", "ANATOMY", 43, 49], ["vaginal", "ANATOMY", 95, 102], ["rectal prolapse", "DISEASE", 43, 58], ["vaginal prolapse", "DISEASE", 95, 111], ["rectal", "ORGAN", 43, 49], ["vaginal", "ORGANISM_SUBDIVISION", 95, 102], ["rectal prolapse", "PROBLEM", 43, 58], ["vaginal prolapse", "PROBLEM", 95, 111], ["rectal", "ANATOMY", 43, 49], ["prolapse", "OBSERVATION", 50, 58], ["without", "UNCERTAINTY", 87, 94], ["vaginal", "ANATOMY", 95, 102], ["prolapse", "OBSERVATION", 103, 111]]], ["Treatment of the underlying cause and surgical repair have been successful [3, 71] .Other complications of the postpartum periodEmergency postpartum complications in camelids include a vast array of conditions which often manifest themselves as lethargy, depression and progress towards a downer female syndrome.", [["camelids", "DISEASE", 166, 174], ["lethargy", "DISEASE", 245, 253], ["depression", "DISEASE", 255, 265], ["the underlying cause", "PROBLEM", 13, 33], ["surgical repair", "TREATMENT", 38, 53], ["Emergency postpartum complications in camelids", "PROBLEM", 128, 174], ["lethargy", "PROBLEM", 245, 253], ["depression", "PROBLEM", 255, 265], ["a downer female syndrome", "PROBLEM", 287, 311], ["surgical repair", "OBSERVATION", 38, 53]]], ["The approach to diagnosis of the causes of downer syndrome is similar to that used in cattle [72] .", [["downer syndrome", "DISEASE", 43, 58], ["cattle", "SPECIES", 86, 92], ["downer syndrome", "PROBLEM", 43, 58], ["downer syndrome", "OBSERVATION", 43, 58]]], ["Predisposing factors include septic metritis, necrotic vaginitis, retained placenta, hypocalcemia, dystocia, pelvic injuries, hemorrhage, and presence of compressive lesions.", [["placenta", "ANATOMY", 75, 83], ["pelvic", "ANATOMY", 109, 115], ["compressive lesions", "ANATOMY", 154, 173], ["septic metritis", "DISEASE", 29, 44], ["necrotic vaginitis", "DISEASE", 46, 64], ["hypocalcemia", "DISEASE", 85, 97], ["dystocia", "DISEASE", 99, 107], ["pelvic injuries", "DISEASE", 109, 124], ["hemorrhage", "DISEASE", 126, 136], ["placenta", "MULTI-TISSUE_STRUCTURE", 75, 83], ["pelvic", "ORGAN", 109, 115], ["lesions", "PATHOLOGICAL_FORMATION", 166, 173], ["Predisposing factors", "PROBLEM", 0, 20], ["septic metritis", "PROBLEM", 29, 44], ["necrotic vaginitis", "PROBLEM", 46, 64], ["retained placenta", "PROBLEM", 66, 83], ["hypocalcemia", "PROBLEM", 85, 97], ["dystocia", "PROBLEM", 99, 107], ["pelvic injuries", "PROBLEM", 109, 124], ["hemorrhage", "PROBLEM", 126, 136], ["compressive lesions", "PROBLEM", 154, 173], ["septic metritis", "OBSERVATION", 29, 44], ["necrotic", "OBSERVATION_MODIFIER", 46, 54], ["vaginitis", "OBSERVATION", 55, 64], ["placenta", "ANATOMY", 75, 83], ["hypocalcemia", "OBSERVATION", 85, 97], ["dystocia", "OBSERVATION", 99, 107], ["pelvic", "ANATOMY", 109, 115], ["injuries", "OBSERVATION", 116, 124], ["hemorrhage", "OBSERVATION", 126, 136], ["compressive", "OBSERVATION_MODIFIER", 154, 165], ["lesions", "OBSERVATION", 166, 173]]], ["A milk fever syndrome (hypocalcemia), similar to the condition in dairy cattle, is also observed in dairy camels.", [["milk fever syndrome", "DISEASE", 2, 21], ["hypocalcemia", "DISEASE", 23, 35], ["milk", "ORGANISM_SUBSTANCE", 2, 6], ["camels", "ORGANISM_SUBDIVISION", 106, 112], ["cattle", "SPECIES", 72, 78], ["cattle", "SPECIES", 72, 78], ["A milk fever syndrome", "PROBLEM", 0, 21], ["hypocalcemia", "PROBLEM", 23, 35]]], ["Toxic mastitis has been described in dairy camels, but not in South American camelids [73] .Other complications of the postpartum periodIn addition to physical evaluation, CBC and blood biochemistry, the evaluation of the downer postpartum camelid should include transrectal and transabdominal ultrasonography and potentially collection and evaluation of cerebrospinal fluid.", [["blood", "ANATOMY", 180, 185], ["transrectal", "ANATOMY", 263, 274], ["cerebrospinal fluid", "ANATOMY", 355, 374], ["Toxic mastitis", "DISEASE", 0, 14], ["CBC", "CELL", 172, 175], ["blood", "ORGANISM_SUBSTANCE", 180, 185], ["transrectal", "MULTI-TISSUE_STRUCTURE", 263, 274], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 355, 374], ["Toxic mastitis", "PROBLEM", 0, 14], ["physical evaluation", "TEST", 151, 170], ["CBC", "TEST", 172, 175], ["blood biochemistry", "TEST", 180, 198], ["the evaluation", "TEST", 200, 214], ["the downer postpartum camelid", "TREATMENT", 218, 247], ["transrectal and transabdominal ultrasonography", "TEST", 263, 309], ["collection and evaluation of cerebrospinal fluid", "TEST", 326, 374], ["mastitis", "OBSERVATION", 6, 14], ["cerebrospinal", "ANATOMY", 355, 368], ["fluid", "OBSERVATION", 369, 374]]], ["More advanced imaging techniques may be required in some cases in order to detect neoplastic masses.", [["neoplastic masses", "ANATOMY", 82, 99], ["neoplastic masses", "CANCER", 82, 99], ["advanced imaging techniques", "TEST", 5, 32], ["neoplastic masses", "PROBLEM", 82, 99], ["neoplastic", "OBSERVATION_MODIFIER", 82, 92], ["masses", "OBSERVATION", 93, 99]]], ["Although, retained placenta is not usually an emergency in camelids, failure of delivery of the placenta following a cesarean section may lead to severe complications.Other complications of the postpartum periodSevere swelling of the vulva and vagina are painful conditions associated with overt obstetrical manipulation.", [["placenta", "ANATOMY", 19, 27], ["placenta", "ANATOMY", 96, 104], ["vulva", "ANATOMY", 234, 239], ["vagina", "ANATOMY", 244, 250], ["swelling of the vulva", "DISEASE", 218, 239], ["placenta", "ORGAN", 19, 27], ["placenta", "ORGAN", 96, 104], ["vulva", "ORGAN", 234, 239], ["vagina", "ORGAN", 244, 250], ["delivery", "TREATMENT", 80, 88], ["the placenta", "PROBLEM", 92, 104], ["a cesarean section", "TREATMENT", 115, 133], ["severe complications", "PROBLEM", 146, 166], ["Other complications", "PROBLEM", 167, 186], ["Severe swelling of the vulva and vagina", "PROBLEM", 211, 250], ["painful conditions", "PROBLEM", 255, 273], ["overt obstetrical manipulation", "PROBLEM", 290, 320], ["retained", "OBSERVATION_MODIFIER", 10, 18], ["placenta", "OBSERVATION", 19, 27], ["placenta", "ANATOMY", 96, 104], ["severe", "OBSERVATION_MODIFIER", 146, 152], ["complications", "OBSERVATION", 153, 166], ["Severe", "OBSERVATION_MODIFIER", 211, 217], ["swelling", "OBSERVATION", 218, 226], ["vulva", "ANATOMY", 234, 239], ["vagina", "ANATOMY", 244, 250], ["painful", "OBSERVATION", 255, 262], ["obstetrical manipulation", "OBSERVATION", 296, 320]]], ["Females experiencing these complications may have persistent straining and abandon their neonate.", [["neonate", "ORGANISM", 89, 96], ["these complications", "PROBLEM", 21, 40], ["persistent straining", "PROBLEM", 50, 70]]], ["Untreated vaginal and cervical inflammation may lead to adhesions and development of pyometra.", [["vaginal", "ANATOMY", 10, 17], ["cervical", "ANATOMY", 22, 30], ["adhesions", "ANATOMY", 56, 65], ["vaginal and cervical inflammation", "DISEASE", 10, 43], ["adhesions", "DISEASE", 56, 65], ["pyometra", "DISEASE", 85, 93], ["vaginal", "ORGANISM_SUBDIVISION", 10, 17], ["cervical", "ORGAN", 22, 30], ["pyometra", "PATHOLOGICAL_FORMATION", 85, 93], ["Untreated vaginal and cervical inflammation", "PROBLEM", 0, 43], ["adhesions", "PROBLEM", 56, 65], ["pyometra", "PROBLEM", 85, 93], ["vaginal", "ANATOMY", 10, 17], ["cervical", "ANATOMY", 22, 30], ["inflammation", "OBSERVATION", 31, 43], ["adhesions", "OBSERVATION", 56, 65], ["pyometra", "OBSERVATION", 85, 93]]], ["Females with severe inflammation of the birth canal should be treated with systemic and local anti-inflammatory drugs.", [["canal", "ANATOMY", 46, 51], ["inflammation of the birth canal", "DISEASE", 20, 51], ["canal", "ORGAN", 46, 51], ["severe inflammation of the birth canal", "PROBLEM", 13, 51], ["systemic and local anti-inflammatory drugs", "TREATMENT", 75, 117], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["inflammation", "OBSERVATION", 20, 32], ["birth canal", "ANATOMY", 40, 51]]], ["Daily application of cold compresses and treatment with ointments with anti-inflammatory and antimicrobial properties may reduce inflammation and adhesions.Neonatal emergenciesIn an epidemiological study in the United Kingdom, 4-11% of deaths amongst llamas and 17-33% of deaths in alpacas occur during the first 6 months of life.", [["inflammation", "DISEASE", 129, 141], ["deaths", "DISEASE", 236, 242], ["deaths", "DISEASE", 272, 278], ["ointments", "SIMPLE_CHEMICAL", 56, 65], ["llamas", "ORGANISM", 251, 257], ["alpacas", "ORGANISM", 282, 289], ["cold compresses", "TREATMENT", 21, 36], ["treatment", "TREATMENT", 41, 50], ["ointments", "TREATMENT", 56, 65], ["anti-inflammatory and antimicrobial properties", "TREATMENT", 71, 117], ["inflammation", "PROBLEM", 129, 141], ["adhesions", "PROBLEM", 146, 155], ["Neonatal emergencies", "PROBLEM", 156, 176], ["an epidemiological study", "TEST", 179, 203], ["llamas", "TEST", 251, 257], ["cold compresses", "OBSERVATION_MODIFIER", 21, 36], ["inflammation", "OBSERVATION", 129, 141], ["adhesions", "OBSERVATION", 146, 155]]], ["A high proportion of these deaths occur within the first week of life [31, 74] .", [["deaths", "DISEASE", 27, 33], ["high", "OBSERVATION_MODIFIER", 2, 6]]], ["In camels, neonatal mortality can reach 50% of the calf crop in the first 10 days of life [45] .Neonatal emergenciesNewborn morbidity and mortality is very high in the immediate neonatal (<1 week old) period following obstetrical manipulations, cesarean section, prematurity, or dysmaturity [75] .", [["prematurity", "DISEASE", 263, 274], ["dysmaturity", "DISEASE", 279, 290], ["camels", "ORGANISM", 3, 9], ["calf", "ORGANISM", 51, 55], ["calf", "SPECIES", 51, 55], ["Neonatal emergenciesNewborn morbidity", "PROBLEM", 96, 133], ["obstetrical manipulations", "TREATMENT", 218, 243], ["cesarean section", "TREATMENT", 245, 261], ["prematurity", "PROBLEM", 263, 274], ["dysmaturity", "PROBLEM", 279, 290], ["calf", "ANATOMY", 51, 55], ["high", "OBSERVATION_MODIFIER", 156, 160]]], ["These losses are often due to complications from hypoxia, failure of passive transfer, and intrapartum infection.", [["hypoxia", "DISEASE", 49, 56], ["intrapartum infection", "DISEASE", 91, 112], ["complications", "PROBLEM", 30, 43], ["hypoxia", "PROBLEM", 49, 56], ["failure of passive transfer", "PROBLEM", 58, 85], ["intrapartum infection", "PROBLEM", 91, 112], ["hypoxia", "OBSERVATION", 49, 56], ["infection", "OBSERVATION", 103, 112]]], ["Infections may be acquired in utero or intrapartum, and should be suspected if the newborn has elevated plasma fibrinogen concentrations in the first 12-24 h of life, the placenta appears abnormal, or the dam exhibited uterine discharge peripartum [75] .", [["plasma", "ANATOMY", 104, 110], ["placenta", "ANATOMY", 171, 179], ["uterine", "ANATOMY", 219, 226], ["Infections", "DISEASE", 0, 10], ["utero", "ORGAN", 30, 35], ["newborn", "ORGANISM", 83, 90], ["plasma", "ORGANISM_SUBSTANCE", 104, 110], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 111, 121], ["placenta", "ORGAN", 171, 179], ["uterine", "ORGAN", 219, 226], ["plasma fibrinogen", "PROTEIN", 104, 121], ["Infections", "PROBLEM", 0, 10], ["elevated plasma fibrinogen concentrations", "PROBLEM", 95, 136], ["abnormal", "PROBLEM", 188, 196], ["uterine discharge peripartum", "PROBLEM", 219, 247], ["abnormal", "OBSERVATION", 188, 196], ["uterine", "ANATOMY", 219, 226]]], ["Therefore, immediate identification and care of the newborn camelid at high risk for sepsis is an important part of reproductive emergencies.Neonatal emergenciesThe newborn should be evaluated within the first hours of life to detect any abnormalities of development or maladjustment to extra-uterine life.", [["sepsis", "DISEASE", 85, 91], ["the newborn camelid", "TREATMENT", 48, 67], ["sepsis", "PROBLEM", 85, 91], ["reproductive emergencies", "PROBLEM", 116, 140], ["Neonatal emergencies", "PROBLEM", 141, 161], ["any abnormalities", "PROBLEM", 234, 251], ["maladjustment to extra-uterine life", "PROBLEM", 270, 305], ["sepsis", "OBSERVATION", 85, 91]]], ["Assessment of the newborn cria should include evaluation of the epidermal membrane and placenta, respiration, cardiac function, and the presence of obvious congenital abnormalities.", [["epidermal membrane", "ANATOMY", 64, 82], ["placenta", "ANATOMY", 87, 95], ["cardiac", "ANATOMY", 110, 117], ["congenital abnormalities", "DISEASE", 156, 180], ["epidermal membrane", "MULTI-TISSUE_STRUCTURE", 64, 82], ["placenta", "MULTI-TISSUE_STRUCTURE", 87, 95], ["cardiac", "ORGAN", 110, 117], ["evaluation", "TEST", 46, 56], ["the epidermal membrane", "TEST", 60, 82], ["cardiac function", "TEST", 110, 126], ["obvious congenital abnormalities", "PROBLEM", 148, 180], ["epidermal membrane", "ANATOMY", 64, 82], ["placenta", "ANATOMY", 87, 95], ["obvious", "OBSERVATION_MODIFIER", 148, 155], ["congenital", "OBSERVATION_MODIFIER", 156, 166], ["abnormalities", "OBSERVATION", 167, 180]]], ["The epidermal membrane, which is normally translucent, may become yellow or brownish due to meconium staining in case of fetal stress due to dystocia.Neonatal emergenciesMany congenital abnormalities have been described in camelids, some of which can be lethal.", [["epidermal membrane", "ANATOMY", 4, 22], ["fetal", "ANATOMY", 121, 126], ["fetal stress", "DISEASE", 121, 133], ["dystocia", "DISEASE", 141, 149], ["congenital abnormalities", "DISEASE", 175, 199], ["epidermal membrane", "CELLULAR_COMPONENT", 4, 22], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 121, 126], ["yellow", "PROBLEM", 66, 72], ["brownish", "PROBLEM", 76, 84], ["meconium staining", "PROBLEM", 92, 109], ["fetal stress", "PROBLEM", 121, 133], ["dystocia", "PROBLEM", 141, 149], ["Neonatal emergencies", "PROBLEM", 150, 170], ["Many congenital abnormalities", "PROBLEM", 170, 199], ["epidermal membrane", "ANATOMY", 4, 22], ["normally", "OBSERVATION_MODIFIER", 33, 41], ["translucent", "OBSERVATION_MODIFIER", 42, 53], ["brownish", "OBSERVATION", 76, 84], ["meconium staining", "OBSERVATION", 92, 109], ["dystocia", "OBSERVATION", 141, 149], ["congenital", "OBSERVATION_MODIFIER", 175, 185], ["abnormalities", "OBSERVATION", 186, 199]]], ["Amongst the most important are: cleft palate, choanal atresia, atresia ani, and heart defects.", [["cleft palate", "ANATOMY", 32, 44], ["choanal", "ANATOMY", 46, 53], ["ani", "ANATOMY", 71, 74], ["heart", "ANATOMY", 80, 85], ["cleft palate", "DISEASE", 32, 44], ["choanal atresia", "DISEASE", 46, 61], ["atresia ani", "DISEASE", 63, 74], ["heart defects", "DISEASE", 80, 93], ["palate", "ORGAN", 38, 44], ["ani", "ORGAN", 71, 74], ["heart", "ORGAN", 80, 85], ["cleft palate", "PROBLEM", 32, 44], ["choanal atresia", "PROBLEM", 46, 61], ["atresia ani", "PROBLEM", 63, 74], ["heart defects", "PROBLEM", 80, 93], ["cleft palate", "ANATOMY", 32, 44], ["choanal", "ANATOMY", 46, 53], ["atresia", "OBSERVATION", 54, 61], ["atresia", "OBSERVATION", 63, 70], ["heart", "ANATOMY", 80, 85], ["defects", "OBSERVATION", 86, 93]]], ["The initial examination of the cria should establish if any of these abnormalities are present (Table 2) , so they can be corrected early or a decision made to humanely euthanize the cria.Neonatal emergenciesNeonatal cases are presented with a wide variety of nonspecific complaints based on deviations from the normal appearance and behavior presented above.", [["The initial examination", "TEST", 0, 23], ["these abnormalities", "PROBLEM", 63, 82], ["Neonatal emergencies", "PROBLEM", 188, 208], ["nonspecific complaints", "PROBLEM", 260, 282], ["abnormalities", "OBSERVATION", 69, 82], ["nonspecific", "OBSERVATION_MODIFIER", 260, 271], ["normal", "OBSERVATION", 312, 318]]], ["The minimum database used to evaluate the cria include: evaluation of maternal transfer of immunogobulins, CBC (including differential count and determination of plasma fibrinogen concentration), arterial blood gas analysis, serum chemistry, and aerobic and anaerobic blood cultures.", [["plasma", "ANATOMY", 162, 168], ["arterial blood", "ANATOMY", 196, 210], ["serum", "ANATOMY", 225, 230], ["blood cultures", "ANATOMY", 268, 282], ["immunogobulins", "GENE_OR_GENE_PRODUCT", 91, 105], ["plasma", "ORGANISM_SUBSTANCE", 162, 168], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 169, 179], ["blood", "ORGANISM_SUBSTANCE", 205, 210], ["serum", "ORGANISM_SUBSTANCE", 225, 230], ["blood", "ORGANISM_SUBSTANCE", 268, 273], ["immunogobulins", "PROTEIN", 91, 105], ["CBC", "PROTEIN", 107, 110], ["plasma fibrinogen", "PROTEIN", 162, 179], ["aerobic and anaerobic blood cultures", "CELL_LINE", 246, 282], ["The minimum database", "TEST", 0, 20], ["evaluation", "TEST", 56, 66], ["immunogobulins", "TEST", 91, 105], ["CBC", "TEST", 107, 110], ["differential count", "TEST", 122, 140], ["plasma fibrinogen concentration", "TEST", 162, 193], ["arterial blood gas analysis", "TEST", 196, 223], ["serum chemistry", "TEST", 225, 240], ["aerobic", "TEST", 246, 253], ["anaerobic blood cultures", "TEST", 258, 282]]], ["Contrast radiographs of the nasopharyngeal area may be indicated if choanal atresia is suspected as a cause of dyspnea [76] .Management of the high-risk neonateAny cria delivered before day 315 of pregnancy should be considered premature.", [["nasopharyngeal area", "ANATOMY", 28, 47], ["choanal", "ANATOMY", 68, 75], ["choanal atresia", "DISEASE", 68, 83], ["dyspnea", "DISEASE", 111, 118], ["nasopharyngeal area", "MULTI-TISSUE_STRUCTURE", 28, 47], ["neonate", "ORGANISM", 153, 160], ["Contrast radiographs of the nasopharyngeal area", "TEST", 0, 47], ["choanal atresia", "PROBLEM", 68, 83], ["dyspnea", "PROBLEM", 111, 118], ["Management", "TREATMENT", 125, 135], ["premature", "PROBLEM", 228, 237], ["nasopharyngeal", "ANATOMY", 28, 42], ["atresia", "OBSERVATION", 76, 83]]], ["Premature birth may be a consequence of a stressful illness during pregnancy or due to a decision to induce parturition because of severe compromise to the dam.", [["Premature birth", "DISEASE", 0, 15], ["Premature birth", "PROBLEM", 0, 15], ["a stressful illness", "PROBLEM", 40, 59], ["severe compromise", "PROBLEM", 131, 148], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["compromise", "OBSERVATION", 138, 148]]], ["Recently, the authors have seen a high rate of premature births following an outbreak of respiratory diseases.", [["respiratory", "ANATOMY", 89, 100], ["respiratory diseases", "DISEASE", 89, 109], ["premature births", "PROBLEM", 47, 63], ["respiratory diseases", "PROBLEM", 89, 109], ["respiratory diseases", "OBSERVATION", 89, 109]]], ["Premature birth may also be secondary to uterine pathology (i.e. placentitis or placental insufficiency) [77] .", [["uterine", "ANATOMY", 41, 48], ["placental", "ANATOMY", 80, 89], ["Premature birth", "DISEASE", 0, 15], ["placentitis", "DISEASE", 65, 76], ["placental insufficiency", "DISEASE", 80, 103], ["uterine", "ORGAN", 41, 48], ["placental", "ORGAN", 80, 89], ["Premature birth", "PROBLEM", 0, 15], ["uterine pathology", "PROBLEM", 41, 58], ["placentitis", "PROBLEM", 65, 76], ["placental insufficiency", "PROBLEM", 80, 103], ["may also be", "UNCERTAINTY", 16, 27], ["uterine", "ANATOMY", 41, 48], ["pathology", "OBSERVATION", 49, 58]]], ["Premature crias display specific phenotypic characteristics, including a birth weight significantly (>20%) lower that that the average for the farm, and a thick epidermal membrane firmly attached to the foot pads and the mucocutaenous junctions.", [["epidermal membrane", "ANATOMY", 161, 179], ["foot pads", "ANATOMY", 203, 212], ["mucocutaenous junctions", "ANATOMY", 221, 244], ["epidermal membrane", "CELLULAR_COMPONENT", 161, 179], ["foot pads", "TISSUE", 203, 212], ["mucocutaenous junctions", "CELLULAR_COMPONENT", 221, 244], ["Premature crias", "PROBLEM", 0, 15], ["a birth weight", "TEST", 71, 85], ["a thick epidermal membrane", "PROBLEM", 153, 179], ["foot pads", "ANATOMY", 203, 212], ["mucocutaenous junctions", "ANATOMY", 221, 244]]], ["A ''floppy'' syndrome, often seen in premature camelids, includes inability to rise, to hold the head up, or to maintain sternal recumbency and floppy ears (new world camelids), due to immaturity of the cartilage.", [["camelids", "ANATOMY", 47, 55], ["head", "ANATOMY", 97, 101], ["cartilage", "ANATOMY", 203, 212], ["floppy'' syndrome", "DISEASE", 4, 21], ["premature camelids", "DISEASE", 37, 55], ["immaturity of the cartilage", "DISEASE", 185, 212], ["head", "ORGANISM_SUBDIVISION", 97, 101], ["ears", "ORGAN", 151, 155], ["cartilage", "TISSUE", 203, 212], ["A ''floppy'' syndrome", "PROBLEM", 0, 21], ["premature camelids", "PROBLEM", 37, 55], ["inability to rise", "PROBLEM", 66, 83], ["sternal recumbency and floppy ears", "PROBLEM", 121, 155], ["new world camelids", "TREATMENT", 157, 175], ["immaturity of the cartilage", "PROBLEM", 185, 212], ["floppy", "OBSERVATION", 4, 10], ["head", "ANATOMY", 97, 101], ["sternal", "ANATOMY", 121, 128], ["immaturity", "OBSERVATION", 185, 195], ["cartilage", "ANATOMY", 203, 212]]], ["The coat appears silky and the limbs are overextended at the carpus and fetlock, due to laxity of the tendon and poor muscle tone.", [["limbs", "ANATOMY", 31, 36], ["carpus", "ANATOMY", 61, 67], ["tendon", "ANATOMY", 102, 108], ["muscle", "ANATOMY", 118, 124], ["limbs", "ORGANISM_SUBDIVISION", 31, 36], ["carpus", "ORGANISM_SUBDIVISION", 61, 67], ["tendon", "TISSUE", 102, 108], ["muscle", "ORGAN", 118, 124], ["laxity of the tendon", "PROBLEM", 88, 108], ["poor muscle tone", "PROBLEM", 113, 129], ["coat", "OBSERVATION_MODIFIER", 4, 8], ["appears", "UNCERTAINTY", 9, 16], ["silky", "OBSERVATION_MODIFIER", 17, 22], ["limbs", "ANATOMY", 31, 36], ["overextended", "OBSERVATION", 41, 53], ["carpus", "ANATOMY", 61, 67], ["fetlock", "ANATOMY", 72, 79], ["laxity", "OBSERVATION", 88, 94], ["tendon", "ANATOMY", 102, 108], ["poor muscle tone", "OBSERVATION", 113, 129]]], ["The incisors are not erupted and the suckling reflex is absent or weak.Management of the high-risk neonatePremature neonates adapt to extrauterine life very slowly.", [["incisors", "ANATOMY", 4, 12], ["incisors", "ORGAN", 4, 12], ["suckling", "ORGANISM_SUBDIVISION", 37, 45], ["neonates", "ORGANISM", 116, 124], ["the suckling reflex", "TEST", 33, 52], ["weak", "PROBLEM", 66, 70], ["Management", "TREATMENT", 71, 81], ["the high-risk neonatePremature neonates", "TREATMENT", 85, 124], ["incisors", "ANATOMY", 4, 12], ["not", "UNCERTAINTY", 17, 20], ["erupted", "OBSERVATION", 21, 28], ["weak", "OBSERVATION_MODIFIER", 66, 70]]], ["Due to the normal elevated fetal cortisol concentrations, they may appear healthy initially, but become comprised a few hours later due to developing metabolic problems.", [["fetal", "ANATOMY", 27, 32], ["cortisol", "CHEMICAL", 33, 41], ["metabolic problems", "DISEASE", 150, 168], ["cortisol", "CHEMICAL", 33, 41], ["fetal", "ANATOMICAL_SYSTEM", 27, 32], ["cortisol", "SIMPLE_CHEMICAL", 33, 41], ["the normal elevated fetal cortisol concentrations", "PROBLEM", 7, 56], ["developing metabolic problems", "PROBLEM", 139, 168], ["normal", "OBSERVATION", 11, 17], ["elevated", "OBSERVATION_MODIFIER", 18, 26], ["fetal cortisol concentrations", "OBSERVATION", 27, 56], ["metabolic problems", "OBSERVATION", 150, 168]]], ["These problems are often due to hypoxemia, acidosis, hypoglycemia, and limited body reserves or poor thermogenic ability.", [["body", "ANATOMY", 79, 83], ["hypoxemia", "DISEASE", 32, 41], ["acidosis", "DISEASE", 43, 51], ["hypoglycemia", "DISEASE", 53, 65], ["body", "ORGANISM_SUBDIVISION", 79, 83], ["hypoxemia", "PROBLEM", 32, 41], ["acidosis", "PROBLEM", 43, 51], ["hypoglycemia", "PROBLEM", 53, 65], ["limited body reserves", "PROBLEM", 71, 92], ["poor thermogenic ability", "PROBLEM", 96, 120], ["hypoxemia", "OBSERVATION", 32, 41], ["acidosis", "OBSERVATION", 43, 51], ["hypoglycemia", "OBSERVATION", 53, 65]]], ["Premature neonates are exposed to a wide range of respiratory and intestinal compromise due to immaturity of these systems.", [["respiratory", "ANATOMY", 50, 61], ["intestinal", "ANATOMY", 66, 76], ["respiratory and intestinal compromise", "DISEASE", 50, 87], ["neonates", "ORGANISM", 10, 18], ["intestinal", "ORGAN", 66, 76], ["Premature neonates", "PROBLEM", 0, 18], ["respiratory and intestinal compromise", "PROBLEM", 50, 87], ["immaturity of these systems", "PROBLEM", 95, 122], ["intestinal", "ANATOMY", 66, 76], ["compromise", "OBSERVATION", 77, 87], ["immaturity", "OBSERVATION", 95, 105]]], ["Respiratory distress may be notice by labored or even open-mouth breathing.", [["mouth", "ANATOMY", 59, 64], ["Respiratory distress", "DISEASE", 0, 20], ["Respiratory distress", "PROBLEM", 0, 20], ["labored", "PROBLEM", 38, 45], ["mouth breathing", "PROBLEM", 59, 74], ["distress", "OBSERVATION", 12, 20]]], ["This syndrome is likely due to lack of surfactants required for normal air sac expansions and inefficient oxygen absorption.", [["air sac", "ANATOMY", 71, 78], ["oxygen", "CHEMICAL", 106, 112], ["oxygen", "CHEMICAL", 106, 112], ["air sac", "MULTI-TISSUE_STRUCTURE", 71, 78], ["oxygen", "SIMPLE_CHEMICAL", 106, 112], ["This syndrome", "PROBLEM", 0, 13], ["surfactants", "TREATMENT", 39, 50], ["normal air sac expansions", "PROBLEM", 64, 89], ["inefficient oxygen absorption", "PROBLEM", 94, 123], ["likely due to", "UNCERTAINTY", 17, 30], ["air sac", "OBSERVATION", 71, 78], ["inefficient", "OBSERVATION_MODIFIER", 94, 105], ["oxygen absorption", "OBSERVATION", 106, 123]]], ["Mortality rate is very high is these crias if they do not receive immediate attention [31, 50] .Management of the high-risk neonateIntestinal immaturity in premature crias predisposes them to failure of passive transfer, even if colostrum is ingested orally in the first hours of life (failure of absorption).", [["Intestinal", "ANATOMY", 131, 141], ["colostrum", "ANATOMY", 229, 238], ["premature crias", "DISEASE", 156, 171], ["neonate", "ORGANISM", 124, 131], ["Intestinal", "ORGAN", 131, 141], ["colostrum", "ORGANISM", 229, 238], ["Mortality rate", "TEST", 0, 14], ["Management", "TREATMENT", 96, 106], ["Intestinal immaturity", "PROBLEM", 131, 152], ["premature crias", "PROBLEM", 156, 171], ["passive transfer", "TREATMENT", 203, 219], ["immaturity", "OBSERVATION", 142, 152], ["premature", "OBSERVATION", 156, 165]]], ["They also tend to be more at risk for bloating and meconium retention due to poor gut motility.Management of the high-risk neonateDysmature or hypoxic neonates are often the result of induction of parturition, severe illness during pregnancy, or prolonged gestation.", [["meconium", "ANATOMY", 51, 59], ["gut", "ANATOMY", 82, 85], ["bloating", "DISEASE", 38, 46], ["meconium retention", "DISEASE", 51, 69], ["neonateDysmature", "DISEASE", 123, 139], ["illness", "DISEASE", 217, 224], ["meconium", "ORGANISM_SUBSTANCE", 51, 59], ["gut", "ORGANISM_SUBDIVISION", 82, 85], ["bloating", "PROBLEM", 38, 46], ["meconium retention", "PROBLEM", 51, 69], ["poor gut motility", "PROBLEM", 77, 94], ["Management", "TREATMENT", 95, 105], ["the high-risk neonateDysmature", "PROBLEM", 109, 139], ["hypoxic neonates", "PROBLEM", 143, 159], ["severe illness during pregnancy", "PROBLEM", 210, 241], ["prolonged gestation", "PROBLEM", 246, 265], ["meconium retention", "OBSERVATION", 51, 69], ["high", "OBSERVATION_MODIFIER", 113, 117], ["hypoxic neonates", "OBSERVATION", 143, 159], ["severe", "OBSERVATION_MODIFIER", 210, 216], ["illness", "OBSERVATION", 217, 224]]], ["They usually present with similar biophysical characteristics as the premature neonates, except that they may have normal body development.Management of the high-risk neonateMature compromised crias are usually the result of lengthy obstetrical manipulation or delivery via cesarean section.", [["body", "ANATOMY", 122, 126], ["neonates", "ORGANISM", 79, 87], ["body", "ORGANISM_SUBDIVISION", 122, 126], ["the premature neonates", "PROBLEM", 65, 87], ["Management", "TREATMENT", 139, 149], ["the high-risk neonateMature compromised crias", "PROBLEM", 153, 198], ["lengthy obstetrical manipulation", "TREATMENT", 225, 257], ["delivery", "TREATMENT", 261, 269], ["cesarean section", "TREATMENT", 274, 290], ["high", "OBSERVATION_MODIFIER", 157, 161], ["neonateMature compromised", "OBSERVATION", 167, 192]]], ["The degree of compromise depends on several factors.Management of the high-risk neonateThere is a complete lack of evidence-based medicine in emergency critical care of newborn camelids; most of the available information is anecdotal and based on clinical experience with other species.", [["neonate", "ORGANISM", 80, 87], ["compromise depends", "PROBLEM", 14, 32], ["Management", "TREATMENT", 52, 62], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["compromise", "OBSERVATION", 14, 24]]], ["Premature or stressed neonates require intensive care in the first few hours of life.", [["neonates", "ORGANISM", 22, 30], ["Premature or stressed neonates", "PROBLEM", 0, 30], ["intensive care", "TREATMENT", 39, 53]]], ["Baseline CBC and blood biochemistry are indicated to determination status of hydration and electrolytes, blood glucose concentration, total protein and IgG at 24-36 h.", [["blood", "ANATOMY", 17, 22], ["blood", "ANATOMY", 105, 110], ["glucose", "CHEMICAL", 111, 118], ["glucose", "CHEMICAL", 111, 118], ["CBC", "CELL", 9, 12], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["electrolytes", "SIMPLE_CHEMICAL", 91, 103], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["glucose", "SIMPLE_CHEMICAL", 111, 118], ["IgG", "GENE_OR_GENE_PRODUCT", 152, 155], ["total protein", "PROTEIN", 134, 147], ["IgG", "PROTEIN", 152, 155], ["Baseline CBC", "TEST", 0, 12], ["blood biochemistry", "TEST", 17, 35], ["hydration", "TEST", 77, 86], ["electrolytes", "TEST", 91, 103], ["blood glucose concentration", "TEST", 105, 132], ["total protein", "TEST", 134, 147], ["IgG", "TEST", 152, 155]]], ["At-risk patients should receive an intravenous plasma transfusion.", [["intravenous", "ANATOMY", 35, 46], ["plasma", "ANATOMY", 47, 53], ["patients", "ORGANISM", 8, 16], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 46], ["plasma", "ORGANISM_SUBSTANCE", 47, 53], ["patients", "SPECIES", 8, 16], ["an intravenous plasma transfusion", "TREATMENT", 32, 65]]], ["If the suckling reflex is absent, tube feeding is necessary and should be restricted to small volumes every 2-3 h, to reach 10-15% of body weight by 24 h of life.Management of the high-risk neonateOxygen supplementation may be required if respiratory distress is pronounced.", [["tube", "ANATOMY", 34, 38], ["body", "ANATOMY", 134, 138], ["respiratory", "ANATOMY", 239, 250], ["neonateOxygen", "CHEMICAL", 190, 203], ["respiratory distress", "DISEASE", 239, 259], ["neonateOxygen", "CHEMICAL", 190, 203], ["tube", "TISSUE", 34, 38], ["body", "ORGANISM_SUBDIVISION", 134, 138], ["neonateOxygen", "SIMPLE_CHEMICAL", 190, 203], ["the suckling reflex", "TEST", 3, 22], ["tube feeding", "TREATMENT", 34, 46], ["Management", "TREATMENT", 162, 172], ["the high-risk neonateOxygen supplementation", "TREATMENT", 176, 219], ["respiratory distress", "PROBLEM", 239, 259]]], ["Lung function should be monitored by blood gas analysis.", [["Lung", "ANATOMY", 0, 4], ["blood", "ANATOMY", 37, 42], ["Lung", "ORGAN", 0, 4], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["Lung function", "TEST", 0, 13], ["blood gas analysis", "TEST", 37, 55]]], ["Aminophylline, an adenosine A (2A)-receptor antagonist like caffeine, has been given for 3 days to stimulate the central nervous system and regulate breathing and to stimulate the type II pneumocytes to produce components for the surfactant production [78, 79] .", [["central nervous system", "ANATOMY", 113, 135], ["type II pneumocytes", "ANATOMY", 180, 199], ["Aminophylline", "CHEMICAL", 0, 13], ["adenosine", "CHEMICAL", 18, 27], ["caffeine", "CHEMICAL", 60, 68], ["Aminophylline", "CHEMICAL", 0, 13], ["adenosine", "CHEMICAL", 18, 27], ["caffeine", "CHEMICAL", 60, 68], ["Aminophylline", "SIMPLE_CHEMICAL", 0, 13], ["adenosine A (2A)-receptor antagonist", "GENE_OR_GENE_PRODUCT", 18, 54], ["caffeine", "SIMPLE_CHEMICAL", 60, 68], ["central nervous system", "ANATOMICAL_SYSTEM", 113, 135], ["type II pneumocytes", "GENE_OR_GENE_PRODUCT", 180, 199], ["surfactant", "SIMPLE_CHEMICAL", 230, 240], ["type II pneumocytes", "CELL_TYPE", 180, 199], ["Aminophylline", "TREATMENT", 0, 13], ["an adenosine A (2A)-receptor antagonist", "TREATMENT", 15, 54], ["caffeine", "TREATMENT", 60, 68], ["the type II pneumocytes", "PROBLEM", 176, 199], ["the surfactant production", "PROBLEM", 226, 251], ["central nervous", "ANATOMY", 113, 128]]], ["Intraoperational administration of aminophylline to the dam may be advantageous if a cesarean section is planned [79, 80] .", [["aminophylline", "CHEMICAL", 35, 48], ["aminophylline", "CHEMICAL", 35, 48], ["aminophylline", "SIMPLE_CHEMICAL", 35, 48], ["aminophylline", "TREATMENT", 35, 48], ["a cesarean section", "TREATMENT", 83, 101]]], ["Doxapram is routinely used to stimulate the central nervous system and relieve neonatal apnea following dystocia or cesarean section [81, 82] .", [["central nervous system", "ANATOMY", 44, 66], ["Doxapram", "CHEMICAL", 0, 8], ["apnea", "DISEASE", 88, 93], ["dystocia", "DISEASE", 104, 112], ["Doxapram", "CHEMICAL", 0, 8], ["Doxapram", "SIMPLE_CHEMICAL", 0, 8], ["central nervous system", "ANATOMICAL_SYSTEM", 44, 66], ["Doxapram", "TREATMENT", 0, 8], ["neonatal apnea", "PROBLEM", 79, 93], ["dystocia", "PROBLEM", 104, 112], ["cesarean section", "TREATMENT", 116, 132], ["central nervous", "ANATOMY", 44, 59]]], ["We general administer a small dose sublingual (5 mg in llama and alpaca crias and 50 mg in camels) initially after a cesarean section or dystocia.", [["dystocia", "DISEASE", 137, 145], ["sublingual", "ORGANISM_SUBDIVISION", 35, 45], ["llama", "ORGANISM", 55, 60], ["alpaca", "ORGANISM", 65, 71], ["a small dose sublingual", "TREATMENT", 22, 45], ["llama and alpaca crias", "TREATMENT", 55, 77], ["a cesarean section", "TREATMENT", 115, 133], ["dystocia", "PROBLEM", 137, 145]]], ["In neonates with severely depressed respiration, this dose, or up to twice this dose, should be given IV or IV.", [["depressed", "DISEASE", 26, 35], ["neonates", "ORGANISM", 3, 11], ["severely depressed respiration", "PROBLEM", 17, 47], ["IV", "TREATMENT", 108, 110], ["severely", "OBSERVATION_MODIFIER", 17, 25], ["depressed", "OBSERVATION", 26, 35]]], ["The neonate should be monitored closely for convulsions or hyperventilation.Management of the high-risk neonateSepsis is a major concern in all compromised neonates.", [["convulsions", "DISEASE", 44, 55], ["hyperventilation", "DISEASE", 59, 75], ["neonateSepsis", "DISEASE", 104, 117], ["neonate", "ORGANISM", 4, 11], ["neonates", "ORGANISM", 156, 164], ["convulsions", "PROBLEM", 44, 55], ["hyperventilation", "PROBLEM", 59, 75], ["Management", "TREATMENT", 76, 86], ["the high-risk neonateSepsis", "PROBLEM", 90, 117], ["all compromised neonates", "PROBLEM", 140, 164], ["high", "OBSERVATION_MODIFIER", 94, 98]]], ["In one study, the median age at presentation of [75, 76, 83] .Management of the high-risk neonateBoth Gram + and Gram \u00c0 organisms have been isolated from neonates with septicemia.", [["septicemia", "DISEASE", 168, 178], ["Gram", "GENE_OR_GENE_PRODUCT", 102, 106], ["neonates", "ORGANISM", 154, 162], ["neonateBoth Gram", "TEST", 90, 106], ["Gram \u00c0 organisms", "PROBLEM", 113, 129], ["septicemia", "PROBLEM", 168, 178], ["septicemia", "OBSERVATION", 168, 178]]], ["Based on common isolates, the antibiotics of choice for camelids at high risk of sepsis include the following combinations (enrofloxacin and PPG, enrofloxacin and ceftiofur, ceftiofur and gentamicin) [75, 76, 83] .", [["sepsis", "DISEASE", 81, 87], ["enrofloxacin", "CHEMICAL", 124, 136], ["PPG", "CHEMICAL", 141, 144], ["enrofloxacin", "CHEMICAL", 146, 158], ["ceftiofur", "CHEMICAL", 163, 172], ["ceftiofur", "CHEMICAL", 174, 183], ["gentamicin", "CHEMICAL", 188, 198], ["enrofloxacin", "CHEMICAL", 124, 136], ["PPG", "CHEMICAL", 141, 144], ["enrofloxacin", "CHEMICAL", 146, 158], ["ceftiofur", "CHEMICAL", 163, 172], ["ceftiofur", "CHEMICAL", 174, 183], ["gentamicin", "CHEMICAL", 188, 198], ["enrofloxacin", "SIMPLE_CHEMICAL", 124, 136], ["PPG", "SIMPLE_CHEMICAL", 141, 144], ["enrofloxacin", "SIMPLE_CHEMICAL", 146, 158], ["ceftiofur", "SIMPLE_CHEMICAL", 163, 172], ["ceftiofur", "SIMPLE_CHEMICAL", 174, 183], ["gentamicin", "SIMPLE_CHEMICAL", 188, 198], ["common isolates", "TREATMENT", 9, 24], ["the antibiotics of choice", "TREATMENT", 26, 51], ["camelids", "TREATMENT", 56, 64], ["sepsis", "PROBLEM", 81, 87], ["enrofloxacin", "TREATMENT", 124, 136], ["PPG", "TREATMENT", 141, 144], ["enrofloxacin", "TREATMENT", 146, 158], ["ceftiofur", "TREATMENT", 163, 172], ["ceftiofur", "TREATMENT", 174, 183], ["gentamicin", "TREATMENT", 188, 198], ["sepsis", "OBSERVATION", 81, 87]]], ["Gentamicin should be used with care, as it can be extremely nephrotoxic to severely dehydrated newborn camelids, or if there is already evidence of renal dysfunction.", [["renal", "ANATOMY", 148, 153], ["Gentamicin", "CHEMICAL", 0, 10], ["nephrotoxic", "DISEASE", 60, 71], ["renal dysfunction", "DISEASE", 148, 165], ["Gentamicin", "CHEMICAL", 0, 10], ["Gentamicin", "SIMPLE_CHEMICAL", 0, 10], ["renal", "ORGAN", 148, 153], ["Gentamicin", "TREATMENT", 0, 10], ["care", "TREATMENT", 31, 35], ["severely dehydrated newborn camelids", "PROBLEM", 75, 111], ["renal dysfunction", "PROBLEM", 148, 165], ["renal", "ANATOMY", 148, 153], ["dysfunction", "OBSERVATION", 154, 165]]], ["Blood cultures may be submitted, but broad-spectrum antimicrobial treatment should be started without delay.Management of the high-risk neonateSupportive treatment should include NSAIDs (ketoprofen 4 mg/kg SID) to control pain and toxemia and antiulcer medication (omeprazol, given orally, 2 mg/kg daily) to offset the effect of stress and NSAID.", [["Blood cultures", "ANATOMY", 0, 14], ["ketoprofen", "CHEMICAL", 187, 197], ["pain", "DISEASE", 222, 226], ["toxemia", "DISEASE", 231, 238], ["omeprazol", "CHEMICAL", 265, 274], ["ketoprofen", "CHEMICAL", 187, 197], ["omeprazol", "CHEMICAL", 265, 274], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["NSAIDs", "SIMPLE_CHEMICAL", 179, 185], ["ketoprofen", "SIMPLE_CHEMICAL", 187, 197], ["omeprazol", "SIMPLE_CHEMICAL", 265, 274], ["NSAID", "SIMPLE_CHEMICAL", 340, 345], ["Blood cultures", "TEST", 0, 14], ["broad-spectrum antimicrobial treatment", "TREATMENT", 37, 75], ["Management", "TREATMENT", 108, 118], ["the high-risk neonateSupportive treatment", "TREATMENT", 122, 163], ["NSAIDs", "TREATMENT", 179, 185], ["ketoprofen", "TREATMENT", 187, 197], ["pain", "PROBLEM", 222, 226], ["toxemia", "PROBLEM", 231, 238], ["antiulcer medication", "TREATMENT", 243, 263], ["omeprazol", "TREATMENT", 265, 274], ["stress and NSAID", "TREATMENT", 329, 345]]], ["Intravenous fluid therapy is indicated in all dehydrated, hypoglycemic newborns, however caution should be exercised regarding the rate of fluid replacement, as camelids are prone to pulmonary edema.", [["fluid", "ANATOMY", 12, 17], ["fluid", "ANATOMY", 139, 144], ["pulmonary", "ANATOMY", 183, 192], ["hypoglycemic", "DISEASE", 58, 70], ["pulmonary edema", "DISEASE", 183, 198], ["newborns", "ORGANISM", 71, 79], ["fluid", "ORGANISM_SUBSTANCE", 139, 144], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 183, 198], ["Intravenous fluid therapy", "TREATMENT", 0, 25], ["hypoglycemic newborns", "PROBLEM", 58, 79], ["fluid replacement", "TREATMENT", 139, 156], ["pulmonary edema", "PROBLEM", 183, 198], ["fluid therapy", "OBSERVATION", 12, 25], ["fluid replacement", "OBSERVATION", 139, 156], ["pulmonary", "ANATOMY", 183, 192], ["edema", "OBSERVATION", 193, 198]]], ["Severely dehydrated crias require fluid therapy.", [["fluid", "ANATOMY", 34, 39], ["fluid", "ORGANISM_SUBSTANCE", 34, 39], ["Severely dehydrated crias", "PROBLEM", 0, 25], ["fluid therapy", "TREATMENT", 34, 47], ["dehydrated", "OBSERVATION", 9, 19], ["fluid therapy", "OBSERVATION", 34, 47]]], ["The type of fluid should be determined based on glucose, electrolyte and blood gas evaluation.", [["blood", "ANATOMY", 73, 78], ["glucose", "CHEMICAL", 48, 55], ["glucose", "CHEMICAL", 48, 55], ["fluid", "ORGANISM_SUBSTANCE", 12, 17], ["glucose", "SIMPLE_CHEMICAL", 48, 55], ["electrolyte", "SIMPLE_CHEMICAL", 57, 68], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["glucose", "TEST", 48, 55], ["electrolyte and blood gas evaluation", "TEST", 57, 93], ["fluid", "OBSERVATION", 12, 17]]], ["Generally, a balanced isotonic solution with 2% dextrose and bicarbonate to correct metabolic acidosis are sufficient.", [["dextrose", "CHEMICAL", 48, 56], ["bicarbonate", "CHEMICAL", 61, 72], ["acidosis", "DISEASE", 94, 102], ["dextrose", "CHEMICAL", 48, 56], ["bicarbonate", "CHEMICAL", 61, 72], ["dextrose", "SIMPLE_CHEMICAL", 48, 56], ["bicarbonate", "SIMPLE_CHEMICAL", 61, 72], ["a balanced isotonic solution", "TREATMENT", 11, 39], ["2% dextrose", "TREATMENT", 45, 56], ["bicarbonate", "TREATMENT", 61, 72], ["metabolic acidosis", "PROBLEM", 84, 102], ["metabolic acidosis", "OBSERVATION", 84, 102]]], ["Dextrose concentration may be increased to 5% in hypoglycemic crias.", [["Dextrose", "CHEMICAL", 0, 8], ["hypoglycemic crias", "DISEASE", 49, 67], ["Dextrose", "CHEMICAL", 0, 8], ["Dextrose", "SIMPLE_CHEMICAL", 0, 8], ["Dextrose concentration", "TREATMENT", 0, 22], ["increased", "OBSERVATION_MODIFIER", 30, 39]]], ["Rate of administration should aim to correct half of the deficit over the first hour, and the other half over the next 2 h.", [["administration", "TREATMENT", 8, 22], ["the deficit", "PROBLEM", 53, 64], ["deficit", "OBSERVATION", 57, 64]]], ["Total or partial parenteral nutrition should be considered in severely depressed crias that are unable to nurse [84] .", [["parenteral", "ANATOMY", 17, 27], ["depressed", "DISEASE", 71, 80], ["Total or partial parenteral nutrition", "TREATMENT", 0, 37], ["severely depressed crias", "PROBLEM", 62, 86]]], ["Prognosis for life and normal growth depends primarily on the interval between birth and providing emergency care.Other emergency problems in first 24 h of lifeDiseases in the first 24 h of life are usually associated with congenital abnormalities, digestive (meconium retention), urinary problems (urine retention), exposure or malnutrition.Congenital abnormalitiesThe most common lethal congenital abnormalities that affect the camelid neonate are: choanal atresia, atresia ani or coli, and heart defects.", [["digestive", "ANATOMY", 249, 258], ["meconium", "ANATOMY", 260, 268], ["urinary", "ANATOMY", 281, 288], ["urine", "ANATOMY", 299, 304], ["choanal", "ANATOMY", 451, 458], ["ani", "ANATOMY", 476, 479], ["heart", "ANATOMY", 493, 498], ["congenital abnormalities", "DISEASE", 223, 247], ["meconium retention", "DISEASE", 260, 278], ["urinary problems", "DISEASE", 281, 297], ["urine retention", "DISEASE", 299, 314], ["malnutrition", "DISEASE", 329, 341], ["Congenital abnormalities", "DISEASE", 342, 366], ["congenital abnormalities", "DISEASE", 389, 413], ["choanal atresia", "DISEASE", 451, 466], ["atresia ani or coli", "DISEASE", 468, 487], ["heart defects", "DISEASE", 493, 506], ["digestive", "ORGANISM_SUBDIVISION", 249, 258], ["meconium", "ORGANISM_SUBDIVISION", 260, 268], ["urinary", "ORGANISM_SUBDIVISION", 281, 288], ["urine", "ORGANISM_SUBSTANCE", 299, 304], ["choanal", "ORGAN", 451, 458], ["atresia", "PATHOLOGICAL_FORMATION", 459, 466], ["heart", "ORGAN", 493, 498], ["coli", "SPECIES", 483, 487], ["emergency care", "TREATMENT", 99, 113], ["Other emergency problems", "PROBLEM", 114, 138], ["lifeDiseases", "TREATMENT", 156, 168], ["congenital abnormalities", "PROBLEM", 223, 247], ["digestive (meconium retention", "PROBLEM", 249, 278], ["urinary problems", "PROBLEM", 281, 297], ["urine retention", "PROBLEM", 299, 314], ["malnutrition", "PROBLEM", 329, 341], ["Congenital abnormalities", "PROBLEM", 342, 366], ["The most common lethal congenital abnormalities", "PROBLEM", 366, 413], ["choanal atresia", "PROBLEM", 451, 466], ["atresia ani", "PROBLEM", 468, 479], ["coli", "PROBLEM", 483, 487], ["heart defects", "PROBLEM", 493, 506], ["growth", "OBSERVATION_MODIFIER", 30, 36], ["urinary", "ANATOMY", 281, 288], ["malnutrition", "OBSERVATION", 329, 341], ["abnormalities", "OBSERVATION", 353, 366], ["abnormalities", "OBSERVATION", 400, 413], ["choanal", "ANATOMY", 451, 458], ["atresia", "OBSERVATION", 459, 466], ["atresia", "OBSERVATION", 468, 475], ["coli", "OBSERVATION", 483, 487], ["heart", "ANATOMY", 493, 498], ["defects", "OBSERVATION", 499, 506]]], ["Most commonly, affected animals will suffer from severe respiratory, circulatory or metabolic complications.", [["respiratory", "ANATOMY", 56, 67], ["animals", "ORGANISM", 24, 31], ["severe respiratory, circulatory or metabolic complications", "PROBLEM", 49, 107], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["respiratory", "ANATOMY", 56, 67], ["metabolic complications", "OBSERVATION", 84, 107]]], ["Heart defects can be very severe and lead to death of the cria within a few hours, but most will survive for a few days to months, with the only abnormality being failure to thrive.", [["Heart", "ANATOMY", 0, 5], ["Heart defects", "DISEASE", 0, 13], ["death", "DISEASE", 45, 50], ["Heart", "ORGAN", 0, 5], ["Heart defects", "PROBLEM", 0, 13], ["failure to thrive", "PROBLEM", 163, 180], ["defects", "OBSERVATION", 6, 13], ["failure", "OBSERVATION", 163, 170]]], ["Syncope or fainting were observed in crias with severe heart defects.Congenital abnormalitiesChoanal atresia is the lack of opening of the nasal air passages, resulting from the presence at the level of the choanae of a membranous or osseous separation between the nasal and pharyngeal cavities [85, 86] .", [["heart", "ANATOMY", 55, 60], ["nasal air", "ANATOMY", 139, 148], ["membranous", "ANATOMY", 220, 230], ["osseous", "ANATOMY", 234, 241], ["nasal", "ANATOMY", 265, 270], ["pharyngeal cavities", "ANATOMY", 275, 294], ["Syncope", "DISEASE", 0, 7], ["fainting", "DISEASE", 11, 19], ["heart defects", "DISEASE", 55, 68], ["Congenital abnormalities", "DISEASE", 69, 93], ["Choanal atresia", "DISEASE", 93, 108], ["heart", "ORGAN", 55, 60], ["nasal", "ORGAN", 265, 270], ["pharyngeal cavities", "MULTI-TISSUE_STRUCTURE", 275, 294], ["Syncope", "PROBLEM", 0, 7], ["fainting", "PROBLEM", 11, 19], ["severe heart defects", "PROBLEM", 48, 68], ["Congenital abnormalities", "PROBLEM", 69, 93], ["Choanal atresia", "PROBLEM", 93, 108], ["the nasal air passages", "PROBLEM", 135, 157], ["a membranous or osseous separation between the nasal and pharyngeal cavities", "PROBLEM", 218, 294], ["fainting", "OBSERVATION", 11, 19], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["heart", "ANATOMY", 55, 60], ["defects", "OBSERVATION", 61, 68], ["abnormalities", "OBSERVATION", 80, 93], ["atresia", "OBSERVATION", 101, 108], ["opening", "OBSERVATION_MODIFIER", 124, 131], ["nasal", "ANATOMY", 139, 144], ["air passages", "OBSERVATION", 145, 157], ["membranous", "OBSERVATION", 220, 230], ["osseous", "ANATOMY", 234, 241], ["separation", "OBSERVATION", 242, 252], ["nasal", "ANATOMY", 265, 270], ["pharyngeal cavities", "ANATOMY", 275, 294]]], ["Diagnosis can be confirmed by mouth to nose artificial breathing or by contrast radiographs of the head after injection of a radio-opaque substance in the nasal cavity.", [["mouth", "ANATOMY", 30, 35], ["nose", "ANATOMY", 39, 43], ["head", "ANATOMY", 99, 103], ["nasal cavity", "ANATOMY", 155, 167], ["mouth", "ORGANISM_SUBDIVISION", 30, 35], ["nose", "ORGANISM_SUBDIVISION", 39, 43], ["head", "ORGANISM_SUBDIVISION", 99, 103], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 155, 167], ["nose artificial breathing", "TEST", 39, 64], ["contrast radiographs of the head", "TEST", 71, 103], ["a radio-opaque substance in the nasal cavity", "TREATMENT", 123, 167], ["head", "ANATOMY", 99, 103], ["opaque substance", "OBSERVATION", 131, 147], ["nasal cavity", "ANATOMY", 155, 167]]], ["Maxillofacial agenesis or dysgenesis ''wry face'' is a head deformity characterized by varying degrees of deviation of the maxilla.", [["head", "ANATOMY", 55, 59], ["maxilla", "ANATOMY", 123, 130], ["Maxillofacial agenesis", "DISEASE", 0, 22], ["dysgenesis", "DISEASE", 26, 36], ["deformity", "DISEASE", 60, 69], ["head", "ORGANISM_SUBDIVISION", 55, 59], ["maxilla", "ORGAN", 123, 130], ["Maxillofacial agenesis", "PROBLEM", 0, 22], ["dysgenesis ''wry face", "PROBLEM", 26, 47], ["a head deformity", "PROBLEM", 53, 69], ["deviation of the maxilla", "PROBLEM", 106, 130], ["agenesis", "OBSERVATION", 14, 22], ["dysgenesis", "OBSERVATION", 26, 36], ["head", "ANATOMY", 55, 59], ["deformity", "OBSERVATION", 60, 69], ["varying", "OBSERVATION_MODIFIER", 87, 94], ["degrees", "OBSERVATION_MODIFIER", 95, 102], ["deviation", "OBSERVATION", 106, 115], ["maxilla", "ANATOMY", 123, 130]]], ["This abnormality may be associated with choanal atresia.", [["choanal", "ANATOMY", 40, 47], ["choanal atresia", "DISEASE", 40, 55], ["This abnormality", "PROBLEM", 0, 16], ["choanal atresia", "PROBLEM", 40, 55], ["may be associated with", "UNCERTAINTY", 17, 39], ["choanal", "ANATOMY", 40, 47], ["atresia", "OBSERVATION", 48, 55]]], ["There is no treatment for this condition and the cria should be euthanized.", [["treatment", "TREATMENT", 12, 21], ["this condition", "PROBLEM", 26, 40], ["no", "UNCERTAINTY", 9, 11], ["treatment", "OBSERVATION", 12, 21]]], ["Respiratory distress associated with congenital goiter has been described in camels [45] .Congenital abnormalitiesAtresia ani and atresia coli are, respectively, the lack of opening of the anal sphincter and lack of connection between the colon and the rectal cavity.", [["Respiratory", "ANATOMY", 0, 11], ["anal sphincter", "ANATOMY", 189, 203], ["colon", "ANATOMY", 239, 244], ["rectal cavity", "ANATOMY", 253, 266], ["Respiratory distress", "DISEASE", 0, 20], ["congenital goiter", "DISEASE", 37, 54], ["Congenital abnormalitiesAtresia ani and atresia coli", "DISEASE", 90, 142], ["Atresia ani", "ORGAN", 114, 125], ["anal sphincter", "ORGAN", 189, 203], ["colon", "ORGAN", 239, 244], ["rectal cavity", "MULTI-TISSUE_STRUCTURE", 253, 266], ["atresia coli", "SPECIES", 130, 142], ["Atresia ani and atresia coli", "SPECIES", 114, 142], ["Respiratory distress", "PROBLEM", 0, 20], ["congenital goiter", "PROBLEM", 37, 54], ["Congenital abnormalities", "PROBLEM", 90, 114], ["Atresia ani", "PROBLEM", 114, 125], ["atresia coli", "PROBLEM", 130, 142], ["opening of the anal sphincter", "PROBLEM", 174, 203], ["lack of connection between the colon and the rectal cavity", "PROBLEM", 208, 266], ["distress", "OBSERVATION", 12, 20], ["congenital", "OBSERVATION_MODIFIER", 37, 47], ["goiter", "OBSERVATION", 48, 54], ["Atresia", "OBSERVATION", 114, 121], ["atresia", "OBSERVATION", 130, 137], ["opening", "OBSERVATION", 174, 181], ["anal sphincter", "ANATOMY", 189, 203], ["colon", "ANATOMY", 239, 244], ["rectal cavity", "ANATOMY", 253, 266]]], ["These abnormalities results in the blockage of the intestinal transit and accumulation of fluid in the gastrointestinal tract.", [["intestinal", "ANATOMY", 51, 61], ["fluid", "ANATOMY", 90, 95], ["gastrointestinal tract", "ANATOMY", 103, 125], ["intestinal", "ORGAN", 51, 61], ["fluid", "ORGANISM_SUBSTANCE", 90, 95], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 103, 125], ["These abnormalities", "PROBLEM", 0, 19], ["the blockage of the intestinal transit", "PROBLEM", 31, 69], ["fluid in the gastrointestinal tract", "PROBLEM", 90, 125], ["abnormalities", "OBSERVATION", 6, 19], ["blockage", "OBSERVATION", 35, 43], ["intestinal", "ANATOMY", 51, 61], ["transit", "OBSERVATION_MODIFIER", 62, 69], ["accumulation", "OBSERVATION_MODIFIER", 74, 86], ["fluid", "OBSERVATION", 90, 95], ["gastrointestinal tract", "ANATOMY", 103, 125]]], ["The cria becomes progressively bloated and depressed.", [["cria", "ANATOMY", 4, 8], ["depressed", "DISEASE", 43, 52], ["progressively bloated", "PROBLEM", 17, 38], ["depressed", "PROBLEM", 43, 52], ["progressively", "OBSERVATION_MODIFIER", 17, 30], ["bloated", "OBSERVATION", 31, 38], ["depressed", "OBSERVATION_MODIFIER", 43, 52]]], ["Ultrasonographic and radiologic examination of the abdominal cavity allows confirmation of the diagnosis.", [["abdominal cavity", "ANATOMY", 51, 67], ["abdominal cavity", "MULTI-TISSUE_STRUCTURE", 51, 67], ["Ultrasonographic", "TEST", 0, 16], ["radiologic examination of the abdominal cavity", "TEST", 21, 67], ["abdominal", "ANATOMY", 51, 60]]], ["Atresia coli may be mistaken for meconium retention.", [["meconium", "ANATOMY", 33, 41], ["Atresia coli", "DISEASE", 0, 12], ["meconium retention", "DISEASE", 33, 51], ["Atresia coli", "ORGANISM", 0, 12], ["meconium", "ORGANISM_SUBSTANCE", 33, 41], ["Atresia coli", "SPECIES", 0, 12], ["Atresia coli", "SPECIES", 0, 12], ["Atresia coli", "PROBLEM", 0, 12], ["meconium retention", "PROBLEM", 33, 51], ["meconium retention", "OBSERVATION", 33, 51]]], ["In the female cria, these abnormalities may involve the genital tract.", [["genital tract", "ANATOMY", 56, 69], ["genital tract", "ORGANISM_SUBDIVISION", 56, 69], ["these abnormalities", "PROBLEM", 20, 39], ["abnormalities", "OBSERVATION", 26, 39], ["genital tract", "ANATOMY", 56, 69]]], ["Surgical correction of the atresia ani has described [87] .Congenital abnormalitiesCongenital blindness associated with different ocular defects has also been reported and will impact neonate behavior and wellness [88] [89] [90] .Congenital abnormalitiesIt is important that the practitioner established the diagnosis of congenital abnormalities with certainty, because some of these may be hereditary [91, 92] .Meconium retentionMeconium is the amniotic fluid ingested by the fetus during pregnancy.", [["ani", "ANATOMY", 35, 38], ["ocular", "ANATOMY", 130, 136], ["amniotic fluid", "ANATOMY", 446, 460], ["fetus", "ANATOMY", 477, 482], ["atresia ani", "DISEASE", 27, 38], ["Congenital blindness", "DISEASE", 83, 103], ["ocular defects", "DISEASE", 130, 144], ["Congenital abnormalities", "DISEASE", 230, 254], ["congenital abnormalities", "DISEASE", 321, 345], ["hereditary", "DISEASE", 391, 401], ["ani", "ORGAN", 35, 38], ["ocular", "ORGAN", 130, 136], ["amniotic fluid", "ORGANISM_SUBSTANCE", 446, 460], ["fetus", "ORGAN", 477, 482], ["Surgical correction", "TREATMENT", 0, 19], ["the atresia ani", "PROBLEM", 23, 38], ["Congenital abnormalities", "PROBLEM", 59, 83], ["Congenital blindness", "PROBLEM", 83, 103], ["different ocular defects", "PROBLEM", 120, 144], ["Congenital abnormalities", "PROBLEM", 230, 254], ["congenital abnormalities", "PROBLEM", 321, 345], ["Meconium retentionMeconium", "PROBLEM", 412, 438], ["the amniotic fluid", "PROBLEM", 442, 460], ["the fetus during pregnancy", "PROBLEM", 473, 499], ["atresia", "OBSERVATION", 27, 34], ["Congenital", "OBSERVATION_MODIFIER", 83, 93], ["blindness", "OBSERVATION", 94, 103], ["different", "OBSERVATION_MODIFIER", 120, 129], ["ocular defects", "OBSERVATION", 130, 144], ["abnormalities", "OBSERVATION", 241, 254], ["congenital", "OBSERVATION", 321, 331], ["retentionMeconium", "OBSERVATION", 421, 438], ["amniotic fluid", "OBSERVATION", 446, 460]]], ["Meconium is usually passed within 18-24 h after birth as dark pasty or stringy feces.", [["Meconium", "CHEMICAL", 0, 8], ["feces", "ORGANISM_SUBSTANCE", 79, 84]]], ["Clinical signs of meconium retention include straining, squatting, tail wagging, anorexia, and signs of abdominal discomfort.", [["meconium", "ANATOMY", 18, 26], ["tail", "ANATOMY", 67, 71], ["abdominal", "ANATOMY", 104, 113], ["meconium retention", "DISEASE", 18, 36], ["wagging", "DISEASE", 72, 79], ["anorexia", "DISEASE", 81, 89], ["abdominal discomfort", "DISEASE", 104, 124], ["meconium", "ORGANISM_SUBSTANCE", 18, 26], ["abdominal", "ORGANISM_SUBDIVISION", 104, 113], ["meconium retention", "PROBLEM", 18, 36], ["straining", "PROBLEM", 45, 54], ["tail wagging", "PROBLEM", 67, 79], ["anorexia", "PROBLEM", 81, 89], ["abdominal discomfort", "PROBLEM", 104, 124], ["meconium retention", "OBSERVATION", 18, 36], ["tail", "OBSERVATION_MODIFIER", 67, 71], ["anorexia", "OBSERVATION", 81, 89], ["abdominal", "ANATOMY", 104, 113], ["discomfort", "OBSERVATION", 114, 124]]], ["Initial treatment consists of one or two warm soapy water enemas (20-40 mL).", [["Initial treatment", "TREATMENT", 0, 17], ["two warm soapy water enemas", "TREATMENT", 37, 64]]], ["If after two enemas, the meconium has not passed, intravenous fluids may be indicated, as multiple soapy water enemas may irritate the rectal mucosa, resulting in severe straining and rectal prolapse [93] .", [["intravenous", "ANATOMY", 50, 61], ["rectal mucosa", "ANATOMY", 135, 148], ["rectal", "ANATOMY", 184, 190], ["rectal prolapse", "DISEASE", 184, 199], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 61], ["rectal mucosa", "MULTI-TISSUE_STRUCTURE", 135, 148], ["rectal", "ORGAN", 184, 190], ["two enemas", "TREATMENT", 9, 19], ["intravenous fluids", "TREATMENT", 50, 68], ["multiple soapy water enemas", "TREATMENT", 90, 117], ["the rectal mucosa", "PROBLEM", 131, 148], ["severe straining", "PROBLEM", 163, 179], ["rectal prolapse", "PROBLEM", 184, 199], ["meconium", "OBSERVATION", 25, 33], ["rectal mucosa", "ANATOMY", 135, 148], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["straining", "OBSERVATION", 170, 179], ["rectal", "ANATOMY", 184, 190], ["prolapse", "OBSERVATION", 191, 199]]], ["Crias that have retained meconium may have other abnormalities and should be examined closely.", [["meconium", "ORGANISM_SUBSTANCE", 25, 33], ["retained meconium", "PROBLEM", 16, 33], ["other abnormalities", "PROBLEM", 43, 62], ["meconium", "OBSERVATION", 25, 33], ["abnormalities", "OBSERVATION", 49, 62]]], ["Routine administration of enemas to every newborn cria should be discouraged.Urine retentionUrine retention may be associated with congenital abnormalities of the urinary and genital tracts [94] .", [["Urine", "ANATOMY", 77, 82], ["urinary", "ANATOMY", 163, 170], ["genital tracts", "ANATOMY", 175, 189], ["congenital abnormalities of the urinary and genital tracts", "DISEASE", 131, 189], ["Urine", "ORGANISM_SUBSTANCE", 77, 82], ["urinary", "ORGANISM_SUBDIVISION", 163, 170], ["genital", "ORGANISM_SUBDIVISION", 175, 182], ["Routine administration of enemas", "TREATMENT", 0, 32], ["Urine retentionUrine retention", "PROBLEM", 77, 107], ["congenital abnormalities of the urinary and genital tracts", "PROBLEM", 131, 189], ["retentionUrine retention", "OBSERVATION", 83, 107], ["may be associated with", "UNCERTAINTY", 108, 130], ["congenital", "OBSERVATION", 131, 141], ["urinary", "ANATOMY", 163, 170], ["genital tracts", "ANATOMY", 175, 189]]], ["In males, urethral blockage (aplasia) results in bladder rupture.", [["urethral", "ANATOMY", 10, 18], ["bladder", "ANATOMY", 49, 56], ["aplasia", "DISEASE", 29, 36], ["bladder rupture", "DISEASE", 49, 64], ["urethral", "ORGAN", 10, 18], ["bladder", "ORGAN", 49, 56], ["urethral blockage (aplasia)", "PROBLEM", 10, 37], ["bladder rupture", "PROBLEM", 49, 64], ["urethral", "ANATOMY", 10, 18], ["blockage", "OBSERVATION", 19, 27], ["aplasia", "OBSERVATION", 29, 36], ["bladder", "ANATOMY", 49, 56], ["rupture", "OBSERVATION", 57, 64]]], ["In females, vulvar agenesis or atresia vulvi present with an obvious bulging of the perineum and often symptoms of pain, due to the large quantity of urine in the uterus and abdominal distension [31, 71] .Umbilical abnormalitiesAccidents to the umbilical stump are not uncommon.", [["vulvar agenesis", "ANATOMY", 12, 27], ["atresia vulvi", "ANATOMY", 31, 44], ["perineum", "ANATOMY", 84, 92], ["urine", "ANATOMY", 150, 155], ["uterus", "ANATOMY", 163, 169], ["abdominal", "ANATOMY", 174, 183], ["Umbilical", "ANATOMY", 205, 214], ["umbilical stump", "ANATOMY", 245, 260], ["vulvar agenesis", "DISEASE", 12, 27], ["atresia vulvi", "DISEASE", 31, 44], ["bulging of the perineum", "DISEASE", 69, 92], ["pain", "DISEASE", 115, 119], ["abdominal distension", "DISEASE", 174, 194], ["Umbilical abnormalities", "DISEASE", 205, 228], ["Accidents to the umbilical stump", "DISEASE", 228, 260], ["vulvar agenesis", "PATHOLOGICAL_FORMATION", 12, 27], ["perineum", "ORGAN", 84, 92], ["urine", "ORGANISM_SUBSTANCE", 150, 155], ["uterus", "ORGAN", 163, 169], ["abdominal", "ORGANISM_SUBDIVISION", 174, 183], ["umbilical stump", "MULTI-TISSUE_STRUCTURE", 245, 260], ["vulvar agenesis", "PROBLEM", 12, 27], ["atresia vulvi", "PROBLEM", 31, 44], ["an obvious bulging of the perineum", "PROBLEM", 58, 92], ["often symptoms of pain", "PROBLEM", 97, 119], ["the large quantity of urine in the uterus", "PROBLEM", 128, 169], ["abdominal distension", "PROBLEM", 174, 194], ["Umbilical abnormalities", "PROBLEM", 205, 228], ["vulvar", "ANATOMY", 12, 18], ["agenesis", "OBSERVATION", 19, 27], ["atresia", "OBSERVATION", 31, 38], ["obvious", "OBSERVATION_MODIFIER", 61, 68], ["bulging", "OBSERVATION", 69, 76], ["perineum", "ANATOMY", 84, 92], ["pain", "OBSERVATION", 115, 119], ["large", "OBSERVATION_MODIFIER", 132, 137], ["quantity", "OBSERVATION_MODIFIER", 138, 146], ["urine", "OBSERVATION", 150, 155], ["uterus", "ANATOMY", 163, 169], ["abdominal distension", "ANATOMY", 174, 194], ["abnormalities", "OBSERVATION", 215, 228], ["umbilical stump", "ANATOMY", 245, 260], ["not", "UNCERTAINTY", 265, 268], ["uncommon", "OBSERVATION", 269, 277]]], ["The simplest form is persistent bleeding, which can be treated with hemostasis provided by a hemostat or sutures.", [["bleeding", "DISEASE", 32, 40], ["persistent bleeding", "PROBLEM", 21, 40], ["hemostasis", "TREATMENT", 68, 78], ["a hemostat or sutures", "TREATMENT", 91, 112], ["persistent", "OBSERVATION_MODIFIER", 21, 31], ["bleeding", "OBSERVATION", 32, 40], ["sutures", "OBSERVATION", 105, 112]]], ["Persistent urachus is not as common as in other species.", [["urachus", "ANATOMY", 11, 18], ["urachus", "ORGAN", 11, 18], ["Persistent urachus", "PROBLEM", 0, 18], ["urachus", "OBSERVATION", 11, 18], ["not as", "UNCERTAINTY", 22, 28], ["species", "OBSERVATION", 48, 55]]], ["Umblical hernia and rupture of the abdominal wall with eventration has been seen by the author following dystocia due to uterine torsion and may be due to wrapping of the cord around the fetus.", [["abdominal wall", "ANATOMY", 35, 49], ["uterine", "ANATOMY", 121, 128], ["cord", "ANATOMY", 171, 175], ["fetus", "ANATOMY", 187, 192], ["Umblical hernia", "DISEASE", 0, 15], ["rupture of the abdominal wall", "DISEASE", 20, 49], ["dystocia", "DISEASE", 105, 113], ["uterine torsion", "DISEASE", 121, 136], ["abdominal wall", "MULTI-TISSUE_STRUCTURE", 35, 49], ["uterine", "ORGAN", 121, 128], ["cord", "ORGAN", 171, 175], ["fetus", "ORGAN", 187, 192], ["Umblical hernia", "PROBLEM", 0, 15], ["rupture of the abdominal wall", "PROBLEM", 20, 49], ["eventration", "PROBLEM", 55, 66], ["dystocia", "PROBLEM", 105, 113], ["uterine torsion", "PROBLEM", 121, 136], ["wrapping of the cord", "PROBLEM", 155, 175], ["hernia", "OBSERVATION", 9, 15], ["rupture", "OBSERVATION", 20, 27], ["abdominal wall", "ANATOMY", 35, 49], ["eventration", "OBSERVATION", 55, 66], ["dystocia", "OBSERVATION", 105, 113], ["uterine", "ANATOMY", 121, 128], ["torsion", "OBSERVATION", 129, 136], ["may be due to", "UNCERTAINTY", 141, 154], ["wrapping", "OBSERVATION", 155, 163], ["cord", "ANATOMY", 171, 175], ["fetus", "ANATOMY", 187, 192]]], ["These are easily replaced surgically.Failure of passive transferFailure of passive transfer is a major cause of neonatal mortality in camelids [95] .", [["neonatal mortality", "PROBLEM", 112, 130]]], ["Assessment of IgG concentrations can be performed 18 h after birth [96] [97] [98] .", [["IgG", "GENE_OR_GENE_PRODUCT", 14, 17], ["IgG", "PROTEIN", 14, 17], ["IgG concentrations", "PROBLEM", 14, 32]]], ["Serum total protein concentrations <5 mg/ dL are also very indicative of failure of passive transfer.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum total protein concentrations", "TEST", 0, 34], ["failure of passive transfer", "PROBLEM", 73, 100], ["very indicative of", "UNCERTAINTY", 54, 72], ["failure", "OBSERVATION", 73, 80]]], ["In these cases, hyperimmune plasma should be given IV or IP (15-25 mL/kg).", [["plasma", "ANATOMY", 28, 34], ["hyperimmune", "ORGANISM", 16, 27], ["plasma", "ORGANISM_SUBSTANCE", 28, 34], ["IP", "SIMPLE_CHEMICAL", 57, 59], ["hyperimmune plasma", "TREATMENT", 16, 34], ["IV or IP", "TREATMENT", 51, 59]]], ["This product is collected from llamas regularly immunized with Clostridium perfringens type C, Escherichia coli bacterin-toxoid, Clostridium chauvoeisepticum, Clostridium haemolyticum, Clostridium novyi, Clostridium tetani and Clostridium perfringens types C and D bacterin-toxoid, killed Equine herpes virus-1, bovine rota-coronavirus modified live virus, J-5 E. coli bacterin, IMRAD 3 killed rabies vaccine, and inactivated cultures of Leptospira canicola, Leptospira grippotyphosa, Leptospira hardjo, Leptospira ichterohaemorrhagiae and Leptospira pomona.ConclusionReproductive emergencies involve not only saving the health but also the reproductive future of the patient.", [["Clostridium chauvoeisepticum", "DISEASE", 129, 157], ["Clostridium haemolyticum", "DISEASE", 159, 183], ["Equine herpes virus", "DISEASE", 289, 308], ["Leptospira canicola", "DISEASE", 438, 457], ["Leptospira grippotyphosa", "DISEASE", 459, 483], ["llamas", "ORGANISM", 31, 37], ["Clostridium perfringens type C", "ORGANISM", 63, 93], ["Escherichia coli", "ORGANISM", 95, 111], ["bacterin-toxoid", "ORGANISM", 112, 127], ["Clostridium chauvoeisepticum", "ORGANISM", 129, 157], ["Clostridium haemolyticum", "ORGANISM", 159, 183], ["Clostridium novyi", "ORGANISM", 185, 202], ["Clostridium tetani", "ORGANISM", 204, 222], ["Clostridium perfringens types C", "ORGANISM", 227, 258], ["D bacterin-toxoid", "ORGANISM", 263, 280], ["Equine", "ORGANISM", 289, 295], ["herpes virus-1", "ORGANISM", 296, 310], ["bovine", "ORGANISM", 312, 318], ["rota-coronavirus", "ORGANISM", 319, 335], ["live virus", "ORGANISM", 345, 355], ["J-5", "ORGANISM", 357, 360], ["E. coli", "ORGANISM", 361, 368], ["bacterin", "ORGANISM", 369, 377], ["IMRAD 3", "ORGANISM", 379, 386], ["rabies", "ORGANISM", 394, 400], ["Leptospira canicola", "ORGANISM", 438, 457], ["Leptospira grippotyphosa", "ORGANISM", 459, 483], ["Leptospira hardjo", "ORGANISM", 485, 502], ["Leptospira ichterohaemorrhagiae", "ORGANISM", 504, 535], ["Leptospira pomona", "ORGANISM", 540, 557], ["patient", "ORGANISM", 668, 675], ["Clostridium perfringens", "SPECIES", 63, 86], ["Escherichia coli bacterin", "SPECIES", 95, 120], ["-toxoid", "SPECIES", 120, 127], ["Clostridium chauvoeisepticum", "SPECIES", 129, 157], ["Clostridium haemolyticum", "SPECIES", 159, 183], ["Clostridium novyi", "SPECIES", 185, 202], ["Clostridium tetani", "SPECIES", 204, 222], ["Clostridium perfringens", "SPECIES", 227, 250], ["Equine herpes virus-1", "SPECIES", 289, 310], ["bovine", "SPECIES", 312, 318], ["rota-coronavirus", "SPECIES", 319, 335], ["E. coli", "SPECIES", 361, 368], ["Leptospira canicola", "SPECIES", 438, 457], ["Leptospira grippotyphosa", "SPECIES", 459, 483], ["Leptospira hardjo", "SPECIES", 485, 502], ["Leptospira ichterohaemorrhagiae", "SPECIES", 504, 535], ["Leptospira pomona", "SPECIES", 540, 557], ["patient", "SPECIES", 668, 675], ["Clostridium perfringens type C", "SPECIES", 63, 93], ["Escherichia coli", "SPECIES", 95, 111], ["Clostridium chauvoeisepticum", "SPECIES", 129, 157], ["Clostridium haemolyticum", "SPECIES", 159, 183], ["Clostridium novyi", "SPECIES", 185, 202], ["Clostridium tetani", "SPECIES", 204, 222], ["Clostridium perfringens", "SPECIES", 227, 250], ["Equine herpes virus-1", "SPECIES", 289, 310], ["bovine rota-coronavirus", "SPECIES", 312, 335], ["E. coli", "SPECIES", 361, 368], ["Leptospira canicola", "SPECIES", 438, 457], ["Leptospira grippotyphosa", "SPECIES", 459, 483], ["Leptospira hardjo", "SPECIES", 485, 502], ["Leptospira ichterohaemorrhagiae", "SPECIES", 504, 535], ["Leptospira pomona", "SPECIES", 540, 557], ["Clostridium perfringens type C", "PROBLEM", 63, 93], ["Escherichia coli bacterin", "TREATMENT", 95, 120], ["toxoid", "TREATMENT", 121, 127], ["Clostridium chauvoeisepticum", "TREATMENT", 129, 157], ["Clostridium haemolyticum", "TREATMENT", 159, 183], ["Clostridium novyi", "TREATMENT", 185, 202], ["Clostridium tetani", "PROBLEM", 204, 222], ["Clostridium perfringens", "PROBLEM", 227, 250], ["D bacterin", "TREATMENT", 263, 273], ["toxoid", "TREATMENT", 274, 280], ["killed Equine herpes virus", "TREATMENT", 282, 308], ["bovine rota", "TREATMENT", 312, 323], ["coronavirus", "PROBLEM", 324, 335], ["J-5 E. coli bacterin", "TREATMENT", 357, 377], ["IMRAD", "TREATMENT", 379, 384], ["rabies vaccine", "TREATMENT", 394, 408], ["inactivated cultures", "TEST", 414, 434], ["Leptospira canicola", "PROBLEM", 438, 457], ["Leptospira grippotyphosa", "TEST", 459, 483], ["Leptospira hardjo", "PROBLEM", 485, 502], ["Leptospira ichterohaemorrhagiae", "PROBLEM", 504, 535], ["Leptospira pomona", "PROBLEM", 540, 557], ["Leptospira ichterohaemorrhagiae", "OBSERVATION", 504, 535], ["Leptospira pomona", "OBSERVATION", 540, 557]]], ["Emergencies in the pregnant female present an additional challenge, in that the fetus has to be considered regarding response to treatment and viability.", [["fetus", "ANATOMY", 80, 85], ["female", "ORGANISM", 28, 34], ["fetus", "ORGANISM", 80, 85], ["treatment", "TREATMENT", 129, 138]]], ["At times, it is important to make a decision as to which of the two (dam or fetus) has more economic or sentimental value, or chances to survive.", [["fetus", "ANATOMY", 76, 81], ["fetus", "ORGAN", 76, 81]]], ["One of the main challenges in emergency care in camelids is the lack of evidence-based scientific data on treatment and outcome assessment.", [["treatment", "TREATMENT", 106, 115], ["outcome assessment", "TEST", 120, 138], ["main", "OBSERVATION_MODIFIER", 11, 15]]], ["Although extrapolation from other species has been possible, it is important to remember species peculiarities, especially with regard to fluid therapy.", [["fluid", "ANATOMY", 138, 143], ["extrapolation from other species", "PROBLEM", 9, 41], ["fluid therapy", "TREATMENT", 138, 151]]], ["Handling of obstetrical situations is particularly important, as many female camelids loose their ability to reproduce due to iatrogenic vaginal adhesions and cervical trauma from prolonged manipulation.ConclusionIn the male, hyperthermia (environmental or pathologic) is the leading cause of reproductive loss and client education regarding its prevention and early recognition is paramount for successful preservation of fertility.ConclusionVeterinarians involved in camelid practice, of which reproductive services (including reproductive emergencies and neonatology) represents over 70% of the complaints, should have a very good understanding regarding anatomical, physiological and medical peculiarities of camelids, and utilize their experience in other species.", [["vaginal adhesions", "ANATOMY", 137, 154], ["cervical", "ANATOMY", 159, 167], ["vaginal adhesions", "DISEASE", 137, 154], ["trauma", "DISEASE", 168, 174], ["hyperthermia", "DISEASE", 226, 238], ["reproductive loss", "DISEASE", 293, 310], ["vaginal", "ORGANISM_SUBDIVISION", 137, 144], ["cervical", "ORGAN", 159, 167], ["iatrogenic vaginal adhesions", "PROBLEM", 126, 154], ["cervical trauma", "PROBLEM", 159, 174], ["prolonged manipulation", "TREATMENT", 180, 202], ["hyperthermia", "PROBLEM", 226, 238], ["reproductive loss", "PROBLEM", 293, 310], ["client education", "TREATMENT", 315, 331], ["vaginal", "ANATOMY", 137, 144], ["adhesions", "OBSERVATION", 145, 154], ["cervical", "ANATOMY", 159, 167], ["trauma", "OBSERVATION", 168, 174], ["hyperthermia", "OBSERVATION", 226, 238]]], ["This makes an excellent point for the importance of comparative approach to training theriogenologists and large animal veterinarians.", [["training theriogenologists", "TREATMENT", 76, 102], ["large", "OBSERVATION_MODIFIER", 107, 112]]], ["Emergency drugs and protocols (Table 3) should be in place to ensure timely delivery of critical care and improved outcomes.", [["Emergency drugs", "TREATMENT", 0, 15], ["critical care", "TREATMENT", 88, 101]]]], "5d67d8b431d35ba87a8cd674b88add5a394f06fa": [["For example, some problems related to 2D (two dimensional) bond percolation with extended neighborhoods may provide a way to understand the spread of coronavirus from a percolation point of view.", [["coronavirus", "DISEASE", 150, 161], ["coronavirus", "ORGANISM", 150, 161], ["some problems", "PROBLEM", 13, 26], ["2D (two dimensional) bond percolation", "TREATMENT", 38, 75], ["coronavirus", "PROBLEM", 150, 161]]], ["Bond percolation with extended neighbors has long-range links similar to small-world networks [8] and is similar to spatial models of the spread of epidemics via long-range links [9] .", [["Bond percolation", "PROBLEM", 0, 16]]], ["Site percolation on lattices with extended neighborhoods corresponds to problems of adsorption of extended shapes on a lattice, such as disks and squares [10, 11] .", [["Site percolation on lattices", "PROBLEM", 0, 28], ["percolation", "OBSERVATION_MODIFIER", 5, 16]]], ["In addition, this kind of lattice structure lies between discrete percolation and continuum percolation, so further study will be helpful to establish the relationship between these two problems [10] [11] [12] . * zpxun@cumt.edu.cn \u2020 dphao@cumt.edu.cn \u2021 rziff@umich.eduI.", [["continuum percolation", "TREATMENT", 82, 103], ["further study", "TEST", 108, 121], ["lattice structure", "OBSERVATION", 26, 43], ["discrete", "OBSERVATION_MODIFIER", 57, 65], ["percolation", "OBSERVATION_MODIFIER", 66, 77], ["continuum percolation", "OBSERVATION", 82, 103]]], ["INTRODUCTIONThe study of percolation on lattices with extended ranges of the bonds goes back to the \"equivalent neighbor model\" of Dalton, Domb and Sykes in 1964 [12] [13] [14] , and many papers have followed since.", [["The study", "TEST", 12, 21], ["percolation on lattices", "TREATMENT", 25, 48]]], ["Gouker and Family [15] studied long-range site percolation on compact regions in a diamond shape on a square lattice, up to a lattice distance of 10.", [["long-range site", "DNA", 31, 46], ["diamond shape", "OBSERVATION_MODIFIER", 83, 96]]], ["Jerauld, Scriven and Davis [16] studied both site and bond percolation on body-centered cubic lattices with nearest and next-nearest-neighbor bonds.", [["body", "ANATOMY", 74, 78], ["bond percolation", "OBSERVATION", 54, 70], ["body", "ANATOMY", 74, 78]]], ["Gawron and Cieplak [17] studied site percolation on face-centered cubic lattices up to fourth nearest neighbors. d'Iribarne, Rasigni and Rasigni [18] [19] [20] studied site percolation on all eleven of the Archimedian lattices (\"mosaics\") with long-range connections up to the 10th nearest neighbors.", [["d'Iribarne", "CHEMICAL", 113, 123], ["Rasigni [18] [19] [20]", "CHEMICAL", 137, 159], ["Gawron", "SIMPLE_CHEMICAL", 0, 6], ["Rasigni", "SIMPLE_CHEMICAL", 125, 132], ["Archimedian lattices", "PROTEIN", 206, 226], ["Gawron and Cieplak", "TREATMENT", 0, 18], ["Rasigni", "TEST", 137, 144]]], ["Malarz and Galam [21] introduced the idea of \"complex neighborhoods\" where various combinations of neighborhoods, not necessarily compact, are studied, and this has been followed up by many subsequent works in two, three, and four dimensions [21] [22] [23] [24] [25] [26] .", [["[21] [22] [23] [24] [25] [26]", "SIMPLE_CHEMICAL", 242, 271]]], ["Koza and collaborators [10, 11] studied percolation of overlapping shapes on a lattice, which can be mapped to long-range site percolation as discussed below.", [["a lattice", "TREATMENT", 77, 86]]], ["Most of the earlier work involved site percolation, but bond percolation has also been studied to high precision in some recent extensive works [27] [28] [29] [30] [31] .", [["[27] [28] [29] [30]", "CHEMICAL", 144, 163], ["[27] [28] [29] [30] [31]", "SIMPLE_CHEMICAL", 144, 168], ["bond percolation", "PROBLEM", 56, 72]]], ["A theoretical analysis of finite-z corrections for the bond thresholds has recently been given by Frei and Perkins [32] .", [["A theoretical analysis", "TEST", 0, 22], ["finite-z corrections", "TREATMENT", 26, 46], ["the bond thresholds", "TREATMENT", 51, 70]]], ["Some related work on polymer systems has also appeared recently [33] .I. INTRODUCTIONCorrelations between percolation thresholds p c and coordination number z and other properties of lattices have long been discussed in the percolation field.", [["Some related work on polymer systems", "PROBLEM", 0, 36]]], ["Domb [12] argued that for long-range site percolation, the asymptotic behavior for large z could be related to the continuum percolation threshold \u03b7 c for objects of the same shape as the neighborhood, and this argument has also been advanced by others [10, 11, 20] .", [["long-range site percolation", "TREATMENT", 26, 53], ["large z", "PROBLEM", 83, 90]]], ["As discussed below, arXiv:2010.02895v1 [cond-mat.stat-mech] 6 Oct 2020A.", [["Oct 2020A", "DNA", 62, 71], ["arXiv:", "TEST", 20, 26]]], ["Simulation methodWe use a single-cluster growth algorithm described in previous papers [29, 30, 34] .", [["a single-cluster growth algorithm", "TREATMENT", 24, 57]]], ["We generate many samples of individual clusters and put the results in bins in a range of (2 n , 2 n+1 \u2212 1) for n = 0, 1, 2, . . ..", [["individual clusters", "PROBLEM", 28, 47]]], ["Clusters still growing when they reach an upper size cutoff are counted in the last bin.", [["upper", "ORGANISM_SUBDIVISION", 42, 47], ["growing", "OBSERVATION_MODIFIER", 15, 22], ["upper size", "OBSERVATION_MODIFIER", 42, 52]]], ["From the values in the bins, we are able to find the quantity P \u2265s , the probability that a cluster grows greater than or equal to size s, for s = 2 n .", [["P \u2265s", "DNA", 62, 66], ["a cluster grows", "TEST", 90, 105]]], ["From the behavior of this function, we can determine if we are above, near, or below the percolation threshold, as discussed below.B. Basic theoryThe method mentioned above depends on knowing the behavior of the size distribution (number of clusters of size s) n s (p).", [["size", "OBSERVATION_MODIFIER", 212, 216]]], ["In the scaling limit, in which s is large and (p \u2212 p c ) is small such that (p \u2212 p c )s \u03c3 is constant, n s (p) behaves asB.", [["asB", "PROTEIN", 119, 122], ["large and (p \u2212 p c )", "PROBLEM", 36, 56], ["scaling limit", "OBSERVATION_MODIFIER", 7, 20], ["large", "OBSERVATION_MODIFIER", 36, 41], ["small", "OBSERVATION_MODIFIER", 60, 65]]], ["Basic theorywhere \u03c4 , \u03c3, and f (x) are universal, while A 0 and B 0 are lattice-dependent \"metric factors.\"", [["B 0", "GENE_OR_GENE_PRODUCT", 64, 67], ["B 0", "PROTEIN", 64, 67], ["metric factors", "PROTEIN", 91, 105]]], ["For finite systems at p c , there are corrections to this of the formB.", [["formB", "DNA", 65, 70]]], ["Basic theoryThe probability that a point belongs to a cluster of size greater than or equal to s is given by P \u2265s = \u221e s =s s n s , and it follows by expanding Eq.", [["P \u2265s", "TEST", 109, 113], ["s n s", "TEST", 123, 128], ["size", "OBSERVATION_MODIFIER", 65, 69], ["greater", "OBSERVATION_MODIFIER", 70, 77]]], ["(4) that, for p close to p c and s large (see Refs.", [["large", "OBSERVATION_MODIFIER", 35, 40]]], ["[29, 30] for more details), [37] , 0.60(8) [38] , 0.64(5) [39] for \u2126, and 0.4522(8) [35] , 0.45237(8) [36] , 0.4419 [40] for \u03c3.B. Basic theoryWe set the upper size cutoff to be 2 16 occupied sites.", [["\u2126", "TEST", 67, 68], ["upper size", "OBSERVATION_MODIFIER", 153, 163], ["cutoff", "OBSERVATION", 164, 170]]], ["Monte Carlo simulations were performed on system size L \u00d7 L \u00d7 L with L = 512 under periodic boundary conditions.", [["Monte Carlo simulations", "TEST", 0, 23], ["periodic boundary conditions", "TREATMENT", 83, 111]]], ["We chose \u03c4 = 2.18905 (15) , \u2126 = 0.63(4), and \u03c3 = 0.4522 (2) .", [["\u03c3", "TEST", 45, 46]]], ["Here we take large error bars on these values for the sake of safety.", [["these values", "TEST", 33, 45]]], ["Then the number of clusters greater than or equal to size s could be found based on the data from our simulation, and the quantity s \u03c4 \u22122 P \u2265s could be easily calculated.B. Basic theoryFirst, we can see from Eq.", [["our simulation", "TEST", 98, 112], ["clusters", "OBSERVATION_MODIFIER", 19, 27], ["greater", "OBSERVATION_MODIFIER", 28, 35]]], ["(5) that if we use s \u03c3 as the abscissa and s \u03c4 \u22122 P \u2265s as ordinate, then Eq.", [["P", "DNA", 50, 51]]], ["(5) predicts that s \u03c4 \u22122 P \u2265s will convergence to a constant value at p c for large s, while it deviates linearly from that constant value when p is away from p c .", [["a constant value", "PROBLEM", 50, 66], ["large s", "PROBLEM", 78, 85]]], ["Fig. 3 shows the relation of s \u03c4 \u22122 P \u2265s vs s \u03c3 for the sc-1,4 lattice under probabilities p = 0.150377, 0.150378, 0.150379, 0.150380, 0.150381, and 0.150382.", [["the sc", "TEST", 52, 58]]], ["A steep rise can be seen for small clusters, due to the finite-size-effect term (s \u2212\u2126 ).", [["A steep rise", "PROBLEM", 0, 12], ["small clusters", "PROBLEM", 29, 43], ["size", "OBSERVATION_MODIFIER", 63, 67]]], ["Then the plot shows a linear region for large clusters.", [["the plot", "TEST", 5, 13], ["linear", "OBSERVATION_MODIFIER", 22, 28], ["large", "OBSERVATION_MODIFIER", 40, 45], ["clusters", "OBSERVATION", 46, 54]]], ["The linear portion of the curve become more nearly horizontal when p is close to p c .", [["linear", "OBSERVATION_MODIFIER", 4, 10], ["portion", "OBSERVATION_MODIFIER", 11, 18], ["curve", "OBSERVATION_MODIFIER", 26, 31], ["more", "OBSERVATION_MODIFIER", 39, 43], ["nearly", "OBSERVATION_MODIFIER", 44, 50], ["horizontal", "OBSERVATION_MODIFIER", 51, 61]]], ["The central value of p c can then be deduced using these propertiesB.", [["p c", "PROTEIN", 21, 24], ["propertiesB", "PROTEIN", 57, 68], ["these propertiesB", "TREATMENT", 51, 68], ["central", "OBSERVATION_MODIFIER", 4, 11]]], ["Basic theoryas shown in the inset of Fig. 3 , p c = 0.1503793 can be calculated from the p intercept of the plot of the above derivative vs p.", [["Basic theoryas", "TEST", 0, 14]]], ["When p is very close to p c , percolation thresholds can also be estimated based on the s \u2212\u2126 terms in Eq.", [["p c , percolation thresholds", "TREATMENT", 24, 52]]], ["(5).B. Basic theoryAt p = p c , there will be a linear relationship between s \u03c4 \u22122 P \u2265s and s \u2212\u2126 for large s, while for p = p c the behavior will be nonlinear.", [["large s", "TEST", 101, 108], ["the behavior", "TEST", 128, 140]]], ["A plot of s \u03c4 \u22122 P \u2265s vs s \u2212\u2126 for the sc-1,4 lattice under probabilities p = 0.150377, 0.150378, 0.150379, 0.150380, 0.150381, and 0.150382, is shown in Fig. 4 .", [["A plot", "TEST", 0, 6], ["s", "TEST", 10, 11], ["\u2265s", "TEST", 19, 21], ["vs s", "TEST", 22, 26], ["the sc", "TEST", 34, 40], ["lattice under probabilities p", "TEST", 45, 74], ["sc", "ANATOMY", 38, 40], ["Fig", "OBSERVATION", 153, 156]]], ["If p is away from p c , we can see the curves show an obvious deviation from linearity for large s.", [["the curves", "TEST", 35, 45], ["an obvious deviation from linearity", "PROBLEM", 51, 86], ["large s.", "PROBLEM", 91, 99], ["obvious", "OBSERVATION_MODIFIER", 54, 61], ["deviation", "OBSERVATION", 62, 71]]], ["The range 0.150379 < p c < 0.150380 can be concluded here, which is consistent with the value we deduced from Fig. 3 .", [["The range", "TEST", 0, 9], ["consistent with", "UNCERTAINTY", 68, 83]]], ["Comprehensively considering the two methods above, as well as the errors for the values of \u03c4 = 2.18905 (15) and \u2126 = 0.63(4), we conclude the site percolation threshold of the sc-1,4 lattice to be p c = 0.1503793 (7), where the number in parentheses represents the estimated error in the last digit.B. Basic theoryThe simulation results for the other fifteen 3D lattices we considered are shown in the Supplementary Material [41] in Figs.", [["the values", "TEST", 77, 87], ["the site percolation threshold", "TEST", 137, 167], ["estimated error", "OBSERVATION", 264, 279]]], ["1-30, and the corresponding percolation thresholds are summarized in Table III .B. Results in two dimensionsIn 2D, the universal exponents of \u03c4 = 187/91, \u2126 = 72/91, and \u03c3 = 36/91 are known exactly [2, 43] .", [["the corresponding percolation thresholds", "TEST", 10, 50], ["the universal exponents", "TEST", 115, 138]]], ["We set upper size cutoff to be 2 16 occupied sites.", [["upper size", "OBSERVATION_MODIFIER", 7, 17], ["cutoff", "OBSERVATION", 18, 24]]], ["Monte Carlo simulations were performed on system size L \u00d7 L with L = 16384 under periodic boundary conditions.", [["Monte Carlo simulations", "TEST", 0, 23], ["periodic boundary conditions", "TREATMENT", 81, 109]]], ["More than 3\u00d710 8 independent samples were produced for each lattice.B. Results in two dimensionsFigs.", [["samples", "ANATOMY", 29, 36], ["two dimensions", "OBSERVATION_MODIFIER", 82, 96]]], ["5 and 6 show the plots of s \u03c4 \u22122 P \u2265s vs s \u03c3 and s \u2212\u2126 , respectively, for the sq-1,...,8 lattice under probabilities p = 0.095763, 0.095765, 0.095766, 0.095767, and 0.095769.", [["the plots", "TEST", 13, 22], ["s", "TEST", 26, 27], ["\u2265s", "TEST", 35, 37], ["the sq", "TEST", 74, 80]]], ["Similar to the analysis process of 3D, we deduce the site percolation threshold of the lattice here to (7) 0.11330(12) 24 sc-1,2,3,4 32 0.0801171 (9) 0.10000(12) 24 sc-1,...,5 56 0.0461815 (5) sc-1,...,6 80 0.0337049 (9) 0.033702 (10) Table IV .", [["the lattice", "TEST", 83, 94], ["sc", "TEST", 122, 124]]], ["(14) 0.292 14 , 0.290 (5) In Tables III and IV, we also compare our results with previous values, which are shown in the last column of each table.", [["previous values", "TEST", 81, 96]]], ["For some lattices, we get new thresholds that apparently were not studied before.B. Results in two dimensionsFor several lattices in 3D, we find significant differences in the threshold values from those of Refs.", [["the threshold values", "TEST", 172, 192], ["two dimensions", "OBSERVATION_MODIFIER", 95, 109], ["significant", "OBSERVATION_MODIFIER", 145, 156], ["differences", "OBSERVATION_MODIFIER", 157, 168]]], ["For example, for the sc-1,2,3,4 lattice, we find p c = 0.0801171(9) compared to the value p c = 0.10000 (12) given in Ref.", [["the value p c", "TEST", 80, 93]]], ["But the latter cannot be correct as it is higher than the value \u2248 0.097 for the sc-1,2,3 lattice found by others as well as by us.", [["higher", "OBSERVATION_MODIFIER", 42, 48]]], ["If one neighborhood is a subset of another's, its threshold must be higher, not lower.", [["higher", "OBSERVATION_MODIFIER", 68, 74]]], ["Likewise, the threshold for sc-2,3,4 should be lower than that of sc-2,3, but it was found to be higher in Ref.", [["sc-2,3,4", "SIMPLE_CHEMICAL", 28, 36], ["sc-2,3", "SIMPLE_CHEMICAL", 66, 72], ["sc", "TEST", 28, 30], ["higher", "OBSERVATION", 97, 103]]], ["Our results also make sense because they consistently follow the expected asymptotic scaling discussed below.B. Results in two dimensionsOur results in 2D are consistent with previous works.", [["two dimensions", "OBSERVATION_MODIFIER", 123, 137], ["consistent with", "UNCERTAINTY", 159, 174]]], ["It is interesting to note that the early series results of Dalton, Domb and Sykes [13, 14] are substantially correct to the number of digits given, and the same is true of the work of d'Iribarne et al. [20] .", [["digits", "ANATOMY", 134, 140]]], ["The model sq-1,2 is just the matching lattice to site percolation on a simple square lattice, and the threshold is 1 \u2212 p sq c = 1 \u2212 0.59274605 . . ..", [["a simple square lattice", "TREATMENT", 69, 92], ["sq c", "TEST", 121, 125]]], ["[10] , Koza et al. investigated the percolation thresholds of a model of overlapping squares or cubes of linear size k > 1 randomly distributed on a square or cubic lattice.", [["linear size k", "TEST", 105, 118], ["linear", "OBSERVATION_MODIFIER", 105, 111], ["size", "OBSERVATION_MODIFIER", 112, 116], ["cubic lattice", "OBSERVATION", 159, 172]]], ["Some of lattices investigated in this paper can be mapped to their problem of extended shapes on a lattice.", [["lattices", "OBSERVATION", 8, 16]]], ["For overlapping squares or cubes, suppose \u03c6 c is the net fraction of sites in the system that are occupied, and choose one of the sites of the object (the central site or any other site) to be the index site.", [["\u03c6 c", "GENE_OR_GENE_PRODUCT", 42, 45], ["\u03c6 c", "DNA", 42, 45], ["overlapping squares or cubes", "TREATMENT", 4, 32]]], ["Then the case of a k d object is equivalent to long-range site percolation between those index sites with thresholds p c determined by the probability that there is at least one index site within the boundaries of the object, or one minus the probability that there is no occupied site in that bound-B.", [["a k d object", "TREATMENT", 17, 29], ["long-range site percolation", "TREATMENT", 47, 74], ["occupied site", "PROBLEM", 272, 285], ["index", "OBSERVATION", 178, 183], ["no", "UNCERTAINTY", 269, 271]]], ["Results in two dimensionswhere d is the dimension of the system.", [["system", "ANATOMY", 57, 63]]], ["Here we have introduced \u03b7 c (k) = \u2212 ln(1 \u2212 \u03c6 c (k)) which is the analog of the threshold in terms of the total area of all objects adsorbed, including overlapping areas, for a lattice system.", [["a lattice system", "TREATMENT", 174, 190], ["total", "OBSERVATION_MODIFIER", 105, 110], ["area", "OBSERVATION_MODIFIER", 111, 115], ["all objects", "OBSERVATION", 119, 130]]], ["The range of the neighborhoods on those index sites is determined by a simple geometric construction [11] and is essentially the same shape as the object but twice as large as discussed below.", [["range", "OBSERVATION_MODIFIER", 4, 9]]], ["In 3D, Koza et al. find \u03c6 c (2) = 0.23987 (2) , and in 2D, \u03c6 c (2) = 0.58365 (2) and \u03c6 c (3) = 0.59586 (2) , and these three systems correspond to the sc-1,...,6 lattice, the sq-1,2,3,4 lattice, and the sq-1,...,8 lattice respectively.", [["sc-1", "GENE_OR_GENE_PRODUCT", 151, 155], ["2D", "TEST", 55, 57]]], ["(7), we find p c = 0.033702(10) for k = 2 and d = 3, 0.196724(10) for k = 2 and d = 2, 0.095765(10) for k = 3 and d = 2, respectively.", [["k", "TEST", 36, 37], ["d", "TEST", 46, 47], ["k", "TEST", 70, 71], ["d", "TEST", 80, 81], ["k", "TEST", 104, 105]]], ["It can be seen clearly from Tables III and IV that our results for the sc-1,...,6, sq-1,2,3,4, and sq-1,...,8 lattices are consistent with these values, and an order of magnitude more precise.B. Asymptotic behaviorFor systems of compact neighborhoods, such as all of those studied here in 2D and most in 3D, one can use a mapping to continuum percolation to predict the large-z behavior of p c .", [["sc-1", "GENE_OR_GENE_PRODUCT", 71, 75], ["p c", "PROTEIN", 390, 393], ["sq", "TEST", 83, 85], ["sq", "TEST", 99, 101], ["continuum percolation", "TREATMENT", 333, 354], ["consistent with", "UNCERTAINTY", 123, 138], ["large", "OBSERVATION_MODIFIER", 370, 375]]], ["Consider the percolation of N overlapping objects in a continuum of volume V , where the percolation threshold corresponds to a total volume fraction of adsorbed objects \u03b7 c defined byB.", [["the percolation of N overlapping objects", "TREATMENT", 9, 49], ["the percolation threshold", "PROBLEM", 85, 110], ["a total volume fraction", "TREATMENT", 126, 149], ["volume V", "OBSERVATION", 68, 76], ["adsorbed objects", "OBSERVATION", 153, 169]]], ["Asymptotic behaviorwhere r is the radius or other length scale of the object and a d r d is its volume, with a d depending upon its shape.B. Asymptotic behaviorCovering the space with a fine lattice, the system maps to site percolation with extended neighbors of the same shape up to a length scale 2r about the central point, because two objects of length scale r whose centers are separated a distance 2r will just touch.", [["a d r d is its volume", "PROBLEM", 81, 102], ["Asymptotic behavior", "PROBLEM", 141, 160], ["a length scale", "TREATMENT", 284, 298], ["radius", "ANATOMY", 34, 40], ["length", "OBSERVATION_MODIFIER", 50, 56], ["shape", "OBSERVATION_MODIFIER", 272, 277], ["central point", "OBSERVATION_MODIFIER", 312, 325]]], ["The ratio N/V corresponds to the site occupation threshold p c .", [["The ratio N/V", "PROBLEM", 0, 13]]], ["The effective z is equal to the number of sites in an object of length scale 2r, z = a d (2r) d , assuming the lattice points are on a simple square or cubic lattice.", [["length scale", "TEST", 64, 76], ["z", "TEST", 81, 82], ["a simple square or cubic lattice", "TREATMENT", 133, 165], ["cubic lattice", "OBSERVATION", 152, 165]]], ["(8) it follows thatB.", [["thatB", "GENE_OR_GENE_PRODUCT", 15, 20], ["thatB", "PROTEIN", 15, 20]]], ["Asymptotic behaviorfor large z.", [["large", "OBSERVATION_MODIFIER", 23, 28], ["z.", "OBSERVATION", 29, 31]]], ["Note that this is also consistent with Eq.", [["consistent with", "UNCERTAINTY", 23, 38]]], ["(7) for the square and cubic lattices with z = (2k) d , in the limit that \u03b7 c /k d is small or in other words the continuum limit where k is large and \u03b7 c (k) for a discrete system is replaced by \u03b7 c of the continuum.", [["\u03b7 c", "PROTEIN", 74, 77], ["\u03b7 c", "PROTEIN", 196, 199], ["the square and cubic lattices", "TREATMENT", 8, 37], ["z", "TEST", 43, 44], ["a discrete system", "PROBLEM", 163, 180], ["small", "OBSERVATION_MODIFIER", 86, 91], ["large", "OBSERVATION_MODIFIER", 141, 146]]], ["For circular neighborhoods, where \u03b7 c of a disk equals 1.128087 [31, [45] [46] [47] [48] , one should thus expect from Eq.", [["\u03b7 c", "PROTEIN", 34, 37], ["a disk equals", "TEST", 41, 54]]], ["(9)B. Asymptotic behaviorwhile for 3D, where \u03b7 c for spheres equals 0.34189 [49, 50] , one should expectB.", [["expectB", "PROTEIN", 98, 105]]], ["Asymptotic behaviorInterestingly, in Ref.", [["Asymptotic behavior", "PROBLEM", 0, 19]]], ["[12] , Domb related that coefficient to continuum percolation threshold, which of course was not known to high precision at that time.B. Asymptotic behaviorIn Table V , we show the values of zp c under different coordination numbers both in 2D and 3D.", [["zp c", "GENE_OR_GENE_PRODUCT", 191, 195], ["zp c", "PROTEIN", 191, 195]]], ["As z increases, the values of zp c show a trend of growth in general toward these predicted values.", [["zp c", "GENE_OR_GENE_PRODUCT", 30, 34], ["zp c", "PROTEIN", 30, 34], ["the values of zp c", "TEST", 16, 34]]], ["We find that this finite-z effect can be taken into account by assuming p c = c/(z + b) where b and c are constants.", [["c", "PROTEIN", 100, 101]]], ["Note that we can write this relation asB.", [["asB", "GENE_OR_GENE_PRODUCT", 37, 40], ["asB", "PROTEIN", 37, 40]]], ["Asymptotic behaviorSo if we plot z vs 1/p c , one can directly get the value of c from the slope and \u2212b from the intercept.", [["Asymptotic behavior", "PROBLEM", 0, 19]]], ["Fig. 7 shows such a plot for the lattices we studied with compact neighborhoods.", [["the lattices", "TREATMENT", 29, 41]]], ["Indeed we find c = 2.722 (3D) and c = 4.527 (2D), both close to the predictions c = 2 d \u03b7 c in Eqs.", [["c", "TEST", 34, 35], ["the predictions c", "TEST", 64, 81]]], ["To find this fitting form, we considered a variety of other plots, including p c vs 1/z, zp c vs z \u2212x , ln p c vs ln z, etc. The plot of z vs 1/p c seemed to give an excellent fit in both 2D and 3D, suggesting that adding a constant b to z is an accurate way to take into account the finite-z corrections to the asymptotic continuum percolation formula.", [["\u2212x", "PROTEIN", 99, 101], ["z vs 1/p c", "TREATMENT", 137, 147], ["a constant b to z", "TREATMENT", 222, 239], ["the finite-z corrections", "TREATMENT", 280, 304], ["the asymptotic continuum percolation formula", "TREATMENT", 308, 352], ["ln", "ANATOMY", 104, 106], ["ln", "ANATOMY", 114, 116]]], ["[23] , it was found that the site thresholds for several 3D lattices can be fitted by p c (z) \u223c z \u2212a , with a = 0.790 (26) .", [["several 3D lattices", "TREATMENT", 49, 68], ["z \u2212a", "TEST", 96, 100]]], ["For bond percolation, we found a = 1.087 for many lattices in 4D [29] and a = 1.111 in 3D [30] .", [["bond percolation", "PROBLEM", 4, 20]]], ["Other formulas have also been proposed to correlate percolation thresholds with z and other lattice properties [51] [52] [53] .", [["z and other lattice properties", "TEST", 80, 110]]], ["Fig. 8 shows a log-log plot of p c vs z for lattices with compact nearest neighborhoods both in 2D and 3D.", [["p c vs z for lattices", "TREATMENT", 31, 52]]], ["The percolation thresholds decrease monotonically with the coordination number, and linear behavior implies that the dependence of p c on z follows a power law p c \u223c cz \u2212a .", [["p c", "PROTEIN", 131, 134], ["The percolation thresholds", "PROBLEM", 0, 26], ["percolation thresholds", "OBSERVATION", 4, 26]]], ["Data fittings lead to a = 0.960 for 3D site percolation and a = 0.844 for 2D site percolation.", [["3D site percolation", "TREATMENT", 36, 55], ["2D site percolation", "TREATMENT", 74, 93]]], ["Analysis of other workswhile for aligned cubes one has \u03b7 c = 0.324766 [11, 55] , implying the asymptotic behavior zp c = 8\u03b7 c = 2.59813.D. Analysis of other worksIn a relatively early work, Gouker and Family [15] studied diamond-shaped systems (rotated squares) on a square lattice, with a lattice distance of R steps from the origin.", [["aligned cubes", "TEST", 33, 46], ["zp c", "TEST", 114, 118], ["studied diamond-shaped systems", "TREATMENT", 213, 243], ["a square lattice", "TREATMENT", 265, 281], ["origin", "ANATOMY_MODIFIER", 327, 333]]], ["This system is effectively a square rotated by 45 \u2022 , and the slope 4.175 is obtained from the data fitting.", [["the slope", "TEST", 58, 67]]], ["This value is somewhat lower than the prediction in Eq.", [["This value", "TEST", 0, 10], ["somewhat", "OBSERVATION_MODIFIER", 14, 22], ["lower", "OBSERVATION_MODIFIER", 23, 28]]], ["More recently, Koza et al. [10] and Koza and Pola [11] studied overlapping squares, cubes, and higherdimensional hypercubes.", [["hypercubes", "DISEASE", 113, 123], ["Koza", "TREATMENT", 36, 40], ["cubes", "TEST", 84, 89], ["higherdimensional hypercubes", "PROBLEM", 95, 123], ["higherdimensional hypercubes", "OBSERVATION", 95, 123]]], ["As discussed above, their results for a critical coverage fraction \u03c6 c can be translated to a site percolation threshold according to Eq.", [["\u03c6 c", "GENE_OR_GENE_PRODUCT", 67, 70], ["a critical coverage fraction", "TREATMENT", 38, 66], ["a site percolation threshold", "TREATMENT", 92, 120]]], ["(7), and the effective neighborhood is a square with the corners cut out, containing z = (2k + 1) 2 \u2212 5, not counting the site at the origin.", [["origin", "ANATOMY_MODIFIER", 134, 140]]], ["In 3D, the corresponding value of z is given by z = (2k \u2212 1) 2 (2k + 5) \u2212 1.", [["z", "TEST", 34, 35], ["z", "TEST", 48, 49]]], ["In Tables VII and VIII we give the results for p c and z, and plot them in Fig. 10 .", [["VIII", "GENE_OR_GENE_PRODUCT", 18, 22], ["VII", "PROTEIN", 10, 13], ["VIII", "PROTEIN", 18, 22], ["p c and z", "PROBLEM", 47, 56]]], ["Data fittings give 4.398 for 2D (consistent with Eq.", [["Data fittings", "TEST", 0, 13]]], ["(13)) and 2.617 for 3D (consistent with Eq.", [["consistent with", "UNCERTAINTY", 24, 39]]], ["(14)).D. Analysis of other worksFinally, very recently, Malarz [26] has studied site percolation on various neighborhoods on the triangular lattice, including hexagonal shells around the origin, which TABLE VII.", [["TABLE VII", "GENE_OR_GENE_PRODUCT", 201, 210], ["TABLE VII", "PROTEIN", 201, 210], ["studied site percolation", "PROBLEM", 72, 96], ["triangular", "ANATOMY_MODIFIER", 129, 139], ["hexagonal shells", "OBSERVATION", 159, 175], ["origin", "ANATOMY_MODIFIER", 187, 193]]], ["Values of pc for 2D systems related to the overlap of k \u00d7 k objects on a sq lattice, from the work of Koza et al. [10] .", [["Values", "TEST", 0, 6], ["pc", "TEST", 10, 12], ["2D systems", "TEST", 17, 27], ["a sq lattice", "TREATMENT", 71, 83]]], ["(7), and z = (2k + 1) 2 \u2212 5. is somewhat analogous to the shells Gouker and Family considered on the square lattice.", [["z", "TEST", 9, 10]]], ["The data are shown in Table IX and the z vs 1/p c plot is shown in Fig. 11 .", [["the z vs 1/p c plot", "PROBLEM", 35, 54]]], ["Again a good fit is seen.", [["good fit", "OBSERVATION", 8, 16]]], ["Note, here the continuum threshold \u03c6 c (or \u03b7 c ) for aligned hexagons is not known, but presumably it is close to the case of disks, and indeed the value c = 4.517 is not far from that predicted by Eq.", [["aligned hexagons", "PROBLEM", 53, 69], ["the value c", "TEST", 144, 155]]], ["(10).V. CONCLUSIONSTo summarize, we have carried out extensive Monte Carlo simulations for site percolation on square and simple cubic lattices with various combinations of nearest neighbors, and found precise estimates of the percolation threshold for sixteen 3D systems and seven 2D systems, based upon an effective single-cluster growth method.", [["site percolation on square and simple cubic lattices", "TREATMENT", 91, 143]]], ["Site percolation on lattices with some compact neighbors can be mapped to the problems of adsorption of extended shapes on a lattice, such as disks and spheres, and also k \u00d7 k \u00d7 k cubes (or k \u00d7 k squares) on a cubic (or square) lattice as investigated by Koza et al [10] .", [["Site percolation on lattices", "TREATMENT", 0, 28], ["a lattice, such as disks and spheres", "TREATMENT", 123, 159], ["k", "TEST", 170, 171], ["a cubic (or square) lattice", "TREATMENT", 208, 235], ["percolation", "OBSERVATION_MODIFIER", 5, 16]]], ["For large z, we predicted their continuum limits of zp c = 2.73512 for 3D site percolation and zp c = 4.51235 for 2D site percolation, by mapping to the percolation of overlapping spheres (or disks) in a continuum.V. CONCLUSIONSThe finite-z effect in the simulation can be accurately taken into account by writing (z +b)p c = c.", [["zp c", "TEST", 52, 56], ["3D site percolation", "TREATMENT", 71, 90], ["zp c", "TEST", 95, 99], ["2D site percolation", "TREATMENT", 114, 133], ["overlapping spheres", "PROBLEM", 168, 187], ["overlapping spheres", "OBSERVATION", 168, 187]]], ["The values of c that we found were consistent with the continuum percolation predictions.", [["The values", "TEST", 0, 10], ["the continuum percolation predictions", "TREATMENT", 51, 88], ["consistent with", "UNCERTAINTY", 35, 50]]], ["The values of b, which were found by the intercepts in our plots of z vs 1/p c , varied over a range of 1 to 12.V. CONCLUSIONSWe also looked at power-law correlations between site threshold and coordination number for the lattices with compact neighborhoods, and found that the thresholds decrease monotonically with the coordination number according to p c \u223c cz \u2212a , with the exponent a = 0.960 in 3D and a = 0.844 in 2D.", [["p c", "PROTEIN", 354, 357], ["cz", "PROTEIN", 360, 362], ["The values", "TEST", 0, 10], ["the thresholds", "PROBLEM", 274, 288]]], ["While these power-laws fit the data well in the range of the values of z we considered, they are not correct asymptotically for large z.V. CONCLUSIONSLattices with extended neighborhoods locate between discrete percolation and continuum percolation.", [["large z.V. CONCLUSIONSLattices", "PROBLEM", 128, 158], ["discrete percolation", "TREATMENT", 202, 222], ["continuum percolation", "TREATMENT", 227, 248], ["discrete", "OBSERVATION_MODIFIER", 202, 210], ["percolation", "OBSERVATION", 211, 222], ["continuum percolation", "OBSERVATION", 227, 248]]]], "d1304e1a273c7ceb5845e21de5dafff4d4e9ebbf": [["Entre las principales complicaciones cabe destacar neumon\u00eda leve (50% de casos confirmados), insuficiencia respiratoria o s\u00edndrome de distr\u00e9s respiratorio (13,8%) y s\u00edndrome de activaci\u00f3n macrof\u00e1gica con fallo multiorg\u00e1nico (6,1%), repercutiendo negativamente en los diferentes vol\u00famenes y capacidades pulmonares 2 .EFECTOS DEL EJERCICIO F\u00cdSICOEl ejercicio terap\u00e9utico fisioter\u00e1pico, en combinaci\u00f3n con intervenciones de car\u00e1cter respiratorio ha demostrado ser efectivo en enfermedad pulmonar obstructiva cr\u00f3nica, fibrosis qu\u00edstica, asma bronquial y/o en pacientes postquir\u00fargicos, por lo que puede resultar interesante evaluar su eficacia como herramienta en la prevenci\u00f3n de complicaciones graves secundarias a Covid-19.", [["fibrosis qu\u00edstica", "DISEASE", 514, 531], ["asma bronquial y/o en pacientes postquir\u00fargicos, por lo que puede resultar interesante evaluar su eficacia como herramienta en la prevenci\u00f3n de complicaciones graves secundarias a Covid-19", "SPECIES", 533, 721], ["Entre las principales", "TEST", 0, 21], ["y s\u00edndrome", "PROBLEM", 163, 173], ["fisioter\u00e1pico", "TEST", 369, 382], ["cr\u00f3nica", "PROBLEM", 505, 512], ["fibrosis qu\u00edstica", "PROBLEM", 514, 531], ["a Covid", "TEST", 711, 718], ["fibrosis", "OBSERVATION", 514, 522]]], ["No obstante, mientras que en cuadros de neumon\u00eda adquirida ya instaurada no se han constatado beneficios significativos, en pacientes que han recibido tratamiento fisioter\u00e1pico antes de producirse esta complicaci\u00f3n s\u00ed se han evidenciado efectos positivos en determinadas medidas de resultado.", [["obstante", "PROBLEM", 3, 11]]], ["Estos tratamientos se centran en ejercicio f\u00edsico y t\u00e9cnicas respiratorias, que, combin\u00e1ndose con un programa de tratamiento farmacol\u00f3gico en neumon\u00eda, exhiben una mayor eficacia frente a la ausencia de fisioterapia 3 .EFECTOS DEL EJERCICIO F\u00cdSICOPor ello, resulta fundamental la evaluaci\u00f3n de las variables del entrenamiento y el conocimiento de la fisiolog\u00eda de la actividad f\u00edsica, determinantes atendiendo a la neumon\u00eda secundaria al coronavirus.", [["coronavirus", "DISEASE", 438, 449], ["Estos tratamientos", "TREATMENT", 0, 18], ["a la neumon\u00eda secundaria al coronavirus", "PROBLEM", 410, 449]]], ["En este sentido, el ejercicio aer\u00f3bico podr\u00eda tener una gran implicaci\u00f3n, pues aplicado a intensidades medias/altas produce adaptaciones en la ventilaci\u00f3n y perfusi\u00f3n pulmonares, as\u00ed como en la cantidad de volumen de aire por respiraci\u00f3n.", [["una gran implicaci\u00f3n", "TREATMENT", 52, 72], ["a intensidades medias", "TREATMENT", 88, 109], ["en la ventilaci\u00f3n y perfusi\u00f3n pulmonares", "TREATMENT", 137, 177]]], ["Adem\u00e1s, a trav\u00e9s del ejercicio de alta intensidad se incrementa el consumo m\u00e1ximo de ox\u00edgeno, traduci\u00e9ndose en una mayor rentabilidad en el intercambio gaseoso, aspectos que pueden resultar fundamentales en futuros cuadros cl\u00ednicos de instauraci\u00f3n de Covid-19 4 .EFECTOS DEL EJERCICIO F\u00cdSICOEl sistema inmunol\u00f3gico es otro de los grandes implicados por coronavirus, constat\u00e1ndose la presencia de niveles elevados de IL-6 y otras citoquinas proinflamatorias en casos graves 5 .", [["coronavirus", "PROBLEM", 353, 364]]], ["El ejercicio f\u00edsico de intensidad m\u00e1xima/subm\u00e1xima es capaz de producir una respuesta de estr\u00e9s celular, llevando a una leucocitosis transitoria que provoca incrementos en la perfusi\u00f3n sangu\u00ednea de peque\u00f1os vasos pulmonares, as\u00ed como aumentos puntuales de linfocitos, c\u00e9lulas NK y actividad fagoc\u00edtica.", [["NK", "ANATOMY", 276, 278], ["a una leucocitosis transitoria", "PROBLEM", 114, 144]]], ["El ajuste en la carga de entrenamiento es primordial para estresar al sistema osteomuscular, obteni\u00e9ndose adaptaciones como la hipertrofia con intensidades de alrededor del 70% del 1 RM.", [["El ajuste", "TEST", 0, 9], ["obteni\u00e9ndose adaptaciones", "TREATMENT", 93, 118]]], ["No obstante, se requieren futuros trabajos experimentales que constaten cient\u00edfica y estad\u00edsticamente estas hip\u00f3tesis, para su posterior implementaci\u00f3n en la poblaci\u00f3n susceptible de contraer la enfermedad.", [["obstante", "PROBLEM", 3, 11]]]], "PMC6382173": [["IntroductionZika virus (ZIKV) was first isolated from a sentinel rhesus macaque in Uganda in 1947 and subsequently from Aedes africanus mosquitoes in the same location [1].", [["IntroductionZika virus", "ORGANISM", 0, 22], ["ZIKV", "GENE_OR_GENE_PRODUCT", 24, 28], ["rhesus", "ORGANISM", 65, 71], ["macaque", "ORGANISM", 72, 79], ["Aedes africanus mosquitoes", "ORGANISM", 120, 146], ["rhesus macaque", "SPECIES", 65, 79], ["Aedes africanus", "SPECIES", 120, 135], ["IntroductionZika virus", "SPECIES", 0, 22], ["ZIKV", "SPECIES", 24, 28], ["rhesus macaque", "SPECIES", 65, 79], ["Aedes africanus", "SPECIES", 120, 135], ["IntroductionZika virus (ZIKV)", "PROBLEM", 0, 29]]], ["The first human cases were identified in 1954 in Nigeria and serosurveys found evidence of a broad geographic distribution for ZIKV throughout Africa and Asia with sporadic cases in humans [2, 3].", [["human", "ORGANISM", 10, 15], ["humans", "ORGANISM", 182, 188], ["human", "SPECIES", 10, 15], ["humans", "SPECIES", 182, 188], ["human", "SPECIES", 10, 15], ["ZIKV", "SPECIES", 127, 131], ["humans", "SPECIES", 182, 188], ["ZIKV", "PROBLEM", 127, 131], ["sporadic cases in humans", "PROBLEM", 164, 188], ["broad", "OBSERVATION_MODIFIER", 93, 98]]], ["The first recognized ZIKV epidemic occurred in Yap State, Federated State of Micronesia in 2007.", [["ZIKV", "SPECIES", 21, 25], ["ZIKV", "OBSERVATION", 21, 25]]], ["An estimated 73% of residents were infected, and of those 18% presented with clinical disease [4].", [["infected", "PROBLEM", 35, 43], ["clinical disease", "PROBLEM", 77, 93]]], ["During the latter outbreak, the incidence rate of Guillain-Barr\u00e9 syndrome (GBS) increased 20-fold and first indication of a connection between ZIKV infection and GBS was established [5].", [["Guillain-Barr\u00e9 syndrome", "DISEASE", 50, 73], ["GBS", "DISEASE", 75, 78], ["ZIKV infection", "DISEASE", 143, 157], ["GBS", "DISEASE", 162, 165], ["Guillain-Barr\u00e9", "ORGANISM", 50, 64], ["ZIKV", "SPECIES", 143, 147], ["Barr\u00e9 syndrome", "PROBLEM", 59, 73], ["GBS", "TEST", 75, 78], ["a connection between ZIKV infection", "PROBLEM", 122, 157], ["GBS", "PROBLEM", 162, 165], ["ZIKV", "OBSERVATION_MODIFIER", 143, 147], ["infection", "OBSERVATION", 148, 157]]], ["The virus spread to Brazil in 2015 [6, 7] and has since disseminated throughout much of tropical South America, Central America, the Caribbean, and the southern United States, with more than 200,000 confirmed cases [8].", [["virus", "OBSERVATION", 4, 9], ["disseminated", "OBSERVATION", 56, 68]]], ["ZIKV can also cause congenital Zika syndrome (CZS) in na\u00efve populations and is therefore a virus of high concern [3].IntroductionZika virus is maintained in an urban cycle, transmitted between an Aedes mosquito vector and humans thereby maintaining endemicity [9].", [["ZIKV", "CHEMICAL", 0, 4], ["congenital Zika syndrome", "DISEASE", 20, 44], ["CZS", "DISEASE", 46, 49], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["IntroductionZika virus", "ORGANISM", 117, 139], ["humans", "ORGANISM", 222, 228], ["humans", "SPECIES", 222, 228], ["ZIKV", "SPECIES", 0, 4], ["IntroductionZika virus", "SPECIES", 117, 139], ["Aedes mosquito", "SPECIES", 196, 210], ["humans", "SPECIES", 222, 228], ["ZIKV", "PROBLEM", 0, 4], ["congenital Zika syndrome", "PROBLEM", 20, 44], ["CZS) in na\u00efve populations", "PROBLEM", 46, 71], ["IntroductionZika virus", "PROBLEM", 117, 139], ["an Aedes mosquito vector", "TREATMENT", 193, 217], ["Zika syndrome", "OBSERVATION", 31, 44]]], ["It is generally accepted that the virus transmits between non-human primates and vectors in a sylvatic cycle; however, the sylvatic cycle has not been well characterized in the Old World and little is known about a New World sylvatic cycle [9, 10].", [["non-human primates", "ORGANISM", 58, 76], ["the virus", "PROBLEM", 30, 39], ["non-human primates and vectors", "TREATMENT", 58, 88], ["virus", "OBSERVATION", 34, 39]]], ["Molecular analysis of ZIKV to better understand viral phylogenetics suggests that animal hosts affected viral evolution and therefore may play an important role in viral ecology [11].IntroductionIn the 1950s and \u201860s, the susceptibility of bats to ZIKV was investigated.", [["ZIKV", "GENE_OR_GENE_PRODUCT", 22, 26], ["bats", "ORGANISM", 240, 244], ["ZIKV", "SPECIES", 22, 26], ["ZIKV", "SPECIES", 248, 252], ["Molecular analysis", "TEST", 0, 18], ["ZIKV", "PROBLEM", 22, 26], ["viral phylogenetics", "TEST", 48, 67], ["animal hosts affected viral evolution", "PROBLEM", 82, 119], ["ZIKV", "PROBLEM", 248, 252]]], ["Shepherd and Williams [12] screened 172 wild bats from 12 different species in Uganda for antibodies against ZIKV and found 16/44 little free-tail bats (Tadarida pumila) and 26/36 Angolan free-tail bats (T. condylura) were seropositive by hemagglutination inhibition assay.", [["bats", "ORGANISM", 45, 49], ["ZIKV", "GENE_OR_GENE_PRODUCT", 109, 113], ["Tadarida pumila", "ORGANISM", 153, 168], ["free-tail bats", "ORGANISM", 188, 202], ["T. condylura", "ORGANISM", 204, 216], ["antibodies", "PROTEIN", 90, 100], ["Tadarida pumila", "SPECIES", 153, 168], ["T. condylura", "SPECIES", 204, 216], ["ZIKV", "SPECIES", 109, 113], ["Tadarida pumila", "SPECIES", 153, 168], ["T. condylura", "SPECIES", 204, 216], ["antibodies", "TEST", 90, 100], ["ZIKV", "PROBLEM", 109, 113], ["Tadarida pumila", "TEST", 153, 168], ["Angolan free-tail bats", "TEST", 180, 202], ["tail", "ANATOMY", 142, 146], ["tail", "ANATOMY", 193, 197]]], ["Additionally, two Angolan free-tail bats were experimentally inoculated with ZIKV and serially bled to test for viremia.", [["viremia", "DISEASE", 112, 119], ["bats", "ORGANISM", 36, 40], ["ZIKV", "SPECIES", 77, 81], ["two Angolan free-tail bats", "TREATMENT", 14, 40], ["ZIKV", "PROBLEM", 77, 81], ["viremia", "PROBLEM", 112, 119], ["tail bats", "OBSERVATION", 31, 40]]], ["Both animals were viremic on days 2, 4 and 6 as determined by paralysis in mice inoculated with the sera from those two bats [12].", [["sera", "ANATOMY", 100, 104], ["paralysis", "DISEASE", 62, 71], ["animals", "ORGANISM", 5, 12], ["mice", "ORGANISM", 75, 79], ["sera", "ORGANISM_SUBSTANCE", 100, 104], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["paralysis", "PROBLEM", 62, 71], ["paralysis", "OBSERVATION", 62, 71]]], ["Simpson and O\u2019Sullivan [13] experimentally inoculated three straw-colored fruit bats (Eidolon helvum), three Egyptian fruit bats (Rousettus aegyptiacusi), and five Angolan free-tail bats.", [["Eidolon helvum", "ORGANISM", 86, 100], ["Rousettus aegyptiacusi", "ORGANISM", 130, 152], ["fruit", "SPECIES", 74, 79], ["Eidolon helvum", "SPECIES", 86, 100], ["fruit", "SPECIES", 118, 123], ["Rousettus aegyptiacusi", "SPECIES", 130, 152], ["straw-colored fruit bats", "SPECIES", 60, 84], ["Eidolon helvum", "SPECIES", 86, 100], ["Egyptian fruit bats", "SPECIES", 109, 128], ["Rousettus aegyptiacusi", "SPECIES", 130, 152], ["Eidolon helvum)", "TREATMENT", 86, 101], ["fruit bats", "OBSERVATION", 74, 84], ["tail bats", "OBSERVATION", 177, 186]]], ["Two of the straw-colored fruit bats were viremic and had seroconverted.", [["bats", "ORGANISM", 31, 35], ["viremic", "PROBLEM", 41, 48], ["fruit bats", "OBSERVATION", 25, 35]]], ["One of the Egyptian fruit bats was viremic and two had seroconverted.", [["Egyptian fruit bats", "SPECIES", 11, 30], ["viremic", "PROBLEM", 35, 42], ["fruit bats", "OBSERVATION", 20, 30]]], ["The Angolan free-tail bats were euthanized on days 1, 3, 5, 7 and 10 days post inoculation and screened for viral tropism.", [["bats", "ORGANISM", 22, 26], ["The Angolan free-tail bats", "TREATMENT", 0, 26], ["inoculation", "TEST", 79, 90], ["viral tropism", "PROBLEM", 108, 121], ["free", "OBSERVATION_MODIFIER", 12, 16], ["tail bats", "OBSERVATION", 17, 26], ["viral tropism", "OBSERVATION", 108, 121]]], ["At one day post infection, a kidney was trace positive [13].", [["kidney", "ANATOMY", 29, 35], ["infection", "DISEASE", 16, 25], ["kidney", "ORGAN", 29, 35], ["infection", "PROBLEM", 16, 25], ["trace positive", "PROBLEM", 40, 54], ["infection", "OBSERVATION", 16, 25], ["kidney", "ANATOMY", 29, 35], ["trace", "OBSERVATION_MODIFIER", 40, 45], ["positive", "OBSERVATION", 46, 54]]], ["Finally, Reagan et al. [14] inoculated 20 New World little brown bats (Myotis lucifigus) by 5 different routes: intracranial, intraperitoneal, intradermal, intrarectal and intranasal.", [["intracranial", "ANATOMY", 112, 124], ["intraperitoneal", "ANATOMY", 126, 141], ["bats", "ORGANISM", 65, 69], ["Myotis lucifigus", "ORGANISM", 71, 87], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 126, 141], ["Myotis lucifigus", "SPECIES", 71, 87], ["brown bats", "SPECIES", 59, 69], ["Myotis lucifigus", "SPECIES", 71, 87], ["intracranial, intraperitoneal, intradermal, intrarectal and intranasal", "PROBLEM", 112, 182], ["brown bats", "OBSERVATION", 59, 69], ["intracranial", "ANATOMY", 112, 124], ["intraperitoneal", "ANATOMY", 126, 141], ["intrarectal", "ANATOMY", 156, 167]]], ["Bats in all groups, with the exception of the intranasal group, developed fatal neurological disease 4\u20137 days post inoculation.", [["neurological", "ANATOMY", 80, 92], ["neurological disease", "DISEASE", 80, 100], ["Bats", "CELL", 0, 4], ["fatal neurological disease", "PROBLEM", 74, 100], ["fatal", "OBSERVATION_MODIFIER", 74, 79], ["neurological disease", "OBSERVATION", 80, 100]]], ["Brain tissue was virus-positive in all animals with clinical disease, determined by inoculation of mice with brain homogenate suspension [14].IntroductionConsidering the evidence that African bats are naturally susceptible to ZIKV and that little brown bats develop disease, the question emerged: could bats serve as a natural reservoir host for ZIKV in the New World?", [["Brain tissue", "ANATOMY", 0, 12], ["brain homogenate", "ANATOMY", 109, 125], ["Brain tissue", "TISSUE", 0, 12], ["mice", "ORGANISM", 99, 103], ["brain homogenate", "ORGANISM_SUBSTANCE", 109, 125], ["African bats", "ORGANISM", 184, 196], ["brown bats", "ORGANISM", 247, 257], ["ZIKV", "ORGANISM", 346, 350], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 99, 103], ["African bats", "SPECIES", 184, 196], ["ZIKV", "SPECIES", 226, 230], ["brown bats", "SPECIES", 247, 257], ["ZIKV", "SPECIES", 346, 350], ["Brain tissue", "TEST", 0, 12], ["virus", "PROBLEM", 17, 22], ["clinical disease", "PROBLEM", 52, 68], ["brain homogenate suspension", "TREATMENT", 109, 136], ["African bats", "PROBLEM", 184, 196], ["ZIKV", "PROBLEM", 226, 230], ["little brown bats develop disease", "PROBLEM", 240, 273], ["a natural reservoir host", "TREATMENT", 317, 341], ["ZIKV", "PROBLEM", 346, 350], ["brown bats", "OBSERVATION", 247, 257]]], ["To test this hypothesis, we inoculated Jamaican fruit bats (Artibeus jamaicensis), among the most abundant bats in the Caribbean, Central America and Mexico, with ZIKV to examine virology, immunology and pathology of the infection.", [["infection", "DISEASE", 221, 230], ["Artibeus jamaicensis", "ORGANISM", 60, 80], ["fruit", "SPECIES", 48, 53], ["Artibeus jamaicensis", "SPECIES", 60, 80], ["Jamaican fruit bats", "SPECIES", 39, 58], ["Artibeus jamaicensis", "SPECIES", 60, 80], ["ZIKV", "SPECIES", 163, 167], ["ZIKV", "TREATMENT", 163, 167], ["the infection", "PROBLEM", 217, 230], ["fruit bats", "OBSERVATION", 48, 58], ["infection", "OBSERVATION", 221, 230]]], ["Although virus was detected in several organs, including the testes and brains, no overt clinical signs were detected, and substantial viremia or viruria was not evident.", [["organs", "ANATOMY", 39, 45], ["testes", "ANATOMY", 61, 67], ["brains", "ANATOMY", 72, 78], ["viremia", "DISEASE", 135, 142], ["viruria", "DISEASE", 146, 153], ["organs", "ORGAN", 39, 45], ["testes", "ORGAN", 61, 67], ["brains", "ORGAN", 72, 78], ["virus", "PROBLEM", 9, 14], ["overt clinical signs", "PROBLEM", 83, 103], ["substantial viremia", "PROBLEM", 123, 142], ["viruria", "PROBLEM", 146, 153], ["virus", "OBSERVATION", 9, 14], ["testes", "ANATOMY", 61, 67], ["brains", "ANATOMY", 72, 78], ["no", "UNCERTAINTY", 80, 82], ["overt", "OBSERVATION_MODIFIER", 83, 88], ["substantial", "OBSERVATION_MODIFIER", 123, 134], ["viremia", "OBSERVATION", 135, 142], ["viruria", "OBSERVATION", 146, 153], ["not evident", "UNCERTAINTY", 158, 169]]], ["These results suggest that Jamaican fruit bats are unlikely to serve as amplification hosts but that ZIKV infection may constitute a wildlife disease threat to bats.Experimental infections ::: ResultsBats for this project were obtained from the Colorado State University breeding colony approved by the Institutional Animal Care and Use Committee (protocol 16-6512A).", [["infection", "DISEASE", 106, 115], ["infections", "DISEASE", 178, 188], ["Jamaican fruit bats", "ORGANISM", 27, 46], ["Jamaican fruit bats", "SPECIES", 27, 46], ["ZIKV", "SPECIES", 101, 105], ["Jamaican fruit bats", "PROBLEM", 27, 46], ["ZIKV infection", "PROBLEM", 101, 115], ["infections", "OBSERVATION", 178, 188]]], ["Two experimental infections were conducted; a pilot study and a time course study.", [["infections", "DISEASE", 17, 27], ["Two experimental infections", "PROBLEM", 0, 27], ["a pilot study", "TEST", 44, 57], ["a time course study", "TEST", 62, 81], ["experimental", "OBSERVATION_MODIFIER", 4, 16], ["infections", "OBSERVATION", 17, 27]]], ["In the pilot-study, three male bats (AJ-z7, AJ-z8, AJ-z9) were intradermally inoculated with 7.5x105 plaque forming units (pfu) ZIKV, strain PRVABC59; a high dose to assess susceptibility.", [["AJ-z8", "ANATOMY", 44, 49], ["AJ-z9", "ANATOMY", 51, 56], ["bats", "ORGANISM", 31, 35], ["AJ-z7", "CELL", 37, 42], ["AJ-z8", "CELL", 44, 49], ["AJ-z9", "CELL", 51, 56], ["ZIKV", "SPECIES", 128, 132], ["ZIKV", "PROBLEM", 128, 132], ["susceptibility", "PROBLEM", 173, 187]]], ["No signs of disease were apparent during this 28 day experiment; however, all three bats had antibody titers of 3200 on day 28 (Table 1).", [["bats", "ORGANISM", 84, 88], ["disease", "PROBLEM", 12, 19], ["antibody titers", "TEST", 93, 108], ["signs of", "UNCERTAINTY", 3, 11], ["disease", "OBSERVATION", 12, 19]]], ["After demonstration of susceptibility in the pilot study, a time course study was conducted.", [["the pilot study", "TEST", 41, 56], ["a time course study", "TEST", 58, 77], ["susceptibility", "OBSERVATION_MODIFIER", 23, 37]]], ["Six male bats (AJ-z1 through AJ-z6) were identically inoculated and two were euthanized at 2, 5 and 10 days post inoculation (dpi).", [["AJ-z6", "ANATOMY", 29, 34], ["bats", "ORGANISM", 9, 13], ["AJ-z1", "CELL", 15, 20], ["AJ-z6", "CELL", 29, 34], ["inoculated", "OBSERVATION", 53, 63]]], ["No conspicuous signs of disease were observed in any of the inoculated bats.", [["disease", "PROBLEM", 24, 31], ["conspicuous", "OBSERVATION_MODIFIER", 3, 14], ["signs", "OBSERVATION_MODIFIER", 15, 20], ["disease", "OBSERVATION", 24, 31], ["inoculated bats", "OBSERVATION", 60, 75]]], ["Necropsies immediately followed euthanasia and no significant gross pathology was evident.Detection of viral RNA in urine and brain ::: ResultsQuantitative probe-based reverse transcription PCR (qRT-PCR) was performed on serum-inoculated Vero cell supernatants, serum, brain, lung, liver, spleen, kidney, urinary bladder, prostate and testes from bats from both studies.", [["urine", "ANATOMY", 116, 121], ["brain", "ANATOMY", 126, 131], ["serum", "ANATOMY", 221, 226], ["Vero cell supernatants", "ANATOMY", 238, 260], ["serum", "ANATOMY", 262, 267], ["brain", "ANATOMY", 269, 274], ["lung", "ANATOMY", 276, 280], ["liver", "ANATOMY", 282, 287], ["spleen", "ANATOMY", 289, 295], ["kidney", "ANATOMY", 297, 303], ["urinary bladder", "ANATOMY", 305, 320], ["prostate", "ANATOMY", 322, 330], ["testes", "ANATOMY", 335, 341], ["urine", "ORGANISM_SUBSTANCE", 116, 121], ["brain", "ORGAN", 126, 131], ["serum", "ORGANISM_SUBSTANCE", 221, 226], ["Vero cell", "CELL", 238, 247], ["serum", "ORGANISM_SUBSTANCE", 262, 267], ["brain", "ORGAN", 269, 274], ["lung", "ORGAN", 276, 280], ["liver", "ORGAN", 282, 287], ["spleen", "ORGAN", 289, 295], ["kidney", "ORGAN", 297, 303], ["urinary bladder", "MULTI-TISSUE_STRUCTURE", 305, 320], ["prostate", "ORGAN", 322, 330], ["testes", "ORGAN", 335, 341], ["viral RNA", "RNA", 103, 112], ["Vero", "SPECIES", 238, 242], ["Necropsies", "TEST", 0, 10], ["euthanasia", "PROBLEM", 32, 42], ["significant gross pathology", "PROBLEM", 50, 77], ["viral RNA in urine", "TEST", 103, 121], ["ResultsQuantitative probe", "TEST", 136, 161], ["reverse transcription PCR", "TEST", 168, 193], ["qRT", "TEST", 195, 198], ["PCR", "TEST", 199, 202], ["serum", "TEST", 221, 226], ["inoculated Vero cell supernatants", "TEST", 227, 260], ["serum", "TEST", 262, 267], ["no", "UNCERTAINTY", 47, 49], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["gross", "OBSERVATION_MODIFIER", 62, 67], ["pathology", "OBSERVATION", 68, 77], ["viral RNA", "OBSERVATION", 103, 112], ["brain", "ANATOMY", 126, 131], ["Vero cell supernatants", "OBSERVATION", 238, 260], ["brain", "ANATOMY", 269, 274], ["lung", "ANATOMY", 276, 280], ["liver", "ANATOMY", 282, 287], ["spleen", "ANATOMY", 289, 295], ["kidney", "ANATOMY", 297, 303], ["urinary bladder", "ANATOMY", 305, 320], ["prostate", "ANATOMY", 322, 330], ["testes", "ANATOMY", 335, 341]]], ["In addition, urine collected during the time course study was similarly assayed.", [["urine", "ANATOMY", 13, 18], ["urine", "ORGANISM_SUBSTANCE", 13, 18], ["urine", "TEST", 13, 18], ["course study", "TEST", 45, 57], ["urine", "OBSERVATION", 13, 18]]], ["Urine from bats AJ-z6 at 3 dpi and AJ-z7 at 5 dpi had low levels of vRNA whereas bat AJ-z1, euthanized at 2 dpi, had low levels of vRNA in its brain (Fig 1).", [["Urine", "ANATOMY", 0, 5], ["brain", "ANATOMY", 143, 148], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["AJ-z6", "CELL", 16, 21], ["AJ", "GENE_OR_GENE_PRODUCT", 35, 37], ["AJ-z1", "GENE_OR_GENE_PRODUCT", 85, 90], ["brain", "ORGAN", 143, 148], ["AJ", "PROTEIN", 85, 87], ["z1", "PROTEIN", 88, 90], ["vRNA", "RNA", 131, 135], ["Urine", "TEST", 0, 5], ["AJ", "TEST", 35, 37], ["low levels of vRNA", "PROBLEM", 54, 72], ["low levels of vRNA in its brain", "PROBLEM", 117, 148], ["vRNA", "OBSERVATION", 68, 72], ["low levels", "OBSERVATION_MODIFIER", 117, 127], ["vRNA", "OBSERVATION", 131, 135], ["brain", "ANATOMY", 143, 148]]], ["All other samples were negative.", [["samples", "ANATOMY", 10, 17], ["samples", "CANCER", 10, 17], ["All other samples", "TEST", 0, 17], ["negative", "OBSERVATION", 23, 31]]], ["Sera from AJ-z2 at 2 dpi, and AJ-z3 and AJ-z4 at 5 dpi were negative by ELISA.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["AJ-z2", "CELL", 10, 15], ["AJ-z3", "CELL", 30, 35], ["AJ-z4", "GENE_OR_GENE_PRODUCT", 40, 45], ["AJ", "PROTEIN", 30, 32], ["AJ", "PROTEIN", 40, 42], ["Sera", "TEST", 0, 4]]], ["Sera were blind passaged on Vero E6 cells in an attempt to isolate ZIKV and all were negative for cpe and PCR.Hematoxylin and Eosin Stain (H&E) ::: Histopathology ::: ResultsHeart, lung, liver, kidney, testes, prostate, urinary bladder, and brain were collected from all 9 animals as well as salivary glands from 3/9 bats.", [["Sera", "ANATOMY", 0, 4], ["cells", "ANATOMY", 36, 41], ["Heart", "ANATOMY", 174, 179], ["lung", "ANATOMY", 181, 185], ["liver", "ANATOMY", 187, 192], ["kidney", "ANATOMY", 194, 200], ["testes", "ANATOMY", 202, 208], ["prostate", "ANATOMY", 210, 218], ["urinary bladder", "ANATOMY", 220, 235], ["brain", "ANATOMY", 241, 246], ["salivary glands", "ANATOMY", 292, 307], ["Hematoxylin", "CHEMICAL", 110, 121], ["Eosin", "CHEMICAL", 126, 131], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["Vero E6 cells", "CELL", 28, 41], ["ZIKV", "CANCER", 67, 71], ["cpe", "GENE_OR_GENE_PRODUCT", 98, 101], ["Hematoxylin", "SIMPLE_CHEMICAL", 110, 121], ["Eosin Stain", "SIMPLE_CHEMICAL", 126, 137], ["Heart", "ORGAN", 174, 179], ["lung", "ORGAN", 181, 185], ["liver", "ORGAN", 187, 192], ["kidney", "ORGAN", 194, 200], ["testes", "ORGAN", 202, 208], ["prostate", "MULTI-TISSUE_STRUCTURE", 210, 218], ["urinary bladder", "ORGAN", 220, 235], ["brain", "ORGAN", 241, 246], ["salivary glands", "ORGAN", 292, 307], ["Vero E6 cells", "CELL_LINE", 28, 41], ["Vero E6", "SPECIES", 28, 35], ["ZIKV", "SPECIES", 67, 71], ["Sera", "TREATMENT", 0, 4], ["blind", "PROBLEM", 10, 15], ["Vero E6 cells", "TREATMENT", 28, 41], ["ZIKV", "PROBLEM", 67, 71], ["cpe", "PROBLEM", 98, 101], ["PCR", "TEST", 106, 109], ["Eosin Stain", "TEST", 126, 137], ["Heart, lung, liver, kidney, testes, prostate, urinary bladder", "TEST", 174, 235], ["Heart", "ANATOMY", 174, 179], ["lung", "ANATOMY", 181, 185], ["liver", "ANATOMY", 187, 192], ["kidney", "ANATOMY", 194, 200], ["testes", "ANATOMY", 202, 208], ["prostate", "ANATOMY", 210, 218], ["urinary bladder", "ANATOMY", 220, 235], ["brain", "ANATOMY", 241, 246], ["salivary glands", "ANATOMY", 292, 307]]], ["All samples were blindly read by one pathologist.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11]]], ["A summary of the consistent histopathology findings is listed in Table 2.Hematoxylin and Eosin Stain (H&E) ::: Histopathology ::: ResultsFor the time course study, AJ-z1 at 2 dpi showed mild pulmonary congestion with multifocal areas of interstitial pneumonia, mild intra-alveolar hemorrhage and mild atelectasis.", [["pulmonary", "ANATOMY", 191, 200], ["interstitial", "ANATOMY", 237, 249], ["intra-alveolar", "ANATOMY", 266, 280], ["pulmonary congestion", "DISEASE", 191, 211], ["interstitial pneumonia", "DISEASE", 237, 259], ["intra-alveolar hemorrhage", "DISEASE", 266, 291], ["atelectasis", "DISEASE", 301, 312], ["Hematoxylin", "CHEMICAL", 73, 84], ["Eosin", "CHEMICAL", 89, 94], ["Hematoxylin", "SIMPLE_CHEMICAL", 73, 84], ["Eosin Stain", "SIMPLE_CHEMICAL", 89, 100], ["AJ-z1", "CELL", 164, 169], ["pulmonary", "ORGAN", 191, 200], ["intra-alveolar", "IMMATERIAL_ANATOMICAL_ENTITY", 266, 280], ["AJ", "PROTEIN", 164, 166], ["Eosin Stain", "TEST", 89, 100], ["the time course study", "TEST", 141, 162], ["mild pulmonary congestion", "PROBLEM", 186, 211], ["interstitial pneumonia", "PROBLEM", 237, 259], ["mild intra-alveolar hemorrhage", "PROBLEM", 261, 291], ["mild atelectasis", "PROBLEM", 296, 312], ["mild", "OBSERVATION_MODIFIER", 186, 190], ["pulmonary", "ANATOMY", 191, 200], ["congestion", "OBSERVATION", 201, 211], ["multifocal", "OBSERVATION_MODIFIER", 217, 227], ["interstitial", "ANATOMY_MODIFIER", 237, 249], ["pneumonia", "OBSERVATION", 250, 259], ["mild", "OBSERVATION_MODIFIER", 261, 265], ["intra-alveolar", "ANATOMY_MODIFIER", 266, 280], ["hemorrhage", "OBSERVATION", 281, 291], ["mild", "OBSERVATION_MODIFIER", 296, 300], ["atelectasis", "OBSERVATION", 301, 312]]], ["Terminal airways had slightly increased amounts of mucus.", [["airways", "ANATOMY", 9, 16], ["mucus", "ANATOMY", 51, 56], ["airways", "MULTI-TISSUE_STRUCTURE", 9, 16], ["mucus", "ORGANISM_SUBSTANCE", 51, 56], ["slightly increased amounts of mucus", "PROBLEM", 21, 56], ["airways", "ANATOMY", 9, 16], ["slightly", "OBSERVATION_MODIFIER", 21, 29], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["amounts", "OBSERVATION_MODIFIER", 40, 47], ["mucus", "OBSERVATION", 51, 56]]], ["Kidneys had multifocal interstitial infiltrates of small numbers of lymphocytes.", [["Kidneys", "ANATOMY", 0, 7], ["interstitial infiltrates", "ANATOMY", 23, 47], ["lymphocytes", "ANATOMY", 68, 79], ["Kidneys", "ORGAN", 0, 7], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 23, 47], ["lymphocytes", "CELL", 68, 79], ["lymphocytes", "CELL_TYPE", 68, 79], ["multifocal interstitial infiltrates", "PROBLEM", 12, 47], ["small numbers of lymphocytes", "PROBLEM", 51, 79], ["multifocal", "OBSERVATION_MODIFIER", 12, 22], ["interstitial", "ANATOMY_MODIFIER", 23, 35], ["infiltrates", "OBSERVATION", 36, 47], ["small", "OBSERVATION_MODIFIER", 51, 56], ["numbers", "OBSERVATION_MODIFIER", 57, 64], ["lymphocytes", "ANATOMY", 68, 79]]], ["All other tissues were within normal limits.", [["tissues", "ANATOMY", 10, 17], ["tissues", "TISSUE", 10, 17], ["tissues", "ANATOMY", 10, 17], ["within normal limits", "OBSERVATION", 23, 43]]], ["In AJ-z2 at 2 dpi, lungs showed milder pathology than AJ-z1 with minimal interstitial to perivascular infiltrates predominately lymphocytes and macrophages with a band of collapsed air spaces subjacent to the pleural surface.", [["AJ-z2", "ANATOMY", 3, 8], ["lungs", "ANATOMY", 19, 24], ["AJ-z1", "ANATOMY", 54, 59], ["interstitial", "ANATOMY", 73, 85], ["perivascular", "ANATOMY", 89, 101], ["lymphocytes", "ANATOMY", 128, 139], ["macrophages", "ANATOMY", 144, 155], ["pleural surface", "ANATOMY", 209, 224], ["AJ-z2", "GENE_OR_GENE_PRODUCT", 3, 8], ["lungs", "ORGAN", 19, 24], ["AJ-z1", "CELL", 54, 59], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 73, 85], ["perivascular", "IMMATERIAL_ANATOMICAL_ENTITY", 89, 101], ["lymphocytes", "CELL", 128, 139], ["macrophages", "CELL", 144, 155], ["pleural surface", "MULTI-TISSUE_STRUCTURE", 209, 224], ["AJ", "PROTEIN", 3, 5], ["lymphocytes", "CELL_TYPE", 128, 139], ["macrophages", "CELL_TYPE", 144, 155], ["milder pathology than AJ-z1", "PROBLEM", 32, 59], ["minimal interstitial to perivascular infiltrates predominately lymphocytes and macrophages", "PROBLEM", 65, 155], ["collapsed air spaces", "PROBLEM", 171, 191], ["lungs", "ANATOMY", 19, 24], ["milder", "OBSERVATION_MODIFIER", 32, 38], ["pathology", "OBSERVATION", 39, 48], ["minimal", "OBSERVATION_MODIFIER", 65, 72], ["interstitial", "ANATOMY_MODIFIER", 73, 85], ["perivascular", "ANATOMY_MODIFIER", 89, 101], ["infiltrates", "OBSERVATION", 102, 113], ["lymphocytes", "OBSERVATION", 128, 139], ["macrophages", "OBSERVATION_MODIFIER", 144, 155], ["band", "OBSERVATION_MODIFIER", 163, 167], ["collapsed", "OBSERVATION_MODIFIER", 171, 180], ["air spaces", "OBSERVATION", 181, 191], ["pleural", "ANATOMY", 209, 216], ["surface", "ANATOMY_MODIFIER", 217, 224]]], ["There were focal lesions in the left ventricle of the heart where there was individual cell loss or else fragmentation of the sarcoplasm of scattered cardiomyocytes.", [["focal lesions", "ANATOMY", 11, 24], ["left ventricle", "ANATOMY", 32, 46], ["heart", "ANATOMY", 54, 59], ["cell", "ANATOMY", 87, 91], ["sarcoplasm", "ANATOMY", 126, 136], ["cardiomyocytes", "ANATOMY", 150, 164], ["focal lesions", "PATHOLOGICAL_FORMATION", 11, 24], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 32, 46], ["heart", "ORGAN", 54, 59], ["cell", "CELL", 87, 91], ["cardiomyocytes", "CELL", 150, 164], ["scattered cardiomyocytes", "CELL_TYPE", 140, 164], ["focal lesions in the left ventricle of the heart", "PROBLEM", 11, 59], ["individual cell loss", "PROBLEM", 76, 96], ["scattered cardiomyocytes", "PROBLEM", 140, 164], ["focal", "OBSERVATION_MODIFIER", 11, 16], ["lesions", "OBSERVATION", 17, 24], ["left ventricle", "ANATOMY", 32, 46], ["heart", "ANATOMY", 54, 59], ["individual cell loss", "OBSERVATION", 76, 96], ["sarcoplasm", "ANATOMY", 126, 136], ["scattered", "OBSERVATION_MODIFIER", 140, 149], ["cardiomyocytes", "ANATOMY", 150, 164]]], ["Degenerate/necrotic cardiomyocytes were accompanied by infiltrations of small numbers of macrophages, lymphocytes and satellite cells.", [["necrotic cardiomyocytes", "ANATOMY", 11, 34], ["macrophages", "ANATOMY", 89, 100], ["lymphocytes", "ANATOMY", 102, 113], ["satellite cells", "ANATOMY", 118, 133], ["necrotic", "DISEASE", 11, 19], ["necrotic cardiomyocytes", "CELL", 11, 34], ["macrophages", "CELL", 89, 100], ["lymphocytes", "CELL", 102, 113], ["satellite cells", "CELL", 118, 133], ["necrotic cardiomyocytes", "CELL_TYPE", 11, 34], ["macrophages", "CELL_TYPE", 89, 100], ["lymphocytes", "CELL_TYPE", 102, 113], ["satellite cells", "CELL_TYPE", 118, 133], ["Degenerate/necrotic cardiomyocytes", "PROBLEM", 0, 34], ["infiltrations", "PROBLEM", 55, 68], ["small numbers of macrophages", "PROBLEM", 72, 100], ["lymphocytes", "TEST", 102, 113], ["satellite cells", "PROBLEM", 118, 133], ["necrotic cardiomyocytes", "OBSERVATION", 11, 34], ["infiltrations", "OBSERVATION", 55, 68], ["small", "OBSERVATION_MODIFIER", 72, 77], ["numbers", "OBSERVATION_MODIFIER", 78, 85], ["macrophages", "OBSERVATION", 89, 100], ["lymphocytes", "ANATOMY", 102, 113], ["satellite cells", "OBSERVATION", 118, 133]]], ["All other tissues were within normal limits.Hematoxylin and Eosin Stain (H&E) ::: Histopathology ::: ResultsLungs from AJ-z3 at 5 dpi had minimal focal interstitial histiocytic pneumonia with atelectasis.", [["tissues", "ANATOMY", 10, 17], ["AJ-z3", "ANATOMY", 119, 124], ["focal interstitial histiocytic", "ANATOMY", 146, 176], ["interstitial histiocytic pneumonia", "DISEASE", 152, 186], ["atelectasis", "DISEASE", 192, 203], ["Hematoxylin", "CHEMICAL", 44, 55], ["Eosin", "CHEMICAL", 60, 65], ["tissues", "TISSUE", 10, 17], ["Hematoxylin", "SIMPLE_CHEMICAL", 44, 55], ["Eosin Stain", "SIMPLE_CHEMICAL", 60, 71], ["AJ-z3", "CELL", 119, 124], ["interstitial histiocytic", "PATHOLOGICAL_FORMATION", 152, 176], ["Hematoxylin", "TEST", 44, 55], ["Eosin Stain", "TEST", 60, 71], ["minimal focal interstitial histiocytic pneumonia", "PROBLEM", 138, 186], ["atelectasis", "PROBLEM", 192, 203], ["tissues", "ANATOMY", 10, 17], ["within normal limits", "OBSERVATION", 23, 43], ["minimal", "OBSERVATION_MODIFIER", 138, 145], ["focal", "OBSERVATION_MODIFIER", 146, 151], ["interstitial", "OBSERVATION_MODIFIER", 152, 164], ["histiocytic", "OBSERVATION_MODIFIER", 165, 176], ["pneumonia", "OBSERVATION", 177, 186], ["atelectasis", "OBSERVATION", 192, 203]]], ["Kidneys showed multifocal chronic lymphohistiocytic pyelitis with a few degenerate and detached epithelial cells accumulating in the renal pelvis and infiltration of pelvic stroma by small numbers of mixed inflammatory cells.", [["Kidneys", "ANATOMY", 0, 7], ["epithelial cells", "ANATOMY", 96, 112], ["renal pelvis", "ANATOMY", 133, 145], ["pelvic stroma", "ANATOMY", 166, 179], ["inflammatory cells", "ANATOMY", 206, 224], ["Kidneys", "ORGAN", 0, 7], ["epithelial cells", "CELL", 96, 112], ["renal pelvis", "MULTI-TISSUE_STRUCTURE", 133, 145], ["pelvic stroma", "TISSUE", 166, 179], ["cells", "CELL", 219, 224], ["epithelial cells", "CELL_TYPE", 96, 112], ["mixed inflammatory cells", "CELL_TYPE", 200, 224], ["multifocal chronic lymphohistiocytic pyelitis", "PROBLEM", 15, 60], ["a few degenerate and detached epithelial cells", "PROBLEM", 66, 112], ["infiltration of pelvic stroma", "PROBLEM", 150, 179], ["mixed inflammatory cells", "PROBLEM", 200, 224], ["multifocal", "OBSERVATION_MODIFIER", 15, 25], ["chronic", "OBSERVATION_MODIFIER", 26, 33], ["lymphohistiocytic pyelitis", "OBSERVATION", 34, 60], ["few", "OBSERVATION_MODIFIER", 68, 71], ["degenerate", "OBSERVATION_MODIFIER", 72, 82], ["detached", "OBSERVATION_MODIFIER", 87, 95], ["epithelial cells", "OBSERVATION", 96, 112], ["renal", "ANATOMY_MODIFIER", 133, 138], ["pelvis", "ANATOMY", 139, 145], ["infiltration", "OBSERVATION", 150, 162], ["pelvic", "ANATOMY", 166, 172], ["stroma", "ANATOMY_MODIFIER", 173, 179], ["small", "OBSERVATION_MODIFIER", 183, 188], ["numbers", "OBSERVATION_MODIFIER", 189, 196], ["mixed", "OBSERVATION_MODIFIER", 200, 205], ["inflammatory cells", "OBSERVATION", 206, 224]]], ["Mandibular salivary gland showed focal moderate cellular infiltrates of periductular lymphocytes and macrophages.", [["Mandibular salivary gland", "ANATOMY", 0, 25], ["cellular", "ANATOMY", 48, 56], ["periductular lymphocytes", "ANATOMY", 72, 96], ["macrophages", "ANATOMY", 101, 112], ["salivary gland", "ORGAN", 11, 25], ["cellular", "CELL", 48, 56], ["periductular lymphocytes", "CELL", 72, 96], ["macrophages", "CELL", 101, 112], ["periductular lymphocytes", "CELL_TYPE", 72, 96], ["macrophages", "CELL_TYPE", 101, 112], ["Mandibular salivary gland", "TEST", 0, 25], ["focal moderate cellular infiltrates of periductular lymphocytes and macrophages", "PROBLEM", 33, 112], ["salivary gland", "ANATOMY", 11, 25], ["focal", "OBSERVATION_MODIFIER", 33, 38], ["moderate", "OBSERVATION_MODIFIER", 39, 47], ["cellular", "OBSERVATION_MODIFIER", 48, 56], ["infiltrates", "OBSERVATION", 57, 68], ["periductular lymphocytes", "OBSERVATION", 72, 96], ["macrophages", "OBSERVATION_MODIFIER", 101, 112]]], ["Affected salivary ducts contained detached and degenerate epithelial cells and leukocytes.", [["salivary ducts", "ANATOMY", 9, 23], ["epithelial cells", "ANATOMY", 58, 74], ["leukocytes", "ANATOMY", 79, 89], ["salivary ducts", "MULTI-TISSUE_STRUCTURE", 9, 23], ["epithelial cells", "CELL", 58, 74], ["leukocytes", "CELL", 79, 89], ["detached and degenerate epithelial cells", "CELL_TYPE", 34, 74], ["leukocytes", "CELL_TYPE", 79, 89], ["Affected salivary ducts", "PROBLEM", 0, 23], ["degenerate epithelial cells and leukocytes", "PROBLEM", 47, 89], ["salivary ducts", "ANATOMY", 9, 23], ["degenerate epithelial cells", "OBSERVATION", 47, 74], ["leukocytes", "OBSERVATION_MODIFIER", 79, 89]]], ["Occasional ducts were encircled by granulation tissue and a few heterophils.", [["ducts", "ANATOMY", 11, 16], ["granulation tissue", "ANATOMY", 35, 53], ["heterophils", "ANATOMY", 64, 75], ["ducts", "MULTI-TISSUE_STRUCTURE", 11, 16], ["granulation tissue", "TISSUE", 35, 53], ["heterophils", "CELL", 64, 75], ["heterophils", "CELL_TYPE", 64, 75], ["Occasional ducts", "PROBLEM", 0, 16], ["ducts", "ANATOMY", 11, 16], ["granulation tissue", "OBSERVATION", 35, 53], ["few", "OBSERVATION_MODIFIER", 60, 63], ["heterophils", "OBSERVATION", 64, 75]]], ["Rare apoptosis was evident in the lining epithelium of such ducts.", [["lining epithelium", "ANATOMY", 34, 51], ["ducts", "ANATOMY", 60, 65], ["lining epithelium", "TISSUE", 34, 51], ["ducts", "MULTI-TISSUE_STRUCTURE", 60, 65], ["Rare apoptosis", "PROBLEM", 0, 14], ["apoptosis", "OBSERVATION", 5, 14], ["lining", "ANATOMY_MODIFIER", 34, 40], ["epithelium", "ANATOMY_MODIFIER", 41, 51], ["such ducts", "ANATOMY", 55, 65]]], ["All other tissues were within normal limits.", [["tissues", "ANATOMY", 10, 17], ["tissues", "TISSUE", 10, 17], ["tissues", "ANATOMY", 10, 17], ["within normal limits", "OBSERVATION", 23, 43]]], ["AJ-z4 at 5 dpi had lungs with minimal alveolar septal infiltrates scattered within collapsed lung parenchyma along with multifocal microscopic hemorrhages.", [["lungs", "ANATOMY", 19, 24], ["alveolar septal infiltrates", "ANATOMY", 38, 65], ["lung parenchyma", "ANATOMY", 93, 108], ["hemorrhages", "DISEASE", 143, 154], ["AJ-z4", "GENE_OR_GENE_PRODUCT", 0, 5], ["lungs", "ORGAN", 19, 24], ["alveolar", "PATHOLOGICAL_FORMATION", 38, 46], ["septal infiltrates", "PATHOLOGICAL_FORMATION", 47, 65], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 93, 108], ["AJ", "PROTEIN", 0, 2], ["z4", "PROTEIN", 3, 5], ["minimal alveolar septal infiltrates", "PROBLEM", 30, 65], ["collapsed lung parenchyma", "PROBLEM", 83, 108], ["multifocal microscopic hemorrhages", "PROBLEM", 120, 154], ["lungs", "ANATOMY", 19, 24], ["minimal", "OBSERVATION_MODIFIER", 30, 37], ["alveolar", "ANATOMY_MODIFIER", 38, 46], ["septal", "ANATOMY_MODIFIER", 47, 53], ["infiltrates", "OBSERVATION", 54, 65], ["collapsed", "OBSERVATION_MODIFIER", 83, 92], ["lung", "ANATOMY", 93, 97], ["parenchyma", "ANATOMY_MODIFIER", 98, 108], ["multifocal", "OBSERVATION_MODIFIER", 120, 130], ["microscopic", "OBSERVATION_MODIFIER", 131, 142], ["hemorrhages", "OBSERVATION", 143, 154]]], ["Kidneys had multifocal areas of mineralization.", [["Kidneys", "ANATOMY", 0, 7], ["Kidneys", "ORGAN", 0, 7], ["multifocal areas of mineralization", "PROBLEM", 12, 46], ["multifocal", "OBSERVATION_MODIFIER", 12, 22], ["mineralization", "OBSERVATION", 32, 46]]], ["In the outer medulla and at the cortico-medullary junction were rare perivascular infiltrates of lymphoplasmacytes.", [["outer medulla", "ANATOMY", 7, 20], ["cortico-medullary junction", "ANATOMY", 32, 58], ["perivascular infiltrates", "ANATOMY", 69, 93], ["lymphoplasmacytes", "ANATOMY", 97, 114], ["outer medulla", "MULTI-TISSUE_STRUCTURE", 7, 20], ["cortico-medullary junction", "TISSUE", 32, 58], ["perivascular infiltrates", "PATHOLOGICAL_FORMATION", 69, 93], ["lymphoplasmacytes", "CANCER", 97, 114], ["lymphoplasmacytes", "CELL_TYPE", 97, 114], ["rare perivascular infiltrates of lymphoplasmacytes", "PROBLEM", 64, 114], ["outer", "ANATOMY_MODIFIER", 7, 12], ["medulla", "ANATOMY", 13, 20], ["cortico", "ANATOMY_MODIFIER", 32, 39], ["medullary junction", "ANATOMY", 40, 58], ["rare", "OBSERVATION_MODIFIER", 64, 68], ["perivascular", "ANATOMY_MODIFIER", 69, 81], ["infiltrates", "OBSERVATION", 82, 93], ["lymphoplasmacytes", "OBSERVATION", 97, 114]]], ["Esophagus and lymphoid tissue associated with palatine salivary gland showed focal mild lymphoplasmacytic inflammation.", [["Esophagus", "ANATOMY", 0, 9], ["lymphoid tissue", "ANATOMY", 14, 29], ["palatine salivary gland", "ANATOMY", 46, 69], ["inflammation", "DISEASE", 106, 118], ["Esophagus", "CANCER", 0, 9], ["lymphoid tissue", "TISSUE", 14, 29], ["palatine salivary gland", "ORGAN", 46, 69], ["lymphoplasmacytic inflammation", "PATHOLOGICAL_FORMATION", 88, 118], ["Esophagus and lymphoid tissue", "PROBLEM", 0, 29], ["palatine salivary gland", "TEST", 46, 69], ["focal mild lymphoplasmacytic inflammation", "PROBLEM", 77, 118], ["lymphoid tissue", "OBSERVATION", 14, 29], ["palatine", "ANATOMY_MODIFIER", 46, 54], ["salivary gland", "ANATOMY", 55, 69], ["focal", "OBSERVATION_MODIFIER", 77, 82], ["mild", "OBSERVATION_MODIFIER", 83, 87], ["lymphoplasmacytic inflammation", "OBSERVATION", 88, 118]]], ["Moderate numbers of lymphocytes and plasma cells were arranged in columns parallel to the respiratory mucosal epithelium of the nasophayrnx.", [["lymphocytes", "ANATOMY", 20, 31], ["plasma cells", "ANATOMY", 36, 48], ["respiratory mucosal epithelium", "ANATOMY", 90, 120], ["nasophayrnx", "ANATOMY", 128, 139], ["lymphocytes", "CELL", 20, 31], ["plasma cells", "CELL", 36, 48], ["respiratory mucosal epithelium", "TISSUE", 90, 120], ["nasophayrnx", "CANCER", 128, 139], ["lymphocytes", "CELL_TYPE", 20, 31], ["plasma cells", "CELL_TYPE", 36, 48], ["Moderate numbers of lymphocytes", "PROBLEM", 0, 31], ["plasma cells", "PROBLEM", 36, 48], ["lymphocytes", "OBSERVATION", 20, 31], ["plasma cells", "OBSERVATION", 36, 48], ["columns", "ANATOMY_MODIFIER", 66, 73], ["respiratory", "ANATOMY_MODIFIER", 90, 101], ["mucosal", "ANATOMY_MODIFIER", 102, 109], ["epithelium", "ANATOMY_MODIFIER", 110, 120], ["nasophayrnx", "ANATOMY", 128, 139]]], ["The lumen contained increased amounts of mucus and a few inflammatory cells, mainly heterophils and lymphocytes.", [["lumen", "ANATOMY", 4, 9], ["mucus", "ANATOMY", 41, 46], ["inflammatory cells", "ANATOMY", 57, 75], ["heterophils", "ANATOMY", 84, 95], ["lymphocytes", "ANATOMY", 100, 111], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 9], ["mucus", "ORGANISM_SUBSTANCE", 41, 46], ["inflammatory cells", "CELL", 57, 75], ["heterophils", "CELL", 84, 95], ["lymphocytes", "CELL", 100, 111], ["inflammatory cells", "CELL_TYPE", 57, 75], ["heterophils", "CELL_TYPE", 84, 95], ["lymphocytes", "CELL_TYPE", 100, 111], ["increased amounts of mucus", "PROBLEM", 20, 46], ["a few inflammatory cells", "PROBLEM", 51, 75], ["lymphocytes", "TEST", 100, 111], ["lumen", "ANATOMY_MODIFIER", 4, 9], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["amounts", "OBSERVATION_MODIFIER", 30, 37], ["mucus", "OBSERVATION", 41, 46], ["few", "OBSERVATION_MODIFIER", 53, 56], ["inflammatory cells", "OBSERVATION", 57, 75], ["mainly", "OBSERVATION_MODIFIER", 77, 83], ["heterophils", "OBSERVATION_MODIFIER", 84, 95], ["lymphocytes", "ANATOMY", 100, 111]]], ["In the testicles, there was focal testicular degeneration manifested by presence of giant spermatids in the lumina of affected seminiferous tubules and accumulation of a small numbers of interstitial lymphocytes and macrophages.", [["testicles", "ANATOMY", 7, 16], ["testicular", "ANATOMY", 34, 44], ["spermatids", "ANATOMY", 90, 100], ["lumina", "ANATOMY", 108, 114], ["seminiferous tubules", "ANATOMY", 127, 147], ["interstitial lymphocytes", "ANATOMY", 187, 211], ["macrophages", "ANATOMY", 216, 227], ["testicular degeneration", "DISEASE", 34, 57], ["testicles", "ORGAN", 7, 16], ["testicular", "ORGAN", 34, 44], ["giant spermatids", "CELLULAR_COMPONENT", 84, 100], ["lumina", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 114], ["seminiferous tubules", "TISSUE", 127, 147], ["interstitial lymphocytes", "CELL", 187, 211], ["macrophages", "CELL", 216, 227], ["giant spermatids", "CELL_TYPE", 84, 100], ["interstitial lymphocytes", "CELL_TYPE", 187, 211], ["macrophages", "CELL_TYPE", 216, 227], ["focal testicular degeneration", "PROBLEM", 28, 57], ["giant spermatids", "PROBLEM", 84, 100], ["affected seminiferous tubules", "PROBLEM", 118, 147], ["a small numbers of interstitial lymphocytes and macrophages", "PROBLEM", 168, 227], ["testicles", "ANATOMY", 7, 16], ["focal", "OBSERVATION_MODIFIER", 28, 33], ["testicular", "ANATOMY", 34, 44], ["degeneration", "OBSERVATION", 45, 57], ["giant", "OBSERVATION_MODIFIER", 84, 89], ["spermatids", "OBSERVATION", 90, 100], ["lumina", "ANATOMY_MODIFIER", 108, 114], ["affected", "OBSERVATION_MODIFIER", 118, 126], ["seminiferous tubules", "OBSERVATION", 127, 147], ["accumulation", "OBSERVATION_MODIFIER", 152, 164], ["small", "OBSERVATION_MODIFIER", 170, 175], ["numbers", "OBSERVATION_MODIFIER", 176, 183], ["interstitial lymphocytes", "OBSERVATION", 187, 211], ["macrophages", "OBSERVATION", 216, 227]]], ["All other tissues were within normal limits.Hematoxylin and Eosin Stain (H&E) ::: Histopathology ::: ResultsLungs from AJ-z5 at 10 dpi had minimal interstitial to perivascular infiltrates with multifocal atelectasis and microscopic hemorrhages.", [["tissues", "ANATOMY", 10, 17], ["AJ-z5", "ANATOMY", 119, 124], ["interstitial", "ANATOMY", 147, 159], ["perivascular infiltrates", "ANATOMY", 163, 187], ["atelectasis", "DISEASE", 204, 215], ["hemorrhages", "DISEASE", 232, 243], ["Hematoxylin", "CHEMICAL", 44, 55], ["Eosin", "CHEMICAL", 60, 65], ["tissues", "TISSUE", 10, 17], ["Hematoxylin", "SIMPLE_CHEMICAL", 44, 55], ["Eosin Stain", "SIMPLE_CHEMICAL", 60, 71], ["AJ-z5", "CELL", 119, 124], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 147, 159], ["perivascular infiltrates", "PATHOLOGICAL_FORMATION", 163, 187], ["Hematoxylin", "TEST", 44, 55], ["Eosin Stain", "TEST", 60, 71], ["ResultsLungs", "TEST", 101, 113], ["AJ", "TEST", 119, 121], ["minimal interstitial to perivascular infiltrates", "PROBLEM", 139, 187], ["multifocal atelectasis", "PROBLEM", 193, 215], ["microscopic hemorrhages", "PROBLEM", 220, 243], ["tissues", "ANATOMY", 10, 17], ["within normal limits", "OBSERVATION", 23, 43], ["minimal", "OBSERVATION_MODIFIER", 139, 146], ["interstitial", "ANATOMY_MODIFIER", 147, 159], ["perivascular", "ANATOMY_MODIFIER", 163, 175], ["infiltrates", "OBSERVATION", 176, 187], ["multifocal", "OBSERVATION_MODIFIER", 193, 203], ["atelectasis", "OBSERVATION", 204, 215], ["microscopic", "OBSERVATION_MODIFIER", 220, 231], ["hemorrhages", "OBSERVATION", 232, 243]]], ["The left papillary muscle of the heart showed rare multifocal cardiomyocyte necrosis characterized by rounding up of individual cardiomyocytes.", [["left papillary muscle", "ANATOMY", 4, 25], ["heart", "ANATOMY", 33, 38], ["cardiomyocyte", "ANATOMY", 62, 75], ["cardiomyocytes", "ANATOMY", 128, 142], ["necrosis", "DISEASE", 76, 84], ["left papillary muscle", "TISSUE", 4, 25], ["heart", "ORGAN", 33, 38], ["cardiomyocyte", "CELL", 62, 75], ["cardiomyocytes", "CELL", 128, 142], ["cardiomyocytes", "CELL_TYPE", 128, 142], ["rare multifocal cardiomyocyte necrosis", "PROBLEM", 46, 84], ["individual cardiomyocytes", "PROBLEM", 117, 142], ["left", "ANATOMY_MODIFIER", 4, 8], ["papillary muscle", "ANATOMY", 9, 25], ["heart", "ANATOMY", 33, 38], ["rare", "OBSERVATION_MODIFIER", 46, 50], ["multifocal", "OBSERVATION_MODIFIER", 51, 61], ["cardiomyocyte", "ANATOMY", 62, 75], ["necrosis", "OBSERVATION", 76, 84], ["cardiomyocytes", "ANATOMY", 128, 142]]], ["Necrotic cardiomyocytes appeared with hypereosinophilic cytoplasm, devoid of cross striations or fragmented and rarely vacuolated.", [["Necrotic cardiomyocytes", "ANATOMY", 0, 23], ["hypereosinophilic cytoplasm", "ANATOMY", 38, 65], ["Necrotic cardiomyocytes", "CELL", 0, 23], ["cytoplasm", "ORGANISM_SUBSTANCE", 56, 65], ["Necrotic cardiomyocytes", "CELL_TYPE", 0, 23], ["Necrotic cardiomyocytes", "PROBLEM", 0, 23], ["hypereosinophilic cytoplasm", "PROBLEM", 38, 65], ["cross striations", "PROBLEM", 77, 93], ["cardiomyocytes", "ANATOMY", 9, 23], ["appeared with", "UNCERTAINTY", 24, 37], ["hypereosinophilic cytoplasm", "OBSERVATION", 38, 65], ["cross striations", "OBSERVATION_MODIFIER", 77, 93], ["fragmented", "OBSERVATION_MODIFIER", 97, 107], ["vacuolated", "OBSERVATION_MODIFIER", 119, 129]]], ["Minimal interstitial hypercellularity due to increased activity of satellite cells and infiltration of small numbers of lymphocytes was observed in the vicinity of degenerate/necrotic cardiac muscle fibers.", [["interstitial", "ANATOMY", 8, 20], ["satellite cells", "ANATOMY", 67, 82], ["lymphocytes", "ANATOMY", 120, 131], ["necrotic cardiac muscle fibers", "ANATOMY", 175, 205], ["necrotic", "DISEASE", 175, 183], ["satellite cells", "CELL", 67, 82], ["lymphocytes", "CELL", 120, 131], ["cardiac muscle fibers", "TISSUE", 184, 205], ["satellite cells", "CELL_TYPE", 67, 82], ["lymphocytes", "CELL_TYPE", 120, 131], ["Minimal interstitial hypercellularity", "PROBLEM", 0, 37], ["increased activity of satellite cells", "PROBLEM", 45, 82], ["infiltration of small numbers of lymphocytes", "PROBLEM", 87, 131], ["degenerate/necrotic cardiac muscle fibers", "PROBLEM", 164, 205], ["interstitial", "ANATOMY_MODIFIER", 8, 20], ["hypercellularity", "OBSERVATION", 21, 37], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["activity", "OBSERVATION_MODIFIER", 55, 63], ["satellite cells", "OBSERVATION", 67, 82], ["infiltration", "OBSERVATION_MODIFIER", 87, 99], ["small", "OBSERVATION_MODIFIER", 103, 108], ["numbers", "OBSERVATION_MODIFIER", 109, 116], ["lymphocytes", "OBSERVATION", 120, 131], ["necrotic", "OBSERVATION", 175, 183], ["cardiac muscle", "ANATOMY", 184, 198], ["fibers", "ANATOMY_MODIFIER", 199, 205]]], ["Kidneys had an area of focal lymphoplasmactyic pyelitis.", [["Kidneys", "ANATOMY", 0, 7], ["focal lymphoplasmactyic pyelitis", "ANATOMY", 23, 55], ["lymphoplasmactyic pyelitis", "DISEASE", 29, 55], ["Kidneys", "ORGAN", 0, 7], ["focal lymphoplasmactyic pyelitis", "CANCER", 23, 55], ["focal lymphoplasmactyic pyelitis", "PROBLEM", 23, 55], ["area", "OBSERVATION_MODIFIER", 15, 19], ["focal", "OBSERVATION_MODIFIER", 23, 28], ["lymphoplasmactyic pyelitis", "OBSERVATION", 29, 55]]], ["Additionally, there was a focal area of mineralization and inflammation in the inner medulla.", [["focal area", "ANATOMY", 26, 36], ["inner medulla", "ANATOMY", 79, 92], ["inflammation", "DISEASE", 59, 71], ["inner medulla", "TISSUE", 79, 92], ["a focal area of mineralization", "PROBLEM", 24, 54], ["inflammation in the inner medulla", "PROBLEM", 59, 92], ["focal", "OBSERVATION_MODIFIER", 26, 31], ["area", "OBSERVATION_MODIFIER", 32, 36], ["mineralization", "OBSERVATION", 40, 54], ["inflammation", "OBSERVATION", 59, 71], ["inner", "ANATOMY_MODIFIER", 79, 84], ["medulla", "ANATOMY", 85, 92]]], ["All other tissues were within normal limits.", [["tissues", "ANATOMY", 10, 17], ["tissues", "TISSUE", 10, 17], ["tissues", "ANATOMY", 10, 17], ["within normal limits", "OBSERVATION", 23, 43]]], ["AJ-z6 at 10 dpi had occasional focal inflammation and cardiomyocyte degeneration in the left ventricle and interventricular septum.", [["cardiomyocyte", "ANATOMY", 54, 67], ["left ventricle", "ANATOMY", 88, 102], ["interventricular septum", "ANATOMY", 107, 130], ["inflammation", "DISEASE", 37, 49], ["cardiomyocyte", "CELL", 54, 67], ["left ventricle", "MULTI-TISSUE_STRUCTURE", 88, 102], ["interventricular septum", "MULTI-TISSUE_STRUCTURE", 107, 130], ["AJ", "PROTEIN", 0, 2], ["z6", "PROTEIN", 3, 5], ["AJ", "TEST", 0, 2], ["occasional focal inflammation", "PROBLEM", 20, 49], ["cardiomyocyte degeneration in the left ventricle and interventricular septum", "PROBLEM", 54, 130], ["occasional", "OBSERVATION_MODIFIER", 20, 30], ["focal", "OBSERVATION_MODIFIER", 31, 36], ["inflammation", "OBSERVATION", 37, 49], ["cardiomyocyte", "ANATOMY", 54, 67], ["degeneration", "OBSERVATION", 68, 80], ["left ventricle", "ANATOMY", 88, 102], ["interventricular septum", "ANATOMY", 107, 130]]], ["Area CA3 of the hippocampus in the brain showed focal pyrimidal neuronal necrosis with a focal area of mineralization around a vessel in the cerebral cortex along with focal gliosis and individual neuronal necrosis (Fig 2).", [["hippocampus", "ANATOMY", 16, 27], ["brain", "ANATOMY", 35, 40], ["neuronal", "ANATOMY", 64, 72], ["focal area", "ANATOMY", 89, 99], ["vessel", "ANATOMY", 127, 133], ["cerebral cortex", "ANATOMY", 141, 156], ["neuronal", "ANATOMY", 197, 205], ["necrosis", "DISEASE", 73, 81], ["gliosis", "DISEASE", 174, 181], ["neuronal necrosis", "DISEASE", 197, 214], ["CA3", "MULTI-TISSUE_STRUCTURE", 5, 8], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 16, 27], ["brain", "ORGAN", 35, 40], ["vessel", "MULTI-TISSUE_STRUCTURE", 127, 133], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 141, 156], ["neuronal", "CELL", 197, 205], ["Area CA3 of the hippocampus in the brain", "TEST", 0, 40], ["focal pyrimidal neuronal necrosis", "PROBLEM", 48, 81], ["a focal area of mineralization", "PROBLEM", 87, 117], ["a vessel in the cerebral cortex", "PROBLEM", 125, 156], ["focal gliosis", "PROBLEM", 168, 181], ["individual neuronal necrosis", "PROBLEM", 186, 214], ["hippocampus", "ANATOMY", 16, 27], ["brain", "ANATOMY", 35, 40], ["focal", "OBSERVATION_MODIFIER", 48, 53], ["pyrimidal neuronal", "OBSERVATION", 54, 72], ["necrosis", "OBSERVATION", 73, 81], ["focal", "OBSERVATION_MODIFIER", 89, 94], ["area", "OBSERVATION_MODIFIER", 95, 99], ["mineralization", "OBSERVATION", 103, 117], ["vessel", "ANATOMY", 127, 133], ["cerebral cortex", "ANATOMY", 141, 156], ["focal", "OBSERVATION_MODIFIER", 168, 173], ["gliosis", "OBSERVATION", 174, 181], ["individual", "OBSERVATION_MODIFIER", 186, 196], ["neuronal", "OBSERVATION_MODIFIER", 197, 205], ["necrosis", "OBSERVATION", 206, 214]]], ["All other tissues were within normal limits.", [["tissues", "ANATOMY", 10, 17], ["tissues", "TISSUE", 10, 17], ["tissues", "ANATOMY", 10, 17], ["within normal limits", "OBSERVATION", 23, 43]]], ["Testicular, neural and salivary glands\u2019 lesions are believed to be associated with ZIKV infection as they were not seen with other viral infections.Hematoxylin and Eosin Stain (H&E) ::: Histopathology ::: ResultsIn the pilot study bats, AJ-z7 at 28 dpi had more prominent interstitial pneumonia with congestion of the lungs compared to earlier time points.", [["Testicular", "ANATOMY", 0, 10], ["neural", "ANATOMY", 12, 18], ["salivary glands", "ANATOMY", 23, 38], ["lesions", "ANATOMY", 40, 47], ["interstitial", "ANATOMY", 272, 284], ["lungs", "ANATOMY", 318, 323], ["infection", "DISEASE", 88, 97], ["viral infections", "DISEASE", 131, 147], ["pneumonia", "DISEASE", 285, 294], ["Hematoxylin", "CHEMICAL", 148, 159], ["Eosin", "CHEMICAL", 164, 169], ["Testicular", "ORGAN", 0, 10], ["salivary glands", "ORGAN", 23, 38], ["\u2019 lesions", "PATHOLOGICAL_FORMATION", 38, 47], ["ZIKV", "GENE_OR_GENE_PRODUCT", 83, 87], ["Hematoxylin", "SIMPLE_CHEMICAL", 148, 159], ["Eosin Stain", "SIMPLE_CHEMICAL", 164, 175], ["bats", "ORGANISM", 231, 235], ["AJ-z7", "CELL", 237, 242], ["interstitial pneumonia", "PATHOLOGICAL_FORMATION", 272, 294], ["lungs", "ORGAN", 318, 323], ["ZIKV", "SPECIES", 83, 87], ["Testicular, neural and salivary glands\u2019 lesions", "PROBLEM", 0, 47], ["ZIKV infection", "PROBLEM", 83, 97], ["other viral infections", "PROBLEM", 125, 147], ["Hematoxylin", "TEST", 148, 159], ["Eosin Stain", "TEST", 164, 175], ["the pilot study", "TEST", 215, 230], ["more prominent interstitial pneumonia", "PROBLEM", 257, 294], ["congestion of the lungs", "PROBLEM", 300, 323], ["neural", "ANATOMY_MODIFIER", 12, 18], ["salivary glands", "ANATOMY", 23, 38], ["lesions", "OBSERVATION", 40, 47], ["ZIKV", "OBSERVATION_MODIFIER", 83, 87], ["infection", "OBSERVATION", 88, 97], ["viral", "OBSERVATION_MODIFIER", 131, 136], ["infections", "OBSERVATION", 137, 147], ["more", "OBSERVATION_MODIFIER", 257, 261], ["prominent", "OBSERVATION_MODIFIER", 262, 271], ["interstitial", "ANATOMY_MODIFIER", 272, 284], ["pneumonia", "OBSERVATION", 285, 294], ["congestion", "OBSERVATION", 300, 310], ["lungs", "ANATOMY", 318, 323]]], ["The heart had minimal cardiomyocyte degeneration and necrosis with hypercellular interstitium and increased amounts of mature fibrous connective tissue.", [["heart", "ANATOMY", 4, 9], ["cardiomyocyte", "ANATOMY", 22, 35], ["hypercellular interstitium", "ANATOMY", 67, 93], ["fibrous connective tissue", "ANATOMY", 126, 151], ["necrosis", "DISEASE", 53, 61], ["heart", "ORGAN", 4, 9], ["cardiomyocyte", "CELL", 22, 35], ["hypercellular interstitium", "TISSUE", 67, 93], ["fibrous connective tissue", "TISSUE", 126, 151], ["minimal cardiomyocyte degeneration", "PROBLEM", 14, 48], ["necrosis", "PROBLEM", 53, 61], ["hypercellular interstitium", "PROBLEM", 67, 93], ["increased amounts of mature fibrous connective tissue", "PROBLEM", 98, 151], ["heart", "ANATOMY", 4, 9], ["minimal", "OBSERVATION_MODIFIER", 14, 21], ["cardiomyocyte", "ANATOMY", 22, 35], ["degeneration", "OBSERVATION", 36, 48], ["necrosis", "OBSERVATION", 53, 61], ["hypercellular", "OBSERVATION_MODIFIER", 67, 80], ["interstitium", "OBSERVATION", 81, 93], ["increased", "OBSERVATION_MODIFIER", 98, 107], ["amounts", "OBSERVATION_MODIFIER", 108, 115], ["mature", "OBSERVATION_MODIFIER", 119, 125], ["fibrous connective tissue", "OBSERVATION", 126, 151]]], ["The kidney had focal interstitial infiltrates of the cortical and outer medullary interstitium.", [["kidney", "ANATOMY", 4, 10], ["focal interstitial infiltrates", "ANATOMY", 15, 45], ["cortical", "ANATOMY", 53, 61], ["outer medullary interstitium", "ANATOMY", 66, 94], ["kidney", "ORGAN", 4, 10], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 21, 45], ["cortical", "TISSUE", 53, 61], ["outer medullary interstitium", "TISSUE", 66, 94], ["focal interstitial infiltrates of the cortical and outer medullary interstitium", "PROBLEM", 15, 94], ["kidney", "ANATOMY", 4, 10], ["focal", "OBSERVATION_MODIFIER", 15, 20], ["interstitial", "ANATOMY_MODIFIER", 21, 33], ["infiltrates", "OBSERVATION", 34, 45], ["cortical", "ANATOMY_MODIFIER", 53, 61], ["outer", "ANATOMY_MODIFIER", 66, 71], ["medullary", "ANATOMY", 72, 81], ["interstitium", "ANATOMY_MODIFIER", 82, 94]]], ["The brain showed degenerate neurons in area A3 of the hippocampus.", [["brain", "ANATOMY", 4, 9], ["neurons", "ANATOMY", 28, 35], ["area A3", "ANATOMY", 39, 46], ["hippocampus", "ANATOMY", 54, 65], ["brain", "ORGAN", 4, 9], ["neurons", "CELL", 28, 35], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 54, 65], ["degenerate neurons", "PROBLEM", 17, 35], ["brain", "ANATOMY", 4, 9], ["degenerate neurons", "OBSERVATION", 17, 35], ["hippocampus", "ANATOMY", 54, 65]]], ["All other tissues were within normal limits.", [["tissues", "ANATOMY", 10, 17], ["tissues", "TISSUE", 10, 17], ["tissues", "ANATOMY", 10, 17], ["within normal limits", "OBSERVATION", 23, 43]]], ["AJ-z8 had minimal focal testicular degeneration (Fig 3).", [["focal testicular", "ANATOMY", 18, 34], ["testicular degeneration", "DISEASE", 24, 47], ["testicular", "ORGAN", 24, 34], ["AJ", "PROTEIN", 0, 2], ["AJ", "TEST", 0, 2], ["minimal focal testicular degeneration", "PROBLEM", 10, 47], ["minimal", "OBSERVATION_MODIFIER", 10, 17], ["focal", "OBSERVATION_MODIFIER", 18, 23], ["testicular", "ANATOMY", 24, 34], ["degeneration", "OBSERVATION", 35, 47]]], ["All other tissues were normal.", [["tissues", "ANATOMY", 10, 17], ["tissues", "TISSUE", 10, 17], ["tissues", "ANATOMY", 10, 17], ["normal", "OBSERVATION", 23, 29]]], ["AJ-z9 had perivascular lymphocyte pulmonary infiltrates and atelectasis.", [["AJ-z9", "ANATOMY", 0, 5], ["perivascular lymphocyte pulmonary", "ANATOMY", 10, 43], ["atelectasis", "DISEASE", 60, 71], ["perivascular lymphocyte", "CELL", 10, 33], ["pulmonary", "PATHOLOGICAL_FORMATION", 34, 43], ["AJ", "PROTEIN", 0, 2], ["AJ", "TEST", 0, 2], ["perivascular lymphocyte pulmonary infiltrates", "PROBLEM", 10, 55], ["atelectasis", "PROBLEM", 60, 71], ["perivascular", "ANATOMY_MODIFIER", 10, 22], ["lymphocyte", "ANATOMY_MODIFIER", 23, 33], ["pulmonary", "ANATOMY", 34, 43], ["infiltrates", "OBSERVATION", 44, 55], ["atelectasis", "OBSERVATION", 60, 71]]], ["Heart demonstrated locally extensive lymphocytic and histiocytic pericarditis.", [["Heart", "ANATOMY", 0, 5], ["lymphocytic", "ANATOMY", 37, 48], ["pericarditis", "DISEASE", 65, 77], ["Heart", "ORGAN", 0, 5], ["lymphocytic", "CANCER", 37, 48], ["histiocytic pericarditis", "CANCER", 53, 77], ["locally extensive lymphocytic and histiocytic pericarditis", "PROBLEM", 19, 77], ["locally", "OBSERVATION_MODIFIER", 19, 26], ["extensive", "OBSERVATION_MODIFIER", 27, 36], ["lymphocytic", "OBSERVATION", 37, 48], ["histiocytic pericarditis", "OBSERVATION", 53, 77]]], ["Kidneys showed multifocal interstitial lymphocytic infiltrates.", [["Kidneys", "ANATOMY", 0, 7], ["interstitial lymphocytic infiltrates", "ANATOMY", 26, 62], ["interstitial lymphocytic infiltrates", "DISEASE", 26, 62], ["Kidneys", "ORGAN", 0, 7], ["interstitial lymphocytic infiltrates", "PATHOLOGICAL_FORMATION", 26, 62], ["multifocal interstitial lymphocytic infiltrates", "PROBLEM", 15, 62], ["multifocal", "OBSERVATION_MODIFIER", 15, 25], ["interstitial", "ANATOMY_MODIFIER", 26, 38], ["lymphocytic infiltrates", "OBSERVATION", 39, 62]]], ["Brain had focal, perivascular infiltrates of small numbers of lymphocytes at the subfornical commissure.", [["Brain", "ANATOMY", 0, 5], ["perivascular infiltrates", "ANATOMY", 17, 41], ["lymphocytes", "ANATOMY", 62, 73], ["subfornical commissure", "ANATOMY", 81, 103], ["Brain", "ORGAN", 0, 5], ["perivascular infiltrates", "PATHOLOGICAL_FORMATION", 17, 41], ["lymphocytes", "CELL", 62, 73], ["subfornical commissure", "MULTI-TISSUE_STRUCTURE", 81, 103], ["lymphocytes", "CELL_TYPE", 62, 73], ["focal, perivascular infiltrates", "PROBLEM", 10, 41], ["small numbers of lymphocytes", "PROBLEM", 45, 73], ["focal", "OBSERVATION_MODIFIER", 10, 15], ["perivascular", "ANATOMY_MODIFIER", 17, 29], ["infiltrates", "OBSERVATION", 30, 41], ["small", "OBSERVATION_MODIFIER", 45, 50], ["numbers", "OBSERVATION_MODIFIER", 51, 58], ["lymphocytes", "OBSERVATION", 62, 73], ["subfornical", "ANATOMY_MODIFIER", 81, 92], ["commissure", "ANATOMY_MODIFIER", 93, 103]]], ["The reticular formation showed multifocal neuronal degeneration/necrosis.Immunohistochemistry and immunofluorescence ::: Histopathology ::: ResultsTissues were stained with a polyclonal antibody for ZIKV (CDC, Fort Collins).", [["reticular", "ANATOMY", 4, 13], ["neuronal", "ANATOMY", 42, 50], ["neuronal degeneration", "DISEASE", 42, 63], ["necrosis", "DISEASE", 64, 72], ["reticular", "TISSUE", 4, 13], ["neuronal", "CELL", 42, 50], ["polyclonal antibody", "PROTEIN", 175, 194], ["ZIKV", "SPECIES", 199, 203], ["The reticular formation", "TEST", 0, 23], ["multifocal neuronal degeneration", "PROBLEM", 31, 63], ["necrosis", "PROBLEM", 64, 72], ["a polyclonal antibody", "TEST", 173, 194], ["ZIKV", "PROBLEM", 199, 203], ["reticular", "ANATOMY_MODIFIER", 4, 13], ["multifocal", "OBSERVATION_MODIFIER", 31, 41], ["neuronal degeneration", "OBSERVATION", 42, 63], ["necrosis", "OBSERVATION", 64, 72]]], ["AJz-3 at 5 dpi with inflammation of the mandibular salivary gland had moderate immunoreactivity in the lumen of affected ducts (Fig 4).", [["mandibular salivary gland", "ANATOMY", 40, 65], ["lumen", "ANATOMY", 103, 108], ["ducts", "ANATOMY", 121, 126], ["inflammation", "DISEASE", 20, 32], ["AJz-3", "GENE_OR_GENE_PRODUCT", 0, 5], ["mandibular", "ORGAN", 40, 50], ["salivary gland", "ORGAN", 51, 65], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 108], ["ducts", "MULTI-TISSUE_STRUCTURE", 121, 126], ["AJz", "TEST", 0, 3], ["inflammation of the mandibular salivary gland", "PROBLEM", 20, 65], ["moderate immunoreactivity in the lumen of affected ducts", "PROBLEM", 70, 126], ["inflammation", "OBSERVATION", 20, 32], ["mandibular", "ANATOMY_MODIFIER", 40, 50], ["salivary gland", "ANATOMY", 51, 65], ["moderate", "OBSERVATION_MODIFIER", 70, 78], ["immunoreactivity", "OBSERVATION", 79, 95], ["lumen", "ANATOMY_MODIFIER", 103, 108], ["affected ducts", "ANATOMY", 112, 126]]], ["AJ-z5 at 10 dpi had immunoreactive cells in the brain and mononuclear cell immunoreactivity in the testes (Fig 5).", [["cells", "ANATOMY", 35, 40], ["brain", "ANATOMY", 48, 53], ["mononuclear cell", "ANATOMY", 58, 74], ["testes", "ANATOMY", 99, 105], ["AJ-z5", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 35, 40], ["brain", "ORGAN", 48, 53], ["mononuclear cell", "CELL", 58, 74], ["testes", "ORGAN", 99, 105], ["AJ", "PROTEIN", 0, 2], ["z5", "PROTEIN", 3, 5], ["AJ", "TEST", 0, 2], ["immunoreactive cells in the brain", "PROBLEM", 20, 53], ["mononuclear cell immunoreactivity", "TEST", 58, 91], ["immunoreactive cells", "OBSERVATION", 20, 40], ["brain", "ANATOMY", 48, 53], ["mononuclear cell immunoreactivity", "OBSERVATION", 58, 91], ["testes", "ANATOMY", 99, 105]]], ["Additionally, AJ-z5 demonstrated immunoreactivity in purkinje cells of the cerebellum (Fig 6A).", [["purkinje cells", "ANATOMY", 53, 67], ["cerebellum", "ANATOMY", 75, 85], ["AJ-z5", "GENE_OR_GENE_PRODUCT", 14, 19], ["purkinje cells", "CELL", 53, 67], ["cerebellum", "ORGAN", 75, 85], ["AJ", "PROTEIN", 14, 16], ["z5", "PROTEIN", 17, 19], ["purkinje cells", "CELL_TYPE", 53, 67], ["AJ-z5", "TEST", 14, 19], ["immunoreactivity", "OBSERVATION", 33, 49], ["purkinje cells", "OBSERVATION", 53, 67], ["cerebellum", "ANATOMY", 75, 85]]], ["AJ-z8 at 28 dpi had immunoreactive cells around the pulmonary arteries in the lungs (Fig 7A).", [["cells", "ANATOMY", 35, 40], ["pulmonary arteries", "ANATOMY", 52, 70], ["lungs", "ANATOMY", 78, 83], ["AJ-z8", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 35, 40], ["pulmonary arteries", "MULTI-TISSUE_STRUCTURE", 52, 70], ["lungs", "ORGAN", 78, 83], ["AJ", "PROTEIN", 0, 2], ["z8", "PROTEIN", 3, 5], ["immunoreactive cells", "CELL_TYPE", 20, 40], ["AJ", "TEST", 0, 2], ["immunoreactive cells", "PROBLEM", 20, 40], ["immunoreactive cells", "OBSERVATION", 20, 40], ["pulmonary arteries", "ANATOMY", 52, 70], ["lungs", "ANATOMY", 78, 83]]], ["AJ-z8 also had immunoreactivity perivascullarly in the tunica albuginea of the testes (Fig 8A).", [["tunica albuginea", "ANATOMY", 55, 71], ["testes", "ANATOMY", 79, 85], ["AJ-z8", "GENE_OR_GENE_PRODUCT", 0, 5], ["tunica albuginea", "TISSUE", 55, 71], ["testes", "ORGAN", 79, 85], ["AJ", "PROTEIN", 0, 2], ["z8", "PROTEIN", 3, 5], ["immunoreactivity perivascullarly", "PROBLEM", 15, 47], ["immunoreactivity", "OBSERVATION", 15, 31], ["tunica albuginea", "ANATOMY", 55, 71], ["testes", "ANATOMY", 79, 85]]], ["Scrotal skin had focal lymphocytic dermatitis with immunoreactive mononuclear cells (Fig 8D).", [["Scrotal skin", "ANATOMY", 0, 12], ["focal lymphocytic", "ANATOMY", 17, 34], ["mononuclear cells", "ANATOMY", 66, 83], ["focal lymphocytic dermatitis", "DISEASE", 17, 45], ["skin", "ORGAN", 8, 12], ["mononuclear cells", "CELL", 66, 83], ["immunoreactive mononuclear cells", "CELL_TYPE", 51, 83], ["focal lymphocytic dermatitis", "PROBLEM", 17, 45], ["immunoreactive mononuclear cells", "PROBLEM", 51, 83], ["skin", "ANATOMY", 8, 12], ["focal", "OBSERVATION_MODIFIER", 17, 22], ["lymphocytic dermatitis", "OBSERVATION", 23, 45], ["immunoreactive mononuclear cells", "OBSERVATION", 51, 83]]], ["Cell morphology consistently identified mononuclear cells compatible with macrophages and fibroblasts as the primary cell types showing immunoreactivity against ZIKV antigen.Immunohistochemistry and immunofluorescence ::: Histopathology ::: ResultsBrain and testicular tissues stained with both goat polyclonal goat anti-Iba1 (green) and monoclonal 4G-2 flavivirus E specific antibodies (red) showed co-localization (yellow) of ZIKV antigen in cytoplasm of activated microglial cells with their characteristic morphology in the cerebral cortex of infected bats 10 dpi in the time course study and 28 day dpi in the pilot study (Fig 9).", [["Cell", "ANATOMY", 0, 4], ["mononuclear cells", "ANATOMY", 40, 57], ["macrophages", "ANATOMY", 74, 85], ["fibroblasts", "ANATOMY", 90, 101], ["cell", "ANATOMY", 117, 121], ["ResultsBrain", "ANATOMY", 241, 253], ["testicular tissues", "ANATOMY", 258, 276], ["cytoplasm", "ANATOMY", 444, 453], ["microglial cells", "ANATOMY", 467, 483], ["cerebral cortex", "ANATOMY", 528, 543], ["Cell", "CELL", 0, 4], ["mononuclear cells", "CELL", 40, 57], ["macrophages", "CELL", 74, 85], ["fibroblasts", "CELL", 90, 101], ["cell", "CELL", 117, 121], ["ZIKV antigen", "GENE_OR_GENE_PRODUCT", 161, 173], ["testicular tissues", "TISSUE", 258, 276], ["goat", "ORGANISM", 295, 299], ["goat", "ORGANISM", 311, 315], ["anti-Iba1", "GENE_OR_GENE_PRODUCT", 316, 325], ["ZIKV antigen", "GENE_OR_GENE_PRODUCT", 428, 440], ["cytoplasm", "ORGANISM_SUBSTANCE", 444, 453], ["microglial cells", "CELL", 467, 483], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 528, 543], ["mononuclear cells", "CELL_TYPE", 40, 57], ["macrophages", "CELL_TYPE", 74, 85], ["fibroblasts", "CELL_TYPE", 90, 101], ["ZIKV antigen", "PROTEIN", 161, 173], ["goat polyclonal goat anti-Iba1 (green) and monoclonal 4G-2 flavivirus E specific antibodies", "PROTEIN", 295, 386], ["red", "PROTEIN", 388, 391], ["ZIKV antigen", "PROTEIN", 428, 440], ["activated microglial cells", "CELL_TYPE", 457, 483], ["goat", "SPECIES", 295, 299], ["goat", "SPECIES", 311, 315], ["ZIKV", "SPECIES", 161, 165], ["goat", "SPECIES", 295, 299], ["goat", "SPECIES", 311, 315], ["ZIKV", "SPECIES", 428, 432], ["Cell morphology", "TEST", 0, 15], ["mononuclear cells", "PROBLEM", 40, 57], ["macrophages", "PROBLEM", 74, 85], ["fibroblasts", "PROBLEM", 90, 101], ["the primary cell types", "TEST", 105, 127], ["immunoreactivity", "PROBLEM", 136, 152], ["ZIKV antigen", "PROBLEM", 161, 173], ["Histopathology", "TEST", 222, 236], ["testicular tissues", "PROBLEM", 258, 276], ["goat polyclonal goat anti-Iba1", "TEST", 295, 325], ["monoclonal 4G", "TEST", 338, 351], ["flavivirus E specific antibodies", "TEST", 354, 386], ["co-localization (yellow) of ZIKV antigen", "PROBLEM", 400, 440], ["activated microglial cells", "PROBLEM", 457, 483], ["the pilot study", "TEST", 611, 626], ["mononuclear cells", "OBSERVATION", 40, 57], ["compatible with", "UNCERTAINTY", 58, 73], ["macrophages", "OBSERVATION", 74, 85], ["primary cell types", "OBSERVATION", 109, 127], ["testicular tissues", "ANATOMY", 258, 276], ["activated microglial cells", "OBSERVATION", 457, 483], ["morphology", "OBSERVATION_MODIFIER", 510, 520], ["cerebral cortex", "ANATOMY", 528, 543], ["infected bats", "OBSERVATION", 547, 560]]], ["Increased microgliosis was noted in the vicinity of co-localization sites.", [["Increased microgliosis", "PROBLEM", 0, 22], ["microgliosis", "OBSERVATION", 10, 22], ["co-localization sites", "OBSERVATION", 52, 73]]], ["The gliosis was also prominent in the cerebellum and hippocampus especially around dead neurons.", [["cerebellum", "ANATOMY", 38, 48], ["hippocampus", "ANATOMY", 53, 64], ["neurons", "ANATOMY", 88, 95], ["gliosis", "DISEASE", 4, 11], ["cerebellum", "ORGAN", 38, 48], ["hippocampus", "ORGAN", 53, 64], ["neurons", "CELL", 88, 95], ["dead neurons", "CELL_TYPE", 83, 95], ["The gliosis", "PROBLEM", 0, 11], ["gliosis", "OBSERVATION", 4, 11], ["prominent", "OBSERVATION_MODIFIER", 21, 30], ["cerebellum", "ANATOMY", 38, 48], ["hippocampus", "ANATOMY", 53, 64], ["dead neurons", "OBSERVATION", 83, 95]]], ["In the testicles, occasional macrophages showed similar co-localization similar to that noted in the brain in the testicular interstitium, inner layer of tunica albuginea and scrotum.", [["testicles", "ANATOMY", 7, 16], ["macrophages", "ANATOMY", 29, 40], ["brain", "ANATOMY", 101, 106], ["testicular interstitium", "ANATOMY", 114, 137], ["inner layer", "ANATOMY", 139, 150], ["tunica albuginea", "ANATOMY", 154, 170], ["scrotum", "ANATOMY", 175, 182], ["testicles", "ORGAN", 7, 16], ["macrophages", "CELL", 29, 40], ["brain", "ORGAN", 101, 106], ["testicular interstitium", "TISSUE", 114, 137], ["inner layer", "TISSUE", 139, 150], ["tunica albuginea", "TISSUE", 154, 170], ["scrotum", "ORGAN", 175, 182], ["macrophages", "CELL_TYPE", 29, 40], ["occasional macrophages", "PROBLEM", 18, 40], ["similar co-localization", "PROBLEM", 48, 71], ["testicles", "ANATOMY", 7, 16], ["occasional", "OBSERVATION_MODIFIER", 18, 28], ["macrophages", "OBSERVATION", 29, 40], ["similar", "OBSERVATION_MODIFIER", 48, 55], ["co-localization", "OBSERVATION", 56, 71], ["brain", "ANATOMY", 101, 106], ["testicular", "ANATOMY", 114, 124], ["interstitium", "ANATOMY_MODIFIER", 125, 137], ["inner", "ANATOMY_MODIFIER", 139, 144], ["layer", "ANATOMY_MODIFIER", 145, 150], ["tunica albuginea", "ANATOMY", 154, 170], ["scrotum", "ANATOMY", 175, 182]]], ["Cells consistent in morphology with Leydig cells were similarly highlighted by ZIKA viral antigen only showing strong immunoreactivity using polyclonal anti-ZIKV antibody.DiscussionTwo bat infection experiments were conducted in this investigation; 1) a pilot study to determine susceptibility of Jamaican fruit bats to ZIKV infection, and 2) a time course study to better understand pathophysiology and chronology of events pertaining to the dynamics of viremia, viral tropism, replication and shedding of the virus in a New World bat species.", [["Cells", "ANATOMY", 0, 5], ["Leydig cells", "ANATOMY", 36, 48], ["bat infection", "DISEASE", 185, 198], ["ZIKV infection", "DISEASE", 320, 334], ["viremia", "DISEASE", 455, 462], ["Cells", "CELL", 0, 5], ["Leydig cells", "CELL", 36, 48], ["ZIKA", "GENE_OR_GENE_PRODUCT", 79, 83], ["Leydig cells", "CELL_TYPE", 36, 48], ["ZIKA viral antigen", "PROTEIN", 79, 97], ["polyclonal anti-ZIKV antibody", "PROTEIN", 141, 170], ["anti-ZIKV", "SPECIES", 152, 161], ["Jamaican fruit bats", "SPECIES", 297, 316], ["ZIKV", "SPECIES", 320, 324], ["Cells", "TEST", 0, 5], ["Leydig cells", "PROBLEM", 36, 48], ["ZIKA viral antigen", "TEST", 79, 97], ["strong immunoreactivity", "PROBLEM", 111, 134], ["polyclonal anti-ZIKV antibody", "TREATMENT", 141, 170], ["Two bat infection experiments", "PROBLEM", 181, 210], ["a pilot study", "TEST", 252, 265], ["Jamaican fruit bats", "PROBLEM", 297, 316], ["ZIKV infection", "PROBLEM", 320, 334], ["a time course study", "TEST", 343, 362], ["viremia", "PROBLEM", 455, 462], ["viral tropism", "PROBLEM", 464, 477], ["the virus", "PROBLEM", 507, 516], ["Leydig cells", "OBSERVATION", 36, 48], ["viremia", "OBSERVATION", 455, 462]]], ["The goal was to determine whether bats can be used as an animal model for ZIKV pathogenesis and to assess the possible role of bats in ZIKV ecology in the New World.DiscussionIn the pilot experiment, no signs of disease were apparent during the 28-day study.", [["bats", "ORGANISM", 34, 38], ["ZIKV", "ORGANISM", 74, 78], ["bats", "ORGANISM", 127, 131], ["ZIKV", "SPECIES", 74, 78], ["ZIKV", "SPECIES", 135, 139], ["ZIKV pathogenesis", "PROBLEM", 74, 91], ["disease", "PROBLEM", 212, 219], ["no signs of", "UNCERTAINTY", 200, 211], ["disease", "OBSERVATION", 212, 219]]], ["Sera collected at euthanasia indicated modest antibody titers of 3200 for each bat by ELISA (Table 1), whereas the human -convalescent control serum titer was \u226512,800.", [["Sera", "ANATOMY", 0, 4], ["serum", "ANATOMY", 143, 148], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["human", "ORGANISM", 115, 120], ["convalescent", "ORGANISM", 122, 134], ["serum", "ORGANISM_SUBSTANCE", 143, 148], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 115, 120], ["Sera collected at euthanasia", "TEST", 0, 28], ["modest antibody titers", "PROBLEM", 39, 61], ["the human", "TEST", 111, 120], ["convalescent control serum titer", "TEST", 122, 154]]], ["Bats typically have low to modest antibody titers, perhaps due to limited somatic hypermutation and affinity maturation [15\u201322].DiscussionConcerning viremia, cell-serum supernatants, blind passage supernatants, and neat serum results were all negative.", [["cell", "ANATOMY", 158, 162], ["serum supernatants", "ANATOMY", 163, 181], ["supernatants", "ANATOMY", 197, 209], ["serum", "ANATOMY", 220, 225], ["viremia", "DISEASE", 149, 156], ["Bats", "CELL", 0, 4], ["cell", "CELL", 158, 162], ["serum", "ORGANISM_SUBSTANCE", 163, 168], ["serum", "ORGANISM_SUBSTANCE", 220, 225], ["low to modest antibody titers", "PROBLEM", 20, 49], ["limited somatic hypermutation", "PROBLEM", 66, 95], ["affinity maturation", "TEST", 100, 119], ["viremia", "PROBLEM", 149, 156], ["cell-serum supernatants", "TEST", 158, 181], ["blind passage supernatants", "TEST", 183, 209], ["neat serum results", "TEST", 215, 233], ["viremia", "OBSERVATION", 149, 156], ["negative", "OBSERVATION", 243, 251]]], ["Although serum is routinely used for ZIKV diagnostics in humans, it may not be the most suitable sample [23\u201327].", [["serum", "ANATOMY", 9, 14], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["humans", "ORGANISM", 57, 63], ["humans", "SPECIES", 57, 63], ["ZIKV", "SPECIES", 37, 41], ["humans", "SPECIES", 57, 63], ["serum", "TEST", 9, 14], ["ZIKV diagnostics", "TEST", 37, 53]]], ["In one investigation ZIKV patient had negative serum sample for the duration of the study, whereas whole blood yielded positive qRT-PCR results from days 9 to 101 [27].", [["serum sample", "ANATOMY", 47, 59], ["whole blood", "ANATOMY", 99, 110], ["ZIKV", "ORGANISM", 21, 25], ["patient", "ORGANISM", 26, 33], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["patient", "SPECIES", 26, 33], ["ZIKV", "SPECIES", 21, 25], ["serum sample", "TEST", 47, 59], ["the study", "TEST", 80, 89], ["whole blood", "TEST", 99, 110], ["PCR", "TEST", 132, 135]]], ["One possible explanation for the phenomenon of negative serum in human patients is that the virus during acute infection disseminates via a cell-associated viremia or as novel findings suggest that the virus gets phagocytized in neutrophils and therefore whole blood is a more sensitive diagnostic sample than serum.DiscussionViruria is commonly detected in ZIKV-infected humans [26]; therefore, urine may be an equally important diagnostic sample with higher viral load in early infection when compared to blood in humans and other primates [23\u201326].", [["serum", "ANATOMY", 56, 61], ["cell", "ANATOMY", 140, 144], ["neutrophils", "ANATOMY", 229, 240], ["whole blood", "ANATOMY", 255, 266], ["sample", "ANATOMY", 298, 304], ["serum", "ANATOMY", 310, 315], ["urine", "ANATOMY", 396, 401], ["blood", "ANATOMY", 507, 512], ["infection", "DISEASE", 111, 120], ["viremia", "DISEASE", 156, 163], ["infection", "DISEASE", 480, 489], ["serum", "ORGANISM_SUBSTANCE", 56, 61], ["human", "ORGANISM", 65, 70], ["patients", "ORGANISM", 71, 79], ["cell", "CELL", 140, 144], ["neutrophils", "CELL", 229, 240], ["blood", "ORGANISM_SUBSTANCE", 261, 266], ["serum", "ORGANISM_SUBSTANCE", 310, 315], ["ZIKV", "ORGANISM", 358, 362], ["humans", "ORGANISM", 372, 378], ["urine", "ORGANISM_SUBSTANCE", 396, 401], ["blood", "ORGANISM_SUBSTANCE", 507, 512], ["humans", "ORGANISM", 516, 522], ["neutrophils", "CELL_TYPE", 229, 240], ["human", "SPECIES", 65, 70], ["patients", "SPECIES", 71, 79], ["humans", "SPECIES", 372, 378], ["humans", "SPECIES", 516, 522], ["human", "SPECIES", 65, 70], ["ZIKV", "SPECIES", 358, 362], ["humans", "SPECIES", 372, 378], ["humans", "SPECIES", 516, 522], ["the phenomenon of negative serum in human patients", "PROBLEM", 29, 79], ["the virus", "PROBLEM", 88, 97], ["acute infection", "PROBLEM", 105, 120], ["a cell-associated viremia", "PROBLEM", 138, 163], ["the virus", "PROBLEM", 198, 207], ["phagocytized in neutrophils", "PROBLEM", 213, 240], ["whole blood", "TEST", 255, 266], ["urine", "TEST", 396, 401], ["higher viral load", "PROBLEM", 453, 470], ["early infection", "PROBLEM", 474, 489], ["blood in humans", "TEST", 507, 522], ["possible explanation for", "UNCERTAINTY", 4, 28], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["infection", "OBSERVATION", 111, 120], ["viremia", "OBSERVATION", 156, 163], ["viral load", "OBSERVATION", 460, 470], ["early", "OBSERVATION_MODIFIER", 474, 479], ["infection", "OBSERVATION", 480, 489]]], ["Although urine collection from bats was challenging, we collected urine from some of the inoculated bats in the time course study.", [["urine", "ANATOMY", 9, 14], ["urine", "ANATOMY", 66, 71], ["urine", "ORGANISM_SUBSTANCE", 9, 14], ["urine", "ORGANISM_SUBSTANCE", 66, 71], ["urine collection", "TEST", 9, 25], ["collected urine", "TEST", 56, 71], ["course study", "TEST", 117, 129], ["urine", "OBSERVATION", 9, 14], ["collection", "OBSERVATION_MODIFIER", 15, 25], ["inoculated bats", "OBSERVATION", 89, 104]]], ["AJ-z6 exhibited viruria only at 3 dpi, and AJ-z7 was equivocal only at 5 dpi, corroborating the findings in other mammals that urine may be a route of viral shedding early in infection.", [["urine", "ANATOMY", 127, 132], ["infection", "DISEASE", 175, 184], ["AJ-z6", "GENE_OR_GENE_PRODUCT", 0, 5], ["AJ-z7", "GENE_OR_GENE_PRODUCT", 43, 48], ["urine", "ORGANISM_SUBSTANCE", 127, 132], ["AJ", "PROTEIN", 0, 2], ["z6", "PROTEIN", 3, 5], ["AJ", "PROTEIN", 43, 45], ["AJ", "TEST", 0, 2], ["viruria", "PROBLEM", 16, 23], ["viral shedding", "PROBLEM", 151, 165], ["infection", "PROBLEM", 175, 184], ["viruria", "OBSERVATION", 16, 23], ["viral", "OBSERVATION", 151, 156], ["infection", "OBSERVATION", 175, 184]]], ["Urine from one human patient was positive from the first time point (6 dpi) through 14 dpi and again on day 56.", [["Urine", "ANATOMY", 0, 5], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["human", "ORGANISM", 15, 20], ["patient", "ORGANISM", 21, 28], ["human", "SPECIES", 15, 20], ["patient", "SPECIES", 21, 28], ["human", "SPECIES", 15, 20], ["Urine", "TEST", 0, 5], ["one human", "OBSERVATION_MODIFIER", 11, 20], ["positive", "OBSERVATION", 33, 41]]], ["Similarly, saliva from that same patient was positive from day nine through day 14 and again on day 49 [27].", [["saliva", "ORGANISM_SUBSTANCE", 11, 17], ["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["positive", "OBSERVATION", 45, 53]]], ["Another investigation compared diagnostic samples of 80 infected patients and showed that urine was positive in 50 of them, whereas serum was only positive in 19 patients by qRT-PCR.", [["samples", "ANATOMY", 42, 49], ["urine", "ANATOMY", 90, 95], ["serum", "ANATOMY", 132, 137], ["patients", "ORGANISM", 65, 73], ["urine", "ORGANISM_SUBSTANCE", 90, 95], ["serum", "ORGANISM_SUBSTANCE", 132, 137], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 162, 170], ["Another investigation", "TEST", 0, 21], ["diagnostic samples", "TEST", 31, 49], ["urine", "TEST", 90, 95], ["serum", "TEST", 132, 137], ["qRT", "TEST", 174, 177], ["PCR", "TEST", 178, 181]]], ["The study concluded that viral loads in urine were ten-fold higher compared to serum and that uremia lasted longer [25].", [["urine", "ANATOMY", 40, 45], ["serum", "ANATOMY", 79, 84], ["uremia", "DISEASE", 94, 100], ["urine", "ORGANISM_SUBSTANCE", 40, 45], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["The study", "TEST", 0, 9], ["viral loads in urine", "TEST", 25, 45], ["ten-fold", "PROBLEM", 51, 59], ["serum", "TEST", 79, 84], ["uremia", "PROBLEM", 94, 100], ["viral loads", "OBSERVATION", 25, 36], ["uremia", "OBSERVATION", 94, 100]]], ["These data corroborated the first study that identified ZIKV shed in urine in which there was a higher viral load in urine for longer duration compared to serum [26].", [["urine", "ANATOMY", 69, 74], ["urine", "ANATOMY", 117, 122], ["serum", "ANATOMY", 155, 160], ["ZIKV", "GENE_OR_GENE_PRODUCT", 56, 60], ["urine", "ORGANISM_SUBSTANCE", 69, 74], ["urine", "ORGANISM_SUBSTANCE", 117, 122], ["serum", "ORGANISM_SUBSTANCE", 155, 160], ["ZIKV", "SPECIES", 56, 60], ["the first study", "TEST", 24, 39], ["ZIKV shed in urine", "PROBLEM", 56, 74], ["a higher viral load in urine", "PROBLEM", 94, 122], ["serum", "TEST", 155, 160], ["ZIKV", "OBSERVATION", 56, 60], ["viral load", "OBSERVATION", 103, 113]]], ["ZIKV RNA in plasma was detected in the bats by qRT-PCR between 2 and 6 dpi, but between 2 to 17 dpi in urine [26].", [["plasma", "ANATOMY", 12, 18], ["urine", "ANATOMY", 103, 108], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["plasma", "ORGANISM_SUBSTANCE", 12, 18], ["urine", "ORGANISM_SUBSTANCE", 103, 108], ["ZIKV RNA", "RNA", 0, 8], ["ZIKV", "SPECIES", 0, 4], ["ZIKV RNA in plasma", "PROBLEM", 0, 18], ["PCR", "TEST", 51, 54], ["dpi in urine", "TEST", 96, 108]]], ["The lack of detectable viremia in the serum of bats is congruent with some of the human and NHP investigations in that viremia is low and short-lived.", [["serum", "ANATOMY", 38, 43], ["viremia", "DISEASE", 23, 30], ["viremia", "DISEASE", 119, 126], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["human", "ORGANISM", 82, 87], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["detectable viremia in the serum of bats", "PROBLEM", 12, 51], ["the human and NHP investigations", "TEST", 78, 110], ["viremia", "PROBLEM", 119, 126], ["detectable", "OBSERVATION_MODIFIER", 12, 22], ["viremia", "OBSERVATION", 23, 30], ["viremia", "OBSERVATION", 119, 126], ["low", "OBSERVATION_MODIFIER", 130, 133]]], ["Detached renal pelvic urothelial cells and degenerate salivary gland ductular epithelium as seen in the current study will make urine and saliva equally important fluids to collect in order to maximize detection of ZIKV in the acute and established stages of infections.DiscussionFor this experiment, all male bats were used because female bats are prioritized for colony expansion.", [["renal pelvic urothelial cells", "ANATOMY", 9, 38], ["salivary gland ductular epithelium", "ANATOMY", 54, 88], ["urine", "ANATOMY", 128, 133], ["colony", "ANATOMY", 365, 371], ["infections", "DISEASE", 259, 269], ["renal pelvic urothelial cells", "CELL", 9, 38], ["salivary gland ductular epithelium", "TISSUE", 54, 88], ["urine", "ORGANISM_SUBSTANCE", 128, 133], ["saliva", "ORGANISM_SUBSTANCE", 138, 144], ["bats", "ORGANISM", 310, 314], ["bats", "ORGANISM", 340, 344], ["renal pelvic urothelial cells", "CELL_TYPE", 9, 38], ["ZIKV", "SPECIES", 215, 219], ["Detached renal pelvic urothelial cells", "PROBLEM", 0, 38], ["degenerate salivary gland ductular epithelium", "PROBLEM", 43, 88], ["the current study", "TEST", 100, 117], ["urine", "TEST", 128, 133], ["saliva", "TREATMENT", 138, 144], ["ZIKV", "PROBLEM", 215, 219], ["infections", "PROBLEM", 259, 269], ["colony expansion", "PROBLEM", 365, 381], ["renal", "ANATOMY", 9, 14], ["pelvic", "ANATOMY_MODIFIER", 15, 21], ["urothelial cells", "OBSERVATION", 22, 38], ["salivary gland", "ANATOMY", 54, 68], ["ductular", "ANATOMY_MODIFIER", 69, 77], ["epithelium", "ANATOMY_MODIFIER", 78, 88], ["ZIKV", "OBSERVATION", 215, 219], ["acute", "OBSERVATION_MODIFIER", 227, 232], ["infections", "OBSERVATION", 259, 269]]], ["ZIKV exhibited tropism for the testes with strong immunoreactivity in reproductive organs (Figs 4 & 7).", [["testes", "ANATOMY", 31, 37], ["reproductive organs", "ANATOMY", 70, 89], ["ZIKV", "CHEMICAL", 0, 4], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["testes", "ORGAN", 31, 37], ["organs", "ORGAN", 83, 89], ["ZIKV", "SPECIES", 0, 4], ["ZIKV", "PROBLEM", 0, 4], ["strong immunoreactivity in reproductive organs", "PROBLEM", 43, 89], ["Figs", "TEST", 91, 95], ["tropism", "OBSERVATION", 15, 22], ["testes", "ANATOMY", 31, 37], ["strong", "OBSERVATION_MODIFIER", 43, 49], ["immunoreactivity", "OBSERVATION", 50, 66]]], ["Histologically, minimal focal testicular degeneration in two bats (Fig 2) suggests viral related pathology may be minimal.", [["testicular", "ANATOMY", 30, 40], ["testicular degeneration", "DISEASE", 30, 53], ["testicular", "ORGAN", 30, 40], ["minimal focal testicular degeneration", "PROBLEM", 16, 53], ["viral related pathology", "PROBLEM", 83, 106], ["minimal", "OBSERVATION_MODIFIER", 16, 23], ["focal", "OBSERVATION_MODIFIER", 24, 29], ["testicular", "ANATOMY", 30, 40], ["degeneration", "OBSERVATION", 41, 53], ["two bats", "OBSERVATION_MODIFIER", 57, 65], ["viral related", "OBSERVATION_MODIFIER", 83, 96], ["pathology", "OBSERVATION", 97, 106], ["may be", "UNCERTAINTY", 107, 113], ["minimal", "OBSERVATION_MODIFIER", 114, 121]]], ["In humans it has yet to be completely elucidated what reproductive organs harbor ZIKV, it has been determined that semen contains ZIKV both in both vasectomized and unvasectomized men [27, 28].", [["organs", "ANATOMY", 67, 73], ["semen", "ANATOMY", 115, 120], ["humans", "ORGANISM", 3, 9], ["organs", "ORGAN", 67, 73], ["ZIKV", "GENE_OR_GENE_PRODUCT", 81, 85], ["semen", "ORGANISM_SUBSTANCE", 115, 120], ["ZIKV", "GENE_OR_GENE_PRODUCT", 130, 134], ["men", "ORGANISM", 180, 183], ["humans", "SPECIES", 3, 9], ["men", "SPECIES", 180, 183], ["humans", "SPECIES", 3, 9], ["ZIKV", "SPECIES", 130, 134], ["ZIKV", "PROBLEM", 130, 134]]], ["This suggests that ZIKV is sequestered in the testes and/or accessory sex glands.", [["testes", "ANATOMY", 46, 52], ["accessory sex glands", "ANATOMY", 60, 80], ["ZIKV", "GENE_OR_GENE_PRODUCT", 19, 23], ["testes", "ORGAN", 46, 52], ["glands", "ORGAN", 74, 80], ["ZIKV", "PROTEIN", 19, 23], ["ZIKV", "SPECIES", 19, 23], ["ZIKV", "PROBLEM", 19, 23], ["ZIKV", "OBSERVATION", 19, 23], ["testes", "ANATOMY", 46, 52], ["glands", "ANATOMY", 74, 80]]], ["Mouse models have demonstrated ZIKV infection and associated pathology in the testes [29\u201331] of humanized BLT mouse model with infection primarily targeting macrophages and Leydig cells [32].", [["testes", "ANATOMY", 78, 84], ["macrophages", "ANATOMY", 157, 168], ["Leydig cells", "ANATOMY", 173, 185], ["infection", "DISEASE", 36, 45], ["infection", "DISEASE", 127, 136], ["Mouse", "ORGANISM", 0, 5], ["ZIKV", "GENE_OR_GENE_PRODUCT", 31, 35], ["testes", "ORGAN", 78, 84], ["BLT mouse", "ORGANISM", 106, 115], ["macrophages", "CELL", 157, 168], ["Leydig cells", "CELL", 173, 185], ["macrophages", "CELL_TYPE", 157, 168], ["Leydig cells", "CELL_TYPE", 173, 185], ["Mouse", "SPECIES", 0, 5], ["mouse", "SPECIES", 110, 115], ["ZIKV", "SPECIES", 31, 35], ["mouse", "SPECIES", 110, 115], ["Mouse models", "PROBLEM", 0, 12], ["ZIKV infection", "PROBLEM", 31, 45], ["associated pathology in the testes", "PROBLEM", 50, 84], ["humanized BLT mouse model", "TREATMENT", 96, 121], ["infection", "PROBLEM", 127, 136], ["Leydig cells", "PROBLEM", 173, 185], ["ZIKV infection", "OBSERVATION", 31, 45], ["testes", "ANATOMY", 78, 84], ["infection", "OBSERVATION", 127, 136]]], ["Limited investigation has been done relating to infection of accessory sex glands in mouse models, but one study that assessed the prostate found no virus, possibly due to differential expression of the receptor candidate in the testes but not in the prostate [29].", [["accessory sex glands", "ANATOMY", 61, 81], ["prostate", "ANATOMY", 131, 139], ["testes", "ANATOMY", 229, 235], ["prostate", "ANATOMY", 251, 259], ["infection", "DISEASE", 48, 57], ["glands", "ORGAN", 75, 81], ["mouse", "ORGANISM", 85, 90], ["prostate", "CANCER", 131, 139], ["testes", "ORGAN", 229, 235], ["prostate", "ORGAN", 251, 259], ["mouse", "SPECIES", 85, 90], ["mouse", "SPECIES", 85, 90], ["Limited investigation", "TEST", 0, 21], ["infection of accessory sex glands in mouse models", "PROBLEM", 48, 97], ["one study", "TEST", 103, 112], ["the prostate", "PROBLEM", 127, 139], ["virus", "PROBLEM", 149, 154], ["infection", "OBSERVATION", 48, 57], ["prostate", "ANATOMY", 131, 139], ["no", "UNCERTAINTY", 146, 148], ["virus", "OBSERVATION", 149, 154], ["testes", "ANATOMY", 229, 235], ["prostate", "ANATOMY", 251, 259]]], ["For this experiment the finding of viral antigen and viral RNA in the testes but not in the prostate is consistent with published animal models and may suggest the potential for bats to serve as another animal model.DiscussionThree bats had histopathological alterations in the hippocampus at later time points and one bat had viral nucleic acid present in the brain as determined by qRT-PCR demonstrating tropism for the CNS, a tissue predilection also documented in humans and animal models.", [["testes", "ANATOMY", 70, 76], ["prostate", "ANATOMY", 92, 100], ["hippocampus", "ANATOMY", 278, 289], ["brain", "ANATOMY", 361, 366], ["CNS", "ANATOMY", 422, 425], ["tissue", "ANATOMY", 429, 435], ["nucleic acid", "CHEMICAL", 333, 345], ["viral antigen", "GENE_OR_GENE_PRODUCT", 35, 48], ["testes", "ORGAN", 70, 76], ["prostate", "ORGAN", 92, 100], ["bats", "ORGANISM", 178, 182], ["hippocampus", "ORGAN", 278, 289], ["brain", "ORGAN", 361, 366], ["CNS", "ANATOMICAL_SYSTEM", 422, 425], ["tissue", "TISSUE", 429, 435], ["humans", "ORGANISM", 468, 474], ["viral antigen", "PROTEIN", 35, 48], ["viral RNA", "RNA", 53, 62], ["humans", "SPECIES", 468, 474], ["humans", "SPECIES", 468, 474], ["viral antigen", "PROBLEM", 35, 48], ["viral RNA in the testes", "PROBLEM", 53, 76], ["histopathological alterations in the hippocampus", "PROBLEM", 241, 289], ["viral nucleic acid present in the brain", "PROBLEM", 327, 366], ["PCR", "TEST", 388, 391], ["tropism", "PROBLEM", 406, 413], ["the CNS", "PROBLEM", 418, 425], ["a tissue predilection", "PROBLEM", 427, 448], ["viral", "OBSERVATION", 35, 40], ["viral RNA", "OBSERVATION", 53, 62], ["testes", "ANATOMY", 70, 76], ["prostate", "ANATOMY", 92, 100], ["consistent with", "UNCERTAINTY", 104, 119], ["hippocampus", "ANATOMY", 278, 289], ["nucleic acid", "OBSERVATION", 333, 345], ["brain", "ANATOMY", 361, 366], ["CNS", "ANATOMY", 422, 425]]], ["ZIKV has a predilection for nervous tissue in animal studies and disease manifestation in humans.", [["nervous tissue", "ANATOMY", 28, 42], ["ZIKV", "CHEMICAL", 0, 4], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["nervous tissue", "TISSUE", 28, 42], ["humans", "ORGANISM", 90, 96], ["humans", "SPECIES", 90, 96], ["ZIKV", "SPECIES", 0, 4], ["humans", "SPECIES", 90, 96], ["nervous tissue", "PROBLEM", 28, 42], ["animal studies", "TEST", 46, 60], ["disease manifestation in humans", "PROBLEM", 65, 96]]], ["As a neurological teratogen, ZIKV has been detected in the brain mononuclear cells in human newborns with fatal microcephaly and fetal miscarriages.", [["neurological", "ANATOMY", 5, 17], ["brain mononuclear cells", "ANATOMY", 59, 82], ["fetal", "ANATOMY", 129, 134], ["neurological teratogen", "DISEASE", 5, 27], ["ZIKV", "CHEMICAL", 29, 33], ["microcephaly", "DISEASE", 112, 124], ["fetal miscarriages", "DISEASE", 129, 147], ["ZIKV", "GENE_OR_GENE_PRODUCT", 29, 33], ["brain mononuclear cells", "CELL", 59, 82], ["human", "ORGANISM", 86, 91], ["newborns", "ORGANISM", 92, 100], ["fetal", "ORGAN", 129, 134], ["brain mononuclear cells", "CELL_TYPE", 59, 82], ["human", "SPECIES", 86, 91], ["ZIKV", "SPECIES", 29, 33], ["human", "SPECIES", 86, 91], ["a neurological teratogen", "PROBLEM", 3, 27], ["ZIKV", "PROBLEM", 29, 33], ["fatal microcephaly", "PROBLEM", 106, 124], ["fetal miscarriages", "PROBLEM", 129, 147], ["brain", "ANATOMY", 59, 64], ["mononuclear cells", "OBSERVATION", 65, 82], ["fatal", "OBSERVATION_MODIFIER", 106, 111], ["microcephaly", "OBSERVATION", 112, 124], ["fetal miscarriages", "OBSERVATION", 129, 147]]], ["Histological lesions are varied but may include parenchymal calcification, microglial nodules, gliosis, cell degeneration, mononuclear infiltration and necrosis [33\u201335].", [["lesions", "ANATOMY", 13, 20], ["parenchymal", "ANATOMY", 48, 59], ["microglial nodules", "ANATOMY", 75, 93], ["cell", "ANATOMY", 104, 108], ["mononuclear", "ANATOMY", 123, 134], ["parenchymal calcification", "DISEASE", 48, 73], ["gliosis", "DISEASE", 95, 102], ["mononuclear infiltration", "DISEASE", 123, 147], ["necrosis", "DISEASE", 152, 160], ["Histological lesions", "CANCER", 0, 20], ["parenchymal", "TISSUE", 48, 59], ["microglial nodules", "PATHOLOGICAL_FORMATION", 75, 93], ["cell", "CELL", 104, 108], ["mononuclear", "TISSUE", 123, 134], ["Histological lesions", "PROBLEM", 0, 20], ["parenchymal calcification", "PROBLEM", 48, 73], ["microglial nodules", "PROBLEM", 75, 93], ["gliosis", "PROBLEM", 95, 102], ["cell degeneration", "PROBLEM", 104, 121], ["mononuclear infiltration", "PROBLEM", 123, 147], ["necrosis", "PROBLEM", 152, 160], ["lesions", "OBSERVATION", 13, 20], ["may include", "UNCERTAINTY", 36, 47], ["parenchymal", "ANATOMY_MODIFIER", 48, 59], ["calcification", "OBSERVATION", 60, 73], ["microglial", "OBSERVATION_MODIFIER", 75, 85], ["nodules", "OBSERVATION", 86, 93], ["gliosis", "OBSERVATION", 95, 102], ["cell degeneration", "OBSERVATION", 104, 121], ["mononuclear infiltration", "OBSERVATION", 123, 147], ["necrosis", "OBSERVATION", 152, 160]]], ["In non-human animal models, evidence for viral tropism has been found in brain and/or peripheral nervous tissue [36\u201339].", [["brain", "ANATOMY", 73, 78], ["peripheral nervous tissue", "ANATOMY", 86, 111], ["brain", "ORGAN", 73, 78], ["peripheral nervous tissue", "TISSUE", 86, 111], ["viral tropism", "PROBLEM", 41, 54], ["peripheral nervous tissue", "PROBLEM", 86, 111], ["evidence for", "UNCERTAINTY", 28, 40], ["viral tropism", "OBSERVATION", 41, 54], ["brain", "ANATOMY", 73, 78], ["peripheral", "ANATOMY_MODIFIER", 86, 96], ["nervous tissue", "ANATOMY", 97, 111]]], ["In immunocompromised mouse models, the virus has a predilection for the brain but with the mice engineered for specific immune traits it is difficult to know to what extent this recapitulates natural ZIKV pathophysiology [40].", [["brain", "ANATOMY", 72, 77], ["mouse", "ORGANISM", 21, 26], ["brain", "ORGAN", 72, 77], ["mice", "ORGANISM", 91, 95], ["ZIKV", "GENE_OR_GENE_PRODUCT", 200, 204], ["mouse", "SPECIES", 21, 26], ["mice", "SPECIES", 91, 95], ["mouse", "SPECIES", 21, 26], ["mice", "SPECIES", 91, 95], ["immunocompromised mouse models", "PROBLEM", 3, 33], ["the virus", "PROBLEM", 35, 44], ["a predilection for the brain", "PROBLEM", 49, 77], ["the mice engineered", "TREATMENT", 87, 106], ["specific immune traits", "PROBLEM", 111, 133], ["immunocompromised mouse models", "OBSERVATION", 3, 33], ["brain", "ANATOMY", 72, 77]]], ["In the bats used in this experiment, evidence of ZIKV-induced pathology in the brain is consistent with what has been seen in human newborns and fetuses.DiscussionThe novel finding of co-localizing ZIKV antigen in bat Iba1+ microglial/macrophage cells lends support to the earlier evidence of microglial cell infection via Axl ligand bridging ZIKV particles to glial cells [41].", [["brain", "ANATOMY", 79, 84], ["fetuses", "ANATOMY", 145, 152], ["Iba1+ microglial/macrophage cells", "ANATOMY", 218, 251], ["microglial cell", "ANATOMY", 293, 308], ["glial cells", "ANATOMY", 361, 372], ["ZIKV", "CHEMICAL", 49, 53], ["infection", "DISEASE", 309, 318], ["ZIKV", "GENE_OR_GENE_PRODUCT", 49, 53], ["brain", "ORGAN", 79, 84], ["human", "ORGANISM", 126, 131], ["newborns", "DEVELOPING_ANATOMICAL_STRUCTURE", 132, 140], ["fetuses", "ORGAN", 145, 152], ["ZIKV antigen", "GENE_OR_GENE_PRODUCT", 198, 210], ["bat", "ORGANISM", 214, 217], ["Iba1", "GENE_OR_GENE_PRODUCT", 218, 222], ["microglial", "CELL", 224, 234], ["macrophage cells", "CELL", 235, 251], ["microglial cell", "CELL", 293, 308], ["Axl ligand", "GENE_OR_GENE_PRODUCT", 323, 333], ["ZIKV", "GENE_OR_GENE_PRODUCT", 343, 347], ["glial cells", "CELL", 361, 372], ["ZIKV antigen", "PROTEIN", 198, 210], ["bat Iba1+ microglial/macrophage cells", "CELL_LINE", 214, 251], ["Axl ligand", "PROTEIN", 323, 333], ["glial cells", "CELL_TYPE", 361, 372], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["ZIKV-induced pathology in the brain", "PROBLEM", 49, 84], ["co-localizing ZIKV antigen", "TEST", 184, 210], ["bat Iba1", "TEST", 214, 222], ["microglial/macrophage cells", "TREATMENT", 224, 251], ["microglial cell infection", "PROBLEM", 293, 318], ["Axl ligand bridging ZIKV particles", "TREATMENT", 323, 357], ["glial cells", "TEST", 361, 372], ["ZIKV", "OBSERVATION", 49, 53], ["pathology", "OBSERVATION", 62, 71], ["brain", "ANATOMY", 79, 84], ["consistent with", "UNCERTAINTY", 88, 103], ["fetuses", "OBSERVATION", 145, 152], ["macrophage cells", "OBSERVATION", 235, 251], ["evidence of", "UNCERTAINTY", 281, 292], ["microglial cell infection", "OBSERVATION", 293, 318]]], ["Iba1 (aka, allograft inflammatory factor 1, Aif1) is a microglia/macrophage-specific calcium-binding protein, which has actin-bundling activity that participates in membrane ruffling and phagocytic activity of activated microglia.", [["microglia", "ANATOMY", 55, 64], ["macrophage", "ANATOMY", 65, 75], ["membrane", "ANATOMY", 165, 173], ["microglia", "ANATOMY", 220, 229], ["calcium", "CHEMICAL", 85, 92], ["calcium", "CHEMICAL", 85, 92], ["Iba1", "GENE_OR_GENE_PRODUCT", 0, 4], ["aka, allograft inflammatory factor 1", "GENE_OR_GENE_PRODUCT", 6, 42], ["Aif1", "GENE_OR_GENE_PRODUCT", 44, 48], ["microglia", "CELL", 55, 64], ["macrophage", "CELL", 65, 75], ["calcium", "SIMPLE_CHEMICAL", 85, 92], ["actin", "GENE_OR_GENE_PRODUCT", 120, 125], ["membrane", "CELLULAR_COMPONENT", 165, 173], ["microglia", "CELL", 220, 229], ["Iba1", "PROTEIN", 0, 4], ["aka, allograft inflammatory factor 1", "PROTEIN", 6, 42], ["Aif1", "PROTEIN", 44, 48], ["microglia/macrophage-specific calcium-binding protein", "PROTEIN", 55, 108], ["actin", "PROTEIN", 120, 125], ["activated microglia", "CELL_TYPE", 210, 229], ["Iba1", "TEST", 0, 4], ["allograft inflammatory factor", "TEST", 11, 40], ["a microglia/macrophage", "TEST", 53, 75], ["calcium", "TEST", 85, 92], ["binding protein", "TEST", 93, 108], ["activated microglia", "PROBLEM", 210, 229], ["aka", "ANATOMY", 6, 9], ["allograft", "OBSERVATION_MODIFIER", 11, 20], ["inflammatory", "OBSERVATION_MODIFIER", 21, 33], ["membrane ruffling", "OBSERVATION", 165, 182], ["phagocytic activity", "OBSERVATION", 187, 206], ["activated microglia", "OBSERVATION", 210, 229]]], ["Activated microglial cells appeared with increased ability of cell migration and phagocytosis, which is controlled by remodeling of membrane cytoskeleton [42].", [["microglial cells", "ANATOMY", 10, 26], ["cell", "ANATOMY", 62, 66], ["membrane cytoskeleton", "ANATOMY", 132, 153], ["microglial cells", "CELL", 10, 26], ["cell", "CELL", 62, 66], ["membrane cytoskeleton", "CELLULAR_COMPONENT", 132, 153], ["Activated microglial cells", "CELL_TYPE", 0, 26], ["Activated microglial cells", "PROBLEM", 0, 26], ["cell migration", "PROBLEM", 62, 76], ["phagocytosis", "PROBLEM", 81, 93], ["microglial cells", "OBSERVATION", 10, 26], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["cell migration", "OBSERVATION", 62, 76], ["phagocytosis", "OBSERVATION_MODIFIER", 81, 93], ["membrane cytoskeleton", "OBSERVATION", 132, 153]]], ["The morphology of cells with co-localization in the brain of infected bats is consistent with activated microglia depicting prominent branched processes.", [["cells", "ANATOMY", 18, 23], ["brain", "ANATOMY", 52, 57], ["microglia", "ANATOMY", 104, 113], ["cells", "CELL", 18, 23], ["brain", "ORGAN", 52, 57], ["bats", "ORGANISM", 70, 74], ["microglia", "CELL", 104, 113], ["activated microglia", "CELL_TYPE", 94, 113], ["co-localization in the brain of infected bats", "PROBLEM", 29, 74], ["activated microglia depicting prominent branched processes", "PROBLEM", 94, 152], ["cells", "OBSERVATION", 18, 23], ["brain", "ANATOMY", 52, 57], ["infected bats", "OBSERVATION", 61, 74], ["consistent with", "UNCERTAINTY", 78, 93], ["microglia", "OBSERVATION", 104, 113], ["prominent", "OBSERVATION_MODIFIER", 124, 133], ["branched", "OBSERVATION_MODIFIER", 134, 142]]], ["Recent primate models in rhesus and cynomolgus macaques demonstrated similar viral distribution of ZIKV antigen to that in bats, described herein.", [["rhesus", "ORGANISM", 25, 31], ["cynomolgus macaques", "ORGANISM", 36, 55], ["ZIKV antigen", "GENE_OR_GENE_PRODUCT", 99, 111], ["ZIKV antigen", "PROTEIN", 99, 111], ["cynomolgus macaques", "SPECIES", 36, 55], ["cynomolgus macaques", "SPECIES", 36, 55], ["ZIKV", "SPECIES", 99, 103], ["Recent primate models in rhesus", "PROBLEM", 0, 31], ["ZIKV antigen", "PROBLEM", 99, 111], ["viral distribution", "OBSERVATION", 77, 95], ["ZIKV", "OBSERVATION", 99, 103]]], ["High-level of ZIKV was evident in cerebellar neurons and the same studies documented involvement of Iba1 positive microglial cells in CNS infections.", [["cerebellar neurons", "ANATOMY", 34, 52], ["microglial cells", "ANATOMY", 114, 130], ["CNS", "ANATOMY", 134, 137], ["infections", "DISEASE", 138, 148], ["ZIKV", "GENE_OR_GENE_PRODUCT", 14, 18], ["cerebellar neurons", "CELL", 34, 52], ["Iba1", "GENE_OR_GENE_PRODUCT", 100, 104], ["microglial cells", "CELL", 114, 130], ["CNS", "ANATOMICAL_SYSTEM", 134, 137], ["ZIKV", "PROTEIN", 14, 18], ["cerebellar neurons", "CELL_TYPE", 34, 52], ["Iba1 positive microglial cells", "CELL_TYPE", 100, 130], ["ZIKV", "PROBLEM", 14, 18], ["cerebellar neurons", "PROBLEM", 34, 52], ["Iba1 positive microglial cells", "PROBLEM", 100, 130], ["CNS infections", "PROBLEM", 134, 148], ["ZIKV", "OBSERVATION", 14, 18], ["cerebellar neurons", "ANATOMY", 34, 52], ["Iba1 positive", "OBSERVATION", 100, 113], ["microglial cells", "OBSERVATION", 114, 130], ["CNS", "ANATOMY", 134, 137], ["infections", "OBSERVATION", 138, 148]]], ["In primate models there is increasing evidence that ZIKV antigen was detected in individuals with the highest peak plasma viremia, which in part implies that ZIKV may initially seed the CNS by a passive spillover from circulating monocytes to resident microglial cells.", [["plasma", "ANATOMY", 115, 121], ["CNS", "ANATOMY", 186, 189], ["monocytes", "ANATOMY", 230, 239], ["microglial cells", "ANATOMY", 252, 268], ["viremia", "DISEASE", 122, 129], ["primate", "ORGANISM", 3, 10], ["ZIKV antigen", "GENE_OR_GENE_PRODUCT", 52, 64], ["plasma", "ORGANISM_SUBSTANCE", 115, 121], ["ZIKV", "GENE_OR_GENE_PRODUCT", 158, 162], ["CNS", "ANATOMICAL_SYSTEM", 186, 189], ["monocytes", "CELL", 230, 239], ["microglial cells", "CELL", 252, 268], ["ZIKV antigen", "PROTEIN", 52, 64], ["circulating monocytes", "CELL_TYPE", 218, 239], ["resident microglial cells", "CELL_TYPE", 243, 268], ["ZIKV", "SPECIES", 52, 56], ["ZIKV", "SPECIES", 158, 162], ["ZIKV antigen", "PROBLEM", 52, 64], ["the highest peak plasma viremia", "PROBLEM", 98, 129], ["ZIKV", "PROBLEM", 158, 162], ["a passive spillover", "PROBLEM", 193, 212], ["increasing", "OBSERVATION_MODIFIER", 27, 37], ["ZIKV", "OBSERVATION", 52, 56], ["peak plasma viremia", "OBSERVATION", 110, 129], ["ZIKV", "OBSERVATION", 158, 162], ["microglial cells", "OBSERVATION", 252, 268]]], ["This is further substantiated in all of human and animal studies, which did not show any evidence of disruption to BBB or viral distribution reminiscent of circumventricular distribution seen in alphavirus animal models [43].DiscussionIn addition to brain and testes immunoreactivity, scrotal skin and mandibular salivary gland also harbored viral antigen.", [["BBB", "ANATOMY", 115, 118], ["circumventricular", "ANATOMY", 156, 173], ["brain", "ANATOMY", 250, 255], ["testes", "ANATOMY", 260, 266], ["scrotal skin", "ANATOMY", 285, 297], ["mandibular salivary gland", "ANATOMY", 302, 327], ["human", "ORGANISM", 40, 45], ["BBB", "MULTI-TISSUE_STRUCTURE", 115, 118], ["circumventricular", "ANATOMICAL_SYSTEM", 156, 173], ["brain", "ORGAN", 250, 255], ["testes", "ORGAN", 260, 266], ["scrotal skin", "ORGAN", 285, 297], ["mandibular", "ORGAN", 302, 312], ["salivary gland", "ORGAN", 313, 327], ["viral antigen", "PROTEIN", 342, 355], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["animal studies", "TEST", 50, 64], ["disruption to BBB", "PROBLEM", 101, 118], ["circumventricular distribution", "PROBLEM", 156, 186], ["brain and testes immunoreactivity", "TEST", 250, 283], ["scrotal skin and mandibular salivary gland", "PROBLEM", 285, 327], ["harbored viral antigen", "PROBLEM", 333, 355], ["disruption", "OBSERVATION", 101, 111], ["viral distribution", "OBSERVATION", 122, 140], ["circumventricular distribution", "OBSERVATION", 156, 186], ["alphavirus", "OBSERVATION", 195, 205], ["brain", "ANATOMY", 250, 255], ["testes", "ANATOMY", 260, 266], ["scrotal skin", "ANATOMY", 285, 297], ["mandibular", "ANATOMY_MODIFIER", 302, 312], ["salivary gland", "ANATOMY", 313, 327], ["viral antigen", "OBSERVATION", 342, 355]]], ["Distribution of viral antigen in bat tissues suggests that infection in this species recapitulates human infection, which is thought to start with infection of epidermal and dermal cells with subsequent dissemination to multiple organs including salivary glands as viral RNA can be detected in human saliva [44, 45].", [["bat tissues", "ANATOMY", 33, 44], ["epidermal", "ANATOMY", 160, 169], ["dermal cells", "ANATOMY", 174, 186], ["organs", "ANATOMY", 229, 235], ["salivary glands", "ANATOMY", 246, 261], ["infection", "DISEASE", 59, 68], ["infection", "DISEASE", 105, 114], ["infection", "DISEASE", 147, 156], ["viral antigen", "GENE_OR_GENE_PRODUCT", 16, 29], ["bat tissues", "TISSUE", 33, 44], ["human", "ORGANISM", 99, 104], ["epidermal", "CELL", 160, 169], ["dermal cells", "CELL", 174, 186], ["organs", "ORGAN", 229, 235], ["salivary glands", "ORGAN", 246, 261], ["human", "ORGANISM", 294, 299], ["saliva", "ORGANISM_SUBSTANCE", 300, 306], ["viral antigen", "PROTEIN", 16, 29], ["epidermal and dermal cells", "CELL_TYPE", 160, 186], ["viral RNA", "RNA", 265, 274], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 294, 299], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 294, 299], ["viral antigen in bat tissues", "PROBLEM", 16, 44], ["infection", "PROBLEM", 59, 68], ["this species", "PROBLEM", 72, 84], ["human infection", "PROBLEM", 99, 114], ["infection of epidermal and dermal cells", "PROBLEM", 147, 186], ["salivary glands", "PROBLEM", 246, 261], ["viral RNA", "PROBLEM", 265, 274], ["viral antigen", "OBSERVATION", 16, 29], ["infection", "OBSERVATION", 59, 68], ["infection", "OBSERVATION", 105, 114], ["dermal cells", "OBSERVATION", 174, 186], ["salivary glands", "ANATOMY", 246, 261]]], ["The histopathology for AJ-z5, 5 dpi showed sialoadenitis and the presence ZIKV antigen by IHC (Fig 3).", [["AJ-z5", "ANATOMY", 23, 28], ["sialoadenitis", "DISEASE", 43, 56], ["AJ-z5", "CELL", 23, 28], ["ZIKV antigen", "GENE_OR_GENE_PRODUCT", 74, 86], ["AJ", "PROTEIN", 23, 25], ["ZIKV antigen", "PROTEIN", 74, 86], ["The histopathology", "TEST", 0, 18], ["AJ-z5", "TEST", 23, 28], ["sialoadenitis", "PROBLEM", 43, 56], ["the presence ZIKV antigen", "PROBLEM", 61, 86]]], ["This suggests ZIKV may be shed in the saliva, although additional animal experiments need to be performed to confirm such a route of shedding.", [["saliva", "ANATOMY", 38, 44], ["ZIKV", "CHEMICAL", 14, 18], ["ZIKV", "GENE_OR_GENE_PRODUCT", 14, 18], ["saliva", "ORGANISM_SUBSTANCE", 38, 44], ["ZIKV", "SPECIES", 14, 18], ["ZIKV", "PROBLEM", 14, 18], ["ZIKV", "OBSERVATION", 14, 18]]], ["The results presented here suggest that Jamaican fruit bats may be a suitable animal model for examining ZIKV infection to elucidate its pathogenesis.", [["infection", "DISEASE", 110, 119], ["ZIKV", "ORGANISM", 105, 109], ["Jamaican fruit bats", "SPECIES", 40, 59], ["ZIKV", "SPECIES", 105, 109], ["Jamaican fruit bats", "PROBLEM", 40, 59], ["ZIKV infection", "PROBLEM", 105, 119], ["its pathogenesis", "PROBLEM", 133, 149]]], ["Jamaican fruit bats may also serve as a model to ascertain sexual transmission, in utero transmission, teratogenesis and neurological pathophysiology.", [["neurological", "ANATOMY", 121, 133], ["teratogenesis", "DISEASE", 103, 116], ["neurological pathophysiology", "DISEASE", 121, 149], ["Jamaican fruit bats", "SPECIES", 0, 19], ["Jamaican fruit bats", "TREATMENT", 0, 19], ["teratogenesis", "PROBLEM", 103, 116], ["neurological pathophysiology", "PROBLEM", 121, 149]]], ["It may be that ZIKV is a wildlife disease threat for bats that could lead to infertility in some males, which could impact bat populations.DiscussionZIKV is thought to be maintained in two different distinct cycles: sylvatic\u2014cycling between non-human primates (NHP) and mosquito species, and urban\u2014cycling between humans and mosquito species [3].", [["ZIKV", "CHEMICAL", 15, 19], ["infertility", "DISEASE", 77, 88], ["bats", "ORGANISM", 53, 57], ["non-human primates", "ORGANISM", 241, 259], ["NHP", "ORGANISM", 261, 264], ["humans", "ORGANISM", 314, 320], ["humans", "SPECIES", 314, 320], ["ZIKV", "SPECIES", 15, 19], ["humans", "SPECIES", 314, 320], ["ZIKV", "PROBLEM", 15, 19], ["a wildlife disease threat", "PROBLEM", 23, 48], ["infertility", "PROBLEM", 77, 88], ["sylvatic\u2014cycling between non-human primates (NHP)", "PROBLEM", 216, 265], ["mosquito species", "PROBLEM", 270, 286], ["may be", "UNCERTAINTY", 3, 9], ["ZIKV", "OBSERVATION", 15, 19], ["thought to be", "UNCERTAINTY", 157, 170]]], ["While there are limited data on what mosquito species feed on Jamaican fruit bats, evidence for natural flavivirus infection has been identified in wild New World bats.", [["flavivirus infection", "DISEASE", 104, 124], ["natural flavivirus", "ORGANISM", 96, 114], ["Jamaican fruit bats", "SPECIES", 62, 81], ["New World bats", "SPECIES", 153, 167], ["natural flavivirus infection", "PROBLEM", 96, 124], ["evidence for", "UNCERTAINTY", 83, 95], ["natural", "OBSERVATION_MODIFIER", 96, 103], ["flavivirus", "OBSERVATION", 104, 114], ["New", "OBSERVATION_MODIFIER", 153, 156], ["World bats", "OBSERVATION", 157, 167]]], ["Dengue virus (DENV) RNA and antibodies to DENV were detected in multiple species of bats, including Jamaican fruit bats, in Mexico [46].", [["Dengue", "DISEASE", 0, 6], ["Dengue virus", "ORGANISM", 0, 12], ["DENV", "ORGANISM", 14, 18], ["DENV", "ORGANISM", 42, 46], ["bats", "ORGANISM", 84, 88], ["Dengue virus (DENV) RNA", "RNA", 0, 23], ["antibodies", "PROTEIN", 28, 38], ["Dengue virus", "SPECIES", 0, 12], ["Dengue virus", "SPECIES", 0, 12], ["DENV", "SPECIES", 14, 18], ["DENV", "SPECIES", 42, 46], ["Jamaican fruit bats", "SPECIES", 100, 119], ["Dengue virus (DENV) RNA and antibodies", "PROBLEM", 0, 38], ["DENV", "PROBLEM", 42, 46]]], ["Additionally, antibodies to DENV were detected in multiple bat species including those of the Artibeus genus in Costa Rica and Ecuador [47, 48].", [["DENV", "ORGANISM", 28, 32], ["antibodies", "PROTEIN", 14, 24], ["DENV", "SPECIES", 28, 32], ["antibodies", "TEST", 14, 24], ["DENV", "PROBLEM", 28, 32], ["multiple bat species", "PROBLEM", 50, 70], ["Costa Rica", "ANATOMY", 112, 122]]], ["These data indirectly provide evidence for mosquito-bat interactions in the wild; either through consumption of bat-blood meals taken by mosquitoes or bat consumption of infected mosquitoes.DiscussionAs it pertains to a wildlife reservoir, wild NHPs have antibody to ZIKV including several monkey species trapped near Ziika Forest [10], and wild and semi-captive orangutans in Borneo [49].", [["blood", "ANATOMY", 116, 121], ["infected mosquitoes", "DISEASE", 170, 189], ["bat", "ORGANISM", 52, 55], ["bat", "ORGANISM", 112, 115], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["bat", "ORGANISM_SUBDIVISION", 151, 154], ["NHPs", "ORGANISM", 245, 249], ["monkey", "ORGANISM", 290, 296], ["orangutans", "ORGANISM", 363, 373], ["ZIKV", "SPECIES", 267, 271], ["mosquito-bat interactions", "PROBLEM", 43, 68], ["bat-blood meals", "TREATMENT", 112, 127], ["infected mosquitoes", "PROBLEM", 170, 189], ["a wildlife reservoir", "TREATMENT", 218, 238], ["ZIKV", "PROBLEM", 267, 271], ["infected mosquitoes", "OBSERVATION", 170, 189]]], ["Not only have NHP been found to be seropositive, but also many other mammals, including rodents, horses, cows, and goats [50, 51].", [["cows", "ORGANISM_SUBDIVISION", 105, 109], ["horses", "SPECIES", 97, 103], ["cows", "SPECIES", 105, 109], ["goats", "SPECIES", 115, 120], ["goats", "SPECIES", 115, 120], ["seropositive", "OBSERVATION", 35, 47]]], ["Furthermore, experimental inoculation of various North American species resulted in seroconversion (cottontail rabbits, boar goats, pigs, and leopard frogs) and demonstrated viremia (nine-banded armadillo and leopard frogs) [52].", [["viremia", "DISEASE", 174, 181], ["rabbits", "ORGANISM", 111, 118], ["boar", "ORGANISM", 120, 124], ["goats", "ORGANISM_SUBDIVISION", 125, 130], ["pigs", "ORGANISM", 132, 136], ["frogs", "ORGANISM_SUBDIVISION", 150, 155], ["armadillo", "ORGANISM", 195, 204], ["frogs", "ORGANISM_SUBDIVISION", 217, 222], ["rabbits", "SPECIES", 111, 118], ["boar", "SPECIES", 120, 124], ["goats", "SPECIES", 125, 130], ["pigs", "SPECIES", 132, 136], ["rabbits", "SPECIES", 111, 118], ["goats", "SPECIES", 125, 130], ["pigs", "SPECIES", 132, 136], ["experimental inoculation of various North American species", "PROBLEM", 13, 71], ["seroconversion (cottontail rabbits", "TREATMENT", 84, 118], ["pigs, and leopard frogs", "PROBLEM", 132, 155], ["viremia", "PROBLEM", 174, 181], ["inoculation", "OBSERVATION_MODIFIER", 26, 37], ["viremia", "OBSERVATION", 174, 181]]], ["Much about the enzootic cycle of ZIKV has yet to be understood but it stands to reason that bats may be capable of maintaining the virus in nature.", [["ZIKV", "CHEMICAL", 33, 37], ["ZIKV", "GENE_OR_GENE_PRODUCT", 33, 37], ["bats", "ORGANISM", 92, 96], ["ZIKV", "SPECIES", 33, 37], ["ZIKV", "PROBLEM", 33, 37], ["virus", "OBSERVATION", 131, 136]]], ["Jamaican fruit bats are found in northern South America, Central America, and the Caribbean\u2014areas that now have ZIKV potentially exposing bat populations to the virus [8, 53].", [["ZIKV", "CHEMICAL", 112, 116], ["Jamaican fruit bats", "SPECIES", 0, 19], ["ZIKV", "SPECIES", 112, 116], ["ZIKV", "PROBLEM", 112, 116], ["fruit bats", "OBSERVATION", 9, 19], ["Central", "ANATOMY_MODIFIER", 57, 64]]], ["However, the data presented here suggest it is unlikely that Jamaican fruit bats can serve as amplification hosts of ZIKV, unless virus sequesters in some as-yet unidentified way that could lead to periodic shedding of virus.", [["Jamaican", "ORGANISM", 61, 69], ["fruit bats", "ORGANISM", 70, 80], ["ZIKV", "GENE_OR_GENE_PRODUCT", 117, 121], ["Jamaican fruit bats", "SPECIES", 61, 80], ["ZIKV", "SPECIES", 117, 121], ["Jamaican fruit bats", "PROBLEM", 61, 80], ["ZIKV", "PROBLEM", 117, 121], ["virus sequesters", "PROBLEM", 130, 146], ["periodic shedding of virus", "PROBLEM", 198, 224]]], ["It may also be that some bats become persistently infected and can transmit sexually to maintain virus within populations of bats.", [["bats", "ORGANISM", 125, 129], ["persistently infected", "PROBLEM", 37, 58], ["may also be", "UNCERTAINTY", 3, 14], ["persistently", "OBSERVATION_MODIFIER", 37, 49], ["infected", "OBSERVATION", 50, 58]]], ["Further experimental and field studies will be necessary to fully understand the ecological role of bats in ZIKV maintenance.Ethics statement ::: Materials and methodsAll animal procedures were approved by the Colorado State University (CSU) Institutional Animal Care and Use Committee (protocol 16-6512A) and were in compliance with U.S. Animal Welfare Act.Bats ::: Materials and methodsCSU has a captive colony of Jamaican fruit bats (Artibeus jamaicensis), a neotropical fruit bat indigenous to much of South America, Central America and the Caribbean [53].", [["bats", "ORGANISM", 100, 104], ["ZIKV", "SIMPLE_CHEMICAL", 108, 112], ["Artibeus jamaicensis", "ORGANISM", 437, 457], ["fruit", "SPECIES", 425, 430], ["Artibeus jamaicensis", "SPECIES", 437, 457], ["ZIKV", "SPECIES", 108, 112], ["Jamaican fruit bats", "SPECIES", 416, 435], ["Artibeus jamaicensis", "SPECIES", 437, 457], ["Further experimental and field studies", "TEST", 0, 38], ["ZIKV maintenance", "TREATMENT", 108, 124], ["All animal procedures", "TREATMENT", 167, 188], ["captive colony", "OBSERVATION", 398, 412], ["Jamaican fruit bats", "OBSERVATION", 416, 435], ["neotropical", "OBSERVATION", 462, 473], ["fruit bat", "OBSERVATION", 474, 483]]], ["Roosting baskets are hung from the ceiling throughout the room and drapes of different cloth material are positioned for hanging and roosting.", [["Roosting baskets", "TREATMENT", 0, 16], ["different cloth material", "TREATMENT", 77, 101]]], ["Ambient temperature is maintained between 20\u00b0C and 25\u00b0C, with humidity between 50% and 70%, and a 12 hour light/12 hour dark light cycle via a computer-controlled system.", [["Ambient temperature", "TEST", 0, 19], ["humidity", "TREATMENT", 62, 70], ["a computer-controlled system", "TREATMENT", 141, 169]]], ["Diets consist of a combination of fruits (Shamrock Foods, Fort Collins, CO), Tekald primate diet (Envigo, Huntington, UK), molasses, nonfat dry milk and cherry gelatin that are placed in multiple feeding trays around the room once a day.", [["fruits", "ANATOMY", 34, 40], ["milk", "ANATOMY", 144, 148], ["fruits", "ORGANISM_SUBDIVISION", 34, 40], ["milk", "ORGANISM_SUBSTANCE", 144, 148], ["milk", "SPECIES", 144, 148], ["cherry", "SPECIES", 153, 159], ["cherry", "SPECIES", 153, 159], ["fruits (Shamrock Foods", "TREATMENT", 34, 56], ["molasses", "TREATMENT", 123, 131], ["cherry gelatin", "TREATMENT", 153, 167], ["multiple feeding trays", "TREATMENT", 187, 209]]], ["In addition, fruit is hung around the room to stimulate foraging behavior and serve as enrichment.Bats ::: Materials and methodsFor infection experiments, bats were trapped using a butterfly net and placed in an 20\u201dd x 12\u201dw x 18\u201dh cage for 24 hours prior to inoculations to allow for acclimation.", [["infection", "DISEASE", 132, 141], ["bats", "ORGANISM", 155, 159], ["Materials", "TREATMENT", 107, 116], ["infection experiments", "PROBLEM", 132, 153], ["a butterfly net", "TREATMENT", 179, 194], ["an 20\u201dd x 12\u201dw x 18\u201dh cage", "TREATMENT", 209, 235], ["inoculations", "TREATMENT", 258, 270], ["fruit", "OBSERVATION", 13, 18], ["infection", "OBSERVATION", 132, 141]]], ["Hanging clothes were provided for roosting and coverage.", [["Hanging clothes", "TREATMENT", 0, 15], ["roosting and coverage", "TREATMENT", 34, 55]]], ["Food and water are placed in open trays in the bottom of the cage and changed daily.", [["open trays", "TREATMENT", 29, 39], ["bottom", "ANATOMY_MODIFIER", 47, 53], ["cage", "ANATOMY", 61, 65]]], ["Tray liners were changed every two days, and cages and hanging clothes are changed every two weeks.", [["Tray liners", "TREATMENT", 0, 11], ["cages and hanging clothes", "TREATMENT", 45, 70]]], ["Due to the social nature of these bats, minimums of two bats were kept in cages at all times to mitigate potential stress.Experimental inoculations ::: Materials and methodsTwo sets of experiments were performed; a pilot study and a time course study.", [["bats", "ORGANISM", 56, 60], ["potential stress", "PROBLEM", 105, 121], ["a pilot study", "TEST", 213, 226], ["a time course study", "TEST", 231, 250]]], ["Zika virus strain PRVABC59.", [["Zika virus", "ORGANISM", 0, 10], ["Zika virus", "SPECIES", 0, 10], ["Zika virus strain PRVABC59", "TREATMENT", 0, 26]]], ["PRVABC59 was isolated in 2015 by Centers for Disease Control and Prevention (Fort Collins, CO) from an infected individual who traveled to Puerto Rico (GenBank accession no. HQ234499).", [["PRVABC59", "CHEMICAL", 0, 8], ["HQ234499", "CHEMICAL", 174, 182], ["HQ234499", "CHEMICAL", 174, 182], ["PRVABC59", "GENE_OR_GENE_PRODUCT", 0, 8], ["PRVABC59", "TREATMENT", 0, 8], ["Disease Control", "TREATMENT", 45, 60], ["infected", "OBSERVATION", 103, 111]]], ["The virus stock titer is 3x107 plaque forming units (pfu) per ml of media, and the fourth passage was used for both studies.Experimental inoculations ::: Materials and methodsFor the pilot study, three male bats were anesthetized with 1% to 3% isoflurane to effect with an oxygen flow rate of 1.5 L/min, administered with a gas mask.", [["isoflurane", "CHEMICAL", 244, 254], ["oxygen", "CHEMICAL", 273, 279], ["isoflurane", "CHEMICAL", 244, 254], ["oxygen", "CHEMICAL", 273, 279], ["bats", "ORGANISM", 207, 211], ["isoflurane", "SIMPLE_CHEMICAL", 244, 254], ["oxygen", "SIMPLE_CHEMICAL", 273, 279], ["The virus stock titer", "TREATMENT", 0, 21], ["media", "TREATMENT", 68, 73], ["both studies", "TEST", 111, 123], ["the pilot study", "TEST", 179, 194], ["3% isoflurane", "TREATMENT", 241, 254], ["an oxygen flow rate", "TREATMENT", 270, 289], ["a gas mask", "TREATMENT", 322, 332], ["virus stock", "OBSERVATION", 4, 15], ["titer", "OBSERVATION_MODIFIER", 16, 21], ["gas mask", "OBSERVATION", 324, 332]]], ["Animals were placed on a heating pad to maintain body temperature and respirations continuously monitored.", [["body", "ANATOMY", 49, 53], ["Animals", "ORGANISM", 0, 7], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["a heating pad", "TREATMENT", 23, 36], ["body temperature", "TEST", 49, 65], ["respirations", "TEST", 70, 82]]], ["The dorsum of each animal was disinfected with 70% ethanol and 25ul containing 7.5x105 p.f.u of virus was administered subcutaneously (sc) at the level of the scapula with a sterile hypodermic 25 gauge needle in a biosafety cabinet.", [["dorsum", "ANATOMY", 4, 10], ["subcutaneously", "ANATOMY", 119, 133], ["scapula", "ANATOMY", 159, 166], ["ethanol", "CHEMICAL", 51, 58], ["25ul", "CHEMICAL", 63, 67], ["ethanol", "CHEMICAL", 51, 58], ["dorsum", "ORGAN", 4, 10], ["animal", "ORGANISM", 19, 25], ["ethanol", "SIMPLE_CHEMICAL", 51, 58], ["25ul", "SIMPLE_CHEMICAL", 63, 67], ["scapula", "ORGAN", 159, 166], ["70% ethanol", "TREATMENT", 47, 58], ["virus", "TREATMENT", 96, 101], ["a sterile hypodermic 25 gauge needle", "TREATMENT", 172, 208], ["dorsum", "ANATOMY", 4, 10], ["scapula", "ANATOMY", 159, 166]]], ["When procedures were finished, bats were removed from isoflurane and placed back in the cage in ventral recumbency.", [["ventral", "ANATOMY", 96, 103], ["isoflurane", "CHEMICAL", 54, 64], ["isoflurane", "CHEMICAL", 54, 64], ["bats", "ORGANISM", 31, 35], ["isoflurane", "SIMPLE_CHEMICAL", 54, 64], ["ventral", "ORGANISM_SUBDIVISION", 96, 103], ["recumbency", "ORGANISM_SUBDIVISION", 104, 114], ["isoflurane", "TREATMENT", 54, 64], ["cage", "ANATOMY", 88, 92], ["ventral", "ANATOMY_MODIFIER", 96, 103], ["recumbency", "OBSERVATION", 104, 114]]], ["Bats were identified as AJ-z7, AJ-z8 and AJ-z9.", [["AJ-z9", "CHEMICAL", 41, 46], ["Bats", "CELL", 0, 4], ["AJ-z7", "CELL", 24, 29], ["AJ-z8", "CELL", 31, 36], ["AJ-z9", "CELL", 41, 46], ["AJ", "PROTEIN", 24, 26], ["AJ", "PROTEIN", 31, 33], ["z8", "PROTEIN", 34, 36], ["AJ", "PROTEIN", 41, 43], ["z9", "PROTEIN", 44, 46]]], ["Animals were euthanized at 28 days post-inoculation (dpi).Experimental inoculations ::: Materials and methodsFor the time course study, six male bats were anesthetized under the same protocol as the pilot study.", [["Animals", "ORGANISM", 0, 7], ["bats", "ORGANISM", 145, 149], ["the time course study", "TEST", 113, 134], ["the pilot study", "TEST", 195, 210], ["inoculations", "OBSERVATION", 71, 83]]], ["Animals were placed in ventral recumbency.", [["ventral", "ANATOMY", 23, 30], ["Animals", "ORGANISM", 0, 7], ["recumbency", "ORGANISM_SUBDIVISION", 31, 41], ["ventral", "ANATOMY_MODIFIER", 23, 30], ["recumbency", "OBSERVATION_MODIFIER", 31, 41]]], ["After disinfecting the dorsum of each animal with 70% ethanol, 0.15mls of 1% lidocaine was administered sc at the level of the last rib with a 25 gauge sterile hypodermic needle as a local anesthetic.", [["dorsum", "ANATOMY", 23, 29], ["rib", "ANATOMY", 132, 135], ["ethanol", "CHEMICAL", 54, 61], ["lidocaine", "CHEMICAL", 77, 86], ["ethanol", "CHEMICAL", 54, 61], ["lidocaine", "CHEMICAL", 77, 86], ["dorsum", "ORGANISM_SUBDIVISION", 23, 29], ["ethanol", "SIMPLE_CHEMICAL", 54, 61], ["lidocaine", "SIMPLE_CHEMICAL", 77, 86], ["rib", "ORGAN", 132, 135], ["70% ethanol", "TREATMENT", 50, 61], ["1% lidocaine", "TREATMENT", 74, 86], ["a 25 gauge sterile hypodermic needle", "TREATMENT", 141, 177], ["a local anesthetic", "TREATMENT", 181, 199], ["dorsum", "ANATOMY", 23, 29], ["rib", "ANATOMY", 132, 135]]], ["IPTT300 transponders (BioMedic Data Systems, Inc., Seaford, DE) were inserted sc at the level of the caudal edge of the scapula.", [["caudal edge", "ANATOMY", 101, 112], ["scapula", "ANATOMY", 120, 127], ["caudal edge", "MULTI-TISSUE_STRUCTURE", 101, 112], ["scapula", "ORGAN", 120, 127], ["caudal", "ANATOMY_MODIFIER", 101, 107], ["edge", "ANATOMY_MODIFIER", 108, 112], ["scapula", "ANATOMY", 120, 127]]], ["Twenty-five microliters containing 7.5x105 p.f.u of virus was administered sc at the level of the cranial edge of the scapula.", [["cranial edge", "ANATOMY", 98, 110], ["scapula", "ANATOMY", 118, 125], ["cranial edge", "MULTI-TISSUE_STRUCTURE", 98, 110], ["scapula", "ORGAN", 118, 125], ["virus", "PROBLEM", 52, 57], ["virus", "OBSERVATION", 52, 57], ["cranial", "ANATOMY_MODIFIER", 98, 105], ["edge", "ANATOMY_MODIFIER", 106, 110], ["scapula", "ANATOMY", 118, 125]]], ["Recovery followed the same protocol as for the pilot study bats.", [["the pilot study", "TEST", 43, 58]]], ["Animals were identified as AJ-z1 through AJ-z6.", [["Animals", "ORGANISM", 0, 7], ["AJ-z1", "GENE_OR_GENE_PRODUCT", 27, 32], ["AJ", "GENE_OR_GENE_PRODUCT", 41, 43], ["AJ", "PROTEIN", 27, 29], ["AJ", "PROTEIN", 41, 43], ["z6", "DNA", 44, 46]]], ["AJ-z1 and AJ-z2 were euthanized at two dpi.", [["AJ-z2", "ANATOMY", 10, 15], ["AJ-z1", "CELL", 0, 5], ["AJ-z2", "CELL", 10, 15], ["AJ", "PROTEIN", 0, 2], ["z1", "PROTEIN", 3, 5], ["AJ", "PROTEIN", 10, 12], ["z2", "DNA", 13, 15]]], ["AJ-z3 and AJ-z4 were euthanized at 5 dpi.", [["AJ-z3", "CELL", 0, 5], ["AJ-z4", "CELL", 10, 15], ["AJ", "PROTEIN", 0, 2], ["AJ", "PROTEIN", 10, 12], ["z4", "PROTEIN", 13, 15], ["AJ-z4", "TREATMENT", 10, 15]]], ["AJ-z5 and AJ-z6 were euthanized at 10 dpi.Experimental inoculations ::: Materials and methodsFemale bats were excluded from the study because they are prioritized for breeding to sustain and expand upon the colony.Monitoring ::: Materials and methodsFor the pilot study, bats were visually monitored twice daily for fourteen days, and then monitored once a day for an additional fourteen days.", [["colony", "ANATOMY", 207, 213], ["AJ-z5", "CELL", 0, 5], ["AJ-z6", "CELL", 10, 15], ["bats", "ORGANISM", 100, 104], ["bats", "ORGANISM", 271, 275], ["AJ-z5 and AJ-z6", "CELL_LINE", 0, 15], ["AJ-z6", "TREATMENT", 10, 15], ["the study", "TEST", 124, 133], ["the pilot study", "TEST", 254, 269]]], ["For the time course study, bats were monitored twice a day throughout the experiment.", [["bats", "ORGANISM", 27, 31], ["the time course study", "TEST", 4, 25]]], ["For both studies, energy levels, behavior, ability to ambulate, respirations, presence of oral or nasal discharge, and fecal consistency were all assessed.Urine collection ::: Materials and methodsDuring the time course study urine was collected at 2, 3, 5 and 10 dpi from as many bats as possible.", [["oral", "ANATOMY", 90, 94], ["nasal", "ANATOMY", 98, 103], ["fecal", "ANATOMY", 119, 124], ["Urine", "ANATOMY", 155, 160], ["urine", "ANATOMY", 226, 231], ["respirations", "DISEASE", 64, 76], ["oral", "ORGANISM_SUBDIVISION", 90, 94], ["nasal", "ORGANISM_SUBDIVISION", 98, 103], ["fecal", "ORGANISM_SUBDIVISION", 119, 124], ["Urine", "ORGANISM_SUBSTANCE", 155, 160], ["urine", "ORGANISM_SUBSTANCE", 226, 231], ["both studies", "TEST", 4, 16], ["energy levels", "TEST", 18, 31], ["respirations", "TEST", 64, 76], ["oral or nasal discharge", "PROBLEM", 90, 113], ["Urine collection", "TEST", 155, 171], ["study urine", "TEST", 220, 231], ["nasal", "ANATOMY", 98, 103], ["fecal", "ANATOMY", 119, 124], ["collection", "OBSERVATION", 161, 171]]], ["Urine was collected by allowing bats to grasp screen cloth with their feet and then the bat was placed in a clear solo cup (Dart Container, Lake Forest, IL) with the screen covering the top of the cup as a lid, and kept in place with a rubber band.", [["Urine", "ANATOMY", 0, 5], ["cup", "ANATOMY", 197, 200], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["feet", "ORGANISM_SUBDIVISION", 70, 74], ["bat", "ORGANISM", 88, 91], ["cup", "ORGANISM_SUBDIVISION", 197, 200], ["Urine", "TEST", 0, 5], ["a clear solo cup (Dart Container", "TREATMENT", 106, 138], ["Lake Forest, IL)", "TREATMENT", 140, 156], ["the screen", "TEST", 162, 172], ["a rubber band", "TREATMENT", 234, 247], ["feet", "ANATOMY", 70, 74], ["bat", "ANATOMY", 88, 91], ["lid", "ANATOMY", 206, 209], ["rubber band", "OBSERVATION", 236, 247]]], ["Bats were monitored for 45 minutes.", [["Bats", "CELL", 0, 4]]], ["If they urinated, bats were removed from the collection contraption and placed back in the cage without disrupting the urine.", [["urine", "ANATOMY", 119, 124], ["bats", "ORGANISM", 18, 22], ["urine", "ORGANISM_SUBSTANCE", 119, 124], ["the collection contraption", "TREATMENT", 41, 67], ["cage", "ANATOMY", 91, 95]]], ["Urine collection was attempted on all remaining bats at each time point, but not all bats would urinate at each collection attempt.", [["Urine", "ANATOMY", 0, 5], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["Urine collection", "TEST", 0, 16], ["collection", "OBSERVATION", 6, 16]]], ["Urine was successfully collected as follows: two dpi from AJ-z3 and AJ-z4; three dpi from AJ-z3, AJ-z5 and AJ-z6; five dpi from AJ-z3, AJ-z4, AJ-z5 and AJ-z6; and ten dpi from AJ-z5 and AJ-z6.", [["Urine", "ANATOMY", 0, 5], ["AJ-z6", "CHEMICAL", 107, 112], ["AJ-z6", "CHEMICAL", 152, 157], ["AJ-z6", "CHEMICAL", 186, 191], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["AJ-z3", "CELL", 58, 63], ["AJ-z4", "CELL", 68, 73], ["AJ-z3", "CELL", 90, 95], ["AJ-z5", "CELL", 97, 102], ["AJ-z6", "CELL", 107, 112], ["AJ-z3", "CELL", 128, 133], ["AJ-z4", "CELL", 135, 140], ["AJ-z5", "CELL", 142, 147], ["AJ-z6", "CELL", 152, 157], ["AJ-z5", "CELL", 176, 181], ["AJ-z6", "CELL", 186, 191], ["AJ", "PROTEIN", 68, 70], ["AJ", "PROTEIN", 90, 92], ["AJ", "PROTEIN", 97, 99], ["z5", "PROTEIN", 100, 102], ["AJ", "PROTEIN", 107, 109], ["z6", "PROTEIN", 110, 112], ["AJ", "PROTEIN", 128, 130], ["z3", "PROTEIN", 131, 133], ["AJ", "PROTEIN", 135, 137], ["z4", "PROTEIN", 138, 140], ["AJ", "PROTEIN", 142, 144], ["z5", "PROTEIN", 145, 147], ["AJ", "PROTEIN", 152, 154], ["z6", "PROTEIN", 155, 157], ["AJ", "PROTEIN", 176, 178], ["z5", "PROTEIN", 179, 181], ["AJ", "PROTEIN", 186, 188], ["z6", "PROTEIN", 189, 191], ["Urine", "TEST", 0, 5], ["AJ", "TEST", 135, 137], ["AJ", "TEST", 142, 144], ["AJ", "TEST", 152, 154], ["z6", "TEST", 155, 157], ["ten dpi", "TEST", 163, 170], ["AJ", "TEST", 176, 178], ["AJ", "ANATOMY", 186, 188]]], ["Urine was pipetted off the surface of the cup with a sterile pipette tip and put in a 1.5 ml microcentrifuge tube and stored at -80\u00b0C for future use.", [["Urine", "ANATOMY", 0, 5], ["surface", "ANATOMY", 27, 34], ["cup", "ANATOMY", 42, 45], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["Urine", "TEST", 0, 5], ["a sterile pipette tip", "TREATMENT", 51, 72], ["a 1.5 ml microcentrifuge tube", "TREATMENT", 84, 113], ["surface", "OBSERVATION_MODIFIER", 27, 34]]], ["Urine volume ranged between 5 ul and 15 ul.Euthanasia, blood collection and necropsy ::: Materials and methodsBats were deeply anesthetized and maintained with 3% isoflurane and an oxygen flow rate of 1.5 L/min.", [["Urine", "ANATOMY", 0, 5], ["blood", "ANATOMY", 55, 60], ["isoflurane", "CHEMICAL", 163, 173], ["oxygen", "CHEMICAL", 181, 187], ["isoflurane", "CHEMICAL", 163, 173], ["oxygen", "CHEMICAL", 181, 187], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["isoflurane", "SIMPLE_CHEMICAL", 163, 173], ["oxygen", "SIMPLE_CHEMICAL", 181, 187], ["Urine volume", "TEST", 0, 12], ["Euthanasia", "PROBLEM", 43, 53], ["blood collection", "TEST", 55, 71], ["methodsBats", "TREATMENT", 103, 114], ["3% isoflurane", "TREATMENT", 160, 173], ["an oxygen flow rate", "TREATMENT", 178, 197], ["volume", "OBSERVATION_MODIFIER", 6, 12], ["blood collection", "OBSERVATION", 55, 71]]], ["Deep pain was assessed by firmly pinching skin and toes with forceps and assessed for any response.", [["skin", "ANATOMY", 42, 46], ["toes", "ANATOMY", 51, 55], ["pain", "DISEASE", 5, 9], ["skin", "ORGAN", 42, 46], ["toes", "ORGANISM_SUBDIVISION", 51, 55], ["Deep pain", "PROBLEM", 0, 9], ["forceps", "TREATMENT", 61, 68], ["pain", "OBSERVATION", 5, 9], ["skin", "ANATOMY", 42, 46], ["toes", "ANATOMY", 51, 55]]], ["A thoracotomy was then performed with sterile standard scissors to puncture through the skin, muscle and diaphragm just caudal to the sternum and cut through the wall of the chest cavity caudally to cranially\u2014removing and preventing negative pressure from building in the thorax.Euthanasia, blood collection and necropsy ::: Materials and methodsCardiac blood was collected with a 21 gauge sterile needle inserted into the apex of the heart.", [["skin", "ANATOMY", 88, 92], ["muscle", "ANATOMY", 94, 100], ["diaphragm", "ANATOMY", 105, 114], ["caudal", "ANATOMY", 120, 126], ["sternum", "ANATOMY", 134, 141], ["wall", "ANATOMY", 162, 166], ["chest cavity", "ANATOMY", 174, 186], ["thorax", "ANATOMY", 272, 278], ["blood", "ANATOMY", 291, 296], ["Cardiac blood", "ANATOMY", 346, 359], ["heart", "ANATOMY", 435, 440], ["skin", "ORGAN", 88, 92], ["muscle", "ORGAN", 94, 100], ["diaphragm", "ORGAN", 105, 114], ["sternum", "ORGAN", 134, 141], ["wall", "TISSUE", 162, 166], ["chest cavity", "ORGANISM_SUBDIVISION", 174, 186], ["thorax", "ORGAN", 272, 278], ["blood", "ORGANISM_SUBSTANCE", 291, 296], ["blood", "ORGANISM_SUBSTANCE", 354, 359], ["heart", "ORGAN", 435, 440], ["A thoracotomy", "TREATMENT", 0, 13], ["sterile standard scissors", "TREATMENT", 38, 63], ["Euthanasia", "PROBLEM", 279, 289], ["blood collection", "TEST", 291, 307], ["a 21 gauge sterile needle", "TREATMENT", 379, 404], ["thoracotomy", "OBSERVATION", 2, 13], ["skin", "ANATOMY", 88, 92], ["muscle", "ANATOMY", 94, 100], ["diaphragm", "ANATOMY", 105, 114], ["sternum", "ANATOMY", 134, 141], ["wall", "ANATOMY_MODIFIER", 162, 166], ["chest cavity", "ANATOMY", 174, 186], ["caudally", "ANATOMY_MODIFIER", 187, 195], ["negative pressure", "OBSERVATION", 233, 250], ["thorax", "ANATOMY", 272, 278], ["blood collection", "OBSERVATION", 291, 307], ["blood", "ANATOMY", 354, 359], ["apex", "ANATOMY_MODIFIER", 423, 427], ["heart", "ANATOMY", 435, 440]]], ["A maximum blood volume of between 1 and 1.5mls is collected in a syringe and transferred to a red top tube (RTT).", [["blood", "ANATOMY", 10, 15], ["RTT", "DISEASE", 108, 111], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["tube", "TISSUE", 102, 106], ["A maximum blood volume", "TEST", 0, 22], ["a syringe", "TREATMENT", 63, 72], ["a red top tube", "TREATMENT", 92, 106], ["maximum", "OBSERVATION_MODIFIER", 2, 9], ["volume", "OBSERVATION_MODIFIER", 16, 22], ["tube", "OBSERVATION", 102, 106]]], ["RTTs sat at room temperature for one hour to allow a clot to form and then centrifuged at 1000 x g for 10 min at room temperature.", [["clot", "ANATOMY", 53, 57], ["clot", "ORGANISM_SUBSTANCE", 53, 57], ["a clot", "PROBLEM", 51, 57], ["clot", "OBSERVATION", 53, 57]]], ["Serum was removed from the clot, placed in a new microcentrifuge tube and stored at -20\u00b0C.Euthanasia, blood collection and necropsy ::: Materials and methodsSerum from bats at 2 and 5 dpi were used to assess for viremia.", [["Serum", "ANATOMY", 0, 5], ["clot", "ANATOMY", 27, 31], ["blood", "ANATOMY", 102, 107], ["Serum", "ANATOMY", 157, 162], ["viremia", "DISEASE", 212, 219], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["clot", "ORGANISM_SUBSTANCE", 27, 31], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["Serum", "ORGANISM_SUBSTANCE", 157, 162], ["bats", "ORGANISM", 168, 172], ["Serum", "TEST", 0, 5], ["the clot", "PROBLEM", 23, 31], ["a new microcentrifuge tube", "TREATMENT", 43, 69], ["Euthanasia", "PROBLEM", 90, 100], ["blood collection", "TEST", 102, 118], ["methodsSerum", "TEST", 150, 162], ["viremia", "PROBLEM", 212, 219], ["clot", "OBSERVATION", 27, 31], ["new", "OBSERVATION_MODIFIER", 45, 48], ["microcentrifuge tube", "OBSERVATION", 49, 69], ["blood collection", "OBSERVATION", 102, 118]]], ["Serum from 10 dpi and the 28 dpi pilot study bats were used to determine antibody titers.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["bats", "ORGANISM", 45, 49], ["Serum", "TEST", 0, 5], ["the 28 dpi pilot study bats", "TEST", 22, 49], ["antibody titers", "TEST", 73, 88]]], ["Because blood draws yield a small volume of blood (50 \u03bcl whole blood for a non-terminal blood draw, 500 \u03bcl whole blood for terminal blood draw) it was necessary to prioritize samples to optimize data retrieved.", [["blood", "ANATOMY", 8, 13], ["blood", "ANATOMY", 44, 49], ["blood", "ANATOMY", 63, 68], ["blood", "ANATOMY", 88, 93], ["blood", "ANATOMY", 113, 118], ["blood", "ANATOMY", 132, 137], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["blood", "ORGANISM_SUBSTANCE", 132, 137], ["blood draws", "TEST", 8, 19], ["a non-terminal blood draw", "TEST", 73, 98], ["terminal blood draw", "TEST", 123, 142], ["small", "OBSERVATION_MODIFIER", 28, 33]]], ["In order to assay the serum for viral RNA and perform serology, earlier time points were used to assess for viremia and later time points for seroconversion.", [["serum", "ANATOMY", 22, 27], ["viremia", "DISEASE", 108, 115], ["serum", "ORGANISM_SUBSTANCE", 22, 27], ["viral RNA", "RNA", 32, 41], ["the serum", "TEST", 18, 27], ["viral RNA", "PROBLEM", 32, 41], ["serology", "TEST", 54, 62], ["viremia", "PROBLEM", 108, 115], ["seroconversion", "PROBLEM", 142, 156]]], ["Along with sample partitioning for data maximization, the small blood volume led to concerns that there would be an undetectably small viral load.", [["blood", "ANATOMY", 64, 69], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["data maximization", "TREATMENT", 35, 52], ["the small blood volume", "PROBLEM", 54, 76], ["an undetectably small viral load", "PROBLEM", 113, 145], ["small", "OBSERVATION_MODIFIER", 58, 63], ["small", "OBSERVATION_MODIFIER", 129, 134], ["viral load", "OBSERVATION", 135, 145]]], ["To circumvent this issue, neat serum and 1:10 diluted serum were inoculated onto Vero cells to amplify any virus that may have been present at low levels.", [["serum", "ANATOMY", 31, 36], ["serum", "ANATOMY", 54, 59], ["Vero cells", "ANATOMY", 81, 91], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["serum", "ORGANISM_SUBSTANCE", 54, 59], ["Vero cells", "CELL", 81, 91], ["Vero cells", "CELL_LINE", 81, 91], ["neat serum", "TEST", 26, 36], ["diluted serum", "TEST", 46, 59], ["Vero cells", "PROBLEM", 81, 91], ["any virus", "PROBLEM", 103, 112]]], ["One blind passage on Vero cells was done and cell supernatants assayed by qRT-PCR.", [["Vero cells", "ANATOMY", 21, 31], ["cell supernatants", "ANATOMY", 45, 62], ["Vero cells", "CELL", 21, 31], ["cell", "CELL", 45, 49], ["Vero cells", "CELL_LINE", 21, 31], ["One blind passage on Vero cells", "PROBLEM", 0, 31], ["cell supernatants", "TEST", 45, 62], ["qRT", "TEST", 74, 77], ["PCR", "TEST", 78, 81], ["blind", "OBSERVATION", 4, 9], ["passage", "OBSERVATION_MODIFIER", 10, 17], ["Vero cells", "OBSERVATION", 21, 31]]], ["The remaining serum from three of the four bats was assayed directly for ZIKV RNA.Euthanasia, blood collection and necropsy ::: Materials and methodsNecropsies were performed immediately after euthanasia.", [["serum", "ANATOMY", 14, 19], ["blood", "ANATOMY", 94, 99], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["bats", "ORGANISM", 43, 47], ["ZIKV", "GENE_OR_GENE_PRODUCT", 73, 77], ["blood", "ORGANISM_SUBSTANCE", 94, 99], ["ZIKV RNA", "RNA", 73, 81], ["ZIKV", "SPECIES", 73, 77], ["The remaining serum", "TEST", 0, 19], ["ZIKV RNA", "PROBLEM", 73, 81], ["Euthanasia", "PROBLEM", 82, 92], ["blood collection", "TEST", 94, 110], ["methodsNecropsies", "TEST", 142, 159], ["euthanasia", "PROBLEM", 193, 203], ["serum", "OBSERVATION_MODIFIER", 14, 19], ["blood collection", "OBSERVATION", 94, 110]]], ["Bats were assessed for gross pathology.", [["Bats", "CELL", 0, 4], ["gross pathology", "PROBLEM", 23, 38]]], ["The following tissues were collected for both experiments: heart, lung, liver, spleen, kidney, urinary bladder, prostate, testes, and brain.", [["tissues", "ANATOMY", 14, 21], ["heart", "ANATOMY", 59, 64], ["lung", "ANATOMY", 66, 70], ["liver", "ANATOMY", 72, 77], ["spleen", "ANATOMY", 79, 85], ["kidney", "ANATOMY", 87, 93], ["urinary bladder", "ANATOMY", 95, 110], ["prostate", "ANATOMY", 112, 120], ["testes", "ANATOMY", 122, 128], ["brain", "ANATOMY", 134, 139], ["tissues", "TISSUE", 14, 21], ["heart", "ORGAN", 59, 64], ["lung", "ORGAN", 66, 70], ["liver", "ORGAN", 72, 77], ["spleen", "ORGAN", 79, 85], ["kidney", "ORGAN", 87, 93], ["urinary bladder", "MULTI-TISSUE_STRUCTURE", 95, 110], ["prostate", "MULTI-TISSUE_STRUCTURE", 112, 120], ["testes", "ORGAN", 122, 128], ["brain", "ORGAN", 134, 139], ["heart", "ANATOMY", 59, 64], ["lung", "ANATOMY", 66, 70], ["liver", "ANATOMY", 72, 77], ["spleen", "ANATOMY", 79, 85], ["kidney", "ANATOMY", 87, 93], ["urinary bladder", "ANATOMY", 95, 110], ["prostate", "ANATOMY", 112, 120], ["testes", "ANATOMY", 122, 128], ["brain", "ANATOMY", 134, 139]]], ["A portion of tissues were collected and kept at -80\u00b0C for RNA extraction, and a portion placed in 10% buffered formalin for histology at a 1:10 weight to volume ratio for histology.Euthanasia, blood collection and necropsy ::: Materials and methodsFor a negative control animal a male bat was trapped from the colony and euthanized under the same protocol as the experimental infection bats.Serology ::: Materials and methodsVero E6 cells (ATCC) were propagated to 60% confluency in a 96-well tissue culture plate and infected with ZIKV strain PRVABC at an m.o.i. of 0.1.", [["tissues", "ANATOMY", 13, 20], ["blood", "ANATOMY", 193, 198], ["colony", "ANATOMY", 310, 316], ["Vero E6 cells", "ANATOMY", 425, 438], ["ATCC", "ANATOMY", 440, 444], ["tissue", "ANATOMY", 493, 499], ["infection", "DISEASE", 376, 385], ["formalin", "CHEMICAL", 111, 119], ["tissues", "TISSUE", 13, 20], ["formalin", "SIMPLE_CHEMICAL", 111, 119], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["bat", "ORGANISM", 285, 288], ["Vero E6 cells", "CELL", 425, 438], ["ATCC", "CELL", 440, 444], ["tissue", "TISSUE", 493, 499], ["Vero E6 cells", "CELL_LINE", 425, 438], ["ATCC", "CELL_LINE", 440, 444], ["Vero E6", "SPECIES", 425, 432], ["ZIKV", "SPECIES", 532, 536], ["RNA extraction", "TREATMENT", 58, 72], ["histology", "TEST", 124, 133], ["volume ratio", "TEST", 154, 166], ["histology", "TEST", 171, 180], ["Euthanasia", "PROBLEM", 181, 191], ["blood collection", "TEST", 193, 209], ["the experimental infection bats", "PROBLEM", 359, 390], ["Serology", "TEST", 391, 399], ["Materials", "TREATMENT", 404, 413], ["methodsVero E6 cells (ATCC)", "TREATMENT", 418, 445], ["ZIKV strain PRVABC", "TREATMENT", 532, 550], ["tissues", "ANATOMY", 13, 20], ["blood collection", "OBSERVATION", 193, 209], ["infection", "OBSERVATION", 376, 385]]], ["After a one hour incubation period, unbound virus was removed and replaced with 2% FBS-DMEM and incubated for a maximum of three days.", [["FBS", "CHEMICAL", 83, 86], ["FBS", "ORGANISM_SUBSTANCE", 83, 86], ["unbound virus", "PROBLEM", 36, 49], ["2% FBS", "TREATMENT", 80, 86], ["virus", "OBSERVATION", 44, 49]]], ["Media was then replaced with 85% acetone for 20 minutes at -20\u00b0C to fix virus-infected cells to plate and serve as an antigen for enzyme-linked-immunosorbent assay (ELISA).", [["cells", "ANATOMY", 87, 92], ["acetone", "CHEMICAL", 33, 40], ["acetone", "CHEMICAL", 33, 40], ["acetone", "SIMPLE_CHEMICAL", 33, 40], ["cells", "CELL", 87, 92], ["85% acetone", "TREATMENT", 29, 40], ["infected cells", "PROBLEM", 78, 92], ["an antigen", "TEST", 115, 125], ["enzyme", "TEST", 130, 136], ["immunosorbent assay", "TEST", 144, 163], ["infected cells", "OBSERVATION", 78, 92]]], ["Plates were stored at 4\u00b0C until use and used within two weeks.", [["Plates", "TEST", 0, 6]]], ["Plates were washed 5x with 0.05% Tween 20-PBS and blocked with SuperBlock T20 (TBS) Blocking Buffer (Thermo Fisher Scientific, Waltham, MA) for one hour at room temperature.", [["SuperBlock T20", "CHEMICAL", 63, 77], ["Tween 20", "CHEMICAL", 33, 41], ["SuperBlock T20", "SIMPLE_CHEMICAL", 63, 77], ["Plates", "TEST", 0, 6], ["PBS", "TREATMENT", 42, 45], ["SuperBlock T20 (TBS", "TREATMENT", 63, 82]]], ["Serum from an uninfected bat was used for a negative control.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["bat", "ORGANISM", 25, 28], ["Serum", "TEST", 0, 5], ["an uninfected bat", "TEST", 11, 28], ["uninfected bat", "OBSERVATION", 14, 28]]], ["A convalescent human serum sample (kindly provided by B. Foy, CSU) was used as a positive control.", [["serum sample", "ANATOMY", 21, 33], ["human", "ORGANISM", 15, 20], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["A convalescent human serum sample", "TEST", 0, 33], ["a positive control", "TREATMENT", 79, 97]]], ["A two-fold serial dilution was used starting at 1:100 to 1:12800.", [["A two-fold serial dilution", "TREATMENT", 0, 26]]], ["Diluted serum was placed in wells and incubated for two hours at room temperature.", [["serum", "ANATOMY", 8, 13], ["serum", "ORGANISM_SUBSTANCE", 8, 13], ["Diluted serum", "TEST", 0, 13]]], ["Serum was removed and plates washed.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum", "TEST", 0, 5], ["plates", "OBSERVATION_MODIFIER", 22, 28], ["washed", "OBSERVATION_MODIFIER", 29, 35]]], ["HRP-conjugated protein A/G (Thermo Fisher Scientific, Waltham, MA) was added at a concentration of 2 \u03bcg/ml to each well, and incubated for 30 minutes at room temperature.", [["HRP", "SIMPLE_CHEMICAL", 0, 3], ["HRP", "PROTEIN", 0, 3], ["HRP", "TEST", 0, 3]]], ["HRP-conjugated protein A/G was used in place of a secondary antibody as it targets the Fc portion of an antibody, which is highly conserved and therefore can be used for multiple animal species [54].", [["HRP", "SIMPLE_CHEMICAL", 0, 3], ["HRP-conjugated protein A/G", "PROTEIN", 0, 26], ["secondary antibody", "PROTEIN", 50, 68], ["Fc portion", "PROTEIN", 87, 97], ["HRP", "TEST", 0, 3], ["conjugated protein A/G", "TREATMENT", 4, 26], ["a secondary antibody", "PROBLEM", 48, 68], ["an antibody", "TEST", 101, 112], ["multiple animal species", "PROBLEM", 170, 193], ["antibody", "OBSERVATION", 104, 112]]], ["Plates were washed and 150 \u03bcl of ABTS Peroxidase Substrate (2 component) (KPL, Gaithersburg, MD) added according to manufacturers\u2019 instructions, incubated at room temperature for 30 minutes, and then 150 \u03bcl of ABTS Peroxidase Stop solution (KPL, Gaithersburg, MD) added.", [["ABTS", "CHEMICAL", 33, 37], ["ABTS", "CHEMICAL", 210, 214], ["ABTS", "CHEMICAL", 33, 37], ["ABTS", "CHEMICAL", 210, 214], ["ABTS Peroxidase Substrate", "SIMPLE_CHEMICAL", 33, 58], ["ABTS Peroxidase", "SIMPLE_CHEMICAL", 210, 225], ["Plates", "TEST", 0, 6], ["ABTS Peroxidase Substrate", "TREATMENT", 33, 58], ["ABTS Peroxidase Stop solution", "TREATMENT", 210, 239]]], ["Plates were read on an EMax Plus Microplate Reader (Cambridge Scientific, Watertown, MA).", [["an EMax", "TREATMENT", 20, 27]]], ["Absorbance was measured at 405 nm and the limit of detectable response was set at three standard deviation values above mean negative control serum.RNA extraction ::: Materials and methodsTRIzol Reagent was used for RNA extraction from serum-cell supernatants, serum, urine and tissues according to Ambion, Life Technologies protocol.", [["serum", "ANATOMY", 142, 147], ["serum-cell supernatants", "ANATOMY", 236, 259], ["serum", "ANATOMY", 261, 266], ["urine", "ANATOMY", 268, 273], ["tissues", "ANATOMY", 278, 285], ["serum", "ORGANISM_SUBSTANCE", 142, 147], ["TRIzol", "ORGANISM", 188, 194], ["serum", "ORGANISM_SUBSTANCE", 236, 241], ["-cell", "CELL", 241, 246], ["serum", "ORGANISM_SUBSTANCE", 261, 266], ["urine", "ORGANISM_SUBSTANCE", 268, 273], ["tissues", "TISSUE", 278, 285], ["Absorbance", "TEST", 0, 10], ["methodsTRIzol Reagent", "TREATMENT", 181, 202], ["RNA extraction", "TREATMENT", 216, 230], ["serum-cell supernatants", "TEST", 236, 259], ["serum, urine and tissues", "TEST", 261, 285], ["Life Technologies protocol", "TREATMENT", 307, 333], ["tissues", "ANATOMY", 278, 285]]], ["For tissues, approximately 50 mg of tissue was homogenized with one mL of TRIzol Reagent.", [["tissues", "ANATOMY", 4, 11], ["tissue", "ANATOMY", 36, 42], ["tissues", "TISSUE", 4, 11], ["tissue", "TISSUE", 36, 42], ["TRIzol Reagent", "TREATMENT", 74, 88]]], ["A 5mm stainless steel bead (Qiagen, Valencia, CA) was used with a TissueLyser LT (Qiagen, Valencia, CA) at 50 Hz for 5 minutes.", [["A 5mm stainless steel bead", "TREATMENT", 0, 26], ["a TissueLyser LT", "TREATMENT", 64, 80], ["5mm", "OBSERVATION_MODIFIER", 2, 5], ["stainless", "OBSERVATION_MODIFIER", 6, 15], ["steel", "OBSERVATION_MODIFIER", 16, 21], ["bead", "OBSERVATION_MODIFIER", 22, 26]]], ["One ml of TRIzol was added to urine to 5 to 15 \u03bcl of urine.", [["urine", "ANATOMY", 30, 35], ["urine", "ANATOMY", 53, 58], ["TRIzol", "ORGANISM", 10, 16], ["urine", "ORGANISM_SUBSTANCE", 30, 35], ["urine", "ORGANISM_SUBSTANCE", 53, 58], ["TRIzol", "TREATMENT", 10, 16]]], ["One ml of TRIzol was added to 160 \u03bcl of serum from AJ-z2, AJ-z3, and AJ-z4.", [["serum", "ANATOMY", 40, 45], ["AJ-z4", "CHEMICAL", 69, 74], ["TRIzol", "ORGANISM", 10, 16], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["AJ-z2", "CELL", 51, 56], ["AJ-z3", "CELL", 58, 63], ["AJ-z4", "SIMPLE_CHEMICAL", 69, 74], ["TRIzol", "TREATMENT", 10, 16], ["AJ", "ANATOMY", 69, 71]]], ["Two-hundred microliters of serum-cell supernatants were added to one ml of TRIzol.", [["serum-cell supernatants", "ANATOMY", 27, 50], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["-cell", "CELL", 32, 37], ["TRIzol", "ORGANISM", 75, 81], ["serum-cell supernatants", "TREATMENT", 27, 50], ["TRIzol", "TREATMENT", 75, 81]]], ["Samples were then incubated at room temperature for 5 minutes.", [["Samples", "ANATOMY", 0, 7]]], ["Chloroform (Thermo Fisher Scientific, Waltham, MA) was added, samples were mixed, incubated for 3 minutes at room temperature and centrifuged at 12,000 x g for 15 minutes at 4\u00b0C. The aqueous phase was removed, 4 \u03bcg of glycogen (Thermo Fisher Scientific, Waltham, MA) and 100% molecular grade isopropanol added (Thermo Fisher Scientific, Waltham, MA).", [["samples", "ANATOMY", 62, 69], ["Chloroform", "CHEMICAL", 0, 10], ["glycogen", "CHEMICAL", 218, 226], ["Chloroform", "CHEMICAL", 0, 10], ["isopropanol", "CHEMICAL", 292, 303], ["Chloroform", "SIMPLE_CHEMICAL", 0, 10], ["glycogen", "SIMPLE_CHEMICAL", 218, 226], ["Chloroform", "TREATMENT", 0, 10], ["Waltham, MA)", "TREATMENT", 38, 50], ["aqueous phase", "OBSERVATION_MODIFIER", 183, 196]]], ["Samples were incubated at room temperature for 10 minutes and then centrifuged at 12,000 x g for 10 minutes at 4\u00b0C. Supernatant was removed and 75% molecular grade ethanol (Thermo Fisher Scientific, Waltham, MA) was added to RNA pellet.", [["Samples", "ANATOMY", 0, 7], ["Supernatant", "ANATOMY", 116, 127], ["ethanol", "CHEMICAL", 164, 171], ["ethanol", "CHEMICAL", 164, 171], ["Supernatant", "ORGANISM_SUBSTANCE", 116, 127], ["ethanol", "SIMPLE_CHEMICAL", 164, 171]]], ["Samples were vortexed and centrifuged at 7500 x g for 5 minutes at 4\u00b0C. Wash was removed and air-dried.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["RNA was resuspended in RNase-free water and stored at -80\u00b0C for future use.Viral RNA detection in serum samples ::: Materials and methodsVero cells were grown to 70 to 80% confluency in a 48-well tissue culture plate with 10% FBS-DMEM.", [["serum samples", "ANATOMY", 98, 111], ["Vero cells", "ANATOMY", 137, 147], ["RNase", "GENE_OR_GENE_PRODUCT", 23, 28], ["Viral", "ORGANISM", 75, 80], ["serum samples", "ORGANISM_SUBSTANCE", 98, 111], ["Vero cells", "CELL", 137, 147], ["tissue", "TISSUE", 196, 202], ["FBS", "ORGANISM_SUBSTANCE", 226, 229], ["RNA", "RNA", 0, 3], ["RNase", "PROTEIN", 23, 28], ["Viral RNA", "RNA", 75, 84], ["Vero cells", "CELL_LINE", 137, 147], ["Viral RNA detection in serum samples", "TEST", 75, 111], ["methodsVero cells", "TEST", 130, 147]]], ["Media was removed and 100 ul of bat serum from 2 dpi bats and 5 dpi bats was inoculated onto cells.", [["serum", "ANATOMY", 36, 41], ["cells", "ANATOMY", 93, 98], ["bat", "ORGANISM", 32, 35], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["cells", "CELL", 93, 98], ["bat serum", "TEST", 32, 41]]], ["Additionally, serum from each bat was diluted 10-fold in 2% FBS (Millipore Sigma) PBS supplemented with 1% calcium and magnesium, and inoculated onto cells.", [["serum", "ANATOMY", 14, 19], ["FBS", "ANATOMY", 60, 63], ["cells", "ANATOMY", 150, 155], ["calcium", "CHEMICAL", 107, 114], ["magnesium", "CHEMICAL", 119, 128], ["calcium", "CHEMICAL", 107, 114], ["magnesium", "CHEMICAL", 119, 128], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["bat", "ORGANISM", 30, 33], ["FBS", "ORGANISM_SUBSTANCE", 60, 63], ["calcium", "SIMPLE_CHEMICAL", 107, 114], ["magnesium", "SIMPLE_CHEMICAL", 119, 128], ["cells", "CELL", 150, 155], ["serum from each bat", "TEST", 14, 33], ["PBS", "TEST", 82, 85], ["1% calcium", "TREATMENT", 104, 114], ["magnesium", "TREATMENT", 119, 128]]], ["Samples were incubated for one hour at 37\u00b0C. Inoculum was removed and cells washed twice in sterile PBS.", [["Samples", "ANATOMY", 0, 7], ["cells", "ANATOMY", 70, 75], ["cells", "CELL", 70, 75], ["Samples", "TEST", 0, 7], ["Inoculum", "TREATMENT", 45, 53], ["cells", "TREATMENT", 70, 75]]], ["Two-percent FBS-DMEM was added to wells and plates were incubated at 37\u00b0C, 5% CO2.", [["FBS", "CHEMICAL", 12, 15], ["CO2", "CHEMICAL", 78, 81], ["CO2", "CHEMICAL", 78, 81], ["FBS", "ORGANISM_SUBSTANCE", 12, 15], ["CO2", "SIMPLE_CHEMICAL", 78, 81], ["plates", "TEST", 44, 50]]], ["Cells were assessed daily for cytopathology (CPE) through day 7 but none was observed.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["cytopathology (CPE", "TEST", 30, 48]]], ["Two-hundred microliters of the supernatant was removed on day 7 and used for RNA extractions.", [["supernatant", "ANATOMY", 31, 42], ["the supernatant", "TREATMENT", 27, 42], ["RNA extractions", "TREATMENT", 77, 92]]], ["An additional 100 \u03bcl of supernatant was blind passaged onto Vero cells at 70 to 80% confluency.", [["supernatant", "ANATOMY", 24, 35], ["Vero cells", "ANATOMY", 60, 70], ["Vero cells", "CELL", 60, 70], ["Vero cells", "CELL_LINE", 60, 70], ["supernatant", "TREATMENT", 24, 35], ["Vero cells", "TREATMENT", 60, 70]]], ["Cells were incubated for one hour at 37\u00b0C, washed twice with sterile PBS and 2% FBS-DMEM added.", [["Cells", "ANATOMY", 0, 5], ["FBS", "CHEMICAL", 80, 83], ["Cells", "CELL", 0, 5], ["FBS", "ORGANISM_SUBSTANCE", 80, 83], ["sterile PBS", "TREATMENT", 61, 72], ["2% FBS", "TREATMENT", 77, 83]]], ["On day seven, supernatant was removed and TRIzol extractions performed for RNA recovery.", [["supernatant", "ANATOMY", 14, 25], ["TRIzol extractions", "TREATMENT", 42, 60]]], ["Serum was treated as such in an attempt to amplify viral load and increase assay sensitivity serum may not be the most sensitive diagnostic sample [23\u201326].Viral RNA detection in serum samples ::: Materials and methodsIf any serum was remaining it was directly used for TRIzol RNA extractions.", [["Serum", "ANATOMY", 0, 5], ["serum", "ANATOMY", 93, 98], ["serum samples", "ANATOMY", 178, 191], ["serum", "ANATOMY", 224, 229], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 93, 98], ["Viral", "ORGANISM", 155, 160], ["serum samples", "ORGANISM_SUBSTANCE", 178, 191], ["serum", "ORGANISM_SUBSTANCE", 224, 229], ["Viral RNA", "RNA", 155, 164], ["Serum", "TEST", 0, 5], ["viral load", "TEST", 51, 61], ["increase assay sensitivity serum", "TEST", 66, 98], ["Viral RNA detection in serum samples", "TEST", 155, 191], ["any serum", "PROBLEM", 220, 229], ["TRIzol RNA extractions", "TREATMENT", 269, 291]]], ["Serum samples remained from AJ-z2 at 2 dpi, and AJ-z3 and AJ-z4 at 5 dpi.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["AJ-z2", "CELL", 28, 33], ["AJ-z3", "CELL", 48, 53], ["AJ-z4", "CELL", 58, 63], ["AJ", "PROTEIN", 48, 50], ["AJ", "PROTEIN", 58, 60], ["Serum samples", "TEST", 0, 13], ["AJ-z3", "TREATMENT", 48, 53]]], ["No serum remained from AJ-z1.Reverse transcription probe based real time PCR ::: Materials and methodsRoche Real Time Ready RNA Virus Master Kit (Roche, Indianapolis, IN) was used on RNA extracted from serum-cell supernatants, serum, urine and tissue to assay for ZIKV RNA according to manufacturers\u2019 instructions.", [["serum", "ANATOMY", 3, 8], ["serum-cell supernatants", "ANATOMY", 202, 225], ["serum", "ANATOMY", 227, 232], ["urine", "ANATOMY", 234, 239], ["tissue", "ANATOMY", 244, 250], ["serum", "ORGANISM_SUBSTANCE", 3, 8], ["serum", "ORGANISM_SUBSTANCE", 202, 207], ["-cell", "CELL", 207, 212], ["serum", "ORGANISM_SUBSTANCE", 227, 232], ["urine", "ORGANISM_SUBSTANCE", 234, 239], ["tissue", "TISSUE", 244, 250], ["AJ", "PROTEIN", 23, 25], ["ZIKV RNA", "RNA", 264, 272], ["ZIKV", "SPECIES", 264, 268], ["RNA", "TEST", 183, 186], ["serum-cell supernatants", "TEST", 202, 225], ["serum, urine", "TEST", 227, 239], ["ZIKV RNA", "PROBLEM", 264, 272], ["serum", "OBSERVATION_MODIFIER", 3, 8]]], ["Primers used were ZIKV 1086 (CCGCTGCCCAACACAAG) and ZIKV 1162c (CCACTAACGTTCTTTTGCAGACAT).", [["ZIKV 1086", "DNA", 18, 27], ["ZIKV 1162c", "DNA", 52, 62], ["ZIKV 1162c (CCACTAACGTTCTTTTGCAGACAT)", "TREATMENT", 52, 89]]], ["Probe was ZIKV 1107-FAM (AGCCTACCTTGACAAGCAGTCAGACACTCAA) [55].", [["ZIKV 1107-FAM", "CHEMICAL", 10, 23], ["ZIKV 1107-FAM", "CHEMICAL", 10, 23]]], ["Two-hundred nanograms of sample RNA was added to each reaction.", [["sample RNA", "TREATMENT", 25, 35]]], ["Standards were a non-infectious clone of full length ZIKV strain PRVABC59 by which concentration was determined through optical density.", [["full length ZIKV strain PRVABC59", "TREATMENT", 41, 73], ["optical density", "OBSERVATION", 120, 135]]], ["Molecular weight of the genome sequence was used to calculate copy number [56].", [["genome sequence", "DNA", 24, 39]]], ["A log10 dilution series of the standard was made and linear regression used to determine copy number equivalents of positive samples.", [["samples", "ANATOMY", 125, 132], ["A log10 dilution series", "TREATMENT", 0, 23], ["linear regression", "PROBLEM", 53, 70], ["positive samples", "PROBLEM", 116, 132], ["positive samples", "OBSERVATION", 116, 132]]], ["Amplification was performed according to manufacturers\u2019 protocol for Roche Real Time Ready RNA Virus Master Kit (Roche Diagnostics Corporation, Indianapolis, IN) with PCR conditions as follows: 8 min at 50\u00b0C, 30 s at 95\u00b0C, and 45 cycles of 10 s at 95\u00b0C, 20 s at 60\u00b0C and 10 s at 72\u00b0C.Histology ::: Materials and methodsTissues fixed in 10%-buffered formalin were cut in and submitted to Colorado State University Veterinary Diagnostic Laboratory (CSU VDL, Fort Collins, CO) for paraffin embedding, sectioning and staining with hematoxylin and eosin, as well as immunohistochemistry (IHC).", [["Tissues", "ANATOMY", 319, 326], ["formalin", "CHEMICAL", 349, 357], ["hematoxylin", "CHEMICAL", 527, 538], ["eosin", "CHEMICAL", 543, 548], ["formalin", "SIMPLE_CHEMICAL", 349, 357], ["hematoxylin", "SIMPLE_CHEMICAL", 527, 538], ["PCR conditions", "TEST", 167, 181], ["Histology", "TEST", 284, 293], ["paraffin embedding", "TREATMENT", 478, 496], ["hematoxylin", "TREATMENT", 527, 538], ["eosin", "TREATMENT", 543, 548]]], ["Tissues cut in on bats to assess for histology included: heart, lung, liver, kidney, testes, prostate, urinary bladder and brain.", [["Tissues", "ANATOMY", 0, 7], ["heart", "ANATOMY", 57, 62], ["lung", "ANATOMY", 64, 68], ["liver", "ANATOMY", 70, 75], ["kidney", "ANATOMY", 77, 83], ["testes", "ANATOMY", 85, 91], ["prostate", "ANATOMY", 93, 101], ["urinary bladder", "ANATOMY", 103, 118], ["brain", "ANATOMY", 123, 128], ["Tissues", "TISSUE", 0, 7], ["heart", "ORGAN", 57, 62], ["lung", "ORGAN", 64, 68], ["liver", "ORGAN", 70, 75], ["kidney", "ORGAN", 77, 83], ["testes", "ORGAN", 85, 91], ["prostate", "MULTI-TISSUE_STRUCTURE", 93, 101], ["urinary bladder", "MULTI-TISSUE_STRUCTURE", 103, 118], ["brain", "ORGAN", 123, 128], ["histology", "TEST", 37, 46], ["heart, lung, liver, kidney, testes, prostate, urinary bladder and brain", "PROBLEM", 57, 128], ["heart", "ANATOMY", 57, 62], ["lung", "ANATOMY", 64, 68], ["liver", "ANATOMY", 70, 75], ["kidney", "ANATOMY", 77, 83], ["testes", "ANATOMY", 85, 91], ["prostate", "ANATOMY", 93, 101], ["urinary bladder", "ANATOMY", 103, 118], ["brain", "ANATOMY", 123, 128]]], ["Additionally, for AJ-z3 and AJ-z5 mandibular salivary gland was cut in.", [["AJ-z3", "ANATOMY", 18, 23], ["AJ-z5 mandibular salivary gland", "ANATOMY", 28, 59], ["AJ-z3", "CELL", 18, 23], ["AJ", "CELL", 28, 30], ["salivary gland", "ORGAN", 45, 59], ["AJ-z3", "TREATMENT", 18, 23], ["mandibular", "ANATOMY_MODIFIER", 34, 44], ["salivary gland", "ANATOMY", 45, 59]]], ["AJ-z4 had esophagus and lymphoid tissue that included palatine salivary gland cut in.", [["AJ-z4", "ANATOMY", 0, 5], ["esophagus", "ANATOMY", 10, 19], ["lymphoid tissue", "ANATOMY", 24, 39], ["palatine salivary gland", "ANATOMY", 54, 77], ["esophagus", "ORGAN", 10, 19], ["lymphoid tissue", "TISSUE", 24, 39], ["palatine salivary gland", "ORGAN", 54, 77], ["AJ", "PROTEIN", 0, 2], ["esophagus and lymphoid tissue", "PROBLEM", 10, 39], ["esophagus", "ANATOMY", 10, 19], ["lymphoid tissue", "OBSERVATION", 24, 39], ["palatine", "ANATOMY_MODIFIER", 54, 62], ["salivary gland", "ANATOMY", 63, 77]]], ["Antibody for IHC was a polyclonal rabbit antibody that targets preM and E proteins of ZIKV and was provided by CSU VDL\u2019s pathology department.", [["rabbit", "ORGANISM", 34, 40], ["preM", "GENE_OR_GENE_PRODUCT", 63, 67], ["ZIKV", "CANCER", 86, 90], ["polyclonal rabbit antibody", "PROTEIN", 23, 49], ["preM", "PROTEIN", 63, 67], ["E proteins", "PROTEIN", 72, 82], ["rabbit", "SPECIES", 34, 40], ["rabbit", "SPECIES", 34, 40], ["ZIKV", "SPECIES", 86, 90], ["Antibody", "TEST", 0, 8], ["IHC", "TEST", 13, 16], ["a polyclonal rabbit antibody", "TEST", 21, 49], ["ZIKV", "PROBLEM", 86, 90]]], ["The Bond-III automated instrument (Leica Biosystems, Wetzlar, Germany) was used for IHC staining.", [["Leica Biosystems", "TREATMENT", 35, 51], ["IHC staining", "PROBLEM", 84, 96]]], ["All slides were blindly read by a diplomat of the American College of Veterinary Pathologists.Tissue preparation for immunohistochemistry and immunofluorescence ::: Materials and methodsBrain tissues was prepared for immunohistochemical and immunofluorescence staining as previously reported [57].", [["Tissue", "ANATOMY", 94, 100], ["Brain tissues", "ANATOMY", 186, 199], ["Tissue", "TISSUE", 94, 100], ["Brain tissues", "TISSUE", 186, 199], ["immunohistochemical and immunofluorescence staining", "TEST", 217, 268], ["Brain tissues", "ANATOMY", 186, 199]]], ["Tissue was dehydrated by using a graded ethanol series of 70% ethanol for 2 h, 80% overnight, 90% for 2 h and 100% for 2 h.", [["Tissue", "ANATOMY", 0, 6], ["ethanol", "CHEMICAL", 40, 47], ["ethanol", "CHEMICAL", 62, 69], ["ethanol", "CHEMICAL", 40, 47], ["ethanol", "CHEMICAL", 62, 69], ["Tissue", "TISSUE", 0, 6], ["ethanol", "SIMPLE_CHEMICAL", 40, 47], ["ethanol", "SIMPLE_CHEMICAL", 62, 69], ["a graded ethanol series", "TREATMENT", 31, 54], ["dehydrated", "OBSERVATION", 11, 21]]], ["Brain tissues were then post-fixed in dimethylbenzene for 30 min and embedded in dimethylbenzene-paraffin at 60\u00b0C for 2 h, after which samples were embedded in a metal frame.", [["Brain tissues", "ANATOMY", 0, 13], ["samples", "ANATOMY", 135, 142], ["dimethylbenzene", "CHEMICAL", 38, 53], ["dimethylbenzene", "CHEMICAL", 81, 96], ["dimethylbenzene", "CHEMICAL", 38, 53], ["dimethylbenzene", "CHEMICAL", 81, 96], ["paraffin", "CHEMICAL", 97, 105], ["Brain tissues", "TISSUE", 0, 13], ["dimethylbenzene", "SIMPLE_CHEMICAL", 38, 53], ["dimethylbenzene-paraffin", "SIMPLE_CHEMICAL", 81, 105], ["dimethylbenzene", "TREATMENT", 38, 53], ["dimethylbenzene-paraffin", "TREATMENT", 81, 105], ["a metal frame", "TREATMENT", 160, 173], ["tissues", "ANATOMY", 6, 13]]], ["Sagittal sections were collected at 5um thick.", [["sections", "ANATOMY", 9, 17], ["Sagittal sections", "MULTI-TISSUE_STRUCTURE", 0, 17], ["Sagittal sections", "TEST", 0, 17]]], ["All dewaxing, antigen retrieval and immunofluorescence staining was automated using a Leica Bond RXM.", [["antigen retrieval", "TREATMENT", 14, 31], ["immunofluorescence staining", "TEST", 36, 63], ["a Leica Bond RXM", "TREATMENT", 84, 100]]], ["In short, sections were dewaxed using ethanol and then boiled in antigen retrieval solution for 10 minutes.", [["sections", "ANATOMY", 10, 18], ["ethanol", "CHEMICAL", 38, 45], ["ethanol", "CHEMICAL", 38, 45], ["ethanol", "SIMPLE_CHEMICAL", 38, 45], ["ethanol", "TREATMENT", 38, 45], ["antigen retrieval solution", "TREATMENT", 65, 91]]], ["The cooled sections were incubated in 3% H2O2 for 15 min at room temperature and then blocked with 2% donkey and goat serum (Millipore Sigma) for 1 hour.", [["sections", "ANATOMY", 11, 19], ["serum", "ANATOMY", 118, 123], ["H2O2", "CHEMICAL", 41, 45], ["H2O2", "CHEMICAL", 41, 45], ["H2O2", "SIMPLE_CHEMICAL", 41, 45], ["donkey", "ORGANISM", 102, 108], ["goat", "ORGANISM", 113, 117], ["serum", "ORGANISM_SUBSTANCE", 118, 123], ["donkey", "SPECIES", 102, 108], ["goat", "SPECIES", 113, 117], ["goat", "SPECIES", 113, 117], ["The cooled sections", "TREATMENT", 0, 19], ["3% H2O2", "TREATMENT", 38, 45], ["2% donkey", "TREATMENT", 99, 108]]], ["Rabbit anti-Iba1 (Wako Chemicals USA, Irvine, CA) and 4G-2 Flavivirus E specific monoclonal antibodies (CDC, Fort Collins) were diluted in TBS to final concentrations of 1:250 and 1:50, respectively.", [["Rabbit", "ORGANISM", 0, 6], ["anti-Iba1", "GENE_OR_GENE_PRODUCT", 7, 16], ["Wako Chemicals USA", "ORGANISM", 18, 36], ["CA", "GENE_OR_GENE_PRODUCT", 46, 48], ["anti-Iba1", "PROTEIN", 7, 16], ["Flavivirus E specific monoclonal antibodies", "PROTEIN", 59, 102], ["Rabbit", "SPECIES", 0, 6], ["Rabbit", "SPECIES", 0, 6], ["Rabbit anti-Iba1", "TEST", 0, 16], ["CA", "TEST", 46, 48], ["4G", "TEST", 54, 56], ["Flavivirus E specific monoclonal antibodies", "TEST", 59, 102]]], ["Sections were incubated in primary antibodies concurrently at room temperature for one hour.", [["primary antibodies", "PROTEIN", 27, 45]]], ["Following removal of unbound primary antibodies by washing, goat anti-rabbit secondary (AlexaFluor-555) and donkey anti-mouse secondary (AlexaFluor-647) was added and incubated for 1 hour at room temperature.", [["AlexaFluor-555", "CHEMICAL", 88, 102], ["AlexaFluor-647", "CHEMICAL", 137, 151], ["goat", "ORGANISM", 60, 64], ["AlexaFluor-555", "SIMPLE_CHEMICAL", 88, 102], ["donkey", "ORGANISM", 108, 114], ["AlexaFluor-647", "SIMPLE_CHEMICAL", 137, 151], ["unbound primary antibodies", "PROTEIN", 21, 47], ["goat anti-rabbit", "PROTEIN", 60, 76], ["AlexaFluor-555", "PROTEIN", 88, 102], ["goat", "SPECIES", 60, 64], ["anti-rabbit", "SPECIES", 65, 76], ["donkey", "SPECIES", 108, 114], ["anti-mouse", "SPECIES", 115, 125], ["goat", "SPECIES", 60, 64], ["donkey", "SPECIES", 108, 114], ["removal", "TREATMENT", 10, 17], ["unbound primary antibodies", "TREATMENT", 21, 47], ["goat anti-rabbit", "TREATMENT", 60, 76], ["AlexaFluor", "TREATMENT", 88, 98], ["donkey anti-mouse secondary (AlexaFluor", "TREATMENT", 108, 147]]], ["Finally, DAPI counterstain (Vector Laboratories, Burlingame, CA) was applied and sections were washed with TBS prior to cover slipping for imaging.Confocal microscopy ::: Materials and methodsStained sections were imaged on a Ziess LSM 800 with Airyscan laser-scanning confocal microscope (Ziess, Oberkochen, Germany) using a 63\u00d7 oil immersion objective.", [["sections", "ANATOMY", 81, 89], ["sections", "ANATOMY", 200, 208], ["DAPI", "CHEMICAL", 9, 13], ["DAPI", "SIMPLE_CHEMICAL", 9, 13], ["TBS", "TREATMENT", 107, 110], ["imaging", "TEST", 139, 146], ["Confocal microscopy", "TEST", 147, 166], ["a Ziess LSM", "TEST", 224, 235], ["Airyscan laser", "TREATMENT", 245, 259]]], ["Each field of view was imaged as a z-stack (8\u201310 planes, .5-\u03bcm step size) transformed into a single maximum projection image using the Ziess Zen (blue) imaging software.", [["a z-stack (8\u201310 planes", "TREATMENT", 33, 55], ["imaging software", "TEST", 152, 168]]]], "8e0ad88c998cfd9bca4fd637c9757c65bbc5becd": [["IntroductionGlucose-Regulated Protein 78 (GRP78) or immunoglobulin heavy chain binding protein (BiP) is a member of the Heat Shock Protein 70 (HSP70) family.", [["IntroductionGlucose", "CHEMICAL", 0, 19], ["IntroductionGlucose", "CHEMICAL", 0, 19], ["IntroductionGlucose-Regulated Protein 78", "GENE_OR_GENE_PRODUCT", 0, 40], ["GRP78", "GENE_OR_GENE_PRODUCT", 42, 47], ["immunoglobulin heavy chain binding protein", "GENE_OR_GENE_PRODUCT", 52, 94], ["BiP", "GENE_OR_GENE_PRODUCT", 96, 99], ["Heat Shock Protein 70", "GENE_OR_GENE_PRODUCT", 120, 141], ["HSP70", "GENE_OR_GENE_PRODUCT", 143, 148], ["IntroductionGlucose-Regulated Protein 78", "PROTEIN", 0, 40], ["GRP78", "PROTEIN", 42, 47], ["immunoglobulin heavy chain binding protein", "PROTEIN", 52, 94], ["BiP", "PROTEIN", 96, 99], ["Heat Shock Protein 70 (HSP70) family", "PROTEIN", 120, 156], ["IntroductionGlucose", "TEST", 0, 19], ["Protein", "TEST", 30, 37], ["the Heat Shock Protein", "TEST", 116, 138]]], ["It is found in all eukaryotes on the membrane of Endoplasmic Reticulum (ER) [1] .", [["membrane", "ANATOMY", 37, 45], ["Endoplasmic Reticulum", "ANATOMY", 49, 70], ["ER", "ANATOMY", 72, 74], ["membrane", "CELLULAR_COMPONENT", 37, 45], ["Endoplasmic Reticulum", "CELLULAR_COMPONENT", 49, 70], ["ER", "GENE_OR_GENE_PRODUCT", 72, 74], ["ER", "PROTEIN", 72, 74], ["membrane", "ANATOMY_MODIFIER", 37, 45], ["Endoplasmic Reticulum", "OBSERVATION", 49, 70]]], ["The 654 amino acid protein, GRP78, corrects the folding and assembly and prevents the transport of proteins or protein subunits that are folded incorrectly [2] [3] [4] .", [["amino acid", "CHEMICAL", 8, 18], ["amino acid", "CHEMICAL", 8, 18], ["amino acid", "AMINO_ACID", 8, 18], ["GRP78", "GENE_OR_GENE_PRODUCT", 28, 33], ["[2] [3] [4]", "SIMPLE_CHEMICAL", 156, 167], ["654 amino acid protein", "PROTEIN", 4, 26], ["GRP78", "PROTEIN", 28, 33], ["protein subunits", "PROTEIN", 111, 127], ["The 654 amino acid protein", "TEST", 0, 26], ["GRP78", "TEST", 28, 33], ["the transport of proteins or protein subunits", "TREATMENT", 82, 127]]], ["GRP78 expression is increased in cases of ER stressors like when the cell is abridged from sugar, treated with reagents that inhibit the process of protein glycosylation or disturb the intercellular calcium storage [5] .", [["ER", "ANATOMY", 42, 44], ["cell", "ANATOMY", 69, 73], ["intercellular", "ANATOMY", 185, 198], ["calcium", "CHEMICAL", 199, 206], ["sugar", "CHEMICAL", 91, 96], ["calcium", "CHEMICAL", 199, 206], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["ER", "GENE_OR_GENE_PRODUCT", 42, 44], ["cell", "CELL", 69, 73], ["sugar", "SIMPLE_CHEMICAL", 91, 96], ["intercellular", "IMMATERIAL_ANATOMICAL_ENTITY", 185, 198], ["calcium", "SIMPLE_CHEMICAL", 199, 206], ["GRP78", "PROTEIN", 0, 5], ["ER", "PROTEIN", 42, 44], ["ER stressors", "PROBLEM", 42, 54], ["reagents", "TREATMENT", 111, 119], ["protein glycosylation", "TREATMENT", 148, 169], ["the intercellular calcium storage", "TREATMENT", 181, 214], ["increased", "OBSERVATION_MODIFIER", 20, 29]]], ["It is a watersoluble protein, and only small patches are reported to be hydrophobic.", [["watersoluble protein", "PROTEIN", 8, 28], ["a watersoluble protein", "PROBLEM", 6, 28], ["small patches", "PROBLEM", 39, 52], ["small", "OBSERVATION_MODIFIER", 39, 44], ["patches", "OBSERVATION", 45, 52], ["hydrophobic", "OBSERVATION_MODIFIER", 72, 83]]], ["These hydrophobic patches are essential for its function as it recognizes the unfolded proteins that are directed either to the degradation or refolding mechanisms [6] .", [["unfolded proteins", "PROTEIN", 78, 95], ["These hydrophobic patches", "TREATMENT", 0, 25], ["the unfolded proteins", "PROBLEM", 74, 95], ["hydrophobic patches", "OBSERVATION", 6, 25]]], ["GRP78 structure is divided into two domains, ATP binding domain (ABD) (or nucleotide binding domain NBD), at the amino terminal and substrate binding domain (SBD) at the carboxyl-terminal [7] .", [["ATP", "CHEMICAL", 45, 48], ["nucleotide", "CHEMICAL", 74, 84], ["ATP", "CHEMICAL", 45, 48], ["nucleotide", "CHEMICAL", 74, 84], ["amino", "CHEMICAL", 113, 118], ["carboxyl", "CHEMICAL", 170, 178], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["ATP binding domain (ABD) (or nucleotide binding domain NBD", "GENE_OR_GENE_PRODUCT", 45, 103], ["amino terminal", "AMINO_ACID", 113, 127], ["GRP78", "PROTEIN", 0, 5], ["ATP binding domain", "PROTEIN", 45, 63], ["ABD", "PROTEIN", 65, 68], ["nucleotide binding domain NBD", "PROTEIN", 74, 103], ["amino terminal and substrate binding domain", "PROTEIN", 113, 156], ["SBD", "PROTEIN", 158, 161], ["carboxyl-terminal [7]", "PROTEIN", 170, 191], ["GRP78 structure", "PROBLEM", 0, 15], ["ATP binding domain (ABD) (or nucleotide binding domain NBD", "PROBLEM", 45, 103], ["ATP binding", "OBSERVATION", 45, 56], ["ABD", "ANATOMY", 65, 68]]], ["Fig. 1 shows the x-ray apo form of GRP78 solved structure (PDB ID 6EOC) at 1.67 \u00c5 resolution and ABD domain with bound ATP molecule (PDB ID 5F1X) at 1.90 \u00c5 resolution.IntroductionGRP78 shares 60% homology with the HSP70 family, with the conservation of ABD and SBD domains.", [["ATP", "CHEMICAL", 119, 122], ["ATP", "CHEMICAL", 119, 122], ["GRP78", "GENE_OR_GENE_PRODUCT", 35, 40], ["ATP", "SIMPLE_CHEMICAL", 119, 122], ["IntroductionGRP78", "GENE_OR_GENE_PRODUCT", 167, 184], ["HSP70", "GENE_OR_GENE_PRODUCT", 214, 219], ["ABD", "GENE_OR_GENE_PRODUCT", 253, 256], ["GRP78 solved structure", "PROTEIN", 35, 57], ["6EOC", "PROTEIN", 66, 70], ["ABD domain", "PROTEIN", 97, 107], ["ATP molecule", "PROTEIN", 119, 131], ["PDB ID 5F1X", "PROTEIN", 133, 144], ["IntroductionGRP78", "PROTEIN", 167, 184], ["HSP70 family", "PROTEIN", 214, 226], ["ABD", "PROTEIN", 253, 256], ["SBD domains", "PROTEIN", 261, 272], ["the x-ray", "TEST", 13, 22], ["GRP78 solved structure", "PROBLEM", 35, 57], ["ABD domain", "PROBLEM", 97, 107], ["bound ATP molecule", "PROBLEM", 113, 131], ["ABD and SBD domains", "PROBLEM", 253, 272], ["ABD", "ANATOMY", 97, 100], ["ABD", "ANATOMY", 253, 256], ["SBD", "ANATOMY", 261, 264]]], ["ABD domain shows the most considerable sequence conservation over the HSP70 family [1, 7, 8] .", [["HSP70", "GENE_OR_GENE_PRODUCT", 70, 75], ["ABD domain", "PROTEIN", 0, 10], ["HSP70 family", "PROTEIN", 70, 82], ["ABD domain", "TEST", 0, 10]]], ["Although GRP78 is an HSP70 family A member and shares the properties of abnormal protein binding under conditions of stress, it differs in protein expression regulation.", [["GRP78", "GENE_OR_GENE_PRODUCT", 9, 14], ["HSP70", "GENE_OR_GENE_PRODUCT", 21, 26], ["GRP78", "PROTEIN", 9, 14], ["HSP70 family A member", "PROTEIN", 21, 42], ["abnormal protein binding", "PROBLEM", 72, 96], ["stress", "PROBLEM", 117, 123], ["protein expression regulation", "TREATMENT", 139, 168], ["protein binding", "OBSERVATION", 81, 96]]], ["GRP78, but HSP70, is sensitive to the protein synthesis inhibitor cycloheximide [9, 10] , which is a protein synthesis inhibitor in eukaryotic cells [11] .", [["cells", "ANATOMY", 143, 148], ["cycloheximide", "CHEMICAL", 66, 79], ["9, 10]", "CHEMICAL", 81, 87], ["cycloheximide", "CHEMICAL", 66, 79], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["HSP70", "GENE_OR_GENE_PRODUCT", 11, 16], ["cycloheximide", "SIMPLE_CHEMICAL", 66, 79], ["9, 10]", "SIMPLE_CHEMICAL", 81, 87], ["cells", "CELL", 143, 148], ["GRP78", "PROTEIN", 0, 5], ["HSP70", "PROTEIN", 11, 16], ["eukaryotic cells", "CELL_TYPE", 132, 148], ["GRP78", "TEST", 0, 5], ["HSP70", "TEST", 11, 16], ["the protein synthesis inhibitor cycloheximide", "TREATMENT", 34, 79], ["a protein synthesis inhibitor", "TREATMENT", 99, 128]]], ["The most potent induction reasons for GRP78 expression, like calcium ionophore A23187 and \u03b2-mercaptoethanol, doesn't affect the expression level of HSP70 proteins [12] [13] [14] .", [["calcium", "CHEMICAL", 61, 68], ["A23187", "CHEMICAL", 79, 85], ["\u03b2-mercaptoethanol", "CHEMICAL", 90, 107], ["calcium", "CHEMICAL", 61, 68], ["A23187", "CHEMICAL", 79, 85], ["\u03b2-mercaptoethanol", "CHEMICAL", 90, 107], ["GRP78", "GENE_OR_GENE_PRODUCT", 38, 43], ["calcium ionophore A23187", "SIMPLE_CHEMICAL", 61, 85], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 90, 107], ["HSP70", "GENE_OR_GENE_PRODUCT", 148, 153], ["GRP78", "PROTEIN", 38, 43], ["HSP70 proteins", "PROTEIN", 148, 162], ["GRP78 expression", "PROBLEM", 38, 54], ["calcium ionophore A23187", "TREATMENT", 61, 85], ["\u03b2-mercaptoethanol", "TREATMENT", 90, 107], ["HSP70 proteins", "TEST", 148, 162], ["most potent", "OBSERVATION_MODIFIER", 4, 15]]], ["Treating cells with such inducers increases the GRP78 gene expression up to 10-25 folds in 5 h [12, 15] .IntroductionGRP78 expression appears to be in a direct correlation with the activity of the ER.", [["cells", "ANATOMY", 9, 14], ["ER", "ANATOMY", 197, 199], ["cells", "CELL", 9, 14], ["GRP78", "GENE_OR_GENE_PRODUCT", 48, 53], ["IntroductionGRP78", "GENE_OR_GENE_PRODUCT", 105, 122], ["ER", "GENE_OR_GENE_PRODUCT", 197, 199], ["GRP78", "PROTEIN", 48, 53], ["IntroductionGRP78", "PROTEIN", 105, 122], ["ER", "PROTEIN", 197, 199], ["Treating cells", "PROBLEM", 0, 14], ["such inducers", "PROBLEM", 20, 33], ["gene expression", "TEST", 54, 69]]], ["This means that intermediate molecules must exist and travel between both membranes of the ER and the nucleus to reach the GRP78 gene and communicate the signal.", [["membranes", "ANATOMY", 74, 83], ["ER", "ANATOMY", 91, 93], ["nucleus", "ANATOMY", 102, 109], ["membranes", "CELLULAR_COMPONENT", 74, 83], ["ER", "GENE_OR_GENE_PRODUCT", 91, 93], ["nucleus", "CELLULAR_COMPONENT", 102, 109], ["GRP78", "GENE_OR_GENE_PRODUCT", 123, 128], ["ER", "PROTEIN", 91, 93], ["GRP78 gene", "DNA", 123, 133], ["intermediate molecules", "PROBLEM", 16, 38], ["intermediate molecules", "OBSERVATION", 16, 38], ["nucleus", "ANATOMY", 102, 109]]], ["The way between the two membranes is not tricky as the ER membrane is associated with the prenuclear membrane.", [["membranes", "ANATOMY", 24, 33], ["ER membrane", "ANATOMY", 55, 66], ["prenuclear membrane", "ANATOMY", 90, 109], ["membranes", "CELLULAR_COMPONENT", 24, 33], ["ER", "GENE_OR_GENE_PRODUCT", 55, 57], ["membrane", "CELLULAR_COMPONENT", 58, 66], ["prenuclear membrane", "CELLULAR_COMPONENT", 90, 109], ["ER", "PROTEIN", 55, 57], ["not", "UNCERTAINTY", 37, 40], ["tricky", "OBSERVATION", 41, 47]]], ["GRP78 is regulated over the transcriptional level [8] .GRP78 geneIn human, the gene responsible for GRP78 encoding is on chromosome number 9 with a length of 4532 nucleotides [1, 2] .", [["chromosome", "ANATOMY", 121, 131], ["nucleotides", "CHEMICAL", 163, 174], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["GRP78", "GENE_OR_GENE_PRODUCT", 55, 60], ["human", "ORGANISM", 68, 73], ["GRP78", "GENE_OR_GENE_PRODUCT", 100, 105], ["GRP78", "PROTEIN", 0, 5], ["GRP78", "PROTEIN", 55, 60], ["GRP78", "PROTEIN", 100, 105], ["chromosome number 9", "DNA", 121, 140], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["a length", "TEST", 146, 154]]], ["Fluorescence in situ hybridization with a 24,000 bases genome phage clone that contains the whole coding region of GRP78 gene is used to prove the positive signals of hybridization at the distal end of the long arm of chromosome 9, at band 9q34 [2] .", [["long arm", "ANATOMY", 206, 214], ["chromosome 9", "ANATOMY", 218, 230], ["GRP78", "GENE_OR_GENE_PRODUCT", 115, 120], ["long arm", "CELLULAR_COMPONENT", 206, 214], ["chromosome 9", "CELLULAR_COMPONENT", 218, 230], ["24,000 bases genome phage clone", "DNA", 42, 73], ["GRP78 gene", "DNA", 115, 125], ["long arm of chromosome 9", "DNA", 206, 230], ["Fluorescence in situ hybridization", "PROBLEM", 0, 34], ["a 24,000 bases genome phage clone", "TREATMENT", 40, 73], ["hybridization", "TEST", 167, 180], ["distal", "ANATOMY_MODIFIER", 188, 194]]], ["In human there are two genes sequences are found at highly hydrophilic domains at the carboxyl third of the protein [6, 16, 17] .GRP78 geneA deletion of 12 nucleotides near the amino-terminal and insertion of four nucleotides within exon number 5 was found in pseudogene compared to the functional gene.", [["amino-terminal", "CHEMICAL", 177, 191], ["carboxyl", "CHEMICAL", 86, 94], ["nucleotides", "CHEMICAL", 156, 167], ["amino", "CHEMICAL", 177, 182], ["nucleotides", "CHEMICAL", 214, 225], ["human", "ORGANISM", 3, 8], ["GRP78", "GENE_OR_GENE_PRODUCT", 129, 134], ["amino-terminal", "AMINO_ACID", 177, 191], ["carboxyl third", "PROTEIN", 86, 100], ["GRP78", "PROTEIN", 129, 134], ["exon number 5", "DNA", 233, 246], ["functional gene", "DNA", 287, 302], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["two genes sequences", "PROBLEM", 19, 38], ["GRP78 geneA deletion of 12 nucleotides", "PROBLEM", 129, 167], ["the amino-terminal and insertion of four nucleotides", "TREATMENT", 173, 225], ["pseudogene", "PROBLEM", 260, 270], ["insertion", "OBSERVATION_MODIFIER", 196, 205]]], ["GRP78 pseudogene is surrounded by GAAAATTAAACAA sequence. upstream from the pseudogene, 100 nucleotides are 66% A-T rich while this ratio is 75% for the 200 downstream nucleotides [6] .GRP78 geneIn human, the 5\u2032 flanking region is 1650 nucleotides.", [["nucleotides", "CHEMICAL", 92, 103], ["nucleotides", "CHEMICAL", 168, 179], ["nucleotides", "CHEMICAL", 236, 247], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["GRP78", "GENE_OR_GENE_PRODUCT", 185, 190], ["human", "ORGANISM", 198, 203], ["GRP78 pseudogene", "DNA", 0, 16], ["GAAAATTAAACAA sequence", "DNA", 34, 56], ["GRP78", "PROTEIN", 185, 190], ["5\u2032 flanking region", "DNA", 209, 227], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 198, 203], ["GRP78 pseudogene", "PROBLEM", 0, 16], ["nucleotides", "TEST", 92, 103], ["this ratio", "TEST", 127, 137], ["pseudogene", "OBSERVATION", 6, 16], ["1650 nucleotides", "OBSERVATION", 231, 247]]], ["When this region is reduced to 358 nucleotides, no changes are observed in the basal or induced activity.", [["nucleotides", "CHEMICAL", 35, 46], ["reduced", "OBSERVATION_MODIFIER", 20, 27], ["basal", "ANATOMY_MODIFIER", 79, 84], ["activity", "OBSERVATION_MODIFIER", 96, 104]]], ["On the other hand, the reduction of this region to 170 nucleotides results in two folds decline in both basal and induced activity [6, 8] .", [["nucleotides", "CHEMICAL", 55, 66], ["two folds decline", "PROBLEM", 78, 95], ["two", "OBSERVATION_MODIFIER", 78, 81], ["folds", "OBSERVATION_MODIFIER", 82, 87], ["decline", "OBSERVATION_MODIFIER", 88, 95], ["both", "ANATOMY_MODIFIER", 99, 103], ["basal", "ANATOMY_MODIFIER", 104, 109], ["activity", "OBSERVATION_MODIFIER", 122, 130]]], ["Analysis of the human GRP78 gene reveals that GRP78 promotor contains a region that is sensitive to stress.", [["human", "ORGANISM", 16, 21], ["GRP78", "GENE_OR_GENE_PRODUCT", 22, 27], ["GRP78", "GENE_OR_GENE_PRODUCT", 46, 51], ["human GRP78 gene", "DNA", 16, 32], ["GRP78 promotor", "DNA", 46, 60], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["the human GRP78 gene", "TEST", 12, 32], ["GRP78 promotor", "PROBLEM", 46, 60], ["stress", "PROBLEM", 100, 106]]], ["This region is within the 170 nucleotides upstream from the transcription initiation site [6] .Function in normal cellsGRP78 function is to work as a molecular chaperone.", [["nucleotides", "CHEMICAL", 30, 41], ["cellsGRP78", "GENE_OR_GENE_PRODUCT", 114, 124], ["170 nucleotides upstream", "DNA", 26, 50], ["transcription initiation site", "DNA", 60, 89], ["cellsGRP78", "PROTEIN", 114, 124], ["molecular chaperone", "PROTEIN", 150, 169], ["normal", "OBSERVATION", 107, 113]]], ["It binds to misfolded proteins and unassembled complexes and initiates ER- Fig. 1.", [["ER", "GENE_OR_GENE_PRODUCT", 71, 73], ["misfolded proteins", "PROTEIN", 12, 30], ["unassembled complexes", "PROTEIN", 35, 56], ["ER", "PROTEIN", 71, 73], ["misfolded proteins", "PROBLEM", 12, 30], ["unassembled complexes", "PROBLEM", 35, 56], ["misfolded proteins", "OBSERVATION", 12, 30], ["unassembled complexes", "OBSERVATION", 35, 56]]], ["A) shows the x-ray apo form of GRP78 solved structure (PDB ID 6EOC) at 1.67 \u00c5 resolution.", [["GRP78", "GENE_OR_GENE_PRODUCT", 31, 36], ["GRP78 solved structure", "PROTEIN", 31, 53], ["PDB ID 6EOC", "PROTEIN", 55, 66], ["the x-ray", "TEST", 9, 18]]], ["The protein is represented by cartoon colored green (NBD), red (SBD) and purple (linker).", [["NBD", "SIMPLE_CHEMICAL", 53, 56], ["NBD", "PROTEIN", 53, 56], ["red", "PROTEIN", 59, 62], ["SBD", "PROTEIN", 64, 67], ["red (SBD) and purple (linker)", "PROBLEM", 59, 88], ["purple", "OBSERVATION_MODIFIER", 73, 79]]], ["GRP78 sequence is represented also with the same color as the protein domains.", [["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["GRP78", "PROTEIN", 0, 5], ["protein domains", "PROTEIN", 62, 77], ["GRP78 sequence", "TEST", 0, 14]]], ["B) ATP binding domain with pound ATP molecule (PDB ID 5F1X) at 1.90 \u00c5 resolution represented as the rainbow-colored cartoon.", [["ATP", "CHEMICAL", 3, 6], ["ATP", "CHEMICAL", 33, 36], ["ATP", "CHEMICAL", 3, 6], ["ATP", "CHEMICAL", 33, 36], ["ATP", "SIMPLE_CHEMICAL", 3, 6], ["ATP", "SIMPLE_CHEMICAL", 33, 36], ["ATP binding domain", "PROTEIN", 3, 21], ["pound ATP molecule", "PROTEIN", 27, 45], ["PDB ID 5F1X", "PROTEIN", 47, 58], ["ATP binding domain", "PROBLEM", 3, 21], ["pound ATP molecule", "PROBLEM", 27, 45]]], ["The binding site with ATP is enlarged to show the amino acids involved in the interaction.", [["ATP", "CHEMICAL", 22, 25], ["amino acids", "CHEMICAL", 50, 61], ["ATP", "CHEMICAL", 22, 25], ["amino acids", "CHEMICAL", 50, 61], ["ATP", "SIMPLE_CHEMICAL", 22, 25], ["amino acids", "AMINO_ACID", 50, 61], ["binding site", "DNA", 4, 16], ["ATP", "PROBLEM", 22, 25], ["the amino acids", "TREATMENT", 46, 61], ["enlarged", "OBSERVATION", 29, 37]]], ["PyMOL software is used to represent the entire figure [127] .", [["PyMOL", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) associated degradation (ERAD) responsible for UPR regulation [18] [19] [20] .", [["[18] [19] [20]", "SIMPLE_CHEMICAL", 191, 205], ["ERAD", "PROTEIN", 154, 158], ["associated degradation", "PROBLEM", 130, 152], ["UPR regulation", "TEST", 176, 190]]], ["It binds to unfolded peptides with the SBD and gets the energy to prevent aggregation by the mean of ATP hydrolysis in the (NBD) [21] .", [["aggregation", "DISEASE", 74, 85], ["ATP", "CHEMICAL", 101, 104], ["ATP", "CHEMICAL", 101, 104], ["ATP", "SIMPLE_CHEMICAL", 101, 104], ["SBD", "PROTEIN", 39, 42], ["the SBD", "PROBLEM", 35, 42], ["aggregation", "PROBLEM", 74, 85], ["ATP hydrolysis", "TREATMENT", 101, 115], ["unfolded", "OBSERVATION_MODIFIER", 12, 20], ["peptides", "OBSERVATION", 21, 29], ["ATP hydrolysis", "OBSERVATION", 101, 115]]], ["In the standard conditions of balance in the cell (homeostasis) GRP78 is bounded in an inactive form to Activating transcription factor 6 (ATF6), protein kinase RNA-like endoplasmic reticulum kinase (PERK), and Inositol-requiring enzyme 1 (IRE1) which are UPR transmembrane stress sensors.", [["cell", "ANATOMY", 45, 49], ["transmembrane", "ANATOMY", 260, 273], ["Inositol", "CHEMICAL", 211, 219], ["Inositol", "CHEMICAL", 211, 219], ["cell", "CELL", 45, 49], ["GRP78", "GENE_OR_GENE_PRODUCT", 64, 69], ["Activating transcription factor 6", "GENE_OR_GENE_PRODUCT", 104, 137], ["ATF6", "GENE_OR_GENE_PRODUCT", 139, 143], ["protein kinase RNA-like endoplasmic reticulum kinase", "GENE_OR_GENE_PRODUCT", 146, 198], ["PERK", "GENE_OR_GENE_PRODUCT", 200, 204], ["Inositol-requiring enzyme 1", "GENE_OR_GENE_PRODUCT", 211, 238], ["IRE1", "GENE_OR_GENE_PRODUCT", 240, 244], ["GRP78", "PROTEIN", 64, 69], ["Activating transcription factor 6", "PROTEIN", 104, 137], ["ATF6", "PROTEIN", 139, 143], ["protein kinase RNA-like endoplasmic reticulum kinase", "PROTEIN", 146, 198], ["PERK", "PROTEIN", 200, 204], ["Inositol-requiring enzyme 1", "PROTEIN", 211, 238], ["IRE1", "PROTEIN", 240, 244], ["Activating transcription factor", "TEST", 104, 135], ["ATF6", "TEST", 139, 143], ["protein kinase RNA", "TEST", 146, 164], ["endoplasmic reticulum kinase", "TEST", 170, 198], ["Inositol", "TEST", 211, 219], ["enzyme", "TEST", 230, 236], ["UPR transmembrane stress sensors", "TEST", 256, 288], ["reticulum kinase", "ANATOMY", 182, 198]]], ["When the cell is exposed to unfolded proteins that are accumulated in the ER, this stress can be revealed when GRP78 is released from the UPR sensors.", [["cell", "ANATOMY", 9, 13], ["ER", "ANATOMY", 74, 76], ["cell", "CELL", 9, 13], ["ER", "GENE_OR_GENE_PRODUCT", 74, 76], ["GRP78", "GENE_OR_GENE_PRODUCT", 111, 116], ["unfolded proteins", "PROTEIN", 28, 45], ["ER", "PROTEIN", 74, 76], ["GRP78", "PROTEIN", 111, 116], ["unfolded proteins", "PROBLEM", 28, 45], ["GRP78", "PROBLEM", 111, 116], ["the UPR sensors", "TEST", 134, 149], ["unfolded", "OBSERVATION_MODIFIER", 28, 36], ["proteins", "OBSERVATION", 37, 45]]], ["The active form of UPR then decreases the translation of protein and enhance the correct folding [19] (see Fig. 2 ).Function in normal cellsPERK, when activated, phosphorylates the alpha (\u03b1) subunit of eukaryotic translation initiation factor (eIF2\u03b1).", [["cells", "ANATOMY", 135, 140], ["UPR", "GENE_OR_GENE_PRODUCT", 19, 22], ["cells", "CELL", 135, 140], ["PERK", "GENE_OR_GENE_PRODUCT", 140, 144], ["alpha (\u03b1)", "GENE_OR_GENE_PRODUCT", 181, 190], ["eukaryotic translation initiation factor", "GENE_OR_GENE_PRODUCT", 202, 242], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 244, 249], ["UPR", "PROTEIN", 19, 22], ["PERK", "PROTEIN", 140, 144], ["alpha (\u03b1) subunit", "PROTEIN", 181, 198], ["eukaryotic translation initiation factor", "PROTEIN", 202, 242], ["eIF2\u03b1", "PROTEIN", 244, 249], ["UPR", "PROBLEM", 19, 22], ["active", "OBSERVATION_MODIFIER", 4, 10], ["normal cellsPERK", "OBSERVATION", 128, 144]]], ["The phosphorylated eIF2\u03b1 then can inhibit the initiation of translation and inhibit protein synthesis reducing the influx of nascent proteins into the lumen of the ER [20, 22] .", [["lumen", "ANATOMY", 151, 156], ["ER", "ANATOMY", 164, 166], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 19, 24], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 151, 156], ["ER", "GENE_OR_GENE_PRODUCT", 164, 166], ["phosphorylated eIF2\u03b1", "PROTEIN", 4, 24], ["nascent proteins", "PROTEIN", 125, 141], ["ER", "PROTEIN", 164, 166], ["The phosphorylated eIF2", "TREATMENT", 0, 23], ["translation and inhibit protein synthesis", "TREATMENT", 60, 101], ["lumen", "ANATOMY_MODIFIER", 151, 156]]], ["The activated form of ATF6 translocates to the Golgi apparatus where it is cleaved.", [["Golgi apparatus", "ANATOMY", 47, 62], ["ATF6", "GENE_OR_GENE_PRODUCT", 22, 26], ["Golgi apparatus", "CELLULAR_COMPONENT", 47, 62], ["ATF6", "PROTEIN", 22, 26], ["cleaved", "OBSERVATION", 75, 82]]], ["After that, the cleaved ATF6 moves to the nucleus and works as an active transcription factor and upregulate the transcription of proteins that increase the folding capacity of the ER like GRP78.", [["nucleus", "ANATOMY", 42, 49], ["ER", "ANATOMY", 181, 183], ["ATF6", "GENE_OR_GENE_PRODUCT", 24, 28], ["nucleus", "CELLULAR_COMPONENT", 42, 49], ["ER", "GENE_OR_GENE_PRODUCT", 181, 183], ["GRP78", "GENE_OR_GENE_PRODUCT", 189, 194], ["cleaved ATF6", "PROTEIN", 16, 28], ["transcription factor", "PROTEIN", 73, 93], ["ER", "PROTEIN", 181, 183], ["GRP78", "PROTEIN", 189, 194], ["the cleaved ATF6", "PROBLEM", 12, 28], ["an active transcription factor", "TREATMENT", 63, 93], ["the transcription of proteins", "TREATMENT", 109, 138], ["nucleus", "ANATOMY", 42, 49]]], ["The IRE1 active form has an endoribonuclease activity.", [["IRE1", "GENE_OR_GENE_PRODUCT", 4, 8], ["IRE1 active form", "PROTEIN", 4, 20], ["endoribonuclease", "PROTEIN", 28, 44], ["IRE1", "OBSERVATION_MODIFIER", 4, 8], ["active", "OBSERVATION_MODIFIER", 9, 15], ["endoribonuclease activity", "OBSERVATION", 28, 53]]], ["It breaks a 24-base segment of mRNA intron and encodes X-box binding protein 1 (XBP1).", [["X-box binding protein 1", "GENE_OR_GENE_PRODUCT", 55, 78], ["XBP1", "GENE_OR_GENE_PRODUCT", 80, 84], ["24-base segment", "DNA", 12, 27], ["mRNA intron", "RNA", 31, 42], ["X-box binding protein 1", "PROTEIN", 55, 78], ["XBP1", "PROTEIN", 80, 84], ["mRNA intron", "TREATMENT", 31, 42], ["box binding protein", "TEST", 57, 76]]], ["XBP1 target genes which are responsible for protein folding and ERAD [2] .", [["XBP1", "GENE_OR_GENE_PRODUCT", 0, 4], ["XBP1 target genes", "DNA", 0, 17], ["ERAD", "PROTEIN", 64, 68], ["XBP1 target genes", "PROBLEM", 0, 17], ["protein folding", "PROBLEM", 44, 59]]], ["At this point, if the homeostasis of the ER could not be restored, the unfolded protein response can induce apoptosis [19] .GRP78; other functions to doIn its basal level of expression, GRP78 plays a role in the development of the embryo.", [["ER", "ANATOMY", 41, 43], ["embryo", "ANATOMY", 231, 237], ["ER", "GENE_OR_GENE_PRODUCT", 41, 43], ["GRP78", "GENE_OR_GENE_PRODUCT", 124, 129], ["GRP78", "GENE_OR_GENE_PRODUCT", 186, 191], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 231, 237], ["ER", "PROTEIN", 41, 43], ["GRP78", "PROTEIN", 124, 129], ["GRP78", "PROTEIN", 186, 191], ["the unfolded protein response", "PROBLEM", 67, 96], ["apoptosis", "PROBLEM", 108, 117], ["GRP78", "PROBLEM", 124, 129]]], ["It was found that homozygous mice, with GRP78 gene, knocked down, witnessed fatality at day 3.5 of embryogenesis with a massive apoptotic inner cell mass death [20] .", [["inner cell", "ANATOMY", 138, 148], ["fatality", "DISEASE", 76, 84], ["death", "DISEASE", 154, 159], ["mice", "ORGANISM", 29, 33], ["GRP78", "GENE_OR_GENE_PRODUCT", 40, 45], ["inner cell", "CELL", 138, 148], ["GRP78 gene", "DNA", 40, 50], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["homozygous mice", "PROBLEM", 18, 33], ["embryogenesis", "PROBLEM", 99, 112], ["a massive apoptotic inner cell mass death", "PROBLEM", 118, 159], ["massive", "OBSERVATION_MODIFIER", 120, 127], ["apoptotic", "OBSERVATION_MODIFIER", 128, 137], ["inner cell mass", "OBSERVATION", 138, 153]]], ["In human, when GRP78 is knocked down, the expression of Glucose-regulated protein 94 (GRP94), CCAAT-enhancer-binding protein homologous protein (CHOP), c-Jun N-terminal kinase (JNK), and X-box binding protein 1 (XBP1) are spontaneously increased.", [["Glucose", "CHEMICAL", 56, 63], ["N", "CHEMICAL", 158, 159], ["human", "ORGANISM", 3, 8], ["GRP78", "GENE_OR_GENE_PRODUCT", 15, 20], ["Glucose-regulated protein 94", "GENE_OR_GENE_PRODUCT", 56, 84], ["GRP94", "GENE_OR_GENE_PRODUCT", 86, 91], ["CCAAT-enhancer-binding protein homologous protein", "GENE_OR_GENE_PRODUCT", 94, 143], ["CHOP", "GENE_OR_GENE_PRODUCT", 145, 149], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 152, 175], ["JNK", "GENE_OR_GENE_PRODUCT", 177, 180], ["X-box binding protein 1", "GENE_OR_GENE_PRODUCT", 187, 210], ["XBP1", "GENE_OR_GENE_PRODUCT", 212, 216], ["GRP78", "PROTEIN", 15, 20], ["Glucose-regulated protein 94", "PROTEIN", 56, 84], ["GRP94", "PROTEIN", 86, 91], ["CCAAT-enhancer-binding protein homologous protein", "PROTEIN", 94, 143], ["CHOP", "PROTEIN", 145, 149], ["c-Jun N-terminal kinase", "PROTEIN", 152, 175], ["JNK", "PROTEIN", 177, 180], ["X-box binding protein 1", "PROTEIN", 187, 210], ["XBP1", "PROTEIN", 212, 216], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["Glucose", "TEST", 56, 63], ["protein", "TEST", 74, 81], ["GRP94", "TEST", 86, 91], ["CCAAT", "TEST", 94, 99], ["binding protein homologous protein", "TEST", 109, 143], ["CHOP", "TEST", 145, 149], ["c", "TEST", 152, 153], ["Jun N", "TEST", 154, 159], ["terminal kinase (JNK)", "TEST", 160, 181], ["X-box binding protein", "TEST", 187, 208], ["XBP1", "TEST", 212, 216], ["spontaneously", "OBSERVATION_MODIFIER", 222, 235], ["increased", "OBSERVATION_MODIFIER", 236, 245]]], ["As GRP78 is suppressed down, the UPR sensors are activated.", [["GRP78", "GENE_OR_GENE_PRODUCT", 3, 8], ["UPR", "GENE_OR_GENE_PRODUCT", 33, 36], ["GRP78", "PROTEIN", 3, 8], ["the UPR sensors", "TEST", 29, 44], ["suppressed", "OBSERVATION_MODIFIER", 12, 22]]], ["GRP94 expression is improved, but this increment does not compensate for the GRP78 absence.", [["GRP94", "GENE_OR_GENE_PRODUCT", 0, 5], ["GRP78", "GENE_OR_GENE_PRODUCT", 77, 82], ["GRP94", "PROTEIN", 0, 5], ["GRP78", "PROTEIN", 77, 82], ["the GRP78 absence", "PROBLEM", 73, 90], ["expression", "OBSERVATION", 6, 16], ["improved", "OBSERVATION_MODIFIER", 20, 28]]], ["This result shows that GRP78 has an anti-apoptotic role and it is essential for cell viability.", [["cell", "ANATOMY", 80, 84], ["GRP78", "GENE_OR_GENE_PRODUCT", 23, 28], ["cell", "CELL", 80, 84], ["GRP78", "PROTEIN", 23, 28], ["GRP78", "PROBLEM", 23, 28], ["cell viability", "PROBLEM", 80, 94], ["essential for", "UNCERTAINTY", 66, 79], ["cell viability", "OBSERVATION", 80, 94]]], ["GRP78 binds to caspase 7 and caspase 12 which are the main cytosolic implementers for apoptosis, despite there is no binding to caspase 3 [23] .GRP78; other functions to doThere is a relation between aging and ER stress.", [["cytosolic", "ANATOMY", 59, 68], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["caspase 7", "GENE_OR_GENE_PRODUCT", 15, 24], ["caspase 12", "GENE_OR_GENE_PRODUCT", 29, 39], ["caspase 3", "GENE_OR_GENE_PRODUCT", 128, 137], ["GRP78", "GENE_OR_GENE_PRODUCT", 144, 149], ["ER", "GENE_OR_GENE_PRODUCT", 210, 212], ["GRP78", "PROTEIN", 0, 5], ["caspase 7", "PROTEIN", 15, 24], ["caspase 12", "PROTEIN", 29, 39], ["GRP78", "PROTEIN", 144, 149], ["ER", "PROTEIN", 210, 212], ["caspase", "TREATMENT", 15, 22], ["caspase", "TREATMENT", 29, 36], ["apoptosis", "PROBLEM", 86, 95], ["caspase", "TEST", 128, 135]]], ["Aging causes a decrease in protein expression and a decrease in the activity of several ER chaperones such as GRP78.", [["ER", "GENE_OR_GENE_PRODUCT", 88, 90], ["GRP78", "GENE_OR_GENE_PRODUCT", 110, 115], ["ER chaperones", "PROTEIN", 88, 101], ["GRP78", "PROTEIN", 110, 115], ["a decrease in protein expression", "PROBLEM", 13, 45], ["several ER chaperones", "TREATMENT", 80, 101], ["decrease", "OBSERVATION_MODIFIER", 15, 23], ["protein expression", "OBSERVATION", 27, 45], ["decrease", "OBSERVATION_MODIFIER", 52, 60]]], ["This decline in the expression increases the tendency to ER stress.", [["ER", "GENE_OR_GENE_PRODUCT", 57, 59], ["ER", "PROTEIN", 57, 59], ["This decline", "PROBLEM", 0, 12]]], ["This unmitigated ER stress leads to age-related diseases [19] .GRP78; other functions to doGRP78 has a non-chaperon function as it is the primary binding protein of Ca +2 in the ER and maintain its balance in the lumen.", [["ER", "ANATOMY", 178, 180], ["lumen", "ANATOMY", 213, 218], ["Ca", "CHEMICAL", 165, 167], ["Ca +2", "CHEMICAL", 165, 170], ["ER", "GENE_OR_GENE_PRODUCT", 17, 19], ["GRP78", "GENE_OR_GENE_PRODUCT", 63, 68], ["doGRP78", "GENE_OR_GENE_PRODUCT", 89, 96], ["Ca +2", "GENE_OR_GENE_PRODUCT", 165, 170], ["ER", "GENE_OR_GENE_PRODUCT", 178, 180], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 213, 218], ["ER", "PROTEIN", 17, 19], ["GRP78", "PROTEIN", 63, 68], ["doGRP78", "PROTEIN", 89, 96], ["primary binding protein", "PROTEIN", 138, 161], ["Ca +2", "PROTEIN", 165, 170], ["ER", "PROTEIN", 178, 180], ["related diseases", "PROBLEM", 40, 56], ["GRP78", "PROBLEM", 63, 68], ["balance", "OBSERVATION", 198, 205], ["lumen", "ANATOMY_MODIFIER", 213, 218]]], ["There is no specified domain for Ca +2 binding, but it binds to the anionic amino acid residues.", [["Ca", "CHEMICAL", 33, 35], ["amino acid", "CHEMICAL", 76, 86], ["Ca +2", "CHEMICAL", 33, 38], ["amino acid", "CHEMICAL", 76, 86], ["Ca +2", "SIMPLE_CHEMICAL", 33, 38], ["amino acid", "AMINO_ACID", 76, 86], ["Ca +2 binding", "PROBLEM", 33, 46], ["the anionic amino acid residues", "TREATMENT", 64, 95], ["no", "UNCERTAINTY", 9, 11], ["acid residues", "OBSERVATION", 82, 95]]], ["One hundred eleven anionic residues, from which 19 only paired, are found in GRP78 leaving many residues to be favorable for Ca +2 binding.", [["Ca", "CHEMICAL", 125, 127], ["Ca +2", "CHEMICAL", 125, 130], ["GRP78", "GENE_OR_GENE_PRODUCT", 77, 82], ["Ca +2", "SIMPLE_CHEMICAL", 125, 130], ["GRP78", "PROTEIN", 77, 82], ["Ca +2 binding", "PROBLEM", 125, 138], ["anionic residues", "OBSERVATION", 19, 35]]], ["This binding capacity still less than other ER proteins [24] .Cell surface GRP78 expression in response to stressGRP78 can also be found on the cell surface.", [["Cell surface", "ANATOMY", 62, 74], ["cell surface", "ANATOMY", 144, 156], ["stressGRP78", "CHEMICAL", 107, 118], ["ER", "GENE_OR_GENE_PRODUCT", 44, 46], ["Cell", "CELL", 62, 66], ["GRP78", "GENE_OR_GENE_PRODUCT", 75, 80], ["stressGRP78", "GENE_OR_GENE_PRODUCT", 107, 118], ["cell surface", "CELLULAR_COMPONENT", 144, 156], ["ER proteins", "PROTEIN", 44, 55], ["GRP78", "PROTEIN", 75, 80], ["stressGRP78", "PROTEIN", 107, 118], ["This binding capacity", "TEST", 0, 21], ["Cell surface GRP78 expression", "TEST", 62, 91], ["stressGRP78", "TEST", 107, 118], ["capacity", "OBSERVATION_MODIFIER", 13, 21]]], ["The last four amino acids in the GRP78 protein (the motif KDEL) which are responsible for ER retention, is present in the cell surface GRP78 (CS GRP78).", [["cell surface", "ANATOMY", 122, 134], ["amino acids", "CHEMICAL", 14, 25], ["amino acids", "CHEMICAL", 14, 25], ["amino acids", "AMINO_ACID", 14, 25], ["GRP78", "GENE_OR_GENE_PRODUCT", 33, 38], ["KDEL", "GENE_OR_GENE_PRODUCT", 58, 62], ["ER", "GENE_OR_GENE_PRODUCT", 90, 92], ["cell surface", "CELLULAR_COMPONENT", 122, 134], ["GRP78", "GENE_OR_GENE_PRODUCT", 135, 140], ["CS GRP78", "GENE_OR_GENE_PRODUCT", 142, 150], ["GRP78 protein", "PROTEIN", 33, 46], ["KDEL", "PROTEIN", 58, 62], ["ER", "PROTEIN", 90, 92], ["cell surface GRP78", "PROTEIN", 122, 140], ["CS GRP78", "PROTEIN", 142, 150], ["four amino acids", "TEST", 9, 25], ["the GRP78 protein", "TEST", 29, 46], ["the motif KDEL", "TEST", 48, 62], ["ER retention", "PROBLEM", 90, 102], ["retention", "OBSERVATION", 93, 102]]], ["Thus, the cleavage of this motif sequence is not required in surface expression.", [["surface", "ANATOMY", 61, 68], ["surface", "CELLULAR_COMPONENT", 61, 68], ["this motif sequence", "TEST", 22, 41]]], ["When GRP78 is overexpressed, a fraction of it can escape the motif retention and translocate to the cell surface [20, 25] .", [["cell surface", "ANATOMY", 100, 112], ["GRP78", "GENE_OR_GENE_PRODUCT", 5, 10], ["cell surface", "CELLULAR_COMPONENT", 100, 112], ["GRP78", "PROTEIN", 5, 10], ["the motif retention", "PROBLEM", 57, 76], ["motif retention", "OBSERVATION", 61, 76]]], ["As when the GRP78 is overexpressed, the KDEL motif receptors are fully saturated, and then GRP78 can escape the retention.", [["GRP78", "GENE_OR_GENE_PRODUCT", 12, 17], ["KDEL", "GENE_OR_GENE_PRODUCT", 40, 44], ["GRP78", "GENE_OR_GENE_PRODUCT", 91, 96], ["GRP78", "PROTEIN", 12, 17], ["KDEL motif receptors", "PROTEIN", 40, 60], ["GRP78", "PROTEIN", 91, 96], ["the KDEL motif receptors", "TEST", 36, 60], ["retention", "OBSERVATION_MODIFIER", 112, 121]]], ["Another thing is KDEL receptor can be downregulated under some circumstances.", [["KDEL receptor", "GENE_OR_GENE_PRODUCT", 17, 30], ["KDEL receptor", "PROTEIN", 17, 30], ["KDEL receptor", "TREATMENT", 17, 30]]], ["There is a theory saying that it could be another protein that helps GRP78 to escape retention by masking KDEL sequence, but it has yet to be determined [25] .Cell surface GRP78 expression in response to stressWhen GRP78 moves to the surface of the cell, it can interact with plenty of ligands or other proteins on the cell surface and works as a multifunctional receptor.", [["Cell surface", "ANATOMY", 159, 171], ["surface", "ANATOMY", 234, 241], ["cell", "ANATOMY", 249, 253], ["cell surface", "ANATOMY", 319, 331], ["GRP78", "GENE_OR_GENE_PRODUCT", 69, 74], ["KDEL", "GENE_OR_GENE_PRODUCT", 106, 110], ["Cell", "CELL", 159, 163], ["GRP78", "GENE_OR_GENE_PRODUCT", 172, 177], ["GRP78", "GENE_OR_GENE_PRODUCT", 215, 220], ["surface", "CELLULAR_COMPONENT", 234, 241], ["cell", "CELL", 249, 253], ["cell surface", "CELLULAR_COMPONENT", 319, 331], ["GRP78", "PROTEIN", 69, 74], ["KDEL", "PROTEIN", 106, 110], ["GRP78", "PROTEIN", 172, 177], ["GRP78", "PROTEIN", 215, 220], ["multifunctional receptor", "PROTEIN", 347, 371], ["escape retention", "PROBLEM", 78, 94], ["masking KDEL sequence", "TEST", 98, 119], ["stress", "TEST", 204, 210]]], ["CS-GRP78 plays an essential role as in cellular signaling, proliferation, migration, invasion, apoptosis, inflammation, and immunity.", [["cellular", "ANATOMY", 39, 47], ["inflammation", "DISEASE", 106, 118], ["CS-GRP78", "GENE_OR_GENE_PRODUCT", 0, 8], ["cellular", "CELL", 39, 47], ["GRP78", "PROTEIN", 3, 8], ["proliferation", "PROBLEM", 59, 72], ["migration", "PROBLEM", 74, 83], ["invasion", "PROBLEM", 85, 93], ["apoptosis", "PROBLEM", 95, 104], ["inflammation", "PROBLEM", 106, 118], ["essential", "OBSERVATION_MODIFIER", 18, 27], ["proliferation", "OBSERVATION_MODIFIER", 59, 72], ["migration", "OBSERVATION_MODIFIER", 74, 83], ["invasion", "OBSERVATION_MODIFIER", 85, 93], ["apoptosis", "OBSERVATION_MODIFIER", 95, 104], ["inflammation", "OBSERVATION", 106, 118]]], ["According to the ligand or the peptide that bind to CS-GRP78, it will be activated in a defined signaling pathway that affects Besides, if the cell is cancerous, CS GRP78 will induce resistance to chemotherapy. the cell in different ways.", [["cell", "ANATOMY", 143, 147], ["cancerous", "ANATOMY", 151, 160], ["cell", "ANATOMY", 215, 219], ["CS-GRP78", "GENE_OR_GENE_PRODUCT", 52, 60], ["cell", "CELL", 143, 147], ["cancerous", "CANCER", 151, 160], ["GRP78", "GENE_OR_GENE_PRODUCT", 165, 170], ["cell", "CELL", 215, 219], ["CS", "PROTEIN", 52, 54], ["GRP78", "PROTEIN", 55, 60], ["GRP78", "PROTEIN", 165, 170], ["chemotherapy", "TREATMENT", 197, 209], ["cell", "OBSERVATION", 215, 219]]], ["When GRP78 is on the cell surface, autoantibodies are secreted.", [["cell surface", "ANATOMY", 21, 33], ["GRP78", "GENE_OR_GENE_PRODUCT", 5, 10], ["cell surface", "CELLULAR_COMPONENT", 21, 33], ["GRP78", "PROTEIN", 5, 10], ["autoantibodies", "PROTEIN", 35, 49], ["autoantibodies", "PROBLEM", 35, 49]]], ["Antibodies for the N-terminal of the protein induces cell proliferation while antibodies bind to the C-terminal causes the induction of cell apoptosis [26] .", [["cell", "ANATOMY", 53, 57], ["cell", "ANATOMY", 136, 140], ["N", "CHEMICAL", 19, 20], ["C", "CHEMICAL", 101, 102], ["cell", "CELL", 53, 57], ["cell", "CELL", 136, 140], ["N-terminal", "PROTEIN", 19, 29], ["antibodies", "PROTEIN", 78, 88], ["C-terminal", "PROTEIN", 101, 111], ["Antibodies", "TEST", 0, 10], ["the protein", "PROBLEM", 33, 44], ["cell proliferation", "PROBLEM", 53, 71], ["antibodies bind", "PROBLEM", 78, 93], ["cell apoptosis", "PROBLEM", 136, 150], ["cell proliferation", "OBSERVATION", 53, 71], ["cell apoptosis", "OBSERVATION", 136, 150]]], ["Ligand \u03b12 macroglobulin (\u03b12M), a plasma proteinase inhibitor, affects promoting cell proliferation and viability.", [["plasma", "ANATOMY", 33, 39], ["cell", "ANATOMY", 80, 84], ["\u03b12M", "CHEMICAL", 25, 28], ["\u03b12 macroglobulin", "GENE_OR_GENE_PRODUCT", 7, 23], ["\u03b12M", "GENE_OR_GENE_PRODUCT", 25, 28], ["plasma", "ORGANISM_SUBSTANCE", 33, 39], ["cell", "CELL", 80, 84], ["\u03b12 macroglobulin", "PROTEIN", 7, 23], ["\u03b12M", "PROTEIN", 25, 28], ["macroglobulin", "TEST", 10, 23], ["a plasma proteinase inhibitor", "TREATMENT", 31, 60], ["cell proliferation", "OBSERVATION", 80, 98], ["viability", "OBSERVATION_MODIFIER", 103, 112]]], ["CS-GRP78 has a high affinity to \u03b12M.", [["CS-GRP78", "GENE_OR_GENE_PRODUCT", 0, 8], ["\u03b12M", "GENE_OR_GENE_PRODUCT", 32, 35], ["GRP78", "PROTEIN", 3, 8], ["\u03b12M", "PROTEIN", 32, 35], ["CS", "TEST", 0, 2], ["a high affinity", "PROBLEM", 13, 28], ["high affinity", "OBSERVATION_MODIFIER", 15, 28]]], ["When Isthmin, 60 kDa protein, binds to CS-GRP78, it works as a proapoptotic ligand by induction of mitochondrial dysfunction [27] .", [["mitochondrial", "ANATOMY", 99, 112], ["mitochondrial dysfunction", "DISEASE", 99, 124], ["Isthmin", "GENE_OR_GENE_PRODUCT", 5, 12], ["CS-GRP78", "GENE_OR_GENE_PRODUCT", 39, 47], ["mitochondrial", "CELLULAR_COMPONENT", 99, 112], ["Isthmin", "PROTEIN", 5, 12], ["60 kDa protein", "PROTEIN", 14, 28], ["CS", "PROTEIN", 39, 41], ["GRP78", "PROTEIN", 42, 47], ["CS", "TEST", 39, 41], ["a proapoptotic ligand", "TREATMENT", 61, 82], ["mitochondrial dysfunction", "PROBLEM", 99, 124], ["mitochondrial dysfunction", "OBSERVATION", 99, 124]]], ["Par-4, which is prostate apoptosis response 4, can interact with CS-GRP78 and induce apoptosis through ER stress and the activation of the FADD/caspase-8/caspase-3 pathway.", [["prostate", "ANATOMY", 16, 24], ["Par-4", "GENE_OR_GENE_PRODUCT", 0, 5], ["prostate apoptosis response 4", "GENE_OR_GENE_PRODUCT", 16, 45], ["CS-GRP78", "GENE_OR_GENE_PRODUCT", 65, 73], ["ER", "GENE_OR_GENE_PRODUCT", 103, 105], ["FADD", "GENE_OR_GENE_PRODUCT", 139, 143], ["caspase-8", "GENE_OR_GENE_PRODUCT", 144, 153], ["caspase-3", "GENE_OR_GENE_PRODUCT", 154, 163], ["Par-4", "PROTEIN", 0, 5], ["GRP78", "PROTEIN", 68, 73], ["ER", "PROTEIN", 103, 105], ["FADD", "PROTEIN", 139, 143], ["caspase-8", "PROTEIN", 144, 153], ["caspase-3", "PROTEIN", 154, 163], ["the FADD/caspase", "TREATMENT", 135, 151], ["caspase", "TREATMENT", 154, 161], ["prostate", "ANATOMY", 16, 24], ["apoptosis", "OBSERVATION", 25, 34]]], ["Another way of cell apoptosis induction is by plasminogen Kringle 5 which requires CS-GRP78 to induce apoptosis of dermal microvessel endothelial cells [26] .Cell surface GRP78 expression in response to stressAs we remarked before hypoxia, glucose starvation or tumors cause ER stress.", [["cell", "ANATOMY", 15, 19], ["dermal microvessel endothelial cells", "ANATOMY", 115, 151], ["Cell surface", "ANATOMY", 158, 170], ["tumors", "ANATOMY", 262, 268], ["hypoxia", "DISEASE", 231, 238], ["glucose", "CHEMICAL", 240, 247], ["tumors", "DISEASE", 262, 268], ["glucose", "CHEMICAL", 240, 247], ["cell", "CELL", 15, 19], ["plasminogen Kringle 5", "GENE_OR_GENE_PRODUCT", 46, 67], ["CS-GRP78", "GENE_OR_GENE_PRODUCT", 83, 91], ["dermal microvessel endothelial cells", "CELL", 115, 151], ["Cell", "CELL", 158, 162], ["GRP78", "GENE_OR_GENE_PRODUCT", 171, 176], ["glucose", "SIMPLE_CHEMICAL", 240, 247], ["tumors", "CANCER", 262, 268], ["ER", "GENE_OR_GENE_PRODUCT", 275, 277], ["plasminogen Kringle 5", "PROTEIN", 46, 67], ["GRP78", "PROTEIN", 86, 91], ["dermal microvessel endothelial cells", "CELL_TYPE", 115, 151], ["GRP78", "PROTEIN", 171, 176], ["ER", "PROTEIN", 275, 277], ["cell apoptosis induction", "TREATMENT", 15, 39], ["CS", "TEST", 83, 85], ["dermal microvessel endothelial cells", "PROBLEM", 115, 151], ["stress", "TEST", 203, 209], ["hypoxia", "PROBLEM", 231, 238], ["glucose starvation", "PROBLEM", 240, 258], ["tumors", "PROBLEM", 262, 268], ["ER stress", "PROBLEM", 275, 284], ["cell apoptosis", "OBSERVATION", 15, 29], ["dermal microvessel endothelial cells", "OBSERVATION", 115, 151]]], ["Hypoxia induces CS-GRP78 levels to be increased over fourfold.", [["Hypoxia", "DISEASE", 0, 7], ["CS-GRP78", "GENE_OR_GENE_PRODUCT", 16, 24], ["GRP78", "PROTEIN", 19, 24], ["Hypoxia", "PROBLEM", 0, 7], ["CS", "TEST", 16, 18], ["GRP78 levels", "TEST", 19, 31], ["increased", "OBSERVATION_MODIFIER", 38, 47]]], ["Besides, levels of cell surface GRP78 is correlated to several pathological conditions like many cancers, arthrosclerosis, and rheumatoid arthritis.", [["cell surface", "ANATOMY", 19, 31], ["cancers", "ANATOMY", 97, 104], ["cancers", "DISEASE", 97, 104], ["arthrosclerosis", "DISEASE", 106, 121], ["rheumatoid arthritis", "DISEASE", 127, 147], ["cell", "CELL", 19, 23], ["GRP78", "GENE_OR_GENE_PRODUCT", 32, 37], ["cancers", "CANCER", 97, 104], ["cell surface GRP78", "PROTEIN", 19, 37], ["cell surface GRP78", "TEST", 19, 37], ["several pathological conditions", "PROBLEM", 55, 86], ["many cancers", "PROBLEM", 92, 104], ["arthrosclerosis", "PROBLEM", 106, 121], ["rheumatoid arthritis", "PROBLEM", 127, 147], ["many", "OBSERVATION_MODIFIER", 92, 96], ["cancers", "OBSERVATION", 97, 104], ["arthrosclerosis", "OBSERVATION", 106, 121], ["rheumatoid arthritis", "OBSERVATION", 127, 147]]], ["The presence of GRP78 on the cell surface caused the immune system to generate an autoimmune response and circulating autoantibodies to CS-GRP78 expressed cells [24] .GRP78 and fungal infectionMucorales, which are thermotolerant fungi, can be found in decaying organic material [28] .", [["cell surface", "ANATOMY", 29, 41], ["immune system", "ANATOMY", 53, 66], ["cells", "ANATOMY", 155, 160], ["GRP78", "GENE_OR_GENE_PRODUCT", 16, 21], ["cell surface", "CELLULAR_COMPONENT", 29, 41], ["CS-GRP78", "GENE_OR_GENE_PRODUCT", 136, 144], ["cells", "CELL", 155, 160], ["GRP78", "GENE_OR_GENE_PRODUCT", 167, 172], ["GRP78", "PROTEIN", 16, 21], ["circulating autoantibodies", "PROTEIN", 106, 132], ["GRP78", "PROTEIN", 139, 144], ["GRP78", "PROTEIN", 167, 172], ["GRP78", "PROBLEM", 16, 21], ["the cell surface", "TREATMENT", 25, 41], ["the immune system", "PROBLEM", 49, 66], ["an autoimmune response", "PROBLEM", 79, 101], ["circulating autoantibodies", "TEST", 106, 132], ["CS", "TEST", 136, 138], ["GRP78", "PROBLEM", 167, 172], ["fungal infectionMucorales", "PROBLEM", 177, 202], ["thermotolerant fungi", "PROBLEM", 214, 234], ["GRP78", "OBSERVATION", 16, 21], ["fungal infectionMucorales", "OBSERVATION", 177, 202]]], ["These fungi can cause Mucormycosis disease which is considered as the third common invasive fungal infection in patients who undergo organ transplantations or having hematologic malignant tumors [29] .", [["Mucormycosis", "ANATOMY", 22, 34], ["organ", "ANATOMY", 133, 138], ["hematologic malignant tumors", "ANATOMY", 166, 194], ["Mucormycosis disease", "DISEASE", 22, 42], ["fungal infection", "DISEASE", 92, 108], ["malignant tumors", "DISEASE", 178, 194], ["patients", "ORGANISM", 112, 120], ["organ", "ORGAN", 133, 138], ["hematologic malignant tumors", "CANCER", 166, 194], ["patients", "SPECIES", 112, 120], ["Mucormycosis disease", "PROBLEM", 22, 42], ["the third common invasive fungal infection", "PROBLEM", 66, 108], ["organ transplantations", "TREATMENT", 133, 155], ["hematologic malignant tumors", "PROBLEM", 166, 194], ["Mucormycosis", "OBSERVATION", 22, 34], ["invasive", "OBSERVATION_MODIFIER", 83, 91], ["fungal", "OBSERVATION_MODIFIER", 92, 98], ["infection", "OBSERVATION", 99, 108]]], ["Although there are treatment options for mucormycosis, this disease is characterized by high mortality rates often higher than 40% and in some cases can reach 100% [30, 31] .", [["mucormycosis", "DISEASE", 41, 53], ["treatment options", "TREATMENT", 19, 36], ["mucormycosis", "PROBLEM", 41, 53], ["this disease", "PROBLEM", 55, 67], ["high mortality rates", "PROBLEM", 88, 108], ["mucormycosis", "OBSERVATION", 41, 53], ["high", "OBSERVATION_MODIFIER", 88, 92]]], ["Some of the risk factors that mediate the infection are hematologic malignancy, organ transplantation, and uncontrolled diabetes mellitus [31] .", [["hematologic malignancy", "ANATOMY", 56, 78], ["organ", "ANATOMY", 80, 85], ["infection", "DISEASE", 42, 51], ["malignancy", "DISEASE", 68, 78], ["diabetes mellitus", "DISEASE", 120, 137], ["organ", "ORGAN", 80, 85], ["the risk factors", "PROBLEM", 8, 24], ["the infection", "PROBLEM", 38, 51], ["hematologic malignancy", "PROBLEM", 56, 78], ["organ transplantation", "TREATMENT", 80, 101], ["uncontrolled diabetes mellitus", "PROBLEM", 107, 137], ["infection", "OBSERVATION", 42, 51], ["uncontrolled", "OBSERVATION_MODIFIER", 107, 119]]], ["All Mucorales can cause blood vessel thrombosis leading to tissue necrosis.", [["blood vessel", "ANATOMY", 24, 36], ["tissue", "ANATOMY", 59, 65], ["blood vessel thrombosis", "DISEASE", 24, 47], ["necrosis", "DISEASE", 66, 74], ["blood vessel", "MULTI-TISSUE_STRUCTURE", 24, 36], ["tissue", "TISSUE", 59, 65], ["All Mucorales", "PROBLEM", 0, 13], ["blood vessel thrombosis", "PROBLEM", 24, 47], ["tissue necrosis", "PROBLEM", 59, 74], ["Mucorales", "OBSERVATION", 4, 13], ["vessel", "ANATOMY", 30, 36], ["thrombosis", "OBSERVATION", 37, 47], ["tissue", "OBSERVATION_MODIFIER", 59, 65], ["necrosis", "OBSERVATION", 66, 74]]], ["Therefore, the interaction of Mucorales with the endothelial cells of blood vessels is responsible for their pathogenesis [31] .", [["endothelial cells", "ANATOMY", 49, 66], ["blood vessels", "ANATOMY", 70, 83], ["Mucorales", "GENE_OR_GENE_PRODUCT", 30, 39], ["endothelial cells", "CELL", 49, 66], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 70, 83], ["endothelial cells", "CELL_TYPE", 49, 66], ["the endothelial cells of blood vessels", "TREATMENT", 45, 83], ["endothelial cells", "OBSERVATION", 49, 66], ["vessels", "ANATOMY", 76, 83]]], ["One of the most common fungi belonging to Mucorales order is Rhizopus oryzae (R. oryzae) which is responsible for 70% of reported Mucormycosis cases [31, 32] .", [["Mucormycosis", "DISEASE", 130, 142], ["Mucorales", "ORGANISM", 42, 51], ["Rhizopus oryzae", "ORGANISM", 61, 76], ["R. oryzae", "ORGANISM", 78, 87], ["Rhizopus oryzae", "SPECIES", 61, 76], ["R. oryzae", "SPECIES", 78, 87], ["Rhizopus oryzae", "SPECIES", 61, 76], ["R. oryzae", "SPECIES", 78, 87], ["Mucormycosis", "OBSERVATION", 130, 142]]], ["GRP78 is found to be the receptor mediating the binding of R. oryzae during cell invasion [33] .", [["cell", "ANATOMY", 76, 80], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["R. oryzae", "ORGANISM", 59, 68], ["cell", "CELL", 76, 80], ["GRP78", "PROTEIN", 0, 5], ["R. oryzae", "SPECIES", 59, 68], ["R. oryzae", "SPECIES", 59, 68]]], ["The ligands on the surface of the R. oryzae that bind to GRP78 are spore coat protein homolog (CotH) cell surface proteins [32] .", [["surface", "ANATOMY", 19, 26], ["cell surface", "ANATOMY", 101, 113], ["surface", "CELLULAR_COMPONENT", 19, 26], ["R. oryzae", "ORGANISM", 34, 43], ["GRP78", "GENE_OR_GENE_PRODUCT", 57, 62], ["spore coat protein homolog (CotH) cell surface proteins", "GENE_OR_GENE_PRODUCT", 67, 122], ["GRP78", "PROTEIN", 57, 62], ["spore coat protein homolog (CotH) cell surface proteins", "PROTEIN", 67, 122], ["R. oryzae", "SPECIES", 34, 43], ["R. oryzae", "SPECIES", 34, 43], ["spore coat protein homolog", "TEST", 67, 93], ["cell surface proteins", "TEST", 101, 122], ["ligands", "OBSERVATION_MODIFIER", 4, 11]]], ["There are 3 of these surface proteins named (CotH1, CotH2, and CotH3) surface proteins.", [["surface", "ANATOMY", 21, 28], ["CotH1", "GENE_OR_GENE_PRODUCT", 45, 50], ["CotH2", "GENE_OR_GENE_PRODUCT", 52, 57], ["CotH3) surface proteins", "GENE_OR_GENE_PRODUCT", 63, 86], ["surface proteins", "PROTEIN", 21, 37], ["CotH1", "PROTEIN", 45, 50], ["CotH2", "PROTEIN", 52, 57], ["CotH3", "PROTEIN", 63, 68], ["surface proteins", "PROTEIN", 70, 86], ["these surface proteins", "TEST", 15, 37], ["CotH1", "TEST", 45, 50], ["CotH2", "TEST", 52, 57]]], ["The expression of CotH2 and CotH3 is increased 4-and 16-fold, respectively, when R. oryzae germlings were incubated on endothelial cells [32] .", [["endothelial cells", "ANATOMY", 119, 136], ["CotH2", "GENE_OR_GENE_PRODUCT", 18, 23], ["CotH3", "GENE_OR_GENE_PRODUCT", 28, 33], ["R. oryzae", "ORGANISM", 81, 90], ["germlings", "ORGANISM", 91, 100], ["endothelial cells", "CELL", 119, 136], ["CotH2", "PROTEIN", 18, 23], ["CotH3", "PROTEIN", 28, 33], ["endothelial cells", "CELL_TYPE", 119, 136], ["R. oryzae", "SPECIES", 81, 90], ["R. oryzae", "SPECIES", 81, 90], ["CotH2 and CotH3", "TREATMENT", 18, 33], ["endothelial cells", "TEST", 119, 136], ["increased", "OBSERVATION_MODIFIER", 37, 46]]], ["CotH2 and, to a greater extent, CotH3 surface proteins bind to GRP78 and are responsible for adherence and invasion (endocytosis) of R. oryzae.", [["surface", "ANATOMY", 38, 45], ["CotH2", "GENE_OR_GENE_PRODUCT", 0, 5], ["CotH3 surface proteins", "GENE_OR_GENE_PRODUCT", 32, 54], ["GRP78", "GENE_OR_GENE_PRODUCT", 63, 68], ["R. oryzae", "ORGANISM", 133, 142], ["CotH2", "PROTEIN", 0, 5], ["CotH3 surface proteins", "PROTEIN", 32, 54], ["GRP78", "PROTEIN", 63, 68], ["R. oryzae", "SPECIES", 133, 142], ["R. oryzae", "SPECIES", 133, 142], ["adherence", "PROBLEM", 93, 102], ["invasion", "PROBLEM", 107, 115], ["greater extent", "OBSERVATION_MODIFIER", 16, 30], ["responsible for", "UNCERTAINTY", 77, 92], ["invasion", "OBSERVATION", 107, 115]]], ["Both CotH2 and CotH3 proteins bind to the same alpha-helical bundle domain of GRP78, in silico [32] .GRP78 and viral infectionGRP78 has an essential role in the development of some viruses' envelope proteins such as sindbis virus, hepatitis C virus, vesicular stomatitis virus, and influenza A virus [34] [35] [36] [37] .", [["hepatitis C", "DISEASE", 231, 242], ["vesicular stomatitis", "DISEASE", 250, 270], ["CotH2", "GENE_OR_GENE_PRODUCT", 5, 10], ["CotH3 proteins", "GENE_OR_GENE_PRODUCT", 15, 29], ["GRP78", "GENE_OR_GENE_PRODUCT", 78, 83], ["GRP78", "GENE_OR_GENE_PRODUCT", 101, 106], ["sindbis virus", "ORGANISM", 216, 229], ["hepatitis C virus", "ORGANISM", 231, 248], ["vesicular stomatitis virus", "ORGANISM", 250, 276], ["influenza A virus", "ORGANISM", 282, 299], ["CotH2", "PROTEIN", 5, 10], ["CotH3 proteins", "PROTEIN", 15, 29], ["alpha-helical bundle domain", "PROTEIN", 47, 74], ["GRP78", "PROTEIN", 78, 83], ["GRP78", "PROTEIN", 101, 106], ["viral infectionGRP78", "PROTEIN", 111, 131], ["envelope proteins", "PROTEIN", 190, 207], ["sindbis virus", "SPECIES", 216, 229], ["hepatitis C virus", "SPECIES", 231, 248], ["vesicular stomatitis virus", "SPECIES", 250, 276], ["influenza A virus", "SPECIES", 282, 299], ["sindbis virus", "SPECIES", 216, 229], ["hepatitis C virus", "SPECIES", 231, 248], ["vesicular stomatitis virus", "SPECIES", 250, 276], ["influenza A virus", "SPECIES", 282, 299], ["Both CotH2 and CotH3 proteins bind", "TREATMENT", 0, 34], ["GRP78", "TEST", 78, 83], ["GRP78", "TEST", 101, 106], ["viral infectionGRP78", "PROBLEM", 111, 131], ["some viruses' envelope proteins", "PROBLEM", 176, 207], ["sindbis virus", "PROBLEM", 216, 229], ["hepatitis C virus", "PROBLEM", 231, 248], ["vesicular stomatitis virus", "PROBLEM", 250, 276], ["influenza A virus", "PROBLEM", 282, 299], ["viral infectionGRP78", "OBSERVATION", 111, 131], ["viruses", "OBSERVATION", 181, 188], ["vesicular stomatitis", "ANATOMY", 250, 270]]], ["For some viruses to enter a cell, they need first to attach to a specific cell surface molecule, then uses another molecule that mediates their internalization [38] .", [["cell", "ANATOMY", 28, 32], ["cell surface", "ANATOMY", 74, 86], ["cell", "CELL", 28, 32], ["cell", "CELL", 74, 78], ["some viruses", "PROBLEM", 4, 16], ["viruses", "OBSERVATION", 9, 16]]], ["This complex multi-step process is essential for the viruses to survive the hostile environment of the host immunity [39] .Ebola virusOne of the deadliest re-emerging viruses is filoviruses Ebola virus (EBOV).", [["filoviruses Ebola virus", "DISEASE", 178, 201], ["Ebola virusOne", "ORGANISM", 123, 137], ["filoviruses Ebola virus", "ORGANISM", 178, 201], ["EBOV", "ORGANISM", 203, 207], ["Ebola virus", "SPECIES", 190, 201], ["Ebola virus", "SPECIES", 190, 201], ["EBOV", "SPECIES", 203, 207], ["This complex multi-step process", "PROBLEM", 0, 31], ["the viruses", "PROBLEM", 49, 60], ["filoviruses Ebola virus", "PROBLEM", 178, 201]]], ["Human infection by EBOV causes hemorrhagic fever with case fatality rates in some outbreaks that reached 90% [40] .", [["infection", "DISEASE", 6, 15], ["EBOV", "DISEASE", 19, 23], ["hemorrhagic fever", "DISEASE", 31, 48], ["Human", "ORGANISM", 0, 5], ["EBOV", "ORGANISM", 19, 23], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["EBOV", "SPECIES", 19, 23], ["Human infection", "PROBLEM", 0, 15], ["EBOV", "PROBLEM", 19, 23], ["hemorrhagic fever", "PROBLEM", 31, 48], ["case fatality rates", "PROBLEM", 54, 73], ["some outbreaks", "PROBLEM", 77, 91], ["infection", "OBSERVATION", 6, 15], ["hemorrhagic", "OBSERVATION_MODIFIER", 31, 42]]], ["The epidemic of EBOV requires the utilization of host factors in the different stages of the viral life cycle [41] .", [["EBOV", "DISEASE", 16, 20], ["EBOV", "ORGANISM", 16, 20], ["EBOV", "SPECIES", 16, 20], ["host factors", "TREATMENT", 49, 61], ["EBOV", "OBSERVATION", 16, 20]]], ["Epigallocatechin gallate (EGCG) can inhibit the ability of GRP78 to bind ATP by binding to the ATP-binding site [42] .", [["Epigallocatechin gallate", "CHEMICAL", 0, 24], ["EGCG", "CHEMICAL", 26, 30], ["ATP", "CHEMICAL", 73, 76], ["ATP", "CHEMICAL", 95, 98], ["Epigallocatechin gallate", "CHEMICAL", 0, 24], ["EGCG", "CHEMICAL", 26, 30], ["ATP", "CHEMICAL", 73, 76], ["ATP", "CHEMICAL", 95, 98], ["Epigallocatechin gallate", "SIMPLE_CHEMICAL", 0, 24], ["EGCG", "SIMPLE_CHEMICAL", 26, 30], ["GRP78", "GENE_OR_GENE_PRODUCT", 59, 64], ["ATP", "SIMPLE_CHEMICAL", 73, 76], ["ATP", "SIMPLE_CHEMICAL", 95, 98], ["GRP78", "PROTEIN", 59, 64], ["Epigallocatechin gallate", "TREATMENT", 0, 24]]], ["Using this compound, Shurtleff et al. found that EGCG can inhibit the EBOV infection, demonstrating that the ATPase activity of GRP78 is required for the infection [43] .", [["EGCG", "CHEMICAL", 49, 53], ["EBOV infection", "DISEASE", 70, 84], ["infection", "DISEASE", 154, 163], ["EGCG", "CHEMICAL", 49, 53], ["EGCG", "SIMPLE_CHEMICAL", 49, 53], ["EBOV", "ORGANISM", 70, 74], ["ATPase", "GENE_OR_GENE_PRODUCT", 109, 115], ["GRP78", "GENE_OR_GENE_PRODUCT", 128, 133], ["ATPase", "PROTEIN", 109, 115], ["GRP78", "PROTEIN", 128, 133], ["EBOV", "SPECIES", 70, 74], ["the EBOV infection", "PROBLEM", 66, 84], ["the ATPase activity of GRP78", "PROBLEM", 105, 133], ["the infection", "PROBLEM", 150, 163], ["EBOV", "OBSERVATION_MODIFIER", 70, 74], ["infection", "OBSERVATION", 75, 84]]], ["Besides, they found that using GRP78 siRNA caused a decrease of viral transcript production [43] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 31, 36], ["GRP78", "PROTEIN", 31, 36], ["GRP78 siRNA", "TREATMENT", 31, 42], ["a decrease of viral transcript production", "PROBLEM", 50, 91], ["decrease", "OBSERVATION_MODIFIER", 52, 60], ["viral transcript", "OBSERVATION", 64, 80]]], ["Also, the infection by EBOV results in an increase of HSPA5 expression due to the accumulation of EBOV glycoproteins 1 and 2 (GP1 and GP2) in the endoplasmic reticulum causing a stress response [44] .", [["endoplasmic reticulum", "ANATOMY", 146, 167], ["infection", "DISEASE", 10, 19], ["EBOV", "ORGANISM", 23, 27], ["HSPA5", "GENE_OR_GENE_PRODUCT", 54, 59], ["EBOV glycoproteins 1", "GENE_OR_GENE_PRODUCT", 98, 118], ["2", "GENE_OR_GENE_PRODUCT", 123, 124], ["GP1", "GENE_OR_GENE_PRODUCT", 126, 129], ["GP2", "GENE_OR_GENE_PRODUCT", 134, 137], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 146, 167], ["HSPA5", "PROTEIN", 54, 59], ["EBOV glycoproteins 1 and 2", "PROTEIN", 98, 124], ["GP1", "PROTEIN", 126, 129], ["GP2", "PROTEIN", 134, 137], ["EBOV", "SPECIES", 23, 27], ["EBOV", "SPECIES", 98, 102], ["the infection", "PROBLEM", 6, 19], ["EBOV", "PROBLEM", 23, 27], ["HSPA5 expression", "PROBLEM", 54, 70], ["the accumulation of EBOV glycoproteins", "PROBLEM", 78, 116], ["a stress response", "PROBLEM", 176, 193], ["infection", "OBSERVATION", 10, 19], ["increase", "OBSERVATION_MODIFIER", 42, 50], ["EBOV glycoproteins", "OBSERVATION", 98, 116], ["endoplasmic reticulum", "ANATOMY", 146, 167], ["stress response", "OBSERVATION", 178, 193]]], ["Although GRP78 is involved in the entry of some viruses [38] , knockdown of GRP78 did not affect the entry of EBOV [43] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 9, 14], ["GRP78", "GENE_OR_GENE_PRODUCT", 76, 81], ["EBOV", "ORGANISM", 110, 114], ["GRP78", "PROTEIN", 9, 14], ["GRP78", "PROTEIN", 76, 81], ["GRP78", "PROBLEM", 9, 14], ["some viruses", "PROBLEM", 43, 55], ["knockdown of GRP78", "PROBLEM", 63, 81]]], ["GRP78 has a role in the budding of VP40 protein [43] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["VP40", "GENE_OR_GENE_PRODUCT", 35, 39], ["GRP78", "PROTEIN", 0, 5], ["VP40 protein", "PROTEIN", 35, 47]]], ["This interaction was suggested earlier by Yamayoshi et al. [45] .Zika virusOne of the emerging infectious viruses is Zika virus (ZIKV).", [["infectious viruses", "DISEASE", 95, 113], ["Zika virus", "ORGANISM", 117, 127], ["Zika virus", "SPECIES", 117, 127], ["Zika virus", "SPECIES", 117, 127], ["ZIKV", "SPECIES", 129, 133], ["the emerging infectious viruses", "PROBLEM", 82, 113], ["Zika virus", "PROBLEM", 117, 127], ["infectious", "OBSERVATION", 95, 105]]], ["ZIKV is a flavivirus related to microcephaly, a neurodegenerative disorder, and Guillain-Barr\u00e9 syndrome which is an autoimmune disorder [46, 47] .", [["ZIKV", "CHEMICAL", 0, 4], ["flavivirus", "DISEASE", 10, 20], ["microcephaly", "DISEASE", 32, 44], ["neurodegenerative disorder", "DISEASE", 48, 74], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 80, 103], ["autoimmune disorder", "DISEASE", 116, 135], ["ZIKV", "GENE_OR_GENE_PRODUCT", 0, 4], ["Guillain-Barr\u00e9", "ORGANISM", 80, 94], ["ZIKV", "SPECIES", 0, 4], ["ZIKV", "PROBLEM", 0, 4], ["a flavivirus", "PROBLEM", 8, 20], ["microcephaly", "PROBLEM", 32, 44], ["a neurodegenerative disorder", "PROBLEM", 46, 74], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 80, 103], ["an autoimmune disorder", "PROBLEM", 113, 135], ["flavivirus", "OBSERVATION", 10, 20], ["microcephaly", "OBSERVATION", 32, 44], ["neurodegenerative", "OBSERVATION_MODIFIER", 48, 65], ["disorder", "OBSERVATION", 66, 74], ["Barr\u00e9 syndrome", "OBSERVATION", 89, 103], ["autoimmune", "OBSERVATION", 116, 126]]], ["Two possible routes of transmission are through Aedes mosquitos, as they are the major species of mosquitos responsible for the transmission of the virus, or through sexual intercourse, though it is not significant [48, 49] .", [["mosquitos", "DISEASE", 98, 107], ["sexual intercourse", "DISEASE", 166, 184], ["Aedes mosquitos", "ORGANISM", 48, 63], ["mosquitos", "GENE_OR_GENE_PRODUCT", 98, 107], ["Aedes mosquitos", "SPECIES", 48, 63], ["the virus", "PROBLEM", 144, 153]]], ["The genome of ZIKV is nearly 11 kb long with a single open reading frame (ORF) flanked by noncoding regions at the two ends [50] .", [["ZIKV", "GENE_OR_GENE_PRODUCT", 14, 18], ["ZIKV", "DNA", 14, 18], ["open reading frame", "DNA", 54, 72], ["ORF", "DNA", 74, 77], ["noncoding regions", "DNA", 90, 107], ["ZIKV", "OBSERVATION", 14, 18]]], ["The end products of ORF are capsid, the precursor of membrane, envelope, and seven non-structural proteins [51] .", [["membrane", "ANATOMY", 53, 61], ["ORF", "GENE_OR_GENE_PRODUCT", 20, 23], ["membrane", "CELLULAR_COMPONENT", 53, 61], ["ORF", "DNA", 20, 23], ["non-structural proteins", "PROTEIN", 83, 106], ["ORF", "PROBLEM", 20, 23], ["capsid", "PROBLEM", 28, 34], ["seven non-structural proteins", "TEST", 77, 106], ["capsid", "OBSERVATION_MODIFIER", 28, 34]]], ["The envelope protein is responsible for cellular attachment, entry, and fusion [52] .", [["cellular", "ANATOMY", 40, 48], ["cellular", "CELL", 40, 48], ["envelope protein", "PROTEIN", 4, 20], ["The envelope protein", "TEST", 0, 20], ["cellular attachment", "PROBLEM", 40, 59], ["envelope protein", "OBSERVATION", 4, 20], ["is responsible for", "UNCERTAINTY", 21, 39], ["cellular attachment", "OBSERVATION", 40, 59]]], ["One of the receptors responsible for the endocytosis of the virus is GRP78 [53, 54] .Dengue virusAnother mosquito-borne virus belonging to the flavivirus genus is Dengue virus (DENV) [55, 56] .", [["Dengue", "DISEASE", 85, 91], ["mosquito-borne virus belonging to the flavivirus", "DISEASE", 105, 153], ["Dengue virus", "DISEASE", 163, 175], ["GRP78", "GENE_OR_GENE_PRODUCT", 69, 74], ["Dengue virus", "ORGANISM", 85, 97], ["mosquito-borne virus", "ORGANISM", 105, 125], ["Dengue virus", "ORGANISM", 163, 175], ["DENV", "ORGANISM", 177, 181], ["GRP78", "PROTEIN", 69, 74], ["Dengue virus", "SPECIES", 85, 97], ["mosquito-borne virus", "SPECIES", 105, 125], ["Dengue virus", "SPECIES", 163, 175], ["Dengue virus", "SPECIES", 85, 97], ["mosquito-borne virus", "SPECIES", 105, 125], ["Dengue virus", "SPECIES", 163, 175], ["DENV", "SPECIES", 177, 181], ["the endocytosis of the virus", "PROBLEM", 37, 65], ["Dengue virus", "PROBLEM", 85, 97], ["Another mosquito-borne virus", "PROBLEM", 97, 125], ["Dengue virus", "PROBLEM", 163, 175]]], ["Its genome is positive-stranded RNA, which encodes, after the processing of the polyprotein produced from the RNA, three structural and seven non-structural proteins.", [["positive-stranded RNA", "RNA", 14, 35], ["RNA", "RNA", 110, 113], ["non-structural proteins", "PROTEIN", 142, 165], ["stranded RNA", "PROBLEM", 23, 35], ["the polyprotein", "TREATMENT", 76, 91], ["genome", "OBSERVATION", 4, 10], ["positive", "OBSERVATION_MODIFIER", 14, 22], ["stranded RNA", "OBSERVATION_MODIFIER", 23, 35], ["non-structural proteins", "OBSERVATION", 142, 165]]], ["It has four serotypes (DENV1-4) [57] .", [["serotypes", "OBSERVATION_MODIFIER", 12, 21]]], ["This virus can cause a wide range of diseases such as; dengue fever (benign self -limited febrile illness), dengue hemorrhagic fever, or dengue shock syndrome [55] .", [["dengue fever", "DISEASE", 55, 67], ["febrile illness", "DISEASE", 90, 105], ["dengue hemorrhagic fever", "DISEASE", 108, 132], ["dengue shock syndrome", "DISEASE", 137, 158], ["dengue hemorrhagic fever", "SPECIES", 108, 132], ["This virus", "PROBLEM", 0, 10], ["a wide range of diseases", "PROBLEM", 21, 45], ["dengue fever", "PROBLEM", 55, 67], ["benign self -limited febrile illness", "PROBLEM", 69, 105], ["dengue hemorrhagic fever", "PROBLEM", 108, 132], ["dengue shock syndrome", "PROBLEM", 137, 158], ["wide", "OBSERVATION_MODIFIER", 23, 27], ["hemorrhagic", "OBSERVATION_MODIFIER", 115, 126], ["fever", "OBSERVATION", 127, 132], ["shock syndrome", "OBSERVATION", 144, 158]]], ["GRP78 is identified as a receptor for dengue virus serotype 2 in hepatoma cells (HepG2) [58] .", [["hepatoma cells", "ANATOMY", 65, 79], ["HepG2", "ANATOMY", 81, 86], ["dengue", "DISEASE", 38, 44], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["dengue virus serotype 2", "ORGANISM", 38, 61], ["hepatoma cells", "CELL", 65, 79], ["HepG2", "CELL", 81, 86], ["GRP78", "PROTEIN", 0, 5], ["hepatoma cells", "CELL_TYPE", 65, 79], ["HepG2", "CELL_LINE", 81, 86], ["dengue virus serotype", "SPECIES", 38, 59], ["dengue virus", "SPECIES", 38, 50], ["a receptor", "TREATMENT", 23, 33], ["dengue virus serotype", "PROBLEM", 38, 59], ["hepatoma", "ANATOMY", 65, 73]]], ["Jindadamrongwech et al. found that using an antibody against N-terminal of GRP78 inhibited binding and infection while using antibodies against the C-terminal of GRP78 increase the infection and, to a less noticeable degree, the binding of the virus to the receptor.", [["infection", "DISEASE", 103, 112], ["infection", "DISEASE", 181, 190], ["N", "CHEMICAL", 61, 62], ["C", "CHEMICAL", 148, 149], ["GRP78", "GENE_OR_GENE_PRODUCT", 75, 80], ["GRP78", "GENE_OR_GENE_PRODUCT", 162, 167], ["N-terminal", "PROTEIN", 61, 71], ["GRP78", "PROTEIN", 75, 80], ["antibodies", "PROTEIN", 125, 135], ["C-terminal", "PROTEIN", 148, 158], ["GRP78", "PROTEIN", 162, 167], ["an antibody", "TEST", 41, 52], ["GRP78 inhibited binding", "PROBLEM", 75, 98], ["infection", "PROBLEM", 103, 112], ["antibodies", "TREATMENT", 125, 135], ["the C-terminal of GRP78", "PROBLEM", 144, 167], ["the infection", "PROBLEM", 177, 190], ["infection", "OBSERVATION", 103, 112], ["increase", "OBSERVATION_MODIFIER", 168, 176], ["infection", "OBSERVATION", 181, 190], ["less noticeable degree", "OBSERVATION_MODIFIER", 201, 223]]], ["This increase is related to the concentration of antibodies [58] .", [["antibodies", "PROTEIN", 49, 59], ["the concentration of antibodies", "PROBLEM", 28, 59]]], ["This may be due to the conformational changes produced from the C-terminal antibody binding to GRP78, enhancing the binding ability of the virus to the protein [58] .Japanese Encephalitis VirusJapanese Encephalitis Virus (JEV) is a member of the Flaviviridae family.", [["Encephalitis VirusJapanese Encephalitis Virus", "DISEASE", 175, 220], ["JEV", "DISEASE", 222, 225], ["C", "CHEMICAL", 64, 65], ["GRP78", "GENE_OR_GENE_PRODUCT", 95, 100], ["Japanese Encephalitis VirusJapanese Encephalitis Virus", "ORGANISM", 166, 220], ["JEV", "ORGANISM", 222, 225], ["C-terminal antibody", "PROTEIN", 64, 83], ["GRP78", "PROTEIN", 95, 100], ["VirusJapanese Encephalitis Virus", "SPECIES", 188, 220], ["Japanese Encephalitis VirusJapanese Encephalitis Virus", "SPECIES", 166, 220], ["JEV", "SPECIES", 222, 225], ["the conformational changes", "PROBLEM", 19, 45], ["the C-terminal antibody binding", "PROBLEM", 60, 91], ["Japanese Encephalitis VirusJapanese Encephalitis Virus", "PROBLEM", 166, 220], ["may be due to", "UNCERTAINTY", 5, 18]]], ["Other mosquito-borne, and medically important pathogens viruses belonging to this family are DENV and West Nile virus [59] .", [["DENV", "ORGANISM", 93, 97], ["West Nile virus", "ORGANISM", 102, 117], ["West Nile virus", "SPECIES", 102, 117], ["DENV", "SPECIES", 93, 97], ["West Nile virus", "SPECIES", 102, 117], ["DENV", "PROBLEM", 93, 97]]], ["JEV is a neurotropic virus which causes encephalitis in humans and has a mortality rate ranging from 25% to 30% [59] .", [["JEV", "DISEASE", 0, 3], ["encephalitis", "DISEASE", 40, 52], ["JEV", "ORGANISM", 0, 3], ["humans", "ORGANISM", 56, 62], ["humans", "SPECIES", 56, 62], ["JEV", "SPECIES", 0, 3], ["humans", "SPECIES", 56, 62], ["JEV", "PROBLEM", 0, 3], ["a neurotropic virus", "PROBLEM", 7, 26], ["encephalitis", "PROBLEM", 40, 52], ["a mortality rate", "TEST", 71, 87], ["neurotropic virus", "OBSERVATION", 9, 26], ["encephalitis", "OBSERVATION", 40, 52]]], ["For the JEV to enter a cell, it needs first to attach to the cell membrane through the help of specific receptors such as heparan sulfate proteoglycans (HSPGs) and glycosaminoglycans (GAGs) [60, 61] .", [["cell", "ANATOMY", 23, 27], ["cell membrane", "ANATOMY", 61, 74], ["heparan sulfate", "CHEMICAL", 122, 137], ["JEV", "ORGANISM", 8, 11], ["cell", "CELL", 23, 27], ["cell membrane", "CELLULAR_COMPONENT", 61, 74], ["heparan sulfate proteoglycans", "GENE_OR_GENE_PRODUCT", 122, 151], ["HSPGs", "GENE_OR_GENE_PRODUCT", 153, 158], ["glycosaminoglycans", "SIMPLE_CHEMICAL", 164, 182], ["GAGs", "GENE_OR_GENE_PRODUCT", 184, 188], ["heparan sulfate proteoglycans", "PROTEIN", 122, 151], ["HSPGs", "PROTEIN", 153, 158], ["JEV", "SPECIES", 8, 11], ["the JEV", "PROBLEM", 4, 11], ["specific receptors", "TREATMENT", 95, 113], ["heparan sulfate proteoglycans", "TREATMENT", 122, 151]]], ["Nain et al. identified GRP78 as a receptor for JEV envelope domain III (ED3) [62] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 23, 28], ["JEV envelope domain III", "GENE_OR_GENE_PRODUCT", 47, 70], ["GRP78", "PROTEIN", 23, 28], ["JEV envelope domain III", "PROTEIN", 47, 70], ["ED3", "PROTEIN", 72, 75]]], ["They checked the interaction between GRP78 and JEV ED3 by using firefly luciferase gene which showed a substantial activity, confirming this interaction [62] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 37, 42], ["JEV", "ORGANISM", 47, 50], ["ED3", "GENE_OR_GENE_PRODUCT", 51, 54], ["luciferase", "GENE_OR_GENE_PRODUCT", 72, 82], ["GRP78", "PROTEIN", 37, 42], ["JEV ED3", "PROTEIN", 47, 54], ["firefly luciferase gene", "DNA", 64, 87], ["JEV", "SPECIES", 47, 50], ["JEV ED3", "TEST", 47, 54], ["firefly luciferase gene", "TEST", 64, 87], ["substantial", "OBSERVATION_MODIFIER", 103, 114], ["activity", "OBSERVATION_MODIFIER", 115, 123]]], ["Using N-terminal GRP78 antibody, the interaction is revealed to be between the N-terminal GRP78 and JEV ED3 as the binding between GRP78 and JEV ED3 reduced by nearly 38% [62] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 17, 22], ["GRP78", "GENE_OR_GENE_PRODUCT", 90, 95], ["JEV", "ORGANISM", 100, 103], ["ED3", "GENE_OR_GENE_PRODUCT", 104, 107], ["GRP78", "GENE_OR_GENE_PRODUCT", 131, 136], ["JEV", "ORGANISM", 141, 144], ["ED3", "GENE_OR_GENE_PRODUCT", 145, 148], ["N-terminal GRP78 antibody", "PROTEIN", 6, 31], ["N-terminal GRP78", "PROTEIN", 79, 95], ["JEV ED3", "PROTEIN", 100, 107], ["GRP78", "PROTEIN", 131, 136], ["JEV ED3", "PROTEIN", 141, 148], ["JEV", "SPECIES", 100, 103], ["JEV", "SPECIES", 141, 144], ["N-terminal GRP78 antibody", "TEST", 6, 31], ["the N-terminal GRP78", "TEST", 75, 95], ["GRP78", "TEST", 131, 136], ["JEV ED3", "TEST", 141, 148]]], ["Besides, they confirmed the role of GRP78 in the internalization of JEV by using GRP78 siRNA, then measuring the JEV RNA 2 h post infection, at this time the level of RNA is an indication of the viral entry only.", [["infection", "DISEASE", 130, 139], ["GRP78", "GENE_OR_GENE_PRODUCT", 36, 41], ["JEV", "ORGANISM", 68, 71], ["GRP78", "GENE_OR_GENE_PRODUCT", 81, 86], ["GRP78", "PROTEIN", 36, 41], ["GRP78 siRNA", "RNA", 81, 92], ["JEV RNA", "RNA", 113, 120], ["JEV", "SPECIES", 68, 71], ["JEV", "SPECIES", 113, 116], ["GRP78 siRNA", "TREATMENT", 81, 92], ["infection", "PROBLEM", 130, 139], ["infection", "OBSERVATION", 130, 139], ["RNA", "OBSERVATION", 167, 170], ["viral entry", "OBSERVATION", 195, 206]]], ["This test shows a significant reduction in JEV RNA in cells by nearly 60% [62] .", [["cells", "ANATOMY", 54, 59], ["JEV", "ORGANISM", 43, 46], ["cells", "CELL", 54, 59], ["JEV RNA", "RNA", 43, 50], ["JEV", "SPECIES", 43, 46], ["This test", "TEST", 0, 9], ["a significant reduction in JEV RNA in cells", "PROBLEM", 16, 59], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["reduction", "OBSERVATION_MODIFIER", 30, 39], ["JEV RNA", "OBSERVATION", 43, 50]]], ["GRP78 also has a role in the replication of JEV [62] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["JEV", "ORGANISM", 44, 47], ["GRP78", "PROTEIN", 0, 5], ["JEV", "SPECIES", 44, 47]]], ["This role is demonstrated by using Subtilase cytotoxin which can break GRP78 into its C-and Nterminals leading to its deactivation [63] .", [["Subtilase cytotoxin", "GENE_OR_GENE_PRODUCT", 35, 54], ["GRP78", "GENE_OR_GENE_PRODUCT", 71, 76], ["Nterminals", "SIMPLE_CHEMICAL", 92, 102], ["Subtilase cytotoxin", "PROTEIN", 35, 54], ["GRP78", "PROTEIN", 71, 76], ["C-and Nterminals", "PROTEIN", 86, 102], ["Subtilase cytotoxin", "TREATMENT", 35, 54]]], ["A 90% reduction in the viral RNA in all cells was reported, indicating the significant role of GRP78 JEV replication [62] .Middle-East Respiratory Syndrome coronavirusCoronaviruses are enveloped single-stranded positive-sense RNA viruses that can infect a wide range of species including humans [64] .", [["cells", "ANATOMY", 40, 45], ["cells", "CELL", 40, 45], ["GRP78", "GENE_OR_GENE_PRODUCT", 95, 100], ["Middle-East Respiratory Syndrome coronavirus", "ORGANISM", 123, 167], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 167, 180], ["humans", "ORGANISM", 288, 294], ["viral RNA", "RNA", 23, 32], ["GRP78", "PROTEIN", 95, 100], ["coronavirus", "SPECIES", 156, 167], ["humans", "SPECIES", 288, 294], ["JEV", "SPECIES", 101, 104], ["Middle-East Respiratory Syndrome coronavirus", "SPECIES", 123, 167], ["humans", "SPECIES", 288, 294], ["A 90% reduction", "TREATMENT", 0, 15], ["the viral RNA in all cells", "PROBLEM", 19, 45], ["Middle-East Respiratory Syndrome coronavirus", "PROBLEM", 123, 167], ["Coronaviruses", "PROBLEM", 167, 180], ["sense RNA viruses", "PROBLEM", 220, 237], ["reduction", "OBSERVATION_MODIFIER", 6, 15], ["viral RNA", "OBSERVATION", 23, 32], ["JEV replication", "OBSERVATION", 101, 116], ["Respiratory Syndrome", "OBSERVATION", 135, 155], ["coronavirus", "OBSERVATION", 156, 167], ["sense RNA", "OBSERVATION_MODIFIER", 220, 229], ["viruses", "OBSERVATION", 230, 237], ["wide", "OBSERVATION_MODIFIER", 256, 260]]], ["They are classified into alpha-, beta-, gamma-, and delta coronaviruses [64] .", [["alpha-", "GENE_OR_GENE_PRODUCT", 25, 31], ["beta-", "GENE_OR_GENE_PRODUCT", 33, 38], ["gamma-", "GENE_OR_GENE_PRODUCT", 40, 46], ["delta coronaviruses", "ORGANISM", 52, 71], ["alpha-", "TEST", 25, 31], ["delta coronaviruses", "PROBLEM", 52, 71]]], ["One of the viruses belonging to betacoronaviruses is Middle East Respiratory Syndrome Coronavirus (MERS-CoV) which causes severe lower respiratory tract infection with a high mortality rate reaching 35% [64, 65] .", [["lower respiratory tract", "ANATOMY", 129, 152], ["Middle East Respiratory Syndrome Coronavirus", "DISEASE", 53, 97], ["lower respiratory tract infection", "DISEASE", 129, 162], ["Middle East Respiratory Syndrome Coronavirus", "ORGANISM", 53, 97], ["MERS-CoV", "ORGANISM", 99, 107], ["lower", "ORGANISM_SUBDIVISION", 129, 134], ["respiratory tract", "ORGANISM_SUBDIVISION", 135, 152], ["Middle East Respiratory Syndrome Coronavirus (MERS-CoV", "SPECIES", 53, 107], ["Middle East Respiratory Syndrome Coronavirus", "PROBLEM", 53, 97], ["severe lower respiratory tract infection", "PROBLEM", 122, 162], ["a high mortality rate", "PROBLEM", 168, 189], ["viruses", "OBSERVATION", 11, 18], ["Middle", "ANATOMY_MODIFIER", 53, 59], ["Respiratory Syndrome", "OBSERVATION", 65, 85], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["lower", "ANATOMY_MODIFIER", 129, 134], ["respiratory tract", "ANATOMY", 135, 152], ["infection", "OBSERVATION", 153, 162]]], ["The MERS-CoV spike protein utilizes dipeptidyl peptidase 4 (DPP4) as its functional receptor for host cell entry [66] .", [["cell", "ANATOMY", 102, 106], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 36, 58], ["DPP4", "GENE_OR_GENE_PRODUCT", 60, 64], ["host cell", "CELL", 97, 106], ["MERS-CoV spike protein", "PROTEIN", 4, 26], ["dipeptidyl peptidase 4", "PROTEIN", 36, 58], ["DPP4", "PROTEIN", 60, 64], ["MERS-CoV", "SPECIES", 4, 12], ["The MERS", "PROBLEM", 0, 8], ["CoV spike protein", "TREATMENT", 9, 26], ["dipeptidyl peptidase 4 (DPP4)", "TREATMENT", 36, 65]]], ["In addition to its functional receptor, MERS-CoV can recognize other molecules to facilitate their attachment and entry, for example, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), and tetraspanin CD9 are identified as a factor promoting the virus entry in permissive cells [67, 68] .", [["cells", "ANATOMY", 290, 295], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 40, 48], ["carcinoembryonic antigen-related cell adhesion molecule 5", "GENE_OR_GENE_PRODUCT", 134, 191], ["CEACAM5", "GENE_OR_GENE_PRODUCT", 193, 200], ["tetraspanin CD9", "GENE_OR_GENE_PRODUCT", 207, 222], ["cells", "CELL", 290, 295], ["MERS-CoV", "PROTEIN", 40, 48], ["carcinoembryonic antigen-related cell adhesion molecule 5", "PROTEIN", 134, 191], ["CEACAM5", "PROTEIN", 193, 200], ["tetraspanin CD9", "PROTEIN", 207, 222], ["permissive cells", "CELL_TYPE", 279, 295], ["carcinoembryonic antigen", "TEST", 134, 158], ["cell adhesion molecule", "PROBLEM", 167, 189], ["tetraspanin CD9", "TREATMENT", 207, 222], ["cell adhesion", "OBSERVATION", 167, 180]]], ["Recently GRP78 was recognized as an attachment factor for MERS-CoV spike protein that enhances the virus entry in the presence of DPP4 [65] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 9, 14], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 58, 66], ["DPP4", "GENE_OR_GENE_PRODUCT", 130, 134], ["GRP78", "PROTEIN", 9, 14], ["attachment factor", "PROTEIN", 36, 53], ["MERS-CoV spike protein", "PROTEIN", 58, 80], ["DPP4", "PROTEIN", 130, 134], ["an attachment factor", "PROBLEM", 33, 53], ["MERS", "PROBLEM", 58, 62], ["CoV spike protein", "PROBLEM", 63, 80], ["DPP4", "TEST", 130, 134]]], ["In addition to GRP78 role in the entrance of the virus, it has a role in the replication of MERS-CoV [65] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 15, 20], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 92, 100], ["GRP78", "PROTEIN", 15, 20], ["MERS-CoV", "SPECIES", 92, 100], ["the virus", "PROBLEM", 45, 54], ["virus", "OBSERVATION", 49, 54]]], ["CS GRP78 is upregulated after the entry of MERS-CoV, which helps in the attachment of the virus [65] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 3, 8], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 43, 51], ["GRP78", "PROTEIN", 3, 8], ["MERS", "PROTEIN", 43, 47], ["MERS-CoV", "SPECIES", 43, 51], ["CoV", "PROBLEM", 48, 51], ["upregulated", "OBSERVATION_MODIFIER", 12, 23]]], ["Although knockdown of GRP78 led to a decrease in the replication of the virus, this decrease is lesser compared to the reduction in the replication of the virus when DPP4 is reduced [65] .Coxsackievirus A9Coxsackievirus A9 (CAV9) is a non-enveloped RNA virus that can cause flaccid paralysis, and chronic dilated cardiomyopathy [69] .", [["flaccid", "ANATOMY", 274, 281], ["flaccid paralysis", "DISEASE", 274, 291], ["chronic dilated cardiomyopathy", "DISEASE", 297, 327], ["GRP78", "GENE_OR_GENE_PRODUCT", 22, 27], ["DPP4", "GENE_OR_GENE_PRODUCT", 166, 170], ["Coxsackievirus A9Coxsackievirus A9", "ORGANISM", 188, 222], ["CAV9", "GENE_OR_GENE_PRODUCT", 224, 228], ["GRP78", "PROTEIN", 22, 27], ["DPP4", "PROTEIN", 166, 170], ["Coxsackievirus A9Coxsackievirus", "SPECIES", 188, 219], ["Coxsackievirus A9Coxsackievirus A9", "SPECIES", 188, 222], ["CAV9", "SPECIES", 224, 228], ["knockdown of GRP78", "PROBLEM", 9, 27], ["a decrease", "PROBLEM", 35, 45], ["the virus", "PROBLEM", 68, 77], ["the reduction", "TREATMENT", 115, 128], ["DPP4", "TEST", 166, 170], ["Coxsackievirus A9Coxsackievirus A9 (CAV9)", "PROBLEM", 188, 229], ["a non-enveloped RNA virus", "PROBLEM", 233, 258], ["flaccid paralysis", "PROBLEM", 274, 291], ["chronic dilated cardiomyopathy", "PROBLEM", 297, 327], ["decrease", "OBSERVATION_MODIFIER", 37, 45], ["virus", "OBSERVATION", 72, 77], ["decrease", "OBSERVATION_MODIFIER", 84, 92], ["lesser", "OBSERVATION_MODIFIER", 96, 102], ["non-enveloped RNA virus", "OBSERVATION", 235, 258], ["flaccid", "OBSERVATION_MODIFIER", 274, 281], ["paralysis", "OBSERVATION", 282, 291], ["chronic", "OBSERVATION_MODIFIER", 297, 304], ["dilated", "OBSERVATION_MODIFIER", 305, 312], ["cardiomyopathy", "OBSERVATION", 313, 327]]], ["Besides, it is involved in autoimmune episodes that result in insulin-dependent diabetes mellitus [70, 71] .", [["autoimmune episodes", "DISEASE", 27, 46], ["diabetes mellitus", "DISEASE", 80, 97], ["insulin", "GENE_OR_GENE_PRODUCT", 62, 69], ["autoimmune episodes", "PROBLEM", 27, 46], ["insulin-dependent diabetes mellitus", "PROBLEM", 62, 97]]], ["Integrin alpha-v beta 3(\u03b1v\u03b23) is a receptor that can be used by CAV9 [72] [73] [74] , but its utilization is not sufficient for its infection [72] .", [["infection", "DISEASE", 132, 141], ["CAV9 [72] [73] [74]", "CHEMICAL", 64, 83], ["Integrin alpha-v beta 3", "GENE_OR_GENE_PRODUCT", 0, 23], ["\u03b1v\u03b23", "GENE_OR_GENE_PRODUCT", 24, 28], ["Integrin alpha-v beta 3", "PROTEIN", 0, 23], ["\u03b1v\u03b23", "PROTEIN", 24, 28], ["Integrin alpha", "TEST", 0, 14], ["its infection", "PROBLEM", 128, 141], ["infection", "OBSERVATION", 132, 141]]], ["GRP78 was identified by Triantafilou et al. to be utilized by CAV9 for infection [38] .", [["CAV9", "CHEMICAL", 62, 66], ["infection", "DISEASE", 71, 80], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["GRP78", "PROTEIN", 0, 5], ["infection", "PROBLEM", 71, 80], ["infection", "OBSERVATION", 71, 80]]], ["GRP78 delivers viral peptides to MHC-I [75] , and it is found that GRP78 is associated with MHC-I molecules on the cell membrane [38] .", [["cell membrane", "ANATOMY", 115, 128], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["MHC-I", "GENE_OR_GENE_PRODUCT", 33, 38], ["GRP78", "GENE_OR_GENE_PRODUCT", 67, 72], ["MHC-I", "GENE_OR_GENE_PRODUCT", 92, 97], ["cell membrane", "CELLULAR_COMPONENT", 115, 128], ["GRP78", "PROTEIN", 0, 5], ["MHC", "PROTEIN", 33, 36], ["GRP78", "PROTEIN", 67, 72], ["MHC-I molecules", "PROTEIN", 92, 107], ["GRP78", "PROBLEM", 67, 72], ["the cell membrane", "TEST", 111, 128], ["cell membrane", "OBSERVATION", 115, 128]]], ["After CAV9 binds to GRP78, it causes an increase in the clustering of GRP78 and MHC-1 molecules [38] .", [["CAV9", "GENE_OR_GENE_PRODUCT", 6, 10], ["GRP78", "GENE_OR_GENE_PRODUCT", 20, 25], ["GRP78", "GENE_OR_GENE_PRODUCT", 70, 75], ["MHC-1", "GENE_OR_GENE_PRODUCT", 80, 85], ["CAV9", "PROTEIN", 6, 10], ["GRP78", "PROTEIN", 20, 25], ["GRP78", "PROTEIN", 70, 75], ["MHC", "PROTEIN", 80, 83], ["an increase", "PROBLEM", 37, 48], ["MHC", "TEST", 80, 83], ["increase", "OBSERVATION_MODIFIER", 40, 48]]], ["Triantafilou et al. used anti-MHC-I antibodies (W6/32, MCA1115) to determine whether MHC-I helps in internalization of the CAV9 virus [38] .", [["anti-MHC-I antibodies", "GENE_OR_GENE_PRODUCT", 25, 46], ["MHC-I", "GENE_OR_GENE_PRODUCT", 85, 90], ["CAV9 virus", "ORGANISM", 123, 133], ["anti-MHC-I antibodies", "PROTEIN", 25, 46], ["W6/32", "PROTEIN", 48, 53], ["MCA1115", "PROTEIN", 55, 62], ["MHC-I", "PROTEIN", 85, 90], ["CAV9 virus", "SPECIES", 123, 133], ["anti-MHC", "TREATMENT", 25, 33], ["I antibodies", "TEST", 34, 46], ["the CAV9 virus", "PROBLEM", 119, 133]]], ["Although there is no change in binding, they found that the internalization is inhibited by 85% using these antibodies [38] .", [["antibodies", "PROTEIN", 108, 118], ["change in binding", "PROBLEM", 21, 38], ["these antibodies", "TEST", 102, 118], ["no", "UNCERTAINTY", 18, 20], ["change", "OBSERVATION_MODIFIER", 21, 27]]], ["They suggested a model in which CAV9 attach to the cell by binding to GRP78 and Integrin \u03b1v\u03b23, then uses MHC-I which is associated with GRP78 for entry so it can use the cell machinery [38] .Borna Disease virusOne of the viruses that belong to Bornaviridae is Borna Disease Virus (BDV) [76] .", [["cell", "ANATOMY", 51, 55], ["cell", "ANATOMY", 170, 174], ["Borna Disease", "DISEASE", 260, 273], ["CAV9", "GENE_OR_GENE_PRODUCT", 32, 36], ["cell", "CELL", 51, 55], ["GRP78", "GENE_OR_GENE_PRODUCT", 70, 75], ["Integrin \u03b1v\u03b23", "GENE_OR_GENE_PRODUCT", 80, 93], ["MHC-I", "GENE_OR_GENE_PRODUCT", 105, 110], ["GRP78", "GENE_OR_GENE_PRODUCT", 136, 141], ["cell", "CELL", 170, 174], ["Borna Disease virusOne", "ORGANISM", 191, 213], ["Borna Disease Virus", "ORGANISM", 260, 279], ["BDV", "ORGANISM", 281, 284], ["CAV9", "PROTEIN", 32, 36], ["GRP78", "PROTEIN", 70, 75], ["Integrin \u03b1v\u03b23", "PROTEIN", 80, 93], ["MHC-I", "PROTEIN", 105, 110], ["GRP78", "PROTEIN", 136, 141], ["Borna Disease Virus", "SPECIES", 260, 279], ["Borna Disease Virus", "SPECIES", 260, 279], ["BDV", "SPECIES", 281, 284], ["a model in which CAV9 attach", "TREATMENT", 15, 43], ["Integrin \u03b1v\u03b23", "TREATMENT", 80, 93], ["the cell machinery", "TREATMENT", 166, 184], ["Borna Disease virusOne", "PROBLEM", 191, 213], ["the viruses", "PROBLEM", 217, 228], ["Borna Disease Virus", "PROBLEM", 260, 279], ["Borna Disease", "OBSERVATION", 260, 273]]], ["BDV is non-segmented, negative-strand RNA virus with high neurotropic and non-cytopathic infection [76] .", [["infection", "DISEASE", 89, 98], ["BDV", "ORGANISM", 0, 3], ["BDV", "SPECIES", 0, 3], ["BDV", "TEST", 0, 3], ["strand RNA virus", "PROBLEM", 31, 47], ["high neurotropic and non-cytopathic infection", "PROBLEM", 53, 98], ["negative", "OBSERVATION", 22, 30], ["strand RNA virus", "OBSERVATION", 31, 47], ["high", "OBSERVATION_MODIFIER", 53, 57], ["neurotropic", "OBSERVATION_MODIFIER", 58, 69], ["non-cytopathic", "OBSERVATION_MODIFIER", 74, 88], ["infection", "OBSERVATION", 89, 98]]], ["This virus infects many animals and causes central nervous system diseases which are associated with behavioral disturbances [77] .", [["central nervous system", "ANATOMY", 43, 65], ["central nervous system diseases", "DISEASE", 43, 74], ["behavioral disturbances", "DISEASE", 101, 124], ["central nervous system", "ANATOMICAL_SYSTEM", 43, 65], ["This virus infects", "PROBLEM", 0, 18], ["central nervous system diseases", "PROBLEM", 43, 74], ["behavioral disturbances", "PROBLEM", 101, 124], ["central nervous system diseases", "OBSERVATION", 43, 74]]], ["Virus entry is mediated by endocytosis after the viral envelope glycoprotein (G) attach to the cell receptor [78, 79] .", [["cell", "ANATOMY", 95, 99], ["Virus", "ORGANISM", 0, 5], ["glycoprotein (G)", "GENE_OR_GENE_PRODUCT", 64, 80], ["cell", "CELL", 95, 99], ["viral envelope glycoprotein", "PROTEIN", 49, 76], ["G", "PROTEIN", 78, 79], ["cell receptor", "PROTEIN", 95, 108], ["Virus entry", "PROBLEM", 0, 11], ["the viral envelope glycoprotein (G)", "TREATMENT", 45, 80], ["endocytosis", "OBSERVATION", 27, 38]]], ["The N terminal in G protein is responsible for the attachment to the cell receptor [78] .", [["cell", "ANATOMY", 69, 73], ["N", "CHEMICAL", 4, 5], ["G protein", "GENE_OR_GENE_PRODUCT", 18, 27], ["cell", "CELL", 69, 73], ["N terminal", "PROTEIN", 4, 14], ["G protein", "PROTEIN", 18, 27], ["The N terminal in G protein", "TREATMENT", 0, 27], ["terminal", "OBSERVATION_MODIFIER", 6, 14]]], ["One of these receptors is GRP78 as demonstrated by Honda et al. [80] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 26, 31], ["GRP78", "PROTEIN", 26, 31]]], ["They used GRP78 antibody and found that binding of the G protein to GRP78 reduced to 40%.", [["GRP78", "GENE_OR_GENE_PRODUCT", 10, 15], ["G protein", "GENE_OR_GENE_PRODUCT", 55, 64], ["GRP78", "GENE_OR_GENE_PRODUCT", 68, 73], ["GRP78 antibody", "PROTEIN", 10, 24], ["G protein", "PROTEIN", 55, 64], ["GRP78", "PROTEIN", 68, 73], ["GRP78 antibody", "TEST", 10, 24], ["the G protein", "TREATMENT", 51, 64], ["GRP78", "TEST", 68, 73]]], ["The GRP78 domain that binds to G protein is the ATP-binding domain [80] .GRP78 and cancerGRP78 has a crucial role in proliferation, invasion, and metastasis of many cancer cells such as renal cell [81] , endometrial [82] , gastric [83] , and prostate cancer [84] .Breast cancerThe most common cancer in females worldwide is breast cancer [85] .", [["cancer cells", "ANATOMY", 165, 177], ["renal cell", "ANATOMY", 186, 196], ["endometrial", "ANATOMY", 204, 215], ["gastric", "ANATOMY", 223, 230], ["prostate cancer", "ANATOMY", 242, 257], ["Breast cancer", "ANATOMY", 264, 277], ["cancer", "ANATOMY", 293, 299], ["breast cancer", "ANATOMY", 324, 337], ["ATP", "CHEMICAL", 48, 51], ["cancer", "DISEASE", 165, 171], ["prostate cancer", "DISEASE", 242, 257], ["Breast cancer", "DISEASE", 264, 277], ["cancer", "DISEASE", 293, 299], ["breast cancer", "DISEASE", 324, 337], ["ATP", "CHEMICAL", 48, 51], ["GRP78", "GENE_OR_GENE_PRODUCT", 4, 9], ["G protein", "GENE_OR_GENE_PRODUCT", 31, 40], ["ATP", "SIMPLE_CHEMICAL", 48, 51], ["GRP78", "GENE_OR_GENE_PRODUCT", 73, 78], ["cancerGRP78", "GENE_OR_GENE_PRODUCT", 83, 94], ["cancer cells", "CELL", 165, 177], ["renal cell", "CELL", 186, 196], ["endometrial [82", "CANCER", 204, 219], ["gastric", "ORGAN", 223, 230], ["prostate cancer", "CANCER", 242, 257], ["Breast cancer", "CANCER", 264, 277], ["cancer", "CANCER", 293, 299], ["breast cancer", "CANCER", 324, 337], ["GRP78 domain", "PROTEIN", 4, 16], ["G protein", "PROTEIN", 31, 40], ["ATP-binding domain", "PROTEIN", 48, 66], ["GRP78", "PROTEIN", 73, 78], ["cancerGRP78", "PROTEIN", 83, 94], ["cancer cells", "CELL_TYPE", 165, 177], ["The GRP78 domain", "PROBLEM", 0, 16], ["G protein", "TEST", 31, 40], ["the ATP", "TEST", 44, 51], ["invasion", "PROBLEM", 132, 140], ["metastasis", "PROBLEM", 146, 156], ["many cancer cells", "PROBLEM", 160, 177], ["renal cell", "PROBLEM", 186, 196], ["prostate cancer", "PROBLEM", 242, 257], ["Breast cancer", "PROBLEM", 264, 277], ["The most common cancer", "PROBLEM", 277, 299], ["breast cancer", "PROBLEM", 324, 337], ["crucial", "OBSERVATION_MODIFIER", 101, 108], ["proliferation", "OBSERVATION", 117, 130], ["invasion", "OBSERVATION_MODIFIER", 132, 140], ["metastasis", "OBSERVATION", 146, 156], ["many", "OBSERVATION_MODIFIER", 160, 164], ["cancer", "OBSERVATION", 165, 171], ["renal", "ANATOMY", 186, 191], ["cell", "ANATOMY_MODIFIER", 192, 196], ["endometrial", "ANATOMY", 204, 215], ["gastric", "ANATOMY", 223, 230], ["prostate", "ANATOMY", 242, 250], ["cancer", "OBSERVATION", 251, 257], ["cancer", "OBSERVATION", 271, 277], ["most common", "OBSERVATION_MODIFIER", 281, 292], ["cancer", "OBSERVATION", 293, 299], ["breast", "ANATOMY", 324, 330], ["cancer", "OBSERVATION", 331, 337]]], ["The treatment of advanced breast cancer patients starts with gemcitabine [86] .", [["breast cancer", "ANATOMY", 26, 39], ["breast cancer", "DISEASE", 26, 39], ["gemcitabine", "CHEMICAL", 61, 72], ["gemcitabine", "CHEMICAL", 61, 72], ["breast cancer", "CANCER", 26, 39], ["patients", "ORGANISM", 40, 48], ["gemcitabine", "SIMPLE_CHEMICAL", 61, 72], ["patients", "SPECIES", 40, 48], ["advanced breast cancer", "PROBLEM", 17, 39], ["gemcitabine", "TREATMENT", 61, 72], ["advanced", "OBSERVATION_MODIFIER", 17, 25], ["breast", "ANATOMY", 26, 32], ["cancer", "OBSERVATION", 33, 39]]], ["Gemcitabine is a pro-drug cytotoxic chemotherapeutic agent similar to cytarabine.", [["Gemcitabine", "CHEMICAL", 0, 11], ["cytarabine", "CHEMICAL", 70, 80], ["Gemcitabine", "CHEMICAL", 0, 11], ["cytarabine", "CHEMICAL", 70, 80], ["Gemcitabine", "SIMPLE_CHEMICAL", 0, 11], ["cytarabine", "SIMPLE_CHEMICAL", 70, 80], ["Gemcitabine", "TREATMENT", 0, 11], ["a pro-drug cytotoxic chemotherapeutic agent", "TREATMENT", 15, 58], ["cytarabine", "TREATMENT", 70, 80]]], ["Its anticancer effects are manifested by its phosphorylated active metabolites (gemcitabine di-and triphosphate) [87] .", [["anticancer", "ANATOMY", 4, 14], ["gemcitabine di-and triphosphate", "CHEMICAL", 80, 111], ["gemcitabine di-and triphosphate", "CHEMICAL", 80, 111], ["anticancer", "CANCER", 4, 14], ["gemcitabine", "SIMPLE_CHEMICAL", 80, 91], ["triphosphate", "SIMPLE_CHEMICAL", 99, 111], ["its phosphorylated active metabolites", "PROBLEM", 41, 78], ["gemcitabine di-and triphosphate", "TREATMENT", 80, 111]]], ["These metabolites are combined with DNA to stop replication and cell growth leading to apoptosis [87] .", [["cell", "ANATOMY", 64, 68], ["DNA", "CELLULAR_COMPONENT", 36, 39], ["cell", "CELL", 64, 68], ["DNA", "TREATMENT", 36, 39], ["cell growth", "PROBLEM", 64, 75], ["apoptosis", "PROBLEM", 87, 96]]], ["The major problem that affects therapy is drug resistance [88] .", [["drug resistance", "PROBLEM", 42, 57], ["major", "OBSERVATION_MODIFIER", 4, 9], ["problem", "OBSERVATION", 10, 17], ["drug resistance", "OBSERVATION", 42, 57]]], ["GRP78 was demonstrated to promote drug resistance in breast cancer against doxorubicin [89] .", [["breast cancer", "ANATOMY", 53, 66], ["breast cancer", "DISEASE", 53, 66], ["doxorubicin", "CHEMICAL", 75, 86], ["doxorubicin", "CHEMICAL", 75, 86], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["breast cancer", "CANCER", 53, 66], ["doxorubicin", "SIMPLE_CHEMICAL", 75, 86], ["GRP78", "PROTEIN", 0, 5], ["breast cancer", "PROBLEM", 53, 66], ["doxorubicin", "TREATMENT", 75, 86], ["drug resistance", "OBSERVATION", 34, 49], ["breast", "ANATOMY", 53, 59], ["cancer", "OBSERVATION", 60, 66]]], ["Extrinsic pathway requires that death receptors on the cell surface be activated.", [["cell surface", "ANATOMY", 55, 67], ["death", "DISEASE", 32, 37], ["cell surface", "CELLULAR_COMPONENT", 55, 67], ["death receptors", "PROTEIN", 32, 47], ["death receptors", "PROBLEM", 32, 47], ["the cell surface", "TREATMENT", 51, 67]]], ["On the other hand, the intrinsic pathway involves a series of events that are processed in the mitochondria [90] .", [["mitochondria", "ANATOMY", 95, 107], ["mitochondria", "CELLULAR_COMPONENT", 95, 107]]], ["Caspase 9 is triggered by the intrinsic pathway [91] and is found to be responsible for gemcitabine resistance and GRP78-regulated chemosensitivity [88] .", [["gemcitabine", "CHEMICAL", 88, 99], ["gemcitabine", "CHEMICAL", 88, 99], ["Caspase 9", "GENE_OR_GENE_PRODUCT", 0, 9], ["gemcitabine", "SIMPLE_CHEMICAL", 88, 99], ["GRP78", "GENE_OR_GENE_PRODUCT", 115, 120], ["Caspase 9", "PROTEIN", 0, 9], ["GRP78", "PROTEIN", 115, 120], ["Caspase", "TREATMENT", 0, 7], ["gemcitabine resistance", "PROBLEM", 88, 110], ["GRP78", "TEST", 115, 120], ["chemosensitivity", "TEST", 131, 147], ["gemcitabine resistance", "OBSERVATION", 88, 110]]], ["Xie et al. show that overexpression of GRP78 reduced the sensitivity of gemcitabine so it may have a critical role in the resistance of breast cancer cells.", [["breast cancer cells", "ANATOMY", 136, 155], ["gemcitabine", "CHEMICAL", 72, 83], ["breast cancer", "DISEASE", 136, 149], ["gemcitabine", "CHEMICAL", 72, 83], ["GRP78", "GENE_OR_GENE_PRODUCT", 39, 44], ["gemcitabine", "SIMPLE_CHEMICAL", 72, 83], ["breast cancer cells", "CELL", 136, 155], ["GRP78", "PROTEIN", 39, 44], ["breast cancer cells", "CELL_TYPE", 136, 155], ["GRP78", "PROBLEM", 39, 44], ["gemcitabine", "TREATMENT", 72, 83], ["breast cancer cells", "PROBLEM", 136, 155], ["breast", "ANATOMY", 136, 142], ["cancer cells", "OBSERVATION", 143, 155]]], ["This reduction in sensitivity is caused by apoptosis inhibition [88] .", [["apoptosis inhibition", "PROBLEM", 43, 63]]], ["The same group shows that caspase 9 and its phosphorylated form p37 were excessively down-regulated in GRP78-overexpressed breast cancer cells and was markedly increased in GRP78downregulated breast cancer cells [88] .", [["breast cancer cells", "ANATOMY", 123, 142], ["breast cancer cells", "ANATOMY", 192, 211], ["breast cancer", "DISEASE", 123, 136], ["breast cancer", "DISEASE", 192, 205], ["caspase 9", "GENE_OR_GENE_PRODUCT", 26, 35], ["p37", "GENE_OR_GENE_PRODUCT", 64, 67], ["GRP78", "GENE_OR_GENE_PRODUCT", 103, 108], ["breast cancer cells", "CELL", 123, 142], ["breast cancer cells", "CELL", 192, 211], ["caspase 9", "PROTEIN", 26, 35], ["p37", "PROTEIN", 64, 67], ["GRP78", "PROTEIN", 103, 108], ["breast cancer cells", "CELL_TYPE", 123, 142], ["GRP78downregulated breast cancer cells", "CELL_LINE", 173, 211], ["caspase", "TEST", 26, 33], ["its phosphorylated form p37", "TEST", 40, 67], ["overexpressed breast cancer cells", "PROBLEM", 109, 142], ["markedly increased in GRP78downregulated breast cancer cells", "PROBLEM", 151, 211], ["breast", "ANATOMY", 123, 129], ["cancer cells", "OBSERVATION", 130, 142], ["markedly", "OBSERVATION_MODIFIER", 151, 159], ["increased", "OBSERVATION_MODIFIER", 160, 169], ["breast", "ANATOMY", 192, 198], ["cancer cells", "OBSERVATION", 199, 211]]], ["The levels of anti-apoptosis protein Bcl-2 is found to be high in GRP78-overexpressing breast cancer cells, on the other hand, the levels of pro-apoptosis proteins, Bax and Bim are low, and vice versa [88] .", [["breast cancer cells", "ANATOMY", 87, 106], ["breast cancer", "DISEASE", 87, 100], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 37, 42], ["GRP78", "GENE_OR_GENE_PRODUCT", 66, 71], ["breast cancer cells", "CELL", 87, 106], ["Bax", "GENE_OR_GENE_PRODUCT", 165, 168], ["Bim", "GENE_OR_GENE_PRODUCT", 173, 176], ["anti-apoptosis protein", "PROTEIN", 14, 36], ["Bcl-2", "PROTEIN", 37, 42], ["GRP78", "PROTEIN", 66, 71], ["overexpressing breast cancer cells", "CELL_TYPE", 72, 106], ["pro-apoptosis proteins", "PROTEIN", 141, 163], ["Bax", "PROTEIN", 165, 168], ["Bim", "PROTEIN", 173, 176], ["The levels", "TEST", 0, 10], ["anti-apoptosis protein Bcl", "TEST", 14, 40], ["overexpressing breast cancer cells", "PROBLEM", 72, 106], ["pro-apoptosis proteins", "PROBLEM", 141, 163], ["Bax", "TEST", 165, 168], ["breast", "ANATOMY", 87, 93], ["cancer cells", "OBSERVATION", 94, 106]]], ["AKT can affect mitochondrial apoptosis by either targeting the pro-apoptotic protein Bad or by inhibition of pro-apoptotic signals produced by transcription factors such as FoxO [88] .", [["mitochondrial", "ANATOMY", 15, 28], ["AKT", "GENE_OR_GENE_PRODUCT", 0, 3], ["mitochondrial", "CELLULAR_COMPONENT", 15, 28], ["Bad", "GENE_OR_GENE_PRODUCT", 85, 88], ["FoxO [88]", "GENE_OR_GENE_PRODUCT", 173, 182], ["AKT", "PROTEIN", 0, 3], ["pro-apoptotic protein", "PROTEIN", 63, 84], ["Bad", "PROTEIN", 85, 88], ["transcription factors", "PROTEIN", 143, 164], ["FoxO [88]", "PROTEIN", 173, 182], ["mitochondrial apoptosis", "PROBLEM", 15, 38], ["the pro-apoptotic protein", "TEST", 59, 84], ["pro-apoptotic signals", "TEST", 109, 130], ["mitochondrial apoptosis", "OBSERVATION", 15, 38]]], ["AKT is found to be markedly increased in gemcitabine resistance breast cancer and is related to the expression of GRP78, so an increase in GRP78 leads to AKT increase.", [["breast cancer", "ANATOMY", 64, 77], ["gemcitabine", "CHEMICAL", 41, 52], ["breast cancer", "DISEASE", 64, 77], ["gemcitabine", "CHEMICAL", 41, 52], ["AKT", "GENE_OR_GENE_PRODUCT", 0, 3], ["gemcitabine", "SIMPLE_CHEMICAL", 41, 52], ["breast cancer", "CANCER", 64, 77], ["GRP78", "GENE_OR_GENE_PRODUCT", 114, 119], ["GRP78", "GENE_OR_GENE_PRODUCT", 139, 144], ["AKT", "GENE_OR_GENE_PRODUCT", 154, 157], ["AKT", "PROTEIN", 0, 3], ["GRP78", "PROTEIN", 114, 119], ["GRP78", "PROTEIN", 139, 144], ["AKT", "PROTEIN", 154, 157], ["AKT", "TEST", 0, 3], ["gemcitabine resistance breast cancer", "PROBLEM", 41, 77], ["GRP78", "PROBLEM", 114, 119], ["found to be", "UNCERTAINTY", 7, 18], ["markedly", "OBSERVATION_MODIFIER", 19, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["gemcitabine resistance", "OBSERVATION", 41, 63], ["breast", "ANATOMY", 64, 70], ["cancer", "OBSERVATION", 71, 77], ["increase", "OBSERVATION_MODIFIER", 127, 135], ["AKT", "OBSERVATION_MODIFIER", 154, 157], ["increase", "OBSERVATION_MODIFIER", 158, 166]]], ["If AKT expression is reduced in GRP78overexpressing breast cancer cells, their sensitivity to gemcitabine increases and apoptosis also increases [88] .", [["breast cancer cells", "ANATOMY", 52, 71], ["breast cancer", "DISEASE", 52, 65], ["gemcitabine", "CHEMICAL", 94, 105], ["gemcitabine", "CHEMICAL", 94, 105], ["AKT", "GENE_OR_GENE_PRODUCT", 3, 6], ["GRP78overexpressing breast cancer cells", "CELL", 32, 71], ["gemcitabine", "SIMPLE_CHEMICAL", 94, 105], ["AKT", "PROTEIN", 3, 6], ["GRP78overexpressing breast cancer cells", "CELL_TYPE", 32, 71], ["AKT expression", "PROBLEM", 3, 17], ["GRP78overexpressing breast cancer cells", "PROBLEM", 32, 71], ["gemcitabine", "TREATMENT", 94, 105], ["apoptosis", "TEST", 120, 129], ["reduced", "OBSERVATION_MODIFIER", 21, 28], ["breast", "ANATOMY", 52, 58], ["cancer cells", "OBSERVATION", 59, 71]]], ["These results are in agreement with other types of cancers such as colon cancer [92] , and prostate cancer [93] .Ovarian carcinomaThe fourth common cause of death in women is ovarian carcinoma which represents the most lethal type of gynecological malignancies [94] .", [["cancers", "ANATOMY", 51, 58], ["colon cancer", "ANATOMY", 67, 79], ["prostate cancer", "ANATOMY", 91, 106], ["Ovarian carcinoma", "ANATOMY", 113, 130], ["ovarian carcinoma", "ANATOMY", 175, 192], ["gynecological malignancies", "ANATOMY", 234, 260], ["cancers", "DISEASE", 51, 58], ["colon cancer", "DISEASE", 67, 79], ["prostate cancer", "DISEASE", 91, 106], ["Ovarian carcinoma", "DISEASE", 113, 130], ["death", "DISEASE", 157, 162], ["ovarian carcinoma", "DISEASE", 175, 192], ["gynecological malignancies", "DISEASE", 234, 260], ["cancers", "CANCER", 51, 58], ["colon cancer", "CANCER", 67, 79], ["prostate cancer", "CANCER", 91, 106], ["Ovarian carcinoma", "CANCER", 113, 130], ["women", "ORGANISM", 166, 171], ["ovarian carcinoma", "CANCER", 175, 192], ["gynecological malignancies", "CANCER", 234, 260], ["women", "SPECIES", 166, 171], ["cancers", "PROBLEM", 51, 58], ["colon cancer", "PROBLEM", 67, 79], ["prostate cancer", "PROBLEM", 91, 106], ["Ovarian carcinoma", "PROBLEM", 113, 130], ["death", "PROBLEM", 157, 162], ["ovarian carcinoma", "PROBLEM", 175, 192], ["gynecological malignancies", "PROBLEM", 234, 260], ["cancers", "OBSERVATION", 51, 58], ["colon", "ANATOMY", 67, 72], ["cancer", "OBSERVATION", 73, 79], ["prostate", "ANATOMY", 91, 99], ["cancer", "OBSERVATION", 100, 106], ["carcinoma", "OBSERVATION", 121, 130], ["death", "OBSERVATION", 157, 162], ["ovarian", "ANATOMY", 175, 182], ["carcinoma", "OBSERVATION", 183, 192], ["most lethal", "OBSERVATION_MODIFIER", 214, 225]]], ["Epithelial ovarian carcinoma has only 30% 5-year survival rate because of the difficulty of early detection due to unclear symptoms [95] .", [["Epithelial ovarian carcinoma", "ANATOMY", 0, 28], ["Epithelial ovarian carcinoma", "DISEASE", 0, 28], ["Epithelial ovarian carcinoma", "CANCER", 0, 28], ["Epithelial ovarian carcinoma", "PROBLEM", 0, 28], ["unclear symptoms", "PROBLEM", 115, 131], ["ovarian", "ANATOMY", 11, 18], ["carcinoma", "OBSERVATION", 19, 28]]], ["GRP78 overexpression in cancer cells and human tumors resulted in cancer malignancy and increased survival of cancer cells due to treatment resistance [96, 97] .", [["cancer cells", "ANATOMY", 24, 36], ["tumors", "ANATOMY", 47, 53], ["cancer", "ANATOMY", 66, 72], ["cancer cells", "ANATOMY", 110, 122], ["cancer", "DISEASE", 24, 30], ["tumors", "DISEASE", 47, 53], ["cancer malignancy", "DISEASE", 66, 83], ["cancer", "DISEASE", 110, 116], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["cancer cells", "CELL", 24, 36], ["human", "ORGANISM", 41, 46], ["tumors", "CANCER", 47, 53], ["cancer", "CANCER", 66, 72], ["cancer cells", "CELL", 110, 122], ["GRP78", "PROTEIN", 0, 5], ["cancer cells", "CELL_TYPE", 24, 36], ["cancer cells", "CELL_TYPE", 110, 122], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["GRP78 overexpression in cancer cells", "PROBLEM", 0, 36], ["human tumors", "PROBLEM", 41, 53], ["cancer malignancy", "PROBLEM", 66, 83], ["cancer cells", "PROBLEM", 110, 122], ["treatment resistance", "PROBLEM", 130, 150], ["cancer cells", "OBSERVATION", 24, 36], ["tumors", "OBSERVATION", 47, 53], ["cancer", "OBSERVATION", 66, 72], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["survival", "OBSERVATION_MODIFIER", 98, 106], ["cancer cells", "OBSERVATION", 110, 122]]], ["The accumulation of polypeptides in endoplasmic reticulum due to the elevated metabolism of ovarian cancer cells leads to the overexpression of GRP78 [98] .", [["endoplasmic reticulum", "ANATOMY", 36, 57], ["ovarian cancer cells", "ANATOMY", 92, 112], ["ovarian cancer", "DISEASE", 92, 106], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 36, 57], ["ovarian cancer cells", "CELL", 92, 112], ["GRP78", "GENE_OR_GENE_PRODUCT", 144, 149], ["ovarian cancer cells", "CELL_TYPE", 92, 112], ["GRP78", "PROTEIN", 144, 149], ["polypeptides in endoplasmic reticulum", "PROBLEM", 20, 57], ["the elevated metabolism of ovarian cancer cells", "PROBLEM", 65, 112], ["GRP78", "TEST", 144, 149], ["accumulation", "OBSERVATION_MODIFIER", 4, 16], ["polypeptides", "OBSERVATION_MODIFIER", 20, 32], ["endoplasmic reticulum", "OBSERVATION", 36, 57], ["elevated", "OBSERVATION_MODIFIER", 69, 77], ["metabolism", "OBSERVATION_MODIFIER", 78, 88], ["ovarian", "ANATOMY", 92, 99], ["cancer", "OBSERVATION", 100, 106]]], ["Although the use of taxane and platinum-based chemotherapy in the treatment of ovary cancer results initially in high response rates, many of the patients suffer a relapse and develop resistance [99] .", [["ovary cancer", "ANATOMY", 79, 91], ["taxane", "CHEMICAL", 20, 26], ["platinum", "CHEMICAL", 31, 39], ["ovary cancer", "DISEASE", 79, 91], ["taxane", "CHEMICAL", 20, 26], ["platinum", "CHEMICAL", 31, 39], ["taxane", "SIMPLE_CHEMICAL", 20, 26], ["platinum", "SIMPLE_CHEMICAL", 31, 39], ["ovary cancer", "CANCER", 79, 91], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["taxane", "TREATMENT", 20, 26], ["platinum-based chemotherapy", "TREATMENT", 31, 58], ["ovary cancer", "PROBLEM", 79, 91], ["resistance", "PROBLEM", 184, 194], ["ovary", "ANATOMY", 79, 84], ["cancer", "OBSERVATION", 85, 91]]], ["Paclitaxel can lead to apoptosis by preventing microtubule formation leading to a mitotic block of the cell [100] and partly to endoplasmic reticulum unfolded protein response [101] .", [["microtubule", "ANATOMY", 47, 58], ["cell", "ANATOMY", 103, 107], ["endoplasmic reticulum", "ANATOMY", 128, 149], ["Paclitaxel", "CHEMICAL", 0, 10], ["Paclitaxel", "CHEMICAL", 0, 10], ["Paclitaxel", "SIMPLE_CHEMICAL", 0, 10], ["microtubule", "CELLULAR_COMPONENT", 47, 58], ["cell", "CELL", 103, 107], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 128, 149], ["microtubule", "PROTEIN", 47, 58], ["Paclitaxel", "TREATMENT", 0, 10], ["apoptosis", "PROBLEM", 23, 32], ["microtubule formation", "PROBLEM", 47, 68], ["a mitotic block of the cell", "PROBLEM", 80, 107], ["microtubule formation", "OBSERVATION", 47, 68]]], ["Zhang et al. [97] demonstrated that treatment of three groups of HO-8910 cells with paclitaxel after transfection with GRP78 siRNA for one group, nonspecific siRNA for the second group, or untreated HO-8910 cells led to a different decrease in survival rates of the three groups to paclitaxel.", [["HO-8910 cells", "ANATOMY", 65, 78], ["HO-8910 cells", "ANATOMY", 199, 212], ["HO-8910", "CHEMICAL", 65, 72], ["paclitaxel", "CHEMICAL", 84, 94], ["HO-8910", "CHEMICAL", 199, 206], ["paclitaxel", "CHEMICAL", 282, 292], ["paclitaxel", "CHEMICAL", 84, 94], ["paclitaxel", "CHEMICAL", 282, 292], ["HO-8910 cells", "CELL", 65, 78], ["paclitaxel", "SIMPLE_CHEMICAL", 84, 94], ["GRP78", "GENE_OR_GENE_PRODUCT", 119, 124], ["HO-8910 cells", "CELL", 199, 212], ["paclitaxel", "SIMPLE_CHEMICAL", 282, 292], ["HO-8910 cells", "CELL_LINE", 65, 78], ["GRP78", "PROTEIN", 119, 124], ["HO-8910 cells", "CELL_LINE", 199, 212], ["paclitaxel", "TREATMENT", 84, 94], ["transfection", "TREATMENT", 101, 113], ["GRP78 siRNA", "TREATMENT", 119, 130], ["nonspecific siRNA", "PROBLEM", 146, 163], ["untreated HO", "PROBLEM", 189, 201], ["survival rates", "TREATMENT", 244, 258], ["paclitaxel", "TREATMENT", 282, 292], ["decrease", "OBSERVATION_MODIFIER", 232, 240]]], ["The survival rates of the GRP78 siRNA treated group is significantly lower than the other two groups which indicate the higher sensitivity of the treated group to paclitaxel treatment after the inhibition of GRP78 protein [97] .", [["paclitaxel", "CHEMICAL", 163, 173], ["paclitaxel", "CHEMICAL", 163, 173], ["GRP78", "GENE_OR_GENE_PRODUCT", 26, 31], ["paclitaxel", "SIMPLE_CHEMICAL", 163, 173], ["GRP78", "GENE_OR_GENE_PRODUCT", 208, 213], ["GRP78", "PROTEIN", 26, 31], ["GRP78 protein", "PROTEIN", 208, 221], ["the GRP78 siRNA", "TREATMENT", 22, 37], ["paclitaxel treatment", "TREATMENT", 163, 183], ["GRP78 protein", "TEST", 208, 221], ["higher", "OBSERVATION_MODIFIER", 120, 126]]], ["In addition to the protective role of GRP78 to paclitaxel, the apoptosis ratio in the siRNA GRP78 treated group reaches 56.92 \u00b1 0.46% after 72 h of transfection, which corresponds to a previous study by Martin et al. [102] .", [["paclitaxel", "CHEMICAL", 47, 57], ["paclitaxel", "CHEMICAL", 47, 57], ["GRP78", "GENE_OR_GENE_PRODUCT", 38, 43], ["paclitaxel", "SIMPLE_CHEMICAL", 47, 57], ["GRP78", "GENE_OR_GENE_PRODUCT", 92, 97], ["GRP78", "PROTEIN", 38, 43], ["GRP78", "PROTEIN", 92, 97], ["paclitaxel", "TREATMENT", 47, 57], ["the apoptosis ratio", "TEST", 59, 78], ["transfection", "PROBLEM", 148, 160], ["a previous study", "TEST", 183, 199], ["siRNA", "ANATOMY", 86, 91]]], ["The increase in apoptosis may be due to the prevention of the interaction between GRP78 and apoptosis pathway compounds such as caspase-7 [103] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 82, 87], ["caspase-7", "GENE_OR_GENE_PRODUCT", 128, 137], ["GRP78", "PROTEIN", 82, 87], ["The increase in apoptosis", "PROBLEM", 0, 25], ["apoptosis pathway compounds", "PROBLEM", 92, 119], ["caspase", "TEST", 128, 135], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["apoptosis", "OBSERVATION", 16, 25], ["may be due to", "UNCERTAINTY", 26, 39]]], ["Chen and Xu [104] studied the effect of cisplatin, which is a platinum-based chemotherapy reagent [105] , on ovarian cancer cells.", [["ovarian cancer cells", "ANATOMY", 109, 129], ["cisplatin", "CHEMICAL", 40, 49], ["platinum", "CHEMICAL", 62, 70], ["ovarian cancer", "DISEASE", 109, 123], ["cisplatin", "CHEMICAL", 40, 49], ["platinum", "CHEMICAL", 62, 70], ["cisplatin", "SIMPLE_CHEMICAL", 40, 49], ["platinum", "SIMPLE_CHEMICAL", 62, 70], ["ovarian cancer cells", "CELL", 109, 129], ["ovarian cancer cells", "CELL_TYPE", 109, 129], ["cisplatin", "TREATMENT", 40, 49], ["a platinum-based chemotherapy reagent", "TREATMENT", 60, 97], ["ovarian cancer cells", "PROBLEM", 109, 129], ["ovarian", "ANATOMY", 109, 116], ["cancer cells", "OBSERVATION", 117, 129]]], ["In their study, they showed that GRP78 overexpression in ovarian chronic cisplatin-treated cells leads to chemoresistance, which reduces the effectiveness of the treatment [98] .Pancreatic cancerOne of the most aggressive types of malignant tumors is pancreatic ductal adenocarcinoma (PDAC) [106] .", [["ovarian", "ANATOMY", 57, 64], ["cells", "ANATOMY", 91, 96], ["Pancreatic cancerOne", "ANATOMY", 178, 198], ["malignant tumors", "ANATOMY", 231, 247], ["pancreatic ductal adenocarcinoma", "ANATOMY", 251, 283], ["PDAC", "ANATOMY", 285, 289], ["cisplatin", "CHEMICAL", 73, 82], ["chemoresistance", "DISEASE", 106, 121], ["Pancreatic cancerOne", "DISEASE", 178, 198], ["malignant tumors", "DISEASE", 231, 247], ["pancreatic ductal adenocarcinoma", "DISEASE", 251, 283], ["PDAC", "DISEASE", 285, 289], ["cisplatin", "CHEMICAL", 73, 82], ["GRP78", "GENE_OR_GENE_PRODUCT", 33, 38], ["ovarian", "ORGAN", 57, 64], ["cisplatin", "SIMPLE_CHEMICAL", 73, 82], ["cells", "CELL", 91, 96], ["Pancreatic cancerOne", "CANCER", 178, 198], ["malignant tumors", "CANCER", 231, 247], ["pancreatic ductal adenocarcinoma", "CANCER", 251, 283], ["PDAC", "CANCER", 285, 289], ["GRP78", "PROTEIN", 33, 38], ["ovarian chronic cisplatin-treated cells", "CELL_LINE", 57, 96], ["their study", "TEST", 3, 14], ["GRP78 overexpression", "PROBLEM", 33, 53], ["ovarian chronic cisplatin-treated cells", "TREATMENT", 57, 96], ["chemoresistance", "PROBLEM", 106, 121], ["the treatment", "TREATMENT", 158, 171], ["malignant tumors", "PROBLEM", 231, 247], ["pancreatic ductal adenocarcinoma", "PROBLEM", 251, 283], ["ovarian", "ANATOMY", 57, 64], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["cisplatin", "OBSERVATION", 73, 82], ["most aggressive", "OBSERVATION_MODIFIER", 206, 221], ["malignant", "OBSERVATION_MODIFIER", 231, 240], ["tumors", "OBSERVATION", 241, 247], ["pancreatic", "ANATOMY", 251, 261], ["ductal", "ANATOMY_MODIFIER", 262, 268], ["adenocarcinoma", "OBSERVATION", 269, 283]]], ["The only cure for PDAC is surgery; however, the 5-year survival rate of patients after removal of the pancreatic cancer is approximately 20-25% [81, 107] .", [["PDAC", "ANATOMY", 18, 22], ["pancreatic cancer", "ANATOMY", 102, 119], ["PDAC", "DISEASE", 18, 22], ["pancreatic cancer", "DISEASE", 102, 119], ["PDAC", "CANCER", 18, 22], ["patients", "ORGANISM", 72, 80], ["pancreatic cancer", "CANCER", 102, 119], ["patients", "SPECIES", 72, 80], ["surgery", "TREATMENT", 26, 33], ["removal", "TREATMENT", 87, 94], ["the pancreatic cancer", "PROBLEM", 98, 119], ["pancreatic", "ANATOMY", 102, 112], ["cancer", "OBSERVATION", 113, 119]]], ["Because of this, the identification of specific new factors that can increase the survivability of patients is critical [81] .", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107]]], ["Zheyu et al. [108] found a strong relationship between the expression of GRP78 and tumor stage indicating a potential role of GRP78 in PDAC progression.", [["tumor", "ANATOMY", 83, 88], ["PDAC", "ANATOMY", 135, 139], ["tumor", "DISEASE", 83, 88], ["PDAC", "DISEASE", 135, 139], ["GRP78", "GENE_OR_GENE_PRODUCT", 73, 78], ["tumor", "CANCER", 83, 88], ["GRP78", "GENE_OR_GENE_PRODUCT", 126, 131], ["PDAC", "CANCER", 135, 139], ["GRP78", "PROTEIN", 73, 78], ["GRP78", "PROTEIN", 126, 131], ["tumor stage", "PROBLEM", 83, 94], ["GRP78 in PDAC progression", "PROBLEM", 126, 151], ["tumor", "OBSERVATION", 83, 88], ["PDAC", "OBSERVATION", 135, 139]]], ["They show that low overall survival of patients was strongly related to the overexpression of GRP78 on tumor cells [108] .", [["tumor cells", "ANATOMY", 103, 114], ["tumor", "DISEASE", 103, 108], ["patients", "ORGANISM", 39, 47], ["GRP78", "GENE_OR_GENE_PRODUCT", 94, 99], ["tumor cells", "CELL", 103, 114], ["GRP78", "PROTEIN", 94, 99], ["tumor cells", "CELL_TYPE", 103, 114], ["patients", "SPECIES", 39, 47], ["GRP78 on tumor cells", "PROBLEM", 94, 114], ["low", "OBSERVATION_MODIFIER", 15, 18]]], ["Overexpression of GRP78 affects proliferation, cell cycle, invasion, and migration of PDAC cells.", [["cell", "ANATOMY", 47, 51], ["PDAC cells", "ANATOMY", 86, 96], ["PDAC", "DISEASE", 86, 90], ["GRP78", "GENE_OR_GENE_PRODUCT", 18, 23], ["cell", "CELL", 47, 51], ["PDAC cells", "CELL", 86, 96], ["GRP78", "PROTEIN", 18, 23], ["PDAC cells", "CELL_TYPE", 86, 96], ["GRP78 affects proliferation", "PROBLEM", 18, 45], ["cell cycle", "TEST", 47, 57], ["invasion", "PROBLEM", 59, 67], ["migration of PDAC cells", "PROBLEM", 73, 96], ["GRP78 affects", "OBSERVATION_MODIFIER", 18, 31], ["proliferation", "OBSERVATION_MODIFIER", 32, 45], ["cell cycle", "OBSERVATION", 47, 57], ["invasion", "OBSERVATION_MODIFIER", 59, 67], ["migration", "OBSERVATION_MODIFIER", 73, 82], ["PDAC cells", "OBSERVATION", 86, 96]]], ["Such that overexpression increases proliferation, invasion, and migration, and increases the percentage of cells in S phase of the cell cycle [108] .Pancreatic cancerThe underlying mechanism of invasion of pancreatic cancer cell was demonstrated by Yuan et al. [109] .", [["cells", "ANATOMY", 107, 112], ["cell", "ANATOMY", 131, 135], ["Pancreatic cancer", "ANATOMY", 149, 166], ["pancreatic cancer cell", "ANATOMY", 206, 228], ["Pancreatic cancer", "DISEASE", 149, 166], ["pancreatic cancer", "DISEASE", 206, 223], ["cells", "CELL", 107, 112], ["cell", "CELL", 131, 135], ["Pancreatic cancer", "CANCER", 149, 166], ["pancreatic cancer cell", "CELL", 206, 228], ["pancreatic cancer cell", "CELL_TYPE", 206, 228], ["overexpression increases proliferation", "PROBLEM", 10, 48], ["invasion", "PROBLEM", 50, 58], ["the cell cycle", "TEST", 127, 141], ["Pancreatic cancer", "PROBLEM", 149, 166], ["invasion of pancreatic cancer cell", "PROBLEM", 194, 228], ["overexpression", "OBSERVATION_MODIFIER", 10, 24], ["increases", "OBSERVATION_MODIFIER", 25, 34], ["proliferation", "OBSERVATION_MODIFIER", 35, 48], ["invasion", "OBSERVATION_MODIFIER", 50, 58], ["migration", "OBSERVATION_MODIFIER", 64, 73], ["cancer", "OBSERVATION", 160, 166], ["invasion", "OBSERVATION_MODIFIER", 194, 202], ["pancreatic", "ANATOMY", 206, 216], ["cancer cell", "OBSERVATION", 217, 228]]], ["He showed that the overexpression of GRP78 caused an elevation of matrix metalloproteinase-2 and 9(MMP-2 and MMP-9) secretion and activity [109] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 37, 42], ["matrix metalloproteinase-2", "GENE_OR_GENE_PRODUCT", 66, 92], ["9", "GENE_OR_GENE_PRODUCT", 97, 98], ["MMP-2", "GENE_OR_GENE_PRODUCT", 99, 104], ["MMP-9", "GENE_OR_GENE_PRODUCT", 109, 114], ["GRP78", "PROTEIN", 37, 42], ["MMP-9", "PROTEIN", 109, 114], ["the overexpression of GRP78", "PROBLEM", 15, 42], ["an elevation of matrix metalloproteinase", "PROBLEM", 50, 90], ["MMP", "TEST", 99, 102], ["MMP", "TEST", 109, 112], ["elevation", "OBSERVATION_MODIFIER", 53, 62]]], ["Although MMPs are degrading proteases, they have a vital role in invasion and metastasis [109] .", [["MMPs", "GENE_OR_GENE_PRODUCT", 9, 13], ["MMPs", "PROTEIN", 9, 13], ["proteases", "PROTEIN", 28, 37], ["MMPs", "PROBLEM", 9, 13], ["metastasis", "PROBLEM", 78, 88], ["invasion", "OBSERVATION", 65, 73], ["metastasis", "OBSERVATION", 78, 88]]], ["Dynamics of actin filaments, especially cytoskeletal F-actin stress fibers, is increased in response to knockdown to GRP78 [109] .", [["filaments", "ANATOMY", 18, 27], ["cytoskeletal F-actin stress fibers", "ANATOMY", 40, 74], ["actin", "GENE_OR_GENE_PRODUCT", 12, 17], ["cytoskeletal F-actin", "CELLULAR_COMPONENT", 40, 60], ["stress fibers", "CELLULAR_COMPONENT", 61, 74], ["GRP78", "GENE_OR_GENE_PRODUCT", 117, 122], ["actin filaments", "PROTEIN", 12, 27], ["GRP78", "PROTEIN", 117, 122], ["cytoskeletal F-actin stress fibers", "TREATMENT", 40, 74], ["GRP78", "TEST", 117, 122], ["actin filaments", "OBSERVATION", 12, 27], ["cytoskeletal F-actin", "OBSERVATION", 40, 60], ["stress fibers", "OBSERVATION", 61, 74], ["increased", "OBSERVATION_MODIFIER", 79, 88]]], ["Ras homolog gene family, member A (RhoA) and Rac have an essential role in cytoskeleton dynamics and act as a downstream of focal adhesion kinase (FAK) [110] , which have a crucial role in cancer invasion [109, 111] .", [["cytoskeleton", "ANATOMY", 75, 87], ["cancer", "ANATOMY", 189, 195], ["cancer", "DISEASE", 189, 195], ["Ras homolog", "GENE_OR_GENE_PRODUCT", 0, 11], ["member A", "GENE_OR_GENE_PRODUCT", 25, 33], ["RhoA", "GENE_OR_GENE_PRODUCT", 35, 39], ["Rac", "GENE_OR_GENE_PRODUCT", 45, 48], ["cytoskeleton", "CELLULAR_COMPONENT", 75, 87], ["focal adhesion kinase", "GENE_OR_GENE_PRODUCT", 124, 145], ["FAK", "GENE_OR_GENE_PRODUCT", 147, 150], ["cancer", "CANCER", 189, 195], ["Ras homolog gene family", "DNA", 0, 23], ["member A", "PROTEIN", 25, 33], ["RhoA", "PROTEIN", 35, 39], ["Rac", "PROTEIN", 45, 48], ["focal adhesion kinase", "PROTEIN", 124, 145], ["FAK", "PROTEIN", 147, 150], ["focal adhesion kinase", "TEST", 124, 145], ["cancer invasion", "PROBLEM", 189, 204], ["focal", "OBSERVATION_MODIFIER", 124, 129], ["cancer", "OBSERVATION", 189, 195]]], ["The activity of Rac and RhoA are related to the levels of GRP78.", [["Rac", "GENE_OR_GENE_PRODUCT", 16, 19], ["RhoA", "GENE_OR_GENE_PRODUCT", 24, 28], ["GRP78", "GENE_OR_GENE_PRODUCT", 58, 63], ["Rac", "PROTEIN", 16, 19], ["RhoA", "PROTEIN", 24, 28], ["GRP78", "PROTEIN", 58, 63], ["activity", "OBSERVATION_MODIFIER", 4, 12], ["Rac", "ANATOMY", 16, 19]]], ["Overexpression of GRP78 increases the activity of Rac but decreases RhoA activity [109] .", [["GRP78", "GENE_OR_GENE_PRODUCT", 18, 23], ["Rac", "GENE_OR_GENE_PRODUCT", 50, 53], ["RhoA", "GENE_OR_GENE_PRODUCT", 68, 72], ["GRP78", "PROTEIN", 18, 23], ["Rac", "PROTEIN", 50, 53], ["RhoA", "PROTEIN", 68, 72], ["Overexpression of GRP78", "PROBLEM", 0, 23], ["RhoA activity", "TEST", 68, 81], ["increases", "OBSERVATION_MODIFIER", 24, 33], ["activity", "OBSERVATION_MODIFIER", 38, 46], ["decreases", "OBSERVATION_MODIFIER", 58, 67], ["RhoA", "OBSERVATION_MODIFIER", 68, 72], ["activity", "OBSERVATION_MODIFIER", 73, 81]]], ["FAK activity is regulated by the expression of GRP78 such that, overexpression of GRP78 increase the phosphorylation of FAK Y397 [109] .", [["FAK", "GENE_OR_GENE_PRODUCT", 0, 3], ["GRP78", "GENE_OR_GENE_PRODUCT", 47, 52], ["GRP78", "GENE_OR_GENE_PRODUCT", 82, 87], ["FAK", "GENE_OR_GENE_PRODUCT", 120, 123], ["FAK", "PROTEIN", 0, 3], ["GRP78", "PROTEIN", 47, 52], ["GRP78", "PROTEIN", 82, 87], ["FAK", "PROTEIN", 120, 123]]], ["The c-Jun N-terminal kinase (JNK), has a critical role in the invasion of many epithelial cancers.", [["epithelial cancers", "ANATOMY", 79, 97], ["epithelial cancers", "DISEASE", 79, 97], ["N", "CHEMICAL", 10, 11], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 4, 27], ["JNK", "GENE_OR_GENE_PRODUCT", 29, 32], ["epithelial cancers", "CANCER", 79, 97], ["c-Jun N-terminal kinase", "PROTEIN", 4, 27], ["JNK", "PROTEIN", 29, 32], ["many epithelial cancers", "PROBLEM", 74, 97], ["terminal kinase", "ANATOMY", 12, 27], ["invasion", "OBSERVATION_MODIFIER", 62, 70], ["many", "OBSERVATION_MODIFIER", 74, 78], ["epithelial cancers", "OBSERVATION", 79, 97]]], ["Its activity is related to the expression of GRP78 in a direct way [109] .Colon cancerColorectal cancer is the third cancer type according to incidence but is considered to be the second for its mortality [112] .", [["Colon cancerColorectal cancer", "ANATOMY", 74, 103], ["cancer", "ANATOMY", 117, 123], ["Colon cancerColorectal cancer", "DISEASE", 74, 103], ["cancer", "DISEASE", 117, 123], ["GRP78", "GENE_OR_GENE_PRODUCT", 45, 50], ["Colon cancerColorectal cancer", "CANCER", 74, 103], ["cancer", "CANCER", 117, 123], ["GRP78", "PROTEIN", 45, 50], ["Colon cancerColorectal cancer", "PROBLEM", 74, 103], ["activity", "OBSERVATION_MODIFIER", 4, 12], ["cancerColorectal", "ANATOMY", 80, 96], ["cancer", "OBSERVATION", 97, 103], ["third", "OBSERVATION_MODIFIER", 111, 116], ["cancer", "OBSERVATION", 117, 123]]], ["This cancer can be treated by surgical intervention if it is still in the primary site; however, metastasis is the main factor leading to death from colorectal cancer patients [113] .", [["cancer", "ANATOMY", 5, 11], ["primary site", "ANATOMY", 74, 86], ["colorectal cancer", "ANATOMY", 149, 166], ["cancer", "DISEASE", 5, 11], ["death", "DISEASE", 138, 143], ["colorectal cancer", "DISEASE", 149, 166], ["cancer", "CANCER", 5, 11], ["colorectal cancer", "CANCER", 149, 166], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["This cancer", "PROBLEM", 0, 11], ["surgical intervention", "TREATMENT", 30, 51], ["metastasis", "PROBLEM", 97, 107], ["death", "PROBLEM", 138, 143], ["colorectal cancer", "PROBLEM", 149, 166], ["cancer", "OBSERVATION", 5, 11], ["metastasis", "OBSERVATION", 97, 107], ["colorectal cancer", "OBSERVATION", 149, 166]]], ["The expression of GRP78 was found to be high in colon cancer cells [114] , and its downregulation led to an increase of epirubicin-induced apoptosis, which is due to an increase in the nuclear factor erythroid 2-related factor 2 (Nrf-2) expression [115] .", [["colon cancer cells", "ANATOMY", 48, 66], ["colon cancer", "DISEASE", 48, 60], ["epirubicin", "CHEMICAL", 120, 130], ["epirubicin", "CHEMICAL", 120, 130], ["GRP78", "GENE_OR_GENE_PRODUCT", 18, 23], ["colon cancer cells", "CELL", 48, 66], ["epirubicin", "SIMPLE_CHEMICAL", 120, 130], ["nuclear factor erythroid 2-related factor 2", "GENE_OR_GENE_PRODUCT", 185, 228], ["Nrf-2", "GENE_OR_GENE_PRODUCT", 230, 235], ["GRP78", "PROTEIN", 18, 23], ["colon cancer cells", "CELL_TYPE", 48, 66], ["nuclear factor erythroid 2-related factor 2 (Nrf-2", "PROTEIN", 185, 235], ["GRP78", "PROBLEM", 18, 23], ["high in colon cancer cells", "PROBLEM", 40, 66], ["its downregulation", "PROBLEM", 79, 97], ["epirubicin", "TREATMENT", 120, 130], ["induced apoptosis", "PROBLEM", 131, 148], ["an increase", "PROBLEM", 166, 177], ["the nuclear factor erythroid", "PROBLEM", 181, 209], ["high", "OBSERVATION_MODIFIER", 40, 44], ["colon", "ANATOMY", 48, 53], ["cancer", "OBSERVATION", 54, 60], ["increase", "OBSERVATION_MODIFIER", 108, 116], ["epirubicin", "OBSERVATION", 120, 130], ["induced apoptosis", "OBSERVATION", 131, 148], ["increase", "OBSERVATION_MODIFIER", 169, 177]]], ["Moreover, silencing of GRP78 resulted in a suppression of colon cancer growth by the downregulation of Vascular endothelial growth factor/Vascular endothelial growth factor Receptor 2 (VEGF/VEGFR2) pathway [115] .", [["colon cancer", "ANATOMY", 58, 70], ["colon cancer", "DISEASE", 58, 70], ["GRP78", "GENE_OR_GENE_PRODUCT", 23, 28], ["colon cancer", "CANCER", 58, 70], ["Vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 103, 137], ["Vascular endothelial growth factor Receptor 2", "GENE_OR_GENE_PRODUCT", 138, 183], ["VEGF", "GENE_OR_GENE_PRODUCT", 185, 189], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 190, 196], ["GRP78", "PROTEIN", 23, 28], ["Vascular endothelial growth factor", "PROTEIN", 103, 137], ["VEGF", "PROTEIN", 185, 189], ["VEGFR2", "PROTEIN", 190, 196], ["silencing of GRP78", "PROBLEM", 10, 28], ["colon cancer growth", "PROBLEM", 58, 77], ["Vascular endothelial growth factor", "PROBLEM", 103, 137], ["colon", "ANATOMY", 58, 63], ["cancer", "OBSERVATION", 64, 70], ["Vascular endothelial", "ANATOMY", 103, 123], ["Vascular endothelial", "ANATOMY", 138, 158]]], ["High surface expression of GRP78 in colon cancer shows a reduction in tumor proliferation and growth [116] , though, an increase in the invasiveness is observed with high surface GRP78 expression [117] .", [["surface", "ANATOMY", 5, 12], ["colon cancer", "ANATOMY", 36, 48], ["tumor", "ANATOMY", 70, 75], ["surface", "ANATOMY", 171, 178], ["colon cancer", "DISEASE", 36, 48], ["tumor", "DISEASE", 70, 75], ["GRP78", "GENE_OR_GENE_PRODUCT", 27, 32], ["colon cancer", "CANCER", 36, 48], ["tumor", "CANCER", 70, 75], ["GRP78", "GENE_OR_GENE_PRODUCT", 179, 184], ["GRP78", "PROTEIN", 27, 32], ["GRP78", "PROTEIN", 179, 184], ["GRP78 in colon cancer", "PROBLEM", 27, 48], ["a reduction in tumor proliferation", "PROBLEM", 55, 89], ["the invasiveness", "PROBLEM", 132, 148], ["colon", "ANATOMY", 36, 41], ["cancer", "OBSERVATION", 42, 48], ["reduction", "OBSERVATION_MODIFIER", 57, 66], ["tumor", "OBSERVATION", 70, 75], ["proliferation", "OBSERVATION_MODIFIER", 76, 89], ["growth", "OBSERVATION_MODIFIER", 94, 100], ["increase", "OBSERVATION_MODIFIER", 120, 128], ["invasiveness", "OBSERVATION_MODIFIER", 136, 148]]], ["The downregulation of GRP78 increased colon cancer metastasis, due to a rise in NRF-2 and Heme oxygenase -1 (HO1) level and change in the epithelial-to-mesenchymal transition (EMT) biomarker expression [113] .", [["colon cancer", "ANATOMY", 38, 50], ["epithelial", "ANATOMY", 138, 148], ["mesenchymal", "ANATOMY", 152, 163], ["colon cancer", "DISEASE", 38, 50], ["GRP78", "GENE_OR_GENE_PRODUCT", 22, 27], ["colon cancer", "CANCER", 38, 50], ["NRF-2", "GENE_OR_GENE_PRODUCT", 80, 85], ["Heme oxygenase -1", "GENE_OR_GENE_PRODUCT", 90, 107], ["HO1", "GENE_OR_GENE_PRODUCT", 109, 112], ["epithelial", "CELL", 138, 148], ["mesenchymal", "CELL", 152, 163], ["GRP78", "PROTEIN", 22, 27], ["NRF", "PROTEIN", 80, 83], ["Heme oxygenase -1", "PROTEIN", 90, 107], ["HO1", "PROTEIN", 109, 112], ["GRP78 increased colon cancer metastasis", "PROBLEM", 22, 61], ["a rise in NRF", "PROBLEM", 70, 83], ["Heme oxygenase", "TEST", 90, 104], ["HO1) level", "TEST", 109, 119], ["the epithelial", "TEST", 134, 148], ["downregulation", "OBSERVATION_MODIFIER", 4, 18], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["colon", "ANATOMY", 38, 43], ["cancer metastasis", "OBSERVATION", 44, 61], ["rise", "OBSERVATION_MODIFIER", 72, 76], ["epithelial", "ANATOMY", 138, 148], ["mesenchymal transition", "OBSERVATION", 152, 174]]], ["NRF-2 has a function in cell migration ability [118] .", [["cell", "ANATOMY", 24, 28], ["NRF-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 24, 28], ["NRF-2", "PROTEIN", 0, 5]]], ["The migration ability of colon cancer is increased after the downregulation of GRP78 [113] .", [["colon cancer", "ANATOMY", 25, 37], ["colon cancer", "DISEASE", 25, 37], ["colon cancer", "CANCER", 25, 37], ["GRP78", "GENE_OR_GENE_PRODUCT", 79, 84], ["GRP78", "PROTEIN", 79, 84], ["colon cancer", "PROBLEM", 25, 37], ["the downregulation of GRP78", "TREATMENT", 57, 84], ["migration", "OBSERVATION_MODIFIER", 4, 13], ["ability", "OBSERVATION_MODIFIER", 14, 21], ["colon", "ANATOMY", 25, 30], ["cancer", "OBSERVATION", 31, 37], ["increased", "OBSERVATION_MODIFIER", 41, 50]]], ["The raised migration is caused by an increase in vimentin and decrease in E-cadherin [113] .", [["vimentin", "GENE_OR_GENE_PRODUCT", 49, 57], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 74, 84], ["vimentin", "PROTEIN", 49, 57], ["E", "PROTEIN", 74, 75], ["The raised migration", "PROBLEM", 0, 20], ["an increase in vimentin", "PROBLEM", 34, 57], ["migration", "OBSERVATION_MODIFIER", 11, 20], ["increase", "OBSERVATION_MODIFIER", 37, 45], ["decrease", "OBSERVATION_MODIFIER", 62, 70]]], ["Vimentin is an intermediate filament protein [119] , one of the EMT markers, and considered to be important in EMT induction [120] .", [["Vimentin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Vimentin", "PROTEIN", 0, 8], ["intermediate filament protein", "PROTEIN", 15, 44], ["119", "PROTEIN", 46, 49], ["EMT markers", "PROTEIN", 64, 75], ["the EMT markers", "TEST", 60, 75]]], ["E-cadherin is essential in cell polarity and organization of epithelium and can be regarded as a significant epithelial marker [121] .", [["cell", "ANATOMY", 27, 31], ["epithelium", "ANATOMY", 61, 71], ["epithelial", "ANATOMY", 109, 119], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 0, 10], ["cell", "CELL", 27, 31], ["epithelium", "TISSUE", 61, 71], ["epithelial", "TISSUE", 109, 119], ["E-cadherin", "PROTEIN", 0, 10], ["a significant epithelial marker", "TEST", 95, 126], ["essential", "OBSERVATION_MODIFIER", 14, 23], ["in cell polarity", "OBSERVATION", 24, 40], ["epithelium", "ANATOMY_MODIFIER", 61, 71], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["epithelial marker", "OBSERVATION", 109, 126]]], ["Its level decreased in some cases such as tumor metastasis, and progression from adenoma to carcinoma [122] .GRP78 targeting; a grant from an ordealUsually treatment of cancer is done by chemotherapy; however, it is limited by its severe side effects.", [["tumor", "ANATOMY", 42, 47], ["adenoma", "ANATOMY", 81, 88], ["carcinoma", "ANATOMY", 92, 101], ["cancer", "ANATOMY", 169, 175], ["tumor", "DISEASE", 42, 47], ["adenoma", "DISEASE", 81, 88], ["carcinoma", "DISEASE", 92, 101], ["cancer", "DISEASE", 169, 175], ["tumor", "CANCER", 42, 47], ["adenoma", "CANCER", 81, 88], ["carcinoma", "CANCER", 92, 101], ["GRP78", "GENE_OR_GENE_PRODUCT", 109, 114], ["cancer", "CANCER", 169, 175], ["GRP78", "PROTEIN", 109, 114], ["tumor metastasis", "PROBLEM", 42, 58], ["adenoma to carcinoma", "PROBLEM", 81, 101], ["cancer", "PROBLEM", 169, 175], ["chemotherapy", "TREATMENT", 187, 199], ["its severe side effects", "PROBLEM", 227, 250], ["decreased", "OBSERVATION_MODIFIER", 10, 19], ["some cases", "OBSERVATION_MODIFIER", 23, 33], ["tumor", "OBSERVATION_MODIFIER", 42, 47], ["metastasis", "OBSERVATION", 48, 58], ["progression", "OBSERVATION_MODIFIER", 64, 75], ["adenoma", "OBSERVATION", 81, 88], ["carcinoma", "OBSERVATION", 92, 101], ["cancer", "OBSERVATION", 169, 175], ["severe", "OBSERVATION_MODIFIER", 231, 237]]], ["Therefore, it is inevitable to develop new methods for cancer treatment [123, 124] .", [["cancer", "ANATOMY", 55, 61], ["cancer", "DISEASE", 55, 61], ["cancer", "CANCER", 55, 61], ["cancer treatment", "TREATMENT", 55, 71]]], ["One of these new methods utilizes peptidic ligands as they can specifically target the tumor cells and deliver drugs [125] .", [["tumor cells", "ANATOMY", 87, 98], ["tumor", "DISEASE", 87, 92], ["tumor cells", "CELL", 87, 98], ["tumor cells", "CELL_TYPE", 87, 98], ["peptidic ligands", "TREATMENT", 34, 50], ["the tumor cells", "PROBLEM", 83, 98], ["deliver drugs", "TREATMENT", 103, 116], ["new", "OBSERVATION_MODIFIER", 13, 16], ["tumor cells", "OBSERVATION", 87, 98]]], ["One of these peptides is Pep42 which is a cyclic 13-mer CTVALPGGYVRVC [126] .", [["Pep42", "GENE_OR_GENE_PRODUCT", 25, 30], ["a cyclic", "TEST", 40, 48]]], ["The internalization of this peptide is studied after it was mutated at position 12 (valine to lysine) (Mut42) for fluorescein isothiocyanate coupling (FITC), and it is found that this mutation doesn't affect Pep42 internalization negatively [126] .", [["lysine", "CHEMICAL", 94, 100], ["fluorescein isothiocyanate", "CHEMICAL", 114, 140], ["valine", "CHEMICAL", 84, 90], ["lysine", "CHEMICAL", 94, 100], ["Mut42", "CHEMICAL", 103, 108], ["fluorescein isothiocyanate", "CHEMICAL", 114, 140], ["FITC", "CHEMICAL", 151, 155], ["valine", "AMINO_ACID", 84, 90], ["lysine", "AMINO_ACID", 94, 100], ["Mut42", "AMINO_ACID", 103, 108], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 114, 140], ["FITC", "SIMPLE_CHEMICAL", 151, 155], ["Pep42", "GENE_OR_GENE_PRODUCT", 208, 213], ["position 12", "PROTEIN", 71, 82], ["Pep42", "PROTEIN", 208, 213], ["this peptide", "TREATMENT", 23, 35], ["valine to lysine)", "TREATMENT", 84, 101], ["fluorescein isothiocyanate coupling", "TREATMENT", 114, 149], ["this mutation", "PROBLEM", 179, 192]]], ["Pep42 can enter the cell through a receptor-mediated pathway, this receptor was identified to be GRP78, and it is found on the surface of human melanoma cells (Me6652/4) [126] .", [["cell", "ANATOMY", 20, 24], ["surface", "ANATOMY", 127, 134], ["melanoma cells", "ANATOMY", 144, 158], ["Pep42", "CHEMICAL", 0, 5], ["melanoma", "DISEASE", 144, 152], ["Pep42", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 20, 24], ["GRP78", "GENE_OR_GENE_PRODUCT", 97, 102], ["surface", "CELLULAR_COMPONENT", 127, 134], ["human", "ORGANISM", 138, 143], ["melanoma cells", "CELL", 144, 158], ["Me6652/4", "CELL", 160, 168], ["Pep42", "PROTEIN", 0, 5], ["GRP78", "PROTEIN", 97, 102], ["human melanoma cells", "CELL_TYPE", 138, 158], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 138, 143], ["GRP78", "TEST", 97, 102], ["human melanoma cells", "PROBLEM", 138, 158], ["melanoma cells", "OBSERVATION", 144, 158]]], ["After internalization, Mut42 was found to be colocalized with the ER but not lysosomes.", [["ER", "ANATOMY", 66, 68], ["lysosomes", "ANATOMY", 77, 86], ["Mut42", "GENE_OR_GENE_PRODUCT", 23, 28], ["ER", "GENE_OR_GENE_PRODUCT", 66, 68], ["lysosomes", "CELLULAR_COMPONENT", 77, 86], ["Mut42", "PROTEIN", 23, 28], ["ER", "PROTEIN", 66, 68]]], ["After using different concentrations of monoclonal antibodies against GRP78, the uptake of Mut42 is reduced according to the level of the antibodies.", [["Mut42", "CHEMICAL", 91, 96], ["GRP78", "GENE_OR_GENE_PRODUCT", 70, 75], ["Mut42", "GENE_OR_GENE_PRODUCT", 91, 96], ["monoclonal antibodies", "PROTEIN", 40, 61], ["GRP78", "PROTEIN", 70, 75], ["Mut42", "PROTEIN", 91, 96], ["antibodies", "PROTEIN", 138, 148], ["monoclonal antibodies", "TEST", 40, 61], ["GRP78", "TEST", 70, 75], ["the uptake of Mut42", "TEST", 77, 96]]], ["Moreover, overexpression of GRP78 increases the entry of Mut42 which indicates the specificity of Pep42 to GRP78.", [["GRP78", "GENE_OR_GENE_PRODUCT", 28, 33], ["Mut42", "GENE_OR_GENE_PRODUCT", 57, 62], ["Pep42", "GENE_OR_GENE_PRODUCT", 98, 103], ["GRP78", "GENE_OR_GENE_PRODUCT", 107, 112], ["GRP78", "PROTEIN", 28, 33], ["Mut42", "PROTEIN", 57, 62], ["Pep42", "PROTEIN", 98, 103], ["GRP78", "PROTEIN", 107, 112], ["overexpression of GRP78", "PROBLEM", 10, 33], ["increases", "OBSERVATION_MODIFIER", 34, 43]]], ["Mut42 is used with Taxol on human Melanoma cells, and 92.1% of the cells are found to be in the late stages of apoptosis [126] .GRP78 targeting; a grant from an ordealThe cyclic shape of this peptide is vital for internalization as reported by Kim et al. [126] .", [["Melanoma cells", "ANATOMY", 34, 48], ["cells", "ANATOMY", 67, 72], ["Mut42", "CHEMICAL", 0, 5], ["Taxol", "CHEMICAL", 19, 24], ["Melanoma", "DISEASE", 34, 42], ["Taxol", "CHEMICAL", 19, 24], ["Mut42", "SIMPLE_CHEMICAL", 0, 5], ["Taxol", "SIMPLE_CHEMICAL", 19, 24], ["human", "ORGANISM", 28, 33], ["Melanoma cells", "CELL", 34, 48], ["cells", "CELL", 67, 72], ["GRP78", "GENE_OR_GENE_PRODUCT", 128, 133], ["human Melanoma cells", "CELL_TYPE", 28, 48], ["GRP78", "PROTEIN", 128, 133], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["Taxol on human Melanoma cells", "TREATMENT", 19, 48], ["apoptosis", "PROBLEM", 111, 120], ["Melanoma cells", "OBSERVATION", 34, 48], ["late stages", "OBSERVATION_MODIFIER", 96, 107], ["cyclic shape", "OBSERVATION", 171, 183]]], ["Besides, the peptide is mainly hydrophobic supporting the selectivity of the peptide to bind to GRP78, which has the affinity to attach to the hydrophobic clusters of unfolded proteins under stress conditions.", [["GRP78", "GENE_OR_GENE_PRODUCT", 96, 101], ["GRP78", "PROTEIN", 96, 101], ["unfolded proteins", "PROTEIN", 167, 184], ["unfolded proteins under stress conditions", "PROBLEM", 167, 208], ["mainly", "OBSERVATION_MODIFIER", 24, 30], ["hydrophobic", "OBSERVATION", 31, 42], ["selectivity", "OBSERVATION_MODIFIER", 58, 69], ["unfolded proteins", "OBSERVATION", 167, 184], ["stress conditions", "OBSERVATION", 191, 208]]], ["These are two crucial points for consideration when studying the interaction between CS GRP78 and pathogenic proteins (envelope and spore coat proteins).", [["GRP78", "GENE_OR_GENE_PRODUCT", 88, 93], ["spore coat proteins", "GENE_OR_GENE_PRODUCT", 132, 151], ["CS GRP78", "PROTEIN", 85, 93], ["pathogenic proteins", "PROTEIN", 98, 117], ["envelope and spore coat proteins", "PROTEIN", 119, 151], ["CS GRP78", "TEST", 85, 93], ["pathogenic proteins", "PROBLEM", 98, 117], ["spore coat proteins", "TEST", 132, 151]]], ["Also, targeting such binding site on the CS GRP78 with cyclic peptides may be the future preventive routine for patients living with diabetes or cancers.", [["cancers", "ANATOMY", 145, 152], ["diabetes", "DISEASE", 133, 141], ["cancers", "DISEASE", 145, 152], ["GRP78", "GENE_OR_GENE_PRODUCT", 44, 49], ["cyclic peptides", "GENE_OR_GENE_PRODUCT", 55, 70], ["patients", "ORGANISM", 112, 120], ["cancers", "CANCER", 145, 152], ["CS GRP78", "PROTEIN", 41, 49], ["patients", "SPECIES", 112, 120], ["such binding site", "PROBLEM", 16, 33], ["cyclic peptides", "TREATMENT", 55, 70], ["diabetes", "PROBLEM", 133, 141], ["cancers", "PROBLEM", 145, 152], ["cancers", "OBSERVATION", 145, 152]]]], "cad994637f061356cd5ea11a7570b2f5ad38ed47": [["IntroductionThe control of hospital-acquired infections (HAI) is largely based on preventive procedures derived from the best available knowledge of potential transmission routes.", [["hospital-acquired infections", "DISEASE", 27, 55], ["HAI", "DISEASE", 57, 60], ["acquired infections (HAI)", "PROBLEM", 36, 61], ["preventive procedures", "TREATMENT", 82, 103], ["infections", "OBSERVATION", 45, 55]]], ["The accurate description of contact patterns between individuals is crucial to this end, as it can help to understand the possible transmission dynamics and the design principles for appropriate control measures.", [["the design principles", "TREATMENT", 157, 178], ["appropriate control measures", "TREATMENT", 183, 211]]], ["In particular, the mutual exposures between patients and health-care workers (HCWs) have been documented for bacterial and viral transmission since decades [1, 2, 3] .", [["bacterial and viral transmission", "DISEASE", 109, 141], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["bacterial and viral transmission", "PROBLEM", 109, 141]]], ["Transmission might be the result of effective contact, as in the cases of S. aureus [4, 5] , K. pneumoniae [6] or rotavirus [7] , of exposure to contaminated aerosols, as for M. tuberculosis [8] , or the result of exposure to droplets, as for influenza [9] .", [["rotavirus", "DISEASE", 114, 123], ["tuberculosis", "DISEASE", 178, 190], ["influenza", "DISEASE", 243, 252], ["S. aureus", "ORGANISM", 74, 83], ["4, 5", "ORGANISM", 85, 89], ["K. pneumoniae", "ORGANISM", 93, 106], ["rotavirus", "ORGANISM", 114, 123], ["S. aureus", "SPECIES", 74, 83], ["K. pneumoniae", "SPECIES", 93, 106], ["M. tuberculosis", "SPECIES", 175, 190], ["S. aureus", "SPECIES", 74, 83], ["K. pneumoniae", "SPECIES", 93, 106], ["M. tuberculosis", "SPECIES", 175, 190], ["S. aureus", "PROBLEM", 74, 83], ["K. pneumoniae", "PROBLEM", 93, 106], ["rotavirus", "PROBLEM", 114, 123], ["contaminated aerosols", "TREATMENT", 145, 166], ["M. tuberculosis", "PROBLEM", 175, 190], ["influenza", "PROBLEM", 243, 252], ["aureus", "OBSERVATION", 77, 83]]], ["Some pathogens such as influenza can also be transmitted by different routes.", [["influenza", "DISEASE", 23, 32], ["Some pathogens", "PROBLEM", 0, 14], ["influenza", "PROBLEM", 23, 32], ["pathogens", "OBSERVATION", 5, 14]]], ["These approaches provide essential information to describe contacts patterns and inform models of infectious disease spread.", [["infectious disease", "DISEASE", 98, 116], ["infectious disease spread", "PROBLEM", 98, 123], ["infectious", "OBSERVATION", 98, 108]]], ["The gathered data, however, often lack the longitudinal dimension [10, 12, 16] and the high spatial and temporal resolution needed to accurately characterize the interactions among individuals in specific environments such as hospitals.", [["The gathered data", "TEST", 0, 17]]], ["Moreover, they are subject to potential biases due to behavioral modifications due to the presence of observers, to short periods of observation, and especially to missing information and recall biases.", [["behavioral modifications", "PROBLEM", 54, 78]]], ["Evaluating biases and understanding the accuracy of the collected data is therefore a difficult task [16] .IntroductionIn this context, the use of electronic devices has recently emerged as an interesting complement to more traditional methods [10] .", [["the collected data", "TEST", 52, 70], ["electronic devices", "TREATMENT", 147, 165]]], ["In particular, wearable sensors based on active Radio-Frequency IDentification (RFID) technology have been used to measure face-to-face proximity relations between individuals with a high spatio-temporal resolution in various contexts [17] that include social gatherings [18, 19] , schools [20, 21] and hospitals [22, 23] .", [["wearable sensors", "TEST", 15, 31], ["a high spatio", "PROBLEM", 181, 194]]], ["The amount of available data, however, is still very limited, high-resolution contact data relevant for the epidemiology of infectious diseases are scarce, and the longitudinal aspects of contact patterns have not been investigated in detail, prompting further investigation.IntroductionIn this paper we report on the use of wearable proximity sensors [17] to measure the numbers and durations of contacts between individuals in an acute care geriatric unit of a university hospital.", [["infectious diseases", "DISEASE", 124, 143], ["infectious diseases", "PROBLEM", 124, 143], ["further investigation", "TEST", 253, 274], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["infectious", "OBSERVATION", 124, 134]]], ["We document the presence of individuals with a high number of contacts, who could be considered as potential super-spreaders of infections.", [["infections", "DISEASE", 128, 138], ["infections", "PROBLEM", 128, 138], ["infections", "OBSERVATION", 128, 138]]], ["Some implications of our results regarding prevention and control of hospital-acquired infections are discussed.Study Design and Data CollectionThe measurement system, developed by the SocioPatterns collaboration [24] , is based on small active RFID devices (''tags'') that are embedded in unobtrusive wearable badges and exchange ultra-low-power radio packets [17, 18, 21, 23] .", [["infections", "DISEASE", 87, 97], ["acquired infections", "PROBLEM", 78, 97], ["Data Collection", "TEST", 129, 144], ["The measurement system", "TEST", 144, 166], ["small active RFID devices", "TREATMENT", 232, 257], ["exchange ultra", "TEST", 322, 336], ["small", "OBSERVATION_MODIFIER", 232, 237], ["active", "OBSERVATION_MODIFIER", 238, 244], ["RFID devices", "OBSERVATION", 245, 257]]], ["Individuals were asked to wear the devices on their chests using lanyards, ensuring that the RFID devices of two individuals can only exchange radio packets when the persons are facing each other, as the human body acts as a RF shield at the frequency used for communication.", [["body", "ANATOMY", 210, 214], ["persons", "ORGANISM", 166, 173], ["human", "ORGANISM", 204, 209], ["body", "ORGANISM_SUBDIVISION", 210, 214], ["persons", "SPECIES", 166, 173], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 204, 209], ["the devices", "TREATMENT", 31, 42], ["lanyards", "TREATMENT", 65, 73], ["the RFID devices", "TREATMENT", 89, 105], ["a RF shield", "TREATMENT", 223, 234]]], ["In summary the system is tuned so that it detects and records close-range encounters during which a communicable disease infection could be transmitted, for example, by cough, sneeze or hand contact.", [["hand", "ANATOMY", 186, 190], ["communicable disease infection", "DISEASE", 100, 130], ["cough", "DISEASE", 169, 174], ["sneeze", "DISEASE", 176, 182], ["hand", "ORGANISM_SUBDIVISION", 186, 190], ["a communicable disease infection", "PROBLEM", 98, 130], ["cough", "PROBLEM", 169, 174], ["infection", "OBSERVATION", 121, 130]]], ["The information on face-to-face proximity events detected by the wearable sensors is relayed to radio receivers installed throughout the hospital ward (bedrooms, offices and hall).Study Design and Data CollectionThe system was tuned so that whenever two individuals wearing the RFID tags were in face-to-face proximity the probability to detect such a proximity event over an time interval of 20 seconds was larger than 99%.", [["Data Collection", "TEST", 197, 212], ["the RFID tags", "TEST", 274, 287], ["larger", "OBSERVATION_MODIFIER", 408, 414]]], ["A contact is therefore symmetric by definition, and in case of contacts involving three or more individuals in the same 20-second interval, all the contact pairs were considered.", [["symmetric", "OBSERVATION_MODIFIER", 23, 32]]], ["After the contact is established, it is considered ongoing as long as the devices continue to exchange at least one packet for every subsequent 20 s interval.", [["the devices", "TREATMENT", 70, 81]]], ["Conversely, a contact is considered broken if a 20-second interval elapses with no exchange of packets.", [["a 20-second interval elapses", "PROBLEM", 46, 74]]], ["We emphasize that this is an operational definition of the human proximity behavior that we choose to quantify, and that all the results we present correspond to this precise and specific definition of ''contact''.", [["human", "ORGANISM", 59, 64], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64]]], ["During that time, 50 professional staff worked in the unit and 31 patients were admitted.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74]]], ["We collected data on the contacts between 46 staff members (92% participation rate) and 29 patients (94% participation rate).", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99]]], ["Visits were allowed from 12:00 am to 8:00 pm but visitors were not included in the study.Ethics and PrivacyIn advance of the study, staff members and patients were informed on the details and aims of the study.", [["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["the study", "TEST", 79, 88], ["the study", "TEST", 121, 130], ["the study", "TEST", 200, 209]]], ["A signed informed consent was obtained for each participating patient and staff member.", [["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69]]], ["All participants were given an RFID tag and asked to wear it properly at all times.", [["participants", "SPECIES", 4, 16]]], ["No personal information was associated with the tag: only the professional category of each HCW and the age of the patients were collected.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123]]], ["The study was approved by the French national bodies responsible for ethics and privacy, the ''Commission Nationale de l'Informatique et des Libert\u00e9s'' (CNIL, http://www.cnil.fr) and the ''Comit\u00e9 de Protection des personnes'' (http://www.cppsudest2.com/) of the hospital.Data AnalysisIndividuals were categorized in four classes according to their activity in the ward: patients (PAT), medical doctors (physicians and interns, MED), paramedical staff (nurses and nurses' aides, NUR) and administrative staff (ADM).", [["patients", "ORGANISM", 370, 378], ["patients", "SPECIES", 370, 378], ["The study", "TEST", 0, 9], ["Data AnalysisIndividuals", "TEST", 271, 295], ["MED", "ANATOMY", 427, 430]]], ["MED and NUR professionals form a group named HCW.Data AnalysisThe contact patterns were analyzed using both the numbers and the durations of contacts between individuals.", [["Data Analysis", "TEST", 49, 62]]], ["These quantities were aggregated for each class and for each pair of role classes in order to define contact matrices that describe the mixing patterns between classes of individuals.Data AnalysisThe longitudinal evolution of the contact patterns was studied by considering, in addition to the entire study duration, several shorter time intervals: We divided the study duration into 5 daytime periods (7:00 am to 8:00 pm) and 4 nights (8:00 pm to 7:00 am); daytime periods were divided in morning (7:00 am to 1:30 pm) and afternoon (1:30 pm to 8:00 pm) shifts, and we also considered data aggregated on a 1-hour timescale.Data AnalysisWe finally considered the similarity of contact patterns between successive days, by measuring the fraction of contacts that were repeated from one day to the next, as such information is particularly relevant when modeling spreading phenomena [18, 25, 26] .Number of ContactsOverall, 14,037 contacts occurred during the study, with a cumulative duration of 648,480 s (approx.", [["Data Analysis", "TEST", 183, 196], ["the study", "TEST", 953, 962]]], ["10,616 contacts (75.6%) included at least one NUR, 4,003 (28.5%) included at least one MED, and 3,849 (27.4%) at least one patient.", [["patient", "ORGANISM", 123, 130], ["patient", "SPECIES", 123, 130], ["MED", "ANATOMY", 87, 90]]], ["Most contacts involve at least one NUR and/or one MED, and NURs and MEDs have on average the largest number of contacts, as well as the largest cumulative duration in contact.", [["MEDs", "TREATMENT", 68, 72], ["MED", "ANATOMY", 50, 53]]], ["Large standard deviations are however observed: the distributions of the contact durations and of the numbers and cumulative durations of contacts are broad, as also observed in many other contexts [20, 21, 23, 27] .", [["Large standard deviations", "PROBLEM", 0, 25], ["standard deviations", "OBSERVATION", 6, 25]]], ["Very few contacts between PATs or between members of the ADM group were observed.Longitudinal StudyAs reported in Table 3 , among the 14,037 contacts detected, 13,206 (94.1%) occurred during daytime, for a total duration of 612,900 s (approx.", [["PATs", "GENE_OR_GENE_PRODUCT", 26, 30], ["ADM", "GENE_OR_GENE_PRODUCT", 57, 60], ["PATs", "PROTEIN", 26, 30], ["the ADM group", "TREATMENT", 53, 66], ["Longitudinal StudyAs", "TEST", 81, 101], ["few", "OBSERVATION_MODIFIER", 5, 8], ["contacts", "OBSERVATION", 9, 17]]], ["On average we recorded 2,265 contacts per morning, 1,041 per afternoon, and 207 per night.Longitudinal StudyThe evolution of the number of contacts at the more detailed resolution of one-hour time windows is reported in Figure 2 .", [["Longitudinal Study", "TEST", 90, 108], ["number", "OBSERVATION_MODIFIER", 129, 135]]], ["The number of contacts varied strongly over the course of a day, but the evolution was similar from one day to another (for day 1 and day 5, contacts were recorded after 1:00 pm and before 2:00 pm respectively, see Methods), with very few contacts at night and a maximum around 10-12 am.", [["number", "OBSERVATION_MODIFIER", 4, 10]]], ["Contacts between NURs, and between NURs and PATs, were predominant in the morning while contacts between MEDs remained similar between mornings and afternoons.", [["NURs", "GENE_OR_GENE_PRODUCT", 17, 21], ["NURs", "GENE_OR_GENE_PRODUCT", 35, 39], ["PATs", "GENE_OR_GENE_PRODUCT", 44, 48], ["NURs", "DNA", 35, 39], ["MEDs", "TREATMENT", 105, 109]]], ["Overall, 63.3% of contacts between NURs and PATs occurred on the morning, 25.5% on the afternoon and 9.2% during the night.", [["PATs", "DISEASE", 44, 48]]], ["The absolute numbers of contacts varied from one morning (resp., afternoon or night) to the next, but the mixing patterns remained very similar.", [["absolute", "OBSERVATION_MODIFIER", 4, 12], ["numbers", "OBSERVATION_MODIFIER", 13, 20], ["very", "OBSERVATION_MODIFIER", 131, 135], ["similar", "OBSERVATION", 136, 143]]], ["The main difference between morning and afternoon periods came from larger numbers of contacts involving NURs in the morning.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19]]], ["Almost only contacts involving NURs and PATs were observed at night.Longitudinal StudyAlthough the aggregated observables reported above are very similar from day to day, the precise structure of the daily contact network varied strongly: the fraction of common neighbors of an individual between two different days is on average just of 48%.", [["NURs", "GENE_OR_GENE_PRODUCT", 31, 35], ["PATs", "GENE_OR_GENE_PRODUCT", 40, 44], ["NURs", "PROTEIN", 31, 35], ["PATs", "PROTEIN", 40, 44], ["Longitudinal StudyAlthough", "TEST", 68, 94]]], ["This value is smaller than the one observed in a school [21] , but much larger than the one measured for the attendees of a conference [18] .''Super-contactors'' among HCWs (NURs and MEDs)The cumulative number and duration of contacts of each individual, as identified by his/her badge identification number, are reported in Figure 4 and Table 4 .", [["MEDs", "TREATMENT", 183, 187], ["smaller", "OBSERVATION_MODIFIER", 14, 21], ["larger", "OBSERVATION_MODIFIER", 72, 78], ["cumulative", "OBSERVATION_MODIFIER", 192, 202], ["number", "OBSERVATION_MODIFIER", 203, 209]]], ["A small number of HCWs accounted for most of the contacts observed between HCWs and PATs, both in terms of number and cumulative duration.", [["small", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["The number of distinct individuals contacted by a given individual was also correlated with the total number of contacts of the same individual (r = 0.69).", [["number", "OBSERVATION_MODIFIER", 4, 10], ["distinct", "OBSERVATION_MODIFIER", 14, 22], ["individuals", "OBSERVATION", 23, 34]]], ["These 6 HCWs had a much larger number and duration of contacts than average, as shown in Table 4 .DiscussionThe objective of the present study was to describe in detail the contacts between individuals in a healthcare setting.", [["the present study", "TEST", 125, 142]]], ["Such data can help to accurately inform computational models of the propagation of infectious diseases and, as a consequence, to improve the design and implementation of prevention or control measures based on the frequency and duration of contacts.", [["infectious diseases", "DISEASE", 83, 102], ["infectious diseases", "PROBLEM", 83, 102], ["prevention", "TREATMENT", 170, 180], ["control measures", "TREATMENT", 184, 200], ["infectious", "OBSERVATION", 83, 93]]], ["Numbers and duration of contacts were characterized for each class of individuals and for individuals belonging to given class pairs, yielding contact matrices that represent important inputs for realistic computational models of nosocomial infections.", [["nosocomial infections", "DISEASE", 230, 251], ["class pairs", "PROBLEM", 121, 132], ["nosocomial infections", "PROBLEM", 230, 251], ["nosocomial infections", "OBSERVATION", 230, 251]]], ["As also measured in other contexts [17, 20, 21, 23, 27] , the numbers and durations of contacts display large variations even across individuals of the same class: the resulting distributions were broad, with no characteristic time scale.", [["large variations", "PROBLEM", 104, 120], ["large", "OBSERVATION_MODIFIER", 104, 109], ["variations", "OBSERVATION", 110, 120]]], ["As a consequence, even though the average durations of contacts were rather short, contacts of much longer durations than average occured with nonnegligible frequency.DiscussionContacts involving either two NURs or between NURs and PATs accounted for the majority of contacts, both in terms of numbers and of global durations.", [["NURs", "DNA", 207, 211], ["NURs", "DNA", 223, 227], ["PATs", "DNA", 232, 236]]], ["Very few contacts occurred between PATs: this might be a specificity of wards with mostly single rooms, and other wards in which patients are not alone in a room or in which they move around more might yield more numerous contacts between PATs.", [["patients", "ORGANISM", 129, 137], ["PATs", "GENE_OR_GENE_PRODUCT", 239, 243], ["patients", "SPECIES", 129, 137], ["few", "OBSERVATION_MODIFIER", 5, 8]]], ["These results are consistent with previous studies [23, 28] carried out in pediatrics, surgery and intensive care units, and provide additional evidence that nurses and assistants may be the most essential target group for prevention measures [27, 28] .DiscussionThe detailed information about the number and duration of contacts also allowed us to highlight the presence of a limited number of ''super-contactors'' among HCWs who account for a large part of all contacts.", [["previous studies", "TEST", 34, 50], ["consistent with", "UNCERTAINTY", 18, 33]]], ["A large number of contacts could correspond to different situations, namely to contacts with many different patients, or to many contacts with few patients.", [["patients", "ORGANISM", 108, 116], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 147, 155], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14]]], ["Our results show that the cumulated number of contacts and the number of distinct persons contacted are correlated; this indicates that in the hospital context under study the super-contactors have contacts with many different patients.", [["persons", "ORGANISM", 82, 89], ["patients", "ORGANISM", 227, 235], ["persons", "SPECIES", 82, 89], ["patients", "SPECIES", 227, 235]]], ["They could therefore potentially play the role of super-spreaders, whose importance in the spread of infectious agents has been highlighted both theoretically [29, 30] and empirically [31] .", [["infectious agents", "TREATMENT", 101, 118]]], ["This suggests that their role class should be targeted for prevention measures.DiscussionThese results are in concordance with the central role of HCWs in hospital wards, as repeated contacts with patients are often necessary for the quality of healthcare.", [["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 197, 205]]], ["However, since outbreaks of measles and influenza involving this population have been observed [32, 33] , the possibility for HCWs to be super-contactors emphasizes the need to reduce their exposure to infection and to limit the risk of transmission to patients.", [["measles", "DISEASE", 28, 35], ["influenza", "DISEASE", 40, 49], ["infection", "DISEASE", 202, 211], ["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 253, 261], ["measles", "PROBLEM", 28, 35], ["influenza", "PROBLEM", 40, 49], ["infection", "PROBLEM", 202, 211], ["infection", "OBSERVATION", 202, 211]]], ["This should stimulate the strict implementation of preventive measures including hand washing, vaccination, or wearing of masks [34] .", [["hand", "ANATOMY", 81, 85], ["hand", "ORGANISM_SUBDIVISION", 81, 85], ["preventive measures", "TREATMENT", 51, 70], ["hand washing", "TREATMENT", 81, 93], ["vaccination", "TREATMENT", 95, 106]]], ["In addition, HCWs could be warned against the risk brought forth by unnecessary large numbers or long durations of contacts, especially with patients.DiscussionLimiting the contacts of HCWs (either with PATs or with other HCWs) might however not be feasible without altering the quality of care.", [["HCWs", "ORGANISM", 13, 17], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149]]], ["The numbers of contacts varied indeed greatly along the course of each day, clearly highlighting the periods of the day (here, the mornings) during which transmission could occur with higher probability.", [["numbers", "OBSERVATION_MODIFIER", 4, 11]]], ["The high numbers of contacts during mornings may indicate a potential overexposure to infection for PATs and NURs, and one may imagine a different organization toward a smoothing of the number of contacts throughout mornings and afternoons.", [["infection", "DISEASE", 86, 95], ["PATs", "DISEASE", 100, 104], ["infection", "PROBLEM", 86, 95], ["high", "OBSERVATION_MODIFIER", 4, 8], ["numbers", "OBSERVATION_MODIFIER", 9, 16], ["infection", "OBSERVATION", 86, 95]]], ["This would decrease the density of contacts, in particular between NURs, at each specific moment, while maintaining the daily number and duration of contacts between NURs and PATs, and overall tend to limit their overexposure [35] .", [["NURs", "GENE_OR_GENE_PRODUCT", 67, 71], ["NURs", "GENE_OR_GENE_PRODUCT", 166, 170], ["density", "OBSERVATION_MODIFIER", 24, 31]]], ["The potential efficacy of such or other changes in the healthcare organization should of course be tested through numerical simulations of spreading phenomena, and their feasibility would moreover need to be asserted through discussions with the staff.", [["spreading phenomena", "PROBLEM", 139, 158]]], ["Strong advantages are the versatility of the sensing strategy (i.e., the unobtrusiveness of wearable sensors and the prompt deployability of receivers) and the fact that it does neither require the constant presence of external observers nor interfere with the delivery of care in the ward.", [["the sensing strategy", "TREATMENT", 41, 61], ["wearable sensors", "TREATMENT", 92, 108], ["the delivery of care", "TREATMENT", 257, 277]]], ["Another strength lies in the high spatial and temporal resolution: behavioral differences across role classes can be detected, and longitudinal studies are possible.", [["longitudinal studies", "TEST", 131, 151]]], ["High participation ratios are also crucial: similarly to a previous study in another hospital [23] , the rate of acceptance among HCWs and patients turned out to be very high (92%).", [["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["a previous study", "TEST", 57, 73]]], ["The information meetings held before the study, providing a clear exposition of the scientific objectives and of the privacy aspects, most probably played an important role in achieving such a high participation rate.DiscussionThe versatility of a system based on wearable sensors and easily deployable data receivers makes it possible to repeat similar studies in different environments and to compare results across contexts [19] .", [["the study", "TEST", 37, 46], ["wearable sensors", "TEST", 264, 280], ["repeat similar studies", "TEST", 339, 361]]], ["In particular, several of the reported findings are very similar to those described in [23] in a different hospital, situated in a different country, and in a different type of ward (paediatric): large variability in the cumulative duration of contacts, small number of contacts between patients, and large numbers and durations of contacts between NURs.", [["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 287, 295], ["large variability", "PROBLEM", 196, 213], ["several", "OBSERVATION_MODIFIER", 15, 22], ["large", "OBSERVATION_MODIFIER", 196, 201], ["variability", "OBSERVATION_MODIFIER", 202, 213], ["small", "OBSERVATION_MODIFIER", 254, 259], ["number", "OBSERVATION_MODIFIER", 260, 266], ["large", "OBSERVATION_MODIFIER", 301, 306], ["numbers", "OBSERVATION_MODIFIER", 307, 314]]], ["Repeating measurements in the same ward and in other wards represents an important step towards understanding the similarities and differences of contact patterns in hospital settings, and allows to generalize the observations to more correctly inform models.DiscussionThe measurement approach we used here has also several limitations.", [["Repeating measurements", "TEST", 0, 22]]], ["Therefore, the assumption that the number of contacts reflects disease exposure can be appropriate for respiratory infections such as influenza, or for similar diseases that can be transmitted by various routes at a distance of 1 meter around an index case [36] .", [["respiratory", "ANATOMY", 103, 114], ["respiratory infections", "DISEASE", 103, 125], ["influenza", "DISEASE", 134, 143], ["disease exposure", "PROBLEM", 63, 79], ["respiratory infections", "PROBLEM", 103, 125], ["influenza", "PROBLEM", 134, 143], ["similar diseases", "PROBLEM", 152, 168]]], ["The use of close-range proximity as a proxy for the transmission of bacterial infection acquired by cross transmission, such as S aureus or Enterobacteriacea, is more questionable.", [["bacterial infection", "DISEASE", 68, 87], ["S aureus", "ORGANISM", 128, 136], ["S aureus", "SPECIES", 128, 136], ["S aureus", "SPECIES", 128, 136], ["bacterial infection", "PROBLEM", 68, 87], ["S aureus", "PROBLEM", 128, 136], ["Enterobacteriacea", "PROBLEM", 140, 157], ["bacterial", "OBSERVATION_MODIFIER", 68, 77], ["infection", "OBSERVATION", 78, 87]]], ["Other factors related to specific attributes of individuals (e.g., vaccination or immunosuppression), of the microbial agent (e.g., resistance or virulence) or of the environment (e.g., specialty of ward) may also alter the relationship between contact frequency/duration and transmission.", [["Other factors", "PROBLEM", 0, 13], ["vaccination", "TREATMENT", 67, 78], ["immunosuppression", "TREATMENT", 82, 99], ["the microbial agent", "TREATMENT", 105, 124]]], ["In this respect, a validation with simultaneous direct observation and human annotation of the contacts would be of particular interest.DiscussionFinally, it is difficult to assess whether individuals modified their behavior in response to wearing RFID badges, but direct observation indicated that HCWs were focusing on their daily activities and most probably were not influenced by the presence of the badges.", [["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["a validation", "TEST", 17, 29], ["simultaneous direct observation", "TEST", 35, 66], ["direct observation", "TEST", 265, 283]]], ["Badges were not proposed to visitors and this potential external source of infection was not studied.Conclusions and Future WorkThis study complements previous work [22, 23, 27, 28, 30, 34] and provides data that can be used to explore the spread of infection in confined settings through mathematical and computational modeling.", [["infection", "DISEASE", 75, 84], ["infection", "DISEASE", 250, 259], ["infection", "PROBLEM", 75, 84], ["Future WorkThis study", "TEST", 117, 138], ["infection", "PROBLEM", 250, 259], ["infection", "OBSERVATION", 75, 84], ["infection", "OBSERVATION", 250, 259]]], ["Models of transmission within hospitals might be based on contact matrices such as those presented here, and used to better understand the epidemiology of different types of microbial agents, to assess the impact of control measures, and to help improve the delivery of care during emergency epidemic situations.", [["microbial agents", "TREATMENT", 174, 190], ["control measures", "TREATMENT", 216, 232], ["the delivery of care", "TREATMENT", 254, 274]]], ["In our study, specific mixing patterns were observed between different classes of individuals, showing a clear departure from homogeneous mixing, as it is expected in a hospital setting, and highlighting the relevance of correctly informed contact matrices.", [["our study", "TEST", 3, 12], ["clear", "OBSERVATION", 105, 110], ["homogeneous", "OBSERVATION_MODIFIER", 126, 137], ["mixing", "OBSERVATION", 138, 144]]], ["Moreover, although an important turnover between the persons in contact with a given individual was observed across different days, and although the average contact durations between different classes of individuals varied between mornings, afternoons and nights, the contact patterns remained statistically very similar across successive days.", [["persons", "ORGANISM", 53, 60], ["persons", "SPECIES", 53, 60]]], ["Additional data sets would also be useful to build and test proxies that could replace systematic detailed measurement of contact patterns, such as the ones put forward in [15, 38, 39] .Conclusions and Future WorkIn order to explore the relationship between complex contacts network and the spreading of infections, it would be particularly interesting to collect simultaneously high-resolution contact data and microbiological data describing the infection status of participating individuals.", [["infections", "DISEASE", 304, 314], ["infection", "DISEASE", 448, 457], ["infections", "PROBLEM", 304, 314], ["microbiological data", "TEST", 412, 432], ["the infection status", "PROBLEM", 444, 464], ["infections", "OBSERVATION", 304, 314], ["infection", "OBSERVATION", 448, 457]]], ["Combining these heterogeneous sources of information within appropriate statistical models would allow elucidating the relation between the risk of disease transmission and contacts patterns, in order to disentangle transmission likelihood from contact frequency.", [["disease transmission", "PROBLEM", 148, 168], ["heterogeneous", "OBSERVATION_MODIFIER", 16, 29], ["disease", "OBSERVATION", 148, 155]]], ["Finally, feedback of the results to HCWs could be an innovative pedagogical tool in health care settings.Supporting InformationFile S1 Dataset S1.", [["InformationFile S1 Dataset S1", "DNA", 116, 145], ["S1", "ANATOMY", 143, 145]]], ["Each node corresponds to one RFID tag and has an attribute ''role'' that indicates the role of the individual wearing the tag: patient (PAT), medical doctor (MED), paramedical staff (NUR) or administrative staff (ADM).", [["node", "ANATOMY", 5, 9], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 127, 134], ["node", "OBSERVATION", 5, 9], ["MED", "ANATOMY", 158, 161]]], ["Each node corresponds to one RFID tag and has an attribute ''role'' that indicates the role of the individual wearing the tag: patient (PAT), medical doctor (MED), paramedical staff (NUR) or administrative staff (ADM).", [["node", "ANATOMY", 5, 9], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 127, 134], ["node", "OBSERVATION", 5, 9], ["MED", "ANATOMY", 158, 161]]], ["Each node corresponds to one RFID tag and has an attribute ''role'' that indicates the role of the individual wearing the tag: patient (PAT), medical doctor (MED), paramedical staff (NUR) or administrative staff (ADM).", [["node", "ANATOMY", 5, 9], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 127, 134], ["node", "OBSERVATION", 5, 9], ["MED", "ANATOMY", 158, 161]]], ["Each node corresponds to one RFID tag and has an attribute ''role'' that indicates the role of the individual wearing the tag: patient (PAT), medical doctor (MED), paramedical staff (NUR) or administrative staff (ADM).", [["node", "ANATOMY", 5, 9], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 127, 134], ["node", "OBSERVATION", 5, 9], ["MED", "ANATOMY", 158, 161]]], ["Each node corresponds to one RFID tag and has an attribute ''role'' that indicates the role of the individual wearing the tag: patient (PAT), medical doctor (MED), paramedical staff (NUR) or administrative staff (ADM).", [["node", "ANATOMY", 5, 9], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 127, 134], ["node", "OBSERVATION", 5, 9], ["MED", "ANATOMY", 158, 161]]]]}